2021-01-18 18:43:17 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': False, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': '/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_underscore/checkpoint_best.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out_fp32_best/nl_underscore_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_underscore', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=False, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_underscore/checkpoint_best.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out_fp32_best/nl_underscore_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-18 18:43:18 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-18 18:43:18 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-18 18:43:18 | INFO | fairseq_cli.generate | loading model(s) from /global/lv71502/clang/fairseq/mBART_termeval/checkpoint_nl_underscore/checkpoint_best.pt
2021-01-18 20:25:27 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.src
2021-01-18 20:25:27 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_underscore/test.src-label.label
2021-01-18 20:25:27 | INFO | fairseq.tasks.translation | ./postprocessed/en_underscore test src-label 2024 examples
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-1.6851412057876587	
D-1685	-1.6851412057876587	
P-1685	-2.9298 -0.4404
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.8187223672866821	
D-664	-0.8187223672866821	
P-664	-1.3804 -0.2570
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.410512775182724	▁EH
D-1528	-0.410512775182724	EH
P-1528	-0.6183 -0.3194 -0.2938
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-0.9624744653701782	
D-1451	-0.9624744653701782	
P-1451	-1.5683 -0.3566
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.3609037697315216	
D-133	-0.3609037697315216	
P-133	-0.5632 -0.1586
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.7574038505554199	▁Clinic al
D-228	-0.7574038505554199	Clinical
P-228	-1.9850 -0.0788 -0.8258 -0.1400
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-0.8676269054412842	▁d XA
D-1496	-0.8676269054412842	dXA
P-1496	-0.8207 -0.3889 -1.9849 -0.2760
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.4168274998664856	▁FM
D-18	-0.4168274998664856	FM
P-18	-0.6524 -0.4554 -0.1427
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf pna
H-1699	-0.762811005115509	▁ HF ▁p na
D-1699	-0.762811005115509	HF pna
P-1699	-1.4805 -0.8122 -0.6171 -1.2534 -0.2982 -0.1155
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.44576922059059143	▁molecular _ ▁mechanism
D-1607	-0.44576922059059143	molecular_ mechanism
P-1607	-0.3107 -1.2570 -0.1190 -0.3458 -0.1963
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.9121989011764526	
D-307	-0.9121989011764526	
P-307	-1.5721 -0.2523
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal_artery_stenosis
H-1592	-0.4372498095035553	▁Ren al _ ▁arter y _ ▁sten osis
D-1592	-0.4372498095035553	Renal_ artery_ stenosis
P-1592	-0.1101 -0.2028 -1.0467 -0.1301 -0.4395 -0.9292 -0.9551 -0.0180 -0.3193 -0.2216
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise cardiovascular health
H-1897	-1.3343313932418823	▁exercise ▁cardiovascular _ ▁health
D-1897	-1.3343313932418823	exercise cardiovascular_ health
P-1897	-3.2598 -0.1449 -1.3651 -2.5230 -0.4345 -0.2789
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-1.188187599182129	▁tertia ry _ ▁refer ral ▁centre
D-1497	-1.188187599182129	tertiary_ referral centre
P-1497	-1.7419 -1.6170 -0.6110 -1.5797 -0.1499 -3.0685 -0.3971 -0.3404
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart_failure
H-1066	-1.1247406005859375	▁devices ▁heart ▁failure
D-1066	-1.1247406005859375	devices heart failure
P-1066	-2.3207 -2.0947 -0.6493 -0.2666 -0.2923
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse_events
H-1916	-1.1469659805297852	
D-1916	-1.1469659805297852	
P-1916	-1.8454 -0.4485
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver_disease
H-233	-0.5138041973114014	▁Live r ▁disease ▁adults
D-233	-0.5138041973114014	Liver disease adults
P-233	-0.3913 -0.1100 -0.6032 -1.6363 -0.1653 -0.1767
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary_end_point inhospital mortality
H-190	-0.7600236535072327	▁in hospital _ ▁mortal ity
D-190	-0.7600236535072327	inhospital_ mortality
P-190	-0.6467 -0.1249 -1.3125 -0.0962 -2.3925 -0.3844 -0.3629
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective_cohort_study
H-1712	-0.7253986597061157	▁DESIGN ▁Retro spec tive _ co hor t
D-1712	-0.7253986597061157	DESIGN Retrospective_cohort
P-1712	-1.9481 -1.2447 -0.0159 -0.8828 -0.3019 -0.2206 -0.3353 -0.5272 -1.5154 -0.2621
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute_care_surgery heart_transplant
H-1279	-1.3977996110916138	▁heart ▁transplant ▁recipient s
D-1279	-1.3977996110916138	heart transplant recipients
P-1279	-5.1618 -0.7265 -0.9083 -0.9381 -0.4105 -0.2415
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-0.7265377044677734	▁ec
D-256	-0.7265377044677734	ec
P-256	-1.2850 -0.7156 -0.1790
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic_breathing heart_beat
H-1345	-0.8271722197532654	▁breath ing ▁heart ▁beat
D-1345	-0.8271722197532654	breathing heart beat
P-1345	-2.4480 -0.2114 -1.5333 -0.1378 -0.4211 -0.2114
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational_cohort_study
H-811	-0.9862276315689087	▁DESIGN
D-811	-0.9862276315689087	DESIGN
P-811	-1.6947 -0.9626 -0.3013
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective_cohort
H-211	-0.4679551422595978	▁Retro spec tive _ co hor t
D-211	-0.4679551422595978	Retrospective_cohort
P-211	-1.5977 -0.0130 -0.6044 -0.2351 -0.2642 -0.2459 -0.4227 -0.5110 -0.3177
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart_failure latin_america
H-1788	-0.6289680600166321	▁heart _ ▁failure ▁Latin ▁America
D-1788	-0.6289680600166321	heart_ failure Latin America
P-1788	-1.8199 -1.2955 -0.2019 -0.2909 -0.3341 -0.2649 -0.1957
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.7166299819946289	
D-1982	-0.7166299819946289	
P-1982	-1.2059 -0.2273
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.5902156233787537	▁ HF
D-346	-0.5902156233787537	HF
P-346	-1.2068 -0.5048 -0.4318 -0.2175
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.9819453954696655	
D-589	-0.9819453954696655	
P-589	-1.7210 -0.2429
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.7213014364242554	
D-796	-0.7213014364242554	
P-796	-1.0740 -0.3686
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.3272451162338257	
D-1944	-0.3272451162338257	
P-1944	-0.4908 -0.1637
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate_models
H-241	-0.5238921642303467	
D-241	-0.5238921642303467	
P-241	-0.7294 -0.3184
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.47326236963272095	▁doctor s
D-1686	-0.47326236963272095	doctors
P-1686	-0.9771 -0.2733 -0.4922 -0.1505
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.9091220498085022	
D-44	-0.9091220498085022	
P-44	-1.4847 -0.3335
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-1.2278785705566406	
D-1846	-1.2278785705566406	
P-1846	-2.0713 -0.3845
S-422	Heart rate was minimally altered.<unk>
T-422	heart_rate
H-422	-0.8296968936920166	▁Heart _ ▁rate
D-422	-0.8296968936920166	Heart_ rate
P-422	-0.2164 -2.2312 -0.6129 -0.7744 -0.3136
S-1620	SETTING: Northwest United States.<unk>
T-1620	united_states
H-1620	-0.5049323439598083	▁North west _ ▁United ▁States
D-1620	-0.5049323439598083	Northwest_ United States
P-1620	-2.1313 -0.0070 -0.2875 -0.3487 -0.2894 -0.2912 -0.1795
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart_failure
H-1356	-0.5444968342781067	▁Nutrition ▁heart ▁failure
D-1356	-0.5444968342781067	Nutrition heart failure
P-1356	-0.8337 -0.8366 -0.6584 -0.2037 -0.1902
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-0.7048566937446594	▁DESIGN
D-795	-0.7048566937446594	DESIGN
P-795	-1.4319 -0.3798 -0.3029
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.4393133521080017	▁unilateral
D-1595	-0.4393133521080017	unilateral
P-1595	-0.3237 -0.6349 -0.3593
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.6992477178573608	▁surgery
D-363	-0.6992477178573608	surgery
P-363	-1.6295 -0.2854 -0.1829
S-1683	She is going into heart failure.<unk>
T-1683	heart_failure
H-1683	-0.6585579514503479	▁heart ▁failure
D-1683	-0.6585579514503479	heart failure
P-1683	-1.0384 -1.0160 -0.3367 -0.2432
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.6791555881500244	▁INTER ven TIONS
D-798	-0.6791555881500244	INTERvenTIONS
P-798	-0.7306 -0.7100 -1.2788 -0.5125 -0.1637
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.40632250905036926	
D-1249	-0.40632250905036926	
P-1249	-0.4099 -0.4028
S-979	Heart failure in the young.<unk>
T-979	heart_failure
H-979	-0.4578682482242584	▁Heart ▁failure
D-979	-0.4578682482242584	Heart failure
P-979	-0.1308 -1.1306 -0.3431 -0.2270
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.6236035823822021	
D-1687	-0.6236035823822021	
P-1687	-1.0061 -0.2411
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.31165429949760437	▁c lin
D-1246	-0.31165429949760437	clin
P-1246	-0.4509 -0.2991 -0.3201 -0.1766
S-1248	Sci.<unk>
T-1248	
H-1248	-0.767257571220398	▁Sci
D-1248	-0.767257571220398	Sci
P-1248	-0.1916 -1.8427 -0.2674
S-1247	Trans.<unk>
T-1247	
H-1247	-1.073353886604309	▁trans
D-1247	-1.073353886604309	trans
P-1247	-0.3734 -2.6129 -0.2338
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end_point
H-1763	-0.37796810269355774	
D-1763	-0.37796810269355774	
P-1763	-0.5533 -0.2026
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.7150740027427673	
D-392	-0.7150740027427673	
P-392	-1.1840 -0.2462
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.38983720541000366	▁inter media te _ fra il ty
D-1005	-0.38983720541000366	intermediate_frailty
P-1005	-0.9434 -0.4042 -0.1339 -0.1217 -0.7854 -0.2387 -0.3124 -0.3508 -0.2183
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.602615237236023	
D-1963	-0.602615237236023	
P-1963	-0.8594 -0.3459
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.7862637639045715	▁CHF
D-222	-0.7862637639045715	CHF
P-222	-0.1876 -1.9923 -0.1789
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.32165107131004333	▁do d son
D-205	-0.32165107131004333	dodson
P-205	-0.3083 -0.0601 -0.0087 -1.1337 -0.0974
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.9647548794746399	
D-575	-0.9647548794746399	
P-575	-1.6943 -0.2352
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.8105764985084534	
D-126	-0.8105764985084534	
P-126	-1.3164 -0.3048
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air heart_failure
H-1805	-0.4650059938430786	▁air ▁pollution ▁heart ▁failure
D-1805	-0.4650059938430786	air pollution heart failure
P-1805	-0.2302 -0.8815 -0.3728 -0.7237 -0.3242 -0.2577
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients cardiovascular_disease
H-247	-1.126814365386963	▁function ▁cardiovascular ▁disease
D-247	-1.126814365386963	function cardiovascular disease
P-247	-2.2150 -0.4950 -2.2467 -0.4420 -0.2353
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients followed_up
H-825	-0.5955926775932312	
D-825	-0.5955926775932312	
P-825	-0.9749 -0.2163
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective_matched_cohort_study
H-1619	-1.0253063440322876	
D-1619	-1.0253063440322876	
P-1619	-1.7472 -0.3034
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal_support
H-1296	-0.38882723450660706	▁extra corp o real
D-1296	-0.38882723450660706	extracorporeal
P-1296	-0.7200 -0.0289 -0.5060 -0.0341 -0.9299 -0.1141
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf mi
H-1101	-0.7669506072998047	▁temporal _ trend s ▁ HF ▁MI
D-1101	-0.7669506072998047	temporal_trends HF MI
P-1101	-2.2741 -0.6384 -0.4015 -0.0488 -0.9122 -0.3714 -1.1800 -0.8050 -0.2711
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart_failure disease therapeutics
H-1073	-0.6780073046684265	▁Heart ▁failure ▁disease
D-1073	-0.6780073046684265	Heart failure disease
P-1073	-0.2429 -0.7160 -1.1612 -1.0869 -0.1831
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary_outcomes hemostasis
H-1116	-0.592826247215271	▁hemos tas is
D-1116	-0.592826247215271	hemostasis
P-1116	-1.8265 -0.4455 -0.1571 -0.3086 -0.2265
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote_ischemic_conditioning patients heart_failure
H-53	-0.877514123916626	▁remote _ ische mic _ condition ing ▁heart _ ▁failure
D-53	-0.877514123916626	remote_ischemic_conditioning heart_ failure
P-53	-1.5170 -0.7880 -0.0998 -0.7690 -0.1770 -0.8343 -0.0368 -3.6984 -1.8061 -0.2223 -0.3580 -0.2235
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart_rate_variability risk_stratification cardiac patients
H-1584	-1.0084530115127563	▁Heart _ ▁rate _ ▁variabil ity ▁cardiac _ ▁patients
D-1584	-1.0084530115127563	Heart_ rate_ variability cardiac_ patients
P-1584	-0.2485 -1.1450 -2.0346 -1.6361 -0.1596 -1.9328 -0.6943 -1.4469 -0.9620 -0.4432 -0.3901
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart_failure
H-1886	-0.9744847416877747	▁Heart ▁failure ▁UK
D-1886	-0.9744847416877747	Heart failure UK
P-1886	-0.8638 -1.3623 -2.0338 -0.3391 -0.2734
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.7811006307601929	
D-1754	-0.7811006307601929	
P-1754	-1.2764 -0.2858
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.48359039425849915	▁CHF
D-673	-0.48359039425849915	CHF
P-673	-0.7745 -0.4652 -0.2111
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-1.4528224468231201	▁Comp liance ▁treatment
D-749	-1.4528224468231201	Compliance treatment
P-749	-3.8576 -0.5446 -2.4896 -0.2450 -0.1273
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.6724991798400879	▁Sham - opera ted _ animal
D-1339	-0.6724991798400879	Sham-operated_animal
P-1339	-0.2682 -0.4951 -0.0335 -0.4366 -0.4687 -1.6463 -1.5951 -0.4367
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-1.0742393732070923	▁policy
D-312	-1.0742393732070923	policy
P-312	-1.2582 -1.8428 -0.1217
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.357852041721344	
D-311	-0.357852041721344	
P-311	-0.5199 -0.1959
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.6818935871124268	
D-885	-0.6818935871124268	
P-885	-1.1332 -0.2306
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.7183253169059753	▁de script ive _ onderzoek
D-1399	-0.7183253169059753	descriptive_onderzoek
P-1399	-0.6989 -0.5150 -0.2867 -0.5429 -1.5446 -1.0972 -0.3429
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-1.2905105352401733	▁tax ono my
D-1125	-1.2905105352401733	taxonomy
P-1125	-4.3081 -0.1170 -1.2767 -0.5649 -0.1859
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse_events
H-1988	-0.5617982745170593	
D-1988	-0.5617982745170593	
P-1988	-0.9056 -0.2180
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin injected
H-957	-0.33122602105140686	▁do xor ubi cin ▁inject ed
D-957	-0.33122602105140686	doxorubicin injected
P-957	-0.2800 -0.0106 -0.0154 -0.2855 -0.8690 -0.5234 -0.4252 -0.2407
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting cell anand
H-1037	-0.12309108674526215	▁Cell ▁Anand
D-1037	-0.12309108674526215	Cell Anand
P-1037	-0.2063 -0.0026 -0.1883 -0.0952
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox_proportional_hazards_models
H-712	-0.5805101990699768	▁co x _ ▁proportion al _ ▁hazard s
D-712	-0.5805101990699768	cox_ proportional_ hazards
P-712	-0.3721 -0.2772 -0.8180 -0.5081 -0.1671 -0.1187 -1.3599 -0.9338 -0.9892 -0.2611
S-949	No major complications occurred during follow-up.<unk>
T-949	complications follow-up
H-949	-0.31000325083732605	▁follow - up
D-949	-0.31000325083732605	follow-up
P-949	-0.7533 -0.3353 -0.0233 -0.2390 -0.1991
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient hf
H-364	-0.7540240287780762	▁ HF
D-364	-0.7540240287780762	HF
P-364	-2.1510 -0.2454 -0.3625 -0.2572
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors blood_transfusions
H-1684	-1.1094177961349487	▁doctor s ▁blood ▁trans fusion s
D-1684	-1.1094177961349487	doctors blood transfusions
P-1684	-3.5105 -1.3600 -1.7135 -0.3279 -0.0210 -0.8222 -0.7237 -0.3965
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart_failure patients bisphosphonates
H-1534	-0.5297930836677551	▁Heart _ ▁failure ▁bis phos phon ates
D-1534	-0.5297930836677551	Heart_ failure bisphosphonates
P-1534	-0.2452 -2.6252 -0.0390 -0.2309 -0.0267 -0.4176 -0.4993 -0.5143 -0.1699
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic heart_failure outcomes
H-1198	-1.1095300912857056	▁di ure tic ▁heart ▁failure
D-1198	-1.1095300912857056	diuretic heart failure
P-1198	-0.8399 -0.6220 -1.1453 -3.5049 -1.1151 -0.3451 -0.1944
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 gene_expression heart_failure
H-169	-0.8577945828437805	▁Cas pas e -3 _ ▁gene _ expression ▁heart ▁failure
D-169	-0.8577945828437805	Caspase-3_ gene_expression heart failure
P-169	-0.1066 -0.0054 -0.1324 -1.3037 -3.8283 -0.3577 -1.6901 -0.1883 -0.7795 -1.2741 -0.3587 -0.2686
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute_right_heart_failure pulmonary_hypertension
H-1090	-0.5414488315582275	▁right _ ▁heart ▁failure ▁pulmonar y _ ▁hyper tension
D-1090	-0.5414488315582275	right_ heart failure pulmonary_ hypertension
P-1090	-1.3494 -0.2066 -1.6239 -0.8004 -0.0009 -0.0481 -0.5517 -0.9659 -0.0358 -0.2138 -0.1596
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise cardiovascular
H-1900	-1.1855976581573486	▁benefits ▁cardiovascular _ system
D-1900	-1.1855976581573486	benefits cardiovascular_system
P-1900	-1.3811 -2.6517 -1.3289 -1.0351 -0.5433 -0.1735
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american hf
H-1843	-1.160525918006897	▁ europe se _ HF
D-1843	-1.160525918006897	europese_HF
P-1843	-1.8207 -3.6302 -0.0412 -0.2969 -1.4947 -0.7367 -0.1033
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.5876781344413757	▁Interna l _ ▁reli ability ▁Cro n bach
D-786	-0.5876781344413757	Internal_ reliability Cronbach
P-786	-0.5598 -0.0844 -0.5331 -2.0536 -0.2821 -0.3413 -0.0628 -0.0336 -1.7651 -0.1609
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients hypertension
H-1889	-1.1071205139160156	▁hyper tension
D-1889	-1.1071205139160156	hypertension
P-1889	-3.7781 -0.1334 -0.2862 -0.2308
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-1.0482109785079956	▁gene s
D-1616	-1.0482109785079956	genes
P-1616	-3.0776 -0.2489 -0.7091 -0.1573
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.6805720329284668	▁Literatur e
D-32	-0.6805720329284668	Literature
P-32	-1.9647 -0.2485 -0.3530 -0.1560
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.5578977465629578	
D-804	-0.5578977465629578	
P-804	-0.9149 -0.2009
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths strokes
H-778	-0.8056911826133728	▁per i pro ced ural ▁stroke s
D-778	-0.8056911826133728	periprocedural strokes
P-778	-1.3372 -0.1237 -0.2097 -0.0097 -0.0267 -5.1465 -0.0963 -0.1950 -0.1063
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty heart_failure
H-1000	-0.733465313911438	▁fra il ty ▁heart _ ▁failure
D-1000	-0.733465313911438	frailty heart_ failure
P-1000	-0.5765 -0.6411 -0.1497 -1.7834 -1.5299 -0.0702 -0.8442 -0.2726
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea afterload
H-518	-2.0374255180358887	▁HR ▁Ea
D-518	-2.0374255180358887	HR Ea
P-518	-3.6074 -3.1020 -1.2412 -0.1990
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.9792768359184265	▁treatment s
D-1469	-0.9792768359184265	treatments
P-1469	-2.8291 -0.3846 -0.5417 -0.1617
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard_ratios cox_regression_analysis
H-1770	-0.5951381325721741	▁Hazard _ ▁ratio s ▁co x ▁re gression _ analyse
D-1770	-0.5951381325721741	Hazard_ ratios cox regression_analyse
P-1770	-0.4136 -1.6790 -0.3933 -0.1688 -0.1456 -0.3829 -0.9687 -0.0746 -1.9946 -0.2080 -0.4580 -0.2547
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras atherosclerosis
H-1594	-1.2598021030426025	RAS ▁at hero sc ler osis
D-1594	-1.2598021030426025	RAS atherosclerosis
P-1594	-0.7157 -3.7815 -0.6108 -0.0655 -4.3131 -0.0812 -0.3299 -0.1807
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient conditions
H-0	-1.3484296798706055	▁patient _ ▁safety
D-0	-1.3484296798706055	patient_ safety
P-0	-2.0985 -2.3714 -1.4298 -0.4447 -0.3978
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss exercise training outcomes
H-1932	-0.9422765970230103	▁PS SS ▁exercise _ training
D-1932	-0.9422765970230103	PSSS exercise_training
P-1932	-1.1221 -0.9296 -2.0165 -1.4061 -0.1684 -0.7301 -0.2231
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas heart_failure disease
H-1479	-0.3899800777435303	▁micro RNA s ▁heart ▁failure ▁disease ▁management
D-1479	-0.3899800777435303	microRNAs heart failure disease management
P-1479	-0.2260 -0.0368 -0.1047 -0.8995 -1.0324 -0.1892 -0.6070 -0.2695 -0.1446
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise quality_of_life heart_failure
H-612	-1.8316774368286133	▁exercise ▁heart ▁failure
D-612	-1.8316774368286133	exercise heart failure
P-612	-3.6452 -3.5871 -1.2496 -0.4565 -0.2200
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology bromodomain halts heart_failure
H-1033	-0.40938669443130493	▁Card i ology ▁bro modo main ▁inhibi tion ▁heart ▁failure
D-1033	-0.40938669443130493	Cardiology bromodomain inhibition heart failure
P-1033	-0.5280 -0.3998 -0.0921 -0.7471 -0.0038 -0.0417 -0.9199 -0.1580 -1.0342 -0.6076 -0.2613 -0.1193
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart_failure_with_preserved_ejection_fraction
H-1885	-0.48111552000045776	▁management ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-1885	-0.48111552000045776	management heart failure preserved_ejection_fraction
P-1885	-0.7686 -1.2038 -1.0920 -1.2145 -0.1078 -0.6122 -0.3973 -0.3771 -0.1467 -0.0831 -0.1560 -0.0401 -0.3387 -0.1979
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.4855024218559265	▁implant ed _ monitor ing ▁devices
D-156	-0.4855024218559265	implanted_monitoring devices
P-156	-0.5506 -0.3001 -0.2133 -0.1018 -0.5254 -1.6953 -0.3379 -0.1597
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.9939145445823669	▁media n _ âge
D-677	-0.9939145445823669	median_âge
P-677	-2.4435 -0.0999 -0.4139 -1.8956 -0.8652 -0.2453
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.42962366342544556	▁AT
D-1759	-0.42962366342544556	AT
P-1759	-0.5415 -0.4921 -0.2553
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart_failure mortality
H-204	-0.6024720072746277	▁Heart _ ▁failure ▁cognitive _ ▁im pair ment ▁mortal ity
D-204	-0.6024720072746277	Heart_ failure cognitive_ impairment mortality
P-204	-0.1838 -1.5767 -0.0370 -0.1322 -0.5236 -1.8636 -0.0165 -0.1665 -0.9663 -1.3732 -0.2154 -0.1749
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv_fibrosis
H-280	-0.3737419545650482	▁LV ▁fibro sis ▁ ANS _ mi ce
D-280	-0.3737419545650482	LV fibrosis ANS_mice
P-280	-0.0876 -0.5188 -0.1192 -1.7511 -0.1874 -0.2777 -0.2218 -0.1941 -0.2518 -0.1278
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology hospital
H-812	-1.0931588411331177	▁card i ology ▁hospital
D-812	-1.0931588411331177	cardiology hospital
P-812	-1.5770 -0.5573 -0.1475 -3.8132 -0.3184 -0.1456
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.5596991181373596	▁ HF p EF
D-1078	-0.5596991181373596	HFpEF
P-1078	-1.8836 -0.3232 -0.0277 -0.3814 -0.6276 -0.1147
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf hf
H-1309	-1.015722632408142	current _ HF ▁incident _ HF
D-1309	-1.015722632408142	current_HF incident_HF
P-1309	-1.7023 -0.2553 -1.0959 -2.0944 -0.6215 -1.0869 -1.0120 -0.2576
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic_balance
H-1375	-0.5951732993125916	▁autonomi c _ ▁balance
D-1375	-0.5951732993125916	autonomic_ balance
P-1375	-0.8220 -0.3734 -0.2628 -1.3270 -0.5270 -0.2589
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty hf
H-624	-0.6819159388542175	▁fra il ty ▁ HF
D-624	-0.6819159388542175	frailty HF
P-624	-1.8904 -0.4915 -0.1932 -0.9877 -0.1826 -0.8220 -0.2061
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient hospital heart_failure
H-1960	-1.5435616970062256	▁heart ▁failure
D-1960	-1.5435616970062256	heart failure
P-1960	-4.4908 -1.1009 -0.3580 -0.2245
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 functional_capacity
H-702	-1.526403784751892	▁ST 2 ▁functional
D-702	-1.526403784751892	ST2 functional
P-702	-2.3855 -0.6323 -0.3435 -4.0426 -0.2281
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient medical conditions
H-1688	-1.1868300437927246	▁in patient ▁medical
D-1688	-1.1868300437927246	inpatient medical
P-1688	-1.1175 -0.0156 -2.2411 -2.2657 -0.2942
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral_stenosis medical_treatment heart_failure
H-332	-1.212502121925354	▁mit ral _ ▁sten osis ▁medical _ ▁treatment ▁heart ▁failure
D-332	-1.212502121925354	mitral_ stenosis medical_ treatment heart failure
P-332	-1.2388 -0.0669 -0.5768 -2.1347 -0.0258 -4.1362 -2.1702 -1.3382 -0.7199 -1.4596 -0.4394 -0.2436
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up_duration
H-495	-0.38408175110816956	▁follow - up
D-495	-0.38408175110816956	follow-up
P-495	-0.7546 -0.3458 -0.0374 -0.5963 -0.1863
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral_growth
H-511	-1.4198917150497437	▁competitive ▁col lateral
D-511	-1.4198917150497437	competitive collateral
P-511	-2.4230 -2.1086 -0.0046 -2.3274 -0.2358
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated mixed_linear_models
H-325	-0.6666975021362305	▁co ▁mix ed _ ▁linear _ ▁models
D-325	-0.6666975021362305	co mixed_ linear_ models
P-325	-2.3178 -0.7642 -0.0660 -0.0660 -0.3862 -0.7366 -0.5135 -0.8663 -0.2836
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart_failure hospitalization cardiovascular_death
H-410	-1.1556769609451294	▁heart ▁failure ▁hospital ization ▁cardiovascular _ ▁death
D-410	-1.1556769609451294	heart failure hospitalization cardiovascular_ death
P-410	-1.1464 -0.9393 -4.2014 -1.3314 -0.0343 -1.3086 -0.9363 -0.3203 -0.1830
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary_outcomes quality_of_life
H-1654	-1.097373366355896	▁cognitive _ function
D-1654	-1.097373366355896	cognitive_function
P-1654	-0.3685 -1.0790 -1.4069 -2.2506 -0.3818
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin congestive_heart_failure
H-633	-0.6285377740859985	▁vaso press in ▁con ges tive _ heart ▁failure
D-633	-0.6285377740859985	vasopressin congestive_heart failure
P-633	-0.0994 -0.3127 -0.6413 -0.0970 -0.0972 -2.2257 -0.0660 -2.3080 -0.6251 -0.3034 -0.1382
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended_criteria_cardiac_transplantation
H-707	-0.6611647009849548	▁cardiac _ ▁transplant ation
D-707	-0.6611647009849548	cardiac_ transplantation
P-707	-0.3814 -1.9477 -0.6183 -0.2888 -0.4798 -0.2510
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness anemia
H-1679	-1.3878364562988281	▁Jehovah s _ ▁Wit ness ▁an emia
D-1679	-1.3878364562988281	Jehovahs_ Witness anemia
P-1679	-0.0500 -5.7364 -0.2448 -0.8475 -1.8638 -2.6135 -0.2562 -0.5705 -0.3078
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 hf
H-1211	-0.3797570466995239	▁p de 2 ▁ HF
D-1211	-0.3797570466995239	pde2 HF
P-1211	-0.6406 -0.2359 -0.0413 -0.8460 -0.5299 -0.2246 -0.1400
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.5324898362159729	▁Res idu al _ con found ing ▁follow - up
D-1839	-0.5324898362159729	Residual_confounding follow-up
P-1839	-4.3778 -0.0746 -0.0703 -0.2988 -0.6493 -0.0439 -0.0274 -0.4127 -0.1138 -0.0241 -0.1669 -0.1302
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.8903871774673462	
D-1998	-0.8903871774673462	
P-1998	-1.5269 -0.2539
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-1.0090163946151733	▁black _ ▁patients
D-1634	-1.0090163946151733	black_ patients
P-1634	-0.7459 -1.8327 -1.8005 -0.3498 -0.3162
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.5938413143157959	
D-1261	-0.5938413143157959	
P-1261	-0.9198 -0.2678
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.7096086740493774	▁ metric _ ▁choice ▁read mission _ ▁metri cs
D-134	-0.7096086740493774	metric_ choice readmission_ metrics
P-134	-0.4145 -0.2628 -0.8997 -0.5327 -0.3664 -2.6128 -0.6711 -0.8895 -0.4696 -0.4408 -0.2456
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-0.9843242764472961	▁mechanism ▁eg ▁CHF
D-261	-0.9843242764472961	mechanism eg CHF
P-261	-0.4062 -3.5668 -0.3775 -0.3360 -0.2351
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.8042468428611755	▁read mission ▁ metric
D-145	-0.8042468428611755	readmission metric
P-145	-0.4653 -2.2359 -1.0111 -0.0257 -0.9344 -0.1531
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-1.1073479652404785	
D-958	-1.1073479652404785	
P-958	-2.0201 -0.1946
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician hospital physician
H-1726	-1.2414730787277222	▁physician _ ▁volume ▁hospital
D-1726	-1.2414730787277222	physician_ volume hospital
P-1726	-0.7548 -1.8299 -0.1108 -1.2589 -3.1398 -0.3545
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.5535934567451477	▁media n ▁follow - up
D-1758	-0.5535934567451477	median follow-up
P-1758	-1.4108 -0.2353 -1.3446 -0.3889 -0.0142 -0.2797 -0.2016
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs expenditures
H-1238	-0.6203103065490723	▁ar rhythm ia - related _ kosten ▁ex pendi tures
D-1238	-0.6203103065490723	arrhythmia-related_kosten expenditures
P-1238	-0.7069 -0.3323 -0.7780 -0.1312 -0.3515 -1.2911 -1.4676 -0.7978 -0.0625 -0.7581 -0.5476 -0.2189
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication sst2
H-403	-0.7370105981826782	▁Medica tion ▁regime n ▁s ST 2
D-403	-0.7370105981826782	Medication regimen sST2
P-403	-0.4039 -0.2046 -1.6746 -0.3953 -0.0035 -2.2356 -0.2241 -1.3194 -0.1722
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable_hf
H-481	-0.6612192988395691	▁ HF
D-481	-0.6612192988395691	HF
P-481	-1.8465 -0.3675 -0.2991 -0.1317
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality sts
H-159	-1.3185540437698364	▁s ts _ HM
D-159	-1.3185540437698364	sts_HM
P-159	-3.2084 -1.7657 -1.0119 -1.0943 -0.5228 -0.3082
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-1.1319150924682617	▁ STU DY _ ▁DESIGN
D-150	-1.1319150924682617	STUDY_ DESIGN
P-150	-3.2150 -0.4546 -0.2501 -2.0107 -0.4522 -1.4006 -0.1401
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.535024106502533	▁pro pens ity
D-1837	-0.535024106502533	propensity
P-1837	-0.3855 -0.0694 -1.5188 -0.5221 -0.1793
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed mortality random-effects_models
H-64	-1.0833946466445923	▁mortal iteit
D-64	-1.0833946466445923	mortaliteit
P-64	-0.5059 -2.1554 -1.3240 -0.3483
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary_outcomes functional_capacity quality_of_life
H-616	-1.2964879274368286	▁functional _ ▁capacity
D-616	-1.2964879274368286	functional_ capacity
P-616	-0.2187 -2.1634 -2.2621 -1.6053 -0.2330
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end_point
H-266	-0.5669869184494019	
D-266	-0.5669869184494019	
P-266	-0.9764 -0.1576
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical hypothermic_circulatory_arrest
H-598	-0.9469125866889954	▁Sur g ical _ ▁tac tics ▁circula tory _ ▁arrest
D-598	-0.9469125866889954	Surgical_ tactics circulatory_ arrest
P-598	-3.6614 -1.0958 -1.0811 -0.4094 -0.1493 -0.3673 -2.8483 -0.5847 -0.2389 -0.4034 -0.3227 -0.2005
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf patients intubated
H-219	-0.4112383723258972	▁CHF ▁in tuba ted
D-219	-0.4112383723258972	CHF intubated
P-219	-0.0257 -1.5981 -0.0709 -0.2586 -0.3866 -0.1275
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection_fraction bnp
H-194	-0.37037280201911926	▁e je ction _ fraction ▁sex ▁b NP
D-194	-0.37037280201911926	ejection_fraction sex bNP
P-194	-0.6984 -0.0606 -0.0084 -0.6021 -0.1197 -0.5726 -0.7908 -0.4407 -0.2390 -0.1713
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic_hf death
H-1796	-0.3161153793334961	▁Chro nic _ HF
D-1796	-0.3161153793334961	Chronic_HF
P-1796	-0.0318 -0.1471 -0.0700 -0.5476 -0.9390 -0.1612
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology diagnosed
H-352	-0.3472680449485779	▁et i ology ▁MR ▁MS
D-352	-0.3472680449485779	etiology MR MS
P-352	-1.1489 -0.1095 -0.0778 -0.1441 -0.2149 -0.6413 -0.0943
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients hfpef
H-787	-0.4726492464542389	▁ HF p EF
D-787	-0.4726492464542389	HFpEF
P-787	-1.2139 -0.4935 -0.0645 -0.4610 -0.3659 -0.2371
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac_amyloidosis
H-997	-0.2271343469619751	▁Card iac _ a my lo idos is
D-997	-0.2271343469619751	Cardiac_amyloidosis
P-997	-0.3110 -0.0112 -0.5451 -0.3167 -0.4927 -0.0422 -0.0987 -0.1602 -0.1877 -0.1058
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic medication death
H-507	-0.4601419270038605	▁Pig s ▁anti ar rhythm ic _ ▁medication
D-507	-0.4601419270038605	Pigs antiarrhythmic_ medication
P-507	-0.4589 -0.1408 -0.0515 -0.3096 -0.0714 -0.0584 -1.8332 -0.1543 -1.2914 -0.2319
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training heart_failure patients
H-1911	-0.825843334197998	▁Robot - assist ed _ training ▁heart ▁failure _ ▁patients
D-1911	-0.825843334197998	Robot-assisted_training heart failure_ patients
P-1911	-1.0915 -0.4576 -0.0237 -0.2087 -0.7591 -0.2871 -2.1275 -1.0208 -2.3399 -0.9420 -0.3545 -0.2976
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients functional_capacity symptoms
H-550	-1.0239943265914917	▁functional _ capaci te
D-550	-1.0239943265914917	functional_capacite
P-550	-1.1130 -1.7185 -0.7219 -1.1507 -1.2839 -0.1560
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up patients
H-1009	-0.6355551481246948	
D-1009	-0.6355551481246948	
P-1009	-1.0785 -0.1926
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic biomarkers chronic_heart_failure
H-1471	-0.40465888381004333	▁bio mark ers ▁chronic _ heart ▁failure
D-1471	-0.40465888381004333	biomarkers chronic_heart failure
P-1471	-0.0718 -0.1727 -0.1500 -0.4481 -0.0937 -1.2841 -1.0445 -0.2229 -0.1542
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart_rate arterial_pressure
H-424	-0.6000566482543945	▁Heart _ ▁rate ▁arterial _ ▁pressure
D-424	-0.6000566482543945	Heart_ rate arterial_ pressure
P-424	-0.3123 -1.7342 -0.4603 -0.1097 -0.3864 -1.2393 -0.4190 -0.1394
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients therapy beta_blockade
H-1736	-1.029146432876587	▁beta _ block ade
D-1736	-1.029146432876587	beta_blockade
P-1736	-3.6258 -1.0747 -0.8246 -0.0471 -0.4130 -0.1898
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb correlated baseline hrqol
H-840	-0.7611996531486511	▁h gb ▁level ▁HR Qo l
D-840	-0.7611996531486511	hgb level HRQol
P-840	-0.1567 -0.0036 -1.9745 -1.3393 -0.0128 -2.1258 -0.3279 -0.1490
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients cardiac inflammatory biomarkers
H-1914	-0.38323327898979187	▁cardiac ▁infla mma tory _ ▁bio mark ers
D-1914	-0.38323327898979187	cardiac inflammatory_ biomarkers
P-1914	-0.0745 -1.4471 -0.4230 -0.3008 -0.3458 -0.2563 -0.0869 -0.1804 -0.4231 -0.2944
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected patients systolic_dysfunction
H-1069	-0.31297633051872253	▁sy sto lic _ ▁dys function
D-1069	-0.31297633051872253	systolic_ dysfunction
P-1069	-0.4429 -0.2123 -0.3908 -0.3220 -0.3063 -0.1268 -0.5300 -0.1727
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved_ejection_fraction outcomes
H-1464	-0.7150442600250244	▁e je ction _ fraction
D-1464	-0.7150442600250244	ejection_fraction
P-1464	-1.1042 -0.1630 -0.1006 -0.6400 -0.2824 -2.4327 -0.2824
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated_hf cardiovascular hospitalization
H-1797	-0.6470257043838501	▁ HF ▁cardiovascular _ hospital ization
D-1797	-0.6470257043838501	HF cardiovascular_hospitalization
P-1797	-1.6301 -0.5206 -0.4745 -1.0258 -0.3228 -0.6330 -0.3380 -0.2314
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes patients heart_failure emergency_department
H-461	-1.57271409034729	▁heart _ ▁failure
D-461	-1.57271409034729	heart_ failure
P-461	-3.1931 -1.9781 -0.3135 -2.1431 -0.2357
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-2.1784801483154297	▁health care _ programm es
D-603	-2.1784801483154297	healthcare_programmes
P-603	-7.6734 -0.5406 -2.7444 -0.3065 -3.0648 -0.6686 -0.2510
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-1.0503082275390625	▁prognos tic _ ▁factors
D-591	-1.0503082275390625	prognostic_ factors
P-591	-1.2842 -1.7886 -1.2988 -1.3069 -0.3418 -0.2815
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.5623207688331604	
D-1923	-0.5623207688331604	
P-1923	-0.9018 -0.2228
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.8301979303359985	
D-800	-0.8301979303359985	
P-800	-1.5117 -0.1487
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.6010856032371521	▁ab normal _ ▁cardiac _ t 2
D-746	-0.6010856032371521	abnormal_ cardiac_t2
P-746	-0.4805 -0.0113 -0.2948 -0.1575 -0.2751 -1.7102 -0.0705 -2.2546 -0.1554
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug japan
H-1197	-0.7907091379165649	▁drug ▁Japan
D-1197	-0.7907091379165649	drug Japan
P-1197	-1.5286 -1.2289 -0.2394 -0.1659
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.8670915365219116	
D-1028	-0.8670915365219116	
P-1028	-1.6073 -0.1269
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-1.0579743385314941	
D-1206	-1.0579743385314941	
P-1206	-1.9176 -0.1983
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max significance
H-1255	-0.592717707157135	▁VO 2 max
D-1255	-0.592717707157135	VO2max
P-1255	-1.9257 -0.2345 -0.0794 -0.4875 -0.2365
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients esrd
H-394	-1.4834599494934082	▁ES RD
D-394	-1.4834599494934082	ESRD
P-394	-4.3581 -0.9231 -0.2579 -0.3948
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.21831101179122925	▁bio mark ers
D-70	-0.21831101179122925	biomarkers
P-70	-0.1192 -0.1023 -0.1299 -0.5366 -0.2036
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated hf
H-608	-0.5806524753570557	▁HR ▁ HF
D-608	-0.5806524753570557	HR HF
P-608	-0.2253 -1.8700 -0.1661 -0.4562 -0.1857
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome tug_test
H-799	-0.8178171515464783	▁m AIN _ o UTC OME _ me as URE ▁tu g
D-799	-0.8178171515464783	mAIN_oUTCOME_measURE tug
P-799	-1.2854 -0.1555 -0.1516 -0.9089 -0.0376 -0.0705 -2.1455 -0.3475 -0.0875 -0.4315 -0.7918 -3.3578 -1.5768 -0.1015
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart_failure
H-1204	-1.3195288181304932	▁heart _ ▁failure
D-1204	-1.3195288181304932	heart_ failure
P-1204	-3.3386 -2.1465 -0.4203 -0.5237 -0.1686
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.6225827932357788	
D-1854	-0.6225827932357788	
P-1854	-1.0055 -0.2396
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality_of_life
H-1919	-1.369720220565796	▁quality _ of _ ▁life
D-1919	-1.369720220565796	quality_of_ life
P-1919	-3.0832 -0.2600 -0.8392 -0.0758 -2.8019 -2.3244 -0.2036
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart_failure_with_preserved_left_ventricular_ejection_fraction
H-1299	-0.5607950687408447	▁Heart _ ▁failure ▁left _ ▁vent ri cular _ e je ction _ fraction
D-1299	-0.5607950687408447	Heart_ failure left_ ventricular_ejection_fraction
P-1299	-0.1496 -1.4988 -0.0345 -1.4163 -0.3779 -0.9770 -0.9285 -0.6349 -0.4189 -0.6174 -0.2323 -0.1819 -0.9244 -0.0259 -0.3922 -0.1623
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet aortic_pressure
H-581	-0.8560482859611511	▁l VET ▁a or tic _ ▁pressure _ ▁cur ve
D-581	-0.8560482859611511	lVET aortic_ pressure_ curve
P-581	-1.9241 -0.2217 -0.2380 -0.6106 -1.4118 -0.0620 -2.8621 -0.5579 -1.6203 -0.2157 -0.3476 -0.2007
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart_failure hf therapy
H-1067	-0.9438744187355042	▁Device s ▁heart ▁failure HF ▁ therapy
D-1067	-0.9438744187355042	Devices heart failureHF therapy
P-1067	-1.7167 -0.0780 -3.2837 -1.0329 -0.1435 -1.7322 -0.0285 -0.2780 -0.2014
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician outcomes discharge
H-1414	-1.1473474502563477	▁physician _ ▁continu ity
D-1414	-1.1473474502563477	physician_ continuity
P-1414	-0.6961 -2.2004 -0.5727 -0.9701 -2.1582 -0.2866
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart_failure public health
H-1606	-1.169950008392334	▁Heart _ ▁failure ▁public _ ▁health _ problem
D-1606	-1.169950008392334	Heart_ failure public_ health_problem
P-1606	-2.0578 -1.4933 -0.4345 -0.5225 -0.4024 -2.0982 -2.8486 -0.3319 -1.1468 -0.3636
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity patients breast_cancer
H-669	-0.7576220035552979	▁Tras tuz um ab - related _ ▁cardio toxic iteit ▁breast ▁cancer
D-669	-0.7576220035552979	Trastuzumab-related_ cardiotoxiciteit breast cancer
P-669	-0.4225 -0.1972 -0.1963 -1.1479 -0.2475 -0.8481 -0.3939 -0.2607 -0.9983 -2.3439 -1.4354 -1.4280 -0.4377 -0.2490
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital coprimary_outcome
H-1651	-1.1777751445770264	▁Night s ▁hospital
D-1651	-1.1777751445770264	Nights hospital
P-1651	-1.2003 -0.0903 -4.0201 -0.3373 -0.2409
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac symptoms congenital lesions
H-983	-0.8144068121910095	▁Card iac
D-983	-0.8144068121910095	Cardiac
P-983	-0.4657 -0.0381 -2.5876 -0.1663
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative albumin
H-539	-0.880481481552124	▁album in ▁level
D-539	-0.880481481552124	albumin level
P-539	-2.1470 -0.4988 -1.0574 -0.5686 -0.1306
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan vasopressin_type_2_receptor_antagonist
H-1195	-0.3517381548881531	▁Tol va p tan ▁vaso press in ▁receptor
D-1195	-0.3517381548881531	Tolvaptan vasopressin receptor
P-1195	-0.0885 -0.0338 -0.2231 -0.0238 -0.0549 -0.1248 -1.0934 -0.2671 -1.4119 -0.1959
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular_scaffolds heart pathology
H-989	-1.0870450735092163	▁e RK ▁molecular _ sc af fold s ▁heart _ path ology
D-989	-1.0870450735092163	eRK molecular_scaffolds heart_pathology
P-989	-2.3889 -0.0733 -2.1842 -0.5579 -2.2902 -3.2001 -1.1270 -0.1597 -0.7379 -0.7474 -0.6971 -0.3443 -0.3894 -0.3212
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional_ms reported patients degenerative_mr
H-339	-0.28930941224098206	▁Fun ction al _ ▁MS ▁de genera tive _ ▁MR
D-339	-0.28930941224098206	Functional_ MS degenerative_ MR
P-339	-0.1023 -0.0066 -0.0273 -0.5068 -0.5331 -0.0968 -0.0060 -0.4542 -0.5038 -0.5877 -0.5095 -0.1378
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart_failure hf leading mortality society
H-1034	-0.81568843126297	▁Heart ▁failure HF
D-1034	-0.81568843126297	Heart failureHF
P-1034	-0.3294 -0.7973 -0.2835 -2.4554 -0.2127
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone systolic_heart_failure
H-437	-0.25463128089904785	▁spi rono lac tone ▁sy sto lic _ heart ▁failure
D-437	-0.25463128089904785	spironolactone systolic_heart failure
P-437	-0.0488 -0.0106 -0.0314 -0.0359 -0.0359 -0.0707 -0.1637 -0.0777 -1.4476 -0.6361 -0.3258 -0.1712
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology chronic_heart_failure bisoprolol
H-645	-0.7220916748046875	▁chronic _ heart _ ▁failure ▁bis o pro lol
D-645	-0.7220916748046875	chronic_heart_ failure bisoprolol
P-645	-3.5647 -0.1952 -1.1942 -1.7626 -0.0705 -0.1507 -0.3824 -0.0354 -0.0571 -0.3861 -0.1440
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate_adjustment cox_proportional_hazards_models
H-785	-0.9721145629882812	▁co x ▁proportion al _ ▁hazard s
D-785	-0.9721145629882812	cox proportional_ hazards
P-785	-0.1396 -3.7556 -0.7591 -0.1551 -0.1270 -0.9567 -0.9174 -1.6251 -0.3135
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic hf
H-1072	-0.6286730170249939	▁stand - a lone _ Diagnos ▁devices ▁ HF
D-1072	-0.6286730170249939	stand-alone_Diagnos devices HF
P-1072	-0.5524 -0.1668 -0.1666 -0.0537 -0.0416 -1.6469 -1.7252 -1.7572 -0.4073 -0.2343 -0.1633
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician hf
H-1732	-0.9209195971488953	▁ HF
D-1732	-0.9209195971488953	HF
P-1732	-1.5251 -0.6528 -1.3486 -0.1572
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.5706925392150879	
D-1576	-0.5706925392150879	
P-1576	-0.8851 -0.2562
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.5574681162834167	▁ therapy
D-1965	-0.5574681162834167	therapy
P-1965	-1.5976 -0.1335 -0.2756 -0.2231
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient circulation
H-1824	-1.2920384407043457	▁circulation
D-1824	-1.2920384407043457	circulation
P-1824	-3.3084 -0.3470 -0.2207
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north_america
H-75	-0.8949088454246521	▁North ▁America
D-75	-0.8949088454246521	North America
P-75	-2.1451 -0.9360 -0.3571 -0.1414
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.9045862555503845	▁c PG s
D-1848	-0.9045862555503845	cPGs
P-1848	-3.1606 -0.6251 -0.0815 -0.4501 -0.2056
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.31246718764305115	▁MS ▁surgery
D-372	-0.31246718764305115	MS surgery
P-372	-0.6180 -0.2327 -0.2810 -0.1182
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis pathophysiological
H-1276	-0.8707936406135559	▁prognos is ▁pat ho phy si ological
D-1276	-0.8707936406135559	prognosis pathophysiological
P-1276	-2.5427 -0.0669 -0.6158 -0.2024 -0.4320 -2.1237 -0.4114 -1.3022 -0.1400
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity outcomes
H-709	-1.2688634395599365	
D-709	-1.2688634395599365	
P-709	-2.2917 -0.2460
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha esc
H-1908	-1.1427948474884033	AHA ▁ESC
D-1908	-1.1427948474884033	AHA ESC
P-1908	-0.4120 -2.6945 -1.2564 -0.2083
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income expenditure health
H-1792	-0.9263852834701538	▁gross _ ▁income ▁ex pendi ture ▁health _ ▁per ▁capita
D-1792	-0.9263852834701538	gross_ income expenditure health_ per capita
P-1792	-3.6260 -0.3358 -0.3802 -0.9125 -0.0417 -0.1795 -2.4900 -1.1868 -0.7659 -0.3333 -0.6207 -0.2442
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients heart_failure
H-1821	-1.5473675727844238	▁patients _ with _ heart ▁failure
D-1821	-1.5473675727844238	patients_with_heart failure
P-1821	-3.7022 -1.0521 -4.3313 -0.2347 -1.0945 -1.4501 -0.3670 -0.1470
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients lvad implantation
H-545	-0.809476912021637	▁l VAD ▁implant ation
D-545	-0.809476912021637	lVAD implantation
P-545	-0.9566 -0.2166 -2.6615 -0.2563 -0.5381 -0.2278
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.6910598874092102	
D-1881	-0.6910598874092102	
P-1881	-1.1094 -0.2727
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis patients implantation
H-913	-0.7627333402633667	▁di al ysis _ ▁patients ▁device ▁implant ation
D-913	-0.7627333402633667	dialysis_ patients device implantation
P-913	-0.2676 -0.0800 -0.0334 -1.7216 -0.6367 -2.3542 -1.5183 -0.2850 -0.5183 -0.2121
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive_statistics cox_proportional_hazards_models
H-675	-0.5527766346931458	▁co x _ ▁proportion al _ ▁hazard s
D-675	-0.5527766346931458	cox_ proportional_ hazards
P-675	-0.3514 -0.1666 -0.8489 -0.5551 -0.0982 -0.1057 -0.8236 -0.8551 -1.4169 -0.3062
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle_heart_failure_model
H-2011	-0.5080442428588867	▁Seattle _ ▁Heart _ ▁Fail ure _ model
D-2011	-0.5080442428588867	Seattle_ Heart_ Failure_model
P-2011	-1.3362 -0.2942 -0.4658 -0.5660 -0.1104 -0.5569 -0.5809 -0.6618 -0.3226 -0.1855
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping baseline heart_failure
H-1059	-1.370847463607788	▁heart _ ▁failure
D-1059	-1.370847463607788	heart_ failure
P-1059	-2.5867 -2.0161 -0.4551 -1.5624 -0.2338
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise life_expectancy
H-1902	-1.3123199939727783	
D-1902	-1.3123199939727783	
P-1902	-2.3105 -0.3141
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate_analyses
H-826	-1.2734346389770508	
D-826	-1.2734346389770508	
P-826	-2.3535 -0.1933
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary_angiography lesions
H-349	-0.976015567779541	▁Corona ry _ Ang i ography
D-349	-0.976015567779541	Coronary_Angiography
P-349	-0.0277 -1.9731 -0.1464 -3.9020 -0.8687 -0.1893 -0.5547 -0.1462
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient surgery echocardiography
H-358	-0.2761498987674713	▁MS ▁e cho card i ography
D-358	-0.2761498987674713	MS echocardiography
P-358	-0.1865 -0.8451 -0.0245 -0.1914 -0.4539 -0.1658 -0.2690 -0.0729
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic_phenotype fontan
H-223	-0.3910863995552063	▁Hem o dynamic _ ▁ph eno type ▁Font an
D-223	-0.3910863995552063	Hemodynamic_ phenotype Fontan
P-223	-0.5860 -0.4528 -0.0035 -0.1600 -0.5121 -0.0300 -0.0020 -0.9998 -0.4282 -1.0185 -0.1091
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal heartmate_ii
H-772	-0.5451407432556152	▁off - pump ▁ster nal _ ▁spar ing _ ▁approach ▁Heart Mate _ ▁II _ ▁exchange
D-772	-0.5451407432556152	off-pump sternal_ sparing_ approach HeartMate_ II_ exchange
P-772	-0.0181 -0.1869 -0.1513 -1.4049 -1.2625 -0.2490 -1.4095 -0.0591 -1.6485 -0.1642 -0.2694 -0.2225 -0.5312 -1.0037 -0.6522 -0.0930 -0.2848 -0.2017
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart_failure cox_proportional_hazard_analyses
H-1537	-0.5889073014259338	▁heart ▁failure ▁co x ▁proportion al _ ▁hazard _ analyse s
D-1537	-0.5889073014259338	heart failure cox proportional_ hazard_analyses
P-1537	-1.9850 -1.3177 -0.0631 -0.0541 -0.3098 -0.0554 -0.1020 -0.6346 -2.4214 -0.0415 -0.1622 -0.3404 -0.1688
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized walking patients severe_heart_failure
H-567	-1.7272518873214722	▁Nordic _ ▁walking ▁heart ▁failure
D-567	-1.7272518873214722	Nordic_ walking heart failure
P-567	-1.6606 -0.6923 -3.3984 -4.5671 -1.0492 -0.4136 -0.3095
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient postoperatively multiorgan_failure sepsis
H-551	-0.37322190403938293	▁multi organ _ ▁failure ▁se psis
D-551	-0.37322190403938293	multiorgan_ failure sepsis
P-551	-0.2779 -0.0198 -2.2390 -0.0326 -0.0495 -0.0078 -0.2035 -0.1557
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological acute_heart_failure
H-1465	-0.850523054599762	▁Pharma c ological _ ▁treatment ▁a cute _ heart _ ▁failure
D-1465	-0.850523054599762	Pharmacological_ treatment acute_heart_ failure
P-1465	-2.1101 -0.0536 -0.4432 -1.2684 -2.2085 -0.7281 -0.0358 -0.0229 -1.9566 -0.9879 -0.1142 -0.9680 -0.1596
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients acute_kidney_injury postoperatively
H-975	-0.9072559475898743	▁ki dne y ▁injury
D-975	-0.9072559475898743	kidney injury
P-975	-1.5262 -0.7913 -0.1752 -1.8752 -0.8719 -0.2037
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial_function flow-mediated_dilatation
H-253	-0.5134206414222717	▁en dot heli al _ ▁function ▁flow - media ted _ di la tation
D-253	-0.5134206414222717	endothelial_ function flow-mediated_dilatation
P-253	-1.7591 -1.1391 -0.2268 -0.0370 -0.4125 -1.1606 -0.8220 -0.0263 -0.1335 -0.4993 -0.1646 -0.8663 -0.2860 -0.0467 -0.4507 -0.1843
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric self-care_of_heart_failure_index_version_6.2
H-1503	-0.5799007415771484	▁Psycho metric _ ▁testing ▁Self - Car e _ of _ ▁Heart _ ▁Fail ure ▁index
D-1503	-0.5799007415771484	Psychometric_ testing Self-Care_of_ Heart_ Failure index
P-1503	-0.8631 -0.0290 -1.0061 -0.2819 -0.3725 -0.0765 -1.9257 -0.0800 -0.2413 -0.8623 -0.1233 -0.6575 -0.8140 -0.1450 -0.8419 -1.6555 -0.2718 -0.1910
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse_events
H-1263	-0.7109158039093018	
D-1263	-0.7109158039093018	
P-1263	-1.2959 -0.1259
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients surgical
H-547	-0.9698997735977173	▁AI
D-547	-0.9698997735977173	AI
P-547	-1.0323 -1.6644 -0.2130
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-0.5496419668197632	▁g LS ▁CV _ ▁events ▁AF
D-810	-0.5496419668197632	gLS CV_ events AF
P-810	-0.3850 -0.6030 -0.6857 -1.5741 -0.3845 -0.4152 -0.2340 -0.1156
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-1.3478139638900757	▁mortal ity
D-1696	-1.3478139638900757	mortality
P-1696	-2.8744 -1.9272 -0.3721 -0.2176
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit_index
H-1006	-0.6309401392936707	▁deficit ▁index ▁deficit s
D-1006	-0.6309401392936707	deficit index deficits
P-1006	-0.2129 -1.2273 -0.3077 -0.8768 -0.9752 -0.1858
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.43389520049095154	
D-1855	-0.43389520049095154	
P-1855	-0.7003 -0.1675
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.6551244258880615	▁follow - up
D-1165	-0.6551244258880615	follow-up
P-1165	-2.3996 -0.2128 -0.0150 -0.5265 -0.1217
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients hospitals
H-3	-0.9747043251991272	
D-3	-0.9747043251991272	
P-3	-1.7242 -0.2252
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing nursing
H-1397	-0.9355564713478088	▁nur sing _ ▁terminologi es
D-1397	-0.9355564713478088	nursing_ terminologies
P-1397	-2.2940 -0.0349 -1.6616 -0.1772 -0.0845 -2.0637 -0.2331
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise training outcomes
H-1640	-1.020206093788147	▁race ▁exercise
D-1640	-1.020206093788147	race exercise
P-1640	-1.8744 -0.4056 -1.6072 -0.1937
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs_duration
H-888	-1.0374140739440918	▁QR s ▁benefit
D-888	-1.0374140739440918	QRs benefit
P-888	-1.6743 -1.3750 -1.7617 -0.1939 -0.1822
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-1.1742502450942993	▁guide line ▁MS
D-370	-1.1742502450942993	guideline MS
P-370	-2.0901 -0.0494 -0.2426 -3.3657 -0.1234
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal_muscle exercise_capacity fontan_circulation
H-1491	-0.6442461609840393	▁s kelet al _ ▁muscle _ ▁ab normal ities ▁exercise _ ▁capacity ▁Font an _ ▁circulation
D-1491	-0.6442461609840393	skeletal_ muscle_ abnormalities exercise_ capacity Fontan_ circulation
P-1491	-2.9925 -0.0172 -0.0951 -0.1898 -0.5812 -1.7879 -0.0753 -0.0682 -0.6899 -0.3345 -1.1171 -1.6399 -1.0551 -0.2432 -0.0786 -0.1244 -0.3578 -0.1486
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone_system_inhibitors heart_failure
H-1486	-0.5203582048416138	▁re nin - angi oten sin - al do ster one _ system ▁inhibi tors ▁heart ▁failure
D-1486	-0.5203582048416138	renin-angiotensin-aldosterone_system inhibitors heart failure
P-1486	-0.1862 -0.4544 -0.0708 -0.0071 -0.0438 -1.3721 -0.2505 -0.0217 -0.8190 -0.0960 -0.6334 -1.6813 -1.6005 -0.5550 -0.1882 -0.3067 -1.1004 -0.2477 -0.2522
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf unilateral_renal_dnx cardiac autonomic_balance
H-1372	-0.35960784554481506	▁CHF ▁unilateral _ ▁renal _ ▁DN x ▁cardiac _ ▁autonomi c _ ▁balance
D-1372	-0.35960784554481506	CHF unilateral_ renal_ DNx cardiac_ autonomic_ balance
P-1372	-0.0082 -0.0031 -0.2409 -0.0478 -0.4902 -1.1539 -0.0652 -0.0344 -1.2005 -0.1210 -0.1487 -0.2504 -1.1497 -0.3715 -0.1089
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute_heart_failure
H-1014	-0.6038631796836853	▁a cute _ heart _ ▁failure
D-1014	-0.6038631796836853	acute_heart_ failure
P-1014	-0.8885 -0.0219 -0.0277 -1.4834 -1.0283 -0.0987 -1.1188 -0.1635
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic anaerobic_threshold heart_failure
H-1752	-0.5245979428291321	▁ana ero bic _ ▁thre s hold ▁heart ▁failure
D-1752	-0.5245979428291321	anaerobic_ threshold heart failure
P-1752	-0.4990 -1.0891 -0.8869 -0.3950 -0.4485 -0.1001 -0.1377 -0.5388 -1.2006 -0.3132 -0.1616
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr_variability cardiac_death
H-1589	-0.45366933941841125	▁ab normal _ HR _ ▁variabil ity ▁sud den _ ▁cardiac _ ▁death
D-1589	-0.45366933941841125	abnormal_HR_ variability sudden_ cardiac_ death
P-1589	-0.3774 -0.0112 -0.2858 -0.8823 -0.6391 -0.0247 -1.1216 -1.0685 -0.0068 -0.5858 -0.2566 -0.6793 -0.4040 -0.2774 -0.1844
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome all-cause_readmissions
H-1580	-0.6818739175796509	▁m AIN _ o UTC OME
D-1580	-0.6818739175796509	mAIN_oUTCOME
P-1580	-1.7845 -0.4455 -0.1225 -1.0162 -0.0395 -0.2282 -1.6621 -0.1565
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac cardiac_hypertrophy
H-1782	-0.5861821174621582	▁a ac ▁cardiac _ ▁hyper trop hy
D-1782	-0.5861821174621582	aac cardiac_ hypertrophy
P-1782	-0.2554 -0.1337 -0.3182 -0.7788 -1.9956 -0.0272 -1.2450 -0.3356 -0.1862
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation postsystolic_function
H-331	-0.9078960418701172	▁indice s ▁posts y sto lic
D-331	-0.9078960418701172	indices postsystolic
P-331	-3.2930 -0.0890 -0.4172 -0.7234 -0.1625 -0.0928 -2.3390 -0.1464
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician outcomes patients heart_failure
H-1720	-2.2958250045776367	▁heart _ ▁failure
D-1720	-2.2958250045776367	heart_ failure
P-1720	-7.9969 -2.5022 -0.2368 -0.4118 -0.3315
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication resting_hemodynamics
H-828	-0.6656973361968994	▁medication ▁rest ing _ hem o dynamic s
D-828	-0.6656973361968994	medication resting_hemodynamics
P-828	-1.0919 -0.6118 -0.1755 -0.2913 -2.1026 -1.4073 -0.0051 -0.1148 -0.7140 -0.1427
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic_blood_pressure
H-1048	-1.0472549200057983	▁ toxic iteit ▁system ic _ ▁blood _ ▁pressure
D-1048	-1.0472549200057983	toxiciteit systemic_ blood_ pressure
P-1048	-0.2253 -0.4234 -2.3427 -1.5670 -0.1344 -0.1465 -3.4096 -1.2142 -1.5247 -0.3623 -0.1699
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary_outcome patient post
H-617	-0.9311875104904175	
D-617	-0.9311875104904175	
P-617	-1.5156 -0.3468
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral_regurgitation hf symptoms surgery
H-362	-0.3879004120826721	▁mit ral _ re gur gi tation ▁ HF
D-362	-0.3879004120826721	mitral_regurgitation HF
P-362	-1.3697 -0.2110 -0.3836 -0.2889 -0.3742 -0.1397 -0.3732 -0.1947 -0.3878 -0.3986 -0.1455
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations hospital longitudinal change
H-143	-1.2295781373977661	
D-143	-1.2295781373977661	
P-143	-2.1786 -0.2806
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence systolic_hf
H-1798	-0.3416217863559723	▁sy sto lic _ HF
D-1798	-0.3416217863559723	systolic_HF
P-1798	-0.1474 -0.1143 -0.0494 -0.0974 -1.4934 -0.3349 -0.1546
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission hospital heart_failure discharge
H-147	-1.6731317043304443	▁hospital _ voor _ heart ▁failure
D-147	-1.6731317043304443	hospital_voor_heart failure
P-147	-5.9447 -1.1682 -1.4775 -0.1103 -1.3696 -2.1537 -0.9410 -0.2201
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end_stage_heart_failure
H-1669	-1.7525484561920166	▁heart _ ▁failure
D-1669	-1.7525484561920166	heart_ failure
P-1669	-6.1733 -2.0837 -0.1628 -0.2401 -0.1029
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease lead hypertension kidney_failure
H-1598	-0.5037574172019958	▁progressive _ ▁disease ▁hyper tension ▁ki dne y ▁failure
D-1598	-0.5037574172019958	progressive_ disease hypertension kidney failure
P-1598	-0.4923 -0.8241 -2.1899 -0.8547 -0.0384 -0.0295 -0.1742 -0.0617 -0.4883 -0.2615 -0.1268
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients chronic_kidney_disease ckd
H-898	-0.7972431778907776	▁chronic _ ▁ki dne y ▁disease CK d
D-898	-0.7972431778907776	chronic_ kidney diseaseCKd
P-898	-1.1740 -0.5616 -1.4982 -0.5179 -0.3377 -1.3573 -0.9096 -1.0054 -0.4157 -0.1950
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.9820106029510498	▁ HF
D-556	-0.9820106029510498	HF
P-556	-2.7979 -0.5046 -0.4701 -0.1555
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu mortality
H-582	-0.6765046119689941	▁ ICU _ ▁mortal ity
D-582	-0.6765046119689941	ICU_ mortality
P-582	-0.3387 -0.0433 -1.8423 -0.2556 -1.2854 -0.8097 -0.1605
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses patients disease
H-2020	-1.6291035413742065	▁disease
D-2020	-1.6291035413742065	disease
P-2020	-4.3199 -0.3175 -0.2499
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt patients
H-905	-0.7751888036727905	▁c RT ▁di al ysis - dependent _ ▁patients
D-905	-0.7751888036727905	cRT dialysis-dependent_ patients
P-905	-0.6002 -3.5774 -0.7616 -0.1221 -0.0195 -0.1686 -0.1006 -1.6245 -0.9804 -0.4125 -0.1597
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf patients
H-217	-0.5378650426864624	▁CHF
D-217	-0.5378650426864624	CHF
P-217	-0.3376 -1.1486 -0.1274
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-1.8184943199157715	▁RM
D-163	-1.8184943199157715	RM
P-163	-4.8730 -0.3841 -0.1984
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic accounting cost
H-1582	-0.7552613615989685	▁net _ economic _ ▁sav ings
D-1582	-0.7552613615989685	net_economic_ savings
P-1582	-0.1890 -0.6096 -0.7476 -1.1066 -0.8755 -0.0797 -2.1939 -0.2403
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western_blot immunohistochemistry electron_microscopy
H-1252	-0.39302387833595276	▁Western _ ▁blot _ analyse ▁immun oh isto che mist ry ▁electro n _ ▁micro s copy
D-1252	-0.39302387833595276	Western_ blot_analyse immunohistochemistry electron_ microscopy
P-1252	-0.1108 -0.5773 -1.0346 -0.6709 -0.2047 -0.0066 -0.0394 -0.6872 -0.2097 -0.3989 -1.2276 -0.0023 -0.0297 -0.0940 -0.9754 -0.3624 -0.2995 -0.3576 -0.1788
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic_cardiomyopathy mortality
H-67	-0.6380609273910522	▁i sche mic _ ▁cardio my o pathy ▁male _ ▁sex ▁mortal ity
D-67	-0.6380609273910522	ischemic_ cardiomyopathy male_ sex mortality
P-67	-1.7475 -0.0014 -0.1664 -0.1179 -0.1410 -1.0679 -0.4522 -0.0156 -0.9169 -0.1657 -0.9840 -1.2331 -2.0465 -0.2785 -0.2364
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence idiopathic_dilated_cardiomyopathy
H-1741	-0.34633561968803406	▁ idio pathi c ▁dil ated _ ▁cardio my o pathy
D-1741	-0.34633561968803406	idiopathic dilated_ cardiomyopathy
P-1741	-0.5769 -0.0139 -0.0153 -0.0631 -1.0089 -0.2856 -0.0731 -0.1092 -1.3826 -0.4514 -0.0107 -0.3585 -0.1532
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf chromatin_hyperacetylation
H-1036	-0.5500434637069702	▁ HF ▁chr omat in _ ▁hyper ace ty lation
D-1036	-0.5500434637069702	HF chromatin_ hyperacetylation
P-1036	-1.6156 -0.1908 -0.3905 -0.1033 -1.4938 -0.3165 -1.2077 -0.3096 -0.5193 -0.0894 -0.2621 -0.1021
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic_dysfunction patients peripheral_artery_disease
H-1566	-0.3776518702507019	▁dia sto lic _ ▁dys function ▁per i pher al _ ▁arter y ▁disease
D-1566	-0.3776518702507019	diastolic_ dysfunction peripheral_ artery disease
P-1566	-0.0083 -0.1109 -0.2270 -0.8660 -0.1188 -0.0533 -0.1967 -0.1751 -0.0890 -0.7260 -0.2488 -0.8648 -0.8081 -0.8476 -0.5000 -0.2019
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded_protein_response cardiac_sodium systolic heart_failure
H-1079	-0.5600681304931641	▁un fold ed _ ▁protein _ ▁response ▁cardiac ▁so dium _ ▁current ▁sy sto lic _ heart _ ▁failure
D-1079	-0.5600681304931641	unfolded_ protein_ response cardiac sodium_ current systolic_heart_ failure
P-1079	-0.2948 -0.0003 -0.0272 -0.3576 -0.9174 -1.4689 -0.1696 -2.0474 -0.8690 -0.0226 -0.0861 -0.3736 -0.0229 -0.0344 -0.0466 -0.0499 -3.6775 -0.8575 -0.0491 -0.2024 -0.1867
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin_receptor_neprilysin_inhibitor heart_failure
H-1461	-0.5404984951019287	▁ang io ten sin ▁receptor ▁nepri ly sin _ ▁inhibi tor ▁heart ▁failure
D-1461	-0.5404984951019287	angiotensin receptor neprilysin_ inhibitor heart failure
P-1461	-1.1838 -0.9973 -0.0971 -1.1191 -1.0213 -0.0072 -0.3288 -1.1268 -0.5322 -0.0672 -0.0201 -0.2213 -0.9231 -0.2529 -0.2094
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient diagnosed hypertensive_lv_dysfunction
H-350	-0.2147662490606308	▁hyper tensi ve _ ▁LV ▁dys function ▁MR ▁MS
D-350	-0.2147662490606308	hypertensive_ LV dysfunction MR MS
P-350	-0.2420 -0.0528 -0.0309 -0.1887 -0.1504 -0.8617 -0.0273 -0.1940 -0.3313 -0.1984 -0.0850
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians patients hf
H-1724	-1.2538509368896484	▁physician s ▁qui nti les HF
D-1724	-1.2538509368896484	physicians quintilesHF
P-1724	-2.4180 -0.0587 -1.1810 -0.1316 -0.7562 -4.9305 -0.4500 -0.1049
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia prognostic patients heart_failure
H-529	-0.6656267046928406	▁hypo album in emia ▁heart ▁failure
D-529	-0.6656267046928406	hypoalbuminemia heart failure
P-529	-0.9171 -0.1227 -0.2415 -0.0237 -2.1084 -1.3965 -0.3271 -0.1879
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute_heart_failure
H-468	-0.6941828727722168	▁a cute _ heart _ ▁failure
D-468	-0.6941828727722168	acute_heart_ failure
P-468	-1.3806 -0.0342 -0.0236 -2.3229 -1.1985 -0.0628 -0.2864 -0.2445
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia patients heart_disease
H-39	-1.824450969696045	▁voordelen ▁an emia _ ▁treatment ▁heart _ ▁disease
D-39	-1.824450969696045	voordelen anemia_ treatment heart_ disease
P-39	-3.3172 -1.6745 -0.2234 -4.3378 -1.5776 -3.6211 -2.2003 -0.7331 -0.3970 -0.1625
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort_study
H-1829	-0.7568865418434143	
D-1829	-0.7568865418434143	
P-1829	-1.3274 -0.1864
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad_ai
H-543	-0.9507052302360535	▁algorithm s ▁post - L VAD _ ▁AI
D-543	-0.9507052302360535	algorithms post-LVAD_ AI
P-543	-2.8644 -0.2402 -0.0828 -0.0267 -4.0134 -0.0265 -0.9853 -0.7568 -0.3270 -0.1841
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative operative outcomes
H-299	-0.3684904873371124	
D-299	-0.3684904873371124	
P-299	-0.6044 -0.1326
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth longitudinal medicare
H-1617	-0.9325188994407654	▁care ▁management ▁tele health ▁medica re
D-1617	-0.9325188994407654	care management telehealth medicare
P-1617	-4.8552 -0.5353 -0.3479 -0.4065 -0.0451 -0.0181 -1.0397 -0.2124
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public_reporting patients hospitals
H-1689	-1.3252838850021362	▁public _ report ing
D-1689	-1.3252838850021362	public_reporting
P-1689	-3.0515 -0.5087 -0.1221 -0.0406 -3.9678 -0.2609
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control outcomes
H-1232	-0.6976369619369507	▁ Rhythm - _ en _ ▁rate - control ▁strategie s
D-1232	-0.6976369619369507	Rhythm-_en_ rate-control strategies
P-1232	-0.3275 -0.0572 -0.0507 -2.5665 -2.0180 -0.3474 -0.5435 -0.2903 -0.0052 -2.0729 -0.1100 -0.4899 -0.1903
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus_rhythm adverse_outcomes
H-1644	-0.4236171543598175	▁sinus _ rhythm ▁AF
D-1644	-0.4236171543598175	sinus_rhythm AF
P-1644	-0.5431 -1.0279 -0.1533 -0.5357 -0.1795 -0.1022
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal diagnostic filling_pressures
H-490	-1.2729566097259521	▁diagnosti ▁performance ▁fill ing _ ▁pressure s
D-490	-1.2729566097259521	diagnosti performance filling_ pressures
P-490	-1.9939 -4.4272 -1.1536 -0.1553 -0.7657 -1.9250 -0.3151 -0.5709 -0.1497
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial_infarction
H-1137	-0.38974833488464355	▁My o card ial _ in far ction ▁Wi star _ ▁rat s
D-1137	-0.38974833488464355	Myocardial_infarction Wistar_ rats
P-1137	-0.4251 -0.3849 -0.3627 -0.7257 -0.3383 -0.1674 -0.2343 -0.0824 -0.6974 -0.4502 -0.9010 -0.2614 -0.0562 -0.5242 -0.2352
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis hf etiologies
H-1795	-0.7437579035758972	▁prognos is ▁c ▁d ▁ HF ▁et i ologie s
D-1795	-0.7437579035758972	prognosis c d HF etiologies
P-1795	-2.1152 -0.0303 -1.2937 -1.7943 -2.2739 -0.3147 -0.2467 -0.2555 -0.0127 -0.1818 -0.2964 -0.1100
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients heart_failure cardiac_rehabilitation
H-568	-1.1068907976150513	▁heart _ ▁failure ▁cardiac _ ▁rehabilita tion
D-568	-1.1068907976150513	heart_ failure cardiac_ rehabilitation
P-568	-3.6466 -1.9666 -0.3866 -0.1411 -1.3797 -1.2246 -0.4859 -0.5130 -0.2180
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity_pathway_analysis
H-875	-0.7026420831680298	▁ingen u ity _ path way
D-875	-0.7026420831680298	ingenuity_pathway
P-875	-0.5280 -0.4287 -1.2066 -0.5217 -0.6436 -0.6066 -1.4220 -0.2639
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone severe_heart_failure
H-1701	-0.46947363018989563	▁Race ▁spi rono lac tone ▁heart ▁failure
D-1701	-0.46947363018989563	Race spironolactone heart failure
P-1701	-0.6338 -0.0558 -0.0138 -0.0908 -0.1235 -2.1657 -0.7050 -0.2326 -0.2043
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins tac
H-872	-0.61089688539505	▁protein s ▁ TAC
D-872	-0.61089688539505	proteins TAC
P-872	-1.6903 -0.1176 -1.4467 -0.0919 -0.2011 -0.1178
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery mva
H-361	-0.42818373441696167	▁MS ▁m VA
D-361	-0.42818373441696167	MS mVA
P-361	-0.8079 -0.1367 -0.8059 -0.2852 -0.1052
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.54271000623703	▁c RF
D-1769	-0.54271000623703	cRF
P-1769	-0.9720 -0.7664 -0.3204 -0.1121
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.6080767512321472	▁Mediterrane an ▁DAS h
D-688	-0.6080767512321472	Mediterranean DASh
P-688	-0.6660 -0.1843 -0.0443 -0.2170 -2.3714 -0.1655
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise exercise
H-1931	-2.443643569946289	▁social _ support ▁exercise
D-1931	-2.443643569946289	social_support exercise
P-1931	-5.4138 -1.3893 -1.6455 -4.6656 -1.2982 -0.2494
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.8600649237632751	▁re hospital ization
D-1711	-0.8600649237632751	rehospitalization
P-1711	-2.9410 -0.1952 -0.6465 -0.3163 -0.2013
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate_models odds_ratios accounting hospital
H-191	-0.5167062878608704	▁odds _ ▁ratio s ▁account ing ▁hospital ▁cluster ing
D-191	-0.5167062878608704	odds_ ratios accounting hospital clustering
P-191	-1.8358 -1.3345 -0.3135 -0.1242 -0.3245 -0.0303 -0.8532 -0.1417 -0.0714 -0.4338 -0.2207
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk_stratification death all-cause_hospitalization heart_failure clinic outpatients
H-377	-1.832441806793213	▁heart _ ▁failure _ ▁clinic
D-377	-1.832441806793213	heart_ failure_ clinic
P-377	-5.9725 -1.6269 -0.3574 -0.7405 -0.4718 -3.3134 -0.3446
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl hno acute heart_failure
H-412	-0.9206899404525757	▁ni tro x yl ▁h no ▁treatment _ van _ heart _ ▁failure
D-412	-0.9206899404525757	nitroxyl hno treatment_van_heart_ failure
P-412	-0.3435 -0.0078 -0.1492 -0.1086 -0.7641 -0.6176 -5.6726 -1.8263 -0.8652 -0.3453 -1.1420 -1.5358 -0.0624 -0.2437 -0.1263
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref hfpef patients regression_line
H-497	-0.6637225151062012	▁h Fr EF ▁ HF p EF
D-497	-0.6637225151062012	hFrEF HFpEF
P-497	-1.1838 -1.4064 -1.0395 -0.1996 -0.2381 -0.0922 -0.4665 -1.1959 -0.1514
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart_block pulmonary_artery bivp
H-322	-0.5890820026397705	▁Heart ▁block ▁pulmonar y _ ▁arter y ▁Bi VP
D-322	-0.5890820026397705	Heart block pulmonary_ artery BiVP
P-322	-0.6260 -1.3061 -0.0057 -0.0394 -1.4803 -0.0466 -0.1844 -2.5106 -0.0674 -0.1273 -0.0861
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute_walk_distance peak_vo2 baseline
H-1636	-0.7787997126579285	▁black s ▁VO 2
D-1636	-0.7787997126579285	blacks VO2
P-1636	-0.7548 -0.0995 -2.3536 -0.1206 -1.0288 -0.3155
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home hospital readmission congestive_heart_failure
H-1573	-1.0488485097885132	▁hospital - to - Home ▁con ges tive _ heart _ ▁failure
D-1573	-1.0488485097885132	hospital-to-Home congestive_heart_ failure
P-1573	-0.9459 -0.4167 -0.0299 -0.0665 -0.4335 -5.7130 -0.3751 -2.2232 -0.0707 -2.1753 -1.4873 -0.1045 -0.4211 -0.2212
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization_therapy heart_failure narrow_qrs_complex
H-844	-0.5945999026298523	▁Card iac - re syn chron ization _ therapy ▁heart _ ▁failure ▁QR s
D-844	-0.5945999026298523	Cardiac-resynchronization_therapy heart_ failure QRs
P-844	-0.6904 -0.0596 -0.0833 -0.0520 -0.1132 -0.0040 -1.3928 -1.1798 -0.4303 -1.3015 -1.1511 -0.2430 -1.4825 -0.8727 -0.3204 -0.1370
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician death readmission discharge patients heart_failure
H-1412	-1.451267957687378	▁physician _ ▁continu ity _ on _ ▁death ▁urgent _ ▁read mission ▁dis charge ▁heart ▁failure
D-1412	-1.451267957687378	physician_ continuity_on_ death urgent_ readmission discharge heart failure
P-1412	-1.5814 -3.8583 -0.2806 -0.5174 -4.6960 -2.2014 -0.4297 -0.3877 -0.2219 -0.2127 -3.6789 -0.8356 -3.0477 -0.4302 -1.9130 -1.2618 -0.3462 -0.2225
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance attrition
H-1319	-0.7774583101272583	
D-1319	-0.7774583101272583	
P-1319	-1.4499 -0.1051
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients diabetes eo-cfus functional_capacity
H-132	-0.6176554560661316	▁diabetes ▁e EO - c FU s
D-132	-0.6176554560661316	diabetes eEO-cFUs
P-132	-0.0880 -1.3985 -1.3017 -0.0318 -0.5219 -0.4189 -0.3811 -1.2663 -0.1506
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life patients
H-161	-1.1692767143249512	▁Care ▁package s
D-161	-1.1692767143249512	Care packages
P-161	-2.2952 -2.1350 -0.1135 -1.0901 -0.2126
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients patients echocardiographic
H-813	-0.7568098306655884	▁AF ▁e cho car dio graphic _ ▁examina tion
D-813	-0.7568098306655884	AF echocardiographic_ examination
P-813	-1.4219 -1.0979 -0.1275 -0.0504 -1.0827 -1.1904 -1.6500 -0.2877 -0.6458 -0.5738 -0.1970
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf surgical
H-353	-0.4508417248725891	▁MS HF ▁sur g ical _ ▁indica tion ▁MS
D-353	-0.4508417248725891	MSHF surgical_ indication MS
P-353	-0.1369 -0.5538 -1.6678 -0.2319 -0.3396 -0.5876 -0.8111 -0.0690 -0.1519 -0.2975 -0.1122
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac_function catheter
H-1143	-0.5657398700714111	▁Card iac _ ▁function ▁pressure - volu me _ ▁conduct ance _ ▁cat heter _ system
D-1143	-0.5657398700714111	Cardiac_ function pressure-volume_ conductance_ catheter_system
P-1143	-0.2928 -0.0523 -0.5519 -0.6409 -0.2230 -0.0413 -0.0190 -0.2407 -0.2618 -1.2516 -0.3053 -0.8936 -2.0240 -0.0267 -1.8993 -0.9529 -0.3929 -0.1134
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 therapy
H-401	-1.056746006011963	▁s st 2 _ ▁concentration s ▁benefit ▁BB _ therapy
D-401	-1.056746006011963	sst2_ concentrations benefit BB_therapy
P-401	-0.0544 -2.3829 -0.1438 -5.0365 -0.2192 -0.2400 -2.0198 -1.0397 -0.9180 -0.0195 -0.4152 -0.1919
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf pb
H-1349	-0.4900854527950287	▁PV f ▁recovery ▁p b
D-1349	-0.4900854527950287	PVf recovery pb
P-1349	-0.0909 -0.8206 -0.9948 -0.3428 -0.5536 -0.5247 -0.1030
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital heart lesions
H-985	-0.6834611892700195	▁con geni tal _ heart _ ▁les ions
D-985	-0.6834611892700195	congenital_heart_ lesions
P-985	-0.9533 -0.0273 -0.1038 -0.1060 -2.5371 -0.8579 -1.5700 -0.0387 -0.5048 -0.1357
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.31893619894981384	▁beta - block ers ▁ad her ence
D-865	-0.31893619894981384	beta-blockers adherence
P-865	-0.4345 -0.1018 -0.2363 -0.1009 -0.7809 -0.3171 -0.5552 -0.2170 -0.1266
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up cardiovascular_events deaths
H-974	-1.0954864025115967	▁follow - up ▁cardiovascular
D-974	-1.0954864025115967	follow-up cardiovascular
P-974	-1.8311 -0.1361 -0.0165 -0.1942 -4.2631 -0.1318
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical patients functional_ms
H-373	-0.778014063835144	▁functional ▁MS
D-373	-0.778014063835144	functional MS
P-373	-1.4178 -1.2710 -0.2817 -0.1414
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic outcomes hf
H-1202	-1.2833682298660278	▁di ure tic ▁ HF
D-1202	-1.2833682298660278	diuretic HF
P-1202	-0.9682 -0.7053 -1.3444 -5.2916 -0.2675 -0.2648 -0.1417
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad systolic_hf prognostic
H-1183	-0.2584517002105713	▁CAD ▁sy sto lic _ HF
D-1183	-0.2584517002105713	CAD systolic_HF
P-1183	-0.1423 -0.0289 -0.0591 -0.0364 -0.0993 -0.7480 -0.8545 -0.0991
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray genes heart_failure
H-1605	-0.8785127997398376	▁bio informati c _ analyse ▁micro arra y _ ▁data ▁heart _ ▁failure
D-1605	-0.8785127997398376	bioinformatic_analyse microarray_ data heart_ failure
P-1605	-0.1465 -0.0583 -0.1364 -1.9588 -0.1110 -0.1350 -0.0184 -0.1070 -1.4449 -0.4981 -6.3165 -1.2176 -0.4055 -0.4274 -0.1962
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change lvet admission follow-up outcome
H-588	-0.413077175617218	▁l VET ▁follow - up _ ▁measure ment
D-588	-0.413077175617218	lVET follow-up_ measurement
P-588	-0.8437 -0.2017 -0.0801 -0.1070 -0.0377 -1.1953 -0.9022 -0.0776 -0.5194 -0.1662
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin inflammation metabolism heart_disease
H-940	-0.7430856823921204	▁ inflammation ▁metabolism ▁heart ▁disease
D-940	-0.7430856823921204	inflammation metabolism heart disease
P-940	-2.1968 -0.1675 -0.0556 -1.0965 -1.0886 -0.3724 -0.2242
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary_disease leading heart_failure
H-981	-0.808684766292572	▁corona ry _ ▁disease ▁heart _ ▁failure
D-981	-0.808684766292572	coronary_ disease heart_ failure
P-981	-0.2793 -2.1832 -0.2660 -1.2499 -1.0367 -1.6411 -0.1727 -0.3151 -0.1343
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative hypoalbuminemia prognosis lvad surgery
H-538	-0.34189552068710327	▁hypo album in emia ▁l VAD ▁surgery
D-538	-0.34189552068710327	hypoalbuminemia lVAD surgery
P-538	-0.7152 -0.1762 -0.2129 -0.0411 -0.2209 -0.0359 -1.2523 -0.2477 -0.1749
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling_pathways cardiac_remodelling
H-992	-1.10410475730896	▁signal ling _ ▁path ways ▁mal adapt ive _ ▁cardiac ▁remodel ling
D-992	-1.10410475730896	signalling_ pathways maladaptive_ cardiac remodelling
P-992	-3.3863 -0.8762 -0.7438 -1.1338 -0.1195 -3.4815 -0.0297 -0.0928 -0.2587 -0.2055 -4.2628 -0.2485 -0.4344 -0.1841
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia right_ventricle heart_failure
H-1457	-0.5691407918930054	▁Fat ▁cache xia ▁vent ric le ▁heart _ ▁failure
D-1457	-0.5691407918930054	Fat cachexia ventricle heart_ failure
P-1457	-0.3735 -0.1535 -0.0262 -0.4808 -1.6423 -0.3979 -0.5755 -1.5731 -0.0605 -0.8450 -0.1323
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial_fibrillation patients heart_failure
H-1231	-0.5793364644050598	▁At rial _ fi bril lation AF ▁heart ▁failure
D-1231	-0.5793364644050598	Atrial_fibrillationAF heart failure
P-1231	-2.7818 -0.0682 -0.4567 -0.3967 -0.0760 -0.1514 -0.5210 -0.7014 -0.7710 -0.2988 -0.1498
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit_index biological_phenotype mortality
H-1012	-0.6720520257949829	▁deficit _ index ▁bi ological _ ▁ph eno type ▁mortal ity
D-1012	-0.6720520257949829	deficit_index biological_ phenotype mortality
P-1012	-1.2955 -0.4173 -0.6856 -0.9805 -0.1988 -0.2547 -0.8389 -0.0862 -0.0015 -1.0501 -2.4955 -0.2217 -0.2105
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical connected elevated resistin heart_failure
H-929	-1.1428855657577515	▁resist in _ ▁levels ▁heart ▁failure
D-929	-1.1428855657577515	resistin_ levels heart failure
P-929	-2.7662 -0.9677 -2.9356 -0.6247 -0.5946 -0.9155 -0.2211 -0.1177
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd vvd free_wall_rs
H-328	-0.8670099377632141	▁AV d ▁VVD ▁free _ wall ▁RS
D-328	-0.8670099377632141	AVd VVD free_wall RS
P-328	-0.4147 -0.5575 -1.6498 -1.4944 -0.0902 -2.1645 -1.0334 -0.2903 -0.1082
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence esrd outpatients hf
H-388	-1.1442642211914062	▁ES RD ▁out patient s ▁ HF
D-388	-1.1442642211914062	ESRD outpatients HF
P-388	-3.1610 -0.9229 -2.6974 -0.0092 -0.0729 -2.8460 -0.1165 -0.3058 -0.1667
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise_intolerance chronic_heart_failure prognosis
H-1273	-0.5745211839675903	▁Exerci se _ in tolerance ▁chronic _ heart _ ▁failure
D-1273	-0.5745211839675903	Exercise_intolerance chronic_heart_ failure
P-1273	-1.1388 -0.0395 -0.3145 -0.3854 -0.0383 -0.7717 -0.1370 -1.7931 -1.3378 -0.1373 -0.6197 -0.1811
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical atherosclerosis linear_models
H-1557	-0.9762712717056274	▁sub clin ical _ at hero sc ler osis ▁linear _ ▁models
D-1557	-0.9762712717056274	subclinical_atherosclerosis linear_ models
P-1557	-2.7671 -0.6161 -0.8405 -0.1508 -0.5266 -0.9844 -0.0546 -3.9774 -0.0495 -0.8058 -0.9702 -1.0635 -0.6036 -0.2575
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling hf haemodynamic neuronal_stressors
H-1039	-0.4418954849243164	▁ HF ▁ha emo dynamic ▁neuron al _ stress ors
D-1039	-0.4418954849243164	HF haemodynamic neuronal_stressors
P-1039	-2.2962 -0.2682 -0.0037 -0.0533 -0.0024 -0.2390 -0.0990 -0.6114 -1.0142 -0.2153 -0.3991 -0.1009
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right_ventricular_function prognosis heart_failure
H-1157	-1.043903112411499	▁right _ ▁vent ri cular _ function ▁body ▁composition ▁heart _ ▁failure
D-1157	-1.043903112411499	right_ ventricular_function body composition heart_ failure
P-1157	-1.4018 -0.4954 -1.5575 -1.2297 -0.6939 -0.3547 -1.3695 -0.9142 -0.9813 -3.4432 -1.4181 -0.3616 -0.1942 -0.1995
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart_transplantation left_ventricular_assist_device
H-306	-1.2179899215698242	▁heart ▁transplant ation ▁left _ ▁vent ri cular _ assist _ ▁device
D-306	-1.2179899215698242	heart transplantation left_ ventricular_assist_ device
P-306	-2.9642 -2.3964 -0.3735 -0.4780 -0.9802 -1.4086 -2.0664 -0.8734 -0.2590 -0.5678 -2.1255 -1.1627 -1.1941 -0.2019
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ecgs electrocardiographers
H-884	-0.48500701785087585	▁e CG s ▁electro car dio graph ers
D-884	-0.48500701785087585	eCGs electrocardiographers
P-884	-1.3017 -0.7196 -0.4272 -0.0342 -0.0167 -0.7881 -0.6694 -0.1226 -0.6419 -0.1288
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart_rate
H-1446	-1.7871601581573486	▁effect ▁heart ▁rate
D-1446	-1.7871601581573486	effect heart rate
P-1446	-3.3641 -1.6572 -1.7347 -1.8880 -0.2918
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end_point neurological cardiovascular_events
H-1872	-1.2142608165740967	▁neurologi cal ▁cardiovascular _ ▁events
D-1872	-1.2142608165740967	neurological cardiovascular_ events
P-1872	-2.1032 -1.0502 -0.3193 -2.5815 -1.7798 -0.4200 -0.2459
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications dialysis patients
H-908	-0.5554953813552856	▁di al ysis
D-908	-0.5554953813552856	dialysis
P-908	-1.0273 -0.1667 -0.1105 -1.3091 -0.1639
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ffm stable
H-20	-1.300795555114746	▁f f ▁f m ▁FM ▁body ▁weight ▁CC
D-20	-1.300795555114746	ff fm FM body weight CC
P-20	-0.2362 -1.9339 -2.0341 -1.6622 -2.2877 -3.0190 -1.1081 -0.3928 -0.1882 -0.1457
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty hf
H-632	-0.6441105604171753	▁fra il ty ▁ HF
D-632	-0.6441105604171753	frailty HF
P-632	-0.8353 -0.7020 -0.0881 -1.5802 -0.2919 -0.8671 -0.1442
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac_cachexia
H-9	-0.5054753422737122	▁Card iac _ ▁cache xia cc
D-9	-0.5054753422737122	Cardiac_ cachexiacc
P-9	-1.0465 -0.0105 -0.2498 -0.5510 -0.1324 -0.3038 -1.6053 -0.1443
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota hf
H-1003	-0.4665442407131195	▁South e a stern _ ▁Minnesota ▁residents ▁ HF
D-1003	-0.4665442407131195	Southeastern_ Minnesota residents HF
P-1003	-1.6983 -0.0182 -0.0403 -0.0574 -0.7130 -0.1374 -0.3810 -0.9900 -0.4102 -0.5478 -0.1385
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart_failure nurse
H-84	-1.1950013637542725	▁multi hospital _ ▁study ▁heart ▁failure
D-84	-1.1950013637542725	multihospital_ study heart failure
P-84	-2.9171 -0.0612 -1.4902 -0.3623 -1.6881 -0.5802 -2.2560 -0.2051
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical hfpef
H-943	-0.902204692363739	▁AF ▁precipit ating _ factor ▁h FP EF
D-943	-0.902204692363739	AF precipitating_factor hFPEF
P-943	-1.1784 -2.6772 -0.2129 -0.1860 -0.5225 -1.3180 -1.6087 -0.8111 -0.3262 -0.1810
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome hdl
H-254	-0.646366536617279	▁prote ome ▁HD l _ ▁parti cles ▁shot gun ▁ LC - MS MS
D-254	-0.646366536617279	proteome HDl_ particles shotgun LC-MSMS
P-254	-1.3887 -0.0994 -1.1040 -2.0882 -0.2722 -1.0668 -0.0507 -0.2657 -0.0214 -1.7977 -0.1096 -0.0441 -0.2603 -1.4453 -0.2119 -0.1158
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left_bundle_branch_block
H-1153	-0.899199903011322	▁bund le _ ▁bran ch _ ▁block ▁electric al _ activa tion _ se que nce
D-1153	-0.899199903011322	bundle_ branch_ block electrical_activation_sequence
P-1153	-0.1818 -2.5872 -0.6054 -0.2156 -0.1811 -0.6770 -1.3818 -1.0638 -0.2696 -0.2698 -0.2385 -0.3348 -0.5390 -0.6190 -3.7808 -2.5431 -0.5181 -0.1790
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients heart_transplant ecct
H-714	-1.0205897092819214	▁heart ▁transplant ▁ec CT
D-714	-1.0205897092819214	heart transplant ecCT
P-714	-3.0959 -1.2235 -0.8576 -0.5765 -0.2149 -0.1551
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise training endothelial_function
H-248	-0.6945117115974426	▁ Protect ive _ effect ▁exercise _ training ET ▁en dot heli al _ function
D-248	-0.6945117115974426	Protective_effect exercise_trainingET endothelial_function
P-248	-1.9796 -0.4800 -0.0515 -0.7023 -0.1273 -2.5436 -0.6051 -0.2460 -1.8663 -0.3950 -0.9276 -0.1643 -0.0465 -0.1790 -1.1329 -0.2472 -0.1123
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death stroke hospitalisation heart_failure
H-815	-0.7349331378936768	▁CV ▁death ▁non - fa tal _ stro t ▁hospital isation ▁heart ▁failure
D-815	-0.7349331378936768	CV death non-fatal_strot hospitalisation heart failure
P-815	-0.0802 -4.1315 -0.1005 -0.0502 -0.0726 -0.0280 -0.0705 -0.1331 -3.1420 -0.6425 -0.0363 -0.8181 -1.0735 -0.3881 -0.2568
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct heart_failure therapy patients
H-718	-0.7709658145904541	▁ec CT ▁advanced _ heart _ ▁failure _ therapy
D-718	-0.7709658145904541	ecCT advanced_heart_ failure_therapy
P-718	-0.5224 -1.9312 -1.1735 -0.0936 -1.3643 -1.3642 -0.2164 -1.0805 -0.0702 -0.4753 -0.1890
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4_inhibitors drugs
H-1834	-0.3614276349544525	▁h HF ▁d PP -4 ▁inhibi tors ▁drugs
D-1834	-0.3614276349544525	hHF dPP-4 inhibitors drugs
P-1834	-0.0206 -0.6024 -0.2561 -0.2496 -0.1084 -0.5551 -0.1544 -1.2034 -0.3362 -0.1282
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade holosystolic_murmur third_heart_sound apex
H-342	-0.6566178202629089	▁holo sy sto lic _ mur mur ▁heart
D-342	-0.6566178202629089	holosystolic_murmur heart
P-342	-0.0196 -0.0213 -0.1276 -0.1023 -0.2630 -0.5839 -1.2027 -3.1054 -1.0153 -0.1252
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain_proteins
H-1042	-0.3328639566898346	bro modo main _ ▁protein s
D-1042	-0.3328639566898346	bromodomain_ proteins
P-1042	-0.8601 -0.0933 -0.0177 -0.2068 -0.8494 -0.0516 -0.4248 -0.1592
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart_failure readmission outcome
H-1030	-0.8694572448730469	▁heart ▁failure _ care
D-1030	-0.8694572448730469	heart failure_care
P-1030	-1.0805 -0.5845 -1.5176 -1.1087 -0.7494 -0.1762
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up hf
H-288	-1.026949405670166	▁follow - up ▁ HF
D-288	-1.026949405670166	follow-up HF
P-288	-3.7525 -0.1270 -0.0118 -2.3085 -0.5662 -0.2814 -0.1413
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.5462610721588135	▁ pharma ce ut ically _ assist ed
D-948	-0.5462610721588135	pharmaceutically_assisted
P-948	-0.2442 -0.5681 -0.7110 -0.1155 -0.4958 -1.1210 -0.6215 -0.4568 -0.9831 -0.1457
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse_event hypotension
H-1970	-0.42539724707603455	▁hypo tension
D-1970	-0.42539724707603455	hypotension
P-1970	-0.6966 -0.1171 -0.7607 -0.1273
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt dt implantation
H-315	-0.5562106370925903	▁b t ▁ DT
D-315	-0.5562106370925903	bt DT
P-315	-0.5418 -0.9427 -0.7171 -0.2326 -0.8016 -0.1014
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient mortality therapeutic
H-1667	-1.1289509534835815	▁ therapeut ic
D-1667	-1.1289509534835815	therapeutic
P-1667	-4.1391 -0.1789 -0.0766 -1.0897 -0.1604
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak_vo2
H-1498	-0.4378492534160614	▁Peak _ vo 2
D-1498	-0.4378492534160614	Peak_vo2
P-1498	-0.4842 -0.3226 -0.4352 -0.6805 -0.4513 -0.2533
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 patients plasma
H-699	-0.7395274639129639	▁ST 2 ▁plasma ▁sample s
D-699	-0.7395274639129639	ST2 plasma samples
P-699	-0.7119 -0.2666 -1.2548 -2.3171 -0.1349 -0.3533 -0.1382
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients discharge follow-up medication
H-730	-1.1561893224716187	▁follow - up ▁medication
D-730	-1.1561893224716187	follow-up medication
P-730	-4.4389 -0.1253 -0.0219 -1.2435 -0.9114 -0.1960
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions septal surgical
H-984	-0.7209818959236145	▁sept al _ ▁defect s
D-984	-0.7209818959236145	septal_ defects
P-984	-0.6618 -0.1402 -0.8422 -0.3310 -0.1000 -2.8402 -0.1315
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients extubated blood transfusion
H-777	-0.6137588024139404	▁ex tuba ted ▁blood ▁loss ▁trans fusion
D-777	-0.6137588024139404	extubated blood loss transfusion
P-777	-1.4340 -0.0194 -0.1475 -1.2529 -0.9044 -0.0231 -0.0160 -1.6133 -0.1134
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis mortality patients
H-61	-0.8558185696601868	▁i CD - HF
D-61	-0.8558185696601868	iCD-HF
P-61	-2.9126 -0.3412 -0.1041 -0.1171 -1.3311 -0.3289
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas cardiac pathogenesis
H-1484	-0.36052995920181274	▁mi RNA s ▁cardiac _ path ogen es is
D-1484	-0.36052995920181274	miRNAs cardiac_pathogenesis
P-1484	-1.2216 -0.0516 -0.1174 -0.1708 -0.4179 -1.0730 -0.2150 -0.0856 -0.1057 -0.3741 -0.1331
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers hf
H-1475	-0.5287597179412842	▁bio mark ers ▁ HF
D-1475	-0.5287597179412842	biomarkers HF
P-1475	-0.0189 -0.1072 -0.1422 -2.7297 -0.2260 -0.3095 -0.1678
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative clinical mortality
H-532	-1.2221684455871582	
D-532	-1.2221684455871582	
P-532	-2.2578 -0.1866
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes hospitalization
H-566	-1.5080689191818237	▁non fa tal _ ▁outcome s
D-566	-1.5080689191818237	nonfatal_ outcomes
P-566	-5.1681 -0.3714 -0.2443 -2.4505 -2.3051 -0.1545 -1.1757 -0.1949
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.2356621026992798	▁FIN ding s
D-1955	-1.2356621026992798	FINdings
P-1955	-1.2358 -2.8929 -0.2706 -1.5964 -0.1826
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals outcome
H-1690	-1.6180288791656494	
D-1690	-1.6180288791656494	
P-1690	-2.9323 -0.3038
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf patients
H-671	-0.7731960415840149	▁tras tuz um ab - related _ ▁CHF
D-671	-0.7731960415840149	trastuzumab-related_ CHF
P-671	-1.6259 -0.1173 -0.1082 -1.7029 -0.3536 -1.8165 -0.7611 -0.4793 -0.5579 -0.2092
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients transplants
H-2000	-0.5427197813987732	▁transplant s
D-2000	-0.5427197813987732	transplants
P-2000	-1.1957 -0.2915 -0.5747 -0.1089
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy engage exercise
H-1903	-1.5135518312454224	▁aero bic _ ▁exercise
D-1903	-1.5135518312454224	aerobic_ exercise
P-1903	-6.1412 -0.3499 -0.5455 -1.2973 -0.4901 -0.2573
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.6976308226585388	▁hospital s
D-1694	-0.6976308226585388	hospitals
P-1694	-1.5078 -0.2464 -0.8972 -0.1391
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients condition economic
H-1575	-1.553128719329834	▁economische
D-1575	-1.553128719329834	economische
P-1575	-3.5839 -0.8061 -0.2693
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-1.7392109632492065	▁patient _ ▁safety
D-1	-1.7392109632492065	patient_ safety
P-1	-4.8526 -2.0889 -1.0766 -0.4349 -0.2430
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon_matched-pairs_signed-rank_tests
H-923	-0.434726357460022	▁Wil co xon ▁signed - rank
D-923	-0.434726357460022	Wilcoxon signed-rank
P-923	-0.3792 -0.0096 -0.3677 -1.0869 -0.0640 -0.0681 -1.2755 -0.2267
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left_ventricular_assist_device right_ventricular_support
H-293	-0.7033541798591614	▁left _ ▁vent ri cular _ assist ▁device ▁right _ ▁vent ri cular _ support
D-293	-0.7033541798591614	left_ ventricular_assist device right_ ventricular_support
P-293	-0.5739 -1.1806 -0.3691 -0.8391 -0.5129 -0.1444 -0.3787 -2.6989 -0.8889 -0.4349 -0.7004 -0.8115 -0.3880 -0.3822 -0.9545 -0.5001 -0.1990
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis atherosclerosis cardiovascular_events rotterdam_study
H-1554	-0.6658228039741516	▁p sori asis ▁at hero sc ler osis ▁incident _ ▁cardiovascular _ ▁events ▁Rotterdam
D-1554	-0.6658228039741516	psoriasis atherosclerosis incident_ cardiovascular_ events Rotterdam
P-1554	-2.9983 -0.1034 -0.0509 -0.6099 -0.2674 -0.0437 -3.0690 -0.0285 -0.3410 -0.1118 -0.0837 -1.0267 -0.2929 -0.3128 -1.1572 -0.1561
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal_artery_stenosis ras peripheral_arterial_disease
H-1593	-0.3385048806667328	▁Ren al _ ▁arter y _ ▁sten osis RAS ▁per i pher al _ ▁arterial _ ▁disease
D-1593	-0.3385048806667328	Renal_ artery_ stenosisRAS peripheral_ arterial_ disease
P-1593	-0.2276 -0.0775 -0.6940 -0.1375 -0.2484 -0.4551 -1.0853 -0.0169 -0.0448 -0.1136 -0.0775 -0.0400 -0.2137 -0.1683 -0.5264 -0.7295 -1.0374 -0.3475 -0.1906
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart_failure patients rheumatoid_arthritis tnf_antagonist
H-600	-0.550296425819397	▁Heart _ ▁failure ▁rhe um ato id _ ▁ar thri tis ▁t NF
D-600	-0.550296425819397	Heart_ failure rheumatoid_ arthritis tNF
P-600	-0.3550 -2.3753 -0.1887 -0.3438 -0.0711 -0.3893 -0.4814 -0.1043 -0.4362 -0.4790 -0.6676 -0.6049 -0.0792 -1.4849 -0.1938
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary_artery_disease cad systolic_heart_failure hf
H-1182	-0.39358705282211304	▁Corona ry _ ▁arter y ▁disease CAD ▁sy sto lic _ heart _ ▁failure HF
D-1182	-0.39358705282211304	Coronary_ artery diseaseCAD systolic_heart_ failureHF
P-1182	-0.0468 -0.7306 -0.4696 -0.1473 -0.1123 -0.7890 -0.0448 -0.0218 -0.0144 -0.2451 -0.0445 -1.8843 -1.3779 -0.0887 -0.3366 -0.2342 -0.1032
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality hf hospital admissions transplant ventricular_assist_device
H-125	-0.5907666683197021	▁mortal ity ▁ HF ▁hospital ▁ad missions ▁transplant ▁vent ri cular _ assist _ ▁device
D-125	-0.5907666683197021	mortality HF hospital admissions transplant ventricular_assist_ device
P-125	-0.7023 -1.3021 -0.8496 -0.0372 -1.9496 -0.5883 -0.0556 -0.0148 -0.0145 -0.9993 -0.4480 -0.1340 -0.4205 -1.5406 -0.4719 -0.3706 -0.1442
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.7800506353378296	
D-154	-0.7800506353378296	
P-154	-1.4038 -0.1563
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.9288701415061951	▁hospital s
D-1713	-0.9288701415061951	hospitals
P-1713	-2.2625 -0.5909 -0.6209 -0.2412
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient heart_failure_with_reduced_ejection_fraction
H-1203	-0.8117237091064453	▁heart ▁failure ▁e je ction _ fraction
D-1203	-0.8117237091064453	heart failure ejection_fraction
P-1203	-2.3000 -0.9978 -2.4828 -0.1041 -0.0971 -0.3450 -0.0915 -0.7510 -0.1362
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral_renal_denervation autonomic_balance chronic_heart_failure
H-1369	-0.7512537240982056	▁Uni lateral _ ▁renal _ ▁den er va tion ▁autonomi c _ ▁balance ▁ conscious ▁rabbi ts ▁chronic _ heart _ ▁failure
D-1369	-0.7512537240982056	Unilateral_ renal_ denervation autonomic_ balance conscious rabbits chronic_heart_ failure
P-1369	-3.3993 -0.0078 -0.2328 -0.1624 -0.3945 -2.0766 -0.6104 -0.3983 -0.4944 -0.0066 -0.3175 -0.1182 -1.1833 -1.0686 -0.0991 -0.6447 -0.0871 -3.5815 -0.0595 -1.2839 -1.0637 -0.2554 -0.3023 -0.1825
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression type_i_regulatory_subunit ri hf
H-1429	-1.051147699356079	▁regulator y _ sub un it RI ▁ HF
D-1429	-1.051147699356079	regulatory_subunitRI HF
P-1429	-3.5703 -0.1544 -0.4559 -0.9165 -1.9008 -0.1240 -1.2629 -2.4016 -0.3663 -0.2487 -0.1613
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat mir-25 transcription_factor hand2 heart_failure
H-638	-0.6259934306144714	▁n fat ▁mi r -25 ▁tran scription _ ▁factor _ hand 2 ▁heart _ ▁failure
D-638	-0.6259934306144714	nfat mir-25 transcription_ factor_hand2 heart_ failure
P-638	-3.0677 -0.1167 -0.3448 -0.9509 -0.0353 -0.0388 -0.0697 -1.0455 -1.1097 -1.4260 -0.0312 -0.2532 -0.3032 -1.4019 -0.0607 -0.2184 -0.1683
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf_inhibition cardiac_function remodeling
H-458	-0.40174639225006104	▁VE GF ▁inhibi tion ▁b ▁cardiac _ ▁function ▁remodel ing
D-458	-0.40174639225006104	VEGF inhibition b cardiac_ function remodeling
P-458	-0.4506 -0.0652 -0.9486 -0.0934 -1.4226 -0.2235 -0.5493 -0.6302 -0.0864 -0.0362 -0.2335 -0.0814
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas right_atrium embolize pulmonary_arterial_vasculature
H-594	-0.37433382868766785	▁My xo mas ▁right _ at rium ▁pulmonar y _ ▁arterial _ vas cula ture
D-594	-0.37433382868766785	Myxomas right_atrium pulmonary_ arterial_vasculature
P-594	-0.4626 -0.0116 -0.3890 -0.6229 -0.1115 -0.9933 -0.0110 -0.0069 -0.1589 -0.6978 -0.1195 -0.6691 -1.1904 -0.1365 -0.0525 -0.5185 -0.2116
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right_atrial_myxoma pulmonary_embolism right_heart_failure
H-592	-0.5554272532463074	▁Right _ at rial _ my xo ma ▁pulmonar y _ e mbol ism ▁right _ ▁heart _ ▁failure
D-592	-0.5554272532463074	Right_atrial_myxoma pulmonary_embolism right_ heart_ failure
P-592	-0.4930 -0.1054 -0.6319 -0.1185 -0.1957 -2.4658 -0.0755 -0.1832 -0.0068 -0.0869 -0.8770 -1.1815 -0.0101 -0.5821 -0.1376 -0.0602 -2.2574 -1.5499 -0.2182 -0.2946 -0.1328
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic_heart_transplantation oht end-stage_heart_failure
H-1280	-0.893050491809845	▁Ort ho topic _ heart _ ▁transplant ation ▁o HT ▁heart _ ▁failure
D-1280	-0.893050491809845	Orthotopic_heart_ transplantation oHT heart_ failure
P-1280	-0.5454 -0.0285 -0.0886 -0.0947 -2.0578 -1.4978 -0.3778 -0.1083 -0.0218 -1.7578 -4.3865 -1.9826 -0.1640 -0.1828 -0.1015
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary_heart_disease stroke heart_failure
H-1564	-0.7140985131263733	▁corona ry _ ▁heart ▁disease ▁stroke ▁heart ▁failure
D-1564	-0.7140985131263733	coronary_ heart disease stroke heart failure
P-1564	-0.0505 -1.2744 -0.1040 -2.6444 -1.4542 -0.0551 -0.2496 -0.9032 -0.2743 -0.1313
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing β-blocker sst2
H-400	-0.522535502910614	▁β - block er bb ▁s st 2
D-400	-0.522535502910614	β-blockerbb sst2
P-400	-0.3973 -0.0904 -0.2951 -0.1174 -1.0719 -0.0832 -1.8958 -0.1839 -0.9212 -0.1693
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone primary_composite_endpoint
H-1227	-0.22589199244976044	▁e pler en one
D-1227	-0.22589199244976044	eplerenone
P-1227	-0.1878 -0.0044 -0.0352 -0.2235 -0.7002 -0.2042
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet exercise_rehabilitation patients chf
H-1884	-0.6018194556236267	▁c PET ▁gu iding _ ▁exercise _ ▁rehabilita tion ▁CHF
D-1884	-0.6018194556236267	cPET guiding_ exercise_ rehabilitation CHF
P-1884	-0.3533 -2.5207 -1.1204 -0.0285 -0.2167 -0.8700 -0.9287 -0.5187 -0.1906 -0.1596 -0.1732 -0.1414
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline outcomes ecct cardiac_transplant
H-711	-0.7090353965759277	▁ec CT ▁cardiac _ ▁transplant ▁recipient s
D-711	-0.7090353965759277	ecCT cardiac_ transplant recipients
P-711	-0.6702 -2.1334 -0.1094 -1.4688 -0.2639 -0.7208 -0.4045 -0.4061 -0.2042
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate_ii lvads patients
H-776	-0.808638334274292	▁techniek ▁mal function ing ▁Heart Mate _ ▁II _ ▁l VAD s
D-776	-0.808638334274292	techniek malfunctioning HeartMate_ II_ lVADs
P-776	-0.6833 -3.3613 -0.1811 -0.0692 -0.7929 -0.0962 -0.2187 -1.3185 -0.3336 -3.0796 -0.0498 -0.1984 -0.6613 -0.2769
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart_failure hf cardiovascular hospitalization
H-1074	-0.47487643361091614	▁Heart ▁failure HF ▁cardiovascular _ hospital ization
D-1074	-0.47487643361091614	Heart failureHF cardiovascular_hospitalization
P-1074	-0.4334 -0.5438 -0.1483 -0.3900 -0.8526 -0.1431 -0.5449 -1.0385 -0.1794
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing medications heart_failure
H-1121	-1.5362046957015991	▁medication s ▁adults ▁heart ▁failure
D-1121	-1.5362046957015991	medications adults heart failure
P-1121	-3.8508 -0.2363 -3.1679 -2.0943 -0.7772 -0.4166 -0.2104
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient asymptomatic follow-up
H-599	-0.8253192901611328	▁as ym pto matic
D-599	-0.8253192901611328	asymptomatic
P-599	-3.1847 -0.0966 -0.0233 -0.1738 -1.3869 -0.0865
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality_of_life mlhf_questionnaire
H-1991	-1.006042242050171	▁ ML HF
D-1991	-1.006042242050171	MLHF
P-1991	-1.7458 -0.7061 -1.0589 -1.2744 -0.2451
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients heart_failure diagnostic medication follow-up
H-732	-1.1248767375946045	▁heart ▁failure ▁medication
D-732	-1.1248767375946045	heart failure medication
P-732	-2.2815 -1.3802 -1.2520 -0.4879 -0.2228
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation resistin correlated ejection_fraction
H-938	-0.3372870683670044	▁resist in ▁e je ction _ fraction
D-938	-0.3372870683670044	resistin ejection_fraction
P-938	-0.1338 -0.6510 -0.1025 -0.0536 -0.0945 -0.6204 -0.0427 -1.1241 -0.2130
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart_failure hf morbidity mortality
H-199	-0.5700110197067261	▁Pediatri c _ ▁heart ▁failure HF ▁morbi d ity ▁mortal ity
D-199	-0.5700110197067261	Pediatric_ heart failureHF morbidity mortality
P-199	-0.2756 -0.0226 -0.2494 -2.3530 -0.9808 -0.2452 -0.1274 -0.0200 -1.5615 -0.0549 -1.0883 -0.2810 -0.1507
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change readmissions follow-up heart_failure readmission
H-720	-0.9831337332725525	▁read missions ▁follow - up _ ▁visit s ▁heart _ ▁failure
D-720	-0.9831337332725525	readmissions follow-up_ visits heart_ failure
P-720	-3.8763 -0.1005 -0.0343 -0.0909 -0.0130 -1.7044 -0.4021 -0.0857 -0.3257 -1.4300 -0.2017 -4.3033 -0.2127
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic inflammatory abdominal
H-1285	-0.6983528137207031	▁ ische mic _ in flam ma tory _ ▁abdominal _ problem ▁MT
D-1285	-0.6983528137207031	ischemic_inflammatory_ abdominal_problem MT
P-1285	-0.5117 -0.1125 -0.8904 -0.4714 -0.0161 -0.0487 -2.1424 -0.3831 -0.0800 -1.3496 -0.8947 -0.6638 -1.6540 -1.0557 -0.2011
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase myocardium
H-171	-0.46316230297088623	▁band ▁activa ted _ ▁Cas pas e ▁pace d _ my o car dium
D-171	-0.46316230297088623	band activated_ Caspase paced_myocardium
P-171	-1.4405 -0.5292 -0.1549 -0.5448 -1.0287 -0.0250 -0.1484 -0.2963 -0.0338 -0.1473 -2.4546 -0.0662 -0.0035 -0.0708 -0.3530 -0.1135
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations acr cms
H-140	-0.3864714503288269	▁a cr ▁CMS
D-140	-0.3864714503288269	acr CMS
P-140	-0.2601 -0.4022 -0.1374 -0.9738 -0.1588
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline embase cinahl
H-62	-0.5349783897399902	▁med line ▁ EMBA se ▁c INA HL
D-62	-0.5349783897399902	medline EMBAse cINAHL
P-62	-0.4023 -1.2089 -0.6501 -0.0348 -0.9637 -0.3459 -0.6705 -0.7395 -0.2363 -0.0980
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal_dysfunction morbidity
H-719	-0.4661199152469635	▁renal _ ▁dys function ▁post - trans plant ▁morbi d ity
D-719	-0.4661199152469635	renal_ dysfunction post-transplant morbidity
P-719	-0.9556 -0.5222 -0.4434 -0.0943 -0.4636 -0.0346 -0.0274 -0.0564 -0.3020 -0.0817 -2.5687 -0.3397 -0.1700
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia heart_disease
H-40	-1.2523112297058105	▁an emia ▁adults ▁heart ▁disease
D-40	-1.2523112297058105	anemia adults heart disease
P-40	-3.0594 -0.2541 -1.9741 -2.2238 -0.7847 -0.3060 -0.1640
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart_failure disease medical
H-2008	-1.1010128259658813	▁Heart ▁failure _ ▁disease ▁management
D-2008	-1.1010128259658813	Heart failure_ disease management
P-2008	-0.8677 -0.8786 -0.6219 -1.1783 -1.1748 -2.7564 -0.2294
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin sitagliptin
H-1828	-0.4719688892364502	▁h HF ▁sax ag lip tin ▁si tag lip tin
D-1828	-0.4719688892364502	hHF saxagliptin sitagliptin
P-1828	-0.0102 -1.3626 -0.4936 -0.0099 -0.2271 -1.5272 -0.3101 -0.0975 -0.0514 -1.1716 -0.3014 -0.1011
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based therapies patients fes
H-1333	-1.1269773244857788	▁ therapie s ▁f es
D-1333	-1.1269773244857788	therapies fes
P-1333	-2.7077 -1.6646 -0.1093 -1.8429 -1.1079 -0.3118 -0.1447
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction pump driveline pump curative
H-774	-0.4460125267505646	▁dys function ▁pump ▁failure ▁drive line _ ▁injury ▁isola ted _ pump ▁replace ment
D-774	-0.4460125267505646	dysfunction pump failure driveline_ injury isolated_pump replacement
P-774	-2.3847 -0.0184 -0.9279 -0.2508 -0.0244 -0.0217 -1.0069 -0.0289 -0.1019 -0.0403 -0.4338 -0.6693 -0.7236 -0.1269 -0.2539 -0.1228
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up hf deaths
H-1771	-0.6940092444419861	▁ HF
D-1771	-0.6940092444419861	HF
P-1771	-1.0295 -0.4299 -1.1070 -0.2097
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital discharge
H-302	-2.040865421295166	▁hospital _ ▁dis charge
D-302	-2.040865421295166	hospital_ discharge
P-302	-7.5609 -1.0544 -2.6481 -0.3272 -0.4482 -0.2064
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal_dnx plasma
H-1381	-0.43137985467910767	▁Ren al _ ▁DN x ▁circula ting _ ▁plasma ▁CHF - in v ▁rabbi ts
D-1381	-0.43137985467910767	Renal_ DNx circulating_ plasma CHF-inv rabbits
P-1381	-0.1794 -0.0263 -0.3347 -1.3127 -0.0698 -0.0007 -0.4513 -0.2279 -0.4117 -2.3212 -0.0866 -0.2227 -0.5762 -0.5476 -0.1148 -0.2911 -0.1587
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna genotyped
H-1454	-0.6855347752571106	▁h ct ▁germ line _ DNA ▁geno type d
D-1454	-0.6855347752571106	hct germline_DNA genotyped
P-1454	-3.6265 -2.0745 -0.3045 -0.1058 -0.0627 -0.3815 -0.1875 -0.0026 -0.2307 -0.4261 -0.1384
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients lvad implantation
H-531	-0.5807461738586426	▁l VAD ▁implant ation
D-531	-0.5807461738586426	lVAD implantation
P-531	-0.4456 -0.1282 -1.8194 -0.1340 -0.7766 -0.1807
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients cad cad
H-1189	-0.6576899886131287	▁deriva tion ▁co hor t ▁CAD ▁severe _ ▁CAD
D-1189	-0.6576899886131287	derivation cohort CAD severe_ CAD
P-1189	-2.0062 -0.1417 -1.7983 -0.1451 -0.0636 -0.1956 -0.7757 -0.5390 -1.1092 -0.3024 -0.1578
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients randomized
H-1874	-0.7799541354179382	
D-1874	-0.7799541354179382	
P-1874	-1.3640 -0.1959
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient clinical symptoms
H-1468	-1.1258031129837036	▁treatment
D-1468	-1.1258031129837036	treatment
P-1468	-2.5746 -0.6753 -0.1275
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients blood medication
H-729	-1.066760778427124	▁blood _ work _ ▁draw n ▁medication
D-729	-1.066760778427124	blood_work_ drawn medication
P-729	-3.0863 -1.8839 -0.6354 -0.7200 -1.1638 -0.2894 -0.5367 -1.0321 -0.2533
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.7836883664131165	▁HD l - bound ▁malo ndi alde hy de ▁ec
D-252	-0.7836883664131165	HDl-bound malondialdehyde ec
P-252	-1.2004 -2.1068 -0.0229 -0.1067 -0.8888 -0.1001 -0.0212 -1.5870 -0.1897 -2.6115 -0.4189 -0.1502
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients trastuzumab
H-676	-0.2949020564556122	▁tras tuz um ab
D-676	-0.2949020564556122	trastuzumab
P-676	-0.6144 -0.1331 -0.0438 -0.3831 -0.4341 -0.1609
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses patients
H-1021	-0.708244264125824	▁ NP _ ▁assessment ▁ED
D-1021	-0.708244264125824	NP_ assessment ED
P-1021	-0.4570 -0.0835 -1.9317 -0.8116 -0.3760 -1.1075 -0.1904
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow_up hf
H-627	-1.070827603340149	▁ HF
D-627	-1.070827603340149	HF
P-627	-2.8446 -0.7971 -0.4754 -0.1661
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical outcomes hfpef
H-1525	-0.4217911958694458	▁EH ▁ HF p EF
D-1525	-0.4217911958694458	EH HFpEF
P-1525	-0.4706 -1.1516 -0.5118 -0.0400 -0.3367 -0.2619 -0.1799
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ambulatory patients heart_failure functional_capacity outcomes
H-695	-0.8820767402648926	▁Solu ble _ ▁ST 2 ▁ambula tory _ ▁patients _ with _ heart _ ▁failure
D-695	-0.8820767402648926	Soluble_ ST2 ambulatory_ patients_with_heart_ failure
P-695	-0.1824 -0.2784 -0.1003 -3.0369 -0.2397 -2.0786 -0.2367 -0.4671 -1.0284 -0.8269 -3.0895 -0.2129 -1.2478 -0.9918 -0.0932 -0.7331 -0.1516
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote_monitoring hospital discharge patients heart_failure meta-analysis
H-146	-1.1364874839782715	▁remote _ monitor ing ▁hospital _ ▁dis charge ▁heart _ ▁failure
D-146	-1.1364874839782715	remote_monitoring hospital_ discharge heart_ failure
P-146	-1.3690 -0.3697 -0.0934 -0.0114 -5.3928 -1.0381 -0.9108 -0.1426 -3.6428 -1.2242 -0.1576 -0.2465 -0.1755
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline echocardiograms evidence reverse_remodeling
H-907	-0.46978336572647095	▁e cho card i ogram s
D-907	-0.46978336572647095	echocardiograms
P-907	-0.3053 -0.0730 -0.3003 -0.4640 -0.0083 -0.2992 -2.1903 -0.1179
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin_hypophosphorylation myocardial_dd
H-771	-0.5404422283172607	▁Tit in ▁hypo phos phor y lation ▁my o card ial DD
D-771	-0.5404422283172607	Titin hypophosphorylation myocardialDD
P-771	-0.0517 -0.4398 -1.8163 -0.0704 -0.1894 -0.8733 -0.0878 -0.9860 -0.1852 -0.3471 -0.4191 -1.7461 -0.2320 -0.1220
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac_overexpression mammalian_enabled mena heart_failure
H-1809	-0.5470917820930481	▁Card iac _ over expression ▁Mamma lian ▁men a ▁heart ▁failure ▁mi ce
D-1809	-0.5470917820930481	Cardiac_overexpression Mammalian mena heart failure mice
P-1809	-0.3394 -0.0105 -1.2796 -0.3599 -0.1061 -0.2451 -0.1026 -2.2267 -0.0731 -0.5391 -0.6419 -1.9056 -0.0561 -0.2016 -0.1190
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis chronic_heart_failure tachycardia
H-164	-1.0319023132324219	▁chronic _ heart _ ▁failure ▁ta chy car dia
D-164	-1.0319023132324219	chronic_heart_ failure tachycardia
P-164	-6.7235 -0.1464 -1.6981 -1.0112 -0.1667 -0.8486 -0.2024 -0.0102 -0.0157 -0.3650 -0.1631
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker uptitration hfpef
H-183	-0.5704210996627808	▁benefit ▁β - block er _ up tit ration ▁ HF p EF
D-183	-0.5704210996627808	benefit β-blocker_uptitration HFpEF
P-183	-0.3976 -2.9987 -0.0844 -0.2522 -0.0914 -0.5946 -0.2608 -0.6119 -0.7580 -1.1320 -0.4979 -0.0435 -0.5257 -0.1932 -0.1143
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise adverse_events coronary_artery_disease cad
H-1899	-0.6577616930007935	▁corona ry _ ▁arter y _ ▁disease CAD
D-1899	-0.6577616930007935	coronary_ artery_ diseaseCAD
P-1899	-1.9259 -1.2927 -0.4474 -0.2771 -0.3029 -1.2244 -0.5921 -0.0472 -0.2959 -0.1720
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv_filling_pressure stable severe_systolic_hf
H-489	-0.4933077096939087	▁LV ▁fill ing _ ▁pressure ▁severe _ sy sto lic _ HF
D-489	-0.4933077096939087	LV filling_ pressure severe_systolic_HF
P-489	-0.6366 -0.6872 -0.1008 -0.6126 -0.4323 -1.6962 -0.2641 -1.1011 -0.0820 -0.0201 -0.1437 -0.6955 -0.3106 -0.1234
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal_bleeding patients ventricular_assist_devices cardiac nurse
H-1656	-0.6540226936340332	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist _ ▁devices ▁cardiac _ ▁nurse
D-1656	-0.6540226936340332	Gastrointestinal_ bleeding ventricular_assist_ devices cardiac_ nurse
P-1656	-0.2060 -0.7699 -1.5870 -0.2594 -0.6341 -0.5701 -0.9161 -0.1652 -0.0746 -1.3119 -0.7765 -0.1687 -0.4102 -2.7143 -0.5057 -0.0443 -0.8924 -0.2696 -0.6318 -0.1727
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas bridge_to_transplantation destination_therapy
H-1999	-0.38528934121131897	▁l VAS ▁ bridge _ to _ ▁transplant ation ▁destination _ therapy
D-1999	-0.38528934121131897	lVAS bridge_to_ transplantation destination_therapy
P-1999	-0.1889 -0.4244 -0.6923 -0.0404 -0.6391 -1.2218 -0.1572 -0.4992 -0.0807 -0.2683 -0.7476 -0.0314 -0.2821 -0.1208
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 prognosis heart_failure
H-399	-1.0490155220031738	▁solu ble ▁s st 2 ▁heart _ ▁failure
D-399	-1.0490155220031738	soluble sst2 heart_ failure
P-399	-2.1608 -0.4787 -0.6201 -3.9120 -0.2193 -0.8292 -1.7506 -0.2138 -0.1698 -0.1359
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs functional_capacity peak_vo2
H-123	-0.8252784013748169	▁c PC s ▁functional _ capaci te ▁VO 2
D-123	-0.8252784013748169	cPCs functional_capacite VO2
P-123	-0.2206 -1.4752 -0.1088 -0.0476 -1.1591 -0.5096 -0.5279 -3.4068 -0.9717 -0.4875 -0.1633
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac_hypertrophy energy_metabolism
H-1778	-0.6893801689147949	▁Card iac _ ▁hyper trop hy ▁energie ▁metabolism
D-1778	-0.6893801689147949	Cardiac_ hypertrophy energie metabolism
P-1778	-1.6902 -0.0840 -0.2851 -0.8172 -0.0530 -1.3842 -1.4269 -0.4925 -0.4968 -0.1640
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east rhythm_control_therapy cardiovascular complications
H-1648	-0.4889691472053528	▁e ast ▁ rhythm _ control _ therapy ▁cardiovascular ▁complica tions ▁AF
D-1648	-0.4889691472053528	east rhythm_control_therapy cardiovascular complications AF
P-1648	-0.4017 -0.5207 -0.1505 -0.4455 -0.5267 -0.0228 -1.3839 -0.0670 -0.4376 -0.6736 -1.4041 -0.4291 -0.2201 -0.1624
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty heart_failure health
H-621	-1.0003215074539185	▁fra il ty ▁heart _ ▁failure ▁older _ ▁adults
D-621	-1.0003215074539185	frailty heart_ failure older_ adults
P-621	-0.8631 -0.1811 -0.0820 -3.6811 -1.3509 -0.3211 -1.4038 -0.6773 -0.8448 -1.4744 -0.1238
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil orally doxorubicin
H-959	-0.28288084268569946	▁Nico rand il ▁do xor ubi cin
D-959	-0.28288084268569946	Nicorandil doxorubicin
P-959	-0.0046 -0.0093 -0.0929 -0.5504 -0.0150 -0.0221 -0.5077 -1.2708 -0.0732
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients clinical radiological hf hospitalization
H-560	-0.731731653213501	▁ HF
D-560	-0.731731653213501	HF
P-560	-1.9468 -0.2405 -0.5554 -0.1842
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart heart_failure arrhythmias
H-747	-0.7717810869216919	▁Heart _ t 2 ▁heart _ ▁failure ▁ar rhythm ias
D-747	-0.7717810869216919	Heart_t2 heart_ failure arrhythmias
P-747	-0.5375 -1.4434 -0.9403 -0.0371 -3.2432 -1.7289 -0.1853 -0.0393 -0.1041 -0.4588 -0.4353 -0.1081
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham_heart_study hf ef
H-1103	-0.4948347508907318	▁Fram ing ham _ ▁Heart ▁Study ▁ HF ▁EF
D-1103	-0.4948347508907318	Framingham_ Heart Study HF EF
P-1103	-0.0650 -0.1195 -0.0593 -0.3118 -0.2319 -0.5373 -1.3701 -0.1547 -2.2364 -0.2468 -0.1105
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations congestive_heart_failure
H-208	-0.8665437698364258	▁in tuba tions ▁con ges tive _ ▁heart ▁failure
D-208	-0.8665437698364258	intubations congestive_ heart failure
P-208	-1.6396 -0.0933 -1.2170 -1.0447 -0.1215 -1.5983 -0.0383 -2.6188 -0.7692 -0.2638 -0.1274
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics symptoms patients heart_failure hf
H-1199	-0.5104497671127319	▁di ure tics ▁con ges tive _ ▁symptoms ▁heart ▁failure HF
D-1199	-0.5104497671127319	diuretics congestive_ symptoms heart failureHF
P-1199	-0.3891 -0.6861 -0.3982 -0.5436 -0.1769 -1.4017 -0.6748 -0.3957 -0.6530 -0.6826 -0.1863 -0.3073 -0.1408
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence acp clinical_practice_guidelines
H-35	-0.7933651804924011	▁a CP ▁clinic al _ ▁practice ▁guidelines
D-35	-0.7933651804924011	aCP clinical_ practice guidelines
P-35	-1.4097 -0.3845 -1.0268 -0.1013 -0.2764 -1.2174 -2.1552 -0.4122 -0.1567
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck_stent chronic_myocardial_ischemia heart_failure
H-502	-0.45414990186691284	▁bottle ne ck _ ▁sten t ▁chronic _ ▁my o card ial _ ische mia ▁heart ▁failure ▁pig s
D-502	-0.45414990186691284	bottleneck_ stent chronic_ myocardial_ischemia heart failure pigs
P-502	-0.4088 -0.0692 -0.0206 -0.2720 -1.8642 -0.0423 -0.6108 -0.2272 -2.8400 -0.2331 -0.5797 -0.4281 -0.1479 -0.1172 -0.6016 -0.2085 -0.3731 -0.0376 -0.0725 -0.2573 -0.1254
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis mortality patients
H-68	-0.8045599460601807	▁i CD - HF
D-68	-0.8045599460601807	iCD-HF
P-68	-2.4000 -0.7620 -0.0880 -0.1284 -1.1852 -0.2638
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient patients discharged hf
H-1400	-0.7398699522018433	▁in patient _ ▁records ▁ HF
D-1400	-0.7398699522018433	inpatient_ records HF
P-1400	-0.1259 -0.0454 -1.9730 -0.0346 -2.7210 -0.4828 -0.3660 -0.1702
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report aric hf
H-290	-0.6892991662025452	▁a RIC _ HF
D-290	-0.6892991662025452	aRIC_HF
P-290	-0.3772 -0.8506 -0.2230 -1.9176 -0.5712 -0.1963
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients therapy hospitalized cardiovascular
H-1223	-1.1326133012771606	▁cardiovascular _ ▁reason
D-1223	-1.1326133012771606	cardiovascular_ reason
P-1223	-2.4776 -2.1602 -0.5034 -0.2924 -0.2295
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients pneumonia surgical conditions
H-5	-0.9134631156921387	▁pneu monia ▁sur g ical
D-5	-0.9134631156921387	pneumonia surgical
P-5	-1.2625 -0.7048 -1.4873 -0.6052 -0.6597 -1.5103 -0.1644
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis therapy
H-1467	-0.4272046983242035	▁ therapy
D-1467	-0.4272046983242035	therapy
P-1467	-1.0570 -0.2055 -0.2616 -0.1847
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.7389688491821289	
D-1852	-0.7389688491821289	
P-1852	-1.3498 -0.1281
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease accounting cardiac_transplants
H-982	-0.4823552668094635	▁pa e dia tric _ ▁cardiac _ ▁transplant s ▁children
D-982	-0.4823552668094635	paediatric_ cardiac_ transplants children
P-982	-0.4541 -0.1539 -0.0665 -0.2565 -0.2048 -0.1010 -1.2983 -0.3783 -0.2818 -2.0795 -0.3043 -0.2092
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter_ablation sinus_rhythm
H-945	-0.9348799586296082	▁AF - free _ ▁probabil ity ▁cat heter ▁ab lation ▁sinus ▁ rhythm
D-945	-0.9348799586296082	AF-free_ probability catheter ablation sinus rhythm
P-945	-3.8849 -0.0867 -0.2211 -0.9319 -4.0926 -0.9150 -0.5783 -0.0737 -0.4288 -0.1945 -0.3957 -1.3233 -0.3566 -0.3726 -0.1676
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc outcomes outcome admission discharge
H-1401	-1.228378415107727	▁no c
D-1401	-1.228378415107727	noc
P-1401	-0.6268 -1.1522 -2.8870 -0.2475
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients implantation crt
H-848	-0.8636345267295837	▁device ▁implant ation ▁c RT
D-848	-0.8636345267295837	device implantation cRT
P-848	-0.6561 -1.4835 -0.2072 -0.2710 -1.7789 -1.5297 -0.1192
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol exercise training baseline hgb
H-843	-0.7819589972496033	▁HR Qo L ▁exercise _ training ▁h gb
D-843	-0.7819589972496033	HRQoL exercise_training hgb
P-843	-1.1450 -0.0186 -2.0190 -0.9983 -1.4779 -0.1271 -1.7001 -0.0178 -0.1981 -0.1176
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs osprey
H-1611	-0.5139233469963074	▁de g s ▁o spre y ▁network s
D-1611	-0.5139233469963074	degs osprey networks
P-1611	-0.1746 -3.1251 -0.2947 -0.0308 -0.0095 -0.0585 -1.1261 -0.0597 -0.1905 -0.0699
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.6193921566009521	▁ir on
D-49	-0.6193921566009521	iron
P-49	-0.3123 -0.3321 -1.6827 -0.1506
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-1.1770628690719604	▁ED ▁CHF
D-216	-1.1770628690719604	ED CHF
P-216	-2.3349 -1.9308 -0.2467 -0.1959
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit_index
H-1008	-0.7209166288375854	▁deficit ▁index SD
D-1008	-0.7209166288375854	deficit indexSD
P-1008	-0.2719 -1.2594 -1.7508 -0.1710 -0.1514
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare policy
H-1716	-0.5912057161331177	▁Medica re ▁post - a cute _ care _ transfer _ policy
D-1716	-0.5912057161331177	Medicare post-acute_care_transfer_policy
P-1716	-0.3481 -0.0120 -0.3108 -0.0405 -0.0319 -0.0254 -0.0378 -1.6484 -0.5193 -1.6109 -1.7894 -0.4442 -1.2266 -0.2314
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-1.228964924812317	▁benefit ▁QR s
D-892	-1.228964924812317	benefit QRs
P-892	-3.1634 -0.8684 -1.5487 -0.4524 -0.1119
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical change
H-792	-0.9982009530067444	
D-792	-0.9982009530067444	
P-792	-1.9064 -0.0900
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-0.8291212916374207	▁Diet _ ▁score ▁vegetables ▁nu ts ▁whole _ ▁grain _ ▁in take ▁mortal ity
D-692	-0.8291212916374207	Diet_ score vegetables nuts whole_ grain_ intake mortality
P-692	-4.8063 -1.0595 -0.5533 -1.1318 -0.1844 -0.0883 -0.2288 -0.2424 -1.1975 -0.4025 -0.8769 -0.3462 -0.4724 -1.2579 -0.2122 -0.2055
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-1.2251702547073364	▁benefit
D-619	-1.2251702547073364	benefit
P-619	-3.2107 -0.2678 -0.1970
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-0.8893479108810425	▁contra s ting _ groep ▁interne _ ▁consiste ncy
D-1508	-0.8893479108810425	contrasting_groep interne_ consistency
P-1508	-2.7240 -0.2248 -0.1269 -0.2620 -1.6430 -2.0766 -0.4642 -0.8838 -0.0865 -1.1248 -0.1662
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt_intervals sd_of_all_qt_intervals sdqt
H-1439	-0.6144003868103027	▁ QT _ ▁interval s ▁SD QT
D-1439	-0.6144003868103027	QT_ intervals SDQT
P-1439	-0.2176 -0.2857 -1.3187 -0.0092 -0.0527 -0.1802 -2.7650 -0.5384 -0.1621
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic right_ventricular_contractile_reserve patients pulmonary_hypertension
H-821	-0.52818363904953	▁vent ri cular _ contract ile ▁reserve ▁pulmonar y _ ▁hyper tension
D-821	-0.52818363904953	ventricular_contractile reserve pulmonary_ hypertension
P-821	-1.5048 -1.1284 -0.5868 -0.1806 -0.4998 -0.4196 -0.4107 -0.1977 -0.1864 -0.4474 -1.3799 -0.0264 -0.3051 -0.1210
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart_rate aortic blood_flow doxorubicin
H-960	-0.48987841606140137	▁Heart _ en _ a or tic _ ▁blood _ ▁flow ▁do xor ubi cin
D-960	-0.48987841606140137	Heart_en_aortic_ blood_ flow doxorubicin
P-960	-0.7111 -0.9772 -1.6865 -0.1914 -0.5068 -0.0505 -0.9632 -0.0189 -1.4413 -0.6720 -0.2385 -0.1558 -0.0103 -0.0296 -0.3076 -0.2936 -0.0735
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute autonomic_nervous_system qtv hf patients
H-1447	-0.7906948924064636	▁a cute _ ▁autonomi c _ ▁ner vous _ system _ modul ation ▁Q TV ▁ HF
D-1447	-0.7906948924064636	acute_ autonomic_ nervous_system_modulation QTV HF
P-1447	-0.7302 -0.0107 -0.0409 -0.7864 -0.2247 -0.0764 -3.1516 -0.9843 -0.3553 -0.9757 -2.7223 -0.7196 -0.1109 -0.5751 -0.8584 -1.4689 -0.4351 -0.6747 -0.1219
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular_death hf hospitalization exercise training patients btes
H-1933	-0.7514302730560303	▁cardiovascular _ ▁death ▁ HF _ hospital ization ▁exercise _ training ▁b tes
D-1933	-0.7514302730560303	cardiovascular_ death HF_hospitalization exercise_training btes
P-1933	-0.2797 -0.8279 -0.7850 -0.3900 -0.0116 -3.1833 -0.5571 -0.4411 -0.0578 -1.1390 -0.1928 -2.6320 -0.4488 -0.2107 -0.1146
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac_resynchronization_therapy patients heart_failure
H-903	-0.6120153665542603	▁cardiac _ re syn chron ization _ therapy ▁di al ysis - dependent _ ▁patients ▁heart ▁failure
D-903	-0.6120153665542603	cardiac_resynchronization_therapy dialysis-dependent_ patients heart failure
P-903	-0.3215 -0.8356 -0.3934 -0.1164 -0.0149 -1.7042 -1.5506 -0.3428 -0.2710 -0.0614 -0.0241 -0.1750 -0.0770 -0.7005 -1.2179 -2.4377 -0.8934 -0.2946 -0.1964
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo bivp correlated rs_synchrony
H-327	-0.7193813323974609	▁ rv po ▁Bi VP ▁co ▁RS ▁synchron y ▁CS
D-327	-0.7193813323974609	rvpo BiVP co RS synchrony CS
P-327	-1.4162 -0.6999 -1.3002 -0.6174 -0.1876 -2.8991 -0.9007 -0.0111 -0.2127 -0.0577 -0.1847 -0.1454
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ventricular-arterial_coupling
H-526	-0.42250457406044006	▁e es ▁vent ri cular - arte rial _ ▁coup ling ▁SV
D-526	-0.42250457406044006	ees ventricular-arterial_ coupling SV
P-526	-0.6647 -0.0685 -0.0521 -1.0200 -0.3975 -0.2264 -0.0757 -0.1616 -0.2630 -1.5015 -0.6887 -0.3013 -0.3093 -0.1847
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial pde2 expression activity hf
H-1213	-0.8980375528335571	▁My o card ial _ p de 2 ▁ HF
D-1213	-0.8980375528335571	Myocardial_pde2 HF
P-1213	-0.7904 -0.2843 -0.1958 -0.4598 -0.3589 -1.4052 -1.3957 -0.0953 -3.7774 -1.5950 -0.2326 -0.1859
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1_mapping clinically myocardial_fibrosis
H-1065	-1.2653990983963013	▁ma pping ▁my o card ial _ ▁fibro sis
D-1065	-1.2653990983963013	mapping myocardial_ fibrosis
P-1065	-5.8148 -0.1516 -2.7306 -0.7897 -1.7898 -1.2210 -0.3625 -0.1716 -0.4785 -0.2634 -0.1460
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat sympathetic_outflow parasympathetic_activity
H-1869	-0.48866572976112366	▁BAT ▁sympa the tic _ out flow ▁para sy mpa the tic _ activ iteit
D-1869	-0.48866572976112366	BAT sympathetic_outflow parasympathetic_activiteit
P-1869	-0.0544 -0.4089 -0.8643 -1.1540 -0.1190 -0.2455 -0.4765 -0.1034 -0.0451 -0.2461 -1.5402 -1.0632 -0.5053 -0.4245 -0.4084 -0.4783 -0.1702
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin acute anthracycline-induced_cardiotoxicity
H-931	-0.6101396679878235	▁resist in ▁an thra cycli ne - indu ced _ ▁cardio toxic iteit
D-931	-0.6101396679878235	resistin anthracycline-induced_ cardiotoxiciteit
P-931	-0.5100 -0.2146 -1.7019 -0.0875 -0.1834 -1.7012 -0.5108 -0.0037 -0.4746 -0.2047 -0.2232 -0.5296 -2.1131 -0.4660 -0.2278
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal_muscle correlated vo2_max
H-1500	-0.81222003698349	▁Low _ ▁skelet al _ ▁muscle _ ▁mass ▁VO 2
D-1500	-0.81222003698349	Low_ skeletal_ muscle_ mass VO2
P-1500	-1.5547 -0.3391 -1.2012 -0.0540 -0.1069 -0.9713 -1.1562 -1.0428 -2.6044 -0.1796 -0.3923 -0.1441
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized double-blind active placebo
H-77	-2.130560874938965	
D-77	-2.130560874938965	
P-77	-3.9977 -0.2634
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac_catheterization patient extubated transferred
H-1297	-0.5075251460075378	▁emergency _ ▁cardiac _ ▁cat heter ization ▁ex tuba ted ▁intermedi ate _ care
D-1297	-0.5075251460075378	emergency_ cardiac_ catheterization extubated intermediate_care
P-1297	-0.4443 -0.2094 -0.0568 -0.7222 -1.6505 -0.0526 -0.8023 -0.3385 -0.0101 -0.0891 -1.2717 -0.9908 -0.2153 -0.8853 -0.2844 -0.0973
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients atrial_fibrillation pacemaker
H-883	-0.5693610310554504	▁at rial _ fi bril lation ▁pace maker
D-883	-0.5693610310554504	atrial_fibrillation pacemaker
P-883	-3.6576 -0.1270 -0.4481 -0.3548 -0.0620 -0.1792 -0.1210 -0.0799 -0.5502 -0.1138
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump pump pump_thrombosis hemolysis
H-2004	-0.5538764595985413	▁pump ▁exchange s ▁pump ▁mal function s ▁pump ▁ thro mbo sis ▁hem ol ysis _ ▁events
D-2004	-0.5538764595985413	pump exchanges pump malfunctions pump thrombosis hemolysis_ events
P-2004	-0.1247 -1.8171 -0.1540 -0.1971 -2.1233 -0.0584 -0.2687 -0.2165 -1.2361 -0.2725 -0.3482 -0.7002 -0.0679 -0.4389 -0.1195 -1.2528 -0.7028 -0.3065 -0.1183
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world_health_organization hf
H-1791	-1.0468982458114624	▁electronic _ ▁database s ▁world _ health _ ▁Organization ▁ HF ▁LA
D-1791	-1.0468982458114624	electronic_ databases world_health_ Organization HF LA
P-1791	-4.4308 -0.1290 -0.2995 -0.0349 -0.6964 -0.0962 -1.9234 -0.2471 -0.6328 -2.3507 -0.4409 -2.2524 -1.0062 -0.1163
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial_tissue pka
H-1426	-0.6616740822792053	▁human _ mi o card ial _ ▁tissu e ▁p ka
D-1426	-0.6616740822792053	human_miocardial_ tissue pka
P-1426	-0.6870 -0.1892 -4.2917 -0.2266 -0.2974 -0.5195 -0.1006 -0.2703 -0.0603 -0.2395 -0.7678 -0.8359 -0.1159
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body_mass_index crf exercise
H-1768	-0.4440971314907074	▁body ▁mass ▁index ▁c RF ▁tre ad m ill _ ▁exercise
D-1768	-0.4440971314907074	body mass index cRF treadmill_ exercise
P-1768	-0.4048 -1.3359 -0.2192 -0.0870 -0.3689 -0.1667 -0.0037 -0.3454 -0.1737 -0.6711 -0.2507 -1.6021 -0.1440
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition compliance exercise injections patients
H-1321	-1.0949023962020874	▁inject ions
D-1321	-1.0949023962020874	injections
P-1321	-3.7758 -0.0123 -0.4660 -0.1256
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic_failure cardiomyopathic
H-986	-0.397162526845932	▁dia sto lic _ ▁failure ▁cardio my o pathi c _ ▁restriction _ to _ ▁flow
D-986	-0.397162526845932	diastolic_ failure cardiomyopathic_ restriction_to_ flow
P-986	-0.0722 -0.0448 -0.0895 -0.3971 -0.0958 -0.1365 -1.3416 -0.6375 -0.0120 -0.0549 -0.8451 -0.3846 -0.7278 -1.0012 -0.1090 -0.5773 -0.4859 -0.1361
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic_nervous_system activity qtv
H-1436	-0.769395649433136	▁autonomi c _ ▁ner vous _ system ▁Q TV
D-1436	-0.769395649433136	autonomic_ nervous_system QTV
P-1436	-0.0645 -0.1898 -0.1250 -2.9475 -0.6820 -0.2854 -0.9021 -1.9280 -0.9645 -0.2474 -0.1270
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial exercise training heart_failure hf patients
H-1925	-0.7781651020050049	▁psycho social _ ▁factors ▁exercise _ training ▁heart ▁failure HF
D-1925	-0.7781651020050049	psychosocial_ factors exercise_training heart failureHF
P-1925	-1.1102 -0.4880 -1.3889 -0.5397 -1.2651 -0.8971 -0.1910 -1.2173 -0.9047 -0.1509 -0.9760 -0.2092
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical outcomes hospitalisations readmissions mortality
H-1850	-1.0493744611740112	▁hospital isation s ▁read missions ▁mortal ity
D-1850	-1.0493744611740112	hospitalisations readmissions mortality
P-1850	-6.5226 -0.1277 -0.1707 -0.2115 -0.1633 -0.1324 -1.5781 -0.3594 -0.1786
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise training patients chronic_heart_failure high-density_lipoprotein
H-245	-0.9400007724761963	▁chronic _ heart _ ▁failure ▁high - dens ity _ ▁lipo prote in
D-245	-0.9400007724761963	chronic_heart_ failure high-density_ lipoprotein
P-245	-4.7424 -0.1107 -1.6124 -0.5783 -0.1078 -2.9766 -0.0731 -0.4616 -0.6526 -0.1000 -0.4637 -0.0595 -0.6921 -1.2907 -0.1785
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf intubation
H-221	-0.7434023022651672	▁ED ▁visit s ▁CHF ▁in tub ation ▁rates
D-221	-0.7434023022651672	ED visits CHF intubation rates
P-221	-2.7369 -2.6505 -0.0954 -0.0982 -0.0101 -0.1674 -0.1529 -0.8594 -0.5259 -0.1373
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty health outcomes
H-623	-0.6920968890190125	▁fra il ty ▁el der ly
D-623	-0.6920968890190125	frailty elderly
P-623	-0.6436 -0.6590 -0.2120 -1.8925 -0.0585 -0.6531 -1.3041 -0.1139
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical therapeutic
H-1368	-0.4641479253768921	▁ therapeut ic
D-1368	-0.4641479253768921	therapeutic
P-1368	-1.5985 -0.1374 -0.0876 -0.3679 -0.1293
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare hospitalizations
H-1714	-0.5027887225151062	▁Medica re ▁fee - for - service
D-1714	-0.5027887225151062	Medicare fee-for-service
P-1714	-0.2241 -0.0163 -1.8481 -0.0728 -0.0721 -0.1077 -0.2611 -1.6834 -0.2396
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician conditions hospital discharge
H-1422	-1.0156351327896118	▁physician _ ▁continu ity
D-1422	-1.0156351327896118	physician_ continuity
P-1422	-0.4963 -1.1026 -1.0179 -0.9555 -2.3405 -0.1810
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-0.8610633015632629	▁Exerci se _ ▁attend ance SD ▁die t ▁ad her ence SD
D-1983	-0.8610633015632629	Exercise_ attendanceSD diet adherenceSD
P-1983	-4.2338 -0.0334 -0.4282 -1.8535 -0.0493 -0.2413 -0.1252 -0.2319 -2.3161 -0.9163 -0.7182 -0.3925 -0.3608 -0.1543
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-1.0532528162002563	
D-1862	-1.0532528162002563	
P-1862	-1.8934 -0.2131
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol mortality
H-650	-0.8867881298065186	▁bis o pro lol ▁ reducing _ ▁mortal ity
D-650	-0.8867881298065186	bisoprolol reducing_ mortality
P-650	-0.6153 -0.4176 -0.0540 -0.4001 -2.7501 -1.2586 -0.4242 -1.5450 -1.8672 -0.2861 -0.1363
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss btes exercise
H-1928	-1.0716415643692017	▁ps s ▁social _ support ▁b tes
D-1928	-1.0716415643692017	pss social_support btes
P-1928	-2.3340 -0.3887 -1.2229 -0.9252 -1.4306 -1.4972 -0.4222 -1.2647 -0.1592
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics_rounds
H-1681	-0.33029669523239136	▁e thi cs _ ▁Round s
D-1681	-0.33029669523239136	ethics_ Rounds
P-1681	-0.8875 -0.1218 -0.3804 -0.4799 -0.2000 -0.0804 -0.3754 -0.1170
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients prognosis
H-1315	-1.0160106420516968	
D-1315	-1.0160106420516968	
P-1315	-1.8931 -0.1389
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac_stress β-ar drive
H-1219	-0.7995091676712036	▁cardiac _ stress ▁β - AR _ ▁drive
D-1219	-0.7995091676712036	cardiac_stress β-AR_ drive
P-1219	-1.6786 -0.3946 -1.1241 -1.7183 -0.0501 -0.5534 -0.9248 -0.9981 -0.3612 -0.1920
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-1.6061091423034668	▁white
D-626	-1.6061091423034668	white
P-626	-4.2852 -0.2955 -0.2376
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.5490829348564148	▁parallel - group ▁single - co hor t
D-2013	-0.5490829348564148	parallel-group single-cohort
P-2013	-3.2598 -0.0775 -0.2642 -0.1670 -0.1019 -0.0836 -0.4723 -0.0635 -0.8627 -0.1384
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart_rate_reduction ivabradine left_ventricle heart_failure patients
H-515	-0.9645504951477051	▁i va bra dine ▁left _ ▁vent ric le ▁heart ▁failure
D-515	-0.9645504951477051	ivabradine left_ ventricle heart failure
P-515	-3.5576 -0.0781 -0.0961 -0.1827 -1.5936 -0.5722 -1.3749 -1.7252 -0.4923 -0.4802 -1.0754 -1.0227 -0.2883
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic reverse_remodeling cardiac_resynchronization_therapy
H-426	-0.3618810772895813	▁e cho car dio graphic ▁rever se _ ▁remodel ing ▁cardiac _ re syn chron ization _ therapy
D-426	-0.3618810772895813	echocardiographic reverse_ remodeling cardiac_resynchronization_therapy
P-426	-0.4201 -0.0417 -0.0417 -0.4614 -0.4955 -0.7528 -0.0381 -0.0301 -0.1584 -0.0440 -0.0536 -0.4680 -0.9333 -0.0241 -0.0047 -1.3878 -1.1189 -0.1829 -0.4399 -0.1405
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers neurohormonal_stimulation inflammation endothelial_dysfunction
H-13	-0.2016446888446808	▁bio mark ers ▁neuro hormon al _ stimul ation ▁ inflammation ▁en dot heli al _ ▁dys function
D-13	-0.2016446888446808	biomarkers neurohormonal_stimulation inflammation endothelial_ dysfunction
P-13	-0.1905 -0.1540 -0.0354 -0.0225 -0.0255 -0.0659 -1.2004 -0.1004 -0.0919 -0.0633 -0.0111 -0.0700 -1.0120 -0.1765 -0.0187 -0.2425 -0.1606 -0.0696 -0.1993 -0.1227
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis medical heart_failure canadian_cardiovascular_society
H-198	-0.9522566795349121	▁medical _ management ▁heart _ ▁failure _ in _ ▁children ▁Canadian _ ▁Card io vas cular _ ▁Society
D-198	-0.9522566795349121	medical_management heart_ failure_in_ children Canadian_ Cardiovascular_ Society
P-198	-4.1475 -0.6264 -0.1590 -1.3226 -1.2316 -0.0968 -3.2832 -0.6742 -0.4531 -0.7061 -0.2193 -0.5096 -1.8038 -1.3366 -0.2023 -0.3089 -0.1711 -0.3282 -1.3172 -0.1477
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal pathophysiology congestive_heart_failure chf
H-634	-0.7239668965339661	▁Neuro hormon al _ ▁ab normal ities ▁pat ho phy si ology ▁con ges tive _ heart _ ▁failure CH f
D-634	-0.7239668965339661	Neurohormonal_ abnormalities pathophysiology congestive_heart_ failureCHf
P-634	-1.1009 -0.0282 -0.0147 -1.5152 -0.2495 -0.0375 -0.8524 -0.6406 -0.0317 -0.1392 -1.8207 -0.1947 -0.1236 -0.1572 -2.4377 -0.0408 -2.9398 -0.8837 -0.0519 -2.0288 -1.0612 -0.2028 -0.0987
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart_failure pathophysiology diagnosis medical_treatment nursing
H-2018	-0.531559944152832	▁Heart _ ▁Fail ure ▁Path o phy si ology ▁Medical ▁Treatment ▁Guide lines ▁Nur sing ▁Management
D-2018	-0.531559944152832	Heart_ Failure Pathophysiology Medical Treatment Guidelines Nursing Management
P-2018	-0.2282 -1.7666 -0.1457 -0.3480 -0.0657 -1.1965 -0.0407 -1.1846 -0.0717 -1.1547 -0.3471 -0.6205 -0.3771 -0.3067 -0.0110 -1.4000 -0.1930 -0.1104
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic_neurotransmission acetylcholinesterase_inhibition
H-1135	-0.3933062255382538	▁para sy mpa the tic _ ▁neuro trans mission ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.3933062255382538	parasympathetic_ neurotransmission acetylcholinesterase inhibition
P-1135	-0.0205 -0.0141 -0.1247 -0.8575 -0.8770 -0.0890 -0.1500 -0.0108 -1.1353 -0.1175 -0.2355 -0.1991 -0.2853 -0.1570 -0.2200 -1.5373 -0.6065 -0.5522 -0.5454 -0.1314
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence end-stage_renal_disease outpatients systolic_heart_failure
H-386	-0.5928794741630554	▁end - s tage _ ▁renal _ ▁disease ▁sy sto lic _ heart _ ▁failure
D-386	-0.5928794741630554	end-stage_ renal_ disease systolic_heart_ failure
P-386	-1.4356 -0.1056 -0.1887 -0.0054 -0.5314 -0.0944 -0.6488 -0.5869 -2.4689 -0.0481 -0.4059 -0.0387 -1.7668 -1.2044 -0.0420 -0.3268 -0.1805
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia patients heart_disease clinical_practice_guideline american_college_of_physicians
H-29	-0.8965128660202026	▁an emia ▁heart _ ▁disease ▁clinic al _ ▁practice ▁guide line ▁American _ ▁College _ of _ ▁Physic ians
D-29	-0.8965128660202026	anemia heart_ disease clinical_ practice guideline American_ College_of_ Physicians
P-29	-1.1054 -0.0426 -2.6171 -1.4972 -0.4254 -4.9774 -0.0719 -0.2153 -0.9425 -1.8448 -0.0178 -1.4009 -0.1099 -1.2289 -0.0609 -1.3983 -0.1170 -0.1046 -0.0966 -0.4020 -0.1505
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal_dnx cardiac autonomic_balance chf sympathetic_tone
H-1382	-0.303168386220932	▁renal ▁DN x ▁cardiac _ ▁autonomi c _ ▁balance ▁CHF ▁sympa the tic _ ▁tone
D-1382	-0.303168386220932	renal DNx cardiac_ autonomic_ balance CHF sympathetic_ tone
P-1382	-0.0159 -1.3456 -0.0705 -0.0210 -0.7731 -0.1616 -0.2015 -0.2308 -0.5327 -0.0079 -0.0099 -0.3973 -0.5458 -0.1585 -0.2053 -0.3719 -0.1047
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right_ventricle rv cardiac_function medical
H-1091	-0.6990224123001099	▁right _ ▁vent ric le RV ▁cardiac _ ▁function ▁medical
D-1091	-0.6990224123001099	right_ ventricleRV cardiac_ function medical
P-1091	-0.2718 -0.4530 -0.9714 -0.9366 -0.3361 -1.2472 -0.3499 -0.8934 -0.7197 -0.9818 -1.0933 -0.1339
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical radiological hf quality_of_life
H-565	-0.9010037779808044	▁radi ological _ ▁sign s ▁ HF
D-565	-0.9010037779808044	radiological_ signs HF
P-565	-2.0805 -0.4864 -0.6564 -2.3149 -0.1006 -0.7979 -0.1393 -1.3707 -0.1622
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive_heart_failure chf
H-209	-1.0001411437988281	▁con ges tive _ heart _ ▁failure CH f
D-209	-1.0001411437988281	congestive_heart_ failureCHf
P-209	-1.6197 -0.1912 -1.4450 -0.0540 -2.1349 -1.3403 -0.0517 -2.2875 -1.5240 -0.2090 -0.1443
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri_scanner baseline heart_failure
H-1057	-0.9131002426147461	▁m RI ▁scanner ▁heart ▁failure
D-1057	-0.9131002426147461	mRI scanner heart failure
P-1057	-2.5397 -0.6435 -1.0689 -0.3795 -1.2515 -0.3046 -0.2040
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness sickle_cell_disease anemia
H-1682	-0.8605169653892517	▁Jehovah ' s _ ▁Wit ness ▁sick le _ ▁Cell _ ▁disease ▁an emia
D-1682	-0.8605169653892517	Jehovah's_ Witness sickle_ Cell_ disease anemia
P-1682	-0.0210 -4.2223 -0.3971 -0.1990 -1.0661 -1.3806 -0.3390 -0.1701 -0.0832 -2.8587 -0.9371 -0.2442 -0.9819 -0.0617 -0.4536 -0.3528
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin_subproteome diseased heart
H-99	-0.45302730798721313	▁chr omat in _ sub prote ome ▁mouse _ ▁heart
D-99	-0.45302730798721313	chromatin_subproteome mouse_ heart
P-99	-0.5901 -0.1005 -1.7437 -0.1296 -0.4202 -0.1813 -0.0467 -0.6896 -0.3009 -0.8686 -0.2463 -0.1188
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash mortality heart_failure health
H-684	-0.7410082817077637	▁Mediterrane an ▁DAS h ▁die t ▁score s ▁mortal ity ▁heart _ ▁failure ▁Women _ s _ Health _ ▁Initiative
D-684	-0.7410082817077637	Mediterranean DASh diet scores mortality heart_ failure Women_s_Health_ Initiative
P-684	-0.8974 -0.1070 -0.0329 -0.1999 -2.4308 -0.1154 -0.8346 -0.0556 -0.1595 -0.9799 -2.2694 -0.7925 -0.1486 -1.3239 -1.4018 -0.4435 -0.3295 -1.6041 -1.4337 -0.3156 -0.2593 -0.1673
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad_variant congestive_heart_failure
H-1670	-0.8191115856170654	▁l - type _ ca 2 _ current s ▁Rad ▁con ges tive _ ▁heart ▁failure
D-1670	-0.8191115856170654	l-type_ca2_currents Rad congestive_ heart failure
P-1670	-2.9395 -0.1106 -0.0033 -0.7325 -0.0704 -0.2218 -1.4621 -1.1605 -0.2147 -1.0248 -0.9414 -0.1145 -1.7197 -0.0737 -2.6971 -0.8064 -0.2933 -0.1577
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary exercise prognostically heart_failure
H-1274	-1.1366146802902222	▁cardio pul mon ary _ ▁exercise ▁heart ▁failure
D-1274	-1.1366146802902222	cardiopulmonary_ exercise heart failure
P-1274	-0.7245 -0.9300 -2.0263 -0.7125 -0.3297 -1.4718 -3.5998 -1.0181 -0.3821 -0.1712
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity mortality quality_of_life patients hf
H-2023	-0.7189698219299316	▁morbi d ity ▁mortal ity ▁ HF
D-2023	-0.7189698219299316	morbidity mortality HF
P-2023	-0.5310 -0.0700 -1.7104 -0.1475 -1.3725 -2.0891 -0.1547 -0.2345 -0.1612
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes costs patients heart_failure hf
H-1721	-1.771414041519165	▁heart _ ▁failure HF
D-1721	-1.771414041519165	heart_ failureHF
P-1721	-7.3038 -2.2504 -0.1236 -0.3308 -0.4608 -0.1591
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome heart_failure fontan
H-1493	-0.2715713679790497	▁muscle - was ting _ ▁syndrome ▁acquire d _ heart _ ▁failure ▁Font an
D-1493	-0.2715713679790497	muscle-wasting_ syndrome acquired_heart_ failure Fontan
P-1493	-0.7540 -0.0943 -0.0444 -0.0172 -0.7071 -0.1049 -0.0287 -0.0199 -0.0313 -1.3635 -0.5756 -0.0441 -0.1093 -0.0840 -0.2571 -0.1097
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas therapeutic heart_failure
H-1485	-0.8254584074020386	▁mi RNA s ▁heart ▁failure
D-1485	-0.8254584074020386	miRNAs heart failure
P-1485	-1.3805 -0.0456 -0.1526 -3.0661 -0.7967 -0.1985 -0.1383
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health_buddy_program telehealth
H-1622	-1.0528992414474487	▁Health _ ▁Budd y _ program ▁tele health _ system ▁care ▁management
D-1622	-1.0528992414474487	Health_ Buddy_program telehealth_system care management
P-1622	-2.8484 -1.1529 -1.1426 -0.0960 -0.2936 -1.8237 -1.9619 -0.2724 -2.1324 -0.7719 -1.0473 -0.5695 -0.4098 -0.2183
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin breast_cancer patients cardiotoxicity
H-936	-0.7043865919113159	▁resist in _ ▁levels ▁an thra cycli ne - tre ated ▁breast ▁cancer ▁cardio toxic iteit
D-936	-0.7043865919113159	resistin_ levels anthracycline-treated breast cancer cardiotoxiciteit
P-936	-0.5007 -0.5205 -2.0969 -0.5811 -0.0973 -0.0472 -0.3720 -1.4008 -0.2793 -0.0168 -1.4393 -0.5579 -1.0962 -0.4786 -0.2473 -2.2977 -0.5097 -0.1396
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine furosemide outcome
H-586	-0.4477928578853607	▁do bu tamine ▁fur os em ide _ ▁dose ▁oxygen _ ▁flow
D-586	-0.4477928578853607	dobutamine furosemide_ dose oxygen_ flow
P-586	-0.5191 -0.0235 -0.1301 -1.6699 -0.1608 -0.0332 -0.0142 -1.7739 -0.0297 -0.5270 -0.6527 -0.2447 -0.4071 -0.0835
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic patients heart_failure
H-1740	-1.2760124206542969	▁ therapeut ic ▁heart ▁failure
D-1740	-1.2760124206542969	therapeutic heart failure
P-1740	-2.5112 -0.4663 -0.0611 -4.7100 -0.7681 -0.2653 -0.1502
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality deaths acs consultation operation
H-1287	-1.0263478755950928	▁Mor t ality ▁a CS
D-1287	-1.0263478755950928	Mortality aCS
P-1287	-1.6856 -0.3027 -0.0409 -1.3720 -3.1687 -0.4569 -0.1577
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs outcomes patients diabetes
H-130	-0.7060907483100891	▁c PC s ▁diabetes
D-130	-0.7060907483100891	cPCs diabetes
P-130	-0.8383 -1.7753 -0.4296 -0.6895 -0.2597 -0.2441
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential_effect lvef mortality
H-118	-0.8297874927520752	▁LV EF ▁long - term _ ▁mortal ity
D-118	-0.8297874927520752	LVEF long-term_ mortality
P-118	-1.3360 -0.5768 -2.3187 -0.1905 -0.2900 -0.1453 -0.9652 -1.7140 -0.5220 -0.2394
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health_buddy_program hospital hospitalized
H-1626	-0.8748456239700317	▁Health ▁Budd y _ program ▁ED ▁hospital ized
D-1626	-0.8748456239700317	Health Buddy_program ED hospitalized
P-1626	-1.6698 -0.8332 -0.1254 -0.3453 -1.9345 -0.3367 -1.1412 -1.9478 -0.2743 -0.1402
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital mortality patients bnp mortality
H-195	-0.8008003234863281	▁in hospital _ ▁mortal ity ▁b NP
D-195	-0.8008003234863281	inhospital_ mortality bNP
P-195	-0.3872 -0.0617 -1.7330 -0.1273 -1.0139 -0.6364 -0.6680 -2.4278 -0.1519
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt nt-probnp hf
H-291	-0.4138721525669098	▁c t n t ▁NT - pro b NP ▁ HF
D-291	-0.4138721525669098	ctnt NT-probNP HF
P-291	-0.0176 -0.3399 -0.0298 -0.1886 -0.2901 -0.0535 -0.0159 -0.8737 -0.2000 -0.6136 -0.5073 -2.0854 -0.1650
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv_dysfunction correlated lean_body_mass
H-1164	-0.8307137489318848	▁ RV _ ▁dys function ▁weight ▁loss ▁fat _ lean _ ▁Body _ ▁mass _ ▁ratio
D-1164	-0.8307137489318848	RV_ dysfunction weight loss fat_lean_ Body_ mass_ ratio
P-1164	-0.8632 -0.6951 -1.3106 -0.1660 -0.0559 -1.1649 -1.4525 -0.5511 -1.2356 -1.2066 -0.0478 -1.7585 -0.2723 -1.4033 -2.1061 -0.0701 -0.3650 -0.2282
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-0.8824942111968994	▁fut ility ▁safety ▁monitoring _ ▁board
D-850	-0.8824942111968994	futility safety monitoring_ board
P-850	-0.9955 -0.0982 -1.6217 -1.7300 -1.4803 -0.5760 -0.4116 -0.1467
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients consultation abdominal
H-1284	-0.8085598349571228	▁MT ▁abdominal _ problem
D-1284	-0.8085598349571228	MT abdominal_problem
P-1284	-1.0904 -0.7569 -0.9108 -0.4080 -1.5361 -0.1492
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic complication
H-1661	-1.1709085702896118	▁complica tion
D-1661	-1.1709085702896118	complication
P-1661	-3.5148 -0.7930 -0.2395 -0.1363
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.7077428698539734	▁Thi r ty - day _ ▁mortal ity
D-2001	-0.7077428698539734	Thirty-day_ mortality
P-2001	-3.0012 -0.3090 -0.2260 -0.0237 -0.6132 -0.1224 -0.3825 -1.1607 -1.0934 -0.1452
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.6330626010894775	▁follow - up
D-727	-0.6330626010894775	follow-up
P-727	-1.2143 -0.3162 -0.0484 -1.4381 -0.1483
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection_fraction clinical cardiac_resynchronization_therapy mild_heart_failure
H-750	-0.38001152873039246	▁e je ction _ fraction ▁cardiac _ re syn chron ization _ therapy ▁mild _ heart _ ▁failure
D-750	-0.38001152873039246	ejection_fraction cardiac_resynchronization_therapy mild_heart_ failure
P-750	-0.2291 -0.0268 -0.0218 -0.2977 -0.0465 -0.1000 -0.6276 -0.8320 -0.0612 -0.0077 -0.9078 -1.0842 -0.2041 -0.5192 -0.0269 -0.8953 -1.2886 -0.0654 -0.2187 -0.1395
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular_pacing left_heart_twist strain right_heart_failure
H-318	-0.8212958574295044	▁bi ven tri cular _ pa cing ▁left _ ▁heart _ ▁twist ▁strain ▁por cine _ model ▁right _ ▁heart _ ▁failure
D-318	-0.8212958574295044	biventricular_pacing left_ heart_ twist strain porcine_model right_ heart_ failure
P-318	-2.3714 -0.0812 -0.1613 -0.9302 -0.1653 -0.6050 -0.0563 -1.9195 -0.1127 -2.7465 -1.8889 -0.1627 -1.8316 -1.5632 -0.0603 -0.5178 -0.8699 -0.6852 -0.0863 -1.0912 -1.3455 -0.0492 -0.1945 -0.2156
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress_doppler_echocardiography prognostic pulmonary_hypertension patients
H-832	-0.5742253065109253	▁Stress ▁do pp ler _ e cho card i ography ▁pulmonar y _ ▁hyper tension
D-832	-0.5742253065109253	Stress doppler_echocardiography pulmonary_ hypertension
P-832	-0.6789 -1.3993 -0.0259 -1.5566 -0.5799 -0.2982 -0.3546 -0.5019 -0.8915 -0.3123 -0.0381 -0.0953 -0.4300 -1.1427 -0.0958 -1.2057 -0.1552
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical aortic_valve_insufficiency left_ventricular_assist_device implantation
H-541	-0.7034672498703003	▁a or tic _ ▁val ve ▁insu ffi cie ncy ▁left _ ▁vent ri cular _ assist _ ▁device ▁implant ation
D-541	-0.7034672498703003	aortic_ valve insufficiency left_ ventricular_assist_ device implantation
P-541	-0.4721 -0.3303 -1.5551 -0.1113 -2.5788 -0.1195 -1.4634 -0.0696 -0.3055 -0.0494 -0.1103 -0.9118 -0.7746 -0.8719 -0.2852 -0.1964 -0.6148 -1.7512 -1.0769 -1.6593 -0.1752 -0.4975 -0.1997
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left_ventricular_ejection_time acute_heart_failure precapillary_pulmonary_hypertension
H-576	-0.4473881423473358	▁vent ri cular _ e je ction _ ▁time ▁a cute _ heart _ ▁failure ▁pre cap illa ry _ ▁pulmonar y _ ▁hyper tension
D-576	-0.4473881423473358	ventricular_ejection_ time acute_heart_ failure precapillary_ pulmonary_ hypertension
P-576	-0.3820 -1.1390 -0.3627 -0.6959 -0.4615 -0.0607 -0.0295 -1.5222 -0.6689 -0.2940 -0.0304 -0.0432 -1.6534 -1.2208 -0.0551 -0.0880 -0.0127 -0.0617 -0.4782 -0.2594 -0.0760 -0.1166 -0.3921 -1.3083 -0.0293 -0.3748 -0.2632
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial_diastolic_dysfunction dd collagen_deposition titin
H-761	-0.35536861419677734	▁my o card ial _ ▁dia sto lic _ ▁dys function DD ▁collage n ▁de position ▁titi n
D-761	-0.35536861419677734	myocardial_ diastolic_ dysfunctionDD collagen deposition titin
P-761	-0.6185 -0.2919 -0.2336 -0.2948 -0.7666 -0.9447 -0.0243 -0.0933 -0.6691 -0.0752 -0.0509 -0.6891 -0.0504 -0.0972 -0.2677 -0.2364 -0.0070 -0.0558 -1.5485 -0.0925
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated septal wall avd free_wall_cs vvd
H-329	-1.0076802968978882	▁co ▁sept al _ wall _ ▁CS ▁v d ▁free _ wall ▁CS ▁VVD
D-329	-1.0076802968978882	co septal_wall_ CS vd free_wall CS VVD
P-329	-2.9036 -0.4809 -0.0931 -0.0571 -2.0525 -1.4317 -0.4500 -3.0292 -0.3518 -0.0724 -0.1425 -2.0231 -1.3378 -1.4241 -0.1326 -0.1405
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic acute_rv_failure left_ventricular_dysfunction
H-1092	-0.6585845351219177	▁et i ologic _ ▁causes ▁a cute _ RV _ ▁failure ▁left _ ▁vent ri cular _ ▁dys function
D-1092	-0.6585845351219177	etiologic_ causes acute_RV_ failure left_ ventricular_ dysfunction
P-1092	-1.7834 -0.0939 -0.0755 -1.2708 -0.3103 -1.3494 -0.0167 -0.0464 -1.3440 -0.6750 -0.0627 -0.1226 -0.5078 -2.3201 -1.8320 -0.5533 -0.5194 -0.1475 -0.0944 -0.4961 -0.2090
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left_pulmonary_artery right_pulmonary_artery
H-597	-0.7074000239372253	▁left ▁pulmonar y ▁arter y ▁pulmonar y _ ▁arter y
D-597	-0.7074000239372253	left pulmonary artery pulmonary_ artery
P-597	-0.4093 -0.6633 -0.0908 -1.6180 -0.3651 -3.1296 -0.1296 -0.8709 -0.2749 -0.4185 -0.3544 -0.1644
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student_t_test confidence_intervals cis regression_analyses
H-215	-0.8246436715126038	▁student _ ▁t _ ▁test ▁confidence _ ▁interval s ▁ci s ▁re gression
D-215	-0.8246436715126038	student_ t_ test confidence_ intervals cis regression
P-215	-1.7986 -0.5333 -0.5361 -0.2955 -2.0682 -0.9468 -1.5230 -0.0419 -0.0562 -1.8894 -0.1158 -0.4910 -0.0069 -1.9387 -0.1284
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv_strain strain echocardiography baseline ablation
H-946	-0.5655804872512817	▁e cho card i ography ▁ab lation
D-946	-0.5655804872512817	echocardiography ablation
P-946	-2.0763 -0.0331 -0.5245 -0.3524 -0.2514 -1.3664 -0.1172 -0.2474 -0.1215
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr_reduction beta_blockers exercise_capacity hfref
H-1937	-0.6683228611946106	▁HR _ re duction ▁beta _ block ers ▁exercise _ ▁capacity ▁h Fr EF
D-1937	-0.6683228611946106	HR_reduction beta_blockers exercise_ capacity hFrEF
P-1937	-0.8295 -3.8648 -0.5070 -0.0268 -0.1358 -0.4567 -0.6023 -0.0164 -0.0822 -0.7202 -1.2523 -0.4210 -0.5842 -0.8481 -0.2456 -0.1003
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle_cohort_study canada
H-1951	-0.6260868906974792	▁ proof - of - princip le _ co hor t ▁Canada
D-1951	-0.6260868906974792	proof-of-principle_cohort Canada
P-1951	-1.5218 -0.5197 -0.0503 -0.1113 -0.1067 -0.0073 -0.4597 -0.1630 -0.3027 -0.3504 -0.1434 -4.6538 -0.2048 -0.1704
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs functional_capacity outcomes heart_failure hf
H-121	-0.563099205493927	▁c PC s ▁functional _ ▁capacity ▁heart ▁failure HF
D-121	-0.563099205493927	cPCs functional_ capacity heart failureHF
P-121	-0.7448 -0.9000 -0.2291 -0.1165 -1.0027 -2.0084 -0.2587 -0.3637 -0.2351 -0.2008 -0.1343
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed_up adverse_events death transplantation circulatory_assist_device
H-1162	-0.6690530180931091	▁circula tory _ assist _ ▁device
D-1162	-0.6690530180931091	circulatory_assist_ device
P-1162	-1.1731 -0.1509 -0.0655 -0.2160 -1.6919 -1.3109 -0.6097 -0.1344
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary_outcome sympathetic_activity myocardial_washout
H-1115	-0.9712156653404236	▁sympa the tic _ activ iteit ▁i - MI BG ▁my o card ial _ was hout
D-1115	-0.9712156653404236	sympathetic_activiteit i-MIBG myocardial_washout
P-1115	-0.4550 -1.1805 -0.4904 -1.1840 -1.0717 -0.2552 -0.1678 -0.6499 -1.2331 -2.4095 -1.8170 -0.5092 -0.7732 -0.4744 -0.8543 -3.7017 -0.5703 -0.3915 -0.2643
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating_progenitor_cells outcome heart_failure patients longitudinal
H-119	-0.7059677243232727	▁circula ting _ pro gen itor _ ▁cell s ▁heart ▁failure
D-119	-0.7059677243232727	circulating_progenitor_ cells heart failure
P-119	-0.0134 -0.3801 -0.1583 -1.7006 -0.0909 -0.3679 -0.7380 -2.0326 -0.0770 -1.1122 -1.0677 -1.2572 -0.1818
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic diastolic_mitral_leaflet_motions organic lesion
H-351	-0.41025102138519287	▁sy sto lic ▁dia sto lic _ met ral _ le a flet _ ▁motion s
D-351	-0.41025102138519287	systolic diastolic_metral_leaflet_ motions
P-351	-0.0424 -0.0516 -0.0389 -0.2035 -0.0442 -0.0574 -0.1789 -0.4651 -0.4945 -0.2024 -1.8438 -0.4411 -0.0170 -1.0659 -0.2178 -0.1021 -1.7193 -0.1985
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein_kinase_a guanylate_cyclase contractile_response
H-418	-0.6439100503921509	▁inhibi tion ▁protein ▁kina se _ a ▁solu ble _ ▁gua ny late _ ▁cy cla se ▁contract ile _ ▁response
D-418	-0.6439100503921509	inhibition protein kinase_a soluble_ guanylate_ cyclase contractile_ response
P-418	-0.5489 -0.2129 -1.2297 -0.6746 -0.0990 -1.8484 -0.6632 -0.7384 -0.7528 -0.1339 -0.2831 -1.1575 -1.2205 -0.1033 -0.8743 -0.0585 -0.6074 -0.0115 -0.1173 -0.7765 -1.9988 -0.4582 -0.2414
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta_blockers mortality patients heart_failure
H-649	-1.198877215385437	▁beta _ block ers ▁mortal iteit ▁heart ▁failure
D-649	-1.198877215385437	beta_blockers mortaliteit heart failure
P-649	-0.6348 -1.8315 -1.2022 -0.1241 -4.0265 -1.9566 -0.9138 -0.9358 -0.2393 -0.1242
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd congestive_heart_failure chf
H-902	-0.7645518779754639	▁PD ▁re frac tory ▁end - s tage _ con ges tive _ heart ▁failure CH f
D-902	-0.7645518779754639	PD refractory end-stage_congestive_heart failureCHf
P-902	-1.3931 -0.2049 -0.1078 -0.0796 -3.2390 -0.0436 -0.1349 -0.0033 -0.2174 -0.5365 -0.1828 -1.2427 -0.0627 -1.9245 -0.9663 -2.6027 -1.1694 -0.2831 -0.1322
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype perioperative deaths
H-279	-0.55931156873703	▁per i operativ e
D-279	-0.55931156873703	perioperative
P-279	-2.4544 -0.1184 -0.0461 -0.0264 -0.5829 -0.1276
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients trastuzumab cardiac comorbidities
H-682	-0.6519547700881958	▁tras tuz um ab ▁cardiac _ ▁como rbi di ties
D-682	-0.6519547700881958	trastuzumab cardiac_ comorbidities
P-682	-0.8329 -0.0571 -0.0170 -0.6196 -0.0535 -1.6144 -3.0825 -0.0037 -0.4832 -0.0652 -0.7949 -0.1995
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic patients heart_failure québec canada
H-1233	-1.307936429977417	▁economische ▁af ▁heart _ ▁failure ▁Québec
D-1233	-1.307936429977417	economische af heart_ failure Québec
P-1233	-1.7828 -2.4288 -1.4266 -1.9498 -0.0812 -0.0806 -2.5993 -0.1143
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression_models comorbidities
H-662	-1.2360632419586182	▁hier archi cal _ re gression
D-662	-1.2360632419586182	hierarchical_regression
P-662	-4.3112 -0.3827 -0.5044 -0.2751 -0.1715 -0.0199 -4.0530 -0.1707
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline st2 interquartile_range
H-701	-1.1799414157867432	▁ST 2
D-701	-1.1799414157867432	ST2
P-701	-2.4895 -0.1722 -1.8778 -0.1802
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac mena_deletion cardiac_dysfunction hypertrophy
H-1811	-0.42360150814056396	▁cardiac _ men a _ ▁dele tion ▁cardiac _ ▁dys function ▁con duction _ ▁ab normal ities ▁hyper trop hy
D-1811	-0.42360150814056396	cardiac_mena_ deletion cardiac_ dysfunction conduction_ abnormalities hypertrophy
P-1811	-0.0486 -0.3751 -1.2618 -0.3236 -1.0579 -0.1221 -0.1347 -0.0405 -0.3608 -0.2674 -0.0563 -0.6681 -0.0158 -1.0613 -0.7601 -0.0554 -0.5806 -0.1139 -0.0138 -1.6620 -0.2208 -0.1189
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left_bundle-branch_block lbbb
H-886	-0.44429081678390503	▁bund le - bran ch _ ▁block LB bb ▁non - LB bb
D-886	-0.44429081678390503	bundle-branch_ blockLBbb non-LBbb
P-886	-0.0162 -0.1894 -0.0598 -0.0317 -0.1971 -0.5813 -1.2206 -0.9590 -0.8771 -0.3744 -0.0326 -0.7266 -1.1126 -0.1570 -0.1289
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf atrial_explants cells explants
H-1341	-0.586456298828125	▁CHF _ at rial _ ex plant s ▁c - K it _ en _ cell s ▁sham _ ▁ex plant s
D-1341	-0.586456298828125	CHF_atrial_explants c-Kit_en_cells sham_ explants
P-1341	-0.0281 -1.9280 -0.8479 -0.0909 -0.1989 -0.9160 -0.0162 -0.2922 -0.9824 -0.1564 -0.6393 -0.0038 -0.2995 -3.8030 -0.0687 -0.9614 -0.1725 -0.2445 -0.6034 -1.0349 -0.0251 -0.3019 -0.3275 -0.1325
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf valve_plasty mva
H-369	-0.40274256467819214	▁ HF ▁val ve _ plast y ▁MS ▁m VA
D-369	-0.40274256467819214	HF valve_plasty MS mVA
P-369	-0.7444 -0.2676 -0.8103 -0.0264 -0.3531 -1.1277 -0.5090 -0.1009 -0.1248 -0.4553 -0.2281 -0.0854
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms patients nyha
H-1893	-1.1807798147201538	▁NY HA ▁functional _ ▁assessment
D-1893	-1.1807798147201538	NYHA functional_ assessment
P-1893	-3.1174 -1.0100 -0.8265 -1.6426 -1.2507 -0.2901 -0.1282
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure_ulcers surgical patients
H-6	-0.6806013584136963	▁pressure _ ▁ul cer s ▁sur g ical _ ▁patients
D-6	-0.6806013584136963	pressure_ ulcers surgical_ patients
P-6	-0.7396 -0.8387 -0.4780 -0.0220 -0.1867 -2.2447 -0.4106 -0.4038 -0.8581 -0.9330 -0.8584 -0.1935
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients chronic_organ_failure
H-793	-0.8808891773223877	▁Time d _ up _ go _ ▁test ▁chronic _ organ _ ▁failure
D-793	-0.8808891773223877	Timed_up_go_ test chronic_organ_ failure
P-793	-0.5490 -0.4594 -0.1221 -0.2605 -0.1761 -2.0615 -1.1253 -1.5465 -3.9919 -0.0854 -0.1539 -2.1164 -0.1238 -0.2509 -0.1908
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome change hospitalized heart_failure
H-1395	-1.239851951599121	▁Nur sing - sensitiv e _ ▁outcome _ ▁change _ ▁score s ▁older _ ▁adults ▁heart _ ▁failure
D-1395	-1.239851951599121	Nursing-sensitive_ outcome_ change_ scores older_ adults heart_ failure
P-1395	-5.2644 -0.0150 -0.0554 -0.0025 -0.0575 -0.6922 -2.5849 -1.5637 -2.1627 -1.3847 -0.3650 -0.0292 -3.8336 -0.5912 -1.9782 -2.3124 -1.1046 -0.3212 -0.1969 -0.2816
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation heart_iron
H-748	-1.0855512619018555	▁che lation _ ▁regime ns ▁heart _ ▁ir on
D-748	-1.0855512619018555	chelation_ regimens heart_ iron
P-748	-0.4519 -0.0510 -2.6631 -0.1007 -0.2704 -5.9544 -0.9845 -0.2146 -0.1898 -0.9497 -0.1111
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter invasive surgery
H-553	-0.5592018961906433	▁trans cat heter ▁surgery
D-553	-0.5592018961906433	transcatheter surgery
P-553	-0.0844 -0.3341 -0.1081 -2.1924 -0.4627 -0.1735
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up outcomes mortality
H-1637	-0.5790713429450989	▁black _ race ▁mortal ity
D-1637	-0.5790713429450989	black_race mortality
P-1637	-0.0222 -0.2350 -1.0978 -1.0951 -1.0859 -0.3073 -0.2102
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise clinical outcomes
H-1926	-1.517774224281311	
D-1926	-1.517774224281311	
P-1926	-2.8777 -0.1578
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin heart_failure breast_cancer
H-927	-0.6889858245849609	▁resist in ▁che mo therapy - indu ced _ heart _ ▁failure ▁human ized _ male _ mi ce ▁breast ▁cancer
D-927	-0.6889858245849609	resistin chemotherapy-induced_heart_ failure humanized_male_mice breast cancer
P-927	-4.4224 -0.2531 -0.3213 -0.3897 -0.0355 -0.2733 -0.0073 -0.2302 -0.1706 -1.4410 -1.3458 -0.0297 -1.4464 -0.1719 -0.2715 -1.7830 -0.4689 -0.4701 -0.1557 -0.5406 -1.0885 -0.3283 -0.2018
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic diagnostic fluid_overload
H-1071	-0.7371165156364441	▁ therapeut ic _ function s ▁devices ▁fluid ▁over load
D-1071	-0.7371165156364441	therapeutic_functions devices fluid overload
P-1071	-0.8760 -0.0550 -0.0349 -0.6185 -1.6066 -0.0878 -0.9349 -2.7502 -0.8420 -0.6136 -0.3008 -0.1251
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing outcomes hospitalized hf
H-1402	-1.4117372035980225	▁nur sing ▁hospital ized ▁older _ ▁adults HF
D-1402	-1.4117372035980225	nursing hospitalized older_ adultsHF
P-1402	-5.8819 -0.0226 -2.4700 -0.1910 -2.5769 -0.6344 -0.5767 -1.2895 -0.3051 -0.1692
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome death hospitalization heart_failure
H-849	-1.7371926307678223	▁heart _ ▁failure
D-849	-1.7371926307678223	heart_ failure
P-849	-5.8597 -2.0987 -0.2731 -0.2406 -0.2139
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical echocardiographic invasive hemodynamic outcome
H-1527	-0.3529126048088074	▁e cho car dio graphic ▁invasi ve _ hem o dynamic
D-1527	-0.3529126048088074	echocardiographic invasive_hemodynamic
P-1527	-0.1090 -0.0332 -0.0284 -0.5081 -0.5431 -0.0053 -0.0622 -0.2325 -1.6063 -0.9548 -0.0017 -0.3854 -0.1179
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right_atrium prolapse tricuspid_valve stenotic_physiology
H-596	-0.30952930450439453	▁right _ at rium _ ▁mass ▁pro lapse ▁tri cus pid _ ▁val ve ▁ste no tic _ ▁physio log y
D-596	-0.30952930450439453	right_atrium_ mass prolapse tricuspid_ valve stenotic_ physiology
P-596	-0.3367 -0.0981 -0.4725 -0.0128 -0.2290 -0.9073 -0.4121 -0.1647 -0.0568 -0.1174 -0.1213 -0.1204 -1.6062 -0.1844 -0.0163 -0.1065 -0.6285 -0.1991 -0.2785 -0.1777 -0.4259 -0.3467 -0.1002
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis pacing-induced_dilated_cardiomyopathy
H-165	-0.669544517993927	▁pa cing - indu ced _ ▁dil ated _ ▁cardio my o pathy
D-165	-0.669544517993927	pacing-induced_ dilated_ cardiomyopathy
P-165	-2.1997 -1.1751 -0.0834 -0.0093 -0.2532 -0.1873 -1.7245 -0.7286 -0.0847 -0.5192 -1.6853 -0.7446 -0.0239 -0.3788 -0.2457
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative serum_albumin patients left_ventricular_assist_device implantation
H-528	-0.9093331694602966	▁pre operativ e _ se rum _ album in ▁survival ▁left _ ▁vent ri cular _ assist _ ▁device ▁implant ation
D-528	-0.9093331694602966	preoperative_serum_albumin survival left_ ventricular_assist_ device implantation
P-528	-3.8460 -0.1517 -0.0105 -0.3688 -0.2896 -0.5378 -1.4209 -0.0473 -0.1278 -4.7559 -0.2835 -0.6854 -1.2098 -1.6151 -0.3560 -0.1904 -0.4428 -1.0902 -1.3318 -1.3379 -0.1157 -0.4928 -0.2070
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac_catheterization thrombotic_obstruction right_coronary_artery
H-1292	-0.5688570737838745	▁cardiac _ ▁cat heter ization ▁ thro mbo tic _ ob struct ion ▁right _ ▁corona ry _ ▁arter y
D-1292	-0.5688570737838745	cardiac_ catheterization thrombotic_obstruction right_ coronary_ artery
P-1292	-1.7708 -0.4412 -1.1721 -0.0653 -0.8064 -0.1425 -0.2609 -0.3803 -2.1383 -0.3277 -0.2722 -0.0334 -0.0334 -0.7519 -0.1499 -0.2350 -1.5972 -0.3323 -0.0780 -0.9286 -0.4124 -0.1850
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western_blots monoclonal_antibodies ser83 phosphorylation hf
H-1431	-0.5897608399391174	▁Western _ ▁blot s ▁mono clo nal _ ▁anti bo dies ▁ser 83 ▁ phos phor y lation ▁ HF
D-1431	-0.5897608399391174	Western_ blots monoclonal_ antibodies ser83 phosphorylation HF
P-1431	-0.0745 -0.5646 -0.3913 -0.0672 -0.0016 -0.0741 -2.4403 -0.2030 -0.5073 -0.1052 -1.4277 -0.9684 -1.0825 -0.6988 -0.0360 -0.6337 -1.3823 -0.1108 -1.7383 -0.1144 -0.2110 -0.1417
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan_failure systolic_ventricular_function liver_disease
H-224	-0.48056191205978394	▁Font an _ ▁failure ▁sy sto lic _ ▁vent ri cular ▁ liver ▁disease
D-224	-0.48056191205978394	Fontan_ failure systolic_ ventricular liver disease
P-224	-0.3313 -0.6965 -0.6254 -0.3267 -0.0253 -0.0273 -0.2840 -0.0927 -0.4397 -0.8228 -0.1909 -0.9987 -0.4659 -1.8878 -0.3529 -0.1212
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary_outcome functional_capacity 6-minute_walk_test 6mwt
H-571	-1.0217922925949097	▁functional _ capaci te
D-571	-1.0217922925949097	functional_capacite
P-571	-0.2457 -1.1140 -0.5764 -0.3165 -3.6848 -0.1934
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine dilated_cardiomyopathy patients heart_failure
H-1257	-0.537300169467926	▁Chinese _ ▁herbal _ ▁medicine ▁ad ju nc tive _ ▁treatment ▁dil ated _ ▁cardio my o pathy ▁heart ▁failure
D-1257	-0.537300169467926	Chinese_ herbal_ medicine adjunctive_ treatment dilated_ cardiomyopathy heart failure
P-1257	-1.1100 -0.4049 -0.2476 -1.1893 -0.6172 -0.8643 -0.0048 -0.0056 -0.2795 -0.3684 -0.8772 -0.2854 -0.3237 -0.0548 -0.3802 -1.8925 -0.5574 -0.0190 -0.6035 -1.0594 -0.4246 -0.2512
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic_heart_failure chf sympathetic_tone autonomic_imbalance
H-1370	-0.6149984002113342	▁chronic _ heart _ ▁failure CH f ▁sympa the tic _ ▁tone ▁autonomi c _ ▁im balance
D-1370	-0.6149984002113342	chronic_heart_ failureCHf sympathetic_ tone autonomic_ imbalance
P-1370	-0.1362 -0.1006 -1.6897 -1.2346 -0.0456 -1.7660 -1.1213 -0.2440 -0.4338 -0.5684 -0.1690 -0.3134 -0.0018 -0.3789 -0.4738 -2.5028 -0.0102 -0.3562 -0.1386
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient implantable_cardioverter-defibrillator
H-1856	-0.3781111538410187	▁implant able _ ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1856	-0.3781111538410187	implantable_ cardioverter-defibrillator_deactivation
P-1856	-1.1942 -0.0805 -0.5632 -0.1935 -0.0532 -0.2201 -0.3648 -0.0340 -0.1821 -0.6639 -0.1706 -0.0918 -0.6749 -1.0235 -0.0119 -0.5142 -0.5074 -0.2623
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical_delay dyssynchronous_heart_failure
H-1146	-0.7375428676605225	▁me chan istic _ ▁insight ▁prolong ed _ ▁electro me chan ical _ de lay ▁dys syn chron ous _ heart _ ▁failure ▁computa tional
D-1146	-0.7375428676605225	mechanistic_ insight prolonged_ electromechanical_delay dyssynchronous_heart_ failure computational
P-1146	-4.2717 -0.0161 -0.2962 -1.4738 -0.4689 -1.3057 -0.1500 -0.7086 -0.4179 -0.0682 -0.0625 -0.5673 -0.2272 -0.8504 -0.2156 -0.0492 -0.0344 -0.0129 -1.8790 -0.0601 -3.1823 -1.2966 -0.0469 -0.0379 -0.0292 -1.9650 -0.2199
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated cardiac_filling_pressures adverse_outcomes
H-1532	-0.7092238664627075	▁EH ▁cardiac _ ▁fill ing _ ▁pressure s
D-1532	-0.7092238664627075	EH cardiac_ filling_ pressures
P-1532	-0.5755 -2.1408 -0.6654 -0.7412 -0.1202 -0.4607 -1.5415 -0.2124 -0.4929 -0.1416
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef sodium ventricular vascular_stiffness
H-917	-0.7483482956886292	▁h FP EF ▁so dium ▁restriction ▁vent ri cular ▁vas cular _ ▁sti ff ness ▁function
D-917	-0.7483482956886292	hFPEF sodium restriction ventricular vascular_ stiffness function
P-917	-0.9013 -1.2347 -1.3891 -0.8630 -0.0754 -1.0859 -0.0136 -0.6553 -0.2520 -0.5258 -0.6281 -1.8725 -0.6539 -0.2968 -1.7917 -0.8306 -0.2806 -0.1203
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart_failure leading mortality western society cardiovascular_diseases
H-1480	-0.9345523118972778	▁Heart _ ▁failure ▁ europe se _ ▁society ▁cardiovascular _ ▁disease s
D-1480	-0.9345523118972778	Heart_ failure europese_ society cardiovascular_ diseases
P-1480	-0.7618 -1.1799 -0.1566 -3.8028 -2.2889 -0.0120 -0.2897 -1.4788 -0.1763 -1.2136 -1.2378 -0.0432 -0.2778 -0.1644
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein genes western_blot dna_fragmentation tunel
H-167	-0.670195996761322	▁protein ▁levels ▁Western _ ▁blot ▁DNA ▁fragment ation ▁tu nel ▁auto psy ▁sample s
D-167	-0.670195996761322	protein levels Western_ blot DNA fragmentation tunel autopsy samples
P-167	-1.0933 -1.8127 -0.4330 -0.2273 -1.1425 -1.5221 -0.5549 -0.0700 -0.3614 -0.2718 -1.1867 -0.0123 -1.5957 -0.0591 -0.2664 -0.1139
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully_magnetically_levitated_left_ventricular_assist_system hf
H-1992	-0.6171668767929077	▁magnet ically _ ▁Lev itate d _ le ft _ ▁Vent ri cular _ ▁Assist _ system _ for _ tre ating _ ▁Advanced _ HF
D-1992	-0.6171668767929077	magnetically_ Levitated_left_ Ventricular_ Assist_system_for_treating_ Advanced_HF
P-1992	-0.2943 -0.2329 -0.2106 -1.0030 -0.6288 -0.0138 -0.5182 -0.5076 -0.0417 -0.0691 -2.1701 -2.1907 -0.5414 -0.1830 -0.4834 -1.9244 -0.5649 -1.7635 -1.1531 -0.2451 -0.3939 -0.0077 -0.9642 -0.2017 -0.1140 -0.5042 -0.2081 -0.1473
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological cardiovascular bound
H-1875	-1.1246689558029175	▁neurologi cal ▁cardiovascular
D-1875	-1.1246689558029175	neurological cardiovascular
P-1875	-0.2643 -0.4482 -2.2140 -2.5473 -0.1494
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart_failure
H-1539	-1.231929898262024	▁heart _ ▁failure
D-1539	-1.231929898262024	heart_ failure
P-1539	-3.4492 -1.9551 -0.1683 -0.4553 -0.1317
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up patients hf
H-1106	-0.5292524695396423	▁ HF
D-1106	-0.5292524695396423	HF
P-1106	-1.3298 -0.2570 -0.3856 -0.1447
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients madit-crt
H-858	-1.0739208459854126	▁MAD it - c r _ ▁study ▁device
D-858	-1.0739208459854126	MADit-cr_ study device
P-858	-0.5550 -1.6487 -0.0317 -0.5352 -4.2191 -1.6597 -0.9719 -0.8101 -0.1633 -0.1445
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical nitrite vascular
H-414	-0.7297202348709106	▁chemical _ in st ability ▁co genera tion ▁nit rite
D-414	-0.7297202348709106	chemical_instability cogeneration nitrite
P-414	-2.5567 -1.7094 -0.2258 -0.0398 -0.0930 -0.4635 -0.0058 -0.2335 -0.1530 -0.4415 -2.6817 -0.1530
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech_republic
H-1972	-0.5076987743377686	▁Czech ▁Republic
D-1972	-0.5076987743377686	Czech Republic
P-1972	-0.2765 -0.8722 -0.7008 -0.1813
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets tac hf
H-1050	-0.5021254420280457	▁ BET s ▁mouse ▁ TAC _ ▁model ▁human _ HF
D-1050	-0.5021254420280457	BETs mouse TAC_ model human_HF
P-1050	-1.3192 -0.2256 -0.1876 -0.1198 -0.8388 -0.0194 -0.8794 -0.5639 -0.2665 -0.4142 -1.3759 -0.1646 -0.1527
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized dopamine nesiritide
H-76	-0.6206309199333191	▁dop amine ▁nesi riti de
D-76	-0.6206309199333191	dopamine nesiritide
P-76	-1.4701 -0.1517 -0.0338 -0.0095 -0.0962 -2.4103 -0.1728
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c_statistics
H-383	-1.3000026941299438	▁concorda nce _ c _ ▁statistic s ▁UM / VA ▁va - RT
D-383	-1.3000026941299438	concordance_c_ statistics UM/VA va-RT
P-383	-3.4398 -1.3844 -0.8348 -1.5734 -0.7730 -0.3137 -0.0412 -1.4370 -2.2709 -0.6291 -3.0607 -0.4560 -2.7181 -0.4058 -0.1621
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion mortality
H-50	-0.7927868962287903	▁trans fusion ▁thre s hold s ▁mortal ity
D-50	-0.7927868962287903	transfusion thresholds mortality
P-50	-0.4786 -0.3510 -1.6432 -0.1762 -0.4542 -0.1693 -0.9161 -1.6824 -1.8541 -0.2028
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations patients patients
H-1282	-0.8966416716575623	
D-1282	-0.8966416716575623	
P-1282	-1.6209 -0.1724
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac nurses
H-1662	-0.45377519726753235	▁cardiac _ ▁nurse s
D-1662	-0.45377519726753235	cardiac_ nurses
P-1662	-0.0923 -1.4479 -0.3319 -0.0506 -0.6467 -0.1533
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients randomization
H-851	-0.8046061992645264	
D-851	-0.8046061992645264	
P-851	-1.4645 -0.1447
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-1.4004087448120117	▁kosten - effect ive
D-614	-1.4004087448120117	kosten-effective
P-614	-4.8676 -0.1277 -0.0049 -0.1072 -3.1464 -0.1487
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california_office_of_statewide_health_planning_and_development_patient_discharge_data_nonpublic_file
H-136	-0.5786066651344299	▁California _ office _ of _ ▁State wide _ Health _ plan ning _ en _ ▁Development ▁Patient _ Dis charge
D-136	-0.5786066651344299	California_office_of_ Statewide_Health_planning_en_ Development Patient_Discharge
P-136	-0.6883 -0.5877 -0.1759 -0.7743 -0.3593 -0.1709 -1.9905 -0.2959 -0.0278 -1.2746 -0.5572 -0.1550 -0.0146 -0.6509 -2.0625 -0.1352 -0.0614 -0.2701 -0.4024 -1.4851 -0.0415 -0.9649 -0.1620
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal_membrane_oxygenation refractory_right_heart_failure
H-1290	-0.385525643825531	▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁in far ction - related ▁re frac tory _ ▁right _ ▁heart ▁failure
D-1290	-0.385525643825531	extracorporeal_ membrane_ oxygenation infarction-related refractory_ right_ heart failure
P-1290	-0.1212 -0.0090 -0.2576 -0.0357 -0.0662 -0.1776 -0.0129 -0.3957 -0.5802 -0.0471 -1.0608 -0.1369 -0.0473 -0.1226 -0.1332 -0.9664 -0.0244 -0.1700 -0.1877 -1.6728 -0.0910 -2.1854 -0.7779 -0.2227 -0.1356
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation therapy heart_disease rate_control
H-1652	-0.7645084261894226	▁antico ag ulation ▁ therapy ▁heart _ ▁disease ▁rate _ control
D-1652	-0.7645084261894226	anticoagulation therapy heart_ disease rate_control
P-1652	-0.5867 -0.1196 -0.0871 -1.0140 -0.0196 -2.9837 -1.5367 -0.6711 -0.0510 -1.9046 -0.0173 -0.8117 -0.1355
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality_of_life seattle_heart_failure_model
H-2012	-0.6227824687957764	▁Seattle _ ▁Heart _ ▁Fail ure
D-2012	-0.6227824687957764	Seattle_ Heart_ Failure
P-2012	-2.1054 -0.1985 -0.7173 -0.6002 -0.2539 -0.4390 -0.4974 -0.1706
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change paco2 cerebral blood_flow perfusion carotid
H-1350	-0.3583025336265564	▁Paco 2 ▁cerebral _ ▁blood _ ▁flow ▁per fusion ▁caro tid _ ▁bo dies
D-1350	-0.3583025336265564	Paco2 cerebral_ blood_ flow perfusion carotid_ bodies
P-1350	-0.0921 -0.0715 -0.0493 -0.2718 -1.3071 -1.2421 -0.0889 -0.1644 -0.0066 -0.2762 -0.0743 -0.4476 -0.8555 -0.3879 -0.2768 -0.1206
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology hf diagnosis medical nursing
H-2021	-0.7921875715255737	▁pat ho phy si ology ▁ HF ▁medical ▁management
D-2021	-0.7921875715255737	pathophysiology HF medical management
P-2021	-1.5971 -0.3045 -0.5172 -2.0731 -0.1834 -0.9466 -0.2975 -0.7298 -1.0769 -0.8860 -0.1020
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients physicians hospitals new_jersey new_york
H-212	-0.7346214056015015	▁ED ▁physician s ▁subur ban _ hospital s ▁New ▁Jersey ▁New ▁York
D-212	-0.7346214056015015	ED physicians suburban_hospitals New Jersey New York
P-212	-2.2820 -1.4912 -0.0766 -1.4621 -0.0884 -0.2248 -0.2186 -0.2164 -0.9685 -0.3159 -1.2723 -1.2370 -0.3159 -0.1150
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart_failure protein_kinase_a expression
H-1423	-0.7943149209022522	▁heart _ ▁failure ▁protein ▁kina se
D-1423	-0.7943149209022522	heart_ failure protein kinase
P-1423	-3.1677 -1.6201 -0.1110 -0.4830 -0.3748 -0.1134 -0.3089 -0.1757
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox_regression cardiovascular_events psoriasis
H-1558	-0.34770554304122925	▁co x _ re gression ▁cardiovascular _ ▁events ▁psoriasis
D-1558	-0.34770554304122925	cox_regression cardiovascular_ events psoriasis
P-1558	-0.1170 -0.1238 -0.5517 -0.7529 -0.0317 -0.3676 -0.5525 -1.0441 -0.0118 -0.1254 -0.1463
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy_metabolism heart_failure hypertrophied heart
H-1779	-0.6845826506614685	▁energy _ ▁metabolism ▁heart _ ▁failure ▁hyper trop hi ed _ heart
D-1779	-0.6845826506614685	energy_ metabolism heart_ failure hypertrophied_heart
P-1779	-2.4811 -1.3016 -0.0652 -0.8795 -1.9644 -0.2958 -0.1155 -0.0206 -0.0316 -0.3371 -0.1313 -1.6108 -0.2336 -0.1160
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients clinical echocardiography baseline shunt implantation
H-1954	-0.3734439015388489	▁e cho card i ography ▁shu nt ▁implant ation
D-1954	-0.3734439015388489	echocardiography shunt implantation
P-1954	-0.1278 -0.0274 -0.3437 -0.5185 -0.2725 -0.6700 -0.0912 -1.4008 -0.1602 -0.3603 -0.1354
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic_effect beta_blockers heart_failure
H-648	-0.7009439468383789	▁in o tropi c _ effect ▁beta ▁block ers ▁heart ▁failure
D-648	-0.7009439468383789	inotropic_effect beta blockers heart failure
P-648	-0.3905 -0.8282 -0.0311 -0.0697 -2.5091 -0.4502 -0.0520 -1.9277 -0.0953 -1.7387 -0.6178 -0.2670 -0.1351
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline mechanical_cardiac_support renal_function
H-1388	-0.6799856424331665	▁mechanic al _ ▁cardiac _ support ▁renal _ ▁function
D-1388	-0.6799856424331665	mechanical_ cardiac_support renal_ function
P-1388	-1.0118 -0.0893 -0.1104 -0.7110 -0.6105 -1.7734 -0.0489 -0.5063 -1.9124 -0.5269 -0.1788
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ecmo patients vad ecmo vad
H-1390	-1.3335014581680298	▁patients ▁ec mo _ groep ▁ VAD ▁ec mo + VAD
D-1390	-1.3335014581680298	patients ecmo_groep VAD ecmo+VAD
P-1390	-2.9718 -0.7070 -1.0181 -2.8343 -0.3296 -1.0893 -0.1151 -1.6156 -1.4622 -3.5135 -0.2101 -1.2376 -0.2314
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional_ms lv_dilatation functional_ms
H-368	-0.5433733463287354	▁functional ▁MS ▁LV ▁di la tation ▁functional ▁MS
D-368	-0.5433733463287354	functional MS LV dilatation functional MS
P-368	-0.0730 -1.3439 -0.3284 -1.3792 -0.1697 -0.0285 -0.2120 -1.5192 -0.2410 -0.1388
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp circulation hf patients
H-1513	-0.5264918804168701	▁NT - pro b NP ▁circulation ▁ HF
D-1513	-0.5264918804168701	NT-probNP circulation HF
P-1513	-0.8567 -0.0713 -0.0094 -0.6678 -0.1833 -0.5611 -0.8198 -0.1844 -1.7313 -0.1799
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality morbidity health-care budget
H-1075	-0.8513951897621155	▁mortal ity ▁morbi d ity ▁cancer s ▁budget
D-1075	-0.8513951897621155	mortality morbidity cancers budget
P-1075	-1.5666 -1.3713 -0.0439 -0.0377 -2.0335 -0.2463 -0.2556 -2.3365 -0.4393 -0.1832
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp sensitivity
H-271	-0.6497055292129517	▁cut off _ ▁level ▁NT - pro b NP
D-271	-0.6497055292129517	cutoff_ level NT-probNP
P-271	-0.5256 -0.1624 -2.5865 -0.3311 -0.8704 -0.0654 -0.0287 -0.5836 -0.2247 -1.6066 -0.1617
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation flow-mediated_dilatation
H-259	-0.619142472743988	▁HD l - indu ced _ ▁NO _ ▁production ▁flow - media ted _ di la tation ▁ET
D-259	-0.619142472743988	HDl-induced_ NO_ production flow-mediated_dilatation ET
P-259	-4.1618 -1.3785 -0.0640 -0.0024 -0.0890 -0.3184 -0.9927 -0.6012 -1.0009 -0.0367 -0.0454 -0.3163 -0.3954 -0.0494 -0.9488 -0.1620 -0.0541 -1.3744 -0.2677 -0.1236
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients systolic_function therapeutic
H-1070	-0.6751534938812256	▁pres er ved _ sy sto lic _ function ▁ therapeut ic
D-1070	-0.6751534938812256	preserved_systolic_function therapeutic
P-1070	-3.1832 -0.1938 -0.4804 -0.7045 -1.2544 -0.2381 -0.1744 -0.1476 -1.2507 -0.6155 -0.1653 -0.0761 -0.8117 -0.1566
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ahf risk_stratification
H-58	-1.1382883787155151	▁a HF
D-58	-1.1382883787155151	aHF
P-58	-1.3030 -1.1432 -1.8756 -0.2314
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients pad ankle-brachial_index
H-1568	-0.48543044924736023	▁ PAD ▁an kle - bra chi al ▁index
D-1568	-0.48543044924736023	PAD ankle-brachial index
P-1568	-1.8116 -0.0893 -0.3134 -0.2473 -0.2446 -0.2005 -0.6528 -0.0971 -1.0864 -0.4324 -0.1643
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective_studies cpg hf
H-1845	-1.0028977394104004	▁c PG ▁recommendations ▁ HF
D-1845	-1.0028977394104004	cPG recommendations HF
P-1845	-0.8524 -0.7206 -2.2858 -2.0515 -0.5555 -0.3799 -0.1746
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr_reduction ivabradine tac ea
H-525	-0.7310138940811157	▁i sol ated _ HR ▁i va bra dine ▁ TAC
D-525	-0.7310138940811157	isolated_HR ivabradine TAC
P-525	-1.1260 -2.4150 -0.1815 -0.2846 -0.7094 -0.5365 -0.0776 -0.0757 -0.1864 -0.8803 -0.0728 -2.7775 -0.1798
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause_hospitalisations sts
H-160	-1.0447652339935303	▁TM ▁s ts
D-160	-1.0447652339935303	TM sts
P-160	-0.8190 -1.2288 -2.1868 -0.7934 -0.1959
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol linear_mixed_models intention-to-treat
H-838	-1.2269874811172485	▁treatment _ groep _ effect s ▁HR Qo l
D-838	-1.2269874811172485	treatment_groep_effects HRQol
P-838	-1.9851 -1.5747 -0.8235 -0.8758 -0.7544 -1.7528 -2.4650 -0.0061 -1.8146 -1.3567 -0.0883
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic clinicians patients
H-1124	-0.7997768521308899	▁Reason s ▁non tre at ment
D-1124	-0.7997768521308899	Reasons nontreatment
P-1124	-1.7658 -0.3557 -2.6882 -0.0833 -0.1071 -0.1526 -1.1196 -0.1260
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions hospital
H-144	-0.7125383615493774	▁computing _ ▁read missions ▁hospital ▁ranking s ▁pay - for - per form ance
D-144	-0.7125383615493774	computing_ readmissions hospital rankings pay-for-performance
P-144	-0.7604 -0.5229 -3.3990 -0.1880 -2.4995 -1.0696 -0.2082 -1.3900 -0.0613 -0.2009 -0.1061 -0.0475 -0.2332 -0.0557 -0.4464 -0.2119
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd patients
H-65	-0.6335391998291016	▁i CD
D-65	-0.6335391998291016	iCD
P-65	-0.2765 -1.0801 -0.8969 -0.2806
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-1.2331781387329102	▁method ▁ HF
D-1002	-1.2331781387329102	method HF
P-1002	-2.6958 -1.1996 -0.3150 -1.7831 -0.1724
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients patients
H-267	-1.0283113718032837	
D-267	-1.0283113718032837	
P-267	-1.8472 -0.2094
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular_assist_device extracorporeal_membrane_oxygenation renal_function heart_failure
H-1383	-0.47075021266937256	▁vent ri cular _ assist _ ▁device ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁renal _ ▁function ▁pediatr ic _ heart _ ▁failure
D-1383	-0.47075021266937256	ventricular_assist_ device extracorporeal_ membrane_ oxygenation renal_ function pediatric_heart_ failure
P-1383	-0.0190 -0.9441 -0.3824 -0.2031 -0.2701 -1.8195 -0.8729 -0.0310 -0.0402 -0.7972 -0.0659 -0.0639 -0.3305 -0.0192 -0.5260 -0.5272 -0.1259 -0.1037 -0.7133 -0.7346 -1.0002 -0.0452 -0.1697 -1.5736 -1.0620 -0.2036 -0.3282 -0.2086
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory_fitness body_mass_index heart_failure mortality cooper_center_longitudinal_study
H-1765	-0.45022091269493103	▁Card i ore spira tory _ ▁fitness ▁body ▁mass ▁index ▁heart _ ▁failure _ ▁mortal ity ▁Cooper _ center _ ▁Long itud in al _ ▁Study
D-1765	-0.45022091269493103	Cardiorespiratory_ fitness body mass index heart_ failure_ mortality Cooper_center_ Longitudinal_ Study
P-1765	-1.2070 -0.9767 -0.6616 -0.0695 -0.0893 -0.4224 -0.5093 -0.0863 -0.5644 -0.0876 -0.5722 -1.3973 -0.3071 -0.4874 -0.0731 -0.4658 -0.2243 -0.3091 -1.5983 -0.7128 -0.5511 -0.0363 -0.1216 -0.0441 -0.2332 -0.3441 -0.3126 -0.1417
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations cox_models st2 functional_capacity outcomes
H-700	-0.5464939475059509	▁co x _ ▁models ▁ST 2 ▁functional _ capaci te
D-700	-0.5464939475059509	cox_ models ST2 functional_capacite
P-700	-0.2305 -0.0410 -1.6368 -0.7242 -0.9497 -0.1249 -0.0275 -0.4681 -0.6681 -0.8181 -0.7418 -0.1271
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new_york_heart_association_classification 6-min_walk_test quality-of-life
H-2005	-0.9110756516456604	▁New _ York _ ▁Heart _ association
D-2005	-0.9110756516456604	New_York_ Heart_association
P-2005	-0.7144 -0.6855 -1.5927 -0.2057 -1.3144 -0.4661 -0.6584 -2.4236 -0.1389
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise_intolerance heart_failure exercise diagnosis prognosis therapeutic
H-1272	-0.7266454100608826	▁Exerci se _ in tolerance ▁heart _ ▁failure
D-1272	-0.7266454100608826	Exercise_intolerance heart_ failure
P-1272	-0.9868 -0.0940 -0.8206 -0.2362 -0.0116 -1.9706 -1.2996 -0.0970 -1.6188 -0.1314
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse_correlation pro-adrenomedullin mr-proadm ffm
H-15	-0.23107339441776276	▁pro - ad re nom edu llin MR - pro ad m ▁f m
D-15	-0.23107339441776276	pro-adrenomedullinMR-proadm fm
P-15	-0.3043 -0.0311 -0.0309 -0.0437 -0.1059 -0.2300 -0.5023 -0.1637 -0.0068 -0.0108 -0.4658 -0.1777 -0.3107 -0.8562 -0.3288 -0.1284
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin_receptor_antagonist tolvaptan heart_failure patients
H-1194	-0.4221656024456024	▁vaso press in _ ▁receptor _ ▁anta gon ist ▁to lv ap tan ▁Japanese _ heart ▁failure
D-1194	-0.4221656024456024	vasopressin_ receptor_ antagonist tolvaptan Japanese_heart failure
P-1194	-0.0344 -0.0745 -0.6040 -0.4665 -0.0156 -1.1798 -0.0193 -0.0050 -0.3921 -0.0121 -0.2212 -0.2880 -0.0283 -0.9707 -0.2287 -1.4049 -0.8578 -1.0929 -0.1254
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional_ms ring_annuloplasty ischemic_mr lv_dilatation
H-366	-0.3915981352329254	▁functional ▁MS ▁ring _ ▁ann ulo plast y ▁ ische mic _ ▁MR ▁LV ▁di la tation
D-366	-0.3915981352329254	functional MS ring_ annuloplasty ischemic_ MR LV dilatation
P-366	-0.0698 -1.2040 -0.0022 -0.7314 -2.3832 -0.0858 -0.0425 -0.3099 -0.2473 -0.0115 -0.0840 -0.2261 -0.6170 -0.1599 -0.6301 -0.0391 -0.0284 -0.4653 -0.1030
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp nt-probnp diagnostic prognostic biomarkers patients heart_failure
H-1365	-0.3227466940879822	▁b NP ▁NT - pro b NP ▁bio mark ers ▁heart ▁failure
D-1365	-0.3227466940879822	bNP NT-probNP biomarkers heart failure
P-1365	-0.1775 -0.3206 -0.7845 -0.1138 -0.0067 -0.3603 -0.2091 -0.4131 -0.1292 -0.1083 -0.8535 -0.7261 -0.2035 -0.1124
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis patients diastolic_blood_pressure body_mass_index
H-1560	-0.7041378617286682	▁p sori asis ▁patients ▁smo ked ▁dia sto lic _ ▁blood _ ▁pressure ▁body ▁mass ▁index
D-1560	-0.7041378617286682	psoriasis patients smoked diastolic_ blood_ pressure body mass index
P-1560	-2.2798 -0.0387 -0.1312 -2.8889 -0.7008 -0.2287 -0.0502 -0.0280 -0.2336 -0.1178 -0.8233 -1.6146 -0.9075 -0.3947 -1.2316 -0.1256 -0.6952 -0.1843
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin_receptor st2 beta-blocker therapy chronic_heart_failure
H-398	-0.617630660533905	▁inter le u kin _ ▁receptor _ family _ ▁member ▁ST 2 ▁beta - block er _ therapy ▁chronic _ heart _ ▁failure
D-398	-0.617630660533905	interleukin_ receptor_family_ member ST2 beta-blocker_therapy chronic_heart_ failure
P-398	-0.0991 -0.3330 -0.0567 -4.3162 -0.2699 -0.0631 -1.6108 -0.5491 -1.6452 -0.8961 -0.2693 -0.0638 -0.0449 -0.0440 -0.0888 -0.0337 -1.2195 -0.0239 -0.4477 -0.0727 -1.5553 -1.2892 -0.1397 -0.2006 -0.1083
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf symptom cardiac_murmurs blood_pressure
H-356	-0.7153936624526978	▁ HF ▁cardiac _ mur mur s ▁blood _ ▁pressure ▁h g
D-356	-0.7153936624526978	HF cardiac_murmurs blood_ pressure hg
P-356	-0.6987 -0.2025 -1.3791 -0.4000 -0.8542 -0.2095 -0.1618 -0.9737 -1.2127 -0.9635 -2.4928 -0.1310 -0.1848 -0.1512
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular_dysfunction outcome patients heartmate_ii
H-305	-0.5961318612098694	▁bi ven tri cular _ ▁dys function ▁isola ted _ ▁Heart Mate _ ▁II
D-305	-0.5961318612098694	biventricular_ dysfunction isolated_ HeartMate_ II
P-305	-1.2874 -0.1325 -0.4300 -2.0571 -0.4170 -0.4844 -0.2316 -0.7137 -0.0749 -0.3395 -0.7169 -0.1669 -1.3123 -0.4769 -0.5039 -0.1931
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal_dysfunction mechanical_cardiac_support
H-1394	-0.4524124264717102	▁renal _ ▁dys function ▁mechanic al _ ▁cardiac _ support
D-1394	-0.4524124264717102	renal_ dysfunction mechanical_ cardiac_support
P-1394	-0.9951 -0.6861 -0.7857 -0.0756 -0.3358 -0.1062 -0.0661 -0.2637 -0.7293 -0.8656 -0.3843 -0.1356
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular_assist_devices therapies
H-203	-0.5677366256713867	▁vent ri cular _ assist ▁devices ▁device ▁ therapie s
D-203	-0.5677366256713867	ventricular_assist devices device therapies
P-203	-0.7115 -1.1500 -0.2960 -0.1448 -0.2270 -2.3433 -0.1298 -0.7982 -0.0717 -0.1348 -0.5999 -0.2058
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional_ms medical_treatment surgical
H-376	-0.7216775417327881	▁Fun ction al _ ▁MS ▁medical
D-376	-0.7216775417327881	Functional_ MS medical
P-376	-0.2516 -0.0091 -0.0233 -0.6771 -1.0091 -1.3138 -2.3869 -0.1026
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients left_ventricular_dilatation dysfunction
H-1746	-1.0461028814315796	▁vent ri cular _ di la tation ▁dys function
D-1746	-1.0461028814315796	ventricular_dilatation dysfunction
P-1746	-5.9778 -1.3765 -0.5542 -0.3364 -1.0477 -0.3719 -0.1111 -0.9861 -0.1623 -0.4307 -0.1525
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade evidence anemia patients heart_disease
H-38	-1.1334738731384277	▁aan emia ▁heart ▁disease
D-38	-1.1334738731384277	aanemia heart disease
P-38	-3.5496 -0.2145 -1.5626 -1.0205 -0.2599 -0.1936
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients heart_failure systolic_heart_failure
H-725	-0.9497701525688171	▁heart ▁failure ▁sy sto lic _ heart ▁failure
D-725	-0.9497701525688171	heart failure systolic_heart failure
P-725	-4.7991 -1.0999 -0.0334 -0.0390 -0.3393 -0.1471 -1.9255 -0.6551 -0.2920 -0.1674
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients hf spontaneous_vt qt_intervals
H-1445	-0.46607619524002075	▁ HF ▁spontane ous _ VT ▁beat - to - beat _ QT ▁interval s
D-1445	-0.46607619524002075	HF spontaneous_VT beat-to-beat_QT intervals
P-1445	-1.3411 -0.1878 -0.4163 -0.3001 -0.4765 -0.7342 -0.0165 -0.0621 -0.0440 -0.0904 -0.1734 -0.7253 -0.8505 -1.8845 -0.0695 -0.4016 -0.1495
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol cxl-1020 myocytes hearts
H-419	-0.37311679124832153	▁iso prot eren ol ▁c XL -10 20 ▁my o cy tes ▁heart s
D-419	-0.37311679124832153	isoproterenol cXL-1020 myocytes hearts
P-419	-0.0041 -0.0466 -0.0639 -0.4908 -0.3684 -0.4436 -0.2171 -0.0301 -1.2734 -0.1879 -0.1189 -0.0318 -1.6474 -0.2468 -0.6504 -0.1484
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted patients adverse_events follow-up
H-1956	-1.0391684770584106	▁device
D-1956	-1.0391684770584106	device
P-1956	-1.7307 -1.2473 -0.1395
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb patients hf
H-1351	-1.2801676988601685	▁p p ▁patients ▁ HF
D-1351	-1.2801676988601685	pp patients HF
P-1351	-0.3971 -2.3202 -1.0153 -2.0541 -0.3930 -2.6420 -0.1394
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug_test patients copd chf crf
H-806	-1.102982521057129	▁tu g _ ▁test ▁advanced _ ▁COP d ▁CHF ▁c RF
D-806	-1.102982521057129	tug_ test advanced_ COPd CHF cRF
P-806	-0.7914 -3.0030 -1.6959 -2.0084 -2.9456 -0.4086 -0.6046 -1.5850 -0.0066 -0.2657 -0.6856 -0.2113 -0.1271
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart_failure hf chronic disease
H-2019	-0.6657384634017944	▁Heart ▁failure HF ▁de bilitat ing ▁chronic _ ▁disease
D-2019	-0.6657384634017944	Heart failureHF debilitating chronic_ disease
P-2019	-0.4226 -0.4799 -0.2601 -2.6581 -0.0047 -0.0601 -1.9016 -0.3580 -0.8473 -0.2033 -0.1274
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline rhythm-control rate-control
H-1237	-0.41948720812797546	▁ rhythm - control ▁rate - control
D-1237	-0.41948720812797546	rhythm-control rate-control
P-1237	-0.3088 -0.9925 -0.3140 -0.0092 -1.0120 -0.3255 -0.0115 -0.6183 -0.1834
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf epidemiology health hf
H-1790	-1.0775552988052368	▁ HF _ ▁epidemi ology ▁health _ service _ ▁provision ▁ HF ▁LA
D-1790	-1.0775552988052368	HF_ epidemiology health_service_ provision HF LA
P-1790	-0.4324 -0.1719 -3.5470 -0.3050 -0.1493 -1.4243 -2.0890 -1.3608 -1.9696 -0.5378 -0.8431 -0.1490 -2.5934 -0.4531 -0.1376
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin health outcomes
H-43	-1.1240744590759277	▁hem o glob in
D-43	-1.1240744590759277	hemoglobin
P-43	-0.9780 -0.7245 -0.3842 -1.8194 -2.7100 -0.1284
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes heart_failure hf
H-555	-1.081632137298584	▁heart ▁failure HF
D-555	-1.081632137298584	heart failureHF
P-555	-3.9816 -0.7404 -0.2174 -0.2717 -0.1970
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates coagulability
H-1113	-1.1004281044006348	▁se rum ▁factors ▁marker s _ for _ co gul ability
D-1113	-1.1004281044006348	serum factors markers_for_cogulability
P-1113	-1.1541 -0.4290 -1.7383 -2.6992 -0.1719 -0.9215 -2.9389 -0.5394 -0.9533 -1.1580 -1.0692 -0.3895 -0.1433
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up lvad patients heart_failure
H-548	-0.740235447883606	▁CF ▁l VAD ▁AI ▁heart ▁failure
D-548	-0.740235447883606	CF lVAD AI heart failure
P-548	-0.2386 -2.1339 -0.0692 -1.7035 -0.4745 -0.8904 -0.2643 -0.1475
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory_factor_analysis cfa
H-1506	-0.6738194227218628	▁explora tory _ factor _ analyse ▁c fa
D-1506	-0.6738194227218628	exploratory_factor_analyse cfa
P-1506	-1.3399 -0.0209 -0.0746 -0.6489 -1.7038 -0.2829 -0.3488 -1.9815 -0.1742 -0.1626
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical patient hemodynamically cpr
H-1294	-1.0578974485397339	▁hem o dynamic ally _ ▁uns table ▁c PR
D-1294	-1.0578974485397339	hemodynamically_ unstable cPR
P-1294	-3.8042 -0.4365 -0.0052 -0.9314 -0.6515 -1.9777 -0.7736 -0.8201 -1.8042 -0.3312 -0.1013
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing mandate accountable outcomes nursing
H-1396	-1.2644410133361816	▁Nur sing ▁social _ ▁mandat e
D-1396	-1.2644410133361816	Nursing social_ mandate
P-1396	-2.7100 -0.0078 -3.3844 -1.0324 -0.2801 -0.0793 -2.3768 -0.2447
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical activity cardiovascular obesity diabetes_mellitus hypertension hyperlipidaemia
H-1898	-0.690910816192627	▁physical _ activ iteit ▁cardiovascular _ ▁risk ▁factors ▁diabetes ▁mell itus ▁hyper tension ▁hyper li pida emia
D-1898	-0.690910816192627	physical_activiteit cardiovascular_ risk factors diabetes mellitus hypertension hyperlipidaemia
P-1898	-3.1666 -0.4632 -0.4243 -0.4674 -0.9898 -0.7323 -2.4047 -1.7269 -1.2772 -0.0084 -0.0634 -0.0889 -0.1514 -0.1065 -0.4416 -0.0743 -0.0473 -0.3282 -0.1648
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-1.0661025047302246	▁die t ▁exercise ▁attention ▁control ▁telephone ▁call s
D-1979	-1.0661025047302246	diet exercise attention control telephone calls
P-1979	-2.4384 -0.0587 -2.1742 -0.8504 -3.0107 -0.0772 -1.3613 -0.1102 -0.3739 -0.2059
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.6351714134216309	▁long - term _ ▁survival
D-272	-0.6351714134216309	long-term_ survival
P-272	-2.1925 -0.1044 -0.0971 -0.3446 -1.0264 -0.5525 -0.1287
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac_death
H-1905	-0.5099108815193176	▁Sud den _ ▁cardiac _ ▁death ▁ath letes
D-1905	-0.5099108815193176	Sudden_ cardiac_ death athletes
P-1905	-1.8586 -0.0203 -0.0777 -0.1053 -0.5926 -0.7441 -0.9144 -0.1064 -0.5069 -0.1728
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital mortality
H-1692	-1.2532373666763306	▁hospital _ ▁mortal ity
D-1692	-1.2532373666763306	hospital_ mortality
P-1692	-3.3030 -1.2126 -0.3568 -1.9439 -0.4433 -0.2599
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration chf
H-683	-0.7917330265045166	▁administratie ▁tras tuz um ab - related ▁CHF
D-683	-0.7917330265045166	administratie trastuzumab-related CHF
P-683	-4.1249 -0.4813 -0.0584 -0.0540 -0.7327 -0.5727 -0.4699 -0.9784 -0.3261 -0.1190
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital rehospitalization
H-1719	-1.002112627029419	▁re hospital ization
D-1719	-1.002112627029419	rehospitalization
P-1719	-1.1475 -2.6801 -0.7205 -0.3087 -0.1538
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.46409788727760315	▁hospital s ▁ metric
D-142	-0.46409788727760315	hospitals metric
P-142	-1.3552 -0.1892 -0.4806 -0.0939 -0.4463 -0.2194
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.5159669518470764	▁bio mark er - guide d ▁clinic al
D-1476	-0.5159669518470764	biomarker-guided clinical
P-1476	-0.1250 -0.0820 -0.0412 -0.1314 -0.0050 -0.0668 -1.6155 -0.2301 -2.6451 -0.2176
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-0.8873050212860107	▁medical _ ▁records
D-1131	-0.8873050212860107	medical_ records
P-1131	-1.5229 -1.6032 -0.3859 -0.7685 -0.1561
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal_pro-b-type_natriuretic_peptides plasma heart_failure patients
H-1510	-0.5891978144645691	▁circula ting _ ▁fragment s ▁na tri ure tic _ pe pti des ▁plasma ▁heart ▁failure
D-1510	-0.5891978144645691	circulating_ fragments natriuretic_peptides plasma heart failure
P-1510	-0.1399 -0.0190 -1.2039 -0.6397 -0.2060 -0.5581 -0.0597 -0.1888 -2.8819 -0.1894 -0.5411 -0.2637 -0.7989 -0.0569 -0.8219 -0.3924 -1.4721 -0.1723
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients heart_failure hf preserved_left_ventricular_ejection_fraction hfpef
H-1300	-0.6380899548530579	▁heart ▁failure HF ▁left _ ▁vent ri cular _ e je ction _ fraction HF p EF
D-1300	-0.6380899548530579	heart failureHF left_ ventricular_ejection_fractionHFpEF
P-1300	-1.7287 -0.8579 -0.4012 -2.0110 -0.2591 -1.3062 -0.8893 -0.6434 -0.2788 -0.4182 -0.1571 -0.1375 -0.5036 -0.0554 -1.5106 -0.0593 -0.4716 -0.3080 -0.1269
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine myocyte collagen left_ventricle
H-1141	-0.33413171768188477	▁Pyr ido stig mine ▁my o cy te ▁diameter ▁collage n _ ▁den s ity ▁left _ ▁vent ric le
D-1141	-0.33413171768188477	Pyridostigmine myocyte diameter collagen_ density left_ ventricle
P-1141	-0.0127 -0.0075 -0.0024 -0.0314 -0.6904 -0.0960 -0.0509 -0.0356 -0.8831 -0.0030 -0.0922 -0.6730 -0.2567 -0.1726 -0.5012 -0.3545 -0.3518 -1.0510 -1.0418 -0.5637 -0.3525 -0.1269
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac_angiogenesis in_vivo_coronary_perfusion cardiac_fibrosis
H-454	-0.6449300050735474	▁cardiac _ ▁ang io gene sis ▁in ▁vivo _ ▁corona ry _ per fusion ▁cardiac _ ▁fibro sis
D-454	-0.6449300050735474	cardiac_ angiogenesis in vivo_ coronary_perfusion cardiac_ fibrosis
P-454	-3.3602 -0.5577 -2.9463 -0.5409 -0.2703 -0.4136 -0.3414 -0.0973 -0.1526 -0.3675 -1.2946 -0.1027 -0.5431 -0.0083 -0.1160 -0.9904 -0.0780 -0.1677 -0.4515 -0.0987
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality patients implantable_cardiac_defibrillator meta-analysis
H-59	-0.6150645613670349	▁implant able _ ▁cardiac _ de fi br illa tor
D-59	-0.6150645613670349	implantable_ cardiac_defibrillator
P-59	-4.6050 -0.1063 -0.0597 -0.1692 -0.2793 -1.0687 -0.1054 -0.2219 -0.1376 -0.0858 -0.3594 -0.1823
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors adenylyl_cyclase g-protein_coupling
H-1406	-0.36050888895988464	▁a den yl yl _ ▁cy cla se ▁g - prote in _ ▁coup ling
D-1406	-0.36050888895988464	adenylyl_ cyclase g-protein_ coupling
P-1406	-0.8060 -0.1382 -0.0915 -0.4474 -0.3538 -0.2707 -0.0114 -0.3563 -0.9257 -0.1834 -0.0557 -0.5735 -0.3544 -0.2266 -0.6968 -0.4588 -0.1783
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization patients heart_failure ventricular_tachycardia
H-1434	-0.9992122054100037	▁repo lar ization _ in st ability ▁heart ▁failure ▁vent ri cular _ ta chy car dia
D-1434	-0.9992122054100037	repolarization_instability heart failure ventricular_tachycardia
P-1434	-8.0765 -0.8179 -0.7239 -1.5406 -0.0680 -0.0712 -0.2557 -1.6082 -0.6581 -0.0582 -1.4086 -0.5677 -0.8511 -1.3245 -0.1808 -0.0142 -0.0297 -0.5583 -0.1716
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling_pathways pressure-overload-induced_heart_failure
H-877	-0.7493994235992432	▁pressure - over load - indu ced _ heart _ ▁failure
D-877	-0.7493994235992432	pressure-overload-induced_heart_ failure
P-877	-5.2301 -0.1073 -0.0036 -0.1122 -0.3179 -0.0117 -0.5933 -0.2179 -0.8968 -1.4852 -0.1519 -0.3366 -0.2776
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise_intolerance symptom chronic_hfpef quality_of_life qol
H-1975	-0.76172935962677	▁Exerci se _ in tolerance ▁chronic _ h FP EF
D-1975	-0.76172935962677	Exercise_intolerance chronic_hFPEF
P-1975	-1.0344 -0.0301 -0.2480 -0.2722 -0.0120 -0.8906 -0.7882 -0.5213 -1.3487 -0.7355 -3.1299 -0.1298
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients systolic_hf etiology coronary_angiography
H-1184	-0.6290668845176697	▁sy sto lic _ HF ▁un clear _ ▁et i ology ▁corona ry _ ▁ang i ography
D-1184	-0.6290668845176697	systolic_HF unclear_ etiology coronary_ angiography
P-1184	-0.0638 -0.0408 -0.0448 -0.1069 -0.6665 -0.4152 -0.1422 -0.1164 -1.1457 -0.0679 -0.0579 -0.0416 -2.3272 -0.2249 -5.0781 -0.5198 -0.1370 -0.6052 -0.1504
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart_failure hf elevated sympathetic_activity parasympathetic_control heart
H-1133	-0.6337796449661255	▁Heart ▁failure HF ▁sympa the tic _ activ iteit ▁para sy mpa the tic _ control e ▁heart
D-1133	-0.6337796449661255	Heart failureHF sympathetic_activiteit parasympathetic_controle heart
P-1133	-0.3489 -0.6783 -0.2687 -0.1572 -0.6342 -0.9671 -0.5202 -0.7876 -0.3707 -0.1323 -0.0175 -0.0715 -1.5711 -1.1686 -0.2551 -0.0056 -1.2712 -3.0068 -0.3071 -0.1359
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp xo-mediated_ros mitochondrial_respiration contractile_function
H-471	-0.2759450078010559	▁ATP ▁demand ▁ XO - media ted _ ROS ▁mito cho ndri al _ ▁respira tion ▁contract ile _ function
D-471	-0.2759450078010559	ATP demand XO-mediated_ROS mitochondrial_ respiration contractile_function
P-471	-0.3974 -0.6641 -0.3013 -0.0038 -0.0118 -0.0694 -0.0224 -0.2361 -0.8966 -0.0506 -0.1051 -0.3882 -0.0673 -0.1969 -0.2978 -0.0930 -0.0018 -0.0326 -0.6429 -1.2045 -0.2828 -0.1046
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients end-stage_heart_failure implantation ventricular_assist_device
H-1657	-0.926693320274353	▁end - s tage _ heart _ ▁failure ▁vent ri cular _ assist _ ▁device
D-1657	-0.926693320274353	end-stage_heart_ failure ventricular_assist_ device
P-1657	-4.2776 -0.1298 -0.3721 -0.0070 -0.0818 -2.0778 -1.0182 -0.1541 -1.3889 -1.7069 -0.4724 -0.1404 -0.2472 -1.9652 -0.7268 -0.7334 -0.2543
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial_fibrillation congestive_heart_failure cost rhythm-control rate-control
H-1230	-0.5579689741134644	▁At rial _ fi bril lation ▁con ges tive _ heart _ ▁failure ▁ rhythm - control ▁rate - control ▁strategie s
D-1230	-0.5579689741134644	Atrial_fibrillation congestive_heart_ failure rhythm-control rate-control strategies
P-1230	-2.9253 -0.0260 -0.5491 -0.3655 -0.0312 -0.0504 -0.0483 -0.1801 -1.2475 -0.0376 -1.6232 -1.3313 -0.0298 -1.3076 -0.8131 -0.0756 -0.0040 -0.7515 -0.2115 -0.0031 -1.2071 -0.0419 -0.4029 -0.1276
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection_fraction ef infarct collateral_growth myocardial_perfusion
H-506	-0.41366147994995117	▁e je ction _ fraction EF ▁in far ct ▁col lateral _ ▁growth ▁my o card ial _ per fusion
D-506	-0.41366147994995117	ejection_fractionEF infarct collateral_ growth myocardial_perfusion
P-506	-0.1999 -0.0403 -0.0096 -0.4254 -0.0495 -1.5795 -0.0511 -0.1824 -0.1210 -1.9990 -0.0008 -0.4156 -0.2005 -0.5321 -0.5410 -0.4937 -1.0534 -0.1099 -0.7021 -0.0138 -0.2374 -0.1426
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf_antagonists nbdmard
H-607	-0.5203461050987244	▁HR ▁t NF ▁n b DM ARD
D-607	-0.5203461050987244	HR tNF nbDMARD
P-607	-0.1046 -1.0613 -0.6120 -0.4199 -0.0236 -0.5777 -1.1065 -0.6549 -0.1226
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical revascularization revascularization
H-1603	-1.1431626081466675	▁Sur g ical _ re vas cular ization ▁cat heter - based
D-1603	-1.1431626081466675	Surgical_revascularization catheter-based
P-1603	-3.1362 -1.4967 -2.7223 -0.6262 -0.1325 -0.5761 -0.5417 -0.8665 -1.3024 -0.0209 -0.1189 -0.0199 -4.1809 -0.2631
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based nucleolin protein_expression
H-96	-0.8634754419326782	▁Mor pho lino - based _ ▁knock down _ of _ ▁nucleo lin ▁protein _ expression
D-96	-0.8634754419326782	Morpholino-based_ knockdown_of_ nucleolin protein_expression
P-96	-1.7706 -0.0332 -0.2235 -0.0819 -0.0239 -1.1748 -1.1248 -0.4601 -2.3911 -1.3197 -0.7941 -0.2884 -3.2084 -0.2867 -0.9987 -0.2548 -0.9668 -0.1411
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence bnp patients pad bnp hf
H-1572	-1.142975091934204	▁b NP ▁ PAD ▁b NP _ ▁measure ments ▁ HF
D-1572	-1.142975091934204	bNP PAD bNP_ measurements HF
P-1572	-1.7217 -0.1225 -3.8503 -0.0549 -1.4968 -0.1069 -3.2426 -1.6930 -0.3223 -1.5954 -0.3830 -0.1732 -0.0960
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd psoriasis hazard_ratio confidence_interval
H-1563	-0.7919989228248596	▁CV d ▁psoriasis
D-1563	-0.7919989228248596	CVd psoriasis
P-1563	-2.2836 -0.5069 -0.0222 -0.9567 -0.1906
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam_study psoriasis cardiovascular outcomes
H-1556	-0.7275553345680237	▁Rotterdam _ ▁Study ▁psoriasis ▁cardiovascular
D-1556	-0.7275553345680237	Rotterdam_ Study psoriasis cardiovascular
P-1556	-1.2651 -1.6745 -0.3134 -0.0420 -0.0457 -1.6474 -0.1048
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes exercise training patients ambulatory hf
H-1631	-1.0726944208145142	▁race ▁exercise ▁training ▁ambula tory _ HF
D-1631	-1.0726944208145142	race exercise training ambulatory_HF
P-1631	-0.9196 -3.0698 -4.2743 -0.1222 -0.1451 -0.2435 -0.4283 -0.2831 -0.1684
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients hfpef adverse_outcomes
H-237	-0.5117071866989136	▁ HF p EF
D-237	-0.5117071866989136	HFpEF
P-237	-1.2283 -0.2233 -0.0467 -0.1814 -1.2093 -0.1811
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence parasympathetic therapeutic hf
H-1134	-0.6504011154174805	▁para sy mpa the tic _ function ▁ therapeut ic ▁ HF
D-1134	-0.6504011154174805	parasympathetic_function therapeutic HF
P-1134	-0.2715 -0.0456 -0.2308 -1.2755 -0.9448 -0.3668 -1.0608 -0.3330 -0.5728 -0.0479 -3.0019 -0.3609 -0.5122 -0.0812
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes_mellitus cardiovascular_disease baseline
H-630	-0.5186886787414551	▁diabetes ▁mell itus ▁cardiovascular _ ▁disease
D-630	-0.5186886787414551	diabetes mellitus cardiovascular_ disease
P-630	-0.6515 -0.0167 -0.0370 -0.0363 -1.3293 -1.4253 -0.4155 -0.2379
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical rule cad systolic_hf
H-1185	-0.43762344121932983	▁clinic al _ ▁predict ion ▁rule ▁CAD ▁sy sto lic _ HF
D-1185	-0.43762344121932983	clinical_ prediction rule CAD systolic_HF
P-1185	-1.6725 -0.0423 -0.3652 -1.3099 -0.0424 -1.3759 -0.0433 -0.0117 -0.0464 -0.0326 -0.1249 -0.6122 -0.3369 -0.1106
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality readmission
H-207	-0.8745722770690918	▁cognitive _ im pair ment ▁mortal ity
D-207	-0.8745722770690918	cognitive_impairment mortality
P-207	-0.4360 -0.5711 -1.9530 -0.1139 -0.2260 -0.8369 -2.2436 -1.3316 -0.1591
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence schfi_v.6.2 clinical
H-1509	-0.7973371148109436	▁ SCH fi
D-1509	-0.7973371148109436	SCHfi
P-1509	-0.9882 -1.0664 -1.2912 -0.5519 -0.0888
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo egfr egfr
H-1392	-1.0579490661621094	▁ec mo _ groep ▁e g FR ▁e g FR
D-1392	-1.0579490661621094	ecmo_groep egFR egFR
P-1392	-0.8250 -1.6206 -2.4581 -0.7498 -0.0713 -1.9229 -0.9459 -0.1763 -2.6979 -0.8103 -0.2991 -0.1180
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise haemodynamic pulmonary
H-1277	-0.2914852797985077	▁ha emo dynamic ▁pulmonar y ▁per i pher al _ ▁ab normal ities
D-1277	-0.2914852797985077	haemodynamic pulmonary peripheral_ abnormalities
P-1277	-0.1387 -0.0411 -0.0024 -0.0511 -0.1042 -0.0656 -0.1443 -0.0399 -0.1691 -1.1566 -0.3194 -0.0617 -1.4191 -0.4531 -0.2059
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic rule prospectively
H-1188	-0.4666229784488678	▁diagnostic _ ▁performance ▁predict ion _ ▁rule
D-1188	-0.4666229784488678	diagnostic_ performance prediction_ rule
P-1188	-1.2937 -1.0023 -0.3027 -0.2630 -0.0571 -0.2445 -0.4534 -0.4387 -0.1442
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule patients cad patients cad
H-1191	-1.2117959260940552	▁CAD ▁severe _ ▁CAD
D-1191	-1.2117959260940552	CAD severe_ CAD
P-1191	-2.4783 -2.8521 -0.4371 -1.0491 -0.3123 -0.1419
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia rv_function
H-1159	-0.695426344871521	▁ HF - related _ ▁cache xia ▁ RV _ ▁function ▁body ▁composition
D-1159	-0.695426344871521	HF-related_ cachexia RV_ function body composition
P-1159	-1.2662 -0.2978 -0.0690 -0.9090 -0.4189 -1.7715 -0.2011 -0.3633 -0.3972 -0.7518 -0.5593 -1.9819 -0.8846 -0.4297 -0.1300
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute_hf
H-1018	-0.5763875842094421	▁a cute _ HF
D-1018	-0.5763875842094421	acute_HF
P-1018	-0.5416 -0.0150 -0.0220 -0.9723 -1.7724 -0.1349
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline hgb exercise training kccq
H-841	-0.6908563375473022	▁base line _ h gb ▁exercise _ training ▁k cc q
D-841	-0.6908563375473022	baseline_hgb exercise_training kccq
P-841	-1.2650 -0.0289 -0.1219 -0.8010 -0.0128 -1.3417 -1.5469 -0.1824 -0.5446 -0.0933 -2.5211 -0.3532 -0.1683
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital cardiac hospital south_dakota
H-1577	-0.773766279220581	▁General _ hospital ▁cardiac _ special ty _ hospital ▁South _ da kota
D-1577	-0.773766279220581	General_hospital cardiac_specialty_hospital South_dakota
P-1577	-4.6922 -0.1355 -0.1444 -0.0188 -0.3714 -0.4017 -0.0510 -0.0727 -0.1741 -2.7045 -1.6527 -0.6740 -0.0336 -0.3110 -0.1690
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications acs patients patients vad
H-1286	-1.0183277130126953	▁a CS _ procedure s ▁MT ▁ VAD
D-1286	-1.0183277130126953	aCS_procedures MT VAD
P-1286	-0.2479 -2.9124 -3.6754 -0.2110 -0.0653 -1.4552 -0.9994 -0.1691 -0.2565 -0.1911
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic histological gastrointestinal
H-1359	-1.1850711107254028	▁sono graphic ▁his t ological ▁functional _ ▁ab normal ities ▁gastro inte stin al
D-1359	-1.1850711107254028	sonographic histological functional_ abnormalities gastrointestinal
P-1359	-5.3369 -1.5762 -2.1651 -0.3747 -0.4391 -0.2887 -1.8397 -1.1693 -0.0448 -1.0715 -0.3967 -0.3793 -1.4744 -0.5396 -1.7036 -0.1616
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy_substrate_metabolism hearts aac
H-1781	-0.4630216062068939	▁energie ▁substrat e _ ▁metabolism ▁isola ted _ ▁working _ heart s ▁a ac
D-1781	-0.4630216062068939	energie substrate_ metabolism isolated_ working_hearts aac
P-1781	-1.4160 -0.7881 -0.0574 -0.2802 -0.0889 -1.1453 -0.0239 -0.1168 -0.9179 -0.0869 -1.8842 -0.0566 -0.1457 -0.2164 -0.0779 -0.1063
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular_venous_pressure peripheral_oedema patient
H-1895	-0.33816641569137573	▁jugu lar _ ve nous _ ▁pressure ▁per i pher al _ ▁oed ema ▁volume
D-1895	-0.33816641569137573	jugular_venous_ pressure peripheral_ oedema volume
P-1895	-0.0065 -0.2143 -0.1242 -0.7233 -0.2941 -0.0983 -0.7813 -0.0318 -0.0285 -0.0123 -0.2082 -0.1374 -1.8862 -0.0243 -0.2103 -0.8471 -0.1207
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone hyperkalemia acute_kidney_injury
H-445	-0.23491503298282623	▁Spir ono lac tone ▁hyper kal emia ▁ki dne y ▁injury
D-445	-0.23491503298282623	Spironolactone hyperkalemia kidney injury
P-445	-0.1674 -0.0486 -0.0222 -0.0469 -0.5420 -0.4417 -0.0736 -0.5326 -0.3827 -0.1315 -0.2657 -0.2913 -0.1077
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up deaths heart_transplantations lv_assist_device_implantations heart_failure admissions
H-434	-0.8723021745681763	▁heart ▁transplant ations LV _ assist _ ▁device _ ▁implant ations ▁heart ▁failure
D-434	-0.8723021745681763	heart transplantationsLV_assist_ device_ implantations heart failure
P-434	-3.7397 -1.4005 -0.0367 -0.5856 -0.8454 -0.4444 -0.3808 -1.0383 -1.0894 -0.4194 -0.0098 -0.6726 -0.8300 -1.3468 -0.2452
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-333	-0.4341799020767212	▁functional _ met ral _ ▁sten osis ▁ring _ ▁ann ulo plast y ▁ ische mic _ met ral _ re gur gi tation
D-333	-0.4341799020767212	functional_metral_ stenosis ring_ annuloplasty ischemic_metral_regurgitation
P-333	-0.0406 -0.8059 -1.1477 -0.3230 -0.2733 -1.0594 -0.0064 -0.0061 -0.5414 -2.1290 -0.0774 -0.0806 -0.1972 -0.4892 -0.0112 -0.1497 -0.1343 -1.3891 -0.5822 -0.4480 -0.3375 -0.1244 -0.0592 -0.1118 -0.6247 -0.1397
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants antiplatelet_drugs heart_failure atrial_fibrillation
H-1352	-0.4298318922519684	▁antico a gul ants ▁anti plate let ▁drugs ▁heart ▁failure ▁at rial _ fi bril lation
D-1352	-0.4298318922519684	anticoagulants antiplatelet drugs heart failure atrial_fibrillation
P-1352	-0.5277 -0.0773 -0.3587 -0.0201 -0.0071 -0.1352 -0.1960 -1.1457 -2.0590 -1.2356 -0.4369 -0.1776 -0.3294 -0.4925 -0.0435 -0.0963 -0.2967 -0.1017
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical_cardiac_support renal_function end-stage_heart_failure
H-1384	-0.8013935089111328	▁mechanic al _ ▁cardiac _ support ▁renal _ ▁function ▁end - s tage _ heart _ ▁failure
D-1384	-0.8013935089111328	mechanical_ cardiac_support renal_ function end-stage_heart_ failure
P-1384	-0.7853 -0.0718 -0.1298 -0.8857 -0.3740 -1.9740 -0.4874 -0.3222 -1.2621 -5.0371 -0.1659 -0.2154 -0.0093 -0.0732 -1.4871 -1.0168 -0.2368 -0.4795 -0.2131
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic_peptide biomarkers point_of_care poc
H-1023	-0.4624898433685303	▁na tri ure tic _ pe pti de ▁bio mark ers
D-1023	-0.4624898433685303	natriuretic_peptide biomarkers
P-1023	-0.1701 -0.0155 -0.2042 -1.5301 -0.1711 -0.5631 -0.0889 -0.3658 -0.0459 -0.0522 -0.1061 -2.6123 -0.0870
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart_failure hf condition morbidity mortality
H-1487	-0.5883059501647949	▁Heart ▁failure HF
D-1487	-0.5883059501647949	Heart failureHF
P-1487	-0.6251 -0.5254 -0.2624 -1.3859 -0.1427
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients systolic_blood_pressure renal_impairment hypertension
H-1529	-0.7493274807929993	▁eh ▁sy sto lic _ ▁blood ▁pressure ▁renal _ ▁im pair ment ▁hyper tension
D-1529	-0.7493274807929993	eh systolic_ blood pressure renal_ impairment hypertension
P-1529	-1.4709 -2.0920 -0.0649 -0.3817 -0.1281 -1.4310 -2.3374 -0.0343 -1.1770 -1.2682 -0.0056 -0.1391 -0.8494 -0.1080 -0.3118 -0.1898
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo_sternotomy cardiopulmonary_bypass
H-775	-1.066112756729126	▁pump - ex change ▁techniek ▁redo _ ster no to my ▁cardio pul mon ary _ by pass
D-775	-1.066112756729126	pump-exchange techniek redo_sternotomy cardiopulmonary_bypass
P-775	-6.3723 -0.1042 -0.0892 -0.0911 -1.9764 -2.2490 -0.9914 -1.2972 -0.0553 -0.1001 -1.1738 -0.0781 -0.6248 -1.4150 -0.4769 -0.5109 -2.7139 -0.0223 -0.7649 -0.2156
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic_myocardial_ischemia heart_failure therapeutic
H-503	-1.0872467756271362	▁chronic _ My o card ial _ ische mia ▁heart ▁failure
D-503	-1.0872467756271362	chronic_Myocardial_ischemia heart failure
P-503	-4.4447 -0.1947 -4.4563 -0.4682 -0.4674 -0.6255 -0.1337 -0.1586 -0.8262 -0.8178 -0.6954 -0.7149 -0.1308
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf transition compensated_lv_hypertrophy hf hhd
H-283	-0.38911184668540955	▁mouse ▁ HF ▁compensa ted _ ▁LV _ ▁hyper trop hy ▁ HF ▁h HD
D-283	-0.38911184668540955	mouse HF compensated_ LV_ hypertrophy HF hHD
P-283	-0.2310 -0.5891 -0.1421 -1.0701 -0.0609 -0.1245 -0.3867 -0.3004 -0.6062 -0.0163 -0.8310 -0.4303 -0.2234 -0.3483 -0.8372 -0.3007 -0.1167
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical_treatment hf functional_ms medical_treatment
H-354	-0.9020939469337463	▁MS ▁ HF ▁functional ▁MS ▁medical
D-354	-0.9020939469337463	MS HF functional MS medical
P-354	-0.2385 -2.4534 -0.1716 -0.3546 -0.9042 -1.2221 -1.7874 -0.0851
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic parasympathetic_activity hf symptoms disease
H-1868	-0.6069772839546204	▁sympa the tic ▁para sy mpa the tic _ activ iteit ▁ HF
D-1868	-0.6069772839546204	sympathetic parasympathetic_activiteit HF
P-1868	-0.3979 -0.7838 -0.8075 -0.2783 -0.0499 -0.1910 -1.8616 -1.3273 -0.8304 -0.3000 -0.2872 -0.2136 -0.2405 -1.4029 -0.1326
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical_treatment hf hf symptom mva
H-371	-0.8215919137001038	▁aggressiv e _ ▁medical _ ▁treatment ▁ HF ▁ HF ▁ HF ▁MS ▁m VA
D-371	-0.8215919137001038	aggressive_ medical_ treatment HF HF HF MS mVA
P-371	-0.4679 -0.0173 -0.3146 -2.0086 -1.4521 -1.5067 -1.0580 -0.1701 -0.8477 -0.1717 -3.4788 -0.1848 -0.8117 -0.3640 -0.7876 -0.2279 -0.0973
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis heart_failure_with_preserved_ejection_fraction clinical doppler_echocardiography
H-21	-0.4114272892475128	▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁do pp ler _ e cho card i ography
D-21	-0.4114272892475128	heart failure preserved_ejection_fraction doppler_echocardiography
P-21	-1.7050 -1.1566 -0.6495 -0.1488 -0.4412 -0.1046 -0.3338 -0.1236 -0.0594 -0.1412 -0.0275 -0.3732 -0.0149 -1.4178 -0.4523 -0.3912 -0.1347 -0.1954 -0.5489 -0.2029 -0.2983 -0.1305
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based patient outcomes
H-85	-1.098441243171692	
D-85	-1.098441243171692	
P-85	-2.0325 -0.1644
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular conditions patients hf
H-694	-1.624931812286377	▁ HF
D-694	-1.624931812286377	HF
P-694	-4.8508 -0.5669 -0.9330 -0.1490
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health health u.s. drug administration
H-1830	-1.0906096696853638	▁health _ ▁insurance ▁health _ system _ data ▁partners ▁u . s . _ food _ en _ drug _ ▁Administration
D-1830	-1.0906096696853638	health_ insurance health_system_data partners u.s._food_en_drug_ Administration
P-1830	-1.6320 -1.8675 -0.3246 -1.0260 -1.1349 -0.9419 -1.2380 -2.6282 -1.1921 -3.2011 -0.1435 -0.4650 -0.5040 -1.1936 -1.5048 -0.4746 -1.7648 -0.1342 -1.0601 -0.5411 -0.3022 -1.4759 -0.3336
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary congenital heart death
H-1906	-0.7993775606155396	▁her edit ary ▁con geni tal _ ▁ab normal ities ▁heart ▁non trau matic _ ▁death ▁sport
D-1906	-0.7993775606155396	hereditary congenital_ abnormalities heart nontraumatic_ death sport
P-1906	-2.4350 -0.1276 -0.5556 -0.5051 -0.0249 -0.0967 -0.4357 -0.6201 -0.2030 -2.2109 -2.7999 -0.1684 -0.1656 -0.8865 -0.1386 -0.7699 -1.1905 -1.5690 -0.2850
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling_pathway remodelling
H-994	-0.5803993344306946	▁Raf - MEK 1/2 - er k 1/2
D-994	-0.5803993344306946	Raf-MEK1/2-erk1/2
P-994	-0.0480 -0.0827 -0.0091 -0.3772 -0.0654 -0.9120 -0.4027 -1.0781 -2.6464 -0.1823
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin lvad postoperative
H-536	-0.6952587366104126	▁album in ▁levels ▁l VAD ▁post operativ e
D-536	-0.6952587366104126	albumin levels lVAD postoperative
P-536	-1.4962 -0.5169 -1.2245 -0.1418 -0.0360 -0.7024 -0.1022 -0.0709 -2.4590 -0.2026
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients heartmate_ii lvad
H-303	-0.809689998626709	▁isola ted _ ▁Heart Mate _ ▁II _ ▁l VAD
D-303	-0.809689998626709	isolated_ HeartMate_ II_ lVAD
P-303	-1.3597 -0.0998 -1.0187 -0.9337 -0.1622 -0.1971 -1.1419 -0.2868 -3.9624 -0.1022 -0.2366 -0.2153
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate heart_failure
H-1544	-1.2104198932647705	▁bis phos phon ate ▁heart ▁failure
D-1544	-1.2104198932647705	bisphosphonate heart failure
P-1544	-1.6873 -0.0287 -0.4320 -2.5897 -3.4150 -1.1841 -0.2313 -0.1153
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary_outcomes
H-620	-0.6253930330276489	▁sustain ability
D-620	-0.6253930330276489	sustainability
P-620	-0.8022 -0.3106 -1.2202 -0.1687
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling emd
H-1151	-0.42587703466415405	▁ HF - indu ced _ ▁remodel ing ▁EM d ▁prolong ation
D-1151	-0.42587703466415405	HF-induced_ remodeling EMd prolongation
P-1151	-1.0557 -0.5182 -0.1259 -0.0037 -0.2601 -0.3498 -0.0740 -0.0342 -1.0182 -0.5928 -1.4488 -0.1569 -0.2111 -0.1130
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi mi hf
H-1104	-1.041135311126709	▁MI ▁ HF
D-1104	-1.041135311126709	MI HF
P-1104	-0.8666 -2.2784 -1.4455 -0.3810 -0.2343
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs outcomes
H-2009	-1.1186786890029907	▁kosten
D-2009	-1.1186786890029907	kosten
P-2009	-2.4729 -0.7342 -0.1490
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.44375234842300415	▁mal adapt ive _ ▁molecular _ process es
D-1473	-0.44375234842300415	maladaptive_ molecular_processes
P-1473	-2.8949 -0.0251 -0.0255 -0.0929 -0.3010 -0.3993 -0.1374 -0.0519 -0.3971 -0.1123
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-1.068882703781128	▁patient _ ▁safety
D-7	-1.068882703781128	patient_ safety
P-7	-0.8793 -1.5132 -1.2934 -1.4796 -0.1789
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine_oxidase_inhibition left_ventricular systolic diastolic_function cardiac_volume_overload
H-469	-0.5736019611358643	▁Xan thi ne _ ▁oxid ase _ ▁inhibi tion ▁vent ri cular _ sy sto lic ▁dia sto lic _ ▁function ▁cardiac _ ▁volume ▁over load
D-469	-0.5736019611358643	Xanthine_ oxidase_ inhibition ventricular_systolic diastolic_ function cardiac_ volume overload
P-469	-0.0014 -0.2742 -0.6768 -0.3791 -0.7701 -2.5021 -0.7583 -0.0231 -0.1729 -0.7588 -1.8029 -0.7106 -0.6573 -0.9316 -0.3787 -0.1374 -0.0685 -0.0897 -0.1242 -1.6974 -0.6867 -0.0252 -0.7541 -0.0821 -0.7069 -0.0966 -0.5731 -0.2211
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global_left_ventricular_longitudinal_systolic_strain cardiovascular_events patients atrial_fibrillation
H-808	-0.5475758910179138	▁left _ ▁vent ri cular _ ▁longitud in al _ ▁sy sto lic _ ▁strain ▁cardiovascular _ ▁events ▁at rial _ fi bril lation
D-808	-0.5475758910179138	left_ ventricular_ longitudinal_ systolic_ strain cardiovascular_ events atrial_fibrillation
P-808	-0.5512 -0.8367 -1.3318 -1.1642 -0.5405 -0.6076 -0.0318 -0.3315 -0.0783 -0.3033 -1.2656 -0.1321 -0.1126 -0.6957 -0.2209 -0.4557 -0.9704 -0.6779 -1.3910 -0.2082 -0.3882 -1.0999 -0.0468 -0.1528 -0.4544 -0.1879
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart_failure clinical medicine prevalence coronary_disease
H-980	-0.9714966416358948	▁Heart _ ▁failure ▁medicine ▁a ther omat ous _ ▁corona ry _ ▁disease
D-980	-0.9714966416358948	Heart_ failure medicine atheromatous_ coronary_ disease
P-980	-0.8128 -2.4135 -0.0937 -3.5821 -0.0239 -0.4751 -0.1377 -2.1836 -0.0865 -0.5061 -2.0849 -0.9304 -0.6978 -0.3832 -0.1611
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications outpatients heart_failure ncdr_pinnacle
H-658	-1.0856655836105347	▁medication s ▁out patient s ▁heart ▁failure ▁NC DR _ ▁PIN NA CLE
D-658	-1.0856655836105347	medications outpatients heart failure NCDR_ PINNACLE
P-658	-1.9861 -0.1409 -5.5254 -0.0056 -0.1766 -2.4790 -0.7160 -0.4725 -0.6187 -1.1148 -0.4823 -0.9117 -0.8626 -0.6359 -0.1570
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart hr_reduction patients systolic_heart_failure
H-527	-0.6380131840705872	▁un load ing _ of _ the _ heart ▁isola ted _ HR ▁sy sto lic _ heart ▁failure
D-527	-0.6380131840705872	unloading_of_the_heart isolated_HR systolic_heart failure
P-527	-0.0888 -0.0587 -0.0263 -1.1524 -2.5364 -0.3608 -1.6165 -0.2001 -1.2155 -0.2947 -0.0186 -0.2176 -0.9306 -1.6492 -0.0677 -0.2883 -0.0659 -1.3655 -0.7910 -0.3003 -0.1531
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic hfpef medical_history physical_examination
H-1892	-0.8743493556976318	▁diagnostic _ test ▁ HF p EF
D-1892	-0.8743493556976318	diagnostic_test HFpEF
P-1892	-2.0929 -0.9927 -1.9434 -0.4391 -0.2457 -0.0734 -0.3442 -1.6030 -0.1346
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical symptoms hfpef symptoms breathlessness fluid_retention
H-1891	-0.7697386145591736	▁ HF p EF ▁breath less heid ▁fatigue ▁fluid ▁re tention
D-1891	-0.7697386145591736	HFpEF breathlessheid fatigue fluid retention
P-1891	-0.9420 -0.5078 -0.1312 -0.6461 -2.8978 -0.3632 -2.6502 -0.0721 -0.0816 -0.9988 -0.2368 -0.3473 -0.1318
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin insulin_resistance monocytes inflammatory
H-928	-0.3489443361759186	▁circula ting _ media tor ▁insulin ▁resist ance ▁mono cy tes ▁infla mma tory _ stimul i
D-928	-0.3489443361759186	circulating_mediator insulin resistance monocytes inflammatory_stimuli
P-928	-0.5555 -0.0728 -0.2416 -0.8643 -0.1243 -1.0157 -1.1014 -0.0514 -0.0062 -0.0353 -0.0222 -0.2141 -0.2184 -0.1819 -0.9711 -0.0805 -0.2421 -0.3891 -0.2422
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp patients acute_heart_failure
H-262	-0.8580601215362549	▁cut off _ waarde ▁NT - pro b NP
D-262	-0.8580601215362549	cutoff_waarde NT-probNP
P-262	-0.7874 -0.1052 -0.8613 -0.7055 -0.4646 -0.0796 -0.0160 -0.7139 -0.1504 -5.4200 -0.1348
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report patients aortic_valve surgery post-lvad_ai
H-544	-0.768319845199585	▁a or tic _ val ve _ ▁surgery ▁post - ▁l VAD
D-544	-0.768319845199585	aortic_valve_ surgery post- lVAD
P-544	-0.2219 -0.0927 -0.9322 -0.0445 -1.9179 -0.1197 -1.0700 -0.2587 -1.1251 -0.0181 -3.4939 -0.0453 -1.2839 -0.1325
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking cardiac_rehabilitation functional_capacity outcomes patients heart_failure
H-574	-1.2493669986724854	▁Nordic _ ▁walking ▁cardiac _ ▁rehabilita tion _ care ▁functional _ capaci te it ▁heart ▁failure
D-574	-1.2493669986724854	Nordic_ walking cardiac_ rehabilitation_care functional_capaciteit heart failure
P-574	-0.6591 -0.4154 -3.0674 -0.4281 -1.7159 -0.8274 -0.1902 -2.6501 -1.7034 -2.8612 -1.8108 -0.5557 -0.7819 -1.8792 -1.4626 -0.8633 -0.4217 -0.1952
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone diagnosed systolic_heart_failure clinical
H-439	-0.2742912173271179	▁spi rono lac tone ▁sy sto lic _ heart ▁failure
D-439	-0.2742912173271179	spironolactone systolic_heart failure
P-439	-0.0499 -0.0100 -0.0467 -0.0705 -0.1378 -0.0658 -0.1948 -0.0592 -1.1671 -1.0452 -0.3438 -0.1007
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape functional_enrichment_analysis david
H-1612	-0.42575353384017944	▁Cy to scape ▁functional _ en rich ment _ analyse ▁DA VID
D-1612	-0.42575353384017944	Cytoscape functional_enrichment_analyse DAVID
P-1612	-0.4519 -0.0662 -0.0611 -0.0685 -0.8881 -0.3926 -0.0851 -0.1100 -1.5337 -0.3040 -1.1798 -0.0116 -0.6704 -0.1376
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension diabetes ischemic etiology
H-1635	-0.3561908006668091	▁black s ▁hyper tension ▁diabetes ▁ ische mic _ ▁et i ology ▁socio economic
D-1635	-0.3561908006668091	blacks hypertension diabetes ischemic_ etiology socioeconomic
P-1635	-0.4014 -0.2678 -0.1009 -0.0298 -0.0387 -0.0299 -0.0111 -0.1089 -0.1683 -1.0319 -0.1008 -0.1304 -0.1992 -0.0306 -2.8778 -0.1717
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection nt-probnp antibodies terminal
H-1521	-0.2616688907146454	▁immun o det ection ▁NT - pro b NP ▁anti bo dies
D-1521	-0.2616688907146454	immunodetection NT-probNP antibodies
P-1521	-0.1302 -0.1368 -0.1568 -0.1373 -1.0045 -0.0810 -0.0134 -0.6962 -0.1766 -0.0307 -0.0490 -0.6038 -0.3442 -0.1028
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients fontan_circulation svr cardiac_index
H-232	-0.5213112831115723	▁Font an _ ▁circulation ▁s VR ▁index ▁cardiac _ ▁index ▁pediatr ic _ co hor t
D-232	-0.5213112831115723	Fontan_ circulation sVR index cardiac_ index pediatric_cohort
P-232	-1.8183 -0.3466 -0.0727 -0.8034 -0.2247 -0.1851 -1.4600 -0.0390 -0.7555 -1.0166 -0.2858 -0.0448 -0.7312 -0.7659 -0.2672 -0.0784 -0.3874 -0.1010
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid_receptor_antagonists
H-1709	-0.6145114898681641	▁mineral o cor tico id _ ▁receptor ▁anta gon ists ▁race
D-1709	-0.6145114898681641	mineralocorticoid_ receptor antagonists race
P-1709	-1.6670 -0.4016 -0.9873 -0.8981 -0.3587 -0.2706 -0.0566 -1.6358 -0.0181 -0.3929 -0.8746 -0.2628 -0.1645
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization medicare discharged nursing
H-1710	-0.5249879956245422	▁re hospital ization ▁medica re ▁fee - for - service
D-1710	-0.5249879956245422	rehospitalization medicare fee-for-service
P-1710	-1.6486 -0.1490 -0.3641 -0.0903 -0.0081 -0.2022 -0.0285 -0.0358 -0.0693 -0.0540 -3.4723 -0.1775
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative_care patients terminal disease therapeutic
H-1820	-1.084281325340271	▁palli ative _ care ▁patients ▁terminal ▁disease ▁ therapeut ic
D-1820	-1.084281325340271	palliative_care patients terminal disease therapeutic
P-1820	-0.0666 -0.1174 -0.6389 -1.4683 -2.1785 -2.5402 -3.9595 -0.7900 -0.0455 -0.0630 -1.0359 -0.1076
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death hf hospitalization crt hazard_ratio
H-755	-0.9061827063560486	▁ HF ▁c RT haz ard _ ▁ratio
D-755	-0.9061827063560486	HF cRThazard_ ratio
P-755	-0.9931 -0.4146 -2.1219 -3.4945 -0.1123 -0.0217 -1.2441 -0.0183 -0.4805 -0.1608
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients lvad patients biventricular_support
H-297	-1.0157042741775513	▁l VAD ▁bi ven tri cular
D-297	-1.0157042741775513	lVAD biventricular
P-297	-2.2985 -0.1294 -2.5147 -0.0537 -0.1766 -0.4214 -2.3841 -0.1471
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative_stress gtpase rac1 activity hearts
H-281	-0.5681045055389404	▁o xi da tive _ stress ▁GT Pas e _ ▁Rac 1 ▁heart s ▁ ANS _ mi ce
D-281	-0.5681045055389404	oxidative_stress GTPase_ Rac1 hearts ANS_mice
P-281	-0.6948 -0.2040 -0.0089 -0.5874 -0.4358 -0.3814 -1.2799 -0.8675 -0.0119 -0.3640 -0.1826 -2.5139 -1.0038 -0.0673 -1.9462 -0.1930 -0.2587 -0.3215 -0.2950 -0.2047 -0.1079
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan_circulation skeletal_muscle metabolic
H-1494	-0.5895478129386902	▁Font an _ ▁circulation ▁skelet al _ ▁muscle ▁mass ▁metabol ic _ ▁ab normal ities
D-1494	-0.5895478129386902	Fontan_ circulation skeletal_ muscle mass metabolic_ abnormalities
P-1494	-0.7280 -0.3112 -0.0766 -0.5267 -1.5650 -0.1357 -0.1207 -1.5832 -1.4686 -0.0147 -0.0221 -1.0015 -0.7943 -0.0933 -1.0774 -0.4130 -0.0904
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right_heart_circulation right_heart_failure
H-1459	-0.9665122032165527	▁right _ heart _ ▁circulation ▁right _ ▁heart _ ▁failure
D-1459	-0.9665122032165527	right_heart_ circulation right_ heart_ failure
P-1459	-3.2685 -0.3091 -2.7679 -0.3878 -0.1988 -1.8153 -0.3196 -1.0794 -0.9143 -0.1034 -0.2750 -0.1592
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart_failure hf latin_america health hf
H-1789	-1.119541049003601	▁Heart _ ▁failure _ HF ▁Latin ▁America ▁l la ▁health ▁service _ ▁planning ▁ HF
D-1789	-1.119541049003601	Heart_ failure_HF Latin America lla health service_ planning HF
P-1789	-0.6582 -1.6721 -0.1864 -1.9287 -0.2106 -0.7480 -0.3819 -2.0453 -1.9313 -3.1972 -1.9455 -1.7329 -0.7651 -1.1991 -0.0869 -0.2334 -0.1095
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd clinical hospitalizations complications therapy end-stage_hf
H-895	-1.0909380912780762	▁PD ▁ therapy ▁ HF
D-895	-1.0909380912780762	PD therapy HF
P-895	-0.6958 -2.2455 -0.1568 -3.9036 -0.2854 -0.1962 -0.1531
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.7060102224349976	
D-86	-0.7060102224349976	
P-86	-1.2398 -0.1722
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.5412012934684753	
D-158	-0.5412012934684753	
P-158	-0.9386 -0.1438
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients heart_failure hf heart_failure_adherence_and_retention_trial hart
H-238	-0.5762390494346619	▁heart ▁failure HF ▁Heart ▁Fail ure _ ad her ence ▁re tention _ tri al HAR t
D-238	-0.5762390494346619	heart failureHF Heart Failure_adherence retention_trialHARt
P-238	-1.5211 -0.5642 -0.1829 -0.5069 -0.9632 -0.8412 -1.5607 -0.1923 -0.1737 -0.3534 -1.4646 -0.0949 -0.4894 -0.5407 -0.0491 -0.1118 -1.0292 -0.2045 -0.1048
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic_receptor_blockade mortality all-cause_hospitalizations patients heart_failure hf
H-1424	-0.8010860681533813	▁β - ad r energi c _ ▁receptor _ block ade ▁cardiac _ ▁failure HF
D-1424	-0.8010860681533813	β-adrenergic_ receptor_blockade cardiac_ failureHF
P-1424	-0.0575 -0.0894 -1.2894 -0.6439 -0.9051 -0.0431 -0.1343 -0.1416 -0.8053 -1.9729 -0.0996 -4.8522 -1.0320 -0.7777 -0.2958 -0.3201 -0.1587
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial_infarction left_anterior_descending_coronary_artery_occlusion
H-1338	-0.5619664788246155	▁My o card ial _ in far ction ▁left _ ▁anterior _ ▁descend ing _ ▁corona ry _ ▁arter y ▁oc clusi on
D-1338	-0.5619664788246155	Myocardial_infarction left_ anterior_ descending_ coronary_ artery occlusion
P-1338	-1.5303 -0.8946 -0.6548 -1.0032 -0.3499 -0.3837 -0.4634 -0.0697 -1.2784 -0.8743 -0.7894 -0.3576 -0.0165 -0.0458 -0.7338 -0.1827 -1.3798 -0.5363 -0.0763 -1.1588 -0.0811 -0.0089 -0.5093 -0.4604 -0.2103
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right_ventricle leads stroke_volume shortens left_ventricular_ejection_time lvet
H-578	-0.7019757032394409	▁right _ ▁vent ric le ▁over load ▁stroke ▁volume ▁left _ ▁vent ri cular _ e je ction _ ▁time ▁l VET
D-578	-0.7019757032394409	right_ ventricle overload stroke volume left_ ventricular_ejection_ time lVET
P-578	-0.9627 -0.4236 -1.8733 -1.4821 -0.3297 -1.0044 -0.0521 -0.9952 -0.7504 -0.5625 -0.3811 -1.0531 -1.2717 -0.4449 -0.5783 -0.6411 -0.2305 -0.1077 -2.1057 -0.5759 -0.3599 -0.0899 -0.3943 -0.1774
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective_beta-blockers cardiac_sympathetic_activity hemostasis patients heart_failure
H-1110	-0.5651093125343323	▁non sel ective ▁beta - block ers ▁cardiac _ ▁sympa the tic _ activ iteit ▁hemos tas is ▁heart ▁failure
D-1110	-0.5651093125343323	nonselective beta-blockers cardiac_ sympathetic_activiteit hemostasis heart failure
P-1110	-1.2332 -0.0575 -0.0361 -2.0236 -0.1374 -0.4150 -0.1451 -0.1088 -0.4883 -0.7871 -0.7036 -2.5897 -0.6298 -0.3226 -0.3548 -0.0702 -0.1734 -0.3599 -0.6679 -0.6390 -0.3195 -0.1698
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end_point cardiovascular_death cardiac_transplant secondary_end_point death
H-1757	-0.7015759348869324	▁cardiovascular _ ▁death ▁urgent _ ▁cardiac _ ▁transplant
D-1757	-0.7015759348869324	cardiovascular_ death urgent_ cardiac_ transplant
P-1757	-1.3513 -0.9828 -1.0794 -0.0196 -0.1621 -0.0984 -0.9761 -0.4173 -1.7098 -0.2188
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated_proteins chromatin_structure changing dna gene_expression_profile
H-90	-0.7131115198135376	▁Chro mat in - as soci ated _ ▁protein s ▁chr omat in _ ▁structure ▁DNA
D-90	-0.7131115198135376	Chromatin-associated_ proteins chromatin_ structure DNA
P-90	-1.3299 -0.1101 -1.6666 -0.0864 -0.0108 -0.0008 -0.4236 -0.1914 -2.4154 -0.0571 -0.1988 -0.1350 -1.6660 -1.0769 -0.9647 -0.9963 -1.3570 -0.1493
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis clinical prognostic diastolic_dysfunction leading hfpef
H-26	-0.3912874758243561	▁dia sto lic _ ▁dys function ▁h FP EF
D-26	-0.3912874758243561	diastolic_ dysfunction hFPEF
P-26	-0.9040 -0.0982 -0.2215 -0.3811 -0.2323 -0.0546 -0.6028 -0.9749 -0.3998 -0.2850 -0.1499
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade cardiac_angiogenesis heart_failure vegf_signaling_pathway
H-459	-0.7127942442893982	▁β - Block ade ▁cardiac _ ▁ang io gene sis ▁heart ▁failure ▁VE GF
D-459	-0.7127942442893982	β-Blockade cardiac_ angiogenesis heart failure VEGF
P-459	-0.5911 -0.0848 -0.3539 -0.3770 -0.2403 -0.8661 -2.7970 -1.1268 -0.4501 -0.7992 -0.3740 -0.8177 -0.8299 -0.0224 -1.4430 -0.2315
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp hf patient plasma immunoprecipitation mass_spectrometric_analysis
H-1515	-0.5448653101921082	▁NT - pro b NP ▁ HF _ plasma ▁immun o preci pit ation ▁mass _ spec tro metric _ analyse
D-1515	-0.5448653101921082	NT-probNP HF_plasma immunoprecipitation mass_spectrometric_analyse
P-1515	-0.3008 -0.0992 -0.0159 -0.5000 -0.2422 -1.6402 -0.3402 -1.6932 -2.2804 -0.0360 -0.2568 -0.4941 -0.0233 -0.1460 -0.0502 -0.6158 -1.3059 -0.3163 -0.1334 -1.2406 -0.2100 -0.4642 -0.1272
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic_tone pyridostigmine ventricular_dysfunction heart_failure
H-1132	-0.4123353958129883	▁para sy mpa the tic _ ▁tone ▁py rido stig mine ▁vent ri cular _ ▁dys function ▁heart ▁failure
D-1132	-0.4123353958129883	parasympathetic_ tone pyridostigmine ventricular_ dysfunction heart failure
P-1132	-0.0837 -0.0548 -0.0658 -0.8511 -0.6167 -0.1388 -0.8155 -0.0232 -0.0116 -0.0058 -0.0531 -0.0253 -1.8762 -0.8742 -1.0326 -0.1364 -0.0434 -0.2788 -1.2284 -0.3320 -0.1116
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes myocardial_ischemic_events patients cardiac_resynchronization_therapy
H-101	-0.7153610587120056	▁my o card ial _ ische mic _ ▁events ▁cardiac _ re syn chron ization _ therapy
D-101	-0.7153610587120056	myocardial_ischemic_ events cardiac_resynchronization_therapy
P-101	-3.1662 -0.7512 -0.5270 -0.9860 -0.3690 -0.0741 -0.4256 -0.5056 -1.6242 -0.1074 -0.5998 -0.7052 -0.0178 -0.0046 -1.2941 -1.6650 -0.1354 -0.4538 -0.1799
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf_with_preserved_ejection_fraction hfpef hypertension
H-1076	-0.537263810634613	HF ▁pres er ved _ e je ction _ fraction HF p EF ▁hyper tension
D-1076	-0.537263810634613	HF preserved_ejection_fractionHFpEF hypertension
P-1076	-0.5262 -3.5238 -0.1158 -0.8560 -0.0535 -0.2986 -0.1539 -0.1287 -0.1215 -0.1496 -1.1043 -0.1057 -0.4151 -1.1300 -0.0751 -0.2435 -0.1322
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end_points nyha_functional_class quality-of-life 6-minute_hall_walk
H-1873	-0.5948469638824463	▁NY ha ▁functional _ class ▁quality - of - life _ ▁score
D-1873	-0.5948469638824463	NYha functional_class quality-of-life_ score
P-1873	-1.8146 -0.7077 -0.8502 -0.5575 -1.1598 -0.1278 -0.0442 -0.0134 -0.1056 -0.3748 -1.3427 -0.3014 -0.6917 -0.2364
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ischemic_heart_failure
H-1613	-0.6066962480545044	▁non - ische mic ▁ ische mic _ heart _ ▁failure
D-1613	-0.6066962480545044	non-ischemic ischemic_heart_ failure
P-1613	-1.2534 -0.0871 -0.0495 -0.4672 -1.8653 -0.0430 -0.5645 -0.2147 -1.8080 -0.9780 -0.0851 -0.3177 -0.1535
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv_dysfunction prognosis hf
H-1160	-0.7411080598831177	▁ RV _ ▁dys function ▁weight ▁loss ▁ab normal _ ▁body ▁composition ▁ HF
D-1160	-0.7411080598831177	RV_ dysfunction weight loss abnormal_ body composition HF
P-1160	-1.6154 -0.6129 -1.4803 -0.1276 -0.0631 -0.7690 -1.0415 -0.3469 -0.0271 -0.0920 -1.7261 -0.6448 -2.7794 -0.2327 -0.1215 -0.1774
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart_failure emergency_department patient outcomes
H-462	-0.5560175180435181	▁he art ▁failure ▁Emer gen cy _ ▁Department ED ▁ED ▁volume
D-462	-0.5560175180435181	heart failure Emergency_ DepartmentED ED volume
P-462	-0.2610 -1.3377 -1.3070 -0.5680 -0.1224 -0.1250 -0.2930 -0.2564 -1.0272 -0.4833 -0.4631 -0.8182 -0.1659
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut inflammation heart_failure patients heart_failure
H-1363	-0.8153722882270813	▁gut ▁ inflammation ▁dieta ry _ intervention s ▁heart ▁failure
D-1363	-0.8153722882270813	gut inflammation dietary_interventions heart failure
P-1363	-1.1495 -0.2310 -0.0536 -2.7690 -1.5192 -1.2943 -0.2938 -0.2082 -0.3483 -0.3368 -1.4026 -0.1782
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf patients emergency_department intubated
H-210	-0.45294347405433655	▁CHF ▁emergency _ ▁department ED ▁in tuba ted
D-210	-0.45294347405433655	CHF emergency_ departmentED intubated
P-210	-0.0461 -2.0204 -0.6057 -0.2994 -0.9063 -0.0536 -0.0413 -0.1138 -0.3237 -0.1189
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait therapy lokomat heart_failure patients
H-1912	-0.5804500579833984	▁robot - assist ed _ ga it _ therapy ▁Lok omat _ systeem ▁heart ▁failure ▁patients
D-1912	-0.5804500579833984	robot-assisted_gait_therapy Lokomat_systeem heart failure patients
P-1912	-1.7352 -0.1545 -0.0254 -0.0972 -0.4825 -1.0188 -0.0642 -0.9552 -0.0207 -0.1985 -0.1065 -1.4175 -1.1889 -0.3407 -0.3299 -1.8919 -0.2589 -0.1617
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient symptomatic therapeutic exercise hemodynamic
H-1179	-0.7853335738182068	▁ex er tion ▁ therapeut ic _ ▁treatment s ▁ab normal _ ▁exercise ▁hem o dynamic
D-1179	-0.7853335738182068	exertion therapeutic_ treatments abnormal_ exercise hemodynamic
P-1179	-1.7002 -0.0777 -0.2274 -0.6943 -0.0361 -0.0590 -2.7816 -1.4509 -0.3595 -1.8441 -0.0200 -0.4139 -1.1063 -0.6772 -0.6877 -0.0050 -1.8360 -0.1592
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-1.3155725002288818	HR
D-609	-1.3155725002288818	HR
P-609	-2.0014 -1.7593 -0.1860
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet sensitivity specificity death icu
H-584	-0.6780092716217041	▁l VET ▁ sensitiv ity ▁death ICU
D-584	-0.6780092716217041	lVET sensitivity deathICU
P-584	-0.6707 -0.2822 -2.0399 -0.1844 -1.0601 -0.9090 -0.6776 -0.1358 -0.1424
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission patients
H-1581	-1.1425453424453735	
D-1581	-1.1425453424453735	
P-1581	-2.0050 -0.2801
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous symptoms patients heart_failure
H-51	-0.7648419141769409	▁Intra ven ous _ ▁ir on ▁heart ▁failure ▁ir on ▁de fici en cy
D-51	-0.7648419141769409	Intravenous_ iron heart failure iron deficiency
P-51	-0.2511 -0.0156 -3.0125 -0.0879 -2.2555 -0.7389 -2.4592 -0.9951 -0.0865 -0.5201 -0.9108 -0.0518 -0.3081 -0.0745 -0.3202 -0.1497
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr acr cms correlated
H-141	-0.45209211111068726	▁p PR ▁a cr ▁CMS
D-141	-0.45209211111068726	pPR acr CMS
P-141	-0.5067 -1.2097 -0.0558 -0.1357 -0.0943 -1.0142 -0.1483
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality lcx lad disease
H-513	-0.6648862957954407	▁mortal ity ▁ LC x ▁ LAD ▁two - ves sel _ ▁disease
D-513	-0.6648862957954407	mortality LCx LAD two-vessel_ disease
P-513	-1.5476 -1.1765 -1.6158 -0.0588 -0.6417 -0.3021 -0.1589 -1.6664 -0.1509 -0.3061 -0.0145 -0.2144 -0.5851 -1.3842 -0.1502
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions remodelling leading heart_failure
H-991	-0.8725732564926147	▁stress _ ▁conditions ▁mal adapt ive _ ▁remodel ling ▁heart ▁failure
D-991	-0.8725732564926147	stress_ conditions maladaptive_ remodelling heart failure
P-991	-3.3698 -2.0731 -0.9536 -1.8960 -0.0285 -0.0644 -0.4930 -0.0912 -0.1671 -0.7337 -1.0252 -0.2883 -0.1596
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis systemic followed_up
H-1559	-0.8024604320526123	▁psoriasis ▁system ic UV
D-1559	-0.8024604320526123	psoriasis systemicUV
P-1559	-0.0362 -0.5033 -0.0452 -1.2707 -2.8094 -0.1500
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients diagnosis congestive_heart_failure
H-1578	-0.9432173371315002	▁con ges tive _ heart _ ▁failure
D-1578	-0.9432173371315002	congestive_heart_ failure
P-1578	-0.9930 -0.1779 -2.2416 -0.0762 -2.4575 -1.8712 -0.0717 -0.4371 -0.1627
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker patients resting_hr bpm p_value
H-1941	-0.8371063470840454	▁Beta - block er ▁dose ▁rest ing ▁HR ▁bp m
D-1941	-0.8371063470840454	Beta-blocker dose resting HR bpm
P-1941	-0.3137 -0.0613 -0.0878 -0.1251 -4.1643 -1.2851 -0.1545 -2.5991 -0.6670 -0.0537 -0.4537 -0.0801
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive patients pulmonary_hypertension heart_failure
H-577	-0.6647887825965881	▁non in va sive _ ▁tools ▁pulmonar y _ ▁hyper tension PH ▁heart ▁failure
D-577	-0.6647887825965881	noninvasive_ tools pulmonary_ hypertensionPH heart failure
P-577	-3.3038 -0.0975 -0.0467 -0.1780 -0.6623 -1.1046 -0.1006 -0.0627 -0.2670 -1.1521 -0.0610 -0.5364 -1.9630 -0.7070 -0.2308 -0.1631
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new_zealand renal_dnx pacing-induced_chf
H-1373	-0.5089874267578125	▁ conscious ▁white _ ▁rabbi ts ▁renal ▁DN x ▁pa cing - indu ced ▁CHF
D-1373	-0.5089874267578125	conscious white_ rabbits renal DNx pacing-induced CHF
P-1373	-1.5961 -0.2574 -3.0997 -0.3455 -0.1644 -0.0492 -0.0298 -0.7527 -0.0452 -0.9026 -0.0423 -0.0559 -0.0023 -0.0322 -0.9445 -0.2056 -0.1274
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 healthy heart_muscle cells phenotype pathological hypertrophy
H-641	-0.7444941401481628	▁line ▁mu tant _ mi ce ▁over express ing ▁hand 2 ▁heart _ ▁muscle _ ▁cell s ▁path ological _ ▁hyper trop hy
D-641	-0.7444941401481628	line mutant_mice overexpressing hand2 heart_ muscle_ cells pathological_ hypertrophy
P-641	-2.9198 -0.1701 -0.1508 -0.1228 -0.3058 -0.1873 -0.0214 -0.4876 -0.0246 -1.2057 -3.7183 -2.2522 -0.7749 -0.6177 -1.1755 -0.6551 -0.0691 -0.2865 -0.4995 -0.2963 -1.5816 -0.0052 -0.7304 -0.2023 -0.1518
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis patients adverse_events echocardiographic outcomes
H-914	-0.7158792614936829	▁di al ysis ▁patients ▁e cho car dio graphic
D-914	-0.7158792614936829	dialysis patients echocardiographic
P-914	-0.2230 -0.1884 -0.0656 -3.0739 -1.0915 -0.1575 -0.0425 -0.5361 -1.3122 -1.0061 -0.1779
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients heart_failure_and_reduced_ejection_fraction
H-668	-0.8431981801986694	▁heart ▁failure ▁reduce d _ e je ction _ fraction
D-668	-0.8431981801986694	heart failure reduced_ejection_fraction
P-668	-4.5363 -1.0764 -2.1683 -0.0881 -0.4592 -0.6201 -0.1819 -0.0879 -0.1552 -0.0651 -0.4607 -0.2192
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt_variability qtv repolarization qtv cardiac_death
H-1435	-0.9394018054008484	▁ QT _ ▁variabil ity Q TV ▁repo lar ization ▁la bility ▁Q TV ▁cardiac _ ▁death
D-1435	-0.9394018054008484	QT_ variabilityQTV repolarization lability QTV cardiac_ death
P-1435	-1.9978 -0.0785 -0.4134 -0.0282 -0.9342 -1.6604 -1.9860 -0.5163 -0.5440 -0.3165 -0.7010 -0.0378 -0.6889 -1.6708 -4.5197 -0.9646 -0.4431 -0.2206 -0.1268
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial_structure sarcomeric_microstructure
H-1250	-0.6352896094322205	▁mito cho ndri al _ structure ▁sar come ric _ micro structure
D-1250	-0.6352896094322205	mitochondrial_structure sarcomeric_microstructure
P-1250	-0.1480 -0.4172 -0.3073 -0.1537 -0.9837 -1.9265 -0.8512 -0.6884 -1.8382 -0.2629 -0.5156 -0.3573 -0.3184 -0.1256
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory hf patients left_ventricular_ejection_fraction
H-122	-0.6784769296646118	▁consenti ng ▁ambula tory _ HF ▁patients ▁le ft _ ▁vent ri cular _ e je ction _ fraction
D-122	-0.6784769296646118	consenting ambulatory_HF patients left_ ventricular_ejection_fraction
P-122	-1.1001 -0.0596 -0.4769 -0.2324 -0.3026 -1.0317 -3.4623 -0.7823 -0.0666 -0.2850 -1.6747 -1.0878 -0.7853 -0.3957 -0.5516 -0.2432 -0.2155 -0.6974 -0.0377 -0.5866 -0.1729
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy hdl chf-nyha-iiib hdl
H-258	-0.9763345718383789	▁et ▁HD l _ ▁function ▁et ▁CHF - NY ha - III b ▁HD l _ ▁function
D-258	-0.9763345718383789	et HDl_ function et CHF-NYha-IIIb HDl_ function
P-258	-1.6219 -4.2036 -2.1150 -0.4300 -0.3455 -1.8376 -0.9170 -0.1455 -0.0875 -0.4074 -0.1405 -0.2653 -0.0635 -2.1350 -2.6103 -0.3339 -0.5155 -0.2775 -0.0980
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient implantable_cardioverter-defibrillator
H-1859	-0.4252232313156128	▁a IM ▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1859	-0.4252232313156128	aIM implantable_ cardioverter-defibrillator deactivation
P-1859	-0.2633 -0.7361 -1.4216 -0.0515 -0.6319 -0.4692 -0.0525 -0.2193 -0.3149 -0.0631 -0.2264 -0.5150 -0.1441 -0.0449 -1.9642 -0.0063 -0.3152 -0.4761 -0.1638
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence micrornas mirnas pathogenesis heart_failure
H-1481	-0.384799599647522	▁micro RNA s mi RNA s ▁heart ▁failure
D-1481	-0.384799599647522	microRNAsmiRNAs heart failure
P-1481	-0.1622 -0.0601 -0.1118 -0.9722 -0.0407 -0.0749 -1.2736 -0.7447 -0.2814 -0.1264
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients uptitration heart_rate renal_function spironolactone
H-180	-1.3284497261047363	▁heart ▁rate ▁renal _ ▁function ▁spi rono lac tone
D-180	-1.3284497261047363	heart rate renal_ function spironolactone
P-180	-8.5621 -1.9836 -0.2307 -2.1340 -0.9517 -0.0883 -0.0137 -0.0357 -0.0631 -0.3491 -0.2008
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis patients chf therapeutic neurohormonal_systems
H-635	-0.5410203337669373	▁CHF ▁activa ted _ ▁neuro hormon al _ systemen
D-635	-0.5410203337669373	CHF activated_ neurohormonal_systemen
P-635	-1.0353 -1.5899 -0.0867 -0.1327 -0.5906 -0.0931 -0.0709 -1.5143 -0.2065 -0.5197 -0.1114
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician follow-up discharge death readmission patients heart_failure
H-1413	-1.367457628250122	▁physician _ ▁follow - up _ ▁after _ ▁dis charge ▁death ▁read mission ▁heart _ ▁failure
D-1413	-1.367457628250122	physician_ follow-up_ after_ discharge death readmission heart_ failure
P-1413	-3.2197 -2.3477 -0.6210 -0.1125 -0.0156 -1.0558 -4.0052 -0.1825 -2.0423 -0.1695 -3.9610 -2.8343 -0.7267 -1.1845 -1.4223 -0.2220 -0.3246 -0.1672
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter_ablation antiarrhythmic_drugs rhythm_control_therapy
H-1647	-0.3951297104358673	▁cat heter ▁ab lation ▁anti ar rhythm ic ▁drugs ▁ rhythm _ control _ therapy
D-1647	-0.3951297104358673	catheter ablation antiarrhythmic drugs rhythm_control_therapy
P-1647	-0.3245 -0.0582 -0.3809 -0.0955 -0.0143 -0.5064 -0.3430 -0.0402 -0.8151 -0.1456 -0.3373 -1.1509 -0.0244 -1.8102 -0.0734 -0.4446 -0.1528
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage poc
H-1029	-1.2941569089889526	▁PO c ▁technologie
D-1029	-1.2941569089889526	POc technologie
P-1029	-2.9465 -1.1483 -1.8808 -0.3109 -0.1842
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac_dysfunction subcellular metoprolol heart_failure myocardial_infarction
H-1546	-0.30188027024269104	▁cardiac _ ▁dys function ▁sub cel lular _ ▁altera tions ▁met o pro lol ▁heart ▁failure ▁my o card ial _ in far ction
D-1546	-0.30188027024269104	cardiac_ dysfunction subcellular_ alterations metoprolol heart failure myocardial_infarction
P-1546	-0.3874 -0.5573 -0.1168 -0.0521 -0.0698 -0.0436 -0.0640 -1.5720 -0.0842 -0.3903 -0.2248 -0.1992 -0.0159 -0.0931 -0.5769 -0.3756 -0.5852 -0.3308 -0.5428 -0.4803 -0.2255 -0.2038 -0.0621 -0.0991 -0.3354 -0.1610
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac_magnetic_resonance_postcontrast_t1_time outcome patients heart_failure preserved_ejection_fraction
H-733	-0.451203316450119	▁Card iac _ ▁magnetic _ ▁res on ance ▁post contra st ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-733	-0.451203316450119	Cardiac_ magnetic_ resonance postcontrast heart failure preserved_ejection_fraction
P-733	-0.3542 -0.0262 -0.2611 -0.1921 -0.1384 -2.2408 -0.3535 -0.2057 -1.2311 -0.0235 -0.0416 -2.4600 -0.9824 -0.0554 -0.1196 -0.4851 -0.4335 -0.3531 -0.1208 -0.0915 -0.1916 -0.0363 -0.3059 -0.1256
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv_diastolic_dysfunction filling_pressures non-invasively doppler_echocardiography
H-28	-0.39163854718208313	▁dia sto lic _ ▁dys function ▁fill ing _ ▁pressure s ▁do pp ler _ e cho card i ography
D-28	-0.39163854718208313	diastolic_ dysfunction filling_ pressures doppler_echocardiography
P-28	-0.1245 -0.0762 -0.0577 -0.5366 -0.1639 -0.0301 -0.1234 -0.0535 -0.3114 -1.4909 -0.0737 -0.4891 -0.0303 -2.0207 -0.5066 -0.3721 -0.1603 -0.4596 -0.6305 -0.2293 -0.4632 -0.2122
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart_magnetic_resonance_imaging chelation compliance heart_disease patients thalassaemia_major
H-744	-0.874410092830658	▁impact ▁heart _ ▁magnetic _ ▁res on ance _ ▁imagin g ▁che lation ▁choice s ▁cardiovascular _ ▁disease ▁tha lassa emia
D-744	-0.874410092830658	impact heart_ magnetic_ resonance_ imaging chelation choices cardiovascular_ disease thalassaemia
P-744	-1.7727 -2.1538 -0.9720 -0.1868 -0.2423 -3.0689 -0.7734 -0.4981 -0.1111 -1.0818 -0.4155 -0.0514 -0.0225 -1.1191 -0.0552 -3.8982 -1.0696 -1.1548 -0.0188 -0.1894 -0.2247 -0.8816 -0.1498
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial_collagen collagen_cross-linking titin isoforms phosphorylation
H-764	-0.24948136508464813	▁My o card ial _ ▁collage n ▁collage n ▁cross - link ing ▁titi n ▁iso form s ▁ phos phor y lation
D-764	-0.24948136508464813	Myocardial_ collagen collagen cross-linking titin isoforms phosphorylation
P-764	-1.2556 -0.1570 -0.2503 -0.5369 -0.3354 -0.1236 -0.2330 -0.1600 -0.1182 -1.5440 -0.0168 -0.0092 -0.0264 -0.0228 -0.0691 -0.0579 -0.1054 -0.0798 -0.0238 -0.0175 -0.1974 -0.5590 -0.0740 -0.1722 -0.0919
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping mri tidal_respiration myocardial_t1 heart_failure
H-1054	-0.5312387347221375	▁m RI ▁tid al _ ▁respira tion ▁my o card ial _ t 1 ▁s win e _ ▁with _ heart _ ▁failure
D-1054	-0.5312387347221375	mRI tidal_ respiration myocardial_t1 swine_ with_heart_ failure
P-1054	-0.6738 -1.3618 -0.9993 -0.0286 -0.1155 -0.7968 -0.0550 -0.4311 -0.2199 -0.1676 -0.0680 -0.3077 -1.7335 -0.5080 -0.0356 -0.0103 -0.0636 -0.7290 -2.0692 -0.0498 -1.2669 -1.0519 -0.0344 -0.3431 -0.1603
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker uptitration clinical outcome patients hfref hfpef
H-185	-0.4423656761646271	RAS - block er _ up tit ration ▁h Fr EF ▁ HF p EF
D-185	-0.4423656761646271	RAS-blocker_uptitration hFrEF HFpEF
P-185	-0.3386 -0.0340 -0.2735 -0.1331 -1.4829 -0.1963 -0.3939 -0.2404 -0.8192 -0.8693 -0.7821 -0.6250 -0.4193 -0.0877 -0.5342 -0.1847 -0.1059
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems_proteomics cardiac_chromatin nucleolin cellular_plasticity cardiomyocytes
H-88	-0.8635092377662659	▁systems _ ▁prote o mics ▁cardiac _ ▁chr omat in ▁nucleo lin ▁cel lular _ ▁plastic ity ▁cardio my o cy tes
D-88	-0.8635092377662659	systems_ proteomics cardiac_ chromatin nucleolin cellular_ plasticity cardiomyocytes
P-88	-1.4702 -1.0715 -2.1356 -1.0763 -0.0023 -0.1085 -0.2268 -0.6113 -0.0664 -1.3034 -0.0905 -3.5742 -5.9899 -0.0481 -0.5208 -0.2533 -0.8066 -0.0223 -0.3402 -0.4201 -0.0433 -0.1065 -0.3173 -0.1186
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac_failure death patients type_2_diabetes diabetes heart_failure
H-652	-0.9460145235061646	▁Card iac _ ▁failure ▁diabetes ▁diabetes ▁heart ▁failure
D-652	-0.9460145235061646	Cardiac_ failure diabetes diabetes heart failure
P-652	-2.1576 -0.0515 -0.9210 -0.1059 -0.7046 -2.5768 -1.4602 -1.1533 -0.1982 -0.1310
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese zsf1 heart_failure_with_preserved_ejection_fraction
H-770	-0.6473793983459473	▁z SF _ ▁rat s ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction
D-770	-0.6473793983459473	zSF_ rats heart_ failure preserved_ejection_fraction
P-770	-0.2945 -0.8380 -4.2206 -0.1234 -0.0244 -2.0197 -1.6795 -0.1636 -0.5793 -0.0915 -0.6894 -0.2202 -0.3717 -0.1475 -0.0939 -0.1647 -0.0804 -0.3108 -0.1870
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin exercise training health patients chronic_heart_failure hf-action randomized
H-833	-0.7229111194610596	▁Hem o glob in ▁exercise _ training ▁chronic _ heart _ ▁failure ▁ HF - ac TION
D-833	-0.7229111194610596	Hemoglobin exercise_training chronic_heart_ failure HF-acTION
P-833	-0.6938 -0.2457 -0.0670 -0.8377 -2.0483 -2.1856 -0.1776 -1.7619 -0.0743 -1.1749 -0.9079 -0.3126 -0.4041 -0.1041 -0.0297 -0.4835 -1.7018 -0.3713 -0.1537
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf shift chronic_heart_failure chronic_heart_failure cardiology
H-1964	-0.8352524042129517	▁para dig m - HF ▁chronic _ heart _ ▁failure ▁Chro nic _ heart ▁failure ▁card i ology
D-1964	-0.8352524042129517	paradigm-HF chronic_heart_ failure Chronic_heart failure cardiology
P-1964	-2.0033 -1.6658 -0.1543 -0.0447 -0.1478 -3.3911 -0.0789 -1.7171 -1.3970 -0.0787 -2.1469 -0.3206 -0.0260 -1.7349 -0.9189 -0.2671 -0.1171 -0.0876 -0.2621 -0.1450
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial_tonometry lvet prognostic patients precapillary_ph heart_failure
H-579	-0.594433069229126	▁arterial _ ▁ton ometr y _ ▁study ▁l VET ▁pre cap illa ry _ ▁PH ▁heart ▁failure
D-579	-0.594433069229126	arterial_ tonometry_ study lVET precapillary_ PH heart failure
P-579	-0.5135 -0.1896 -1.5566 -0.0413 -0.1773 -2.8721 -0.4674 -0.2768 -0.0849 -0.4289 -0.0225 -0.1167 -0.7054 -0.1918 -0.6527 -1.8024 -0.8151 -0.2198 -0.1594
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal_echocardiography shunts thrombosis
H-1957	-0.3467329144477844	▁trans o es op hage al _ e cho card i ography ▁patent ▁ thro mbo sis ▁migration
D-1957	-0.3467329144477844	transoesophageal_echocardiography patent thrombosis migration
P-1957	-0.0750 -0.7229 -0.1616 -0.1212 -0.5327 -0.1697 -0.2220 -0.2758 -0.0739 -0.3565 -0.6393 -0.2304 -1.2756 -0.1649 -0.3608 -0.0724 -0.9844 -0.0185 -0.3753 -0.1017
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk heart adipose_tissue cachectic_heart_failure patients prospective_study
H-8	-0.7438921928405762	▁Cross - talk _ ▁between _ de _ heart ▁adi pose _ ▁tissu e ▁cache ctic _ heart _ ▁failure
D-8	-0.7438921928405762	Cross-talk_ between_de_heart adipose_ tissue cachectic_heart_ failure
P-8	-1.0463 -0.1079 -0.0835 -1.6518 -1.3974 -0.3030 -1.6676 -0.2559 -2.5632 -0.2560 -0.0827 -0.0390 -0.5532 -0.0475 -0.0141 -0.8211 -0.0275 -1.5764 -1.0076 -0.0502 -2.6694 -0.1444
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause_readmissions
H-726	-1.4796408414840698	▁read missions
D-726	-1.4796408414840698	readmissions
P-726	-3.3365 -0.4295 -1.9926 -0.1600
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular_disease baseline
H-1767	-1.4538682699203491	▁cardiovascular _ ▁disease
D-1767	-1.4538682699203491	cardiovascular_ disease
P-1767	-3.9371 -1.0138 -1.6585 -0.3947 -0.2652
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal hospital hf patients cms conditions
H-139	-1.3791340589523315	▁hospital _ ▁rates ▁ HF ▁CMS
D-139	-1.3791340589523315	hospital_ rates HF CMS
P-139	-6.0540 -1.2708 -0.1835 -0.4076 -0.0732 -0.6251 -2.2517 -0.1672
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal likelihood_ratio
H-487	-1.3065377473831177	▁cut off ▁e / e _ sept al
D-487	-1.3065377473831177	cutoff e/e_septal
P-487	-2.2776 -0.1426 -0.4799 -4.1032 -0.0198 -4.3659 -0.0146 -0.0482 -1.4459 -0.1677
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis cardiovascular_disease cvd
H-1555	-0.76364666223526	▁p sori asis ▁cardiovascular _ ▁disease CV d
D-1555	-0.76364666223526	psoriasis cardiovascular_ diseaseCVd
P-1555	-2.8296 -0.1207 -0.0750 -0.4536 -1.6248 -1.0948 -0.7075 -0.3413 -0.2637 -0.1255
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs patients oht transplant vad
H-1288	-0.7853460311889648	▁a CS ▁o HT ▁ bridge d _ to _ ▁transplant ▁MT ▁ VAD
D-1288	-0.7853460311889648	aCS oHT bridged_to_ transplant MT VAD
P-1288	-0.1561 -3.6474 -0.4978 -1.0136 -1.0159 -0.0005 -0.0128 -1.2711 -0.9582 -0.5732 -0.0656 -2.2077 -0.8899 -0.0227 -0.1401 -0.0930
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients beta-blocker therapy
H-1939	-0.7951108813285828	▁beta - block er _ therapy
D-1939	-0.7951108813285828	beta-blocker_therapy
P-1939	-4.4920 -0.0436 -0.1401 -0.0565 -0.9345 -0.0397 -0.3615 -0.2930
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs clinical
H-2015	-1.6388437747955322	
D-2015	-1.6388437747955322	
P-2015	-3.0792 -0.1985
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital_compare ami mortality
H-1697	-0.8923208117485046	▁ AMI _ ▁mortal ity
D-1697	-0.8923208117485046	AMI_ mortality
P-1697	-1.0321 -0.7704 -1.3872 -0.2184 -1.0464 -1.5754 -0.2163
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins subproteome
H-94	-1.254902720451355	▁protein s ▁sub prote ome ▁acid
D-94	-1.254902720451355	proteins subproteome acid
P-94	-2.0709 -0.1968 -2.4114 -0.0769 -0.0591 -4.8856 -0.2423 -0.0961
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma collected hf patients
H-1514	-0.6506547927856445	▁Plas ma ▁sample s ▁ HF
D-1514	-0.6506547927856445	Plasma samples HF
P-1514	-0.3960 -0.7076 -1.8470 -0.0826 -0.5240 -0.2102 -1.3331 -0.1048
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician patient admission admission
H-1417	-0.9283754825592041	▁index ▁ad mission ▁index ▁ad mission
D-1417	-0.9283754825592041	index admission index admission
P-1417	-1.5342 -1.2388 -0.8160 -0.0328 -1.9562 -1.1129 -0.4052 -0.3310
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis medical hf
H-200	-0.8659185171127319	▁early _ ▁medical _ management ▁ HF
D-200	-0.8659185171127319	early_ medical_management HF
P-200	-2.8052 -0.1513 -2.4974 -0.3910 -0.2080 -0.8491 -0.1507 -0.5829 -0.1577
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm_control_therapy
H-1645	-0.5317597985267639	▁ Rhythm _ control _ therapy
D-1645	-0.5317597985267639	Rhythm_control_therapy
P-1645	-0.1035 -0.0666 -0.5088 -0.0202 -1.4871 -0.0885 -1.8726 -0.1068
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy patients follow-up
H-861	-0.6705945134162903	▁in appropria te _ therapy
D-861	-0.6705945134162903	inappropriate_therapy
P-861	-1.0501 -0.1293 -0.0590 -0.2549 -0.0724 -2.9398 -0.1886
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients cardiovascular_disease drs
H-1838	-0.7215873599052429	▁cardiovascular _ ▁disease ▁d RS
D-1838	-0.7215873599052429	cardiovascular_ disease dRS
P-1838	-1.1024 -0.9670 -0.8669 -0.1450 -0.1754 -1.6536 -0.1408
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported heart_failure clcnka snp
H-1804	-1.132798671722412	▁heart ▁failure ▁CL cn ka _ s NP
D-1804	-1.132798671722412	heart failure CLcnka_sNP
P-1804	-5.5429 -1.2781 -0.1430 -1.1036 -0.7328 -1.0535 -0.7880 -0.2318 -0.3215 -0.1329
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas cardiac_remodeling heart_failure
H-1483	-0.31537723541259766	▁mi RNA s ▁cardiac ▁remodel ing ▁heart ▁failure
D-1483	-0.31537723541259766	miRNAs cardiac remodeling heart failure
P-1483	-0.5390 -0.0131 -0.1008 -0.0478 -0.9997 -0.0308 -0.2197 -0.6820 -0.4270 -0.0939
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa immunoassays nt-probnp
H-1516	-0.48895934224128723	▁Alpha LIS a ▁immun o assa ys ▁NT - pro b NP
D-1516	-0.48895934224128723	AlphaLISa immunoassays NT-probNP
P-1516	-2.7093 -0.5282 -0.2379 -0.2869 -0.2658 -0.0629 -0.8892 -0.7834 -0.0315 -0.0109 -0.5743 -0.1071 -0.2633 -0.0949
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf patients rheumatoid_arthritis ra
H-602	-0.6425140500068665	▁ HF ▁rhe um ato id _ ▁ar thri tis RA
D-602	-0.6425140500068665	HF rheumatoid_ arthritisRA
P-602	-1.6028 -0.5599 -3.4134 -0.0740 -0.2171 -0.4594 -0.1410 -0.3647 -0.2581 -0.2519 -0.4457 -0.4203 -0.1443
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction_pathways engage signalling_proteins
H-993	-0.541366696357727	▁trans duction _ path ways ▁signal ling _ ▁protein s
D-993	-0.541366696357727	transduction_pathways signalling_ proteins
P-993	-0.3088 -1.0078 -0.6329 -0.8502 -0.0822 -1.1648 -0.2127 -0.4660 -1.2912 -0.0633 -0.2903 -0.1262
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical diastolic_dysfunction mortality
H-25	-0.37112951278686523	▁dia sto lic _ ▁dys function
D-25	-0.37112951278686523	diastolic_ dysfunction
P-25	-0.4000 -0.0696 -0.2600 -0.3199 -0.4312 -0.0699 -1.2885 -0.1300
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation anti-inflammatory chf
H-1362	-0.48461058735847473	▁regula tion _ of _ ▁feed ing ▁nutrition al ▁anti - in flam ma tory _ effect ▁CHF
D-1362	-0.48461058735847473	regulation_of_ feeding nutritional anti-inflammatory_effect CHF
P-1362	-1.5146 -0.1605 -0.2425 -0.9704 -0.1458 -0.7667 -0.0487 -0.4723 -0.1341 -0.4302 -0.0460 -0.2786 -0.0274 -1.9112 -0.2845 -1.1887 -0.2389 -0.4659 -0.2645 -0.1007
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes hypertrophic
H-1217	-0.4551316499710083	▁p de 2- over express ing ▁cardio my o cy tes ▁no re pine ph rine - indu ced _ ▁hyper trop hic
D-1217	-0.4551316499710083	pde2-overexpressing cardiomyocytes norepinephrine-induced_ hypertrophic
P-1217	-1.9305 -0.1696 -0.0244 -0.0061 -0.6269 -0.0286 -1.3101 -1.1444 -0.6892 -0.2903 -0.1230 -0.0117 -0.0636 -0.0458 -0.8310 -0.0257 -0.1630 -0.0026 -0.1614 -0.5311 -0.9291 -0.0045 -0.4478 -1.6102 -0.2076
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate alendronate heart_failure
H-1545	-1.1368019580841064	▁ale ndr onate ▁risk ▁ale ndr onate ▁heart ▁failure
D-1545	-1.1368019580841064	alendronate risk alendronate heart failure
P-1545	-1.1285 -0.0493 -0.3037 -4.8670 -2.2590 -0.1275 -0.4121 -2.0038 -0.9894 -0.2573 -0.1071
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty heart_failure hf
H-622	-0.7457454204559326	▁fra il ty ▁risk ▁heart ▁failure HF
D-622	-0.7457454204559326	frailty risk heart failureHF
P-622	-0.2092 -0.4295 -0.1452 -1.5166 -2.7375 -0.7818 -0.3348 -0.4415 -0.1157
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression bax bcl-2 proteins pacing
H-170	-0.474517285823822	▁Bax ▁b cl -2 _ ▁protein s
D-170	-0.474517285823822	Bax bcl-2_ proteins
P-170	-0.4062 -0.3133 -0.0520 -0.1608 -1.0217 -0.5667 -0.1052 -1.5065 -0.1384
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients β-blocker patients uptitration
H-179	-0.5175042748451233	▁ RAS - ▁β - block er
D-179	-0.5175042748451233	RAS- β-blocker
P-179	-0.5777 -0.0169 -0.0372 -0.5684 -0.0742 -0.2011 -0.1404 -2.8767 -0.1650
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt gdmt bat
H-1871	-0.5607385635375977	▁GD MT control ▁group ▁GD MT ▁BAT tre at ment _ groep
D-1871	-0.5607385635375977	GDMTcontrol group GDMT BATtreatment_groep
P-1871	-0.3998 -0.6063 -1.0973 -2.1182 -0.4292 -0.7228 -0.2395 -0.3724 -0.0583 -0.0217 -0.5836 -0.7498 -0.3570 -0.0945
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart_failure patients bisphosphonates
H-1535	-0.9795936346054077	▁heart ▁failure ▁bis phos phon ates
D-1535	-0.9795936346054077	heart failure bisphosphonates
P-1535	-4.5488 -1.2933 -0.4805 -0.0515 -0.4240 -0.3497 -0.5073 -0.1817
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline patients resting_hr bpm
H-1940	-1.511624813079834	▁rest ing ▁HR
D-1940	-1.511624813079834	resting HR
P-1940	-4.7045 -0.0903 -1.8843 -0.7777 -0.1013
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac_angiogenesis therapy cardiac_function remodeling
H-460	-0.4485751986503601	▁β - Block er - indu ced _ ▁enhance ment ▁cardiac _ ▁ang io gene sis ▁ therapy ▁cardiac _ ▁function ▁remodel ing
D-460	-0.4485751986503601	β-Blocker-induced_ enhancement cardiac_ angiogenesis therapy cardiac_ function remodeling
P-460	-0.1646 -0.0600 -0.1846 -0.0236 -0.0632 -0.0032 -0.4773 -0.7348 -1.3839 -0.0623 -0.7806 -0.2023 -3.0258 -0.6812 -0.2950 -0.3987 -0.7491 -0.0469 -0.1387 -0.2739 -0.8672 -0.2019 -0.0416 -0.2487 -0.1052
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil cytotoxic doxorubicin ehrlich_carcinoma
H-966	-0.3025626540184021	▁nic oran dil ▁cy to toxic ▁do xor ubi cin ▁eh r lich _ car cino ma
D-966	-0.3025626540184021	nicorandil cytotoxic doxorubicin ehrlich_carcinoma
P-966	-0.0233 -0.0559 -0.1619 -0.7836 -0.0484 -0.0962 -1.9497 -0.0225 -0.0187 -0.3347 -0.3387 -0.0744 -0.0113 -0.1377 -0.4848 -0.1504 -0.5245 -0.3751 -0.1569
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death c-statistics biological_phenotype deficit_index
H-1011	-0.6529271602630615	▁death ▁c - stat istic s ▁bi ological _ ▁ph eno type ▁deficit ▁index
D-1011	-0.6529271602630615	death c-statistics biological_ phenotype deficit index
P-1011	-5.5459 -0.6062 -0.6766 -0.0075 -0.0196 -0.0526 -0.8207 -0.2214 -0.4079 -0.3649 -0.0210 -0.0014 -0.0323 -1.0381 -0.4234 -0.2072
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas cardiac benign_tumors left_atrium right_atrium
H-593	-0.48643848299980164	▁My xo mas ▁cardiac _ ▁benign _ ▁tumor s ▁left _ at rium
D-593	-0.48643848299980164	Myxomas cardiac_ benign_ tumors left_atrium
P-593	-1.5067 -0.0117 -0.1849 -0.1655 -0.7832 -0.1040 -0.4085 -0.3151 -0.1449 -0.7873 -0.2146 -0.6706 -0.0031 -1.8316 -0.1647
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic_peptides point_of_care ambulatory
H-1019	-0.5567810535430908	▁na tri ure tic _ pe pti des
D-1019	-0.5567810535430908	natriuretic_peptides
P-1019	-0.0144 -0.0243 -0.3428 -2.2329 -0.2047 -0.5624 -0.0861 -0.4700 -1.5197 -0.1105
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv_diastolic_dysfunction combination figure hfpef
H-24	-0.5963106155395508	▁dia sto lic _ ▁dys function ▁h FP EF
D-24	-0.5963106155395508	diastolic_ dysfunction hFPEF
P-24	-0.6382 -0.0260 -0.0655 -0.2738 -0.1779 -0.0411 -1.7372 -2.1514 -0.9570 -0.3160 -0.1753
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal_denervation dnx chf patients symptomatic
H-1371	-0.8408088684082031	▁Ren al _ ▁den er va tion ▁d x ▁CHF
D-1371	-0.8408088684082031	Renal_ denervation dx CHF
P-1371	-0.8346 -0.2112 -0.3753 -3.9355 -0.9656 -0.3162 -0.6713 -0.5971 -1.2070 -0.0794 -0.7899 -0.1066
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported patient implantable_cardioverter-defibrillator
H-1858	-0.4705891013145447	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1858	-0.4705891013145447	implantable_ cardioverter-defibrillator deactivation
P-1858	-2.8560 -0.0478 -0.7064 -0.2147 -0.0499 -0.1353 -0.2537 -0.0283 -0.1316 -0.3618 -0.0966 -0.0536 -1.9876 -0.0061 -0.4613 -0.4591 -0.1501
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic_adult_fontan saf patients catheterization
H-226	-0.8003947138786316	▁symptom a tic _ adult _ ▁Font an SAF
D-226	-0.8003947138786316	symptomatic_adult_ FontanSAF
P-226	-3.8514 -0.1005 -0.3597 -0.1664 -0.2114 -0.2323 -0.9022 -0.5231 -0.6739 -1.6182 -0.1653
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients heart_failure left_ventricular ejection_fraction
H-22	-0.8014654517173767	▁heart ▁failure ▁pres er ved _ ▁left _ ▁vent ri cular LV ▁e je ction _ fraction
D-22	-0.8014654517173767	heart failure preserved_ left_ ventricularLV ejection_fraction
P-22	-5.2524 -1.8470 -0.4488 -0.0856 -0.4842 -0.5155 -1.0117 -0.1817 -2.3533 -1.1655 -0.1902 -0.1591 -0.4660 -0.0534 -0.0687 -0.2552 -0.0406 -0.4472 -0.2016
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory icd patients mortality multivariable_regression
H-63	-0.8164065480232239	▁ambula tory _ ▁I CD _ ▁patients ▁predict or ▁mortal ity
D-63	-0.8164065480232239	ambulatory_ ICD_ patients predictor mortality
P-63	-0.4614 -0.1620 -0.4566 -2.7974 -0.0997 -2.5435 -0.2956 -1.3209 -0.0393 -0.1492 -0.9489 -1.1618 -0.1768
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients sinus_rhythm antiplatelet_agents anticoagulants
H-1354	-0.2870686650276184	▁sinus _ rhythm ▁anti plate let ▁agents ▁antico a gul ants
D-1354	-0.2870686650276184	sinus_rhythm antiplatelet agents anticoagulants
P-1354	-0.2286 -0.7200 -0.1651 -0.0141 -0.0756 -0.3660 -0.9676 -0.0797 -0.1063 -0.4465 -0.0500 -0.4076 -0.1049
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician follow-up discharge physician outcomes patients heart_failure
H-1421	-0.9809072613716125	▁physician _ ▁follow - up _ ▁after _ ▁dis charge ▁physician _ ▁continu ity ▁heart ▁failure
D-1421	-0.9809072613716125	physician_ follow-up_ after_ discharge physician_ continuity heart failure
P-1421	-1.8004 -1.9714 -0.4566 -0.1345 -0.0147 -1.0128 -3.5945 -0.1877 -1.7800 -0.1305 -0.0547 -1.3458 -0.5533 -0.6870 -2.2078 -1.2281 -0.3053 -0.1914
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence vad acs consultations operations mortality morbidity
H-1289	-0.8569309711456299	▁MT ▁ VAD _ groep ▁a CS
D-1289	-0.8569309711456299	MT VAD_groep aCS
P-1289	-0.2137 -0.2366 -0.0374 -1.4349 -1.3356 -0.3155 -2.1468 -1.8737 -0.1181
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity doxorubicin anti-neoplastic_agent
H-955	-0.31471309065818787	▁cardio toxic iteit ▁do xor ubi cin ▁anti - neo plast ic _ agent ▁cancer s
D-955	-0.31471309065818787	cardiotoxiciteit doxorubicin anti-neoplastic_agent cancers
P-955	-0.3668 -0.5377 -1.6452 -0.0269 -0.0059 -0.0326 -0.3022 -0.0302 -0.0506 -0.0464 -0.1441 -0.0120 -0.9362 -0.1356 -0.4900 -0.4150 -0.3535 -0.1341
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes patients preserved_ejection_fraction hfpef
H-1328	-0.42515090107917786	▁f es ▁pres er ved _ e je ction _ fraction HF p EF
D-1328	-0.42515090107917786	fes preserved_ejection_fractionHFpEF
P-1328	-1.4690 -0.7571 -0.5631 -0.1131 -0.5508 -0.0894 -0.4285 -0.1838 -0.1207 -0.1497 -0.0930 -1.3409 -0.0351 -0.4786 -0.3191 -0.1105
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs hf_with_reduced_ejection_fraction hfref
H-1077	-1.0863676071166992	▁life sa ving ▁drugs ▁ HF ▁e je ction _ fraction HF r EF
D-1077	-1.0863676071166992	lifesaving drugs HF ejection_fractionHFrEF
P-1077	-3.6898 -2.4536 -0.0298 -1.2123 -2.2998 -0.1368 -4.5644 -0.1016 -0.0587 -0.2369 -0.1038 -1.7064 -0.1027 -0.3314 -0.2657 -0.0884
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations refractory_congestive_heart_failure peritoneal_dialysis
H-893	-0.5450579524040222	▁re frac tory _ con ges tive _ heart _ ▁failure ▁per ito ne al _ di al ysis
D-893	-0.5450579524040222	refractory_congestive_heart_ failure peritoneal_dialysis
P-893	-0.1471 -0.0947 -1.1056 -0.0505 -0.8845 -0.3970 -2.4277 -0.0333 -1.5012 -1.1467 -0.0409 -0.1494 -0.7341 -0.3391 -0.1236 -0.0999 -1.6137 -0.0508 -0.0509 -0.3020 -0.1536
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened lvet icu admission prognostic patients precapillary_ph heart_failure
H-590	-0.7146516442298889	▁l VET ▁ ICU ▁ad mission ▁pre cap illa ry _ ▁PH ▁heart ▁failure
D-590	-0.7146516442298889	lVET ICU admission precapillary_ PH heart failure
P-590	-1.9826 -0.3803 -0.7269 -0.0231 -2.1837 -0.3869 -0.7064 -0.0233 -0.1369 -0.6233 -0.3171 -0.8201 -2.0455 -0.6185 -0.2646 -0.1954
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial irs1 irs2 heart_failure p38alpha mapk insulin_resistance
H-651	-0.466257780790329	▁My o card ial _ ▁loss ▁i RS 1 ▁i RS 2 ▁heart ▁failure ▁p 38 al pha _ ▁MA PK ▁insulin ▁resist ance
D-651	-0.466257780790329	Myocardial_ loss iRS1 iRS2 heart failure p38alpha_ MAPK insulin resistance
P-651	-1.2769 -0.2142 -0.2210 -0.2728 -0.8272 -0.5210 -0.7320 -0.1159 -2.1404 -0.3026 -0.2065 -0.2532 -0.8471 -0.5241 -0.1358 -0.9314 -0.0239 -0.0001 -0.1659 -1.3468 -0.0709 -0.0131 -0.4973 -0.0076 -0.3202 -0.1546
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni_inhibitors angiotensin-receptor_neprilysin_inhibitors
H-1966	-0.4036984443664551	▁AR NI ▁inhibi tors angi oten sin - recept or ▁nepri ly sin _ ▁inhibi tors
D-1966	-0.4036984443664551	ARNI inhibitorsangiotensin-receptor neprilysin_ inhibitors
P-1966	-1.3636 -0.4390 -0.6047 -0.0945 -0.0071 -0.1192 -1.3879 -0.2594 -0.1079 -0.0350 -0.1173 -0.2715 -0.4974 -1.3344 -0.0301 -0.0930 -0.3456 -0.1588
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional_mitral_stenosis ring_annuloplasty ischemic_mitral_regurgitation
H-337	-0.32678860425949097	▁Fun ction al _ met ral _ ▁sten osis ▁m ▁ring _ ▁ann ulo plast y ▁ ische mic _ met ral _ re gur gi tation MR
D-337	-0.32678860425949097	Functional_metral_ stenosis m ring_ annuloplasty ischemic_metral_regurgitationMR
P-337	-0.3018 -0.0105 -0.0547 -0.2255 -0.7329 -0.1680 -0.3716 -0.8732 -0.0188 -0.4536 -0.1071 -0.6564 -1.5041 -0.0719 -0.0524 -0.1236 -0.1900 -0.0182 -0.1537 -0.1086 -0.9554 -0.4361 -0.4926 -0.3462 -0.2210 -0.0614 -0.0730 -0.4895 -0.3931 -0.1388
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence heart_failure_with_preserved_ejection_fraction hfpef prognosis
H-23	-0.5858603715896606	▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁h FP EF
D-23	-0.5858603715896606	heart failure preserved_ejection_fraction hFPEF
P-23	-1.0443 -0.9286 -1.5377 -0.1406 -0.6872 -0.0407 -0.3952 -0.1812 -0.0649 -0.1291 -0.1178 -0.6091 -1.8023 -1.1117 -0.4659 -0.1174
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_reserve
H-916	-0.5257962942123413	▁Heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁h FP ef ▁cardiovascular _ ▁reserve
D-916	-0.5257962942123413	Heart_ failure preserved_ejection_fraction hFPef cardiovascular_ reserve
P-916	-1.3904 -0.8370 -0.1396 -1.8564 -0.1323 -0.5429 -0.0412 -0.3259 -0.1928 -0.0578 -0.0909 -0.0641 -0.4460 -1.6521 -1.3432 -0.6577 -0.3447 -0.0499 -0.2387 -0.1124
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 hypertensive obese zsf1 hypertensive diabetic
H-766	-0.6300598382949829	▁lean ▁z SF 1 _ groep ▁hyper tensi ve ▁obes e ▁z SF 1 ▁groups ▁hyper tensi ve ▁diabet ic
D-766	-0.6300598382949829	lean zSF1_groep hypertensive obese zSF1 groups hypertensive diabetic
P-766	-0.0325 -1.3356 -0.5483 -2.2909 -1.7459 -0.5248 -0.4082 -0.0364 -0.0388 -0.2985 -0.0605 -1.2054 -0.4940 -2.0009 -2.1811 -0.1684 -0.0769 -0.0423 -0.0330 -0.0141 -0.2326 -0.0921
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian_enabled mena cytoskeletal_actin_dynamics heart_failure hf
H-1810	-0.5446401834487915	▁Mamma lian _ ▁enabled ▁men a ▁cy tos kelet al _ act in _ dynamic s ▁heart ▁failure HF
D-1810	-0.5446401834487915	Mammalian_ enabled mena cytoskeletal_actin_dynamics heart failureHF
P-1810	-0.3830 -0.0434 -0.4550 -0.0298 -1.1873 -0.0166 -1.8619 -0.7613 -0.3979 -0.0835 -0.1734 -0.9575 -0.5502 -1.9606 -0.6354 -0.0167 -0.1938 -0.7609 -0.6072 -0.2552 -0.1069
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal_bleeding reported patients ventricular_assist_devices
H-1659	-0.742884635925293	▁Gastro inte stin al _ ▁ble ed ing ▁vent ri cular _ assist _ ▁devices
D-1659	-0.742884635925293	Gastrointestinal_ bleeding ventricular_assist_ devices
P-1659	-0.4981 -1.2184 -1.6003 -0.2440 -0.6381 -0.8556 -1.1289 -0.2687 -0.0818 -1.1393 -0.4387 -0.1984 -0.2535 -2.6628 -0.6268 -0.6045 -0.1710
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart hospitalization death patients preserved_left_ventricular_ejection_fraction
H-235	-0.9670881032943726	▁heart ▁failure - related _ hospital ization ▁death ▁left _ ▁vent ri cular _ e je ction _ fraction
D-235	-0.9670881032943726	heart failure-related_hospitalization death left_ ventricular_ejection_fraction
P-235	-3.9150 -1.5296 -0.2793 -0.1918 -0.3644 -0.0883 -0.6146 -3.2580 -2.4988 -0.4252 -1.8734 -1.4394 -0.9026 -0.2832 -0.6110 -0.3211 -0.2752 -0.6158 -0.0421 -0.4537 -0.3263
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial pde2 intracellular antiadrenergic therapeutic hf
H-1220	-0.6074143648147583	▁activa ting ▁my o card ial _ p de 2 ▁intra cel lular _ ▁anti ad r energi c _ strategi e ▁ HF
D-1220	-0.6074143648147583	activating myocardial_pde2 intracellular_ antiadrenergic_strategie HF
P-1220	-0.5905 -0.1931 -2.1715 -0.2485 -0.1857 -0.5018 -0.3857 -1.5966 -0.7968 -0.0545 -0.7384 -0.1337 -0.0977 -0.5166 -0.7788 -0.1180 -0.4238 -0.2819 -0.0776 -0.8493 -0.4484 -1.0214 -2.4079 -0.6559 -0.2971 -0.2217
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic bnp nt-probnp patients coronary_artery_disease cad
H-1366	-0.4222955107688904	▁b NP ▁NT - pro b NP ▁corona ry _ ▁arter y ▁disease CAD
D-1366	-0.4222955107688904	bNP NT-probNP coronary_ artery diseaseCAD
P-1366	-0.7050 -0.7000 -0.4015 -0.0685 -0.0089 -0.4181 -0.2389 -0.0855 -1.5888 -0.2557 -0.4238 -0.4695 -1.0511 -0.0510 -0.1810 -0.1093
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients heart_failure elevated left_atrial_pressure symptoms hospital admission
H-1949	-1.3886662721633911	▁heart ▁failure ▁eleva ted _ ▁left _ at rial _ ▁pressure
D-1949	-1.3886662721633911	heart failure elevated_ left_atrial_ pressure
P-1949	-2.2551 -1.1007 -5.4698 -0.0802 -0.0761 -3.1761 -0.1208 -2.0816 -0.4079 -0.6098 -0.8372 -1.6844 -0.1529
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia acute_kidney_injury spironolactone clinical
H-444	-0.45897215604782104	▁hyper kal emia ▁ki dne y ▁injury ▁spi rono lac tone
D-444	-0.45897215604782104	hyperkalemia kidney injury spironolactone
P-444	-3.3056 -0.1695 -0.0149 -0.9005 -0.2909 -0.1155 -0.6762 -0.0017 -0.0076 -0.0192 -0.0304 -0.3415 -0.0932
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart_failure_with_preserved_ejection_fraction hfpef cardiovascular_morbidity mortality
H-236	-0.5210089683532715	▁Heart _ ▁failure ▁pres er ved _ e je ction _ fraction HF p EF ▁cardiovascular _ ▁morbi d ity ▁mortal ity
D-236	-0.5210089683532715	Heart_ failure preserved_ejection_fractionHFpEF cardiovascular_ morbidity mortality
P-236	-0.4402 -0.7376 -0.2763 -2.7618 -0.1779 -0.8312 -0.0410 -0.3639 -0.2540 -0.0564 -0.0994 -0.1001 -1.0275 -0.0343 -0.6520 -0.2241 -1.2333 -0.2907 -0.0305 -1.3910 -0.0966 -1.1259 -0.1481 -0.1105
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg crt clinical
H-881	-1.1299790143966675	▁e CG ▁c RT
D-881	-1.1299790143966675	eCG cRT
P-881	-0.8629 -0.3914 -2.2839 -2.7937 -0.3384 -0.1096
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.3656197488307953	▁circula ting _ form s ▁NT - pro b NP ▁as say s
D-1512	-0.3656197488307953	circulating_forms NT-probNP assays
P-1512	-0.0900 -0.0723 -0.4226 -1.3081 -0.1472 -1.6553 -0.0901 -0.0158 -0.6976 -0.1690 -0.2699 -0.0584 -0.0536 -0.3049 -0.1293
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions patients heart_disease
H-48	-0.538245439529419	▁trans fusion s ▁heart ▁disease
D-48	-0.538245439529419	transfusions heart disease
P-48	-0.2557 -0.0737 -0.1964 -2.0228 -0.8536 -0.2271 -0.1383
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone clinical medications
H-447	-0.5738292932510376	▁spi rono lac tone
D-447	-0.5738292932510376	spironolactone
P-447	-1.2067 -0.0135 -0.0506 -0.0731 -1.9623 -0.1368
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination exercise peak_vo2 joint
H-1985	-1.604538083076477	▁exercise ▁die t comp lement ary ▁VO 2 jo int ▁effect
D-1985	-1.604538083076477	exercise dietcomplementary VO2joint effect
P-1985	-3.5586 -6.0363 -0.1013 -5.1418 -0.0057 -0.2330 -1.7372 -0.0985 -1.9723 -0.0788 -1.3113 -0.4363 -0.1478
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up hf hospitalization
H-690	-0.5094513297080994	▁follow - up ▁ HF
D-690	-0.5094513297080994	follow-up HF
P-690	-0.1906 -0.1224 -0.0129 -0.4841 -0.2933 -2.3026 -0.1602
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients sst2 cardiovascular_event
H-407	-1.2007118463516235	▁s st 2 ▁BB ▁cardiovascular _ event _ ▁rate
D-407	-1.2007118463516235	sst2 BB cardiovascular_event_ rate
P-407	-0.0576 -1.3813 -0.2494 -5.3762 -0.5912 -1.0137 -1.8233 -1.3197 -0.3982 -0.8559 -0.1413
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast_cancer patients chf reported clinical
H-681	-0.6360741853713989	▁breast ▁cancer ▁patients ▁tras tuz um b - related _ ▁CHF
D-681	-0.6360741853713989	breast cancer patients trastuzumb-related_ CHF
P-681	-2.0777 -1.3443 -1.8585 -0.5859 -0.0355 -0.0673 -0.1513 -0.2745 -0.3902 -0.7960 -0.2718 -0.3034 -0.1126
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf pb bp
H-1348	-0.8771266341209412	▁PV f ▁p b ▁p b
D-1348	-0.8771266341209412	PVf pb pb
P-1348	-0.1432 -1.0795 -1.2737 -0.7685 -0.7809 -0.4715 -2.3569 -0.1427
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant exercise
H-1883	-0.8773645758628845	▁control ▁group ▁exercise _ groep
D-1883	-0.8773645758628845	control group exercise_groep
P-1883	-1.7223 -1.8515 -0.1203 -1.0389 -0.8236 -0.4417 -0.1433
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ecct
H-713	-1.386744737625122	▁ec CT
D-713	-1.386744737625122	ecCT
P-713	-3.8175 -1.3192 -0.2583 -0.1519
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.41587546467781067	▁aero bic _ ▁capacity ▁left - hand _ grip _ ▁strength ▁body ▁weight ▁wa ist ▁circum ferenc e ▁anxiety
D-573	-0.41587546467781067	aerobic_ capacity left-hand_grip_ strength body weight waist circumference anxiety
P-573	-1.0234 -0.3394 -0.5686 -1.6357 -0.2452 -0.1261 -0.0165 -0.1229 -1.4759 -0.6011 -0.1290 -0.3667 -0.7258 -0.0045 -0.0846 -0.5359 -0.0293 -0.0407 -0.2224 -0.2799 -0.1598
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.7961835861206055	▁Process _ re design ▁context ual _ ▁framework
D-1851	-0.7961835861206055	Process_redesign contextual_ framework
P-1851	-1.1185 -0.6708 -0.1162 -0.9535 -0.6079 -0.0907 -0.6858 -3.2366 -0.3220 -0.1599
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue_doppler left_ventricular_filling_pressure patients stable severe_systolic_heart_failure
H-479	-0.681830644607544	▁tissu e ▁do pp ler _ ▁imagin g ▁left _ ▁vent ri cular _ ▁fill ing _ ▁pressure ▁sy sto lic _ heart ▁failure
D-479	-0.681830644607544	tissue doppler_ imaging left_ ventricular_ filling_ pressure systolic_heart failure
P-479	-0.1606 -0.0501 -0.4331 -0.0149 -2.0471 -0.6419 -0.6634 -0.1836 -0.1466 -0.7678 -2.1792 -1.7364 -0.6290 -0.7209 -1.2739 -0.1242 -0.7777 -1.5829 -0.1899 -0.0582 -0.2593 -0.0780 -1.6382 -0.7881 -0.4089 -0.1737
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart_failure hypertensive_heart_disease angiotensin_ii infusion nephrectomy salt_loading
H-273	-0.4103426933288574	▁heart ▁failure _ mi ce ▁hyper tensi ve _ heart _ ▁disease ▁ang io ten sin _ ▁II ▁in fusion ▁nep hr ecto my ▁salt ▁load ing
D-273	-0.4103426933288574	heart failure_mice hypertensive_heart_ disease angiotensin_ II infusion nephrectomy salt loading
P-273	-0.9427 -0.4421 -1.0758 -0.2514 -0.0175 -0.1386 -0.0906 -0.0652 -0.0433 -3.2010 -1.1108 -0.5149 -0.1274 -0.2676 -0.0771 -0.5336 -0.2621 -0.6880 -0.2582 -0.0027 -0.0041 -0.2329 -0.0509 -0.4245 -0.0036 -0.5529 -0.0238 -0.3714 -0.1251
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas_city_cardiomyopathy_questionnaire patients heart_failure reduced_ejection_fraction
H-779	-0.5833200812339783	▁Kansas ▁City _ card i om yo pathy _ ▁Question naire ▁heart ▁failure ▁e je ction _ fraction
D-779	-0.5833200812339783	Kansas City_cardiomyopathy_ Questionnaire heart failure ejection_fraction
P-779	-0.2268 -1.9030 -0.7000 -1.5146 -0.0577 -0.0554 -1.2936 -0.0947 -2.2710 -0.0315 -0.0028 -0.9397 -0.6672 -0.8108 -0.0600 -0.0522 -0.5288 -0.0218 -0.2463 -0.1885
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians patient anemic patients heart_disease
H-34	-1.0654979944229126	▁guide line ▁a ne mic ▁ir on - d eficient _ adult _ ▁patients ▁heart ▁disease
D-34	-1.0654979944229126	guideline anemic iron-deficient_adult_ patients heart disease
P-34	-4.7104 -0.2387 -1.7603 -0.3321 -0.1355 -1.2871 -0.0858 -0.1095 -0.1382 -0.3453 -1.3847 -0.8903 -1.9058 -1.0575 -3.2281 -1.0524 -0.3598 -0.1575
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence prevalence heart_failure leading death hospitalisation
H-1664	-0.8811447620391846	▁heart ▁failure
D-1664	-0.8811447620391846	heart failure
P-1664	-0.5837 -1.0327 -1.6857 -0.2225
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab chf nontrastuzumab_users
H-678	-0.5100996494293213	▁tras tuz um ab ▁CHF ▁non tras tuz um ab
D-678	-0.5100996494293213	trastuzumab CHF nontrastuzumab
P-678	-0.5414 -0.0582 -0.0428 -0.5781 -0.4356 -0.2223 -0.9509 -0.0779 -0.1312 -0.9533 -2.0229 -0.1066
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration patients hr_reduction beta-blocker therapy
H-1947	-0.9391400814056396	▁aggressiv e _ ▁dose _ up tit ration ▁HR ▁re duction ▁beta - block er
D-1947	-0.9391400814056396	aggressive_ dose_uptitration HR reduction beta-blocker
P-1947	-3.1466 -0.0173 -1.0002 -0.0855 -1.6403 -0.5616 -0.3164 -0.2886 -1.7300 -3.1008 -0.0417 -0.0602 -0.0657 -0.0659 -0.0547 -3.6376 -0.1523
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary_occlusion collateral_growth stent
H-510	-0.36549824476242065	▁corona ry _ ▁oc clusi on ▁col lateral _ ▁growth ▁sten t ▁oc clusi on
D-510	-0.36549824476242065	coronary_ occlusion collateral_ growth stent occlusion
P-510	-0.2150 -1.7168 -0.5144 -0.0856 -0.0263 -0.2568 -0.0334 -0.0013 -0.4751 -0.5210 -0.3426 -0.1412 -0.9545 -0.0328 -0.4293 -0.3419 -0.1255
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis patients disease atherosclerosis cardiovascular_events psoriasis
H-1565	-1.8063162565231323	▁p sori asis ▁psoriasis
D-1565	-1.8063162565231323	psoriasis psoriasis
P-1565	-4.9791 -0.1100 -0.1036 -4.3660 -1.0486 -0.2307
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid_intima-media_thickness psoriasis
H-1561	-0.5295304656028748	▁caro tid ▁intim a - media _ ▁thi ck ness ▁psoriasis
D-1561	-0.5295304656028748	carotid intima-media_ thickness psoriasis
P-1561	-1.1511 -0.2248 -0.4642 -0.0451 -0.1206 -0.2078 -0.3593 -1.8866 -0.0308 -2.1222 -0.0068 -0.1500 -0.1147
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 hearts acute β-ar
H-1218	-0.7489694952964783	▁p de 2 ▁fail ing _ heart s ▁β - AR _ stimul ation
D-1218	-0.7489694952964783	pde2 failing_hearts β-AR_stimulation
P-1218	-0.7745 -0.3415 -0.0962 -1.1115 -0.0940 -0.3219 -1.8706 -0.0840 -4.3881 -0.0197 -0.4957 -1.4012 -0.0927 -0.1860 -0.4312 -0.2748
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients narrow_qrs_complex crt patients
H-846	-0.5659687519073486	▁Mechanic al _ ▁dys syn chron y ▁n arrow _ ▁QR s _ ▁complex ▁c RT
D-846	-0.5659687519073486	Mechanical_ dyssynchrony narrow_ QRs_ complex cRT
P-846	-0.1693 -0.0258 -0.2302 -1.1788 -0.0076 -0.0020 -0.4182 -2.6626 -0.0014 -0.3085 -0.2034 -1.0242 -0.7238 -0.0461 -0.4297 -2.1151 -0.4627 -0.1780
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote_monitoring rm heart_failure
H-148	-0.8002453446388245	▁remote _ monitor ing RM ▁heart ▁failure
D-148	-0.8002453446388245	remote_monitoringRM heart failure
P-148	-0.9038 -0.2036 -0.0830 -0.0303 -0.3040 -4.2690 -0.2266 -1.0784 -0.1035
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart_failure hf death crt-d
H-105	-0.8856184482574463	▁i ▁heart ▁failure HF ▁death ▁c RT - d
D-105	-0.8856184482574463	i heart failureHF death cRT-d
P-105	-0.5982 -3.3184 -0.3131 -0.6134 -1.9686 -0.7640 -0.5929 -0.0174 -1.1005 -0.3109 -0.1446
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv_dysfunction cardiac_cachexia
H-1168	-0.6327981948852539	▁ rv ▁dys function ▁cardiac _ ▁cache xia
D-1168	-0.6327981948852539	rv dysfunction cardiac_ cachexia
P-1168	-1.8605 -0.9199 -0.6499 -0.0780 -0.0186 -0.2311 -0.7161 -0.2631 -1.3925 -0.1984
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr diuretics hypertension patients esrd
H-397	-0.45882052183151245	▁e g FR ▁di ure tics ▁un control led _ ▁hyper tension ▁ES RD
D-397	-0.45882052183151245	egFR diuretics uncontrolled_ hypertension ESRD
P-397	-0.1416 -1.9381 -0.1991 -0.1682 -0.1627 -0.2510 -0.0099 -0.0032 -1.0241 -0.1364 -1.0446 -0.0303 -1.4254 -0.4848 -0.1957 -0.1260
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence chronic_heart_failure hungary
H-646	-0.8740746974945068	▁chronic _ heart _ ▁failure ▁Hungary
D-646	-0.8740746974945068	chronic_heart_ failure Hungary
P-646	-1.3952 -0.1367 -2.1470 -1.5450 -0.2400 -0.8155 -0.5309 -0.1823
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic clinical pharmacologic
H-1470	-0.59896320104599	▁ pharma c ologic _ ▁treatment ▁ pharma c ologic
D-1470	-0.59896320104599	pharmacologic_ treatment pharmacologic
P-1470	-0.1373 -1.1251 -0.0864 -0.0772 -1.2174 -2.1549 -0.4211 -0.2790 -0.0767 -0.0910 -1.3812 -0.1403
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care outpatient acute_heart_failure
H-1026	-0.7329562306404114	▁Point - of - care _ systemen ▁ NP ▁ED ▁community _ out patient _ setting s ▁a cute _ heart ▁failure
D-1026	-0.7329562306404114	Point-of-care_systemen NP ED community_outpatient_settings acute_heart failure
P-1026	-0.6824 -0.0704 -0.0057 -0.0491 -0.0829 -2.7657 -0.7130 -0.7438 -0.0355 -3.1230 -1.7232 -0.3202 -0.1784 -0.0211 -2.7778 -1.0838 -0.0252 -0.2628 -0.0449 -0.0222 -1.3826 -0.9893 -0.3164 -0.1718
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal_dysfunction all-cause_mortality cardiovascular_events postoperative cabg
H-978	-0.5234885215759277	▁Ren al _ ▁dys function ▁cardiovascular _ ▁events ▁ca BG
D-978	-0.5234885215759277	Renal_ dysfunction cardiovascular_ events caBG
P-978	-0.6214 -0.1330 -0.3522 -0.2906 -0.0622 -0.7164 -0.9629 -0.6391 -0.9455 -1.2342 -0.1730 -0.1514
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea total_arterial_compliance tac end-systolic_elastance ees baseline
H-520	-0.41173866391181946	▁Ea ▁total _ ▁arterial _ ▁compliance TAC ▁end - sy sto lic _ ▁elastan ce ▁e es
D-520	-0.41173866391181946	Ea total_ arterial_ complianceTAC end-systolic_ elastance ees
P-520	-2.3755 -1.2644 -0.4994 -0.0179 -0.4548 -0.2170 -0.2381 -1.0740 -0.0495 -0.0337 -0.0240 -0.0353 -0.1273 -0.0434 -0.4121 -0.1968 -0.0127 -0.6520 -0.0950
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal_dysfunction mortality myocardial_infarction coronary_artery_bypass_grafting cabg
H-969	-0.5999647974967957	▁Ren al _ ▁dys function ▁long - term _ ▁mortal ity ▁my o card ial _ in far ction ▁corona ry _ ▁arter y _ by pass ▁graf ting ▁ca BG
D-969	-0.5999647974967957	Renal_ dysfunction long-term_ mortality myocardial_infarction coronary_ artery_bypass grafting caBG
P-969	-0.7010 -0.1450 -0.9810 -0.1896 -0.0351 -3.2385 -0.0719 -0.0480 -0.2599 -0.4239 -1.4657 -0.4838 -0.3585 -0.4022 -0.5788 -0.2354 -0.2303 -0.1118 -0.0544 -0.0594 -1.2177 -0.2827 -0.1163 -0.9200 -0.5093 -2.1798 -0.0803 -0.7676 -0.6853 -1.3052 -1.2371 -0.2622 -0.1610
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular diabetes_mellitus atrial_fibrillation coronary_artery_disease hfpef
H-1890	-0.4215836822986603	▁cardiovascular _ risk ▁factors ▁diabetes ▁mell itus ▁at rial _ fi bril lation ▁corona ry _ ▁arter y _ ▁disease ▁ HF p EF
D-1890	-0.4215836822986603	cardiovascular_risk factors diabetes mellitus atrial_fibrillation coronary_ artery_ disease HFpEF
P-1890	-0.3180 -0.7322 -1.2926 -0.6914 -0.0558 -0.0066 -0.0323 -0.3798 -0.0256 -0.3361 -0.5107 -0.0276 -0.0654 -0.0119 -1.5624 -0.1668 -0.2376 -0.5581 -1.3154 -0.7768 -0.8497 -0.1802 -0.0445 -0.2831 -0.3601 -0.1404
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical coronary_artery_disease patients systolic_heart_failure etiology
H-1181	-0.4960779845714569	▁corona ry _ ▁arter y ▁disease ▁sy sto lic _ heart ▁failure ▁un clear _ ▁et i ology
D-1181	-0.4960779845714569	coronary_ artery disease systolic_heart failure unclear_ etiology
P-1181	-0.2668 -1.4599 -0.3979 -0.2560 -0.3195 -1.1062 -0.0168 -0.0269 -0.2283 -0.0501 -1.7261 -0.8126 -0.9478 -0.2505 -0.2538 -1.1732 -0.1327 -0.1366 -0.2210 -0.1386
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic congestive_heart_failure haematopoietic_cell_transplantation
H-1448	-0.6430628299713135	▁an thra cycli ne - related _ con ges tive _ heart ▁failure ▁ha e mato po ie tic _ cell ▁transplant ation
D-1448	-0.6430628299713135	anthracycline-related_congestive_heart failure haematopoietic_cell transplantation
P-1448	-0.9657 -0.3044 -0.7225 -0.7322 -0.5324 -0.2857 -0.3541 -0.8470 -0.1738 -2.9595 -0.0647 -1.8367 -0.9936 -0.0023 -0.1089 -0.0201 -0.1950 -0.5928 -1.4760 -0.1267 -1.5416 -0.6202 -0.1077 -0.3266 -0.1862
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular_support heartmate_ii lvad centrimag rvad mortality hospital discharge
H-304	-0.8272979259490967	▁Bi ven tri cular _ support ▁Heart Mate _ ▁II _ ▁l VAD ▁Centri Mag _ r VAD
D-304	-0.8272979259490967	Biventricular_support HeartMate_ II_ lVAD CentriMag_rVAD
P-304	-2.5181 -0.0688 -0.2010 -1.1552 -0.4482 -0.7730 -2.2142 -0.0602 -0.1758 -0.8335 -0.1886 -1.7312 -0.0275 -0.1492 -1.3475 -0.1388 -2.2844 -0.3088 -1.6505 -0.2715
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus mortality hazard_ratio confidence_interval
H-129	-0.9483813643455505	▁ EO - c FU s ▁reduc d _ ▁mortal ity haz ard _ ▁ratio
D-129	-0.9483813643455505	EO-cFUs reducd_ mortalityhazard_ ratio
P-129	-2.8666 -0.1622 -0.0592 -0.7910 -1.9608 -0.6674 -3.7592 -1.1573 -0.1945 -0.7290 -1.2404 -0.0278 -0.0141 -0.4995 -0.0603 -1.7653 -0.1677
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart_failure preserved_ejection_fraction myocardial_infarction
H-1098	-0.5763287544250488	▁heart ▁failure ▁e je ction _ fraction ▁my o card ial _ in far ction
D-1098	-0.5763287544250488	heart failure ejection_fraction myocardial_infarction
P-1098	-1.8519 -1.1002 -0.6211 -0.0612 -0.0336 -0.5849 -0.0521 -1.7715 -0.5077 -1.0062 -1.0434 -0.1282 -0.2185 -0.1286 -0.0785 -0.4338 -0.1763
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline isoprenaline infusion sdqt hf patients
H-1443	-0.4635521471500397	▁iso pren a line _ in fusion ▁SD QT ▁h Nor m ▁ HF
D-1443	-0.4635521471500397	isoprenaline_infusion SDQT hNorm HF
P-1443	-0.0109 -0.2037 -0.1305 -0.0836 -0.2988 -0.5048 -0.0091 -0.2175 -1.0552 -0.4852 -3.0132 -0.0520 -0.4034 -0.2041 -0.6007 -0.1440
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis post-myocardial_infarction heart heart_failure
H-449	-0.9841614365577698	▁ang io gene sis ▁post - my o card ial _ in far ction _ heart ▁heart ▁failure
D-449	-0.9841614365577698	angiogenesis post-myocardial_infarction_heart heart failure
P-449	-4.8432 -2.0015 -0.4275 -0.8272 -0.0435 -0.0439 -2.2555 -0.8982 -1.2373 -1.2339 -0.1934 -0.3483 -0.1868 -0.1816 -0.3353 -1.9035 -1.6818 -0.5785 -0.3263 -0.1361
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical clinical outcomes aldosterone_antagonist heart_failure
H-1734	-0.4263199269771576	▁al do ster one _ ▁anta gon ist ▁heart ▁failure
D-1734	-0.4263199269771576	aldosterone_ antagonist heart failure
P-1734	-0.7175 -0.1979 -0.0601 -0.3965 -0.6991 -0.0774 -0.0117 -0.6152 -0.7804 -1.0947 -0.3526 -0.1127
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute_heart_failure ahf symptoms heart_failure hf
H-1466	-0.8330720663070679	▁a cute _ ▁heart ▁failure ▁a HF ▁heart ▁failure HF
D-1466	-0.8330720663070679	acute_ heart failure aHF heart failureHF
P-1466	-0.5104 -0.0159 -0.0212 -1.9867 -0.7152 -1.2121 -0.6156 -2.3210 -0.7135 -1.4964 -0.2529 -0.1360
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery medical_treatment hf hypertension vasodilators diuretics
H-355	-0.4343143701553345	▁surgery ▁ HF ▁hyper tension ▁vaso dila tors ▁di ure tics
D-355	-0.4343143701553345	surgery HF hypertension vasodilators diuretics
P-355	-1.0534 -2.2489 -0.1076 -0.5405 -0.0787 -0.0275 -0.0028 -0.1048 -0.1755 -0.3432 -0.3282 -0.5423 -0.0926
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf remodeling emd dyssynchronous_failing_heart
H-1150	-0.7153377532958984	▁ HF ▁remodel ing ▁EM d ▁dys syn chron ous _ ▁fail ing _ heart
D-1150	-0.7153377532958984	HF remodeling EMd dyssynchronous_ failing_heart
P-1150	-0.2127 -0.2965 -4.4388 -0.0165 -0.9822 -0.5850 -0.0398 -0.0143 -0.0116 -1.9210 -0.2314 -0.3726 -0.0594 -0.1282 -2.4227 -0.2785 -0.1497
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt implants transseptal_catheterisation transoesophageal_echocardiographic general_anaesthesia
H-1953	-0.4585065245628357	▁Shu nt _ ▁implant s ▁trans sept al _ ▁cat heter isation ▁trans o es op hage al _ e cho car dio graphic
D-1953	-0.4585065245628357	Shunt_ implants transseptal_ catheterisation transoesophageal_echocardiographic
P-1953	-0.2600 -0.0514 -1.0903 -1.3374 -0.0715 -0.0139 -0.0911 -0.6021 -0.3237 -0.6849 -0.0210 -0.0915 -0.0050 -1.3322 -0.1277 -0.0674 -0.3636 -0.2174 -0.3692 -0.2695 -0.1077 -0.0384 -0.5732 -0.9671 -2.6877 -0.1564
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine nesiritide placebo
H-78	-0.3703514337539673	▁dop amine ▁nesi riti de ▁poole d _ ▁place bo _ groep
D-78	-0.3703514337539673	dopamine nesiritide pooled_ placebo_groep
P-78	-0.0113 -0.0328 -0.0853 -0.0068 -0.0664 -2.0130 -0.0368 -0.1002 -1.0259 -0.0096 -0.6360 -0.4473 -0.6031 -0.1104
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients hfpef prospective
H-736	-1.1496433019638062	▁h FP EF
D-736	-1.1496433019638062	hFPEF
P-736	-1.9330 -1.9977 -1.2463 -0.4415 -0.1298
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline embase cochrane clinical
H-41	-0.44717755913734436	▁MED line ▁ EMBA se ▁co ch rane _ ▁database s ▁clinic al _ ▁trial ▁registri es
D-41	-0.44717755913734436	MEDline EMBAse cochrane_ databases clinical_ trial registries
P-41	-1.2220 -0.5621 -0.6822 -0.0102 -0.3596 -0.1136 -0.1038 -0.0239 -1.0384 -0.5365 -0.0824 -0.4910 -0.0414 -0.1047 -0.8429 -0.8511 -0.0083 -1.2351 -0.1872
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr vad ecmo vad ecmo
H-1393	-1.0601215362548828	▁e g FR ▁ VAD _ groep ▁ec mo + VAD _ groep ▁ec mo _ groep
D-1393	-1.0601215362548828	egFR VAD_groep ecmo+VAD_groep ecmo_groep
P-1393	-0.0681 -1.2541 -1.2319 -0.3578 -0.1140 -1.5287 -0.7447 -1.3084 -1.4692 -4.6273 -0.2799 -1.1447 -0.5224 -1.7360 -1.2753 -1.2993 -0.8147 -0.2491 -0.1169
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf hospitalization cardiovascular_mortality
H-1639	-0.7251016497612	▁black _ race ▁ HF ▁cardiovascular _ ▁mortal ity
D-1639	-0.7251016497612	black_race HF cardiovascular_ mortality
P-1639	-0.0447 -0.1838 -1.0066 -0.5508 -0.0600 -3.1413 -0.9783 -0.0738 -1.3831 -0.3306 -0.2231
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical nonprescribing patients
H-1128	-0.5104601979255676	▁bio medic al _ ▁reasons ▁non pre scribi ng
D-1128	-0.5104601979255676	biomedical_ reasons nonprescribing
P-1128	-0.0104 -0.0477 -0.0145 -1.9606 -0.2426 -1.8926 -0.1867 -0.0781 -0.1718 -0.8720 -0.1380
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician nonprescribing patient
H-1127	-0.9682440161705017	▁non pre scribi ng ▁chart _ review
D-1127	-0.9682440161705017	nonprescribing chart_review
P-1127	-4.4155 -0.2357 -0.0472 -0.0351 -1.2377 -1.1505 -0.8489 -0.5649 -0.1787
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients severe_hf prognostic hf
H-1764	-1.0606725215911865	▁ HF ▁ HF
D-1764	-1.0606725215911865	HF HF
P-1764	-1.3120 -0.6999 -2.7973 -0.3086 -0.9925 -0.2537
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth health outcomes medicare
H-1628	-1.0628893375396729	▁Care ▁management ▁content - driv en _ tech n ology ▁health _ ▁outcome s ▁Medica re
D-1628	-1.0628893375396729	Care management content-driven_technology health_ outcomes Medicare
P-1628	-3.3682 -0.4117 -1.0018 -0.0373 -0.0320 -0.0452 -0.2449 -3.8308 -0.5602 -0.4017 -3.4412 -2.9063 -1.5428 -0.0355 -0.5241 -0.0093 -0.5953 -0.1438
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective lvas
H-1995	-0.9026298522949219	▁l VAS
D-1995	-0.9026298522949219	lVAS
P-1995	-2.6312 -0.6324 -0.1831 -0.1637
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant erc epicatechin muscle
H-1256	-0.6829389929771423	▁ ERC ▁pure _ epi cate chin
D-1256	-0.6829389929771423	ERC pure_epicatechin
P-1256	-0.5579 -0.0460 -0.0367 -0.1191 -1.1637 -0.0129 -0.6251 -3.4229 -0.1622
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ea tac ees patients
H-522	-0.4639366567134857	▁Ea ▁ TAC ▁HR ▁e es ▁i va bra dine
D-522	-0.4639366567134857	Ea TAC HR ees ivabradine
P-522	-0.4790 -0.5501 -0.0594 -0.8996 -0.5201 -0.0252 -0.0759 -0.0314 -0.0379 -0.0980 -2.6382 -0.1522
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician hf cpgs
H-1853	-0.6103004813194275	▁physician ▁ad her ence ▁ HF _ c PG s
D-1853	-0.6103004813194275	physician adherence HF_cPGs
P-1853	-1.3810 -0.3766 -0.3232 -0.6756 -0.7656 -0.0935 -0.7735 -1.8266 -0.4037 -0.0762 -0.3935 -0.2347
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf hf mortality
H-1774	-0.7457559704780579	▁ HF _ risk ▁factors ▁fit _ ▁men ▁ HF _ ▁mortal ity ▁un fit _ ▁men
D-1774	-0.7457559704780579	HF_risk factors fit_ men HF_ mortality unfit_ men
P-1774	-0.9308 -0.2873 -2.6011 -0.8290 -1.3017 -0.0976 -0.7950 -0.9258 -0.2246 -0.2350 -1.2108 -0.4414 -1.4457 -0.0967 -0.0552 -0.3680 -1.6837 -0.4752 -0.1647
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl chf vascular
H-260	-1.0044269561767578	▁HD l _ ▁function ▁CHF ▁ET ▁HD l - media ted _ vas cular _ effect
D-260	-1.0044269561767578	HDl_ function CHF ET HDl-mediated_vascular_effect
P-260	-1.7032 -2.1307 -1.4266 -0.8522 -0.0378 -1.7456 -2.1913 -2.7519 -0.0426 -0.1179 -0.0756 -0.0607 -0.9574 -0.2605 -2.0394 -0.3046 -1.2813 -0.1004
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine vascular_endothelial_growth_factor protein left_ventricle myocardial_angiogenesis
H-1142	-0.580323338508606	▁Pyr ido stig mine ▁vas cular _ en dot heli al _ ▁growth _ factor _ ▁protein ▁left _ ▁vent ric le ▁my o card ial _ ang io gene sis
D-1142	-0.580323338508606	Pyridostigmine vascular_endothelial_ growth_factor_ protein left_ ventricle myocardial_angiogenesis
P-1142	-0.0263 -0.0078 -0.0015 -0.0520 -0.1678 -0.2301 -0.6447 -0.7317 -1.3232 -0.1152 -0.0271 -0.1771 -0.5362 -1.0646 -0.3562 -1.1429 -0.3209 -0.1507 -0.3736 -1.1836 -1.5470 -0.3937 -0.9246 -0.2552 -0.6673 -0.4301 -0.2070 -3.2510 -1.8156 -0.2203 -0.2473 -0.3800 -0.1785
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis idiopathic_dilated_cardiomyopathy
H-1742	-0.4954051673412323	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy
D-1742	-0.4954051673412323	idiopathic_ dilated_ cardiomyopathy
P-1742	-0.8126 -0.1006 -0.0871 -0.2319 -0.4987 -0.4981 -0.3087 -0.0530 -0.2393 -2.0508 -0.7483 -0.0273 -1.0966 -0.1828
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics chromatin-associated_proteins disease
H-93	-0.46024250984191895	▁quantitat ive _ prote o mics ▁chr omat in - as soci ated _ ▁protein s ▁detergent ▁disease
D-93	-0.46024250984191895	quantitative_proteomics chromatin-associated_ proteins detergent disease
P-93	-0.0830 -0.0696 -0.2226 -1.1993 -1.4864 -0.0071 -0.2849 -0.0825 -0.7365 -0.0640 -0.0222 -0.0008 -0.3394 -0.1550 -1.2174 -0.0575 -0.6049 -2.2278 -0.2303 -0.1136
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf_antagonists hf hospital admissions nbdmards ra
H-611	-0.47539225220680237	▁t NF ▁anta gon ists ▁ HF ▁hospital ▁ad missions ▁n b DM ARD s ▁RA
D-611	-0.47539225220680237	tNF antagonists HF hospital admissions nbDMARDs RA
P-611	-0.6281 -0.1336 -1.3726 -0.0161 -0.2858 -0.3604 -0.2465 -3.3916 -0.4474 -0.1588 -0.0472 -0.0200 -0.2023 -0.2839 -0.0942 -0.1891 -0.5228 -0.1566
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic acute_hf adverse_event chronic_hf
H-1016	-0.3900097906589508	▁ pharma c ologic _ management ▁a cute _ HF ▁chronic _ HF
D-1016	-0.3900097906589508	pharmacologic_management acute_HF chronic_HF
P-1016	-0.2401 -0.3472 -0.0361 -0.0526 -0.5002 -0.5741 -0.3244 -0.0157 -0.0335 -0.4711 -1.9679 -0.2414 -0.5528 -0.3842 -0.1088
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients heartmate_ii biventricular_support heartmate_ii implantation
H-300	-0.8086293339729309	▁Heart Mate _ ▁II _ insertion ▁bi ven tri cular _ support ▁Heart Mate _ ▁II _ ▁implant ation
D-300	-0.8086293339729309	HeartMate_ II_insertion biventricular_support HeartMate_ II_ implantation
P-300	-1.6980 -0.1528 -0.5245 -1.0719 -2.2242 -0.0089 -2.3317 -0.0825 -0.3871 -0.5953 -1.4702 -0.7368 -0.8621 -0.2635 -0.4544 -0.9181 -1.4705 -0.9892 -0.1112 -0.3930 -0.2353
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv_dysfunction body_mass_index fat_mass cachexia
H-1163	-0.5631728172302246	▁ RV _ ▁dys function ▁lower _ ▁body _ ▁mass ▁index ▁lower _ ▁fat _ ▁mass ▁index ▁cache xia
D-1163	-0.5631728172302246	RV_ dysfunction lower_ body_ mass index lower_ fat_ mass index cachexia
P-1163	-0.6838 -0.6483 -0.7998 -0.1513 -0.0812 -1.5249 -0.0951 -1.6821 -0.4673 -1.3384 -0.1718 -0.9465 -0.0380 -1.6620 -0.3274 -0.3460 -0.2090 -0.0929 -0.1131 -0.2399 -0.2079
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy atrial_fibrillation patients carvedilol metoprolol
H-867	-0.5389164090156555	▁at rial _ fi bril lation ▁car vedi lol ▁met o pro lol
D-867	-0.5389164090156555	atrial_fibrillation carvedilol metoprolol
P-867	-4.5348 -0.2476 -0.5353 -0.3612 -0.0771 -0.1208 -0.1829 -0.0111 -0.0399 -0.4335 -0.6462 -0.0186 -0.0828 -0.6584 -0.1334
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline crf hf mortality hf
H-1775	-0.8629269599914551	▁base line _ c RF ▁ HF _ ▁mortal ity _ ▁risk ▁ HF _ risk ▁factors
D-1775	-0.8629269599914551	baseline_cRF HF_ mortality_ risk HF_risk factors
P-1775	-3.0302 -0.0331 -0.4395 -0.6187 -1.2018 -0.1444 -0.3693 -1.3857 -0.0999 -0.7290 -1.5583 -1.6154 -0.4892 -0.4255 -1.6049 -0.8373 -1.3534 -0.3210 -0.1388
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients chf international_classification_of_diseases
H-213	-0.5280898809432983	▁CHF ▁Classifica tion _ of _ ▁Disease s ▁Nin th _ re vision ▁code s
D-213	-0.5280898809432983	CHF Classification_of_ Diseases Ninth_revision codes
P-213	-4.9725 -1.7015 -0.0574 -0.2706 -0.5949 -0.3332 -0.0284 -0.0141 -0.0363 -0.0275 -0.1081 -0.1256 -0.0738 -0.0582 -0.0463 -0.3163 -0.2129
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise health cardiac_disease heart_failure
H-1904	-1.8733150959014893	▁cardiovascular _ ▁disease ▁heart _ ▁failure
D-1904	-1.8733150959014893	cardiovascular_ disease heart_ failure
P-1904	-8.1591 -1.1713 -1.4068 -1.0403 -2.4040 -0.1297 -0.5036 -0.1716
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 hno cxl-1051 t1
H-416	-0.5622746348381042	▁c XL -10 20 ▁h no ▁in active ▁c XL -10 51
D-416	-0.5622746348381042	cXL-1020 hno inactive cXL-1051
P-416	-1.0310 -0.8915 -0.2592 -0.0932 -1.3710 -0.4796 -0.0539 -0.4192 -1.4535 -0.6297 -0.4751 -0.1873 -0.3574 -0.1703
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium expression pka downstream_signaling
H-1433	-0.6094322204589844	▁my o car dium _ ▁display s ▁p ka ▁down stream _ signal ing
D-1433	-0.6094322204589844	myocardium_ displays pka downstream_signaling
P-1433	-0.8425 -0.1117 -0.0120 -0.0648 -2.2469 -0.2727 -0.0850 -2.1594 -0.8549 -1.5427 -0.0891 -0.3025 -0.4221 -0.1429 -0.4316 -0.1700
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests cardiac_growth disease chromatin remodeling
H-92	-0.43610554933547974	▁cardiac _ ▁growth ▁plastic ity ▁disease ▁recap it ulat es ▁chr omat in ▁remodel ing
D-92	-0.43610554933547974	cardiac_ growth plasticity disease recapitulates chromatin remodeling
P-92	-0.2228 -0.5169 -0.5293 -0.6373 -1.9609 -0.2029 -0.0189 -0.0134 -0.0050 -0.1248 -0.0954 -0.0579 -0.8055 -0.5818 -0.0266 -1.5141 -0.1002
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 n2bus s12884 pevk
H-769	-0.6904624700546265	▁elastic _ n 2 bu s _ ▁segment ▁PE v k
D-769	-0.6904624700546265	elastic_n2bus_ segment PEvk
P-769	-0.6143 -0.2388 -1.7988 -0.1313 -0.5789 -0.6366 -1.2562 -0.2572 -0.2911 -0.8557 -1.0899 -1.0850 -0.1421
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait therapy lokomat heart_failure patients
H-1921	-0.4708225727081299	▁Robot - assist ed _ ga it _ therapy ▁Lok omat _ system ▁heart ▁failure
D-1921	-0.4708225727081299	Robot-assisted_gait_therapy Lokomat_system heart failure
P-1921	-0.5918 -0.1565 -0.0243 -0.1750 -0.3161 -0.6814 -0.0949 -0.7732 -0.0266 -0.2828 -0.1937 -1.1894 -1.4520 -0.3845 -0.4168 -1.1040 -0.1409
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil mitochondrial_dysfunction heart_failure cardioprotection
H-954	-0.3311501443386078	▁Nico rand il ▁mito cho ndri al _ ▁dys function ▁do xor ubi cin - indu ced _ heart _ ▁failure ▁rat s ▁cardio protec tion
D-954	-0.3311501443386078	Nicorandil mitochondrial_ dysfunction doxorubicin-induced_heart_ failure rats cardioprotection
P-954	-0.0022 -0.0332 -0.0722 -0.0527 -0.4547 -0.3146 -0.0615 -0.6873 -0.0569 -0.0219 -0.0443 -0.0049 -0.0057 -0.9806 -0.0851 -0.0104 -0.5787 -0.0895 -1.4416 -1.1713 -0.0583 -0.5518 -0.0260 -0.7337 -0.8840 -0.2710 -0.4350 -0.1431
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ras asymptomatic clinically hypertension nephropathy congestive_heart_failure
H-1597	-0.5377381443977356	▁ RAS ▁hyper tension ▁nep hro pathy ▁con ges tive _ heart ▁failure
D-1597	-0.5377381443977356	RAS hypertension nephropathy congestive_heart failure
P-1597	-2.4636 -0.0302 -0.4598 -0.0555 -0.0195 -0.0082 -0.0179 -0.0228 -0.1332 -2.0791 -0.0749 -1.6634 -0.5046 -0.3866 -0.1470
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic admission brain_natriuretic_peptide bnp creatinine natremia
H-585	-0.5417699217796326	▁brain ▁na tri ure tic _ pe pti de ▁b NP ▁creati nine ▁na trem ia
D-585	-0.5417699217796326	brain natriuretic_peptide bNP creatinine natremia
P-585	-3.3562 -0.0955 -0.0258 -0.0805 -1.7550 -0.1586 -0.4466 -0.1760 -0.9311 -0.4105 -0.3802 -0.0115 -0.2189 -0.0787 -0.0987 -1.0646 -0.3052 -0.1582
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart_failure cardiology-cardiovascular_surgery_consensus_report heart_failure disease
H-1818	-0.5877670645713806	▁advanced _ heart _ ▁failure ▁mechanic al _ support ▁devices ▁Card i ology - car dio vas cular _ Sur ger y ▁Cons en sus _ report ▁Heart ▁failure ▁progressive _ ▁disease
D-1818	-0.5877670645713806	advanced_heart_ failure mechanical_support devices Cardiology-cardiovascular_Surgery Consensus_report Heart failure progressive_ disease
P-1818	-3.1425 -0.2840 -1.1080 -0.9358 -0.0434 -0.1777 -0.0148 -0.1261 -0.3343 -0.3718 -1.1619 -0.0788 -0.2010 -0.2388 -0.3793 -0.8354 -0.3800 -0.3849 -0.0782 -2.9303 -0.9632 -0.2148 -0.3735 -0.0162 -0.0788 -0.1434 -0.6345 -1.1487 -0.6638 -1.1102 -0.1867 -0.9016 -0.1960 -0.1457
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart_rate_reduction exercise heart_failure_with_reduced_ejection_fraction beta-blocker
H-1935	-0.45894962549209595	▁Heart _ re duction ▁exercise ▁performance ▁heart ▁failure ▁e je ction _ fraction ▁beta - block er ▁hypo - respons e
D-1935	-0.45894962549209595	Heart_reduction exercise performance heart failure ejection_fraction beta-blocker hypo-response
P-1935	-0.7354 -1.2310 -1.1361 -0.1134 -0.7033 -0.9583 -1.3866 -1.0572 -0.7549 -0.0372 -0.0165 -0.5179 -0.0077 -0.5537 -0.0209 -0.0571 -0.0210 -0.8220 -0.0265 -0.0057 -0.0227 -0.2436 -0.1273
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt sd_of_rr_intervals sdrr qtv heart_rate_variability
H-1440	-1.1230583190917969	▁SD QT ▁SD ▁ RR _ ▁interval s SD RR ▁index ▁Q TV ▁heart ▁rate ▁variabil ity
D-1440	-1.1230583190917969	SDQT SD RR_ intervalsSDRR index QTV heart rate variability
P-1440	-0.8736 -0.3460 -1.3025 -2.6841 -1.0372 -1.3239 -0.0159 -0.0132 -2.9222 -2.8661 -0.0663 -1.7631 -1.5390 -0.3361 -1.2434 -1.3601 -1.1212 -0.3487 -0.1753
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care_of_heart_failure_index_version_6.2 schfi_v.6.2 psychometric
H-1504	-0.47652196884155273	▁Self - car e _ of _ heart _ ▁Fail ure _ index ▁ SCH fi ▁psycho metric _ ▁profile
D-1504	-0.47652196884155273	Self-care_of_heart_ Failure_index SCHfi psychometric_ profile
P-1504	-0.1206 -0.0572 -1.1890 -0.5331 -0.2115 -0.3174 -0.0965 -0.9971 -0.3893 -0.3043 -0.5833 -0.2682 -0.2360 -2.0181 -0.6503 -1.0557 -0.1314 -0.0164 -0.8064 -0.1835 -0.2266 -0.0916
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric_focusing riα ser77 ser83 in_vivo phosphorylation
H-1430	-0.46465981006622314	▁iso electric _ ▁focus ing ▁RI α ▁ser 77 ▁ser 83 ▁vivo _ phos phor y lation
D-1430	-0.46465981006622314	isoelectric_ focusing RIα ser77 ser83 vivo_phosphorylation
P-1430	-0.4990 -0.7808 -0.3572 -0.2467 -0.0250 -0.5791 -0.2692 -0.5269 -0.2145 -0.3338 -1.4524 -0.0633 -0.3209 -0.0796 -0.3911 -1.0965 -0.1184 -1.3811 -0.0929
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient functional_ms patient valve_plasty degenerative_mr dilated disease
H-367	-0.34735777974128723	▁functional ▁MS ▁val ve _ plast y ▁de genera tive _ ▁MR ▁LV ▁disease
D-367	-0.34735777974128723	functional MS valve_plasty degenerative_ MR LV disease
P-367	-0.0380 -0.6566 -0.4612 -0.0132 -0.9293 -0.9176 -0.3680 -0.0751 -0.0018 -0.2729 -0.2009 -0.5504 -0.0435 -0.7128 -0.2290 -0.0875
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end_stage_heart_failure heart_failure public health patient europe north_america
H-1663	-1.1512118577957153	▁management _ of _ ▁end _ ▁stage _ heart _ ▁failure _ ▁Heart _ ▁failure ▁public _ ▁health
D-1663	-1.1512118577957153	management_of_ end_ stage_heart_ failure_ Heart_ failure public_ health
P-1663	-1.5023 -0.9444 -3.2195 -0.1634 -1.9683 -0.4311 -0.6638 -0.0204 -1.9333 -1.5397 -0.0445 -2.2499 -0.5588 -1.4763 -0.0555 -0.9502 -0.2257 -1.4539 -3.4401 -0.1831
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient st-segment-elevation_mis killip_class comorbid conditions
H-1105	-0.7964553236961365	▁MI s ▁Kill ip ▁class
D-1105	-0.7964553236961365	MIs Killip class
P-1105	-3.8354 -0.0441 -0.1914 -0.0733 -1.1318 -0.1525 -0.1467
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology myocardial_infarction mi outcomes heart_failure hf
H-1099	-0.6724704504013062	▁my o card ial _ in far ction ▁m ▁heart ▁failure HF
D-1099	-0.6724704504013062	myocardial_infarction m heart failureHF
P-1099	-2.9402 -0.3621 -0.7815 -0.8550 -0.1570 -0.3009 -0.2257 -0.1046 -1.3923 -1.0733 -0.3830 -0.3681 -0.3329 -0.1381
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial_elastance ea pulsatile_afterload heart pressure_volume_relation
H-517	-0.6365393996238708	▁arterial _ ▁elastan ce ▁e a ▁pulsa tile _ ▁after load ▁heart ▁pressure _ ▁volume _ ▁relation
D-517	-0.6365393996238708	arterial_ elastance ea pulsatile_ afterload heart pressure_ volume_ relation
P-517	-0.6218 -0.7858 -0.3455 -0.6488 -0.5241 -0.0093 -0.0654 -0.0084 -0.1870 -3.5823 -0.0202 -1.1752 -0.0616 -1.5646 -0.1008 -1.2143 -0.5956 -0.4461 -0.1374
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated baseline nt-probnp mr-proanp mr-proadm
H-17	-0.36629724502563477	▁NT - pro b NP ▁MR - pro AN p ▁MR - pro ad m
D-17	-0.36629724502563477	NT-probNP MR-proANp MR-proadm
P-17	-1.2500 -0.1251 -0.0120 -0.8644 -0.2676 -0.0783 -0.0451 -0.0108 -2.0107 -0.4633 -0.0820 -0.0614 -0.0211 -0.4769 -0.0927 -0.2374 -0.1283
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect heart_failure patients implantable_cardioverter-defibrillator
H-1860	-0.6996607780456543	▁heart ▁failure ▁implant able _ ▁cardio ver ter - de fi br illa tor
D-1860	-0.6996607780456543	heart failure implantable_ cardioverter-defibrillator
P-1860	-5.8295 -0.4273 -2.2260 -0.0527 -0.5396 -0.1522 -0.0226 -0.0990 -0.4639 -0.0436 -0.0465 -0.2023 -0.1474 -0.0589 -0.7206 -0.1626
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate left_ventricular_assist_system lvas patients heart_failure
H-1993	-0.9015393853187561	▁Heart Mate ▁left _ ▁vent ri cular _ assist _ system ▁l VAS ▁heart ▁failure
D-1993	-0.9015393853187561	HeartMate left_ ventricular_assist_system lVAS heart failure
P-1993	-0.6852 -0.3658 -1.6227 -0.2804 -1.4231 -1.4779 -0.6418 -0.1874 -0.4558 -1.3948 -0.9521 -0.0694 -0.2758 -3.3663 -1.6925 -0.2844 -0.1509
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed patients hf drug_treatment paf biosynthetic_enzymes lyso-paf-at
H-1271	-0.5818913578987122	▁ HF ▁bio syn the tic _ ▁enzym es ▁lys o - pa f - AT
D-1271	-0.5818913578987122	HF biosynthetic_ enzymes lyso-paf-AT
P-1271	-1.3585 -0.2314 -4.1099 -0.0151 -0.3749 -0.9316 -0.1289 -0.1261 -0.0319 -0.0406 -0.0797 -0.0257 -0.3760 -1.3101 -0.0531 -0.7255 -0.4199 -0.1351
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 sst2 outcomes
H-406	-0.76734459400177	▁s st 2/ low - dos e ▁BB ▁s st 2/ high - dos e _ bb
D-406	-0.76734459400177	sst2/low-dose BB sst2/high-dose_bb
P-406	-0.3935 -1.3317 -0.8933 -0.2413 -0.0299 -1.0574 -0.1136 -1.2559 -0.0493 -1.6632 -0.7177 -1.9416 -0.1326 -1.6153 -0.1547 -1.6903 -0.8377 -0.2905 -0.1700
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence hf ami mortality
H-1314	-1.2341537475585938	▁ HF ▁complicat ing ▁ AMI
D-1314	-1.2341537475585938	HF complicating AMI
P-1314	-1.1100 -0.2739 -3.2638 -0.0801 -1.8660 -0.1106 -3.0300 -0.1388
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin genomic_reprogramming disease
H-100	-0.2387903332710266	▁zebra fish ▁nu cle olin ▁genom ic _ re programm ing
D-100	-0.2387903332710266	zebrafish nucleolin genomic_reprogramming
P-100	-0.0842 -0.0506 -0.0868 -0.0016 -0.0563 -0.1738 -0.0245 -0.2480 -0.2973 -0.0679 -0.0118 -1.9100 -0.0916
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients t1_times cardiac_events
H-740	-0.6657074689865112	▁cardiac _ ▁events
D-740	-0.6657074689865112	cardiac_ events
P-740	-0.9514 -1.0384 -0.9184 -0.3118 -0.1085
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv_ejection_fraction pcwp
H-483	-0.4954753518104553	▁LV _ e je ction _ fraction ▁pc WP
D-483	-0.4954753518104553	LV_ejection_fraction pcWP
P-483	-0.4671 -1.4639 -0.5362 -0.1527 -0.1025 -0.4562 -0.0578 -0.3061 -1.0315 -0.7308 -0.1455
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf chf patients intubated
H-214	-1.0341031551361084	▁CHF _ ▁visit _ ▁rates ▁ED _ ▁visit s ▁CHF ▁patients ▁in tuba ted
D-214	-1.0341031551361084	CHF_ visit_ rates ED_ visits CHF patients intubated
P-214	-0.3625 -3.3529 -1.4199 -2.2764 -0.1015 -2.1003 -2.6947 -0.8096 -0.1089 -0.5797 -1.9995 -0.2324 -0.0248 -0.0424 -0.3413 -0.0988
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate_analysis gls
H-817	-1.4773770570755005	▁g LS HR ▁CV
D-817	-1.4773770570755005	gLSHR CV
P-817	-1.8064 -1.2620 -1.8214 -2.0891 -1.5885 -0.2968
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr vad ecmo vad renal_function
H-1391	-0.9454087615013123	▁e g FR ▁ VAD _ groep ▁ec mo + VAD _ groep ▁renal _ ▁function
D-1391	-0.9454087615013123	egFR VAD_groep ecmo+VAD_groep renal_ function
P-1391	-0.0480 -1.2248 -0.9790 -0.8659 -0.0638 -2.1099 -0.5947 -1.0635 -1.9811 -2.8906 -0.1562 -1.7650 -0.2977 -0.0733 -0.9339 -1.3849 -0.4514 -0.1336
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician mortality hf physicians
H-1731	-0.6374794244766235	▁Physic ian _ ▁volume ▁ HF ▁non car dio logist _ ▁physician s
D-1731	-0.6374794244766235	Physician_ volume HF noncardiologist_ physicians
P-1731	-2.0674 -0.7063 -0.3385 -0.0889 -3.2985 -0.2883 -0.1476 -0.0558 -0.6546 -0.2114 -1.0550 -0.1200 -0.0370 -0.3749 -0.1177
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ejection_fraction
H-1236	-0.27127233147621155	▁e je ction _ fraction
D-1236	-0.27127233147621155	ejection_fraction
P-1236	-0.5437 -0.1769 -0.1091 -0.3738 -0.0909 -0.3744 -0.2302
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality hospitals
H-1695	-0.6629800200462341	▁risk - ad just ed _ ▁mortal ity
D-1695	-0.6629800200462341	risk-adjusted_ mortality
P-1695	-2.1438 -0.0551 -0.0232 -0.0149 -0.1074 -0.3027 -0.3142 -1.3411 -2.1294 -0.1981
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized exercise exercise
H-1981	-0.7456166744232178	▁exercise ▁die t
D-1981	-0.7456166744232178	exercise diet
P-1981	-2.5667 -0.2933 -0.1172 -0.5906 -0.1602
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses magnet
H-87	-1.8055845499038696	▁magnet ( ® ▁research
D-87	-1.8055845499038696	magnet(® research
P-87	-2.7703 -2.7133 -1.6692 -2.1624 -1.3901 -0.1282
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician evidence
H-1842	-0.9721487164497375	▁physician ▁ad her ence ▁class _ ▁I ▁recommendations
D-1842	-0.9721487164497375	physician adherence class_ I recommendations
P-1842	-1.1108 -0.6928 -0.3004 -0.7909 -2.2108 -0.3931 -1.6002 -0.9787 -1.4766 -0.1672
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-868	-0.4534916877746582	▁m ADI t - c RT ▁multi center _ automat ic _ de ib rilla tor ▁Implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-868	-0.4534916877746582	mADIt-cRT multicenter_automatic_deibrillator Implantation Cardiac_resynchronization Therapy
P-868	-0.5865 -0.0253 -0.1689 -0.0081 -0.3525 -2.9965 -0.4109 -0.0133 -0.2915 -0.1977 -0.0100 -0.1497 -1.9709 -0.1022 -0.6435 -0.0509 -0.6836 -0.1014 -0.7366 -0.0771 -0.2242 -0.2566 -0.0435 -0.0021 -0.8664 -0.2625 -1.3446 -0.1207
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic tests cardiac_magnetic_resonance_imaging t1_mapping invasive_hemodynamic_assessments baseline
H-737	-0.5502111911773682	▁cardiac _ ▁magnetic _ re on ance _ ▁imagin g ▁t 1 ▁ma pping ▁invasi ve _ hem o dynamic _ ▁assessment s
D-737	-0.5502111911773682	cardiac_ magnetic_reonance_ imaging t1 mapping invasive_hemodynamic_ assessments
P-737	-0.0829 -0.3706 -0.3128 -0.1474 -2.1669 -0.7376 -0.5785 -0.2768 -0.5499 -0.2206 -0.8456 -0.4313 -0.4665 -0.0170 -0.0220 -0.0820 -0.1179 -2.2735 -0.8280 -0.0022 -2.1073 -0.4603 -0.0760 -0.4304 -0.1513
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity mortality hfpef patients hf reduced_ef
H-1301	-0.8372656106948853	▁Morbi d ity ▁mortal ity ▁ HF p EF ▁ HF ▁EF
D-1301	-0.8372656106948853	Morbidity mortality HFpEF HF EF
P-1301	-0.0538 -0.0613 -1.5449 -0.3468 -1.0808 -0.4881 -0.0770 -0.1115 -0.2031 -1.1272 -0.1714 -5.2817 -1.0759 -0.0980
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic_regression primary_outcome secondary_outcome death
H-973	-0.8438380360603333	▁Log istic _ re gression _ ▁models
D-973	-0.8438380360603333	Logistic_regression_ models
P-973	-0.3676 -0.0274 -0.0906 -0.1612 -0.0179 -2.1095 -0.6831 -3.9843 -0.1529
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence intravenous exercise_tolerance quality_of_life patients heart_failure
H-46	-0.9925360083580017	▁intra ven ous _ ▁ir on ▁exercise ▁ tolerance ▁heart ▁failure
D-46	-0.9925360083580017	intravenous_ iron exercise tolerance heart failure
P-46	-4.1454 -0.0283 -3.0515 -0.0731 -1.7682 -0.2573 -0.5059 -0.9270 -0.0057 -1.1985 -0.5006 -0.3185 -0.1230
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency_department acute_heart_failure clinical patient collins
H-56	-0.7561224699020386	▁emergency _ ▁department ▁a cute _ heart _ ▁failure
D-56	-0.7561224699020386	emergency_ department acute_heart_ failure
P-56	-2.5027 -0.1953 -0.3261 -0.2113 -0.0151 -0.0118 -1.7924 -0.6136 -0.2225 -2.2812 -0.1456
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence biomarkers pathophysiology chronic_hf therapeutic
H-1474	-0.5337353348731995	▁molecular _ ▁bio mark ers ▁pat ho phy si ology ▁chronic _ HF ▁ therapeut ic
D-1474	-0.5337353348731995	molecular_ biomarkers pathophysiology chronic_HF therapeutic
P-1474	-0.5677 -0.5795 -0.5721 -0.2228 -0.0872 -1.8068 -0.0995 -0.1768 -1.7661 -0.1428 -0.1566 -0.1550 -1.0377 -1.1070 -0.2526 -0.0803 -0.6705 -0.1264
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet bromodomain-containing_protein_4 brd4 cardiac
H-1045	-0.4432368278503418	▁knock down ▁ BET ▁bro modo main - conta ining _ ▁protein br d 4) ▁cardiac _ ▁tissu es
D-1045	-0.4432368278503418	knockdown BET bromodomain-containing_ proteinbrd4) cardiac_ tissues
P-1045	-1.2049 -0.4433 -1.5183 -0.2029 -0.1061 -0.0302 -0.0395 -0.1209 -0.0007 -0.1042 -0.1340 -0.4552 -1.6681 -0.2037 -1.5009 -0.0262 -0.9158 -0.0933 -0.0823 -0.3405 -0.1168
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission hospital congestive_heart_failure united_states
H-1574	-0.9475436210632324	▁con ges tive _ heart _ ▁failure
D-1574	-0.9475436210632324	congestive_heart_ failure
P-1574	-2.6015 -0.1428 -1.1921 -0.0369 -1.2803 -1.1671 -0.0502 -1.8883 -0.1688
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs septal qrs resynchronization
H-486	-0.8041192293167114	▁e sept al ▁e eme an ▁s ' sept al ▁QR s _ width ▁re syn chron ization
D-486	-0.8041192293167114	eseptal eemean s'septal QRs_width resynchronization
P-486	-1.4026 -3.7130 -0.0684 -0.7443 -2.7935 -0.0346 -0.9082 -2.4650 -0.0937 -0.0599 -0.0989 -0.7357 -1.1388 -0.0384 -0.0854 -0.0302 -0.0023 -1.2217 -0.3330 -0.1148
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart_failure hf risk_stratification inpatient outpatient
H-378	-1.068847417831421	▁heart ▁failure HF
D-378	-1.068847417831421	heart failureHF
P-378	-0.7125 -1.0317 -0.2839 -3.1518 -0.1642
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective diuretics morbidity mortality
H-1200	-0.8087987899780273	▁di ure tics ▁ HF - related
D-1200	-0.8087987899780273	diuretics HF-related
P-1200	-0.3119 -0.4213 -0.4869 -2.1530 -0.2516 -0.3566 -0.5190 -2.6563 -0.1225
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc_occlusion correlated rs rs_synchrony
H-326	-0.3960466682910919	▁IV c ▁oc clusi on ▁co ▁twist ▁ap ical _ ▁ro tation ▁RS ▁RS ▁synchron y ▁CS
D-326	-0.3960466682910919	IVc occlusion co twist apical_ rotation RS RS synchrony CS
P-326	-0.3817 -0.4796 -0.0512 -0.0099 -0.1966 -1.3616 -2.9748 -0.1806 -0.0865 -0.1081 -0.4115 -0.0193 -0.0382 -0.6642 -0.0085 -0.1222 -0.1746 -0.1441 -0.1117
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol metoprolol therapy heart_failure patients
H-857	-0.4619949758052826	▁car vedi lol ▁met o pro lol ▁in appropria te _ therapy ▁heart ▁failure ▁devices
D-857	-0.4619949758052826	carvedilol metoprolol inappropriate_therapy heart failure devices
P-857	-0.3137 -0.0194 -0.0495 -0.1571 -0.4579 -0.0274 -0.1284 -2.6037 -0.0993 -0.0553 -0.7060 -0.0504 -0.4402 -0.3476 -1.8514 -0.3766 -0.1702
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health_care clinically gastrointestinal_bleeding
H-1658	-0.8794410228729248	▁devices ▁gastro inte stin al _ ▁ble ed ing
D-1658	-0.8794410228729248	devices gastrointestinal_ bleeding
P-1658	-3.6183 -1.4632 -0.4730 -0.9888 -0.2501 -0.5502 -0.4039 -0.9118 -0.2197 -0.6829 -0.1120
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital readmission patients heart_failure follow-up
H-731	-1.4875776767730713	▁heart _ ▁failure ▁follow - up
D-731	-1.4875776767730713	heart_ failure follow-up
P-731	-8.3205 -1.5712 -0.2816 -0.2405 -0.1876 -0.0165 -1.0795 -0.2032
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians public health air cardiovascular health lead hospitalisation death
H-1808	-1.2002027034759521	▁public _ ▁health ▁air ▁pollution ▁industrial _ ▁areas ▁cardiovascular _ ▁health ▁hospital isation
D-1808	-1.2002027034759521	public_ health air pollution industrial_ areas cardiovascular_ health hospitalisation
P-1808	-2.9683 -0.3359 -2.5493 -0.1377 -0.6423 -1.1105 -2.1527 -1.1136 -0.9111 -0.8120 -1.9841 -1.3021 -0.0889 -1.6490 -0.2456
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare inpatient hf admissions acute hospitals united_states
H-1723	-0.5902632474899292	▁Medica re _ in patient ▁ HF ▁ad missions ▁a cute _ care _ hospital s ▁United ▁States
D-1723	-0.5902632474899292	Medicare_inpatient HF admissions acute_care_hospitals United States
P-1723	-0.0451 -0.0045 -1.3345 -0.1063 -0.0095 -1.7697 -0.5427 -1.8474 -0.2221 -0.3042 -0.0322 -0.0393 -2.3477 -0.4378 -0.2332 -0.0996 -0.8771 -1.0163 -0.3694 -0.1666
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping tidal_respiration administration gadolinium-chelate_contrast_agent
H-1058	-0.808959424495697	▁tid al _ ▁respira tion ▁ gado lini um - che late _ ▁contrast ▁agent
D-1058	-0.808959424495697	tidal_ respiration gadolinium-chelate_ contrast agent
P-1058	-3.2603 -0.0720 -0.1123 -1.9420 -0.1419 -0.1490 -0.0477 -0.2521 -0.1415 -0.1033 -0.0156 -1.3240 -0.0223 -4.7842 -0.8124 -0.4096 -0.1621
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf heart_failure t2d type_2_diabetes skm skeletal_muscle
H-1244	-0.4958134591579437	HF heart ▁failure ▁t 2 d ▁type _ ▁2 _ ▁diabetes ▁Sk m ▁s kelet al _ ▁muscle
D-1244	-0.4958134591579437	HFheart failure t2d type_ 2_ diabetes Skm skeletal_ muscle
P-1244	-0.3062 -0.9709 -0.2040 -0.7661 -0.0249 -0.3742 -0.4362 -0.4222 -1.8409 -1.2398 -0.1660 -0.1229 -0.1971 -1.7495 -0.1185 -0.0883 -0.2130 -0.2771 -0.3084 -0.0901
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction
H-941	-0.43537354469299316	▁cat heter ▁ab lation ▁at rial _ fi bril lation ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-941	-0.43537354469299316	catheter ablation atrial_fibrillation heart failure preserved_ejection_fraction
P-941	-1.2335 -0.4080 -0.5250 -0.1695 -2.4879 -0.3000 -0.2673 -0.4044 -0.1299 -0.0651 -0.6223 -0.5522 -0.3145 -0.1800 -0.6448 -0.1925 -0.4755 -0.2020 -0.1557 -0.1529 -0.0239 -0.3225 -0.1842
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine nesiritide acute_heart_failure renal_dysfunction rose acute_heart_failure randomized
H-71	-0.4771851599216461	▁dop amine ▁nesi riti de ▁a cute _ heart _ ▁failure ▁renal _ ▁dys function ▁a cute _ heart _ ▁failure
D-71	-0.4771851599216461	dopamine nesiritide acute_heart_ failure renal_ dysfunction acute_heart_ failure
P-71	-0.4318 -0.0541 -0.1893 -0.0067 -0.0949 -0.1216 -0.0136 -0.0363 -1.8435 -1.1235 -0.0384 -0.2253 -0.6817 -0.1438 -0.0349 -2.1736 -0.2208 -0.0218 -1.8801 -0.7637 -0.0990 -0.6321 -0.1447
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary_exercise_test quality_of_life muscular peak_quadriceps_force
H-1915	-0.9063361883163452	▁cardio pul mon ary _ ▁exercise _ ▁test ▁quality _ of _ ▁life _ ▁score ▁muscular _ ▁strength ▁quadri cep s _ ▁force
D-1915	-0.9063361883163452	cardiopulmonary_ exercise_ test quality_of_ life_ score muscular_ strength quadriceps_ force
P-1915	-0.0843 -0.8035 -1.4056 -1.0201 -0.3391 -2.1470 -1.7061 -2.2082 -4.2622 -0.1657 -0.3448 -0.0491 -0.6276 -2.3685 -0.1767 -0.2082 -0.5418 -1.5443 -0.3441 -0.3193 -0.0850 -0.5751 -0.7016 -0.4592 -0.1714
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report dapc dystrophin-associated_protein_complex sarcomeric_microstructure baseline
H-1253	-0.41808977723121643	▁DAP c dys trop hin - as soci ated _ ▁protein _ ▁complex ▁sar come ric _ micro structure
D-1253	-0.41808977723121643	DAPcdystrophin-associated_ protein_ complex sarcomeric_microstructure
P-1253	-0.1654 -0.4937 -0.0542 -0.0828 -1.5693 -0.0891 -0.0237 -0.0002 -0.4834 -0.0368 -1.0847 -1.0372 -0.0452 -0.1720 -0.2787 -1.1244 -0.4715 -0.8173 -0.3503 -0.2835 -0.1164
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf pyridostigmine basal_heart_rate sympathetic_control_of_heart_rate
H-1140	-0.6898192763328552	▁ conscious ▁ HF _ ▁rat s ▁py rido stig mine ▁bas al _ heart _ ▁rate ▁va gal ▁sympa the tic _ control e ▁heart ▁rate
D-1140	-0.6898192763328552	conscious HF_ rats pyridostigmine basal_heart_ rate vagal sympathetic_controle heart rate
P-1140	-0.3843 -1.5080 -1.6868 -0.0848 -1.7744 -0.1420 -0.0289 -0.0050 -0.0039 -0.0052 -0.0756 -1.0467 -0.0615 -0.0633 -3.0217 -1.8383 -0.2929 -0.0035 -0.0184 -0.0248 -0.5492 -0.4444 -0.2927 -0.0079 -1.8587 -2.5539 -1.7739 -0.2941 -0.1598
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg congenital accessory ion_channelopathies cardiomyopathy
H-1909	-0.4893456697463989	▁e CG ▁con geni tal _ accesso ry _ path ways ▁ion _ ▁channel o pathi es ▁cardio my o pathy
D-1909	-0.4893456697463989	eCG congenital_accessory_pathways ion_ channelopathies cardiomyopathy
P-1909	-0.5529 -0.9013 -2.0308 -0.0222 -0.0610 -0.2667 -0.3510 -0.7906 -0.1237 -0.5705 -0.0335 -0.0561 -0.1632 -2.6569 -0.8080 -0.0457 -0.0447 -0.2083 -0.8409 -0.1990 -0.0257 -0.3767 -0.1255
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras neprilysin_inhibition change stable chronic_heart_failure systolic_dysfunction
H-1971	-0.5547719597816467	▁Dual _ RAS ▁nepri ly sin _ ▁inhibi tion ▁chronic _ heart _ ▁failure ▁sy sto lic _ ▁dys function
D-1971	-0.5547719597816467	Dual_RAS neprilysin_ inhibition chronic_heart_ failure systolic_ dysfunction
P-1971	-0.9676 -0.2973 -0.0885 -0.0933 -0.4600 -1.3272 -0.5022 -0.0232 -0.1299 -1.2634 -0.1044 -1.7262 -1.6261 -0.0689 -0.0380 -0.0439 -0.1948 -0.1049 -0.2007 -0.0172 -2.7113 -0.2158
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf hhd salt_loading uninephrectomy ang_ii_infusion
H-275	-0.45847517251968384	▁mouse ▁ HF ▁h h ▁salt ▁load ing ▁un ine ph r ecto my ▁ANG _ ▁II ▁in fusion
D-275	-0.45847517251968384	mouse HF hh salt loading uninephrectomy ANG_ II infusion
P-275	-0.0924 -0.5282 -0.0775 -0.9286 -0.9584 -1.1072 -0.4519 -0.0230 -0.0067 -0.9554 -1.3774 -0.0702 -0.0229 -0.5972 -0.1385 -0.4186 -0.7182 -0.7665 -0.0066 -0.2750 -0.1073
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf_with_preserved_ejection_fraction pef uptitration hospitalization
H-176	-0.5668573379516602	▁ HF ▁pres er ved _ e je ction _ fraction ▁p EF ▁up tit ration ▁hospital ization
D-176	-0.5668573379516602	HF preserved_ejection_fraction pEF uptitration hospitalization
P-176	-2.2528 -0.5655 -1.8080 -0.1327 -0.9071 -0.1393 -0.4429 -0.2765 -0.2244 -0.1599 -0.1279 -0.2928 -0.3461 -0.7384 -0.2879 -0.1651 -0.5405 -1.4452 -0.3436 -0.1405
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs québec_health_insurance_board costs ontario_case_costing_initiative
H-1235	-0.6790244579315186	▁in - t rial _ ▁resource ▁utiliza tion ▁unit _ ▁costs ▁Québec _ ▁Health _ ▁Insurance _ ▁Board ▁kosten ▁Ontario ▁Case _ ▁Cost ing _ ▁Initiative
D-1235	-0.6790244579315186	in-trial_ resource utilization unit_ costs Québec_ Health_ Insurance_ Board kosten Ontario Case_ Costing_ Initiative
P-1235	-0.4179 -0.3645 -0.7399 -0.0800 -1.0476 -0.1618 -1.0154 -0.0709 -0.3559 -0.9331 -0.4371 -0.1124 -0.9835 -1.5136 -1.3410 -0.1333 -0.5314 -0.1124 -3.7572 -1.7182 -0.6815 -0.2290 -0.7182 -0.1057 -0.7496 -0.3396 -0.2646 -0.0972
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients idiopathic_dilated_cardiomyopathy tuscany evidence-based
H-1739	-0.39548060297966003	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁tu sca ny
D-1739	-0.39548060297966003	idiopathic_ dilated_ cardiomyopathy tuscany
P-1739	-0.7629 -0.0520 -0.0817 -0.1430 -0.1361 -1.3250 -0.4734 -0.0395 -0.4013 -1.6840 -0.5049 -0.0183 -0.0401 -0.0012 -0.4350 -0.4919 -0.1329
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating_agents patients anemia heart_disease
H-52	-0.7682693600654602	▁er y thro po ies is - stimul ating _ agent ▁an emia ▁heart ▁disease
D-52	-0.7682693600654602	erythropoiesis-stimulating_agent anemia heart disease
P-52	-2.6065 -0.7236 -0.9762 -0.5936 -1.3936 -0.2620 -0.2036 -0.0704 -0.5097 -1.6402 -0.3196 -1.5712 -0.0747 -0.4305 -1.2019 -0.3192 -0.1640
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report mitral_valve_plasty degenerative_mitral_regurgitation
H-335	-0.4325931668281555	▁mit ral _ ▁val ve _ ▁plast y ▁de genera tive _ ▁mit ral _ re gur gi tation
D-335	-0.4325931668281555	mitral_ valve_ plasty degenerative_ mitral_regurgitation
P-335	-0.2993 -0.1030 -0.1993 -1.1922 -0.0582 -0.7002 -0.8765 -0.3810 -0.1228 -0.0023 -0.4514 -0.3744 -2.1456 -0.3437 -0.2500 -0.4114 -0.3616 -0.0743 -0.1567 -0.4628 -0.1176
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial titin_hypophosphorylation heart_failure_with_preserved_ejection_fraction metabolic
H-759	-0.4845093786716461	▁My o card ial _ ▁titi n _ ▁hypo phos phor y lation ▁heart ▁failure ▁e je ction _ fraction ▁rat ▁metabol ic _ risk
D-759	-0.4845093786716461	Myocardial_ titin_ hypophosphorylation heart failure ejection_fraction rat metabolic_risk
P-759	-1.3599 -0.1510 -0.0824 -0.2669 -0.5721 -0.5748 -0.1231 -0.9184 -1.1641 -0.0754 -0.2487 -1.1603 -0.0485 -0.8474 -0.5232 -0.4989 -0.0360 -0.0271 -0.6065 -0.0634 -0.4507 -0.0087 -0.0049 -0.3622 -1.7144 -1.0041 -0.1886
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients hfpef kccq health prognostic
H-791	-0.8507526516914368	▁ HF p EF ▁k cc q
D-791	-0.8507526516914368	HFpEF kccq
P-791	-1.0135 -0.1414 -0.0463 -0.3820 -2.1015 -0.0389 -1.8834 -1.9207 -0.1290
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf mi reduced_ejection_fraction ef
H-1100	-0.6746383309364319	▁ HF ▁MI ▁pres er ved ▁reduce d _ e je ction _ fraction EF
D-1100	-0.6746383309364319	HF MI preserved reduced_ejection_fractionEF
P-1100	-1.9895 -0.2303 -2.7306 -1.6774 -0.0713 -0.2460 -1.4777 -0.0730 -0.1724 -0.4712 -0.1570 -0.0781 -0.1828 -0.0704 -1.2081 -0.4489 -0.1842
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd diuretic peripheral_edema functional_class
H-899	-0.7136742472648621	▁PD _ ▁initiat ion ▁weight ▁loss ▁di ure tic _ ▁response ▁per i pher al _ ▁ed ema ▁functional _ class
D-899	-0.7136742472648621	PD_ initiation weight loss diuretic_ response peripheral_ edema functional_class
P-899	-0.3282 -1.9439 -2.0175 -0.0156 -1.2771 -1.1763 -0.2647 -0.1447 -0.5244 -0.4747 -0.9795 -0.0198 -0.0407 -0.0304 -0.0938 -0.1567 -3.8326 -0.0033 -0.0133 -1.2217 -1.4935 -0.2553 -0.1070
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients baseline serum_creatinine serum_potassium
H-441	-0.5788007378578186	▁se rum _ ▁creati nine ▁level ▁se rum _ po tas s ium
D-441	-0.5788007378578186	serum_ creatinine level serum_potassium
P-441	-1.1323 -0.3066 -0.6281 -1.0923 -0.5738 -0.9893 -0.2642 -0.2946 -0.4439 -0.6429 -0.4551 -0.2143 -0.1787 -1.3359 -0.1300
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv_failure diagnostic left_ventricular_dysfunction
H-1093	-0.5761961936950684	▁ RV _ ▁failure ▁intr in sic _ ▁left _ ▁vent ri cular _ ▁dys function
D-1093	-0.5761961936950684	RV_ failure intrinsic_ left_ ventricular_ dysfunction
P-1093	-0.9603 -0.9545 -2.3562 -0.0739 -0.8748 -0.0557 -0.0204 -0.1545 -0.4278 -0.2360 -1.5176 -1.2049 -0.4094 -0.4400 -0.1266 -0.0529 -0.3319 -0.1741
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality inpatient admissions hospital emergency_department
H-1623	-0.49582013487815857	▁Mor t ality ▁in patient ▁ad missions ▁hospital ▁days ▁emergency _ ▁department ED
D-1623	-0.49582013487815857	Mortality inpatient admissions hospital days emergency_ departmentED
P-1623	-0.8212 -0.0934 -0.1013 -0.0283 -0.0832 -1.5271 -0.1033 -0.1347 -1.2188 -0.0548 -0.3639 -0.8277 -1.5061 -0.4218 -0.1517
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic_heart_failure yield atrial cells
H-1334	-0.7557795643806458	▁Chro nic _ heart _ ▁failure ▁transform ing _ ▁growth _ factor _ ▁beta - dependent _ ▁yi eld ▁at rial _ ex plant - der i ved ▁c - K it _
D-1334	-0.7557795643806458	Chronic_heart_ failure transforming_ growth_factor_ beta-dependent_ yield atrial_explant-derived c-Kit_
P-1334	-0.1523 -0.1353 -0.0298 -1.7286 -1.1224 -0.0525 -1.0296 -0.0274 -0.3220 -1.5474 -1.1402 -0.6768 -3.8555 -0.5021 -0.0063 -0.0373 -0.3654 -0.1844 -0.0002 -3.3901 -0.0426 -1.5560 -0.9273 -0.0028 -0.0728 -0.0572 -0.2530 -0.1796 -0.0894 -0.1125 -1.2400 -0.0033 -0.5505 -4.9330 -0.1267
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia patients chronic_heart_failure hf prevalence outcomes
H-834	-0.6169152855873108	▁an emia ▁chronic _ heart _ ▁failure HF
D-834	-0.6169152855873108	anemia chronic_heart_ failureHF
P-834	-1.1606 -0.0152 -0.3792 -0.1352 -1.7007 -1.5463 -0.0684 -0.3363 -0.6750 -0.1522
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients heartmate_ii lvad centrimag rvad
H-298	-0.7319474220275879	▁Heart Mate _ ▁II _ ▁l VAD ▁Centri Mag _ r VAD
D-298	-0.7319474220275879	HeartMate_ II_ lVAD CentriMag_rVAD
P-298	-0.5817 -0.0718 -0.1438 -1.5494 -0.1392 -3.4839 -0.0326 -0.2090 -1.0633 -0.1450 -2.0030 -0.1341 -0.5409 -0.1496
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change readmission follow-up follow-up
H-724	-0.858000636100769	▁follow - up _ ▁visit s ▁follow - up
D-724	-0.858000636100769	follow-up_ visits follow-up
P-724	-4.0532 -0.1285 -0.0173 -1.7366 -1.1818 -0.0998 -0.2133 -0.1561 -0.0242 -1.6840 -0.1431
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic crt
H-428	-0.7691819667816162	▁e cho car dio graphic _ ▁score ▁c RT
D-428	-0.7691819667816162	echocardiographic_ score cRT
P-428	-1.1239 -0.1386 -0.0367 -0.3863 -0.3797 -1.3644 -0.4939 -0.4664 -2.7268 -1.2100 -0.1343
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence economic lvad outcomes
H-317	-1.0780465602874756	▁economische ▁l VAD
D-317	-1.0780465602874756	economische lVAD
P-317	-0.7293 -3.7771 -0.0622 -0.7057 -0.1160
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection_fraction patients
H-909	-0.8517764210700989	▁het e rogen ous _ ▁improvement ▁e je ction _ fraction
D-909	-0.8517764210700989	heterogenous_ improvement ejection_fraction
P-909	-3.7345 -0.3144 -0.0760 -1.6657 -1.3199 -1.6323 -0.4050 -0.2073 -0.3392 -0.2783 -0.0849 -0.8420 -0.1736
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized af_ablation
H-953	-1.0857226848602295	▁AF ▁ab lation
D-953	-1.0857226848602295	AF ablation
P-953	-4.2975 -0.4953 -0.0982 -0.3694 -0.1682
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac insulin-resistance mitochondrial_energy_production systolic_heart_failure pressure-overload_hypertrophy
H-1777	-0.4249252676963806	▁Card iac ▁insulin - re si stance ▁mito cho ndri al _ energie ▁production ▁sy sto lic _ heart _ ▁failure ▁pressure - over load ▁hyper trop hy
D-1777	-0.4249252676963806	Cardiac insulin-resistance mitochondrial_energie production systolic_heart_ failure pressure-overload hypertrophy
P-1777	-1.5506 -0.0340 -0.9246 -0.0468 -0.0097 -0.4944 -0.0035 -0.0346 -0.3575 -0.3474 -0.0677 -0.1436 -0.9976 -2.2847 -0.0129 -0.0288 -0.1562 -0.0315 -1.9992 -1.1788 -0.0566 -0.0187 -0.1157 -0.0060 -0.0461 -0.7599 -0.0041 -0.7035 -0.2132 -0.1200
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel_inhibition hemodynamic exercise_tolerance heart_failure_with_preserved_ejection_fraction randomized
H-1170	-0.3533517122268677	▁If - chan nel _ ▁inhibi tion ▁hem o dynamic _ status ▁exercise ▁ tolerance ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-1170	-0.3533517122268677	If-channel_ inhibition hemodynamic_status exercise tolerance heart failure preserved_ejection_fraction
P-1170	-2.1609 -0.1225 -0.0208 -0.0494 -0.6714 -0.1508 -0.2908 -0.3087 -0.5905 -0.0051 -1.0979 -0.3437 -0.2853 -0.2910 -0.0039 -0.1879 -0.3331 -0.2319 -0.2345 -0.8138 -0.1500 -0.5100 -0.1894 -0.0777 -0.2549 -0.0373 -0.3379 -0.1427
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients heart_failure heart_failure nurses follow-up cardiology mortality
H-1896	-0.9196141958236694	▁heart ▁failure ▁heart ▁failure ▁nurse s ▁follow - up ▁card i ology
D-1896	-0.9196141958236694	heart failure heart failure nurses follow-up cardiology
P-1896	-1.5115 -0.7606 -3.5339 -0.4526 -1.1930 -0.0283 -2.3715 -0.0355 -0.0092 -0.5040 -0.1332 -0.1256 -2.0437 -0.1720
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline follow-up paf activity metabolic enzymes patients heart_failure healthy
H-1266	-0.6240438222885132	▁PA f ▁metabol ic _ ▁enzym es ▁heart ▁failure
D-1266	-0.6240438222885132	PAf metabolic_ enzymes heart failure
P-1266	-1.8581 -1.9086 -0.1088 -0.0091 -0.1369 -0.3513 -0.0405 -0.8215 -0.9355 -0.5143 -0.1800
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 hearts beta-adrenergic_responses cardiomyocytes
H-1207	-0.46949830651283264	▁Pho s pho dies tera se -2 ▁fail ing _ heart s ▁blu nts ▁beta - ad r energi c _ ▁response s ▁cardio my o cy tes
D-1207	-0.46949830651283264	Phosphodiesterase-2 failing_hearts blunts beta-adrenergic_ responses cardiomyocytes
P-1207	-0.6899 -0.2163 -0.0335 -2.1765 -0.0715 -0.1053 -0.1891 -2.8434 -0.0537 -0.1746 -1.6339 -0.0742 -0.1065 -0.0864 -0.3747 -0.0310 -0.0800 -0.7103 -0.8089 -0.0765 -1.6289 -0.3550 -0.0771 -0.0369 -0.4804 -0.1979 -0.0656 -0.1593 -0.3602 -0.1874
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab adjuvant outcomes cardiotoxicity congestive_heart_failure chf
H-670	-0.7637879848480225	▁tras tuz um ab ▁cardio toxic iteit ▁con ges tive _ ▁heart ▁failure CH f
D-670	-0.7637879848480225	trastuzumab cardiotoxiciteit congestive_ heart failureCHf
P-670	-0.1581 -0.0417 -0.0129 -0.5904 -0.5711 -0.3641 -1.1309 -0.0313 -0.0762 -2.2595 -0.0790 -2.4848 -0.4823 -3.0289 -1.3256 -0.2502 -0.0974
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin protein-c phosphorylation troponin_i phosphorylation hf
H-1427	-0.6657527089118958	▁total ▁my os in _ binding _ ▁protein - c _ phos phor y lation ▁ser 23 /24 ▁trop onin _ ▁I _ phos phor y lation HF
D-1427	-0.6657527089118958	total myosin_binding_ protein-c_phosphorylation ser23/24 troponin_ I_phosphorylationHF
P-1427	-1.9599 -2.8091 -0.0302 -0.7518 -0.3261 -0.0090 -0.1667 -0.2573 -0.0716 -0.9039 -0.3516 -0.0662 -0.8357 -1.5197 -0.0928 -0.8932 -0.5097 -0.0528 -0.2072 -0.0713 -0.1553 -1.8473 -1.2361 -0.0185 -1.0328 -1.5891 -0.1269 -1.7210 -0.2226 -0.1375
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative renal_dysfunction stroke myocardial_infarction heart_failure cabg
H-970	-0.4676685035228729	▁renal _ ▁dys function ▁stroke ▁my o card ial _ in far ction ▁heart ▁failure ▁ca BG
D-970	-0.4676685035228729	renal_ dysfunction stroke myocardial_infarction heart failure caBG
P-970	-0.9928 -0.7451 -0.2677 -0.0314 -1.2907 -0.9486 -0.7238 -0.4682 -0.7103 -0.1507 -0.2603 -0.0802 -0.0947 -0.2690 -0.2826 -0.7323 -0.5254 -0.1806 -0.1311
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine administration methylatropine propranolol cardiac sympathovagal_balance
H-1138	-0.38795721530914307	▁py rido stig mine ▁met hy la tropi ne ▁propra no lol ▁cardiac _ ▁sympa t hova gal _ ▁balance
D-1138	-0.38795721530914307	pyridostigmine methylatropine propranolol cardiac_ sympathovagal_ balance
P-1138	-0.0144 -0.0143 -0.0037 -0.0444 -2.6120 -0.1722 -0.1680 -0.0046 -1.3870 -0.0063 -0.0108 -0.0455 -0.0324 -0.6095 -0.7635 -0.3498 -0.0442 -0.3885 -0.2364 -1.0534 -0.4526 -0.1219
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic cardiac_resynchronization_therapy crt
H-427	-0.6413825154304504	▁e cho car dio graphic ▁response ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-427	-0.6413825154304504	echocardiographic response cardiac_resynchronization_therapy cRT
P-427	-0.0387 -0.0463 -0.0499 -0.6656 -0.3858 -3.2767 -0.7687 -0.3876 -0.6954 -0.0325 -0.0050 -1.2218 -0.6003 -0.2313 -0.6018 -2.1873 -0.2321 -0.1180
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin_subproteomes heart_failure proteins chromatin_structure
H-91	-0.5902767777442932	▁chr omat in _ sub prote om es ▁heart _ ▁failure ▁protein s ▁chr omat in _ ▁structure
D-91	-0.5902767777442932	chromatin_subproteomes heart_ failure proteins chromatin_ structure
P-91	-1.8788 -0.1444 -1.3290 -0.2154 -0.8517 -0.3039 -0.3052 -0.2141 -0.8086 -0.9069 -0.2206 -1.2621 -0.1073 -0.4645 -0.1128 -0.9771 -0.4635 -0.8294 -0.2851 -0.1249
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp antibodies nonterminal_epitopes
H-1519	-0.2759813666343689	▁circula ting ▁NT - pro b NP ▁anti bo dies ▁non gly cos yla ted ▁non termin al _ e pito pes
D-1519	-0.2759813666343689	circulating NT-probNP antibodies nonglycosylated nonterminal_epitopes
P-1519	-0.1852 -0.0432 -0.3938 -0.0673 -0.0182 -0.6790 -0.2799 -0.0597 -0.0572 -1.0044 -0.0835 -0.6669 -0.4305 -0.1791 -0.0717 -0.0419 -0.6065 -0.0168 -0.3727 -0.6077 -0.0949 -0.1425 -0.3972 -0.1237
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac_mrna inflammatory cell_adhesion_genes retn
H-934	-0.4597030282020569	▁Hum - re t n _ mi ce ▁cardiac ▁m RNA ▁infla mma tory ▁cell _ ▁a dhe sion _ ▁gene s ▁Ret n
D-934	-0.4597030282020569	Hum-retn_mice cardiac mRNA inflammatory cell_ adhesion_ genes Retn
P-934	-0.3448 -0.0986 -0.7261 -0.2958 -0.0370 -0.5924 -0.4184 -0.2095 -0.0775 -0.4980 -0.0307 -0.5565 -0.0855 -0.0752 -0.9432 -0.9761 -0.8561 -0.0148 -0.5445 -1.6311 -0.1196 -0.1200 -0.0784 -0.0588 -2.4060 -0.1577
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard tnf_antagonist baseline covariates
H-606	-0.4890606105327606	▁n b DM ARD ▁t NF ▁anta gon ist
D-606	-0.4890606105327606	nbDMARD tNF antagonist
P-606	-0.0395 -0.0274 -0.1555 -0.8187 -1.3943 -0.4308 -1.9856 -0.0079 -0.1335 -0.2440 -0.1426
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage_heart_failure mechanical_cardiac_support
H-1386	-1.3246926069259644	▁heart _ ▁failure ▁mechanic al _ ▁cardiac _ support
D-1386	-1.3246926069259644	heart_ failure mechanical_ cardiac_support
P-1386	-7.5308 -1.5387 -0.1628 -1.2347 -0.4529 -0.0894 -0.1466 -1.7371 -0.9142 -0.5870 -0.1776
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref exercise resting_hr bpm beta-blocker therapy
H-1946	-0.5549348592758179	▁h Fr EF ▁exercise ▁performance ▁rest ing ▁HR ▁beta - block er _ therapy
D-1946	-0.5549348592758179	hFrEF exercise performance resting HR beta-blocker_therapy
P-1946	-1.6395 -1.7177 -1.3098 -0.5741 -0.2713 -0.7651 -0.0520 -0.8980 -0.1523 -0.0529 -0.0617 -0.0341 -0.8159 -0.0209 -0.3855 -0.1281
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods_study exercise patients heart_failure
H-615	-1.7761468887329102	▁voordelen ▁structure d _ ▁exercise _ programm e ▁heart ▁failure
D-615	-1.7761468887329102	voordelen structured_ exercise_programme heart failure
P-615	-6.6003 -4.9537 -0.0290 -0.4233 -2.4385 -0.8407 -0.4170 -1.3472 -2.7817 -0.8293 -0.4455 -0.2077
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox_hazard_models esrd death composite_end_point esrd death esrd
H-391	-1.2721880674362183	▁co x _ ▁hazard _ ▁models ▁ES RD _ to _ ▁death ▁ES RD ▁death ▁ES RD
D-391	-1.2721880674362183	cox_ hazard_ models ESRD_to_ death ESRD death ESRD
P-391	-0.1395 -0.0036 -1.3094 -0.1440 -1.8265 -0.4293 -3.9439 -0.9277 -4.0434 -1.5025 -0.1348 -0.4001 -2.9645 -0.9038 -2.2739 -2.0792 -0.7522 -0.2723 -0.1210
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.9215075969696045	
D-557	-0.9215075969696045	
P-557	-1.6690 -0.1740
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery rheumatic surgery mva
H-359	-0.42126327753067017	▁direct _ ▁observation ▁rhe u matic ▁MS ▁m VA
D-359	-0.42126327753067017	direct_ observation rheumatic MS mVA
P-359	-1.2983 -0.3957 -0.4392 -0.1844 -0.0180 -0.0471 -1.4220 -0.1469 -0.4108 -0.1595 -0.1121
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior_vena_cava ivc
H-321	-1.1680530309677124	▁pig s ▁inferior _ ve na _ ca va ▁i cc ▁snar ed ▁CO
D-321	-1.1680530309677124	pigs inferior_vena_cava icc snared CO
P-321	-2.3667 -0.0688 -1.0912 -0.5856 -0.6163 -1.0318 -1.1512 -0.5958 -0.1662 -1.1103 -2.1861 -4.7958 -0.1964 -1.5737 -1.0191 -0.1340
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin resistin
H-932	-0.419414222240448	▁do xor ubi cin ▁i p ▁se rum ▁resist in ▁Hum - re t n _ mi ce
D-932	-0.419414222240448	doxorubicin ip serum resistin Hum-retn_mice
P-932	-0.0109 -0.0122 -0.0224 -0.1950 -1.3268 -0.0293 -0.3384 -0.2106 -1.0311 -0.4419 -0.7850 -0.1214 -1.1375 -1.3042 -0.0545 -0.3452 -0.2845 -0.2877 -0.2993 -0.1503
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf proteins
H-1361	-0.6080735921859741	▁nutrition al ▁ab normal ities ▁CHF ▁fat ▁car bo hydrat es ▁protein s ▁water ▁micro nutri ents
D-1361	-0.6080735921859741	nutritional abnormalities CHF fat carbohydrates proteins water micronutrients
P-1361	-4.1677 -0.0688 -3.7787 -0.0563 -0.8608 -0.1575 -0.6466 -0.0639 -0.0473 -0.2338 -0.0462 -0.1075 -0.0509 -0.3381 -0.0096 -0.0476 -0.4560 -0.3298 -0.0864
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs physicians hospital
H-1729	-0.7405890226364136	▁kosten ▁high - volu me _ ▁physician s
D-1729	-0.7405890226364136	kosten high-volume_ physicians
P-1729	-2.1187 -1.8028 -0.0985 -0.3412 -0.1235 -0.2241 -0.8023 -0.0915 -1.6673 -0.1360
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.2795964777469635	▁de activa tion
D-1864	-0.2795964777469635	deactivation
P-1864	-0.2442 -0.0141 -0.2428 -0.7634 -0.1335
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university_of_connecticut_heart_failure_center heart_failure nurse_practitioner
H-728	-0.6100918650627136	▁University _ of _ ▁Connect i cut _ ▁Heart _ ▁Fail ure _ ▁Center ▁cardio logist ▁heart ▁failure _ ▁nurse ▁prac ti tioner
D-728	-0.6100918650627136	University_of_ Connecticut_ Heart_ Failure_ Center cardiologist heart failure_ nurse practitioner
P-728	-0.8828 -0.2846 -0.2891 -0.5119 -2.8979 -0.0175 -0.2171 -0.8006 -0.6681 -0.8278 -0.1487 -0.7188 -0.5802 -1.2743 -0.0429 -0.0726 -0.1442 -0.5013 -2.1694 -0.0917 -1.2782 -0.1396 -0.2083 -0.3350 -0.1498
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone_receptor_antagonists randomized morbidity mortality symptomatic_systolic_heart_failure
H-438	-0.4921368956565857	▁al do ster one _ ▁receptor _ ▁anta gon ists ▁morbi d iteit ▁mortal ity ▁sy sto lic _ heart _ ▁failure
D-438	-0.4921368956565857	aldosterone_ receptor_ antagonists morbiditeit mortality systolic_heart_ failure
P-438	-0.2661 -0.2005 -0.0782 -0.3667 -0.3152 -0.0216 -1.4529 -0.0482 -0.0154 -0.6122 -0.3381 -0.0293 -1.6228 -1.1704 -1.0474 -0.4656 -0.0660 -0.5352 -0.0565 -1.2447 -1.3238 -0.0768 -0.3484 -0.1094
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo_inhibition cardiomyocyte_bioenergetics lv_function chronic_acf
H-472	-0.3182865381240845	▁ XO ▁inhibi tion ▁cardio my o cy te _ ▁bio ener ge tics ▁LV ▁chronic _ a cf ▁rat
D-472	-0.3182865381240845	XO inhibition cardiomyocyte_ bioenergetics LV chronic_acf rat
P-472	-0.5992 -0.0283 -0.9615 -0.1917 -0.0302 -0.3487 -0.3048 -0.1583 -0.1835 -0.7535 -0.0454 -0.0269 -0.3657 -0.1172 -0.1029 -0.5134 -0.2050 -0.2445 -1.1150 -0.3549 -0.2446 -0.1071
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory
H-1324	-0.5173162221908569	▁e cho car dio graphic _ ▁measure s ▁n - termin al _ pro - bra in ▁na tri ure tic _ pe pti de ▁infla mma tory _ ▁marker s
D-1324	-0.5173162221908569	echocardiographic_ measures n-terminal_pro-brain natriuretic_peptide inflammatory_ markers
P-1324	-0.8668 -1.2157 -1.8001 -0.2056 -0.3885 -1.7657 -1.3431 -0.0346 -1.6789 -0.0220 -0.0947 -0.0126 -0.1062 -1.0478 -0.0579 -0.0592 -0.1067 -0.3455 -0.0287 -0.1743 -2.2345 -0.1823 -0.5034 -0.1749 -0.6838 -0.0194 -0.3145 -0.3687 -0.2603 -0.5160 -0.0495 -0.2363 -0.1734
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf pyridostigmine stroke_volume ejection_fraction cardiac_output contractility left_ventricle
H-1144	-0.5978649854660034	▁ HF ▁py rido stig mine ▁e je ction _ fraction ▁cardiac ▁output ▁contract ility ▁left _ ▁vent ric le
D-1144	-0.5978649854660034	HF pyridostigmine ejection_fraction cardiac output contractility left_ ventricle
P-1144	-1.7225 -0.0541 -2.2297 -0.0068 -0.0054 -0.1514 -2.4044 -0.0584 -0.0234 -0.8288 -0.0411 -0.0249 -0.4251 -0.0121 -0.3865 -0.1736 -0.2282 -1.7642 -1.3675 -0.8392 -0.3052 -0.1007
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol thromboembolic_events patients heart_failure β2-receptor_haplotype
H-1120	-0.3668552041053772	▁car vedi lol ▁ thro mbo e mbol ic _ ▁events ▁heart ▁failure ▁β 2- recept or ▁ha plo type
D-1120	-0.3668552041053772	carvedilol thromboembolic_ events heart failure β2-receptor haplotype
P-1120	-0.0303 -0.0123 -0.1671 -0.4400 -0.4659 -0.8650 -0.3232 -0.1567 -0.1694 -1.2517 -1.1580 -1.1414 -0.6497 -0.0249 -0.0210 -0.1242 -0.0317 -0.1589 -0.0364 -0.0101 -0.7198 -0.1132
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr protein_kinase_r-like_er_kinase perk calreticulin chop hf
H-1084	-0.42200207710266113	▁u PR ▁protein ▁kina se ▁r - like _ er _ ▁kina se per k ▁cal ret icul in ▁CHO p ▁ HF ▁tissu es
D-1084	-0.42200207710266113	uPR protein kinase r-like_er_ kinaseperk calreticulin CHOp HF tissues
P-1084	-1.1713 -0.0885 -0.8850 -0.3311 -0.0748 -1.7032 -0.0388 -0.4274 -0.0432 -0.5609 -0.4697 -0.0283 -0.0530 -0.4232 -0.6260 -0.0059 -0.0647 -0.0016 -0.4977 -0.0581 -0.2943 -1.2143 -0.3686 -1.6087 -0.0536 -0.2062 -0.0961
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients heart_failure hf cardiopulmonary_exercise_test anaerobic_threshold
H-1753	-0.5969474911689758	▁heart ▁failure HF ▁cardio pul mon ary _ ▁exercise ▁ana ero bic _ ▁thre s hold AT
D-1753	-0.5969474911689758	heart failureHF cardiopulmonary_ exercise anaerobic_ thresholdAT
P-1753	-1.5896 -0.9603 -0.1473 -0.9509 -0.3320 -1.0543 -0.7383 -0.1561 -1.9341 -0.7707 -0.1162 -0.2511 -0.0991 -0.7050 -0.0509 -0.2159 -0.7360 -0.4070 -0.1273
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled_trials rcts observational_cohort_studies contemporaneous_control_group
H-152	-0.6932147145271301	▁random ised - control led _ ▁trial s RC t s ▁observation al _ co hor t _ ▁studies
D-152	-0.6932147145271301	randomised-controlled_ trialsRCts observational_cohort_ studies
P-152	-2.5590 -1.7101 -0.3446 -0.0041 -1.5921 -0.4468 -0.8268 -0.0431 -0.7583 -0.4951 -0.1431 -0.1488 -0.0330 -0.1241 -0.4109 -0.5548 -0.1249 -1.3375 -0.6114 -2.1107 -0.1781
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic biomarkers molecular_dysfunction chronic_hf
H-1477	-0.27720171213150024	▁bio mark ers ▁molecular _ ▁dys function ▁chronic _ HF
D-1477	-0.27720171213150024	biomarkers molecular_ dysfunction chronic_HF
P-1477	-0.3022 -0.1561 -0.0702 -0.2406 -0.8624 -0.0833 -0.0502 -0.0828 -0.1948 -0.8325 -0.3267 -0.1247
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths stroke hospitalisations heart_failure follow-up
H-816	-0.7557669878005981	▁CV ▁non - fa tal _ stro t ▁hospital isation s ▁heart _ ▁failure ▁follow - up
D-816	-0.7557669878005981	CV non-fatal_strot hospitalisations heart_ failure follow-up
P-816	-2.3646 -1.9644 -0.0547 -0.1106 -0.1140 -0.0806 -0.1886 -2.8829 -1.5992 -0.0583 -0.1651 -2.3828 -1.3256 -0.1055 -0.2959 -0.0816 -0.0075 -0.4219 -0.1556
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective patients rule sensitivity specificity cad sensitivity cad
H-1192	-0.7572330832481384	▁ sensitiv ity ▁CAD ▁severe _ ▁CAD
D-1192	-0.7572330832481384	sensitivity CAD severe_ CAD
P-1192	-2.6384 -0.0332 -1.1333 -0.1481 -1.1695 -0.5656 -0.7630 -0.2492 -0.1148
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected clinical death medical hospitalization hf clinic outpatients
H-379	-1.1358827352523804	▁ HF
D-379	-1.1358827352523804	HF
P-379	-2.6214 -0.5014 -1.2283 -0.1924
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a upr downregulation cardiac genes hf
H-1089	-0.6262975335121155	▁s cn 5 a ▁tran script ▁u PR ▁cardiac _ ▁gene s ▁ HF
D-1089	-0.6262975335121155	scn5a transcript uPR cardiac_ genes HF
P-1089	-0.5823 -0.1565 -0.2897 -0.1367 -0.9342 -0.0302 -0.7403 -0.7630 -3.0033 -0.7065 -0.7745 -0.0946 -1.0928 -0.3115 -0.2499 -0.1549
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east rhythm_control_therapy diagnosis cardiovascular complications
H-1655	-0.4625051021575928	▁e ast ▁ rhythm _ control _ therapy ▁AF ▁cardiovascular ▁complica tions ▁AF
D-1655	-0.4625051021575928	east rhythm_control_therapy AF cardiovascular complications AF
P-1655	-0.5019 -0.7129 -0.0370 -0.2357 -0.5468 -0.0198 -1.1035 -0.0516 -0.6941 -0.1408 -0.4180 -1.6503 -0.4814 -0.1932 -0.1506
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air cardiovascular health acute_myocardial_infarction
H-1806	-0.7070214152336121	▁Ambient _ air _ ▁pollution ▁cardiovascular _ ▁health ▁a cute _ My o card ial _ in far ction
D-1806	-0.7070214152336121	Ambient_air_ pollution cardiovascular_ health acute_Myocardial_infarction
P-1806	-0.0240 -0.1459 -0.3357 -1.0512 -0.8071 -0.5184 -0.7120 -2.1241 -0.7505 -0.0545 -0.0717 -4.4146 -1.0657 -0.7136 -0.7376 -0.1758 -0.2417 -0.1244 -0.2456 -0.3743 -0.1590
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic nhs chronic disease exercise acute hospital
H-613	-0.8909599184989929	▁economische ▁NH s ▁behaviour al - change ▁chronic _ ▁disease ▁exercise
D-613	-0.8909599184989929	economische NHs behavioural-change chronic_ disease exercise
P-613	-1.1904 -3.8244 -0.3978 -0.5059 -0.1179 -0.1054 -0.0858 -1.6562 -0.2352 -0.9025 -0.1859 -2.1535 -0.2215
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac_deaths atherosclerotic_cad
H-1907	-0.4868142902851105	▁middle - a ged _ ▁recrea tional _ ▁ath letes ▁sud den _ ▁cardiac _ ▁death s ▁a ther os cle ro tic _ ▁CAD
D-1907	-0.4868142902851105	middle-aged_ recreational_ athletes sudden_ cardiac_ deaths atherosclerotic_ CAD
P-1907	-3.4393 -0.1892 -0.0597 -0.2840 -0.0718 -1.0860 -0.0662 -0.3501 -1.5242 -0.0087 -0.0617 -0.0138 -0.0467 -0.0651 -0.8273 -0.3636 -0.1501 -1.4042 -0.4973 -0.2030 -0.1846 -0.1005 -0.5986 -0.3501 -0.7048 -0.2753 -0.2179
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients hf crt implantation complications
H-912	-0.7007320523262024	▁di al ysis - dependent ▁patients ▁ HF ▁c RT ▁implant ation
D-912	-0.7007320523262024	dialysis-dependent patients HF cRT implantation
P-912	-0.7362 -0.0587 -0.0132 -0.0882 -0.0686 -2.4633 -1.3153 -0.1205 -0.9708 -1.2288 -2.1172 -0.2009 -0.3488 -0.0798
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak_oxygen_consumption pulse patients
H-1918	-0.4212690591812134	▁Peak _ ▁oxygen _ ▁consum p tion ▁oxygen _ ▁puls e
D-1918	-0.4212690591812134	Peak_ oxygen_ consumption oxygen_ pulse
P-1918	-0.0272 -0.0892 -1.2735 -0.3970 -0.7021 -0.1001 -0.6633 -0.5738 -0.6400 -0.2360 -0.2650 -0.3731 -0.1361
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv pathophysiologic rv_dysfunction
H-1094	-1.1740914583206177	▁ RV
D-1094	-1.1740914583206177	RV
P-1094	-1.0084 -0.9391 -2.5957 -0.1532
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf patients hct city_of_hope
H-1452	-0.5903263688087463	▁post - h CT _ ▁CHF ▁h CT ▁City _ of _ ▁Hope
D-1452	-0.5903263688087463	post-hCT_ CHF hCT City_of_ Hope
P-1452	-1.1469 -0.0136 -0.2295 -1.2231 -0.4862 -0.1291 -1.2375 -1.0273 -1.1439 -0.1891 -0.2708 -0.0556 -1.3807 -0.2328 -0.0888
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health followed_up hf hospitalization death contact
H-687	-0.8372366428375244	▁Women _ s _ Health _ ▁Initiative ▁ HF
D-687	-0.8372366428375244	Women_s_Health_ Initiative HF
P-687	-1.8936 -1.1819 -0.5523 -0.3163 -1.2567 -0.7316 -0.4483 -0.5019 -0.3132 -1.7988 -0.2149
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients vad patients ecmo vad patients ecmo
H-1389	-1.0356054306030273	▁ VAD _ groep ▁ec mo + VAD _ groep ▁ec mo _ groep
D-1389	-1.0356054306030273	VAD_groep ecmo+VAD_groep ecmo_groep
P-1389	-0.6714 -0.0895 -2.5037 -0.3446 -1.6027 -1.2792 -3.4880 -0.0813 -1.1899 -0.2779 -1.6782 -1.1784 -1.2754 -0.4807 -0.2642 -0.1646
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin inflammation hepatic prognosis patients lvad implantation
H-540	-0.5815286040306091	▁album in ▁levels ▁nutrition ▁ inflammation ▁he pati c _ ▁function ▁l VAD ▁implant ation
D-540	-0.5815286040306091	albumin levels nutrition inflammation hepatic_ function lVAD implantation
P-540	-0.2890 -0.3109 -3.6396 -0.8946 -0.0339 -0.0036 -0.0137 -0.2126 -0.1945 -1.3081 -0.5077 -0.5788 -0.0526 -1.3546 -0.1010 -0.2622 -0.1288
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right_ventricular rv left_ventricular_assist_device lvad outcomes
H-294	-0.8276876211166382	▁Right _ ▁vent ri cular RV ▁left _ ▁vent ri cular _ assist _ ▁device ▁l VAD
D-294	-0.8276876211166382	Right_ ventricularRV left_ ventricular_assist_ device lVAD
P-294	-1.4962 -0.2981 -1.5150 -1.0124 -0.2624 -2.5652 -1.2127 -0.3992 -1.0523 -1.3846 -0.4102 -0.3871 -0.2934 -1.8370 -0.8070 -0.1199 -0.0372 -0.4613 -0.1748
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration neurohumoral_blockers hf hospitalization patients co-morbidity
H-184	-0.7364307045936584	▁neuro hu moral _ block ers ▁ HF
D-184	-0.7364307045936584	neurohumoral_blockers HF
P-184	-0.6946 -0.0117 -1.3501 -0.9284 -0.8177 -0.1163 -0.4649 -0.0641 -2.8004 -0.1161
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 c_statistic net_reclassification_improvement integrated_discrimination_improvement
H-705	-0.7324116826057434	▁ST 2 ▁re class ification _ of _ risk ▁c _ ▁statistic ▁net _ re class ification ▁integrat ed _ ▁discrimina tion
D-705	-0.7324116826057434	ST2 reclassification_of_risk c_ statistic net_reclassification integrated_ discrimination
P-705	-1.0806 -0.0550 -1.8481 -0.1010 -0.2667 -1.0088 -1.3496 -0.2059 -1.0925 -0.6214 -1.7382 -0.1445 -0.3032 -0.4432 -1.4457 -0.3273 -0.1820 -1.4097 -0.2011 -0.2326 -1.1328 -0.6787 -1.5372 -0.1721
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ami complications heart_failure kidney_infection uti complications rehospitalization
H-1718	-0.643125593662262	AMI ▁heart ▁failure ▁ki dne y ▁infection ▁ UTI
D-1718	-0.643125593662262	AMI heart failure kidney infection UTI
P-1718	-1.3060 -2.4250 -0.2481 -0.0083 -0.0680 -0.0885 -0.5174 -1.3606 -0.0047 -0.9111 -0.1366
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox_proportional_hazards_models health health hazard_ratios confidence_intervals
H-689	-0.7569318413734436	▁co x ▁proportion al _ ▁hazard s
D-689	-0.7569318413734436	cox proportional_ hazards
P-689	-0.0529 -0.0241 -0.8789 -0.0302 -0.0384 -1.3748 -0.3071 -3.9870 -0.1190
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone_therapy exercise_rehabilitation patients chronic_heart_failure testosterone double-blind randomized
H-1316	-0.9365601539611816	▁test o ster one _ therapy ▁exercise ▁rehabilita tion ▁chronic _ heart _ ▁failure ▁testosteron e ▁status
D-1316	-0.9365601539611816	testosterone_therapy exercise rehabilitation chronic_heart_ failure testosterone status
P-1316	-1.2703 -1.0360 -0.0446 -0.3805 -2.1276 -0.0387 -2.3197 -0.8212 -0.2179 -4.2189 -0.0596 -1.3390 -1.0743 -0.1464 -1.2887 -0.0279 -1.0815 -0.1815 -0.1204
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence adjusted_odds_ratio hazard_ratio death hf ami admission discharge
H-1308	-0.8807079792022705	▁odds ▁ratio haz ard _ ▁ratio ▁ HF ▁ AMI
D-1308	-0.8807079792022705	odds ratiohazard_ ratio HF AMI
P-1308	-1.3662 -1.9166 -0.4732 -0.0138 -0.3224 -0.0680 -1.9477 -0.4268 -1.4403 -1.0340 -1.3859 -0.1736
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse pasp downward regression_line shift pasp tapse
H-496	-1.0201709270477295	▁t AP se ▁pas p ▁re gression _ ▁line _ ▁shift ▁non sur viv ors ▁pas p
D-496	-1.0201709270477295	tAPse pasp regression_ line_ shift nonsurvivors pasp
P-496	-3.5322 -0.7773 -1.1041 -1.4074 -0.9139 -2.5978 -0.0187 -0.8866 -0.6814 -0.5841 -0.0141 -0.6507 -0.1044 -0.0080 -0.3416 -1.5107 -0.6783 -3.4450 -0.1270
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq kaplan-meier_curves death all-cause_hospitalization
H-784	-0.8223422765731812	▁ cc q ▁ka plan - me ier _ cur ves ▁death ▁hospital ization
D-784	-0.8223422765731812	ccq kaplan-meier_curves death hospitalization
P-784	-1.8554 -0.1582 -1.4494 -0.4002 -0.0488 -0.0186 -0.3385 -0.1892 -0.3613 -0.9763 -2.5617 -1.5803 -1.6589 -1.1137 -0.2609 -0.1860
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome gls beat cox_proportional_hazards_analyses
H-814	-0.5378275513648987	▁m AIN _ o UTC OME _ me a SU RES ▁g LS ▁index _ ▁beat _ ▁method ▁CV _ ▁events ▁co x ▁proportion al _ ▁hazard s
D-814	-0.5378275513648987	mAIN_oUTCOME_meaSURES gLS index_ beat_ method CV_ events cox proportional_ hazards
P-814	-0.6334 -0.0169 -0.1205 -0.8189 -0.0236 -0.0777 -1.9440 -0.2223 -1.0403 -2.3050 -0.2279 -0.3275 -0.8424 -0.0066 -1.1868 -0.0588 -0.2359 -0.6061 -1.0120 -1.6754 -0.2849 -0.1166 -0.0239 -0.1310 -0.0158 -0.0651 -0.5678 -0.1339 -1.2557 -0.1583
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis expenditure b_natriuretic_peptides nps
H-10	-0.39172685146331787	▁li poly sis ▁energie ▁ex pendi ture ▁na tri ure tic _ pe pti des NP s ▁CC
D-10	-0.39172685146331787	lipolysis energie expenditure natriuretic_peptidesNPs CC
P-10	-0.3994 -0.0118 -0.1858 -1.2468 -0.6946 -0.0864 -0.1390 -0.1593 -0.0482 -0.1315 -2.1411 -0.2268 -0.4604 -0.1170 -0.3825 -0.1955 -0.0128 -0.8837 -0.1557 -0.1563
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ischemic_heart_failure biomarkers heart_failure
H-1615	-0.6017124652862549	▁non - ische mic ▁ ische mic _ heart _ ▁failure ▁bio mark ers ▁heart ▁failure
D-1615	-0.6017124652862549	non-ischemic ischemic_heart_ failure biomarkers heart failure
P-1615	-1.6856 -0.0573 -0.0372 -0.4127 -2.4995 -0.0303 -0.3646 -0.4296 -1.8412 -1.2295 -0.0504 -0.0149 -0.0642 -0.0905 -0.9833 -0.6179 -0.2638 -0.1583
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted left_ventricle_end-diastolic_pressure
H-1340	-0.7312436699867249	▁CHF - develop ed _ in far cted _ ▁animals ▁left _ ▁vent ric le _ ▁end - dia sto lic _ ▁pressure
D-1340	-0.7312436699867249	CHF-developed_infarcted_ animals left_ ventricle_ end-diastolic_ pressure
P-1340	-0.4576 -0.7979 -0.1409 -0.0467 -1.0675 -0.1992 -0.0268 -2.9416 -0.4564 -0.8655 -0.2040 -0.5278 -0.9298 -0.8723 -0.4740 -0.7597 -2.5048 -0.1135 -0.0327 -0.0672 -0.1460 -0.1632 -1.3218 -3.0258 -0.1384
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted_county minnesota mi diagnosed hf followed-up
H-1102	-0.5599138140678406	▁o m sted _ ▁County ▁Minnesota ▁MI ▁diagnose d ▁ HF
D-1102	-0.5599138140678406	omsted_ County Minnesota MI diagnosed HF
P-1102	-0.9865 -0.2066 -0.0134 -0.3945 -1.9958 -0.2343 -0.6940 -1.6027 -0.0102 -0.4266 -0.4115 -0.2129 -0.0900
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts mena cardiac_injury mena hf pathophysiology
H-1817	-0.5969522595405579	▁heart s ▁men a ▁cardiac _ ▁injury ▁men a ▁ HF _ pat ho phy si ology
D-1817	-0.5969522595405579	hearts mena cardiac_ injury mena HF_pathophysiology
P-1817	-1.2526 -0.1476 -0.6086 -0.1047 -2.3985 -1.1781 -0.0911 -0.6645 -0.1167 -0.3875 -0.1738 -0.6146 -0.6761 -0.2019 -0.1571 -2.0137 -0.1437 -0.3111 -0.1004
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ras doppler_ultrasonography tomographic_angiography magnetic_resonance_angiography
H-1599	-0.5023345947265625	▁ RAS ▁do pp ler _ ▁ultra son ography ▁com put ed _ to mo graphic _ ang i ography ▁magnetic _ re on ance _ ang i ography
D-1599	-0.5023345947265625	RAS doppler_ ultrasonography computed_tomographic_angiography magnetic_reonance_angiography
P-1599	-1.6689 -0.0097 -0.1959 -0.0345 -1.6570 -0.1493 -0.5612 -0.0836 -0.2402 -0.0114 -0.0042 -0.0818 -0.4233 -0.2438 -0.2332 -0.3223 -0.0676 -2.0982 -0.6400 -0.1348 -0.0902 -0.1137 -1.3879 -0.3985 -0.2986 -0.0787 -2.7517 -0.8965 -0.1170 -0.4189 -0.1596
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence lvad transplantation patients budget
H-316	-0.9060492515563965	▁l VAD ▁transplant ation
D-316	-0.9060492515563965	lVAD transplantation
P-316	-0.4708 -0.1706 -1.7733 -0.1305 -2.7601 -0.1310
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients terminal diagnostic follow-up
H-1819	-1.1387097835540771	▁diagnose s
D-1819	-1.1387097835540771	diagnoses
P-1819	-2.5366 -0.9350 -0.9474 -0.1359
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d therapy
H-107	-0.6010792255401611	▁c RT - d ▁IE ▁de fi br illa tor - on ly _ therapy HR
D-107	-0.6010792255401611	cRT-d IE defibrillator-only_therapyHR
P-107	-0.5502 -2.4891 -0.0329 -0.8849 -2.1375 -0.6980 -0.0172 -0.1805 -0.1959 -0.0290 -0.1123 -0.2745 -0.9136 -0.3839 -0.0554 -1.4488 -0.2809 -0.1349
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ic multicenter_automatic_defibrillator_implantation_trial-cardiac_resynchronization_therapy
H-103	-0.3679046928882599	▁IC ▁multi center _ automat ic _ de ib rilla tor ▁Implant ation ▁tri al - Card iac _ re syn chron ization ▁Therapy
D-103	-0.3679046928882599	IC multicenter_automatic_deibrillator Implantation trial-Cardiac_resynchronization Therapy
P-103	-1.7049 -0.3033 -0.0283 -0.1624 -0.2276 -0.0147 -0.0757 -2.5076 -0.1341 -0.9696 -0.0586 -0.5369 -0.0858 -0.1260 -0.1096 -0.0864 -0.3330 -0.1488 -0.1473 -0.1561 -0.0267 -0.0012 -0.8321 -0.3571 -0.3072 -0.1245
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health_buddy_program admissions chronic_obstructive_pulmonary_disease mortality congestive_heart_failure
H-1627	-0.720431387424469	▁Health _ ▁Budd y _ programm ▁chronic _ ob struct ive _ ▁pulmonar y _ ▁disease ▁mortal ity ▁con ges tive _ heart _ ▁failure
D-1627	-0.720431387424469	Health_ Buddy_programm chronic_obstructive_ pulmonary_ disease mortality congestive_heart_ failure
P-1627	-1.2542 -1.3033 -0.5443 -0.0731 -0.6494 -1.5038 -0.4812 -0.5637 -0.8970 -0.2494 -0.1375 -0.1149 -0.4011 -0.0945 -1.5107 -0.8957 -0.3920 -1.0596 -0.1420 -0.1134 -2.0478 -0.0724 -2.9074 -1.2645 -0.1271 -0.5185 -0.1333
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary_exercise_testing echocardiographic myocardial_function left_ventricular_filling exercise
H-1174	-0.647115170955658	▁Card io pul mon ary ▁e cho car dio graphic ▁my o card ial _ function ▁left _ ▁vent ri cular _ ▁fill ing
D-1174	-0.647115170955658	Cardiopulmonary echocardiographic myocardial_function left_ ventricular_ filling
P-1174	-1.1252 -1.8352 -0.2448 -0.6806 -0.5601 -1.1587 -0.0201 -0.0193 -0.2452 -0.5415 -2.2205 -0.1626 -0.6072 -0.9390 -0.6103 -1.4001 -0.0997 -0.4963 -0.7384 -0.7310 -0.4020 -0.7849 -0.4697 -0.0294 -0.6057 -0.0972
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle_tracking_echocardiography ste bivp acute right_ventricular_pressure_overload rvpo
H-320	-0.6028265953063965	▁spec kle ▁track ing ▁e cho card i ography ▁ste ▁Bi VP ▁right _ ▁vent ri cular _ ▁pressure ▁over load RV PO
D-320	-0.6028265953063965	speckle tracking echocardiography ste BiVP right_ ventricular_ pressure overloadRVPO
P-320	-0.0240 -0.4927 -1.1454 -0.0374 -0.3786 -0.0145 -0.1414 -0.4126 -0.1309 -1.2922 -1.4035 -0.0740 -2.4723 -0.1988 -1.3483 -0.7233 -0.6063 -0.1813 -0.6296 -1.0512 -0.0837 -1.0980 -0.7026 -0.2971 -0.1310
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia postoperative mortality patients left_ventricular_assist_device lvad implantation
H-530	-0.44898006319999695	▁hypo album in emia ▁post operativ e _ ▁mortal ity ▁left _ ▁vent ri cular _ assist _ ▁device ▁l VAD
D-530	-0.44898006319999695	hypoalbuminemia postoperative_ mortality left_ ventricular_assist_ device lVAD
P-530	-0.0305 -0.0980 -0.1786 -0.0493 -0.0623 -0.3207 -0.0607 -0.4661 -0.0624 -0.9186 -0.1095 -0.5375 -1.2626 -1.6029 -0.3623 -0.1978 -0.3463 -1.5991 -1.0813 -0.1229 -0.0294 -0.6470 -0.1810
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular_endothelial_growth_factor vegf transition compensatory_hypertrophy cardiac_failure
H-450	-0.5561678409576416	▁inhibi tion _ van _ ▁vas cular _ en dot heli al _ ▁growth _ factor ve GF ▁compensa tory _ ▁hyper trop hy ▁cardiac _ ▁failure
D-450	-0.5561678409576416	inhibition_van_ vascular_endothelial_ growth_factorveGF compensatory_ hypertrophy cardiac_ failure
P-450	-0.9524 -0.2099 -1.5004 -1.1536 -0.3359 -0.7008 -0.3596 -0.2283 -0.6337 -1.8633 -0.1008 -0.0310 -0.0895 -0.6445 -0.7694 -0.6650 -1.2539 -0.5354 -0.4492 -0.0750 -0.1372 -1.1513 -0.0048 -0.8930 -0.0107 -0.8476 -0.2159 -0.2336 -0.0833
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left_ventricular_ejection_fraction mortality patients heart_failure heart_failure_survey israel
H-110	-0.81350177526474	▁left _ ▁vent ri cular _ e je ction _ fraction ▁long - term _ ▁mortal ity ▁heart _ ▁failure ▁Heart _ ▁Fail ure _ ▁Survey ▁i ra el
D-110	-0.81350177526474	left_ ventricular_ejection_fraction long-term_ mortality heart_ failure Heart_ Failure_ Survey irael
P-110	-2.9362 -0.6623 -1.1349 -1.2887 -1.1354 -0.3057 -0.3795 -0.0994 -0.1427 -0.6170 -0.0948 -5.6374 -0.1066 -0.2571 -0.2774 -0.2446 -0.7636 -0.7953 -1.2016 -0.3236 -0.6578 -1.0005 -0.1591 -1.1003 -0.3985 -0.0506 -2.1324 -0.8248 -0.0110 -0.2340 -0.2456
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity diabetes_mellitus metabolic comorbidities heart_failure_with_preserved_ejection_fraction
H-760	-0.7070465087890625	▁obes iteit ▁diabetes ▁mell itus ▁metabol ic _ risk _ ▁factors ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction
D-760	-0.7070465087890625	obesiteit diabetes mellitus metabolic_risk_ factors heart_ failure preserved_ejection_fraction
P-760	-2.5476 -2.6105 -0.0840 -0.0337 -0.0535 -0.3724 -0.0104 -0.3868 -1.1951 -1.9467 -0.7132 -3.2115 -1.5315 -0.0878 -0.3591 -0.1974 -0.5340 -0.1741 -0.4786 -0.1475 -0.1495 -0.1043 -0.0578 -0.4396 -0.2495
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil cardioprotection apoptotic_signaling_pathway dna_fragmentation mitochondrial
H-965	-0.29170337319374084	▁nic oran dil ▁cardio protec tion ▁apo pto tic _ signal ing _ ▁path way ▁DNA ▁fragment ation ▁mito cho ndri al _ ▁ultra struct ural
D-965	-0.29170337319374084	nicorandil cardioprotection apoptotic_signaling_ pathway DNA fragmentation mitochondrial_ ultrastructural
P-965	-0.0240 -0.0667 -0.2598 -0.5463 -0.3601 -0.1753 -0.3340 -0.0384 -0.6189 -0.0328 -0.2303 -0.0899 -0.9011 -0.3348 -0.1659 -0.1140 -0.2091 -0.0671 -0.0028 -0.3544 -0.1531 -0.0602 -0.2072 -1.0943 -0.0753 -0.0230 -1.4738 -0.1552
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous coronary_revascularization hemodynamically stable patient intensive_care_unit icu
H-1293	-0.525938093662262	▁per cuta ne ous _ ▁corona ry _ re vas cular ization ▁hem o dynamic ally
D-1293	-0.525938093662262	percutaneous_ coronary_revascularization hemodynamically
P-1293	-0.0777 -0.0033 -0.2855 -2.1657 -0.0954 -0.3645 -1.6996 -0.1576 -0.2915 -0.3157 -0.4066 -0.8870 -0.1185 -0.1832 -0.0037 -0.7785 -1.5474 -0.0855
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary_endpoints therapy atrial_fibrillation atrial_tachyarrhythmias atp shock_therapy
H-860	-0.5057441592216492	▁ therapy ▁at rial _ fi bril lation ▁at rial _ ta chy ar rhythm ias ▁ATP ▁shock _ therapy
D-860	-0.5057441592216492	therapy atrial_fibrillation atrial_tachyarrhythmias ATP shock_therapy
P-860	-3.3190 -0.2551 -0.6246 -0.0686 -0.7457 -0.4271 -0.0331 -0.0473 -0.1895 -0.0961 -0.5202 -2.0973 -0.3625 -0.0341 -0.0776 -0.4851 -0.2151 -0.0280 -1.0002 -0.0139 -0.3426 -0.1438
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic renal_underperfusion renin-_angiotensin-aldosterone_pathway
H-1596	-0.7116966247558594	▁pat ho phy si ologic _ ▁mechanism ▁stem s ▁renal _ under per fusion ▁re nin - _ ▁ang io ten sin - al do ster one
D-1596	-0.7116966247558594	pathophysiologic_ mechanism stems renal_underperfusion renin-_ angiotensin-aldosterone
P-1596	-2.6187 -0.1529 -0.8317 -1.4836 -0.0664 -1.0002 -0.1324 -1.1177 -0.1195 -0.0737 -0.1523 -4.0935 -0.1351 -0.0570 -0.0159 -0.3641 -0.0359 -0.9691 -3.1455 -0.5384 -0.0830 -0.6579 -0.4264 -0.0205 -0.7114 -0.0310 -0.4332 -0.9468 -0.2256
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics pressure-overload-induced_heart_failure mitochondrial-targeted_peptides
H-869	-0.336327463388443	▁prote o mics ▁pressure - over load - indu ced _ heart _ ▁failure ▁mito cho ndri al - tar get ed _ pe pti des
D-869	-0.336327463388443	proteomics pressure-overload-induced_heart_ failure mitochondrial-targeted_peptides
P-869	-1.9564 -1.1847 -0.0027 -0.2931 -0.0559 -0.0024 -0.0831 -0.1671 -0.0125 -0.3008 -0.0751 -1.3981 -0.9704 -0.0919 -0.0105 -0.1746 -0.4473 -0.0422 -0.0778 -0.0164 -0.0808 -0.0258 -0.5782 -0.5497 -0.0923 -0.2765 -0.3095 -0.1414
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration hr_reduction bpm p_value
H-1942	-1.1027555465698242	▁dose _ up tit ration ▁HR _ re duction
D-1942	-1.1027555465698242	dose_uptitration HR_reduction
P-1942	-1.2660 -1.9006 -0.4084 -0.3723 -0.3386 -2.0656 -3.3127 -0.6030 -0.1485 -1.5646 -0.1500
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv_fractional_shortening lung incidence
H-278	-0.5199301838874817	▁ ANS _ mi ce ▁LV ▁ fraction al _ short en ing ▁lung _ weight
D-278	-0.5199301838874817	ANS_mice LV fractional_shortening lung_weight
P-278	-2.2976 -0.1439 -0.2708 -0.5226 -0.4125 -0.7415 -1.1798 -0.0081 -0.0592 -0.2706 -0.4163 -0.0903 -0.1616 -0.1956 -0.4690 -1.4616 -0.4997 -0.1582
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional_enrichment_analysis regulation cell_death degs
H-1614	-0.6115401983261108	▁functional _ en rich ment _ analyse ▁programme d _ cell _ ▁death ▁de g s
D-1614	-0.6115401983261108	functional_enrichment_analyse programmed_cell_ death degs
P-1614	-0.1484 -0.4359 -0.6038 -0.0981 -0.1477 -1.2333 -0.2323 -1.2002 -0.1325 -0.0275 -1.9766 -0.3114 -0.2579 -0.2423 -3.4087 -0.0980 -0.2770 -0.1761
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction rad_variant q66p congestive_heart_failure
H-1673	-1.0577670335769653	▁Rad _ ▁variant Q 66 p ▁con ges tive _ ▁heart ▁failure
D-1673	-1.0577670335769653	Rad_ variantQ66p congestive_ heart failure
P-1673	-1.3993 -1.5783 -0.4980 -4.1983 -0.4086 -0.2094 -0.0430 -0.0908 -1.6398 -0.0634 -2.2263 -0.4046 -1.9456 -0.1032
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk scn5a kv4.3 mrna mrna_splice
H-1087	-0.6481137275695801	▁PER k ▁inhibi tion ▁s cn 5 a ▁kv 4.3 ▁m RNA ▁m RNA ▁sp lice
D-1087	-0.6481137275695801	PERk inhibition scn5a kv4.3 mRNA mRNA splice
P-1087	-1.3170 -0.9111 -1.2179 -0.0835 -0.6449 -0.3234 -0.9976 -0.1294 -0.4477 -0.4211 -0.0353 -0.0543 -3.4150 -0.2845 -0.3800 -0.2345 -0.6772 -0.0919
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic_heart_failure spironolactone hospitalization death
H-446	-0.4020453095436096	▁sy sto lic _ heart _ ▁failure ▁spi rono lac tone
D-446	-0.4020453095436096	systolic_heart_ failure spironolactone
P-446	-0.8451 -0.0922 -0.2631 -0.0317 -1.2593 -1.4744 -0.0447 -0.0186 -0.0060 -0.0267 -0.0802 -0.9174 -0.1672
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg atherosclerotic_cad cardiac_death
H-1910	-0.44159117341041565	▁e CG ▁a ther os cle ro tic _ ▁CAD ▁sud den _ ▁cardiac _ ▁death
D-1910	-0.44159117341041565	eCG atherosclerotic_ CAD sudden_ cardiac_ death
P-1910	-2.1290 -1.3018 -0.4105 -0.6755 -0.0867 -0.1868 -0.0506 -0.3249 -0.2318 -0.4769 -0.1425 -0.0264 -0.0642 -0.0274 -0.9129 -0.3533 -0.3987 -0.1487
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr_variability risk_stratification
H-1587	-0.9281123876571655	▁HR _ dynamic s ▁spec tral ▁non - line ar _ meter s ▁HR ▁variabil ity ▁risk _ ▁strat ification
D-1587	-0.9281123876571655	HR_dynamics spectral non-linear_meters HR variability risk_ stratification
P-1587	-0.9589 -2.5528 -0.0891 -0.0534 -4.0800 -0.0013 -0.9485 -0.0093 -0.0112 -0.0765 -0.8061 -1.3426 -0.7199 -1.9377 -0.5328 -1.7640 -0.9394 -1.7869 -0.6507 -0.4097 -0.5124 -0.2355
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef bnp hf patients prognostic significance bnp ef
H-188	-1.0183786153793335	▁sex ▁EF ▁b NP ▁ HF ▁b NP ▁sex ▁EF
D-188	-1.0183786153793335	sex EF bNP HF bNP sex EF
P-188	-1.5261 -1.4268 -0.4920 -0.4519 -1.4479 -0.2192 -1.6695 -0.6243 -1.7782 -1.9654 -0.4644 -0.1549
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ami hazard_ratio mortality
H-1313	-0.8862614035606384	▁ HF ▁index ▁ AMI ▁adjust ed _ ▁hazard _ ▁ratio
D-1313	-0.8862614035606384	HF index AMI adjusted_ hazard_ ratio
P-1313	-1.6110 -0.6892 -0.0069 -1.1592 -0.0652 -2.4093 -0.1860 -0.0773 -1.0727 -1.2909 -0.0454 -2.7137 -0.1945
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets transcriptional_pause_release pathological
H-1052	-0.34744665026664734	▁ BET s ▁tran scription al _ ▁pause _ ▁release ▁tran scription ▁path ological _ stress
D-1052	-0.34744665026664734	BETs transcriptional_ pause_ release transcription pathological_stress
P-1052	-0.8549 -0.2204 -0.1931 -0.2021 -0.1404 -0.1864 -0.5521 -0.7968 -0.3725 -0.3752 -0.4202 -0.0504 -0.4340 -0.4302 -0.2905 -0.3067 -0.2845 -0.1435
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis pathogenesis heart_failure
H-173	-0.9755584001541138	▁apo pto sis ▁path ogen es is ▁heart _ ▁failure
D-173	-0.9755584001541138	apoptosis pathogenesis heart_ failure
P-173	-1.8312 -0.2305 -0.5731 -1.9061 -0.1410 -0.0700 -0.1657 -4.2403 -1.6730 -0.0712 -0.6594 -0.1453
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic neurohormonal symptoms fluid_overload
H-1201	-0.46417227387428284	▁di ure tic _ ef fica cy ▁neuro hormon al _ activa tion ▁fluid ▁over load
D-1201	-0.46417227387428284	diuretic_efficacy neurohormonal_activation fluid overload
P-1201	-0.4848 -0.3442 -1.4906 -0.5153 -0.6554 -0.4946 -0.2135 -0.1069 -0.0439 -0.1064 -0.4988 -0.2561 -0.1604 -1.6547 -0.5461 -0.4022 -0.2764 -0.1047
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr mrna_splice cardiac hf
H-1088	-0.6868771314620972	▁u PR ▁na + _ ▁channel ▁m RNA ▁sp lice ▁cardiac _ na + _ ▁current ▁human _ HF
D-1088	-0.6868771314620972	uPR na+_ channel mRNA splice cardiac_na+_ current human_HF
P-1088	-1.4907 -1.3104 -0.1818 -1.6333 -0.6129 -0.2705 -0.1480 -0.0852 -0.4266 -0.3195 -0.1223 -0.5468 -0.9859 -1.3332 -0.3814 -1.0026 -1.8680 -0.2963 -1.0521 -0.2328 -0.1240
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients preserved_lvef lvef
H-114	-0.5731391310691833	▁LV EF ▁LV EF
D-114	-0.5731391310691833	LVEF LVEF
P-114	-0.8643 -0.3553 -1.4419 -0.2760 -0.3672 -0.1342
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated mena_expression correlates hf mena cardiac pathophysiology
H-1812	-0.6107831597328186	▁men a ▁expression ▁ HF ▁men a ▁cardiac _ pat ho phy si ology
D-1812	-0.6107831597328186	mena expression HF mena cardiac_pathophysiology
P-1812	-0.6764 -0.0843 -1.0081 -0.3546 -0.4057 -2.2377 -0.0712 -0.2827 -0.1835 -0.8980 -0.4696 -0.1745 -2.4236 -0.1327 -0.2483 -0.1218
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc nps clinical
H-1024	-0.9134775996208191	▁ NP _ ▁measure ment ▁PO c ▁ NP s ▁clinic al _ care ▁delivery
D-1024	-0.9134775996208191	NP_ measurement POc NPs clinical_care delivery
P-1024	-0.5974 -0.0441 -2.7530 -1.0771 -0.0227 -0.6365 -2.1833 -3.1752 -0.0742 -0.2955 -1.6437 -0.0608 -0.1593 -1.3825 -0.8912 -0.4222 -0.1105
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence intestinal patients chf
H-1358	-0.6202511191368103	▁REC ENT _ ▁FIN DING s ▁intestinal _ morph ology ▁per me ability ▁ab sor p tion _ ▁function ▁CHF
D-1358	-0.6202511191368103	RECENT_ FINDINGs intestinal_morphology permeability absorption_ function CHF
P-1358	-0.3841 -0.6968 -0.0504 -0.2648 -3.1744 -0.2295 -2.3994 -0.3413 -0.0558 -0.4297 -0.5588 -0.1269 -0.2260 -0.0285 -0.5321 -1.0757 -1.0785 -0.8364 -0.3872 -0.3460 -0.2874 -0.1359
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized follow-up
H-1751	-0.5699872970581055	▁benefits ▁follow - up
D-1751	-0.5699872970581055	benefits follow-up
P-1751	-0.7414 -2.0275 -0.0896 -0.0225 -0.4449 -0.0940
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis heart_failure myocardial_tissue left_ventricular trichrome_blue_histologic_analysis
H-1060	-0.5915047526359558	▁fibro sis _ of _ heart _ ▁failure _ ▁my o card ial _ ▁tissu e ▁left _ ▁vent ri cular _ ▁tissu e ▁tri ch rom e _ blue _ ▁his t ologic
D-1060	-0.5915047526359558	fibrosis_of_heart_ failure_ myocardial_ tissue left_ ventricular_ tissue trichrome_blue_ histologic
P-1060	-0.0057 -0.2191 -1.0641 -1.5711 -0.1410 -1.1805 -1.0256 -0.0541 -1.3457 -2.4252 -0.3643 -0.7074 -1.0621 -0.2350 -0.3390 -0.1117 -0.2711 -0.3189 -1.9628 -1.1923 -0.3123 -0.2517 -0.2274 -0.0704 -0.0209 -0.0224 -0.0015 -0.0147 -0.0399 -0.6860 -0.2540 -1.4521 -0.5040 -0.1503 -1.5241 -0.1656
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid_annular_plane_systolic_excursion pulmonary_arterial_systolic_pressure heart_failure right_ventricular_contractile_function prognosis
H-491	-0.48784059286117554	▁tri cus pid _ ▁ann ular _ ▁plane ▁sy sto lic _ excursion ▁pulmonar y _ ▁arterial _ ▁sy sto lic _ ▁pressure ▁heart _ ▁failure ▁index ▁right _ ▁vent ri cular _ contract ile
D-491	-0.48784059286117554	tricuspid_ annular_ plane systolic_excursion pulmonary_ arterial_ systolic_ pressure heart_ failure index right_ ventricular_contractile
P-491	-0.0400 -0.0193 -0.0371 -0.2650 -2.0862 -0.0023 -0.0463 -0.7048 -0.5040 -0.1090 -0.1621 -0.2465 -0.0274 -0.0021 -0.0181 -1.0968 -0.1319 -0.5214 -0.4151 -0.0521 -0.1545 -0.0698 -2.5517 -0.9557 -1.5825 -0.1507 -0.0108 -0.5215 -0.2155 -2.2181 -0.9324 -0.3721 -0.1457 -0.7443 -0.0692 -0.7061 -0.1621
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes patients atrial_fibrillation early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial
H-1642	-0.8553941249847412	▁at rial _ fi bril lation ▁At rial _ fi bril lation ▁Stro ke ▁pre vention ▁tri al
D-1642	-0.8553941249847412	atrial_fibrillation Atrial_fibrillation Stroke prevention trial
P-1642	-4.0490 -0.1829 -0.5507 -0.4171 -0.1608 -0.1702 -5.4834 -0.1116 -0.4269 -0.2951 -0.0974 -0.1118 -0.6589 -0.3305 -2.2386 -0.0034 -1.2367 -0.2455 -0.2241 -0.1132
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas_city_cardiomyopathy_questionnaire kccq hf_with_reduced_ef patients hfpef
H-781	-0.6522352695465088	▁Kansas ▁City _ card i om yo pathy _ ▁Question naire ▁k cc q ▁ HF ▁EF ▁ HF p EF
D-781	-0.6522352695465088	Kansas City_cardiomyopathy_ Questionnaire kccq HF EF HFpEF
P-781	-0.0207 -1.1344 -0.2862 -1.3480 -0.0481 -0.0380 -1.0289 -0.0594 -2.1132 -0.0419 -0.0020 -0.6087 -0.0364 -0.8775 -0.3225 -0.3799 -3.3606 -1.4020 -0.4597 -0.4318 -0.6758 -0.2099 -0.1156
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab chf nontrastuzumab_users hazard_ratio
H-679	-0.6762343049049377	▁Tras tuz um ab ▁CHF ▁non tras tuz um ab _ ▁users haz ard _ ▁ratio HR
D-679	-0.6762343049049377	Trastuzumab CHF nontrastuzumab_ usershazard_ ratioHR
P-679	-1.1871 -0.1167 -0.0412 -0.5044 -0.3453 -0.3076 -0.4495 -0.0525 -0.0966 -1.5960 -4.9625 -0.3084 -0.1056 -0.0077 -0.8461 -0.0231 -0.6543 -1.0715 -0.1722
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood_pressure arm_cuff stroke_volume ejection_fraction end-diastolic_volume echocardiography
H-521	-0.3136981129646301	▁Blood ▁pressure ▁arm ▁cu ff ▁stroke _ ▁volume ▁v ▁e je ction _ fraction ▁end - dia sto lic _ ▁volume ▁e cho card i ography
D-521	-0.3136981129646301	Blood pressure arm cuff stroke_ volume v ejection_fraction end-diastolic_ volume echocardiography
P-521	-0.1000 -0.8233 -0.5880 -0.5960 -0.0303 -0.0994 -1.4139 -0.1119 -0.9833 -0.3891 -0.0356 -0.0196 -0.2517 -0.0822 -1.6917 -0.0637 -0.0321 -0.0566 -0.0865 -0.1178 -0.0764 -0.0300 -0.0567 -0.1716 -0.2324 -0.2694 -0.2526 -0.1218
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients atrial_fibrillation heart_failure hf stroke anticoagulation patients
H-1353	-0.5764700174331665	▁at rial _ fi bril lation AF ▁heart ▁failure HF ▁stroke ▁antico ag ulation
D-1353	-0.5764700174331665	atrial_fibrillationAF heart failureHF stroke anticoagulation
P-1353	-1.9571 -0.0552 -0.3967 -0.3434 -0.0181 -0.0903 -0.8495 -0.5567 -0.5120 -0.4586 -2.3160 -0.6746 -0.0729 -0.1015 -0.7258 -0.0950
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt_loading uninephrectomy ang_ii_infusion cardiac_function hf
H-282	-0.4695524573326111	▁salt ▁load ing ▁un ine ph r ecto my ▁ANG _ ▁II _ in fusion _ ▁mouse _ ▁model ▁cardiac _ ▁function ▁mi ce ▁ HF
D-282	-0.4695524573326111	salt loading uninephrectomy ANG_ II_infusion_ mouse_ model cardiac_ function mice HF
P-282	-0.0454 -0.3596 -0.0163 -0.0031 -1.0654 -0.9697 -0.0535 -0.0242 -0.9752 -0.2379 -0.4119 -0.6406 -0.9136 -0.5892 -0.0022 -0.4231 -0.0652 -0.8471 -0.7770 -0.0054 -0.6423 -0.4298 -1.4186 -0.0483 -1.8817 -0.1131 -0.1101 -0.0778
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck_stent myocardial_infarction antiplatelet_medication
H-508	-0.3889971375465393	▁bottle ne ck _ ▁sten t ▁my o card ial _ in far ction ▁anti plate let ▁medication
D-508	-0.3889971375465393	bottleneck_ stent myocardial_infarction antiplatelet medication
P-508	-0.5984 -0.1396 -0.0287 -0.3856 -1.4940 -0.0428 -1.4652 -0.3662 -0.7262 -0.6108 -0.2221 -0.2294 -0.0986 -0.0199 -0.0082 -0.0910 -0.1767 -0.5098 -0.4344 -0.1324
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential_effect lvef mortality hospitalization acute decompensated_hf
H-112	-0.6000307202339172	▁LV EF ▁long - term _ ▁mortal ity ▁a cute _ de com pensa ted _ HF
D-112	-0.6000307202339172	LVEF long-term_ mortality acute_decompensated_HF
P-112	-0.6887 -0.5642 -4.0001 -0.0974 -0.0984 -0.1364 -0.3152 -1.3993 -1.6914 -0.0791 -0.0790 -0.3067 -0.2275 -0.1297 -0.2998 -0.2036 -0.6797 -0.2372 -0.1673
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination echocardiographic lv_reverse_remodeling sensitivity specificity
H-433	-0.3191596269607544	▁e cho car dio graphic _ ▁score ▁LV ▁rever se _ ▁remodel ing
D-433	-0.3191596269607544	echocardiographic_ score LV reverse_ remodeling
P-433	-0.0697 -0.0423 -0.0611 -0.3697 -0.5941 -1.0721 -0.5764 -0.0921 -0.6191 -0.0629 -0.0546 -0.2703 -0.0450 -0.6868 -0.1712
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan_failure circulatory hemodynamic portal_hypertension cardiac_output
H-234	-0.3382938504219055	▁Font an _ ▁failure ▁circula tory _ de rang ement ▁hem o dynamic ▁portal _ ▁hyper tension ▁cardiac _ ▁output
D-234	-0.3382938504219055	Fontan_ failure circulatory_derangement hemodynamic portal_ hypertension cardiac_ output
P-234	-0.3034 -0.1195 -0.5315 -0.0794 -0.0039 -0.0919 -0.5158 -0.9160 -0.0084 -1.0806 -0.1476 -0.3338 -0.0022 -0.2534 -0.3830 -0.4305 -0.0143 -0.7309 -0.9860 -0.0266 -0.3912 -0.0924
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients biventricular_support heartmate_ii lvad centrimag right_ventricular_assist_device rvad
H-296	-0.5786773562431335	▁bi ven tri cular _ support ▁hybrid _ systeem ▁Heart Mate _ ▁II _ ▁l VAD ▁Centri Mag ▁right _ ▁vent ri cular _ assist ▁device ▁r VAD
D-296	-0.5786773562431335	biventricular_support hybrid_systeem HeartMate_ II_ lVAD CentriMag right_ ventricular_assist device rVAD
P-296	-1.9269 -0.0558 -0.1551 -0.9417 -0.4441 -1.0305 -0.6820 -0.5035 -0.9626 -1.0158 -0.0724 -0.2087 -0.7182 -0.3649 -1.1039 -0.0156 -0.1363 -0.5689 -0.5300 -0.1068 -0.7192 -0.8438 -0.3038 -0.1505 -0.2999 -1.5638 -1.4671 -0.0761 -0.2315 -0.1610
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action correlation baseline hgb baseline hrqol kccq
H-842	-0.4719926118850708	▁ HF - ac tion _ co hor t ▁h gb ▁base line _ ▁HR Qo L ▁k cc q
D-842	-0.4719926118850708	HF-action_cohort hgb baseline_ HRQoL kccq
P-842	-0.6681 -0.2235 -0.0130 -0.3779 -1.4879 -0.4240 -0.5256 -0.3245 -0.0234 -0.7779 -0.0076 -0.3511 -0.0110 -0.3222 -1.1966 -0.0063 -1.5125 -0.6242 -0.0833 -1.1313 -0.2040 -0.0877
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional_ms patients valve_plasty degenerative_mr dilated disease
H-340	-0.3246445655822754	▁functional ▁MS ▁val ve ▁plast y ▁ann ular _ ▁size ▁re duction ▁de genera tive _ ▁MR ▁LV ▁disease
D-340	-0.3246445655822754	functional MS valve plasty annular_ size reduction degenerative_ MR LV disease
P-340	-0.0102 -0.5939 -0.4906 -0.0152 -0.7524 -0.2413 -0.0115 -0.0015 -0.2355 -0.4941 -1.3533 -0.0249 -0.0369 -0.0016 -0.2135 -0.2703 -0.6177 -0.0283 -1.1582 -0.1833 -0.0834
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined_training peak_work_rate peak_quadriceps_force
H-1917	-0.8160627484321594	▁combine d _ training ▁pe ak _ work ▁rate ▁pe ak _ ▁quadri cep s _ ▁force
D-1917	-0.8160627484321594	combined_training peak_work rate peak_ quadriceps_ force
P-1917	-4.6991 -0.1161 -0.8073 -0.2235 -0.7083 -0.1226 -0.0983 -1.6374 -3.8783 -0.4848 -0.1872 -0.1465 -0.5428 -0.2220 -0.0888 -0.3404 -0.5032 -0.4764 -0.2224
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological remodelling heart cardiac_hypertrophy hf death fibrosis inflammation
H-1035	-0.5786839127540588	▁path ological _ ▁remodel ling ▁heart ▁cardiac _ ▁hyper trop hy ▁ HF ▁fibro sis ▁ inflammation
D-1035	-0.5786839127540588	pathological_ remodelling heart cardiac_ hypertrophy HF fibrosis inflammation
P-1035	-2.1262 -0.5984 -0.8032 -0.0171 -0.4096 -3.1291 -0.0593 -0.9521 -0.4696 -0.0137 -1.3583 -0.1898 -0.0850 -0.0930 -0.0859 -0.1571 -0.0068 -0.3088 -0.1321
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based prognosis idiopathic_dilated_cardiomyopathy
H-1750	-0.5564388036727905	▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy
D-1750	-0.5564388036727905	idiopathic_ dilated_ cardiomyopathy
P-1750	-1.1622 -1.5179 -0.1217 -0.1558 -0.5534 -0.6628 -0.3917 -0.0617 -0.6606 -1.6077 -0.4950 -0.0201 -0.2472 -0.1323
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report functional_ms patient valve_plasty degenerative_mr dilated disease
H-375	-0.3999978005886078	▁functional ▁MS ▁val ve _ plast y ▁de genera tive _ ▁MR ▁LV ▁disease
D-375	-0.3999978005886078	functional MS valve_plasty degenerative_ MR LV disease
P-375	-0.0410 -1.0326 -0.6076 -0.0129 -0.9295 -0.9727 -0.2906 -0.0676 -0.0023 -0.2177 -0.2168 -0.5487 -0.0298 -1.1147 -0.2369 -0.0786
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty prognostic heart_failure hf biological_phenotype
H-1001	-0.7626601457595825	▁fra il ty ▁heart ▁failure HF
D-1001	-0.7626601457595825	frailty heart failureHF
P-1001	-0.6336 -0.5238 -0.0553 -2.0087 -1.0020 -0.6370 -1.0867 -0.1542
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients physicians readmission hospital
H-1728	-1.0046088695526123	▁high - volu me _ ▁physician s
D-1728	-1.0046088695526123	high-volume_ physicians
P-1728	-1.8193 -0.0955 -0.4834 -0.1653 -0.0941 -1.1014 -0.0613 -5.0557 -0.1656
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus cells functional_capacity mortality nondiabetic patients
H-131	-0.9035771489143372	▁ EO - c FU s ▁cd 34 ve g FR 2 _ ▁cell s ▁functional _ ▁capacity ▁non dia be tic _ ▁patients
D-131	-0.9035771489143372	EO-cFUs cd34vegFR2_ cells functional_ capacity nondiabetic_ patients
P-131	-2.1720 -0.1044 -0.0527 -0.7103 -0.6899 -0.4629 -0.5696 -0.2688 -2.8084 -1.3170 -1.0153 -0.8888 -2.3046 -0.9985 -0.0662 -1.0876 -1.7269 -1.8080 -0.5872 -0.0314 -0.1303 -1.4021 -0.9784 -0.9058 -0.2901 -0.1160
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology comorbidities patients outcomes
H-564	-0.6462668776512146	▁et i ology ▁como rbi di ties
D-564	-0.6462668776512146	etiology comorbidities
P-564	-3.2596 -0.2030 -0.1072 -0.3169 -0.0216 -0.5206 -0.0202 -1.2134 -0.1539
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni cardiovascular_mortality hospitalization heart_failure quality_of_life
H-1969	-0.8430185914039612	▁AR NI ▁cardiovascular _ ▁mortal ity ▁hospital ization ▁heart _ ▁failure ▁quality _ of _ ▁life
D-1969	-0.8430185914039612	ARNI cardiovascular_ mortality hospitalization heart_ failure quality_of_ life
P-1969	-2.5718 -0.5018 -0.4120 -0.8752 -0.1216 -0.8293 -0.2734 -0.5594 -1.8990 -1.3647 -0.1535 -1.1052 -0.6184 -0.7676 -0.1981 -2.3228 -0.3634 -0.2372
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right_ventricular rv prognosis patients heart_failure hf
H-1158	-0.9809262752532959	▁right _ ▁vent ri cular RV ▁body ▁composition ▁advanced _ heart _ ▁failure HF
D-1158	-0.9809262752532959	right_ ventricularRV body composition advanced_heart_ failureHF
P-1158	-1.1576 -0.2943 -0.8959 -0.6785 -0.1945 -1.4808 -4.0242 -1.2591 -1.3360 -0.0924 -2.1415 -1.2725 -0.0711 -0.3803 -0.2496 -0.1662
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial_dd muscle titin_hypophosphorylation
H-768	-0.5835956335067749	▁my o card ial _ DD ▁muscle _ ▁strip ▁sti ff ness ▁titi n ▁hypo phos phor y lation
D-768	-0.5835956335067749	myocardial_DD muscle_ strip stiffness titin hypophosphorylation
P-768	-1.3162 -0.1407 -0.1016 -0.2227 -1.0868 -0.3462 -3.1590 -1.0297 -0.1761 -0.2172 -0.0626 -1.8900 -0.0358 -0.0546 -0.8666 -0.0680 -0.2520 -0.7968 -0.0488 -0.2717 -0.1123
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins expression cardiac_hypertrophy proteins nucleolin
H-95	-0.563642144203186	▁protein s ▁cardiac _ ▁hyper trop hy ▁nu cle olin
D-95	-0.563642144203186	proteins cardiac_ hypertrophy nucleolin
P-95	-1.8909 -0.0897 -0.1176 -0.6650 -0.5917 -0.0229 -1.0658 -1.7343 -0.0043 -0.1390 -0.2753 -0.1672
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise training outcomes hf patients exercise training therapy clinical
H-1934	-1.0317742824554443	▁exercise _ training ▁ HF
D-1934	-1.0317742824554443	exercise_training HF
P-1934	-0.8328 -1.6198 -0.2815 -1.4944 -0.1530 -2.6695 -0.1714
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients exercise anaerobic_metabolism peak_respiratory_quotient
H-1756	-0.8636018633842468	▁ana ero bic _ ▁metabolism ▁respirator y _ quot ient
D-1756	-0.8636018633842468	anaerobic_ metabolism respiratory_quotient
P-1756	-5.9289 -0.6108 -0.1950 -0.2442 -0.3238 -0.6494 -0.1672 -1.2870 -0.0234 -0.0783 -0.6855 -0.1696
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ef
H-192	-1.8215627670288086	▁border line ▁pres er ved ▁female
D-192	-1.8215627670288086	borderline preserved female
P-192	-6.7006 -0.0625 -2.4178 -0.1151 -0.7256 -2.4599 -1.8956 -0.1953
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-1.124434471130371	▁virtual _ co hor ts
D-2014	-1.124434471130371	virtual_cohorts
P-2014	-1.3431 -0.1785 -0.4630 -0.4087 -0.2702 -5.0758 -0.1317
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac_magnetic_resonance amyloidotic diagnosis multiple_myeloma osteomedullary_biopsy
H-999	-0.44830137491226196	▁cardiac _ ▁magnetic _ ▁res on ance ▁a my lo ido tic ▁multiple _ ▁mye loma ▁osteo me dulla ry _ ▁bio psy
D-999	-0.44830137491226196	cardiac_ magnetic_ resonance amyloidotic multiple_ myeloma osteomedullary_ biopsy
P-999	-0.0044 -0.3703 -0.1145 -0.1122 -0.9659 -0.1664 -0.0734 -0.0529 -0.5246 -0.0378 -0.0326 -1.2976 -1.5978 -0.4455 -1.6830 -0.1587 -0.0292 -0.0310 -0.0364 -2.1916 -0.7424 -0.0334 -0.0162 -0.4017 -0.0881
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash diastolic_function ventricular-arterial_coupling hypertensive_heart_failure_with_preserved_ejection_fraction
H-915	-0.3665924072265625	▁Low - so dium _ ▁DAS h ▁die t ▁dia sto lic _ function ▁vent ri cular - arte rial _ ▁coup ling ▁hyper tensi ve _ heart _ ▁failure ▁pres er ved _ e je ction _ fraction
D-915	-0.3665924072265625	Low-sodium_ DASh diet diastolic_function ventricular-arterial_ coupling hypertensive_heart_ failure preserved_ejection_fraction
P-915	-0.8856 -0.0622 -0.0253 -0.0134 -0.8408 -0.4482 -0.2562 -2.2403 -0.0851 -0.0093 -0.0213 -0.0707 -0.7488 -0.9758 -0.0089 -1.1170 -0.1762 -0.1696 -0.2135 -0.1013 -0.2273 -0.2628 -0.2925 -0.1689 -0.0825 -0.0637 -0.0323 -1.7388 -1.0834 -0.0437 -0.2132 -0.2074 -0.3923 -0.4103 -0.3861 -0.1203 -0.0921 -0.2330 -0.0244 -0.3406 -0.1450
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular_endothelial_growth_factor_blockade beta-blocker therapy cardiac_function angiogenesis remodeling heart_failure
H-448	-0.4360826015472412	▁Vas cular _ en dot heli al _ ▁growth _ factor _ ▁block ade ▁beta - block er _ therapy ▁cardiac _ ▁function ▁ang io gene sis ▁remodel ing ▁heart ▁failure
D-448	-0.4360826015472412	Vascular_endothelial_ growth_factor_ blockade beta-blocker_therapy cardiac_ function angiogenesis remodeling heart failure
P-448	-0.8104 -0.2596 -0.1693 -0.4971 -1.0506 -0.1188 -0.0197 -0.0863 -0.7417 -0.5591 -0.5319 -1.0027 -1.8623 -0.1223 -0.3133 -0.0141 -0.1041 -0.0804 -1.3401 -0.0445 -0.0284 -0.8847 -0.5077 -0.2287 -0.4652 -0.1708 -0.3785 -0.6899 -0.0161 -0.3050 -0.6661 -0.2113 -0.1098
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable_cardioverter-defibrillators icds mortality cardiac_resynchronization_therapy crt symptoms mortality
H-1068	-0.5804768204689026	▁implant able _ ▁cardio ver ter - de fi br illa tors ic d s ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-1068	-0.5804768204689026	implantable_ cardioverter-defibrillatorsicds cardiac_resynchronization_therapy cRT
P-1068	-0.8258 -0.0251 -0.2496 -1.0583 -0.0489 -0.3026 -0.3284 -0.0766 -0.1856 -0.6848 -0.2052 -0.2862 -1.9977 -1.0085 -0.2016 -0.2744 -0.9168 -0.5774 -0.0292 -0.0046 -1.2174 -1.0005 -0.1723 -0.5654 -2.3130 -0.9870 -0.1297
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis hfpef clinical echo-doppler_cardiography invasive_haemodynamic_assessment
H-1303	-0.4678838551044464	▁ HF p EF ▁e cho - D opp ler _ card i ography ▁invasi ve ▁ha emo dynamic _ ▁assessment
D-1303	-0.4678838551044464	HFpEF echo-Doppler_cardiography invasive haemodynamic_ assessment
P-1303	-1.4410 -0.3568 -0.0499 -0.4957 -0.0813 -0.0184 -0.0184 -1.7853 -0.0428 -1.1158 -0.1664 -1.0496 -0.1026 -0.2038 -0.0143 -0.0617 -0.9530 -0.1754 -0.0055 -1.8149 -0.4086 -0.3122 -0.0879
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker uptitrations patients hfref hfpef hospital admission
H-177	-0.671596348285675	▁ RAS - ▁β - block er _ up ti tra tions ▁h Fr ef ▁ HF p EF
D-177	-0.671596348285675	RAS- β-blocker_uptitrations hFref HFpEF
P-177	-1.0605 -0.0230 -0.0302 -0.4694 -0.0902 -0.4438 -0.0746 -1.9275 -0.2585 -0.4671 -2.7035 -1.3784 -0.8949 -0.4823 -1.1344 -0.6515 -0.3171 -0.0972 -0.7340 -0.7165 -0.1488
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular_assist_device vad extracorporeal_membrane_oxygenation ecmo renal_function
H-1385	-0.45242804288864136	▁vent ri cular _ assist _ ▁device VAD ▁extra corp o real _ ▁membran e _ ▁oxygen ation ▁ec mo ▁renal _ ▁function
D-1385	-0.45242804288864136	ventricular_assist_ deviceVAD extracorporeal_ membrane_ oxygenation ecmo renal_ function
P-1385	-0.0167 -0.8214 -0.2671 -0.1813 -0.2500 -1.4223 -0.8947 -0.1311 -0.0158 -0.0554 -1.0528 -0.0881 -0.0557 -0.2150 -0.0215 -0.1940 -0.3371 -0.0745 -1.0476 -1.2251 -0.0657 -0.4153 -1.0413 -1.2807 -0.1402
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american_college_of_cardiology american_heart_association patients ras patients ras
H-1604	-0.7660039067268372	▁American _ ▁College _ of _ ▁Card i ology American _ ▁Heart _ association ▁ RAS
D-1604	-0.7660039067268372	American_ College_of_ CardiologyAmerican_ Heart_association RAS
P-1604	-0.9093 -0.1771 -1.9954 -0.0708 -0.3827 -0.1314 -1.3974 -0.1535 -0.0390 -2.1455 -0.0363 -0.7223 -0.9753 -1.0782 -1.9737 -0.0664 -1.4402 -0.0936
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv_remodeling diastolic xo_inhibition symptoms hospitalizations patients severe_heart_failure
H-478	-0.6493322849273682	▁LV ▁dia sto lic _ ▁properties ▁ XO _ ▁inhibi tion ▁heart ▁failure
D-478	-0.6493322849273682	LV diastolic_ properties XO_ inhibition heart failure
P-478	-0.0214 -0.6233 -0.0622 -0.0311 -1.6942 -0.1007 -0.1138 -0.0340 -1.3237 -0.0288 -0.1226 -4.0299 -1.2321 -0.2034 -0.1189
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile_function lv_dilatation lv_end-diastolic_pressure wall_stress lung
H-476	-0.5924419164657593	▁contract ile ▁function ▁LV ▁di la tation ▁LV ▁end - dia sto lic _ ▁pressure wall ▁stress ▁lung _ weight
D-476	-0.5924419164657593	contractile function LV dilatation LV end-diastolic_ pressurewall stress lung_weight
P-476	-0.0087 -0.0494 -1.4709 -0.4880 -0.8946 -0.1086 -0.0256 -1.4366 -2.3931 -0.0238 -0.0211 -0.0286 -0.0692 -0.0903 -0.5770 -1.6561 -1.2911 -0.0214 -0.5574 -1.4000 -0.3016 -0.1206
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating_progenitor_cells cpcs endothelial prognostic cardiovascular_diseases
H-120	-0.47273239493370056	▁circula ting _ pro gen itor _ ▁cell s ▁c PC s ▁en dot heli al _ ▁repair ▁cardiovascular _ ▁disease s
D-120	-0.47273239493370056	circulating_progenitor_ cells cPCs endothelial_ repair cardiovascular_ diseases
P-120	-0.1074 -0.0995 -0.1421 -1.2011 -0.0690 -0.1670 -0.8961 -1.4631 -0.0554 -0.0890 -1.2006 -0.1840 -0.1587 -0.5588 -0.1662 -0.0189 -0.5027 -0.1753 -0.0582 -1.5117 -2.0657 -0.0356 -0.2907 -0.1286
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable_cardioverter-defibrillator physicians heart_failure patients
H-1857	-0.6661813855171204	▁implant able _ ▁cardio ver ter - de fi br illa tor _ ▁de activa tion ▁heart ▁failure
D-1857	-0.6661813855171204	implantable_ cardioverter-defibrillator_ deactivation heart failure
P-1857	-2.9771 -0.0455 -0.3392 -0.6515 -0.0658 -0.2070 -0.3980 -0.0769 -0.2690 -0.7165 -0.2046 -0.0842 -1.3112 -0.9934 -0.0051 -0.5268 -1.7948 -0.4780 -1.9487 -0.2303
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp plasma patients dyspnea left_ventricular_dysfunction admission
H-265	-0.45081213116645813	▁NT - pro b NP ▁plasma ▁dys pne a ▁left _ ▁vent ri cular _ ▁dys function ▁ED
D-265	-0.45081213116645813	NT-probNP plasma dyspnea left_ ventricular_ dysfunction ED
P-265	-0.5997 -0.0708 -0.0121 -0.7426 -0.2392 -0.2933 -0.0787 -0.0043 -0.1409 -0.0209 -0.4678 -1.8562 -1.5955 -0.7271 -0.5955 -0.1422 -0.0908 -1.0234 -0.1868 -0.1285
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped snp rs10927887 ka_renal_chloride_channel_gene clcnka
H-1802	-0.6236481070518494	▁Cau ca sian ▁s NP ▁ka ▁renal _ ▁chlor ide _ ▁channel _ ▁gene CL cn ka
D-1802	-0.6236481070518494	Caucasian sNP ka renal_ chloride_ channel_ geneCLcnka
P-1802	-1.2997 -0.0030 -0.2139 -0.8959 -0.2050 -2.3717 -0.0982 -0.1210 -0.3772 -0.0528 -0.1177 -0.7489 -1.0731 -0.7439 -1.5391 -1.1822 -0.3516 -0.3180 -0.1365
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician outcomes patients outcomes medically diseases hf
H-1722	-0.6839561462402344	▁Physic ian _ ▁volume ▁med ically _ ▁managed _ ▁disease s HF
D-1722	-0.6839561462402344	Physician_ volume medically_ managed_ diseasesHF
P-1722	-0.2413 -0.6509 -0.5434 -0.0905 -1.4314 -0.3985 -0.5824 -0.3407 -0.4305 -2.3478 -0.0592 -2.0429 -0.2906 -0.1253
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients frail frail biological_phenotype
H-1007	-0.637628436088562	▁fra il ▁intermedi ate _ fra il
D-1007	-0.637628436088562	frail intermediate_frail
P-1007	-0.1935 -0.1517 -0.3508 -2.5431 -0.1591 -0.7564 -0.1191 -1.3180 -0.1468
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients lbbb implantable primary_outcome primary_outcome
H-887	-0.4161031246185303	LB bb ▁implant able _ ▁cardio ver ter _ de fi br illa tor - c RT
D-887	-0.4161031246185303	LBbb implantable_ cardioverter_defibrillator-cRT
P-887	-1.3092 -1.5345 -0.2987 -0.0515 -0.1635 -0.3523 -0.0456 -0.0624 -0.1844 -0.2281 -0.0257 -0.1982 -0.0984 -0.0167 -0.0978 -0.7422 -1.7947 -0.5714 -0.1306
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm outcomes discharged admission heart_failure
H-149	-1.856951355934143	▁RM _ strategi es ▁wind _ ▁failure
D-149	-1.856951355934143	RM_strategies wind_ failure
P-149	-1.8801 -4.7043 -0.2805 -0.6302 -6.7130 -1.7225 -0.3206 -0.3008 -0.1606
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients exercise-induced_pasp pasp patients pasp
H-827	-0.9319016337394714	▁exercise - indu ced ▁pas p ▁h g ▁pas p
D-827	-0.9319016337394714	exercise-induced pasp hg pasp
P-827	-2.7311 -0.0642 -0.0061 -0.1053 -1.9511 -0.3866 -2.1605 -0.1042 -1.3906 -0.3792 -1.7835 -0.1205
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone patients hf-ref hyperkalemia patients
H-1224	-0.40322092175483704	▁e pler en one ▁ HF - re f ▁hyper kal emia ▁w RF
D-1224	-0.40322092175483704	eplerenone HF-ref hyperkalemia wRF
P-1224	-0.1046 -0.0302 -0.0898 -0.2640 -0.3023 -0.1935 -0.0175 -0.3365 -2.0880 -1.4110 -0.1798 -0.0656 -0.0810 -0.8064 -0.3232 -0.1581
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping myocardial heart_failure
H-1063	-0.7333537936210632	▁t 1- ma pping _ techniek ▁diffuse _ My o card ial _ ▁changes ▁heart ▁failure ▁contrast ▁agent ▁breath - hold ing
D-1063	-0.7333537936210632	t1-mapping_techniek diffuse_Myocardial_ changes heart failure contrast agent breath-holding
P-1063	-3.4369 -0.2513 -0.3932 -0.1608 -2.1891 -0.3497 -0.1108 -0.1728 -3.1611 -0.5990 -0.5948 -0.5895 -0.8310 -0.9905 -1.0437 -0.9876 -0.1191 -0.7453 -0.0676 -0.1396 -0.1601 -0.0337 -0.3278 -0.1455
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt dt btt patients
H-314	-1.0903046131134033	▁b t ▁ DT
D-314	-1.0903046131134033	bt DT
P-314	-0.7137 -1.5399 -0.7029 -0.1641 -3.2633 -0.1580
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients hfpef longitudinal cardiac_event
H-738	-0.9771751165390015	▁h FP EF ▁longitud in al _ ▁outcome - monitor ing _ ▁phase ▁cardiac _ event
D-738	-0.9771751165390015	hFPEF longitudinal_ outcome-monitoring_ phase cardiac_event
P-738	-1.2548 -2.2242 -0.9230 -2.2829 -0.1831 -0.2626 -0.3225 -3.8076 -0.2144 -0.0061 -0.0079 -1.9972 -0.4878 -0.0564 -0.6476 -2.3318 -0.4342 -0.1450
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure health income hf
H-1800	-1.0533605813980103	▁ex pendi ture ▁health _ ▁per ▁capita ▁gross _ national _ ▁income _ per _ ▁capita ▁ HF
D-1800	-1.0533605813980103	expenditure health_ per capita gross_national_ income_per_ capita HF
P-1800	-6.0444 -0.1287 -0.0961 -4.4825 -0.8259 -1.0715 -0.4748 -0.6015 -0.0494 -0.6306 -0.1850 -0.2391 -0.8596 -1.1161 -1.0271 -0.0722 -0.8709 -0.2936 -1.8731 -0.1250
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals patients hfpef
H-952	-0.46782127022743225	▁AF ▁ pharma ce u tical s ▁h FP EF
D-952	-0.46782127022743225	AF pharmaceuticals hFPEF
P-952	-0.7165 -0.5582 -0.4200 -0.1861 -0.1044 -0.0621 -0.1140 -1.1262 -1.0507 -0.8581 -0.2710 -0.1465
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies crt-d heart_failure death
H-108	-1.0388022661209106	▁i s ▁c RT - d ▁heart ▁failure
D-108	-1.0388022661209106	is cRT-d heart failure
P-108	-1.6430 -1.0102 -0.2120 -1.1538 -0.0370 -0.7679 -3.3560 -0.7221 -1.3517 -0.1342
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt atrial_pacing
H-1442	-0.6408114433288574	▁SD QT ▁ HF VT ▁ HF VT ▁h Nor m _ groep ▁fixed - rate _ at rial _ pa cing
D-1442	-0.6408114433288574	SDQT HFVT HFVT hNorm_groep fixed-rate_atrial_pacing
P-1442	-0.0308 -0.5979 -0.4801 -0.2130 -0.3208 -0.9309 -0.2697 -0.7163 -1.4249 -5.3404 -0.0224 -1.2512 -0.2314 -0.1341 -0.1331 -0.3903 -0.0380 -0.5032 -0.1517 -0.5467 -0.6486 -0.4589 -0.4141 -0.1311
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical bnp inhospital mortality
H-196	-0.7076516151428223	▁b NP ▁in hospital _ ▁mortal ity ▁p
D-196	-0.7076516151428223	bNP inhospital_ mortality p
P-196	-0.6572 -1.3556 -0.1764 -0.2186 -0.6549 -0.2626 -1.0710 -0.3767 -2.1893 -0.1144
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood_pressure therapy patients ras
H-1600	-0.47906240820884705	▁blood ▁pressure _ control e ▁goal - direct ed _ ▁lipid - lo wering _ therapy ▁smoking ▁ces s ation ▁ RAS
D-1600	-0.47906240820884705	blood pressure_controle goal-directed_ lipid-lowering_therapy smoking cessation RAS
P-1600	-0.9857 -1.3506 -1.5090 -0.0105 -1.7582 -0.6576 -0.0079 -0.0012 -0.0365 -0.5703 -0.1956 -0.0639 -0.1257 -0.0530 -0.6774 -0.0465 -0.0109 -1.1101 -0.0314 -0.1212 -1.8496 -0.0546 -0.1280 -0.1425
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs_morphology cardiac_resynchronization_therapy crt
H-880	-0.546130359172821	▁QR s ▁ morph ology ▁cardiac _ re syn chron ization _ therapy ▁c RT
D-880	-0.546130359172821	QRs morphology cardiac_resynchronization_therapy cRT
P-880	-1.2627 -0.4612 -0.4763 -0.0395 -0.2406 -0.0834 -0.7020 -0.7728 -0.0604 -0.0060 -1.3269 -0.8595 -0.2319 -0.6463 -1.7754 -0.2222 -0.1171
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial_complex_v_activity phosphocreatine atp
H-1786	-0.5061784982681274	▁mito cho ndri al _ ▁complex _ v _ activ iteit ▁a ac ▁ phos pho creati ne ▁ATP
D-1786	-0.5061784982681274	mitochondrial_ complex_v_activiteit aac phosphocreatine ATP
P-1786	-0.5595 -0.4978 -0.6282 -0.0950 -0.0955 -0.4165 -0.2523 -0.3127 -1.5447 -0.4211 -0.5050 -0.7695 -0.1849 -0.3748 -0.0237 -0.1164 -0.6073 -2.0006 -0.8054 -0.3122 -0.1067
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire implanted pacemakers ventricularly beats heart_failure
H-1056	-0.5398359298706055	▁York shire _ ▁s win e ▁pace makers ▁vent ri cular ly _ ▁pace d ▁heart ▁failure
D-1056	-0.5398359298706055	Yorkshire_ swine pacemakers ventricularly_ paced heart failure
P-1056	-0.4948 -0.0088 -0.8041 -1.0398 -0.0312 -0.1706 -0.8515 -0.0516 -0.0206 -0.5645 -0.0845 -0.2543 -1.6835 -0.1612 -0.1000 -2.5707 -0.9608 -0.2805 -0.1238
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality heart_failure hf implantable_cardioverter_defibrillators icds
H-60	-0.6958454251289368	▁heart _ ▁failure HF ▁implant able _ ▁cardio ver ter _ de fi br illa tors ic d s
D-60	-0.6958454251289368	heart_ failureHF implantable_ cardioverter_defibrillatorsicds
P-60	-7.3661 -1.2985 -0.2243 -1.2232 -0.2236 -0.0493 -0.1735 -0.3173 -0.0392 -0.1617 -0.0596 -0.5107 -0.0364 -0.1803 -0.1263 -0.2759 -1.0890 -0.6252 -0.0503 -0.4510 -0.1313
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular_outcomes_in_renal_atherosclerotic_lesions coral stenting ras
H-1602	-0.39616659283638	▁Card io vas cular _ out com es ▁Ren al _ ▁Ath eros cle ro tic _ Les ions co RAL ▁sten ting ▁ RAS
D-1602	-0.39616659283638	Cardiovascular_outcomes Renal_ Atherosclerotic_LesionscoRAL stenting RAS
P-1602	-0.3363 -0.8363 -0.0744 -0.4574 -0.9811 -0.7394 -0.0242 -0.0301 -0.1742 -0.1355 -0.0960 -0.1643 -0.0502 -0.0590 -0.2365 -0.8181 -0.1397 -1.6063 -0.0121 -0.6372 -0.0465 -0.8656 -0.0758 -1.7387 -0.0243 -0.2435 -0.0938
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi metoprolol elevated plasma_norepinephrine dopamine elevated epinephrine
H-1550	-0.425577312707901	▁MI _ animal ▁met o pro lol ▁plasma ▁no re pine ph rine ▁dop amine ▁e pine ph rine
D-1550	-0.425577312707901	MI_animal metoprolol plasma norepinephrine dopamine epinephrine
P-1550	-1.7086 -2.0427 -1.2580 -0.7463 -0.2992 -0.0501 -0.1658 -0.0340 -0.1277 -0.1438 -0.0864 -0.9853 -0.0869 -0.0037 -0.0432 -0.0140 -0.0191 -0.6734 -0.0775 -0.2748 -0.0964
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 cardioprotective_signaling myocardium biomarker heart_failure hf
H-696	-0.38231831789016724	▁ST 2 ▁cardio protec tive _ signal ing ▁my o car dium ▁bio mark er ▁heart ▁failure HF
D-696	-0.38231831789016724	ST2 cardioprotective_signaling myocardium biomarker heart failureHF
P-696	-1.8148 -0.1009 -0.4781 -0.4464 -1.2476 -0.1405 -0.2877 -0.1860 -0.5267 -0.0528 -0.0084 -0.0417 -0.0099 -0.0979 -0.1286 -0.6359 -0.4376 -0.5678 -0.3304 -0.1066
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal_muscle sarcomere patients heart_failure type_2_diabetes
H-1243	-0.4385555386543274	▁skelet al _ ▁muscle _ ▁sar com ere _ ▁structure ▁heart ▁failure ▁diabetes ▁e pica tech in - rich _ ▁coco a
D-1243	-0.4385555386543274	skeletal_ muscle_ sarcomere_ structure heart failure diabetes epicatechin-rich_ cocoa
P-1243	-0.4930 -0.0756 -0.1738 -0.9173 -0.5645 -1.1404 -0.1693 -0.2007 -1.6740 -0.8451 -0.8298 -0.3760 -1.7148 -0.1607 -0.0069 -0.0539 -0.0564 -0.0721 -0.0029 -0.2430 -0.3575 -0.0430 -0.2189 -0.1356
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene pathological heart_disease transcription_factors driving gene
H-639	-1.089511513710022	▁aber rant _ re activa tion _ of _ em bry o nic _ ▁gene ▁programs ▁path ological _ heart _ ▁disease ▁tran scription ▁factors ▁gene ▁programs
D-639	-1.089511513710022	aberrant_reactivation_of_embryonic_ gene programs pathological_heart_ disease transcription factors gene programs
P-639	-6.0078 -1.0302 -0.3039 -0.2827 -0.0082 -0.1376 -1.5353 -2.8145 -0.4786 -0.4394 -0.0996 -0.3719 -2.0178 -0.1420 -3.0928 -1.5947 -0.0888 -0.3659 -0.0991 -2.2234 -1.4266 -0.7752 -0.2678 -0.0322 -0.8757 -2.5007 -2.0705 -0.3070 -0.2060
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart_rate ivabradine afterload patients systolic_heart_failure
H-516	-0.406636506319046	▁isola ted _ heart _ ▁rate HR ▁i va bra dine ▁sy sto lic _ heart _ ▁failure
D-516	-0.406636506319046	isolated_heart_ rateHR ivabradine systolic_heart_ failure
P-516	-0.0656 -0.1090 -0.0805 -1.5876 -0.7278 -0.4273 -1.0596 -0.0827 -0.0483 -0.0513 -0.1746 -0.6879 -0.0434 -0.1505 -0.0491 -1.0959 -1.1922 -0.0360 -0.3177 -0.1458
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard_error_of_measurement mdc clinical change
H-807	-0.5445264577865601	▁m DC
D-807	-0.5445264577865601	mDC
P-807	-0.8854 -0.2540 -0.8279 -0.2108
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient emergency_department acute_heart_failure ahf clinical
H-57	-0.689674973487854	▁a cute _ heart _ ▁failure ▁a HF
D-57	-0.689674973487854	acute_heart_ failure aHF
P-57	-1.2194 -0.0475 -0.0269 -1.7210 -1.3634 -0.0988 -0.7818 -0.8289 -0.6530 -0.1560
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic patients reverse_remodeling crt clinical outcomes
H-436	-0.42366284132003784	▁multi para metric _ e cho car dio graphic _ ▁score ▁rever se _ ▁remodel ing ▁c RT
D-436	-0.42366284132003784	multiparametric_echocardiographic_ score reverse_ remodeling cRT
P-436	-0.1198 -0.1277 -0.2226 -0.3280 -0.3110 -0.1140 -0.0381 -0.6428 -0.7822 -0.7549 -0.5840 -0.7868 -0.0405 -0.0787 -0.1803 -0.0166 -1.0166 -1.6991 -0.4965 -0.1332
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis biomedical biomedical patients dcm heart_failure
H-1264	-0.7491756677627563	▁bio medic al _ ▁treatment ▁CH m ▁bio medic al _ ▁treatment ▁d CM ▁heart ▁failure
D-1264	-0.7491756677627563	biomedical_ treatment CHm biomedical_ treatment dCM heart failure
P-1264	-0.0358 -0.2607 -0.0323 -2.2723 -1.7715 -3.1931 -0.2599 -0.0235 -0.0812 -0.0469 -1.5869 -1.2888 -0.3866 -0.1511 -0.7645 -0.7521 -0.4200 -0.1581
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal_flow_pump hemocompatibility blood-flow pulse
H-1994	-0.44684961438179016	▁centri fu gal _ ▁flow _ pump ▁hem o com pati bility ▁magnet ically ▁le vita ted _ ▁ro tor ▁blood - flow _ ▁path s ▁artificial _ ▁puls e
D-1994	-0.44684961438179016	centrifugal_ flow_pump hemocompatibility magnetically levitated_ rotor blood-flow_ paths artificial_ pulse
P-1994	-0.0370 -0.3063 -0.3195 -0.0409 -2.1751 -0.3891 -0.8462 -0.7598 -0.3853 -0.1372 -0.1113 -0.2691 -0.0266 -0.3048 -1.4969 -0.0079 -0.0861 -0.6719 -0.4260 -0.0224 -2.0327 -0.0675 -0.0578 -0.7307 -0.2152 -0.0215 -0.4403 -0.1404 -0.9759 -0.3373 -0.3353 -0.1251
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients sst2 sst2 odds_ratios cardiovascular_events
H-409	-0.7343488931655884	▁s st 2/ low - dos e ▁BB ▁s st 2/ high - dos e _ bb ▁cardiovascular _ ▁events
D-409	-0.7343488931655884	sst2/low-dose BB sst2/high-dose_bb cardiovascular_ events
P-409	-0.5231 -1.0056 -0.9753 -0.1688 -0.0273 -0.7927 -0.1074 -1.2589 -0.0747 -1.1534 -0.6675 -1.5028 -0.1224 -1.4322 -0.1142 -1.8025 -0.6125 -1.0579 -1.0159 -1.2803 -0.2868 -0.1735
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary_approaches_to_stop_hypertension dash mortality postmenopausal hf
H-686	-0.5424145460128784	▁Mediterrane an _ diet ary _ app ro ach es _ to _ ▁Stop _ ▁Hyper tension DAS h ▁die t ▁score s ▁mortal ity ▁post meno paus al _ ▁women ▁ HF
D-686	-0.5424145460128784	Mediterranean_dietary_approaches_to_ Stop_ HypertensionDASh diet scores mortality postmenopausal_ women HF
P-686	-0.4586 -0.1016 -0.3911 -1.0362 -0.4289 -0.0456 -1.4368 -0.4317 -1.8236 -0.0465 -0.3907 -0.8194 -0.4439 -0.8734 -0.0872 -0.4490 -0.0823 -0.2903 -0.1419 -1.2199 -0.0506 -0.5784 -0.0480 -0.5547 -1.4141 -0.0458 -0.0684 -0.0110 -0.0353 -0.3881 -1.8707 -2.3848 -0.1064 -0.2670 -0.1629
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc diagnostic
H-1025	-0.8789281845092773	▁PO c ▁systems _ voor _ me as uring _ NP _ ▁levels
D-1025	-0.8789281845092773	POc systems_voor_measuring_NP_ levels
P-1025	-0.3548 -1.5855 -1.3101 -1.8497 -1.1995 -0.4261 -1.1367 -0.1744 -0.0318 -0.5471 -0.6422 -1.0039 -1.0580 -1.7645 -0.0996
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality_of_life functional_capacity
H-618	-1.117773413658142	▁functional _ capaci te
D-618	-1.117773413658142	functional_capacite
P-618	-1.7130 -1.8959 -0.6368 -0.8430 -1.4352 -0.1828
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography cardiac cardiac_function
H-453	-0.409710168838501	▁e cho card i ography ▁cardiac _ ▁diameter s ▁cardiac _ ▁function ▁vehicle - tre ated ▁rat s
D-453	-0.409710168838501	echocardiography cardiac_ diameters cardiac_ function vehicle-treated rats
P-453	-0.0363 -0.0392 -0.2202 -0.5304 -0.3787 -0.3111 -0.8102 -0.5165 -0.0903 -0.5279 -0.4851 -0.7042 -0.7704 -0.1016 -0.0156 -0.4100 -1.8119 -0.0560 -0.3022 -0.0763
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients lbbb qrs implantable
H-890	-0.539747416973114	▁l b ▁QR s ▁implant able _ ▁cardio ver ter _ de fi br illa tor - c RT
D-890	-0.539747416973114	lb QRs implantable_ cardioverter_defibrillator-cRT
P-890	-1.0948 -1.1895 -1.9463 -0.9316 -1.2199 -0.0316 -0.4601 -0.1119 -0.0283 -0.0671 -0.2436 -0.2710 -0.0216 -0.0937 -0.0788 -0.0173 -0.1160 -0.6734 -2.2282 -0.3910 -0.1188
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality readmissions costs patient physician hospital
H-1725	-0.7051166296005249	▁risk - ad just ed _ ▁mortal ity ▁read missions ▁costs
D-1725	-0.7051166296005249	risk-adjusted_ mortality readmissions costs
P-1725	-4.2228 -0.0248 -0.0144 -0.0414 -0.0877 -0.1383 -0.4884 -0.7665 -0.1452 -0.1233 -1.4822 -1.4994 -0.1322
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline embase psycinfo
H-151	-0.49092915654182434	▁electronic _ ▁database s ▁med line ▁ EMBA se ▁Psy c INFO
D-151	-0.49092915654182434	electronic_ databases medline EMBAse PsycINFO
P-151	-2.5838 -0.4014 -0.2758 -0.0784 -0.8639 -0.6666 -0.7671 -0.0149 -0.2815 -0.3021 -0.0496 -0.0053 -0.5097 -0.0730
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized medical
H-1977	-1.8740273714065552	▁factor ial _ ▁trial ▁urban _ ▁academic _ medic ▁center
D-1977	-1.8740273714065552	factorial_ trial urban_ academic_medic center
P-1977	-8.0989 -0.3515 -0.5967 -0.9633 -2.5391 -0.3589 -0.6638 -0.3942 -2.9151 -4.9002 -0.4916 -0.2151
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic interatrial_shunting patients heart_failure_with_reduced_ejection_fraction
H-1950	-0.4580298662185669	▁ therapeut ic ▁left - to - right _ inter at rial _ ▁sh unting ▁heart ▁failure ▁e je ction _ fraction
D-1950	-0.4580298662185669	therapeutic left-to-right_interatrial_ shunting heart failure ejection_fraction
P-1950	-2.5809 -0.2283 -0.0326 -0.7920 -0.0843 -0.0766 -0.1371 -0.2120 -0.1323 -0.3229 -0.3465 -0.1912 -0.2983 -1.5633 -0.7034 -0.9700 -0.4565 -0.7816 -0.0690 -0.1008 -0.4399 -0.0341 -0.3049 -0.1340
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients systolic_hf cxl-1020 right_heart_filling_pressures systemic_vascular_resistance cardiac stroke_volume_index
H-423	-0.6158338785171509	▁sy sto lic _ HF ▁c XL -10 20 ▁left _ ▁right _ heart ▁fill ing _ ▁pressure s ▁system ic _ ▁vas cular _ ▁resist ance ▁cardiac ▁stroke ▁volume ▁index
D-423	-0.6158338785171509	systolic_HF cXL-1020 left_ right_heart filling_ pressures systemic_ vascular_ resistance cardiac stroke volume index
P-423	-0.1057 -0.0509 -0.0283 -0.1165 -0.8011 -0.8551 -0.2555 -0.2946 -0.0283 -0.6752 -1.4427 -1.5853 -0.2582 -3.7777 -1.4011 -0.0363 -1.2869 -0.4589 -0.1293 -0.1277 -0.0823 -0.2088 -0.9249 -0.2279 -0.6633 -1.1667 -0.0048 -0.0387 -1.2070 -0.9552 -0.6195 -0.3432 -0.1650
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart_failure hypertension mitral_regurgitation mitral_stenosis medical_treatment heart_failure
H-336	-0.5705306529998779	▁heart ▁failure ▁hyper tension ▁mit ral _ re gur gi tation ▁mit ral _ ▁sten osis ▁heart ▁failure
D-336	-0.5705306529998779	heart failure hypertension mitral_regurgitation mitral_ stenosis heart failure
P-336	-1.4784 -0.3872 -1.3448 -0.0344 -0.1201 -0.0617 -0.4491 -0.2934 -0.1296 -0.0254 -0.0647 -0.0748 -0.0519 -0.2445 -1.0204 -0.0073 -4.2127 -1.0002 -0.2988 -0.1112
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk scn5a kv4.3 mrnas transient_receptor_potential_cation_channel_m7 trpm7 mrna
H-1086	-0.6748570799827576	▁PER k ▁activa tion ▁s cn 5 a ▁kv 4.3 _ ▁channel ▁m RNA s ▁trans ient _ ▁receptor _ potent i cation _ ▁channel ▁m 7 TR PM 7 _ ▁channel ▁m RNA
D-1086	-0.6748570799827576	PERk activation scn5a kv4.3_ channel mRNAs transient_ receptor_potentication_ channel m7TRPM7_ channel mRNA
P-1086	-1.3257 -1.0554 -0.0912 -0.0959 -1.7279 -0.1911 -0.6625 -0.0910 -0.7121 -0.0559 -1.0702 -0.6793 -0.0303 -0.0402 -0.3942 -0.0031 -0.0354 -0.1088 -0.3528 -0.5307 -1.2694 -3.2122 -0.0790 -0.9783 -1.8879 -0.2368 -0.1352 -1.5438 -0.8781 -1.9859 -1.1629 -1.2087 -0.0885 -0.0721 -0.1776 -0.1245
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients implantable_cardioverter-defibrillator heart_function_clinic university_health_network toronto canada
H-1861	-0.5961756110191345	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁Heart _ ▁Fun ction _ ▁Clinic ▁university _ health _ ▁Network Tor onto , _ ▁Canada
D-1861	-0.5961756110191345	implantable_ cardioverter-defibrillator Heart_ Function_ Clinic university_health_ NetworkToronto,_ Canada
P-1861	-0.6558 -0.0439 -0.1763 -1.2101 -0.0506 -0.1468 -0.2642 -0.1090 -0.1147 -0.4847 -0.2011 -0.0365 -0.7544 -0.2455 -0.3369 -0.0014 -0.2610 -0.0855 -2.7388 -0.0866 -1.0734 -0.3435 -0.2775 -1.4055 -0.0005 -2.3441 -2.6936 -1.1344 -0.4766 -0.1322
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients followed_up composite_primary_outcome cardiovascular_death stroke heart_failure myocardial_infarction
H-1650	-0.6446777582168579	▁cardiovascular _ ▁death ▁stroke ▁heart ▁failure ▁my o card ial _ in far ction
D-1650	-0.6446777582168579	cardiovascular_ death stroke heart failure myocardial_infarction
P-1650	-1.5412 -1.4163 -1.3539 -0.3302 -0.8124 -1.0655 -0.7388 -0.3692 -0.3371 -1.0813 -0.2125 -0.2612 -0.0706 -0.1513 -0.3743 -0.1991
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced_pasp clinical prognostic pulmonary_hypertension patients right_ventricular_contractile_reserve
H-831	-0.5382848978042603	▁Exerci se - indu ced ▁pas p ▁pulmonar y _ ▁hyper tension ▁vent ri cular _ contract ile ▁reserve
D-831	-0.5382848978042603	Exercise-induced pasp pulmonary_ hypertension ventricular_contractile reserve
P-831	-3.1606 -0.0865 -0.0686 -0.0109 -0.1219 -2.2126 -0.4309 -0.0503 -0.1443 -0.4531 -0.8227 -0.0292 -0.0679 -0.9998 -0.6509 -0.4146 -0.5338 -0.1889 -0.3208 -0.4017 -0.1343
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists renin-angiotensin-aldosterone sympathetic_nervous_systems clinical outcomes chf
H-636	-0.44222503900527954	▁anta gon ists ▁inhibi tors ▁re nin - angi oten sin - al do ster one ▁sympa the tic _ ▁ner vous _ systemen ▁CHF
D-636	-0.44222503900527954	antagonists inhibitors renin-angiotensin-aldosterone sympathetic_ nervous_systemen CHF
P-636	-1.0859 -0.0213 -0.3299 -0.0371 -0.0569 -0.0298 -0.4449 -0.0546 -0.0210 -0.0384 -1.0871 -0.2931 -0.0216 -0.5719 -0.0246 -0.4645 -0.0078 -0.5075 -0.9085 -0.0377 -2.9530 -0.6715 -1.5602 -0.4013 -0.0800 -0.1223 -0.1078
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization_therapy crt morbidity mortality chronic_systolic_heart_failure wide_qrs_complex
H-845	-0.7127565741539001	▁Card iac - re syn chron ization _ therapy ▁c RT ▁morbi d ity ▁mortal ity ▁chronic _ ▁sy sto lic _ heart _ ▁failure ▁QR s
D-845	-0.7127565741539001	Cardiac-resynchronization_therapy cRT morbidity mortality chronic_ systolic_heart_ failure QRs
P-845	-1.8221 -0.1143 -0.0551 -0.0464 -0.0845 -0.0062 -1.5213 -0.9616 -0.3710 -0.5765 -2.3504 -1.9330 -0.0173 -1.6677 -2.4914 -0.9418 -0.0665 -0.6137 -1.0232 -0.0420 -0.2874 -0.0230 -1.4908 -0.9732 -0.0681 -0.1087 -0.4370 -0.4410 -0.1350
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate unfolded_protein_response upr scn5a remodeling hf
H-1081	-0.37728556990623474	▁tru nca ted _ na + _ ▁channel s ▁un fold ed _ ▁protein _ ▁response ▁u PR ▁s cn 5 a ▁electric _ ▁remodel ing ▁ HF
D-1081	-0.37728556990623474	truncated_na+_ channels unfolded_ protein_ response uPR scn5a electric_ remodeling HF
P-1081	-0.3842 -0.0477 -0.0154 -0.2084 -0.1606 -1.2314 -0.9684 -0.5002 -0.0204 -0.1522 -0.0020 -0.0301 -0.0279 -0.8785 -0.7207 -0.1828 -0.3036 -0.4168 -0.9505 -0.3040 -0.2850 -0.1541 -0.2795 -0.3990 -0.0605 -0.0125 -1.7156 -0.5191 -0.2862 -0.1011
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international_right_heart_foundation_working_group step syndrome right_heart_failure
H-1458	-0.9558700323104858	▁ international _ ▁Right _ ▁Heart _ found ation _ work ing _ groep ▁right _ heart _ ▁failure
D-1458	-0.9558700323104858	international_ Right_ Heart_foundation_working_groep right_heart_ failure
P-1458	-3.1290 -2.3043 -0.4234 -1.2690 -0.2394 -0.2942 -0.1913 -1.4689 -0.3880 -0.3162 -0.3566 -0.3480 -0.4182 -0.7686 -4.4676 -0.2073 -2.0781 -0.9712 -0.0650 -0.2293 -0.1399
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber_dynamics myofiber_shortening emd dyssynchronous_hf
H-1156	-0.5202609896659851	▁my o fi ber _ dynamic s ▁my o fi ber _ short en ing ▁EM d ▁dys syn chron ous _ HF
D-1156	-0.5202609896659851	myofiber_dynamics myofiber_shortening EMd dyssynchronous_HF
P-1156	-1.8231 -0.4093 -0.0231 -0.1477 -2.0282 -0.1653 -0.0322 -0.6953 -0.1706 -0.0265 -0.0955 -1.5932 -0.5586 -0.0294 -0.0705 -1.3614 -0.6373 -0.0204 -0.0133 -0.0036 -1.3728 -0.3044 -0.8543 -0.4471 -0.1234
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial_index pulse-wave coronary_artery_calcium_scores
H-1562	-0.2631100118160248	▁cru de ▁an kle - bra chi al _ index ▁puls e - wa ve _ ▁veloci ty ▁corona ry _ ▁arter y ▁calci um ▁score s
D-1562	-0.2631100118160248	crude ankle-brachial_index pulse-wave_ velocity coronary_ artery calcium scores
P-1562	-0.2424 -0.0532 -0.4881 -0.2643 -0.1034 -0.1020 -0.8239 -0.1867 -0.5784 -0.4337 -0.0171 -0.0509 -0.0627 -0.0731 -0.0895 -0.1758 -0.0834 -0.0474 -0.0210 -1.0944 -0.1922 -0.1536 -0.3470 -0.3324 -0.0312 -1.0988 -0.0672 -0.3233 -0.0931
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol lv_contractile_function xo-mediated_ros myofilament sensitivity
H-477	-0.5657223463058472	▁allo puri nol ▁contract ile _ function ▁efficiency ▁ XO - media ted _ ROS _ effect ▁my o fila ment ▁ sensitiv ity
D-477	-0.5657223463058472	allopurinol contractile_function efficiency XO-mediated_ROS_effect myofilament sensitivity
P-477	-0.0169 -0.0070 -0.2788 -0.5877 -0.0500 -1.3138 -1.1909 -1.5083 -0.1150 -0.0218 -0.0052 -0.1173 -0.0222 -0.2947 -1.4199 -2.2676 -0.1945 -1.8078 -0.0731 -0.0048 -0.1343 -1.5583 -0.0052 -1.3422 -0.2747 -0.0969
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk_stratification antiplatelet_agents combination anticoagulants vascular_diseases
H-1355	-0.5357215404510498	▁anti plate let ▁agents ▁antico a gul ants ▁vas cular _ ▁disease s
D-1355	-0.5357215404510498	antiplatelet agents anticoagulants vascular_ diseases
P-1355	-0.3051 -0.3432 -0.5414 -1.6063 -0.2245 -0.1541 -0.5247 -0.0633 -1.3203 -0.2376 -0.8018 -1.3272 -0.0386 -0.4291 -0.1186
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac_hypertrophy pressure-overload abdominal_aortic_constriction aac
H-1780	-0.4380299746990204	▁cardiac _ ▁hyper trop hy ▁pressure - over load ▁abdominal _ a or tic _ con stri ction ▁a ac
D-1780	-0.4380299746990204	cardiac_ hypertrophy pressure-overload abdominal_aortic_constriction aac
P-1780	-2.2388 -0.3961 -1.0959 -0.0266 -0.9503 -0.1270 -0.0716 -0.0046 -0.0698 -0.0249 -0.4856 -0.6645 -0.4527 -0.8883 -0.0583 -0.4700 -0.5138 -0.0452 -0.4645 -0.2135 -0.1950 -0.1794
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf hf epidemiology rheumatic_fever
H-1799	-0.5552805066108704	▁ HF ▁ HF ▁ HF ▁epidemi ology ▁SH ▁c ' d ▁rhe u matic _ fe ver
D-1799	-0.5552805066108704	HF HF HF epidemiology SH c'd rheumatic_fever
P-1799	-0.9823 -0.3635 -0.8451 -0.1683 -1.5062 -0.1146 -1.0091 -0.1769 -0.5201 -1.7890 -2.5246 -0.0756 -0.0669 -0.0321 -0.1768 -0.0678 -0.1262 -0.0846 -0.3618 -0.1140
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications patients heart_failure_and_reduced_ejection_fraction outpatient
H-667	-0.6212969422340393	▁guide line - re com mend ed ▁medication s ▁heart ▁failure ▁reduce d _ e je ction _ fraction
D-667	-0.6212969422340393	guideline-recommended medications heart failure reduced_ejection_fraction
P-667	-5.0075 -0.0324 -0.2953 -0.0033 -0.0597 -0.0280 -0.0890 -1.3529 -0.1075 -1.6649 -0.8602 -0.9510 -0.0456 -0.2274 -0.6514 -0.1372 -0.0660 -0.2452 -0.0696 -0.9680 -0.1851
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise training exercise exercise_capacity qol obese patients hfpef
H-1976	-0.7065679430961609	▁calor ic _ ▁restriction diet ▁aero bic _ ▁exercise _ training _ exe rci se ▁exercise _ ▁capacity ▁Q OL ▁obes e _ ▁older _ ▁patients ▁h FP EF
D-1976	-0.7065679430961609	caloric_ restrictiondiet aerobic_ exercise_training_exercise exercise_ capacity QOL obese_ older_ patients hFPEF
P-1976	-0.7463 -0.0326 -0.6476 -0.8097 -0.7297 -0.0109 -0.0962 -0.0979 -0.4699 -0.7214 -0.0873 -2.3573 -0.9892 -0.0349 -0.0569 -1.6626 -1.2634 -1.3856 -2.5218 -0.1626 -0.4157 -0.0550 -0.4656 -0.4010 -1.3760 -0.8691 -1.3010 -1.0217 -0.7227 -0.2500 -0.1419
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic_heart_failure hf hemodynamic syndrome dysfunction molecular_pathways
H-1472	-0.44687408208847046	▁chronic _ heart ▁failure HF ▁hem o dynamic _ ▁disorder ▁syndrome ▁dys function ▁inter connect ed _ ▁molecular _ ▁path ways
D-1472	-0.44687408208847046	chronic_heart failureHF hemodynamic_ disorder syndrome dysfunction interconnected_ molecular_ pathways
P-1472	-0.3053 -0.0634 -1.6292 -1.9082 -0.4392 -0.1344 -0.2623 -0.0015 -0.2947 -0.3588 -0.0542 -0.8318 -0.0675 -1.5694 -0.5093 -0.0621 -0.1033 -0.1162 -0.2760 -0.9036 -0.0323 -0.2499 -0.1053
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms hfpef diastolic_filling_time heart_rate symptoms
H-1172	-0.7155638337135315	▁ HF p EF ▁dia sto lic _ ▁fill ing _ ▁time ▁control ling _ ▁heart _ ▁rate
D-1172	-0.7155638337135315	HFpEF diastolic_ filling_ time controlling_ heart_ rate
P-1172	-0.7871 -0.5333 -0.1403 -0.6895 -0.2888 -0.0566 -0.1041 -0.6602 -0.6224 -0.0198 -2.0368 -0.8447 -2.6849 -0.1963 -0.3290 -2.2714 -1.0478 -0.2572 -0.5886 -0.1525
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline hgb correlated baseline kccq hgb exercise training hrqol
H-839	-0.6863259673118591	▁h gb ▁k cc q _ ▁scale s ▁h gb ▁exercise _ training ▁HR Qo l
D-839	-0.6863259673118591	hgb kccq_ scales hgb exercise_training HRQol
P-839	-1.1901 -0.0097 -1.1861 -0.0541 -0.8986 -2.1769 -0.0380 -0.0198 -0.2938 -0.0084 -1.6575 -1.0971 -0.1852 -1.7582 -0.0073 -1.2606 -0.3729 -0.1397
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient patients heart_failure hospital discharge readmissions patient follow-up
H-722	-1.5211230516433716	▁heart _ ▁failure ▁hospital _ ▁dis charge ▁read missions ▁follow - up
D-722	-1.5211230516433716	heart_ failure hospital_ discharge readmissions follow-up
P-722	-4.7910 -1.5865 -0.3368 -4.1984 -2.0047 -2.0332 -0.1106 -0.8812 -0.1009 -3.8885 -0.1734 -0.0164 -0.9941 -0.1801
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac myocyte-specific_mena_overexpression cardiac pathology
H-1813	-0.47370243072509766	▁mi ce ▁cardiac _ ▁my o cy te - specific ▁men a ▁over expression TTA ▁t g t et Men a ▁cardiac _ ▁path ology
D-1813	-0.47370243072509766	mice cardiac_ myocyte-specific mena overexpressionTTA tgtetMena cardiac_ pathology
P-1813	-1.5978 -0.1578 -0.1131 -0.3121 -2.4310 -0.2345 -0.0508 -0.0452 -0.2786 -0.0330 -1.3829 -0.0810 -0.6727 -0.0446 -1.0732 -0.9657 -0.0534 -0.2812 -0.0167 -1.0399 -0.0116 -0.0144 -0.3862 -0.9506 -0.2243 -0.2389 -0.0988
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan_failure hemodynamically heart_failure systemic_vascular_resistance svr cardiac_index
H-225	-0.5032477974891663	▁Font an _ ▁failure ▁hem o dynamic ally ▁heart ▁failure ▁system ic _ ▁vas cular _ ▁resist ance ▁s VR ▁index ▁pres er ved _ ▁cardiac _ ▁index
D-225	-0.5032477974891663	Fontan_ failure hemodynamically heart failure systemic_ vascular_ resistance sVR index preserved_ cardiac_ index
P-225	-0.3305 -0.2600 -0.6384 -0.1863 -0.1467 -0.1925 -0.0028 -0.2294 -3.6404 -0.8697 -0.3002 -0.0625 -0.0838 -1.5243 -0.4782 -0.3032 -0.8148 -0.0069 -0.2133 -0.6571 -2.0355 -0.0177 -0.0847 -0.4255 -0.0556 -0.1246 -0.5317 -0.5123 -0.2605 -0.1085
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients heart_transplant prospectively ecct
H-710	-0.5984621047973633	▁isola ted _ heart _ ▁transplant ▁ec CT
D-710	-0.5984621047973633	isolated_heart_ transplant ecCT
P-710	-0.4952 -0.3159 -0.1167 -1.3766 -1.1553 -0.2599 -0.5893 -1.2812 -0.2021 -0.1923
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential_analysis cluster_analysis
H-1610	-0.4681524634361267	▁r . _ ▁Clu ster _ analyse
D-1610	-0.4681524634361267	r._ Cluster_analyse
P-1610	-0.9164 -0.2383 -0.6182 -0.7444 -0.0276 -1.1597 -0.1239 -0.2751 -0.1097
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis metabolic_exercise cardiac kidney
H-1762	-0.425898939371109	▁AT ▁metabol ic _ ▁exercise ▁cardiac ▁ki dne y ▁index ▁score
D-1762	-0.425898939371109	AT metabolic_ exercise cardiac kidney index score
P-1762	-2.0703 -0.1535 -0.0086 -0.2174 -0.3620 -0.0090 -0.8877 -0.1871 -0.0737 -0.1282 -0.2521 -1.0568 -0.1304
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart_failure compliance etidronate alendronate
H-1543	-0.4726938307285309	▁heart ▁failure ▁re fill ▁compliance ▁et id rona te ▁ale ndr onate
D-1543	-0.4726938307285309	heart failure refill compliance etidronate alendronate
P-1543	-1.3302 -1.0459 -0.4852 -0.0594 -2.0170 -0.0289 -0.0453 -0.0069 -0.0221 -0.8486 -0.0126 -0.0923 -0.5457 -0.0777
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians patients heart_failure equitable therapeutic
H-1823	-1.3236212730407715	▁physician s ▁advanced _ heart _ ▁failure
D-1823	-1.3236212730407715	physicians advanced_heart_ failure
P-1823	-3.1037 -0.0402 -3.9823 -0.0504 -1.4726 -1.0073 -0.1119 -1.9943 -0.1499
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic patients severe_heart_failure financial
H-1242	-0.8513942360877991	▁ therapeut ic _ strategi e ▁AF ▁severe _ heart _ ▁failure ▁financial _ ▁burde n
D-1242	-0.8513942360877991	therapeutic_strategie AF severe_heart_ failure financial_ burden
P-1242	-1.4435 -0.0536 -0.0358 -1.8571 -0.2121 -0.4270 -1.5052 -2.3639 -0.0438 -1.2677 -1.8677 -0.0564 -1.3664 -1.5287 -0.6615 -0.0713 -0.4432 -0.1203
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate_ratio therapy patient comorbidities
H-663	-1.0198618173599243	▁ therapy ▁como rbi di ties
D-663	-1.0198618173599243	therapy comorbidities
P-663	-2.7978 -0.4189 -3.2708 -0.0213 -0.6396 -0.0430 -0.7940 -0.1735
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular_pathways patients chronic_heart_failure chf
H-249	-1.325297474861145	▁et _ en _ ▁HD l - media ted _ ▁protect ive _ effect ▁molecular _ ▁path ways ▁chronic _ heart ▁failure CH f
D-249	-1.325297474861145	et_en_ HDl-mediated_ protective_effect molecular_ pathways chronic_heart failureCHf
P-249	-1.1313 -6.0477 -5.0103 -0.8749 -1.9617 -1.8486 -0.0210 -0.0849 -0.0511 -0.1257 -3.1594 -0.0384 -0.6754 -0.1578 -3.7795 -0.6104 -0.5517 -0.0630 -0.4498 -0.0554 -1.4388 -1.5408 -3.1364 -1.2951 -0.2241 -0.1244
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization medicare hospital medicare policy
H-1715	-0.475568950176239	▁re hospital ization ▁Medica re _ hospital _ ▁claims ▁Medica re ▁post - a cute _ care _ transfer _ policy
D-1715	-0.475568950176239	rehospitalization Medicare_hospital_ claims Medicare post-acute_care_transfer_policy
P-1715	-1.0019 -0.2508 -0.4010 -0.0386 -0.0030 -0.8022 -0.4535 -1.6184 -0.0603 -0.0811 -0.0038 -0.1977 -0.0183 -0.0375 -0.0269 -0.0230 -1.8411 -0.3012 -1.5575 -1.0749 -0.5098 -0.4192 -0.2162
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical activity crf hf mortality
H-1776	-0.7854241132736206	▁physical _ activ iteit ▁c RF ▁ HF _ ▁mortal ity
D-1776	-0.7854241132736206	physical_activiteit cRF HF_ mortality
P-1776	-3.7560 -0.4200 -0.5647 -0.6091 -0.2049 -0.6329 -0.5630 -0.2940 -1.4512 -0.1780 -1.1086 -0.3164 -0.1117
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow_up ffm patients
H-16	-1.278895616531372	▁follow up _ ▁body _ weight ▁FM ▁f FM ▁CC
D-16	-1.278895616531372	followup_ body_weight FM fFM CC
P-16	-1.0662 -2.8097 -0.2793 -2.6448 -0.4106 -0.9333 -1.5866 -0.4045 -2.2000 -2.0754 -0.8043 -0.1321
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary_endpoint intermacs interagency_registry_for_mechanically_assisted_circulatory_support
H-1996	-0.8279666304588318	▁inter ma cs ▁inter age ncy _ registra y _ voor _ ▁Mechanic ally _ ▁Assist ed _ ▁Circula tory _ ▁Support
D-1996	-0.8279666304588318	intermacs interagency_registray_voor_ Mechanically_ Assisted_ Circulatory_ Support
P-1996	-1.3011 -2.6027 -3.6629 -1.5096 -0.2248 -0.0390 -0.1345 -1.0599 -0.8982 -0.9723 -1.0504 -0.7387 -0.0404 -0.3794 -0.3181 -1.0826 -0.6291 -0.0372 -0.9454 -0.2760 -0.2690 -0.5768 -0.8958 -0.2274
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence clinical outcomes concentric_left_ventricular_hypertrophy heart_failure_with_preserved_ejection_fraction
H-1523	-0.518372118473053	▁ecce n tric ▁concentr ic _ ▁left _ ▁vent ri cular _ ▁hyper trop hy ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-1523	-0.518372118473053	eccentric concentric_ left_ ventricular_ hypertrophy heart failure preserved_ejection_fraction
P-1523	-0.5486 -0.0297 -0.1997 -0.6369 -0.0274 -0.0990 -1.1218 -0.2319 -2.8592 -1.5317 -0.7696 -0.2517 -1.1778 -0.0099 -0.8642 -0.2938 -0.5103 -0.7319 -0.1839 -0.5107 -0.4279 -0.5190 -0.1569 -0.1304 -0.1617 -0.0127 -0.3551 -0.1610
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients left_ventricular_ejection_fraction heart_failure_with_preserved_ejection_fraction hfpef
H-1887	-0.48063379526138306	▁left _ ▁vent ri cular _ e je ction _ fraction ▁heart ▁failure ▁pres er ved _ e je ction _ fraction HF p EF
D-1887	-0.48063379526138306	left_ ventricular_ejection_fraction heart failure preserved_ejection_fractionHFpEF
P-1887	-0.2869 -0.7056 -0.8297 -0.8872 -0.6271 -0.1936 -0.2664 -0.1217 -0.1006 -0.3777 -0.0600 -1.5571 -0.7011 -1.6770 -0.1903 -0.4186 -0.0683 -0.3924 -0.2401 -0.1155 -0.1973 -0.1406 -1.5856 -0.0448 -0.6289 -0.3902 -0.1731
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1260	-0.6466154456138611	▁left _ ▁vent ri cular _ e je ction _ fraction ▁left _ ▁vent ri cular ▁dia sto lic _ ▁end _ ▁diameter
D-1260	-0.6466154456138611	left_ ventricular_ejection_fraction left_ ventricular diastolic_ end_ diameter
P-1260	-2.1214 -0.7157 -1.3231 -1.1254 -0.8091 -0.2773 -0.4080 -0.2090 -0.1031 -0.3531 -0.0553 -0.0629 -0.6135 -0.6795 -1.3928 -0.4400 -1.1731 -0.0360 -0.1005 -0.0917 -1.7713 -1.5351 -0.1345 -0.4508 -0.1833
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic_receptor_blocker_therapy myocardial_perfusion neoangiogenesis heart
H-451	-0.37686580419540405	▁β - ad r energi c _ ▁receptor _ block er _ therapy ▁my o card ial _ per fusion ▁neo angi ogen es is ▁fail ing _ heart
D-451	-0.37686580419540405	β-adrenergic_ receptor_blocker_therapy myocardial_perfusion neoangiogenesis failing_heart
P-451	-0.0142 -0.0567 -0.0357 -0.3992 -1.0080 -0.0183 -0.2058 -0.0945 -0.4956 -1.3012 -0.0629 -1.1902 -0.0343 -1.7346 -0.2589 -0.8279 -0.9501 -0.1519 -0.4393 -0.0078 -0.0578 -0.0410 -0.0417 -0.0303 -0.0288 -0.2057 -0.0501 -0.1498 -1.3765 -0.2756 -0.1384
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular_matrix left_ventricular biopsies tissuefaxs correlated t1_time
H-741	-0.388968288898468	▁extra cel lular _ ▁matri x ▁left _ ▁vent ri cular _ ▁bio psi es ▁t issue FAX s ▁technology
D-741	-0.388968288898468	extracellular_ matrix left_ ventricular_ biopsies tissueFAXs technology
P-741	-0.2477 -0.0383 -0.1119 -0.1483 -0.4813 -0.0902 -0.0755 -0.3238 -1.0716 -1.1225 -0.6903 -0.3599 -0.3331 -0.3500 -0.1435 -0.8530 -0.0059 -0.1376 -0.5409 -1.1144 -0.2071 -0.1105
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart patients hfpef hf_with_reduced_ejection_fraction hfref
H-240	-0.6004022359848022	▁h ART ▁ HF p EF ▁ HF _ met _ ▁reduce d _ e je ction _ fraction HF r EF
D-240	-0.6004022359848022	hART HFpEF HF_met_ reduced_ejection_fractionHFrEF
P-240	-0.7820 -0.0862 -0.5374 -0.1532 -0.5332 -0.4986 -0.3582 -0.2445 -3.2660 -1.5857 -0.2732 -2.2412 -0.0837 -0.0381 -0.4050 -0.1139 -0.0737 -0.2410 -0.1331 -1.8226 -0.1400 -0.3963 -0.2883 -0.1146
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced_hf cxl-1020 contractility end-systolic_elastance venoarterial_dilation
H-421	-0.49348998069763184	▁ conscious _ dog s ▁ta chy pac ing - indu ced ▁ HF ▁c XL -10 20 ▁contract ility ▁end - sy sto lic _ ▁elastan ce ▁ve no arte rial _ di lation
D-421	-0.49348998069763184	conscious_dogs tachypacing-induced HF cXL-1020 contractility end-systolic_ elastance venoarterial_dilation
P-421	-0.5955 -0.3265 -0.7598 -0.7542 -0.0332 -3.8873 -0.9181 -0.0107 -0.0784 -0.0317 -0.0044 -0.0719 -1.6006 -0.1985 -1.1002 -0.3311 -0.1979 -0.0215 -0.0086 -0.0749 -2.5413 -0.0440 -0.0682 -0.0227 -0.0162 -1.0572 -0.0113 -0.4896 -0.1741 -0.0715 -0.0727 -0.1394 -0.8812 -1.2169 -0.0233 -0.2662 -0.1581
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin_cytoskeleton mitochondrial_function metabolism glycolysis gluconeogenesis citrate_cycle
H-873	-0.27479949593544006	▁act in _ ▁cy tos kelet on ▁mito cho ndri al _ ▁function ▁intermedi ate _ ▁metabolism ▁gly col ysis glu cone ogen es is ▁cit rate _ ▁cycle
D-873	-0.27479949593544006	actin_ cytoskeleton mitochondrial_ function intermediate_ metabolism glycolysisgluconeogenesis citrate_ cycle
P-873	-0.0387 -0.4012 -0.1202 -0.8643 -0.7302 -0.1368 -0.1605 -0.0085 -0.2633 -0.3438 -0.0486 -0.7337 -0.8278 -0.1116 -0.5838 -0.0329 -0.3226 -0.0081 -0.0226 -0.1571 -0.5935 -0.0498 -0.2540 -0.0282 -0.0330 -0.0723 -0.0624 -0.1750 -1.0401 -0.1848 -0.1092
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated resistin biomarker anthracycline-induced_cardiotoxicity heart_failure macrophages
H-939	-0.3690623342990875	▁eleva ted _ ▁resist in ▁an thra cycli ne - indu ced _ ▁cardio toxic iteit ▁heart ▁failure ▁macro pha ges
D-939	-0.3690623342990875	elevated_ resistin anthracycline-induced_ cardiotoxiciteit heart failure macrophages
P-939	-0.1800 -0.0411 -0.1315 -1.9711 -0.3053 -0.6806 -0.0096 -0.1001 -1.1197 -0.2027 -0.0026 -0.1659 -0.1767 -0.1331 -0.3057 -1.3730 -0.2489 -0.3990 -0.1503 -0.0045 -0.4066 -0.2731 -0.1072
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone_morphogenetic_protein_4 expression rrna_transcription shift heterochromatic_chromatin
H-98	-0.5616328716278076	▁bone _ ▁mor pho gene tic _ ▁protein ▁r RNA ▁tran scription ▁hetero ch ro matic _ ▁chr omat in
D-98	-0.5616328716278076	bone_ morphogenetic_ protein rRNA transcription heterochromatic_ chromatin
P-98	-2.0933 -0.4377 -2.4089 -0.2248 -1.2303 -2.3845 -0.0458 -0.5573 -0.0381 -0.0402 -0.2356 -0.0210 -0.2575 -0.2333 -0.0568 -0.3341 -0.0490 -0.3855 -0.0843 -0.6799 -0.4198 -0.1382
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left_ventricular_assist_devices lvads patients heart_failure incidence pump_dysfunction pump
H-773	-0.6713931560516357	▁left _ ▁vent ri cular _ assist ▁devices ▁l VAD s ▁cardiac _ ▁failure ▁pump ▁dys function ▁pump ▁replace ment
D-773	-0.6713931560516357	left_ ventricular_assist devices lVADs cardiac_ failure pump dysfunction pump replacement
P-773	-0.0428 -0.5803 -0.8659 -0.8478 -0.2018 -0.1323 -0.2472 -2.6876 -0.0965 -0.0305 -0.0672 -4.7194 -0.5324 -0.2676 -0.3652 -0.9524 -0.0320 -0.6196 -0.8024 -0.2375 -0.3128 -0.1291
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a angii hypoxia expression upr downregulation
H-1085	-0.776527464389801	▁s cn 5 a ▁Ang II ▁hypo xia ▁u PR
D-1085	-0.776527464389801	scn5a AngII hypoxia uPR
P-1085	-0.8214 -0.1804 -0.7571 -0.1139 -1.3011 -0.6387 -0.0372 -0.0130 -1.9925 -0.9545 -2.3820 -0.1264
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf multivariate-adjusted_odds_ratio mortality hazard_ratio mortality
H-1312	-1.008798599243164	current _ HF ▁odds _ ▁ratio ▁28- day _ ▁mortal ity ▁hazard _ ▁ratio
D-1312	-1.008798599243164	current_HF odds_ ratio 28-day_ mortality hazard_ ratio
P-1312	-2.4534 -0.1663 -0.6913 -2.8289 -1.3892 -0.1311 -1.6932 -0.5993 -0.4228 -0.0637 -1.3584 -0.1126 -0.8682 -0.1267 -2.9991 -0.2366
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas hf hyperkalemia hypokalemia spironolactone clinical
H-1708	-0.34396761655807495	▁AA s ▁ HF ▁hyper kal emia ▁hypo kal emia ▁spi rono lac tone
D-1708	-0.34396761655807495	AAs HF hyperkalemia hypokalemia spironolactone
P-1708	-0.8403 -0.8473 -0.9890 -0.2790 -0.5886 -0.2102 -0.0480 -0.0635 -0.3101 -0.0609 -0.0126 -0.0048 -0.0185 -0.0814 -1.0692 -0.0799
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate_logistic_regression_analysis bnp patients diastolic_dysfunction
H-1571	-0.35166820883750916	▁b NP ▁dia sto lic _ ▁dys function
D-1571	-0.35166820883750916	bNP diastolic_ dysfunction
P-1571	-0.7391 -1.0992 -0.0638 -0.0196 -0.2341 -0.4709 -0.3073 -0.1605 -0.3088 -0.1134
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo dopamine nesiritide secondary_end_points renal_function clinical outcomes
H-82	-0.4228048622608185	▁dop amine ▁nesi riti de ▁de con gestion ▁renal _ ▁function
D-82	-0.4228048622608185	dopamine nesiritide decongestion renal_ function
P-82	-2.4256 -0.1739 -0.0378 -0.0106 -0.1623 -0.0914 -0.0180 -0.0104 -0.0035 -0.9890 -0.6204 -0.8406 -0.1131
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp nonterminal_epitopes central_glycosylated_region
H-1522	-0.4833845794200897	▁NT - pro b NP ▁as say ▁non termin al _ e pito pes ▁gly cos yla ted _ region
D-1522	-0.4833845794200897	NT-probNP assay nonterminal_epitopes glycosylated_region
P-1522	-0.1939 -0.0811 -0.0120 -0.5304 -0.3202 -1.1278 -0.1367 -0.8019 -0.8614 -0.0187 -0.1962 -0.4721 -0.1352 -0.3098 -0.5036 -0.4336 -0.3486 -0.0706 -0.5910 -1.4593 -1.8728 -0.1574
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors g-protein-coupled_receptor kinase-2 downregulation
H-1407	-0.36991551518440247	▁receptor s ▁g - prote in - co up led _ ▁receptor ▁kina se -2
D-1407	-0.36991551518440247	receptors g-protein-coupled_ receptor kinase-2
P-1407	-0.6346 -0.2747 -0.8384 -0.1217 -0.0453 -0.2181 -0.0821 -0.0115 -0.1095 -1.0789 -0.1637 -0.1022 -0.1170 -0.0475 -0.0726 -2.2467 -0.1241
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic_function hfpef patients long_axis_function exercise
H-1888	-0.5875779986381531	▁sy sto lic _ function ▁ HF p EF ▁long _ a xis _ ▁function ▁exercise
D-1888	-0.5875779986381531	systolic_function HFpEF long_axis_ function exercise
P-1888	-4.3316 -0.1650 -0.2770 -0.3076 -1.0109 -0.3057 -0.0807 -0.0860 -0.2133 -0.8960 -0.1265 -0.6498 -0.0666 -0.2857 -0.4479 -0.8936 -0.2841 -0.1485
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable_models st2 outcomes clinical amino-terminal_pro-b-type_natriuretic_peptide
H-704	-0.45268765091896057	▁ST 2 ▁amino - termin al ▁na tri ure tic _ pe pti de
D-704	-0.45268765091896057	ST2 amino-terminal natriuretic_peptide
P-704	-0.6017 -0.1192 -0.6325 -0.0364 -0.0415 -0.0116 -1.3216 -0.0183 -0.2029 -2.0783 -0.3720 -0.4291 -0.1683 -0.8363 -0.2770 -0.0962
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia medline cochrane_library
H-31	-0.566185474395752	▁aan emia ▁ir on _ de fici en cy ▁MED line ▁co ch rane _ ▁Library
D-31	-0.566185474395752	aanemia iron_deficiency MEDline cochrane_ Library
P-31	-5.7492 -0.1043 -0.0837 -0.1853 -0.6963 -0.4991 -0.0148 -0.2039 -0.0830 -1.1065 -0.7144 -0.0703 -0.0689 -0.0298 -0.0841 -0.0291 -0.2972 -0.1712
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change correlation hospitals longitudinal
H-138	-1.5982046127319336	▁ metric
D-138	-1.5982046127319336	metric
P-138	-1.2330 -0.3925 -4.6023 -0.1650
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine bnp furosemide dobutamine norepinephrine outcome
H-587	-0.32823386788368225	▁creati nine ▁b NP ▁fur os em ide _ ▁dose ▁oxygen ▁flow ▁dobu tamine ▁no re pine ph rine
D-587	-0.32823386788368225	creatinine bNP furosemide_ dose oxygen flow dobutamine norepinephrine
P-587	-0.2905 -0.2741 -0.4236 -0.5163 -0.2364 -0.0615 -0.0208 -0.0171 -1.9714 -0.0291 -0.3528 -0.5982 -0.0181 -0.0319 -0.0011 -0.0325 -0.0100 -0.7379 -0.0186 -1.1830 -0.0680
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical biomedical patients dcm heart_failure pubmed
H-1259	-0.5764920115470886	▁bio medic al _ ▁treatment ▁CH m ▁bio medic al _ ▁treatment ▁d CM ▁heart _ ▁failure ▁Pub Med
D-1259	-0.5764920115470886	biomedical_ treatment CHm biomedical_ treatment dCM heart_ failure PubMed
P-1259	-0.1529 -0.1312 -0.0111 -2.2266 -1.4742 -2.0219 -0.2582 -0.0293 -0.0346 -0.0218 -1.5269 -0.9261 -0.3822 -0.1265 -0.7612 -1.4475 -0.0638 -0.1628 -0.0554 -0.1827 -0.1096
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 myocardial_collagen myocardial
H-1064	-0.6707659363746643	▁my o card ial _ ▁collage n ▁my o card ial ▁de lay ed _ ▁enhance ment _ ▁imagin g
D-1064	-0.6707659363746643	myocardial_ collagen myocardial delayed_ enhancement_ imaging
P-1064	-2.9069 -0.4047 -0.5974 -0.6482 -0.4807 -0.2516 -0.2444 -3.4423 -0.3176 -0.8251 -0.8262 -1.0718 -0.0425 -0.0477 -0.2035 -0.4884 -0.0271 -1.2989 -0.1020 -0.0964 -0.3500 -0.0834
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 sst2 odds_ratio cardiovascular_event
H-408	-1.3208606243133545	▁s st 2/ high - dos e _ bb ▁s st 2 ▁ bb ▁cardiovascular _ ▁event
D-408	-1.3208606243133545	sst2/high-dose_bb sst2 bb cardiovascular_ event
P-408	-0.2397 -1.1373 -2.3793 -0.6635 -0.0760 -1.3818 -0.0761 -1.8203 -0.5414 -0.1029 -1.5808 -0.3361 -5.7523 -3.0936 -2.3557 -0.8420 -2.3200 -0.2642 -0.1333
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley randomized acf allopurinol
H-473	-0.5251526832580566	▁Spr a gue - da w ley ▁rat s ▁sham ▁a CF ▁allo puri nol
D-473	-0.5251526832580566	Sprague-dawley rats sham aCF allopurinol
P-473	-0.3761 -0.1999 -0.1276 -0.0553 -1.4526 -0.0377 -0.1724 -2.4588 -0.0332 -0.0403 -1.0732 -0.8067 -0.4141 -0.0182 -0.9279 -0.5713 -0.1624
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular_pacing bivp cardiac_output cardiac surgery patients
H-319	-0.6813042163848877	▁Bi ven tri cular _ pa cing ▁bi VP ▁cardiac _ ▁output co ▁cardiac ▁surgery
D-319	-0.6813042163848877	Biventricular_pacing biVP cardiac_ outputco cardiac surgery
P-319	-2.2698 -0.1104 -0.4367 -1.0766 -0.2323 -0.5025 -0.5751 -1.3087 -0.3096 -0.1252 -0.8232 -0.1816 -2.0522 -0.0791 -0.6083 -0.7319 -0.1589
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin sitagliptin follow-up
H-1833	-1.103200078010559	▁sax ag lip tin ▁si tag lip tin ▁follow - up ▁pair wise
D-1833	-1.103200078010559	saxagliptin sitagliptin follow-up pairwise
P-1833	-0.1438 -0.0220 -0.2652 -3.7427 -3.1120 -0.1936 -0.1359 -3.1463 -1.3494 -0.1197 -0.0155 -2.3120 -0.4435 -1.4199 -0.1264
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq patients hfpef
H-790	-0.6919518709182739	▁k cc q _ ▁domain s ▁interne _ ▁consiste ncy ▁ HF p EF ▁c ron bach
D-790	-0.6919518709182739	kccq_ domains interne_ consistency HFpEF cronbach
P-790	-1.2874 -0.0568 -1.3148 -2.7165 -0.0514 -0.0483 -1.9687 -0.5739 -0.4217 -0.0103 -0.5823 -0.2157 -0.0936 -0.4332 -2.3820 -0.0831 -0.0104 -0.8177 -0.0793
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable patients qrs_duration
H-891	-0.4106631875038147	▁implant able _ ▁cardio ver ter _ de fi br illa tor - c RT ▁non - LB bb ▁QR s
D-891	-0.4106631875038147	implantable_ cardioverter_defibrillator-cRT non-LBbb QRs
P-891	-0.4798 -0.0404 -0.0964 -0.3188 -0.0478 -0.0527 -0.6481 -0.1594 -0.0109 -0.1200 -0.0482 -0.0177 -0.0811 -1.1187 -2.1971 -1.0720 -0.0317 -0.2800 -0.9896 -0.2662 -0.4128 -0.8539 -0.1019
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up patients
H-1538	-0.60830157995224	▁ale ndr onate ▁et id rona te - ▁ra lo xi fen e - tre ated
D-1538	-0.60830157995224	alendronate etidronate- raloxifene-treated
P-1538	-5.7611 -0.0323 -0.0249 -0.3866 -0.0328 -0.0027 -0.0113 -1.3508 -0.9249 -0.0218 -0.0640 -0.0591 -0.0689 -0.1054 -0.0047 -0.7985 -1.1504 -0.1493
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal diagnostic clinical
H-1304	-1.6606411933898926	▁diagnose s
D-1304	-1.6606411933898926	diagnoses
P-1304	-3.1939 -1.6088 -1.7448 -0.0951
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients systolic_hf the_danish_heart_failure_database esrd danish_registry_on_dialysis
H-389	-0.6096712946891785	▁sy sto lic _ HF ▁Danish _ ▁Heart _ ▁Fail ure _ ▁database ▁ES RD ▁Danish _ ▁Registr y _ ▁on _ dia lys is
D-389	-0.6096712946891785	systolic_HF Danish_ Heart_ Failure_ database ESRD Danish_ Registry_ on_dialysis
P-389	-0.1237 -0.0472 -0.0521 -0.0564 -0.9389 -1.4851 -0.2342 -0.6199 -1.1684 -0.0681 -0.3763 -1.7197 -0.0290 -2.2367 -0.9970 -1.2280 -0.2675 -1.4488 -0.2912 -0.0710 -1.5201 -0.1630 -0.7139 -0.0643 -0.0584 -0.3532 -0.1289
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy trastuzumab comorbidities chf international_classification_of_diseases healthcare_common_procedure_coding_system_codes
H-674	-0.36724650859832764	▁che mo therapy ▁tras tuz um ab ▁CHF ▁international _ ▁Classifica tion _ of _ ▁Disease s ▁health care ▁Common _ ▁Procedur e _ co ding _ system ▁code s
D-674	-0.36724650859832764	chemotherapy trastuzumab CHF international_ Classification_of_ Diseases healthcare Common_ Procedure_coding_system codes
P-674	-0.9891 -0.1764 -0.0196 -0.0384 -0.0262 -0.0163 -0.3449 -1.2393 -2.2796 -0.4747 -0.0115 -0.0138 -0.0689 -0.2944 -0.2820 -0.0344 -0.0079 -1.1822 -0.0643 -0.7316 -0.0432 -0.5658 -0.0353 -0.4101 -0.3119 -0.0267 -0.3006 -0.3950 -0.9904 -0.0343 -0.2185 -0.1247
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart_failure hf therapies outcomes patients hf preserved_left_ventricular_ejection_fraction lvef
H-111	-0.5501484274864197	▁con tempor ary _ heart _ ▁failure HF ▁ therapie s ▁ HF ▁pres er ved ▁left _ ▁vent ri cular _ e je ction _ fraction LV EF
D-111	-0.5501484274864197	contemporary_heart_ failureHF therapies HF preserved left_ ventricular_ejection_fractionLVEF
P-111	-0.6829 -0.0021 -0.2041 -0.0290 -2.2755 -0.9044 -0.0693 -0.7187 -0.6850 -0.2197 -0.0280 -0.6934 -0.4054 -2.4074 -0.0742 -0.3311 -0.8801 -0.3238 -1.1472 -1.1295 -0.4109 -0.2190 -0.5257 -0.2581 -0.1815 -0.3817 -0.1115 -1.2071 -0.2227 -0.2017 -0.1241
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths crt hazard_ratio
H-853	-1.2191098928451538	▁c r _ groep ▁control _ groep ▁hazard _ ▁ratio
D-853	-1.2191098928451538	cr_groep control_groep hazard_ ratio
P-853	-0.6794 -3.7579 -1.6886 -0.4627 -1.4871 -1.3727 -1.1944 -0.1217 -1.4775 -0.0200 -2.1867 -0.1805
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation consultation consultation operation
H-1283	-1.4277633428573608	▁m _ groep
D-1283	-1.4277633428573608	m_groep
P-1283	-2.2608 -3.0867 -0.6315 -1.0673 -0.0925
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized heart_failure saxagliptin sitagliptin antihyperglycemic_drugs retrospective_cohort_study
H-1826	-0.681675136089325	▁risk ▁Hospital ized _ ▁Heart _ ▁Fail ure ▁Sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic _ drug s
D-1826	-0.681675136089325	risk Hospitalized_ Heart_ Failure Saxagliptin sitagliptin antihyperglycemic_drugs
P-1826	-2.7985 -1.3192 -0.1396 -0.0359 -0.4965 -1.2252 -0.0371 -0.4256 -0.0897 -0.0155 -0.3903 -3.1674 -1.3439 -0.1394 -0.0805 -2.7797 -0.0472 -0.3112 -0.0546 -0.5151 -0.3342 -0.3716 -0.7215 -0.7002 -0.0178 -0.7285 -0.1192
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise training outcomes chronic_heart_failure heart_failure_-_a_controlled_trial_investigating_outcomes_in_exercise_training hf-action
H-1629	-0.7085888981819153	▁race ▁exercise _ training ▁chronic _ ▁heart ▁failure ▁Heart _ ▁Fail ure ▁control led _ tri al _ ▁Investiga ting ▁Exerci se _ ▁Tra i N ing HF - ac tion
D-1629	-0.7085888981819153	race exercise_training chronic_ heart failure Heart_ Failure controlled_trial_ Investigating Exercise_ TraiNingHF-action
P-1629	-1.3484 -2.3422 -2.1027 -0.2265 -0.3671 -0.1039 -1.3851 -0.7231 -1.0607 -1.2869 -0.2239 -0.4845 -1.2016 -0.4033 -0.0401 -0.2427 -0.0431 -0.1465 -0.0189 -0.0390 -0.7000 -0.0274 -0.0900 -2.0886 -0.4688 -2.6140 -0.1767 -1.1661 -0.0258 -0.4000 -1.5376 -0.1737 -0.1243
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass_correlation_coefficient icc kappa_coefficient standard_error_of_measurement minimal_detectable_change mdc
H-801	-0.48938918113708496	▁intra class _ ▁corre lation _ co e ffi cient ▁i cc ▁ka ppa ▁co e ffi cient ▁m DC
D-801	-0.48938918113708496	intraclass_ correlation_coefficient icc kappa coefficient mDC
P-801	-0.5842 -0.1776 -0.3573 -0.4075 -0.2659 -0.4920 -0.4893 -0.3043 -0.1895 -0.0847 -0.9413 -0.5049 -0.0217 -0.0715 -1.2395 -0.0884 -0.0819 -0.0336 -3.1035 -0.8646 -0.3418 -0.1219
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil phosphocreatine adenine_nucleotides mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity
H-964	-0.4154263138771057	▁Nico rand il ▁ phos pho creati ne ▁a den ine _ ▁nucleo ti des ▁mito cho ndri al _ ▁oxid ative _ phos phor y lation ▁capacity ▁creati ne ▁kina se _ activ iteit
D-964	-0.4154263138771057	Nicorandil phosphocreatine adenine_ nucleotides mitochondrial_ oxidative_phosphorylation capacity creatine kinase_activiteit
P-964	-0.0022 -0.0242 -0.0449 -0.0623 -0.0486 -0.0607 -0.3453 -1.4946 -0.0185 -0.0093 -2.3172 -0.2273 -0.0618 -0.0597 -0.1242 -0.0931 -0.1789 -0.2272 -0.0301 -0.5838 -0.7894 -0.0326 -0.2074 -0.1282 -0.7070 -1.4667 -0.0773 -2.3757 -0.0053 -0.3675 -0.2750 -0.0622 -1.4068 -0.2043 -0.7522 -0.3636 -0.1356
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox_proportional_hazards_models death transplantation lv_assist_device_implantation heart_failure hospitalization follow-up
H-431	-0.6788299679756165	▁co x ▁proportion al _ ▁hazard s _ ▁models ▁death ▁transplant ation ▁LV _ assist _ ▁device _ ▁implant ation ▁heart ▁failure
D-431	-0.6788299679756165	cox proportional_ hazards_ models death transplantation LV_assist_ device_ implantation heart failure
P-431	-0.0951 -0.0126 -0.5736 -0.0135 -0.0545 -0.3703 -0.1465 -3.5603 -0.7926 -2.9565 -0.3075 -0.0717 -0.0481 -1.0779 -0.7074 -0.5711 -0.6983 -1.4298 -0.4476 -0.0813 -0.1315 -0.4660 -1.5258 -0.1524
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones adipokines fat_free_mass ffm fat_mass
H-11	-0.4979926645755768	▁neuro hormon es ▁adi pok ines ▁body ▁composition ▁CC ▁fat ▁free _ ▁mass ▁f m ▁fat _ ▁mass FM
D-11	-0.4979926645755768	neurohormones adipokines body composition CC fat free_ mass fm fat_ massFM
P-11	-0.0406 -0.0321 -0.0625 -0.0291 -0.0182 -0.0474 -1.9699 -0.2260 -0.3970 -1.5585 -1.4791 -0.2522 -0.5085 -1.1556 -0.1095 -0.2081 -1.0635 -0.4169 -0.5339 -0.2635 -0.0857
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient primary_end_point rehospitalization stroke myocardial_infarction heart_failure cabg
H-972	-0.3779294490814209	▁Swedish _ national _ in patient _ registra y ▁re hospital ization ▁stroke ▁my o card ial _ in far ction ▁heart ▁failure ▁ca BG
D-972	-0.3779294490814209	Swedish_national_inpatient_registray rehospitalization stroke myocardial_infarction heart failure caBG
P-972	-0.0898 -0.1368 -0.1706 -0.0879 -0.0890 -0.0628 -0.9926 -1.0168 -0.7597 -0.0706 -0.0196 -0.3035 -2.3835 -0.4030 -0.4199 -0.2132 -0.4401 -0.0996 -0.1947 -0.0659 -0.0712 -0.2916 -0.5109 -0.2946 -0.7064 -0.2025 -0.1074
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule expression regulation rad q66p rgk_protein in_vivo
H-1678	-0.8732798099517822	▁mis tar ge ting ▁alter ed _ regula tion ▁Rad _ ▁Q 66 p ▁r GK _ ▁protein
D-1678	-0.8732798099517822	mistargeting altered_regulation Rad_ Q66p rGK_ protein
P-1678	-1.5531 -0.0454 -0.0685 -0.0226 -4.1502 -0.0355 -0.3208 -1.0344 -0.0907 -1.8697 -0.8350 -2.0432 -0.4874 -0.2450 -0.6473 -0.3437 -0.9438 -0.1949 -2.4442 -0.0900
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter_ablation patients compensated_hfpef left_ventricular ejection_fraction
H-944	-0.5311542749404907	▁Cat heter ▁ab lation ▁AF ▁compensa ted _ h FP EF ▁le ft _ ▁vent ri cular LV ▁e je ction _ fraction
D-944	-0.5311542749404907	Catheter ablation AF compensated_hFPEF left_ ventricularLV ejection_fraction
P-944	-1.2860 -0.1476 -0.6851 -0.2077 -1.4392 -0.0229 -0.0218 -1.1060 -0.4891 -0.8665 -0.7624 -0.8315 -0.0278 -0.1511 -1.3624 -0.8767 -0.1448 -0.7543 -0.7272 -0.0635 -0.0427 -0.6262 -0.0088 -0.5166 -0.1110
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte_hypertrophy heart_failure global_gene_expression dna genomic
H-89	-0.6258069276809692	▁My o cy te _ ▁hyper trop hy _ ▁antecede nt _ to _ ▁heart _ ▁failure
D-89	-0.6258069276809692	Myocyte_ hypertrophy_ antecedent_to_ heart_ failure
P-89	-0.6863 -0.0797 -0.0723 -0.0219 -0.7863 -0.4852 -0.0073 -0.6809 -1.5623 -0.0092 -0.0251 -0.1312 -0.9477 -0.1190 -1.8159 -0.7589 -0.1778 -3.3679 -0.1555
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully_magnetically_levitated_lvas mortality seattle heart_failure
H-2002	-0.6749656200408936	▁fully _ magnet ically _ le vita ted _ ▁l VAS ▁Seattle _ ▁Heart _ ▁Fail ure
D-2002	-0.6749656200408936	fully_magnetically_levitated_ lVAS Seattle_ Heart_ Failure
P-2002	-1.9954 -0.4005 -0.6698 -0.1803 -0.0837 -1.0216 -0.0309 -0.0476 -0.4397 -1.9316 -0.3799 -2.8238 -0.2528 -0.2253 -0.9742 -0.1088 -0.7071 -0.4041 -0.1471
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa immunoassays antibodies c_termini nt-probnp
H-1518	-0.43251100182533264	▁Alpha LIS a ▁immun o assa ys ▁anti bo dies ▁circula ting ▁NT - pro b NP
D-1518	-0.43251100182533264	AlphaLISa immunoassays antibodies circulating NT-probNP
P-1518	-0.0176 -0.3220 -0.3178 -0.2476 -0.2229 -0.0942 -0.9809 -0.0134 -0.0188 -0.5495 -3.9251 -0.0359 -0.5138 -0.0407 -0.0171 -0.5190 -0.1424 -0.1683 -0.0707
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac_plasma_membrane s1pr1 β1ar heart_failure
H-1411	-0.7702131271362305	▁cardiac _ ▁plasma ▁membran e ▁s 1 PR 1 ▁β 1 AR ▁over stimul ation ▁heart ▁failure
D-1411	-0.7702131271362305	cardiac_ plasma membrane s1PR1 β1AR overstimulation heart failure
P-1411	-2.6355 -0.3956 -0.2504 -0.2071 -0.0228 -1.0193 -0.7034 -0.3863 -3.0247 -0.9091 -1.7024 -1.2346 -0.5922 -0.1272 -0.1142 -0.3529 -0.5071 -0.3182 -0.1311
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients new_york_heart_association nyha chronic_heart_failure reduced_ejection_fraction
H-1952	-0.7711896896362305	▁New ▁York _ ▁Heart _ association NY ha ▁chronic _ heart _ ▁failure ▁reduce d _ e je ction _ fraction
D-1952	-0.7711896896362305	New York_ Heart_associationNYha chronic_heart_ failure reduced_ejection_fraction
P-1952	-1.1999 -1.8991 -0.0967 -1.3896 -0.4497 -0.9083 -0.8189 -1.1327 -1.0395 -0.0444 -1.2769 -1.2826 -0.0837 -2.6120 -0.0646 -0.0507 -0.4292 -0.0875 -0.0518 -0.1383 -0.0771 -2.4690 -0.1353
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological_phenotype clinically deficit_index medical frailty
H-1013	-0.47906410694122314	▁bi ological _ ▁ph eno type ▁deficit _ index ▁medical _ ▁records ▁fra il ty
D-1013	-0.47906410694122314	biological_ phenotype deficit_index medical_ records frailty
P-1013	-1.5910 -0.3168 -0.3382 -0.7691 -0.0466 -0.0016 -1.8639 -0.2285 -0.4346 -0.4067 -0.9865 -0.1907 -0.1528 -0.2127 -0.2985 -0.1998 -0.1060
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel apoptotic_cells tunel-positive_cells
H-172	-0.5098866820335388	▁tu nel _ as say ▁apo pto tic _ ▁cell s ▁tu nel - posi tive _ ▁cell s ▁pace d _ groep
D-172	-0.5098866820335388	tunel_assay apoptotic_ cells tunel-positive_ cells paced_groep
P-172	-0.9331 -0.7392 -0.7003 -0.1570 -0.1316 -1.1190 -0.1808 -0.6223 -0.2825 -1.7895 -0.0461 -0.6989 -0.7445 -0.0662 -0.0025 -0.2978 -0.2701 -1.4470 -0.0262 -0.4962 -0.0272 -0.4395 -0.9199 -0.4783 -0.1314
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt elevated acute β-adrenoceptor_blockade esmolol
H-1444	-0.5892053246498108	▁SD QT ▁ HF VT ▁h Nor m ▁β - ad re no cept or _ block ade ▁es mol ol
D-1444	-0.5892053246498108	SDQT HFVT hNorm β-adrenoceptor_blockade esmolol
P-1444	-0.0208 -0.3713 -0.8007 -0.2024 -0.6027 -0.7220 -3.7644 -0.0170 -0.8483 -0.0316 -0.0409 -0.1374 -0.1351 -0.1753 -0.2873 -1.1163 -0.9413 -0.0947 -2.5172 -0.0037 -0.3111 -0.3260 -0.0843
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically myocardial_infarction heart_failure randomized bisoprolol
H-452	-0.6449466347694397	▁sur g ically _ ▁induc ed ▁my o card ial _ in far ction ▁heart ▁failure ▁bis o pro lol ▁vehicle
D-452	-0.6449466347694397	surgically_ induced myocardial_infarction heart failure bisoprolol vehicle
P-452	-5.0452 -0.3052 -0.3411 -0.7796 -0.2807 -0.1949 -2.3309 -0.2341 -0.5785 -0.8891 -0.1130 -0.2808 -0.1384 -0.0686 -0.3038 -0.3065 -0.8021 -0.1868 -0.0376 -0.2053 -1.0142 -0.2675 -0.1300
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts hh medical all-cause_mortality discharged patients heart_failure
H-162	-2.1847970485687256	▁s s _ HH ▁TM ▁medical _ support
D-162	-2.1847970485687256	ss_HH TM medical_support
P-162	-0.7716 -2.1872 -1.7670 -0.8037 -4.2334 -3.9363 -1.2357 -0.8883 -5.8813 -0.1435
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions readmission patients congestive_heart_failure south_dakota
H-1583	-0.7824991941452026	▁con ges tive _ heart _ ▁failure ▁non - urban ized _ mid we stern _ ▁state ▁South _ da kota
D-1583	-0.7824991941452026	congestive_heart_ failure non-urbanized_midwestern_ state South_dakota
P-1583	-1.3561 -0.4415 -1.3551 -0.0467 -1.8813 -1.0580 -0.0445 -3.4674 -0.0303 -0.0105 -0.1094 -1.2723 -0.0504 -0.0869 -0.1404 -0.8513 -1.7820 -0.7762 -1.7065 -0.8798 -0.0449 -0.3987 -0.2072
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia intravenous atropine cardiac vagal_tone
H-1380	-0.5078825354576111	▁ta chy car dia ▁intra ven ous _ a tropi ne ▁cardiac _ ▁va gal _ ▁tone ▁CHF - DN x ▁CHF - in v ▁animals
D-1380	-0.5078825354576111	tachycardia intravenous_atropine cardiac_ vagal_ tone CHF-DNx CHF-inv animals
P-1380	-1.1568 -0.4886 -0.0164 -0.0085 -0.1246 -0.0141 -3.6937 -0.2530 -0.2897 -0.0456 -2.1742 -0.0299 -0.4519 -0.8962 -0.1080 -0.1996 -0.1081 -0.0738 -0.0681 -0.7344 -0.1639 -0.0852 -0.0517 -0.2517 -0.3633 -2.0660 -0.1881 -0.1157
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes myocardium conditions
H-990	-0.4442276060581207	▁cardio my o cy tes ▁mechanic al ▁humor al _ stimul i ▁my o car dium ▁work load ▁stress
D-990	-0.4442276060581207	cardiomyocytes mechanical humoral_stimuli myocardium workload stress
P-990	-0.1849 -0.4943 -0.1974 -0.1054 -0.0546 -1.4496 -0.0134 -0.3856 -0.0574 -1.6434 -0.3211 -0.1661 -1.0551 -0.0637 -0.0156 -0.1273 -2.0028 -0.0430 -0.5374 -0.2971 -0.1136
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse pasp step rv_function lv_dysfunction
H-501	-0.8224606513977051	▁t AP se ▁pas p ▁length - force _ ▁relationship ▁ RV _ ▁function _ ▁evaluation ▁LV _ ▁dys function
D-501	-0.8224606513977051	tAPse pasp length-force_ relationship RV_ function_ evaluation LV_ dysfunction
P-501	-5.1535 -0.3208 -0.4610 -2.2993 -0.2407 -0.9797 -0.0348 -0.0580 -0.5432 -0.3641 -0.2474 -0.3253 -1.1658 -0.6890 -2.1964 -0.6530 -0.1811 -1.5792 -0.2717 -0.0275 -0.1781 -0.1248
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular_support rvads explanted
H-301	-0.8007506132125854	▁bi ven tri cular _ support ▁r VAD s
D-301	-0.8007506132125854	biventricular_support rVADs
P-301	-2.4162 -0.1150 -0.1219 -0.7131 -0.5266 -1.2445 -1.4934 -0.5491 -0.2027 -1.2497 -0.1759
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno_donor myocardial_function evidence hf
H-425	-0.7767804265022278	▁functional _ ef fica cy ▁pure _ h no _ ▁donor ▁my o card ial _ ▁function ▁ HF
D-425	-0.7767804265022278	functional_efficacy pure_hno_ donor myocardial_ function HF
P-425	-3.0041 -0.6021 -0.2906 -0.4646 -0.1372 -2.9028 -0.1616 -0.3607 -0.3921 -0.3943 -0.0422 -2.9473 -0.2627 -0.3373 -0.8687 -0.3465 -1.0634 -1.0860 -0.3226 -0.1958 -0.1296
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions training patients out-patient follow-up patient health_care
H-1579	-1.1307899951934814	▁transition s _ of _ care _ programm e ▁self - management _ training ▁patients ▁follow - up
D-1579	-1.1307899951934814	transitions_of_care_programme self-management_training patients follow-up
P-1579	-4.1702 -0.4423 -0.2226 -1.3964 -0.1332 -1.1119 -0.9764 -1.7027 -0.3783 -1.6189 -0.0530 -0.0056 -1.8411 -0.2156 -2.0081 -2.5718 -0.1221 -0.0221 -3.4200 -0.2035
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd outpatients systolic_hf patients egfr
H-396	-0.8356545567512512	▁ES RD ▁sy sto lic _ HF ▁e g FR
D-396	-0.8356545567512512	ESRD systolic_HF egFR
P-396	-3.8600 -1.0679 -0.4045 -0.0308 -0.0617 -0.1436 -0.6035 -0.0891 -2.2746 -0.7485 -0.5266 -0.2171
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf phenotype cardiac explant progenitors regulation
H-1337	-0.5065133571624756	▁CHF ▁cardiac _ ex plant ▁c - K it _ ▁pro geni tors ▁mechanism s
D-1337	-0.5065133571624756	CHF cardiac_explant c-Kit_ progenitors mechanisms
P-1337	-0.8957 -0.7773 -0.2437 -1.1979 -0.0075 -0.2049 -0.1092 -1.0892 -0.0078 -0.3485 -2.3197 -0.0154 -0.0933 -0.0849 -0.1338 -1.0006 -0.0814
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy sst2 patients chronic_heart_failure
H-411	-0.9450535178184509	▁BB ▁ therapy ▁s st 2 _ ▁measure ment ▁chronic _ heart _ ▁failure ▁BB
D-411	-0.9450535178184509	BB therapy sst2_ measurement chronic_heart_ failure BB
P-411	-0.8782 -1.4548 -0.0751 -0.3784 -0.6749 -0.0724 -2.6675 -1.4005 -0.0446 -0.1436 -0.0930 -1.6649 -1.5529 -0.0795 -3.9482 -0.7659 -0.1716
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission disease heart_failure hf acute_myocardial_infarction ami pneumonia
H-137	-0.9292664527893066	▁ STU DY _ ▁DESIGN ▁heart ▁failure HF ▁a cute _ My o card ial _ in far ction AMI ▁pneu monia
D-137	-0.9292664527893066	STUDY_ DESIGN heart failureHF acute_Myocardial_infarctionAMI pneumonia
P-137	-4.2617 -0.5537 -0.0754 -1.1218 -0.1548 -6.4274 -0.8841 -0.5763 -0.0468 -0.0096 -0.0308 -4.3439 -0.8169 -0.4573 -1.0065 -0.0808 -0.2416 -0.1135 -0.1392 -0.2888 -0.0223 -0.2583 -0.2557 -0.1352
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed heart_failure left_ventricular_ejection_fraction spironolactone kaiser_permanente northern_california
H-440	-0.4255407154560089	▁heart ▁failure ▁left _ ▁vent ri cular _ e je ction ▁spi rono lac tone ▁Kaiser _ ▁Permanent e _ ▁Northern ▁California
D-440	-0.4255407154560089	heart failure left_ ventricular_ejection spironolactone Kaiser_ Permanente_ Northern California
P-440	-2.0039 -0.9445 -0.0825 -0.3195 -1.0974 -0.9019 -0.4938 -0.2801 -0.3347 -0.0952 -0.0418 -0.0875 -0.0033 -0.0133 -0.0214 -0.6453 -0.7072 -0.8798 -0.0202 -0.3536 -0.0562 -0.4373 -0.2725 -0.1201
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression_analysis echocardiographic lv_reverse_remodeling lv_end-systolic_volume
H-430	-0.2635136544704437	▁e cho car dio graphic _ ▁score ▁LV ▁rever se _ ▁remodel ing ▁LV ▁end - sy sto lic _ ▁volume
D-430	-0.2635136544704437	echocardiographic_ score LV reverse_ remodeling LV end-systolic_ volume
P-430	-0.4004 -0.0574 -0.0423 -0.3209 -0.3189 -0.5861 -0.3582 -0.1738 -0.7889 -0.0410 -0.0400 -0.2366 -0.0299 -0.4961 -1.3043 -0.0595 -0.0763 -0.0528 -0.0310 -0.1955 -0.1076 -0.2339 -0.1093
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative renal_dysfunction cardiovascular_events stroke myocardial_infarction heart_failure death isolated_coronary_artery_bypass_grafting
H-968	-0.4143921136856079	▁renal _ ▁dys function ▁cardiovascular _ ▁events stro ke ▁my o card ial _ in far ction ▁heart ▁failure ▁corona ry _ ▁arter y _ by pass ▁graf ting
D-968	-0.4143921136856079	renal_ dysfunction cardiovascular_ eventsstroke myocardial_infarction heart failure coronary_ artery_bypass grafting
P-968	-1.1735 -0.7625 -0.1032 -0.0172 -0.1921 -1.0023 -0.3571 -0.0257 -0.0172 -0.6531 -0.3795 -0.2992 -0.4468 -0.1315 -0.4108 -0.0499 -0.0372 -0.1209 -0.2306 -0.4203 -1.3209 -0.1414 -0.0893 -0.5220 -0.4131 -2.4371 -0.0458 -0.2753 -0.3909 -0.2416 -0.1382
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone_antagonist therapy chronic_advanced_heart_failure patients post-myocardial_infarction heart_failure patients
H-1738	-0.5522564649581909	▁al do ster one _ ▁anta gon ist _ therapy ▁chronic _ heart _ ▁failure ▁post - my o card ial _ in far ction _ ▁heart ▁failure
D-1738	-0.5522564649581909	aldosterone_ antagonist_therapy chronic_heart_ failure post-myocardial_infarction_ heart failure
P-1738	-0.2679 -0.0952 -0.0703 -0.3464 -0.9556 -0.1182 -0.0081 -0.5245 -0.4937 -0.0168 -1.4966 -0.1245 -3.0305 -1.0073 -0.0765 -0.1166 -0.0309 -0.8982 -0.4494 -0.5609 -0.6441 -0.1054 -0.2052 -0.0775 -0.0647 -0.2073 -1.6667 -0.4027 -2.3464 -0.1594
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial_shunting patients heart_failure_with_reduced_ejection_fraction proof-of-principle_cohort_study
H-1948	-0.8455120921134949	▁left - to - right _ inter at rial _ ▁sh unting ▁heart _ ▁failure ▁e je ction _ fraction
D-1948	-0.8455120921134949	left-to-right_interatrial_ shunting heart_ failure ejection_fraction
P-1948	-4.1089 -0.0783 -0.0523 -0.0777 -0.1101 -0.3314 -0.1331 -0.2134 -0.1643 -0.5655 -2.4988 -0.6862 -4.6799 -1.2472 -0.1054 -1.7192 -0.0808 -0.1269 -0.2462 -0.0839 -1.1364 -0.1553
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial_extracellular_matrix cardiac_magnetic_resonance t1_mapping pathobiology pathophysiology prognosis
H-735	-0.46326062083244324	▁my o card ial _ extra cel lular _ ▁matri x ▁cardiac _ ▁magnetic _ ▁res on ance _ ▁T 1 _ ▁ma pping ▁path obi ology pat ho phy si ology ▁prognos is
D-735	-0.46326062083244324	myocardial_extracellular_ matrix cardiac_ magnetic_ resonance_ T1_ mapping pathobiologypathophysiology prognosis
P-735	-1.3461 -0.2807 -0.2437 -0.3423 -0.1474 -0.9306 -0.2645 -0.0726 -0.3576 -0.4732 -0.2268 -0.0059 -0.3381 -0.2279 -0.1291 -2.3323 -0.1664 -0.0453 -0.6575 -1.4447 -0.3275 -1.9518 -0.6482 -0.0255 -0.6743 -0.0334 -0.2102 -0.0796 -0.1209 -0.0916 -1.0377 -0.0696 -1.0136 -0.0934 -0.1482 -0.1192
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical_examination patient bmi heart_rate rhythm blood_pressure auscultation rule valvular_disease pulmonary_congestion
H-1894	-0.5636841058731079	▁b MI ▁heart ▁rate ▁ rhythm ▁ly ing ▁standing _ ▁blood _ ▁pressure ▁aus cul tation ▁val vu lar _ ▁disease ▁pulmonar y _ con gestion
D-1894	-0.5636841058731079	bMI heart rate rhythm lying standing_ blood_ pressure auscultation valvular_ disease pulmonary_congestion
P-1894	-0.6125 -1.6552 -3.9846 -1.0704 -0.1591 -0.0517 -0.0461 -0.0437 -0.3251 -0.3680 -0.6952 -1.1684 -0.4957 -1.0222 -0.0183 -0.0435 -0.1905 -0.0456 -0.1987 -1.1560 -0.7114 -0.0044 -0.1183 -0.2203 -0.8427 -0.0269 -0.3692 -0.1392
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal_dialysis pd diuretic volume_overload heart_failure hf
H-894	-0.4858950972557068	▁Peri tone al _ di al ysis PD ▁di ure tic _ ▁resist ant _ ▁volume ▁over load ▁heart ▁failure HF
D-894	-0.4858950972557068	Peritoneal_dialysisPD diuretic_ resistant_ volume overload heart failureHF
P-894	-0.2863 -0.1485 -0.0851 -0.1334 -1.1905 -0.0708 -0.1810 -0.2621 -0.6044 -0.1658 -0.8507 -0.3932 -2.5066 -0.0195 -0.1269 -0.1969 -0.5978 -0.1036 -1.0497 -0.7986 -0.7539 -0.5313 -0.1190
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology national_cardiovascular_disease_registry_practice_innovation_and_clinical_excellence_registry
H-660	-0.8396005630493164	▁Card i ology ▁practice s ▁ europe se _ ▁Card io vas cular _ ▁Disease _ ▁Registr y ▁Practic e ▁Innovation ▁Clinic al _ ▁Excellence
D-660	-0.8396005630493164	Cardiology practices europese_ Cardiovascular_ Disease_ Registry Practice Innovation Clinical_ Excellence
P-660	-1.8320 -0.4628 -0.2411 -1.9226 -0.0225 -1.6433 -3.4843 -0.0180 -0.3878 -2.3383 -1.5822 -0.2156 -0.6947 -0.2783 -0.0592 -1.2454 -0.8219 -0.0667 -2.0389 -0.0243 -0.8798 -0.1960 -0.0341 -0.5573 -0.8957 -0.5840 -0.1423
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report stable hno_donor cxl-1020 myoctyes hearts patients heart_failure hf
H-415	-0.6282511353492737	▁h no _ ▁donor ▁c XL -10 20 ▁isola ted _ my oc ty es ▁intact _ ▁heart s ▁heart ▁failure HF
D-415	-0.6282511353492737	hno_ donor cXL-1020 isolated_myoctyes intact_ hearts heart failureHF
P-415	-1.8249 -0.5695 -1.7766 -0.0554 -0.7145 -0.1857 -1.3010 -1.0844 -1.3369 -0.0142 -0.4448 -2.4518 -0.0441 -0.0285 -0.0679 -0.0122 -0.1612 -1.1787 -0.0422 -0.5850 -0.2355 -0.5125 -0.3347 -0.1157
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral_muscle_pump cardiac_filling exercise subpulmonary_ventricle fontan_circulation
H-1492	-0.3239815831184387	▁per i pher al _ ▁muscle _ pump ▁cardiac _ ▁fill ing ▁sub pul mon ary _ ▁vent ric le ▁Font an _ ▁circulation
D-1492	-0.3239815831184387	peripheral_ muscle_pump cardiac_ filling subpulmonary_ ventricle Fontan_ circulation
P-1492	-0.1076 -0.0340 -0.0636 -0.1375 -0.0511 -1.7068 -0.3017 -0.4810 -0.8125 -1.1725 -0.1453 -0.0219 -0.0819 -0.2453 -0.5549 -0.1088 -0.0595 -0.2899 -0.8735 -0.2279 -0.0927 -0.1500 -0.0459 -0.1994 -0.3187 -0.1396
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil heart_rate aortic blood_flow mitochondrial oxidative_stress doxorubicin cardiotoxicity
H-963	-0.48820212483406067	▁Nico rand il ▁heart _ ▁rate ▁a or tic _ ▁blood ▁flow ▁mito cho ndri al _ ▁oxid ative _ stress ▁do xor ubi cin ▁cardio toxic iteit
D-963	-0.48820212483406067	Nicorandil heart_ rate aortic_ blood flow mitochondrial_ oxidative_stress doxorubicin cardiotoxiciteit
P-963	-0.0028 -0.0119 -0.0236 -3.1958 -1.7622 -0.8486 -0.0210 -0.0406 -0.4629 -0.0278 -0.9060 -0.9180 -0.0019 -0.1219 -0.1442 -0.0204 -0.3603 -0.5079 -0.0200 -0.2520 -0.7612 -0.0142 -0.0055 -0.0123 -0.6040 -0.7084 -0.4917 -2.0482 -0.2598 -0.0908
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal_dysfunction prognostic heart_failure hf dysfunction end-stage_renal_disease esrd
H-387	-0.7998961210250854	▁Ren al _ ▁dys function ▁heart ▁failure HF ▁dys function ▁end - s tage _ ▁renal _ ▁disease ▁e RD
D-387	-0.7998961210250854	Renal_ dysfunction heart failureHF dysfunction end-stage_ renal_ disease eRD
P-387	-3.5290 -0.2818 -0.6667 -0.3505 -0.0744 -1.3633 -0.7499 -0.4060 -3.2732 -0.0342 -0.7566 -0.0659 -0.1140 -0.0067 -0.4646 -0.0436 -0.7115 -0.5485 -1.2897 -2.3878 -0.3235 -0.1563
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients heart_failure_with_preserved_ejection_fraction hfpef heart_failure obese
H-1974	-0.5784966349601746	▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁h FP EF ▁heart ▁failure ▁over weight ▁obes e
D-1974	-0.5784966349601746	heart failure preserved_ejection_fraction hFPEF heart failure overweight obese
P-1974	-2.3368 -1.1189 -0.8912 -0.1682 -0.6972 -0.0426 -0.4495 -0.1932 -0.0724 -0.1107 -0.1075 -0.7875 -1.6393 -1.2925 -1.1353 -0.8755 -0.0141 -0.1750 -0.1247 -0.0770 -0.2663 -0.1516
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral_artery_disease pad heart_failure hf prevalence hf patients pad
H-1567	-0.7167466878890991	▁Peri pher al _ ▁arter y _ ▁disease PAD ▁heart ▁failure HF ▁ HF ▁ PAD
D-1567	-0.7167466878890991	Peripheral_ artery_ diseasePAD heart failureHF HF PAD
P-1567	-0.0545 -0.0584 -0.1525 -0.2704 -0.5466 -0.3839 -1.8753 -1.0818 -0.0904 -0.7349 -0.6887 -0.8010 -1.1588 -0.2007 -3.5641 -0.6355 -0.4673 -0.1366
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical outcomes heart_failure charm candesartan_in_heart_failure_assessment_of_reduction_in_mortality_and_morbidity
H-554	-0.6261242032051086	▁heart _ ▁failure ▁CHA r _ programm e Can des ar tan _ in _ ▁Heart _ ▁Fail ure _ ▁Assessment ▁Mor t ality ▁Morbi d ity
D-554	-0.6261242032051086	heart_ failure CHAr_programmeCandesartan_in_ Heart_ Failure_ Assessment Mortality Morbidity
P-554	-4.0703 -2.1664 -0.1064 -0.2978 -2.0226 -1.2553 -0.4056 -0.2049 -0.2667 -0.0174 -0.0321 -0.0090 -0.6082 -0.2905 -0.0708 -0.6310 -1.2110 -0.0791 -0.6044 -1.7525 -0.0676 -0.5744 -0.0878 -0.0159 -0.0114 -0.0454 -0.8837 -0.2380 -0.1313
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic pediatric_fontan patients catheterization
H-227	-0.5912773013114929	▁as ym pto matic _ ▁pediatr ic ▁Font an PF ▁cat heter ization
D-227	-0.5912773013114929	asymptomatic_ pediatric FontanPF catheterization
P-227	-0.4523 -0.1426 -0.0455 -0.3604 -0.6645 -0.0158 -0.0188 -1.3931 -0.3815 -0.9665 -2.3212 -0.0653 -1.2736 -0.6342 -0.1340
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet patient subvalvular annular_ms
H-374	-0.8816915154457092	▁le a flet ▁serial _ ▁evaluation ▁MS ▁sub val vu lar ▁ann ular ▁MS ▁fixed _ ▁ring _ ▁size
D-374	-0.8816915154457092	leaflet serial_ evaluation MS subvalvular annular MS fixed_ ring_ size
P-374	-2.9734 -0.0231 -0.0047 -0.8491 -1.9495 -1.3350 -0.4539 -0.3756 -0.0714 -0.0040 -0.0608 -3.8109 -0.0130 -1.7411 -1.0167 -0.2420 -0.7687 -1.8093 -0.6460 -0.2645 -0.1029
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the_lancet anoop_shah air heart_failure morbidity mortality
H-1807	-0.5141040086746216	▁Lance t ▁Ano op _ ▁Shah ▁air ▁pollution ▁heart ▁failure ▁morbi d ity ▁mortal ity ▁el der ly _ personen
D-1807	-0.5141040086746216	Lancet Anoop_ Shah air pollution heart failure morbidity mortality elderly_personen
P-1807	-0.1015 -0.0247 -0.6985 -0.0138 -0.4609 -0.2035 -0.2526 -0.5913 -0.6943 -0.5513 -0.2602 -0.0255 -1.3718 -0.0386 -0.6682 -0.5592 -0.0237 -0.3429 -0.4101 -3.7181 -0.1816 -0.1179
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell_therapy chronic_heart_failure chf disease progenitor_cells
H-1336	-0.5151196122169495	▁cell ▁ therapy ▁chronic _ heart _ ▁failure CH f ▁disease ▁ex plant - der i ved _ pro gen itor _ cell s
D-1336	-0.5151196122169495	cell therapy chronic_heart_ failureCHf disease explant-derived_progenitor_cells
P-1336	-1.1772 -0.6228 -0.0259 -0.0698 -0.0977 -1.2082 -0.8793 -0.0660 -2.2684 -1.4405 -0.7260 -0.0566 -0.0037 -0.0510 -0.1080 -0.1000 -0.3415 -0.2033 -0.9360 -0.0169 -0.0959 -0.5492 -1.7739 -0.1188 -0.3468 -0.1098
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese patients clinically stable hfpef exercise training peak_vo2
H-1990	-0.6146688461303711	▁obes e _ ▁older _ ▁patients ▁h FP EF ▁calor ic _ ▁restriction ▁aero bic _ ▁exercise _ training ▁VO 2
D-1990	-0.6146688461303711	obese_ older_ patients hFPEF caloric_ restriction aerobic_ exercise_training VO2
P-1990	-1.7515 -0.0478 -0.6478 -0.7131 -1.0682 -1.1444 -0.8307 -1.1463 -0.8350 -0.0545 -0.0281 -0.7308 -0.5530 -0.0051 -0.0816 -0.1239 -0.6586 -1.3565 -0.1121 -1.6729 -0.0571 -0.3561 -0.1623
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia hf health-related_quality_of_life hrqol hf
H-835	-0.6728127002716064	▁an emia ▁ HF ▁health - related _ quality _ of _ ▁life HR Qo L ▁ HF
D-835	-0.6728127002716064	anemia HF health-related_quality_of_ lifeHRQoL HF
P-835	-0.7797 -0.0237 -0.6793 -0.1860 -3.3615 -0.1108 -0.1245 -0.7928 -1.4772 -0.3060 -0.2782 -0.0897 -1.2160 -1.0132 -0.0068 -1.2328 -0.8253 -0.2902 -0.5462 -0.1163
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous_nonfailing hf combinations remodeling
H-1152	-0.42135852575302124	▁m RI - based ▁dys syn chron ous _ non fail ing ▁ HF ▁can ine _ ▁electro me chan ics
D-1152	-0.42135852575302124	mRI-based dyssynchronous_nonfailing HF canine_ electromechanics
P-1152	-0.9004 -0.9239 -0.1003 -0.0066 -0.3905 -0.0114 -0.0084 -1.0171 -0.0283 -0.8522 -0.1561 -0.0245 -0.1993 -0.1787 -1.0902 -1.3591 -0.0218 -0.9707 -0.0959 -0.0666 -0.3259 -0.8226 -0.1408
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients hr_variability mortality ami diagnosis chf lv_dysfunction
H-1586	-0.9558323621749878	▁HR _ ▁variabil ity ▁mortal ity ▁ AMI ▁CHF _ LV _ ▁dys function
D-1586	-0.9558323621749878	HR_ variability mortality AMI CHF_LV_ dysfunction
P-1586	-2.0618 -2.3759 -0.0243 -0.9388 -1.7836 -1.2263 -0.6146 -0.0329 -0.3090 -3.4096 -1.0121 -0.9095 -0.0848 -0.0947 -0.2986 -0.1168
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes chronic_heart_failure hf exercise training
H-1630	-0.9574102163314819	▁race ▁chronic _ heart ▁failure HF ▁exercise _ training _ ▁response
D-1630	-0.9574102163314819	race chronic_heart failureHF exercise_training_ response
P-1630	-3.9500 -0.6423 -0.1752 -1.2975 -0.9638 -0.4523 -0.7933 -1.2068 -0.2222 -1.3508 -0.8471 -0.3936 -0.1516
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.8700679540634155	▁follow - up
D-947	-0.8700679540634155	follow-up
P-947	-1.3273 -0.0929 -0.0254 -2.7724 -0.1323
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence exercise cell_senescence active osteoporosis
H-1901	-0.5894521474838257	▁exercise ▁cell ▁se nesc ence ▁malign a ncies ▁cancer ▁prostat e ▁colon ▁osteo por osis ▁depression ▁dem entia
D-1901	-0.5894521474838257	exercise cell senescence malignancies cancer prostate colon osteoporosis depression dementia
P-1901	-3.5079 -2.8155 -1.4413 -0.0930 -0.3175 -1.1503 -0.4602 -0.1567 -0.2943 -0.1448 -0.0608 -0.2694 -0.0504 -0.2313 -0.0272 -0.0295 -0.3981 -0.0492 -0.1941 -0.0976
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological capillary coronary_perfusion
H-457	-0.6768561005592346	▁cap illa ry ▁corona ry _ per fusion ▁ad - f lk ▁rat s ▁ad - c _ ▁rat s
D-457	-0.6768561005592346	capillary coronary_perfusion ad-flk rats ad-c_ rats
P-457	-3.7367 -0.0581 -0.9655 -0.5616 -1.4288 -0.2534 -0.6675 -0.0103 -0.5373 -0.0637 -1.4203 -0.1851 -0.8381 -0.0418 -0.8948 -0.0917 -0.9135 -1.1846 -0.5771 -0.0304 -0.2978 -0.1327
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle_walk_test hand baseline
H-1322	-0.5783107280731201	▁shu ttle _ ▁walk _ ▁test ▁body ▁mass ▁hand _ ▁grip _ ▁strength
D-1322	-0.5783107280731201	shuttle_ walk_ test body mass hand_ grip_ strength
P-1322	-0.5310 -0.0018 -0.0755 -1.0914 -0.7457 -1.2614 -0.4169 -0.4300 -0.5973 -0.3231 -0.5813 -0.8657 -0.2700 -1.2430 -0.2406
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician mortality internists cardiologists
H-1730	-0.825484037399292	▁physician _ ▁volume ▁mortal iteit ▁intern ists ▁cardio logist s
D-1730	-0.825484037399292	physician_ volume mortaliteit internists cardiologists
P-1730	-0.8570 -1.0029 -0.0894 -2.1413 -2.2246 -0.0250 -2.0024 -0.1821 -0.3996 -0.3270 -0.5304 -0.1244
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc frame patient consultation patients
H-1027	-1.138187050819397	▁protocol - driv en ▁PO c _ ▁testing ▁ NP ▁patient ▁consultation ▁ED
D-1027	-1.138187050819397	protocol-driven POc_ testing NP patient consultation ED
P-1027	-3.0600 -0.0551 -0.0031 -0.0239 -0.7247 -1.8149 -2.2613 -1.0056 -1.1037 -0.0303 -2.7336 -1.4437 -1.2641 -1.3645 -0.1843
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin_t n-terminal_pro-b-type_natriuretic_peptide biomarker heart_failure atherosclerosis_risk_in_communities
H-284	-0.5950540900230408	▁Tro ponin _ t ▁n - termin al _ ▁pro - b - type _ na tri ure tic _ pe pti de ▁bio mark er _ ▁approach ▁heart ▁failure _ ▁risk ▁at hero sc ler osis
D-284	-0.5950540900230408	Troponin_t n-terminal_ pro-b-type_natriuretic_peptide biomarker_ approach heart failure_ risk atherosclerosis
P-284	-1.1013 -0.0085 -0.8201 -0.3602 -1.0509 -0.0160 -0.0618 -0.0061 -0.6886 -0.7343 -0.0150 -1.0603 -0.0154 -0.0045 -0.2412 -1.1344 -0.0246 -0.2088 -1.9072 -0.1300 -0.8790 -0.1633 -0.6812 -0.2296 -0.0389 -0.0484 -1.4496 -0.1972 -1.2163 -0.5359 -1.4240 -1.1325 -1.1062 -0.2267 -0.0370 -2.2718 -0.0393 -1.7945 -0.1467
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients acute_rv_failure chronic_pulmonary_arterial_hypertension pah acute pulmonary_embolism
H-1095	-0.5487372875213623	▁a cute _ RV _ ▁failure ▁chronic _ ▁pulmonar y _ ▁arterial _ ▁hyper tension PA h ▁a cute _ ▁pulmonar y _ e mbol ism
D-1095	-0.5487372875213623	acute_RV_ failure chronic_ pulmonary_ arterial_ hypertensionPAh acute_ pulmonary_embolism
P-1095	-1.6069 -0.0350 -0.0521 -2.0218 -0.9497 -0.0374 -0.2293 -1.0884 -0.0801 -0.0437 -0.4980 -0.0582 -0.1133 -1.0723 -0.0125 -2.3810 -0.5996 -1.0445 -0.0439 -0.0985 -0.2794 -0.1104 -0.1680 -1.4496 -0.0410 -0.7268 -0.3842 -0.1390
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic methylatropine vagal_tone bradycardic propranolol sympathetic_tone
H-1139	-0.5855146646499634	▁ta chy car dic _ ▁response ▁met hy la tropi ne ▁va gal _ ▁tone ▁bra dy car dic _ ▁response ▁propra no lol ▁sympa the tic _ ▁tone
D-1139	-0.5855146646499634	tachycardic_ response methylatropine vagal_ tone bradycardic_ response propranolol sympathetic_ tone
P-1139	-1.9046 -1.1239 -0.0706 -0.3378 -2.3370 -0.7919 -0.2469 -0.2855 -0.3485 -0.0108 -1.6084 -0.1421 -0.0916 -0.4604 -0.5292 -0.3005 -0.8459 -0.0789 -0.4577 -1.7356 -1.2102 -0.0816 -0.0105 -0.0908 -0.1643 -0.5920 -1.2172 -0.3528 -0.4622 -0.1722 -0.0893
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin_inhibitors natriuretic_peptide atrial_natriuretic_peptide b-type_natriuretic_peptide
H-1462	-0.6580043435096741	▁ne pri ly sin ▁inhibi tors ▁na tri ure tic _ pe pti de ▁at rial ▁na tri ure tic _ pe pti de ▁na tri ure tic _ pe pti de
D-1462	-0.6580043435096741	neprilysin inhibitors natriuretic_peptide atrial natriuretic_peptide natriuretic_peptide
P-1462	-0.7600 -0.4675 -0.7048 -0.8945 -0.7665 -0.1279 -0.0333 -0.0523 -0.2668 -2.6532 -0.2072 -0.7814 -0.1837 -0.8032 -2.7288 -0.1129 -0.9317 -0.1107 -0.3857 -2.2285 -0.2858 -0.7189 -0.1206 -0.5702 -0.5258 -0.0659 -0.2981 -2.3219 -0.3722 -0.8119 -0.1272 -0.5689 -0.2443 -0.1397
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2007	-0.9172586798667908	▁Tools _ economic _ analys is _ of _ ▁Patient ▁Management _ ▁Interven tions _ in _ ▁Heart _ ▁Fail ure
D-2007	-0.9172586798667908	Tools_economic_analysis_of_ Patient Management_ Interventions_in_ Heart_ Failure
P-2007	-1.5148 -0.9814 -1.8510 -0.4072 -0.3305 -0.0674 -1.7097 -1.4444 -0.4780 -0.4408 -1.2119 -0.9594 -0.1340 -0.4686 -1.2537 -0.3540 -0.1779 -0.6327 -0.5721 -0.1940 -0.8329 -4.8991 -0.1816
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional_flow_reserve positron_emission_tomography ischemia bottleneck_stenting left_ventricle lad
H-509	-0.3867399990558624	▁fra ction al _ ▁flow ▁reserve ▁posi tron _ e mission _ tom ography _ ▁imagin g ▁ ische mia ▁bottle ne ck _ ▁sten ting ▁left _ ▁vent ric le ▁proxima l _ LAD
D-509	-0.3867399990558624	fractional_ flow reserve positron_emission_tomography_ imaging ischemia bottleneck_ stenting left_ ventricle proximal_LAD
P-509	-0.9962 -0.0018 -0.0651 -0.1040 -0.7650 -0.2047 -0.4194 -0.2074 -0.1806 -0.6865 -0.7588 -0.0776 -0.2307 -0.3637 -1.1264 -0.1141 -0.2104 -0.8357 -0.0134 -0.2667 -0.0086 -0.0972 -0.0145 -1.1525 -0.5039 -0.0688 -0.0257 -0.2484 -0.9307 -1.5452 -0.5103 -0.2129 -0.0068 -0.4005 -0.3707 -0.4784 -0.1058
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac_resynchronization_therapy crt mild_heart_failure hf patients qrs_prolongation ejection_fraction ef
H-751	-0.4590132236480713	▁cardiac _ re syn chron ization _ therapy ▁c RT ▁mild _ heart _ ▁failure HF ▁QR s ▁prolong ation ▁e je ction _ fraction EF
D-751	-0.4590132236480713	cardiac_resynchronization_therapy cRT mild_heart_ failureHF QRs prolongation ejection_fractionEF
P-751	-1.0210 -0.8802 -0.3400 -0.0512 -0.0056 -1.0512 -1.1100 -0.3317 -0.4205 -1.8483 -0.0815 -0.0310 -0.7833 -1.1965 -0.0534 -0.7318 -0.5212 -0.2931 -0.3455 -0.1166 -0.0166 -0.0425 -0.0668 -0.2148 -0.0133 -0.8439 -0.2959 -0.1450
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial_oxidative_phosphorylation_capacity creatine kinase activity oxidative_stress dna_fragmentation
H-962	-0.4159848392009735	▁mito cho ndri al _ ▁oxid ative _ phos phor y lation ▁capacity ▁creati ne ▁kina se _ activ iteit ▁oxid ative _ stress _ ▁marker s ▁DNA ▁fragment ation ▁ultra struct ural
D-962	-0.4159848392009735	mitochondrial_ oxidative_phosphorylation capacity creatine kinase_activiteit oxidative_stress_ markers DNA fragmentation ultrastructural
P-962	-0.0068 -0.2020 -0.1776 -0.0647 -0.5432 -1.4187 -0.0746 -0.0727 -0.1056 -0.4541 -1.7483 -0.0690 -1.6948 -0.0022 -0.2420 -0.0708 -0.0645 -1.0153 -0.2734 -0.3864 -0.0096 -0.0685 -0.0599 -0.9021 -1.1914 -0.1231 -0.0482 -0.2640 -1.4619 -0.1773 -0.3846 -0.0706 -0.0350 -0.9816 -0.0951
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ventricular_assist_devices cardiac nurses gastrointestinal_bleeding
H-1660	-0.5363810658454895	▁vent ri cular _ assist _ ▁devices ▁cardiac _ ▁nurse s ▁gastro inte stin al _ ▁ble ed ing
D-1660	-0.5363810658454895	ventricular_assist_ devices cardiac_ nurses gastrointestinal_ bleeding
P-1660	-0.0139 -1.6229 -0.4102 -0.1594 -0.2954 -1.2891 -0.8654 -0.5045 -1.5274 -0.0755 -0.0211 -1.0639 -0.2620 -0.5141 -0.1665 -0.2371 -0.6049 -0.8249 -0.2256 -0.4176 -0.1626
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox_regression covariates spironolactone death hospitalization hyperkalemia acute_kidney_injury
H-442	-0.4116535782814026	▁co x _ re gression ▁spi rono lac tone ▁death ▁hyper kal emia ▁ki dne y ▁injury
D-442	-0.4116535782814026	cox_regression spironolactone death hyperkalemia kidney injury
P-442	-0.0662 -0.0467 -0.9353 -0.4022 -0.0165 -0.0728 -0.0091 -0.0549 -0.0631 -2.8923 -1.6650 -0.2105 -0.0308 -0.2066 -0.2808 -0.0866 -0.3795 -0.2722 -0.1303
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended_criteria_cardiac_transplant ecct transplant donors transplant comorbidity
H-708	-1.0350167751312256	▁cardiac _ ▁transplant ▁ec CT ▁transplant _ ▁pool
D-708	-1.0350167751312256	cardiac_ transplant ecCT transplant_ pool
P-708	-0.4005 -0.5881 -1.1714 -0.6305 -1.7873 -0.5756 -1.9880 -0.4521 -2.6440 -0.1127
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum systolic lv_posterior_wall lv_internal_diameter metoprolol
H-1549	-0.713890016078949	▁sept um sy sto lic _ ▁thi ck ness ▁LV ▁posterior _ ▁wall _ ▁thi ck ness ▁LV ▁internal _ ▁diameter ▁met o pro lol
D-1549	-0.713890016078949	septumsystolic_ thickness LV posterior_ wall_ thickness LV internal_ diameter metoprolol
P-1549	-0.3265 -0.0280 -0.2340 -0.1443 -0.1247 -1.4073 -3.0576 -0.0212 -1.5974 -1.8509 -0.2915 -0.1001 -3.8944 -1.0981 -0.9180 -0.0192 -0.7917 -0.2619 -1.6775 -0.4160 -0.0611 -0.0902 -0.2448 -0.0232 -0.2109 -0.2445 -0.1401
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat n-terminal_pro-brain_natriuretic_peptide hospitalized hf
H-1877	-0.510345458984375	▁BAT ▁n - termin al _ pro - bra in _ ▁na tri ure tic _ pe pti de ▁ HF
D-1877	-0.510345458984375	BAT n-terminal_pro-brain_ natriuretic_peptide HF
P-1877	-0.1260 -2.9380 -0.0350 -0.0931 -0.0228 -0.1058 -1.2720 -0.1401 -0.0871 -0.1809 -0.6427 -0.7232 -0.0222 -0.2802 -1.6663 -0.3646 -0.3931 -0.1380 -0.4116 -0.9710 -0.7889 -0.2296 -0.1057
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american_college_of_physicians acp evidence clinical anemia patients heart_disease
H-30	-0.5719994902610779	▁American _ ▁College _ of _ ▁Physic ians ▁a CP ▁an emia ▁ir on ▁de fici en cy ▁heart ▁disease
D-30	-0.5719994902610779	American_ College_of_ Physicians aCP anemia iron deficiency heart disease
P-30	-1.5954 -0.1157 -2.2118 -0.0345 -0.4717 -0.0902 -0.1743 -0.2844 -0.6037 -0.3209 -1.9970 -0.0504 -0.0355 -0.1891 -1.2676 -0.0402 -0.2438 -0.0760 -1.5488 -0.8892 -0.2247 -0.1192
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes mortality hospitalization mortality cardiovascular_mortality hf hospitalization cox_models exercise training
H-1633	-0.8226341009140015	mortal ity ▁hospital ization ▁mortal ity ▁cardiovascular _ ▁mortal ity HF _ hospital ization ▁co x _ ▁models ▁exercise _ training
D-1633	-0.8226341009140015	mortality hospitalization mortality cardiovascular_ mortalityHF_hospitalization cox_ models exercise_training
P-1633	-2.6504 -0.8407 -2.8952 -0.5256 -0.0536 -0.8259 -0.0179 -0.4014 -0.2308 -1.0174 -1.0304 -1.1894 -0.3297 -0.3289 -1.0008 -0.0674 -2.8937 -0.8759 -0.0872 -1.0087 -0.1586 -0.3080 -0.1830
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective hf patients hf_with_reduced_ef ef hfpef ef
H-782	-1.2427338361740112	▁ HF _ ▁registr y ▁dicho tom ized ▁patients ▁ HF ▁EF ▁ HF p EF EF EF EF
D-782	-1.2427338361740112	HF_ registry dichotomized patients HF EF HFpEFEFEFEF
P-782	-0.4282 -0.9698 -4.0086 -0.8362 -0.1065 -3.0539 -0.0016 -0.1522 -1.1609 -0.2176 -0.3873 -3.0370 -2.3236 -0.6294 -2.1775 -0.4429 -0.9630 -0.9631 -2.0943 -2.0078 -0.1359
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional_electrical_stimulation peripheral_muscles endothelial_function clinical heart_failure patients preserved_left_ventricular_ejection_fraction
H-1326	-0.5809627175331116	▁Fun ction al _ elektr al _ stimul ation ▁per i pher al _ ▁muscle s ▁en dot heli al _ function ▁heart ▁failure ▁left _ ▁vent ri cular _ e je ction _ fraction
D-1326	-0.5809627175331116	Functional_elektral_stimulation peripheral_ muscles endothelial_function heart failure left_ ventricular_ejection_fraction
P-1326	-0.4015 -0.0047 -0.0815 -0.5156 -1.1782 -0.3175 -0.8580 -0.0742 -0.0904 -0.1410 -0.0887 -0.1447 -0.4040 -0.1806 -2.6616 -0.0330 -0.2864 -1.3680 -0.0778 -0.0091 -1.6631 -0.9258 -0.8203 -0.2332 -2.0760 -0.4816 -1.3543 -1.2496 -0.5911 -0.7167 -0.7183 -0.2508 -0.2979 -0.6036 -0.0236 -0.4106 -0.1627
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.9099990725517273	▁SD QT - to - SD r _ ▁ratio ▁ HF VT ▁ HF VT ▁h Nor m
D-1441	-0.9099990725517273	SDQT-to-SDr_ ratio HFVT HFVT hNorm
P-1441	-0.7490 -0.4576 -0.0470 -0.0220 -0.0220 -0.6060 -3.1407 -1.6701 -0.0146 -0.3621 -0.3953 -0.7631 -1.6964 -1.2092 -2.0740 -0.7218 -3.2299 -0.0199 -0.8859 -0.1134
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular wall_stiffness
H-1148	-0.8924496173858643	▁vent ri cular _ structure ▁ge ometr y ▁fiber she et _ orientation ▁handling ▁slow ed _ con duction ▁wall ▁sti ff ness
D-1148	-0.8924496173858643	ventricular_structure geometry fibersheet_orientation handling slowed_conduction wall stiffness
P-1148	-0.2555 -1.3123 -0.5116 -1.1564 -2.1064 -1.9216 -0.0233 -0.1863 -0.0292 -1.6309 -0.0323 -0.9783 -0.0542 -2.1559 -0.3359 -0.7398 -0.2420 -0.5507 -0.0979 -3.6100 -0.5252 -0.2202 -2.9276 -0.5390 -0.1685
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad q66p cardiomyopathy
H-1677	-0.6760919690132141	▁Rad ▁Q 66 p ▁cardio my o pathy ▁mechanism
D-1677	-0.6760919690132141	Rad Q66p cardiomyopathy mechanism
P-1677	-0.4936 -2.4322 -0.2571 -0.2521 -0.1855 -0.7054 -0.3148 -0.0157 -0.1003 -2.5753 -0.1050
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin chemotherapy elevated cardiotoxicity
H-937	-0.7626274824142456	▁se rum ▁resist in ▁women ▁an thra cycli ne - conta ining _ che mo therapy ▁cardio toxic iteit
D-937	-0.7626274824142456	serum resistin women anthracycline-containing_chemotherapy cardiotoxiciteit
P-937	-0.1688 -0.3564 -1.1647 -0.5537 -3.7743 -0.1899 -0.0668 -0.3746 -1.9058 -0.2117 -0.0014 -0.7162 -0.1110 -2.0867 -0.6743 -0.0494 -0.1276 -0.4617 -2.4832 -0.3952 -0.1416
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients sst2 titrated cardiovascular_event
H-405	-1.146325945854187	▁s st 2 ▁ bb ▁cardiovascular _ event _ ▁rate
D-405	-1.146325945854187	sst2 bb cardiovascular_event_ rate
P-405	-0.1711 -1.1275 -0.1770 -4.0368 -2.3998 -0.3363 -0.9247 -1.8397 -1.4624 -0.1947 -0.9678 -0.1182
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative patients preoperative hypoalbuminemia albumin
H-533	-0.7036134600639343	▁post operativ e _ ▁survival ▁hypo album in emia ▁album in _ ▁concentration
D-533	-0.7036134600639343	postoperative_ survival hypoalbuminemia albumin_ concentration
P-533	-1.0053 -0.0872 -0.0206 -1.0339 -1.0703 -1.2111 -0.3321 -0.3970 -0.0960 -1.9454 -0.3691 -1.8717 -0.1246 -0.8934 -0.0965
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration renin-angiotensin_system_blocker beta-blocker therapy patients hospitalized heart_failure preserved_left_ventricular_ejection_fractions
H-174	-0.6239166855812073	▁re nin - angi oten sin _ system _ ▁block er ▁beta - block er _ therapy ▁heart ▁failure ▁left _ ▁vent ri cular _ e je ction _ fraction s
D-174	-0.6239166855812073	renin-angiotensin_system_ blocker beta-blocker_therapy heart failure left_ ventricular_ejection_fractions
P-174	-0.0363 -0.9460 -0.0681 -0.1244 -0.1462 -0.7953 -0.5836 -0.9948 -0.7108 -1.2223 -0.0573 -0.0852 -0.0317 -0.1214 -0.0728 -2.2485 -0.0475 -0.7276 -0.8874 -1.8321 -0.3555 -2.5809 -1.3833 -0.8619 -0.5107 -0.6374 -0.2274 -0.2056 -1.3029 -0.0195 -0.1077 -0.4594 -0.1980
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use_of_exercise_and_medical_therapies_to_improve_cardiac_function_among_patients_with_exertional_shortness_of_breath_due_to_lung_congestion
H-1180	-0.5659619569778442	▁Exerci se ▁Medical ▁Therapie s ▁Card iac _ ▁Fun ction ▁Short ness _ of _ ▁Breath _ ▁Du e _ ▁to _ ▁Lung _ con gestion ACT RN
D-1180	-0.5659619569778442	Exercise Medical Therapies Cardiac_ Function Shortness_of_ Breath_ Due_ to_ Lung_congestionACTRN
P-1180	-0.9149 -0.0256 -0.9053 -1.1945 -0.0708 -1.4890 -0.1130 -0.0695 -0.5351 -0.0029 -0.5190 -2.7070 -0.4929 -1.3458 -0.1468 -0.1158 -1.2933 -0.3242 -0.0253 -0.5446 -0.9847 -0.2805 -0.1640 -0.2399 -0.3202 -0.0468 -0.4174 -0.5229 -1.0719 -0.0951
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective nicorandil hemodynamic mitochondrial_dysfunction administration doxorubicin
H-956	-0.2831234037876129	▁cardio protec tive _ effect ▁nic oran dil ▁hem o dynamic _ ▁altera tions ▁mito cho ndri al _ ▁dys function ▁do xor ubi cin ▁rat s
D-956	-0.2831234037876129	cardioprotective_effect nicorandil hemodynamic_ alterations mitochondrial_ dysfunction doxorubicin rats
P-956	-0.2348 -0.7119 -0.6975 -0.6869 -0.1206 -0.1409 -0.0511 -0.2573 -0.5420 -0.1981 -0.0012 -1.0251 -0.1047 -0.2901 -0.0041 -0.1754 -0.0666 -0.0305 -0.3262 -0.0258 -0.0165 -0.7559 -0.0229 -0.0240 -0.7254 -0.5776 -0.0698 -0.2386 -0.0889
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex_sensitivity heart_rate_variability hrv renal_dnx
H-1376	-0.4965575337409973	▁Baro re flex _ sensitiv ity ▁time ▁domain _ ▁heart _ ▁rate ▁variabil ity HR v ▁CHF - in v ▁sham - in v ▁sham - in v ▁renal _ ▁DN x
D-1376	-0.4965575337409973	Baroreflex_sensitivity time domain_ heart_ rate variabilityHRv CHF-inv sham-inv sham-inv renal_ DNx
P-1376	-0.0518 -0.0129 -0.0546 -0.8524 -0.0027 -0.4453 -0.1613 -0.3557 -0.2523 -0.8089 -1.0853 -0.4579 -0.8810 -1.0967 -2.1440 -0.9213 -0.2998 -0.0583 -0.2179 -0.2453 -0.1205 -0.1125 -0.5169 -0.1838 -0.2692 -2.2623 -0.6380 -0.1796 -0.1990 -0.9864 -0.6453 -0.0572 -0.1979 -0.1088
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic_cell_transplantation hct congestive_heart_failure chf anthracyclines
H-1449	-1.0359652042388916	▁ha e mato po ie tic _ ▁cell ▁transplant ation ▁h CT ▁con ges tive _ ▁heart ▁failure CH f ▁h CT ▁an thra cycli nes
D-1449	-1.0359652042388916	haematopoietic_ cell transplantation hCT congestive_ heart failureCHf hCT anthracyclines
P-1449	-0.0717 -0.8534 -0.0561 -0.3588 -0.4742 -1.5853 -0.1650 -3.0119 -1.1387 -0.1146 -0.7800 -1.4724 -0.9901 -0.5547 -2.5537 -0.0868 -2.7975 -0.6691 -3.1885 -0.8066 -1.2049 -1.5856 -1.2154 -0.0365 -0.1265 -2.6787 -0.2708 -0.1597
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic proteins histone_acetyltransferases epigenetic histone_deacetylases cardiac disease
H-1041	-0.44811519980430603	▁epi gene tic _ writer _ ▁protein s hi stone _ a ce tyl transfer as es ▁epi gene tic _ eras ers hi stone _ ▁de ace ty las es ▁cardiac
D-1041	-0.44811519980430603	epigenetic_writer_ proteinshistone_acetyltransferases epigenetic_erasershistone_ deacetylases cardiac
P-1041	-0.5985 -0.0858 -0.5312 -0.5257 -0.4797 -2.4078 -0.2929 -0.0317 -0.1612 -0.0262 -0.8461 -0.5215 -0.2858 -0.3645 -0.0167 -0.0438 -0.0705 -0.1495 -0.0604 -0.9310 -2.1607 -0.0546 -0.0216 -0.0802 -0.1386 -0.9031 -0.5219 -0.1462 -0.1397 -0.0287 -0.0185 -0.0159 -2.4212 -0.1543
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated nt-probnp admission all-cause_mortality patients acute_hf admission
H-270	-0.49762198328971863	▁NT - pro b NP ▁mortal ity ▁a cute _ HF
D-270	-0.49762198328971863	NT-probNP mortality acute_HF
P-270	-0.1520 -0.0376 -0.0097 -0.4281 -0.1490 -1.4952 -1.6019 -0.8827 -0.0868 -0.0721 -1.1682 -0.2299 -0.1559
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in_vivo mir-25 antagomir cardiac_dysfunction murine myocardium heart_failure
H-643	-0.4947434365749359	▁in ▁vivo _ ▁inhibi tion ▁mi r -25 ▁anta go mir ▁spontane ous _ ▁cardiac _ ▁dys function ▁mur ine _ my o car dium ▁heart ▁failure ▁hand 2- dependent
D-643	-0.4947434365749359	in vivo_ inhibition mir-25 antagomir spontaneous_ cardiac_ dysfunction murine_myocardium heart failure hand2-dependent
P-643	-0.0900 -0.0328 -1.5376 -0.0496 -0.1536 -0.1984 -1.2520 -0.0301 -0.2096 -0.0156 -0.3357 -1.6065 -0.5684 -0.1306 -0.0341 -0.9219 -0.0285 -0.0181 -0.3166 -0.8966 -0.1185 -2.0240 -0.1078 -0.0194 -0.1633 -1.5369 -0.5385 -1.0434 -0.0581 -0.0542 -1.5266 -0.2145
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left_bundle_branch_block remodeling dyssynchronous_heart_failure hf heart
H-1147	-0.7304867506027222	▁bund le _ ▁bran ch _ ▁block ▁electric al _ activa tion ▁dys syn chron ous _ heart _ ▁failure HF ▁electro me chan ical _ ▁behavior ▁heart
D-1147	-0.7304867506027222	bundle_ branch_ block electrical_activation dyssynchronous_heart_ failureHF electromechanical_ behavior heart
P-1147	-3.9274 -0.4426 -0.5741 -0.2298 -0.0342 -1.1674 -0.5437 -1.2126 -0.1548 -0.4754 -0.2209 -0.1539 -0.0199 -0.0091 -0.0102 -0.9605 -0.0665 -3.1172 -0.9910 -0.0461 -0.5732 -0.0834 -0.0365 -0.0188 -0.2921 -0.5766 -2.3209 -3.1287 -0.3907 -0.1364
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse hospitalization physician discharge patients hospitalized heart_failure
H-206	-0.9979807138442993	▁nurse ▁cognitive _ ▁im pair ment ▁physician ▁dis charge ▁el der ly _ ▁patients ▁heart _ ▁failure
D-206	-0.9979807138442993	nurse cognitive_ impairment physician discharge elderly_ patients heart_ failure
P-206	-1.5936 -0.3766 -0.3487 -2.5632 -0.0598 -0.2110 -1.3407 -3.4958 -0.0588 -2.6481 -0.0544 -0.3472 -1.3394 -0.9026 -1.3446 -1.6706 -0.1987 -0.2669 -0.1410
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension diabetes_mellitus grade systolic diastolic_murmurs apex
H-347	-0.20764896273612976	▁hyper tension ▁diabetes ▁mell itus ▁sy sto lic ▁dia sto lic _ mur mur s
D-347	-0.20764896273612976	hypertension diabetes mellitus systolic diastolic_murmurs
P-347	-0.8008 -0.0334 -0.3326 -0.0055 -0.0186 -0.0264 -0.0269 -0.0254 -0.0356 -0.0170 -0.0683 -0.9121 -0.5251 -0.1424 -0.0826 -0.3688 -0.1088
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients heart_failure heart cardiologists cardiovascular surgeons medical patient
H-1822	-0.7671815752983093	▁advanced _ heart _ ▁failure heart _ team ▁cardio logist s ▁cardiovascular _ ▁surge ons ▁medical _ ▁staff
D-1822	-0.7671815752983093	advanced_heart_ failureheart_team cardiologists cardiovascular_ surgeons medical_ staff
P-1822	-4.2158 -0.1104 -1.3072 -0.4713 -0.3416 -1.7228 -0.3253 -0.1470 -0.9381 -0.2081 -0.0955 -0.0424 -0.5014 -0.6607 -0.8747 -0.9797 -1.2576 -0.4533 -0.5551 -0.1358
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine patients dilated_cardiomyopathy dcm heart_failure
H-1258	-0.5709799528121948	▁Chinese _ ▁herbal _ ▁medicine CH m ▁dil ated _ ▁cardio my o pathy ▁d m ▁heart ▁failure
D-1258	-0.5709799528121948	Chinese_ herbal_ medicineCHm dilated_ cardiomyopathy dm heart failure
P-1258	-1.0298 -0.2778 -0.1473 -1.4254 -0.3674 -2.6747 -0.2217 -0.8741 -0.2381 -0.0559 -0.2414 -1.5415 -0.4583 -0.0085 -0.5116 -0.2841 -0.3283 -0.3816 -0.1879 -0.1644
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse pasp downward hfref hfpef prognostic resolution
H-500	-0.7111400961875916	▁T AP se ▁pas p ▁non sur viv ors ▁h Fr ef ▁ HF p EF
D-500	-0.7111400961875916	TAPse pasp nonsurvivors hFref HFpEF
P-500	-3.3183 -0.2477 -0.4037 -1.4432 -0.3406 -0.4240 -0.1242 -0.0091 -0.1779 -0.6096 -1.1894 -1.2548 -0.3723 -0.3676 -0.0673 -0.5691 -1.7992 -0.0824
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute_rv_failure pulmonary_embolism mortality diagnostic
H-1097	-0.5989189743995667	▁a cute _ RV _ ▁failure ▁pulmonar y _ e mbol ism ▁mortal ity
D-1097	-0.5989189743995667	acute_RV_ failure pulmonary_embolism mortality
P-1097	-1.0166 -0.0381 -0.0369 -1.0373 -1.2245 -0.0604 -0.0347 -0.0715 -0.2040 -1.2113 -0.0798 -0.7666 -1.2101 -1.7228 -0.7480 -0.1201
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates alendronate etidronate heart_failure compliance
H-1542	-0.2553866505622864	▁bis phos phon ates ▁ale ndr onate ▁et id rona te ▁heart ▁failure ▁re fill ▁compliance
D-1542	-0.2553866505622864	bisphosphonates alendronate etidronate heart failure refill compliance
P-1542	-0.1288 -0.0131 -0.1290 -0.1125 -0.1027 -0.0069 -0.0198 -0.0065 -0.0541 -0.0051 -0.0138 -1.9463 -0.4676 -0.0355 -0.0225 -0.5524 -0.8697 -0.1106
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action randomized patients hf ejection_fraction exercise training
H-1632	-0.845360517501831	▁ HF - ac tion ▁ HF ▁ HF ▁e je ction _ fraction
D-1632	-0.845360517501831	HF-action HF HF ejection_fraction
P-1632	-0.5356 -0.8148 -0.0709 -0.4756 -1.7271 -0.6240 -0.4369 -2.8130 -0.2871 -1.8314 -0.2442 -0.0580 -0.5893 -0.0855 -2.7705 -0.1618
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol nonselective_β-blocker selective_β-blocker metoprolol thromboembolic_events heart_failure
H-1111	-0.39276888966560364	▁car vedi lol ▁non sel ective ▁β - block er ▁β - block er ▁met o pro lol ▁ thro mbo e mbol ic _ ▁events ▁heart ▁failure
D-1111	-0.39276888966560364	carvedilol nonselective β-blocker β-blocker metoprolol thromboembolic_ events heart failure
P-1111	-0.1737 -0.0039 -0.0578 -0.5633 -0.0539 -0.0160 -0.9172 -0.0541 -0.4918 -0.1374 -1.2601 -0.0435 -0.3793 -0.1798 -1.4672 -0.3041 -0.0489 -0.1257 -0.3665 -0.8590 -0.5201 -0.2006 -0.0424 -0.1324 -0.5956 -0.7922 -0.6461 -0.9613 -0.2604 -0.1287
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ami pna mortality
H-1700	-0.9081367254257202	▁ HF ▁ AMI ▁p na ▁mortal ity
D-1700	-0.9081367254257202	HF AMI pna mortality
P-1700	-1.6673 -0.6039 -1.6253 -0.2049 -0.7415 -0.9668 -1.2672 -1.5846 -0.2805 -0.1394
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline cardiac_transplant ecct
H-716	-0.7133252620697021	▁cardiac _ ▁transplant _ ▁survival ▁ec CT
D-716	-0.7133252620697021	cardiac_ transplant_ survival ecCT
P-716	-0.6640 -0.7072 -0.6931 -1.7358 -0.3740 -0.6369 -1.2575 -0.1951 -0.1563
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients heart_failure hf evidence outcomes hf
H-685	-1.5229465961456299	▁heart _ ▁failure HF ▁ HF
D-685	-1.5229465961456299	heart_ failureHF HF
P-685	-6.6978 -1.2883 -0.2275 -0.7429 -2.1726 -0.1854 -0.7128 -0.1562
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling arrhythmia ami hr_variability arrhythmia
H-1590	-0.742913007736206	▁ar rhythm ia ▁substrat e AMI ▁HR ▁ar rhythm ia _ ▁events
D-1590	-0.742913007736206	arrhythmia substrateAMI HR arrhythmia_ events
P-1590	-0.4159 -0.1116 -0.8020 -1.1679 -0.0327 -0.9959 -0.4082 -1.9479 -0.5038 -1.1659 -1.6426 -0.8475 -0.2558 -0.1032
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients hypertension compensated_hfpef dash sodium
H-919	-0.605349063873291	▁hyper tension ▁compensa ted _ h FP EF ▁DAS h ▁s rd ▁so dium ▁kcal
D-919	-0.605349063873291	hypertension compensated_hFPEF DASh srd sodium kcal
P-919	-3.2464 -0.1062 -0.0101 -0.0490 -0.5602 -0.2208 -1.1384 -1.2082 -0.2278 -0.0860 -1.3167 -0.8961 -0.1433 -0.0973 -0.3802 -0.5165 -0.0878
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd dyssynchronous_hf remodeling insignificantly
H-1154	-0.4815863370895386	▁de rang ed _ ca (2 +) ▁handling ▁EM d ▁dys syn chron ous _ HF ▁remodel ing
D-1154	-0.4815863370895386	deranged_ca(2+) handling EMd dyssynchronous_HF remodeling
P-1154	-0.7247 -0.0041 -0.0334 -0.7499 -0.1852 -0.6173 -0.0015 -1.5119 -1.3632 -0.5401 -0.0216 -0.0156 -0.0092 -1.4401 -0.0778 -1.3518 -0.6287 -0.0118 -0.2349 -0.1090
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ejection_fraction cardiac_index inotropes medical transplant
H-1997	-0.46081629395484924	▁e je ction _ fraction ▁cardiac ▁index ▁in o trop es ▁in ot rope - dependent ▁medical _ management ▁transplant
D-1997	-0.46081629395484924	ejection_fraction cardiac index inotropes inotrope-dependent medical_management transplant
P-1997	-0.3420 -0.0557 -0.0573 -0.4745 -0.0262 -0.0636 -0.9875 -0.0115 -0.8644 -0.0585 -0.3770 -0.0102 -0.4390 -0.0550 -0.1754 -0.0287 -3.3271 -1.7901 -0.2936 -0.3044 -0.2453 -0.1509
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced_cardiotoxicity resistin retn
H-933	-0.5256577730178833	▁do xor ubi cin - indu ced _ ▁cardio toxic iteit ▁Hum - re t n _ mi ce ▁litt er mate ▁resist in ▁re t n
D-933	-0.5256577730178833	doxorubicin-induced_ cardiotoxiciteit Hum-retn_mice littermate resistin retn
P-933	-0.0054 -0.0069 -0.0127 -0.7174 -0.0613 -0.0041 -0.1582 -0.2492 -0.3329 -0.4416 -1.9008 -0.2530 -0.0454 -1.0498 -1.1968 -0.0953 -1.2699 -0.2658 -0.2944 -0.0062 -0.0163 -0.0226 -4.6551 -0.1830 -0.4390 -1.0828 -0.0272 -0.3620 -0.0889
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic_dysfunction pathophysiology hfpef cardiovascular_function
H-1302	-0.3241347372531891	▁dia sto lic _ ▁dys function ▁pat ho phy si ology ▁ HF p EF ▁non - dia sto lic _ ▁ab normal ities ▁cardiovascular _ function
D-1302	-0.3241347372531891	diastolic_ dysfunction pathophysiology HFpEF non-diastolic_ abnormalities cardiovascular_function
P-1302	-0.0674 -0.0682 -0.3078 -0.2453 -0.5319 -0.0854 -0.4712 -0.0705 -0.1623 -2.3631 -0.2308 -0.3293 -0.1614 -0.0574 -0.2662 -0.2137 -0.0376 -0.1232 -0.0694 -0.0766 -0.3309 -0.2096 -0.0724 -0.5272 -0.1780 -0.4001 -1.3101 -0.3066 -0.1265
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp phosphomimic ser77 ser83 riα proteins riα
H-1432	-0.5395522713661194	▁8- flu o - c AMP ▁ binding ▁ phos pho mi mic ▁ser 77 ▁ser 83 ▁mu tant ▁RI α ▁protein s ▁double _ mu tant ▁w t _ ri α
D-1432	-0.5395522713661194	8-fluo-cAMP binding phosphomimic ser77 ser83 mutant RIα proteins double_mutant wt_riα
P-1432	-0.0710 -0.0970 -0.1680 -0.0320 -0.0579 -0.0592 -0.1454 -0.0120 -1.1249 -0.1842 -0.0148 -0.1825 -0.3100 -0.8288 -0.3124 -0.3800 -2.2707 -2.6323 -0.1347 -0.9651 -0.2787 -2.0120 -0.0315 -0.2487 -0.0527 -0.9230 -0.0792 -0.3805 -0.2829 -1.1712 -1.5718 -1.0866 -0.1568 -0.0862
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density_lipoprotein hdl endothelial_cell nitric_oxide
H-246	-0.6432461738586426	▁high - dens ity _ ▁lipo prote in HD l ▁en dot heli al - protec tive ▁en dot heli al _ ▁cell ▁ec ▁ni tric _ ▁oxid e ▁no
D-246	-0.6432461738586426	high-density_ lipoproteinHDl endothelial-protective endothelial_ cell ec nitric_ oxide no
P-246	-2.1803 -0.1043 -0.7089 -1.1666 -0.1550 -0.5457 -0.2115 -1.0722 -0.9963 -1.6592 -0.4702 -0.9515 -0.2517 -0.0280 -0.7188 -0.4430 -0.9490 -0.8221 -0.9439 -0.2235 -0.0191 -0.2799 -1.3422 -0.8044 -0.0124 -0.1147 -0.4526 -0.7539 -0.0474 -1.3386 -0.6634 -0.1537
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis patients hf hospitalization all-cause_hospitalization mortality hf hospitalization death
H-910	-0.7982991933822632	▁dia lys is ▁ HF
D-910	-0.7982991933822632	dialysis HF
P-910	-0.6247 -0.0519 -0.0549 -1.8370 -0.1163 -2.7734 -0.1299
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome admission discharge hospitalized heart_failure hf nursing_outcomes_classification noc
H-1398	-0.77603679895401	▁ad mission _ to _ ▁dis charge ▁older _ ▁adults ▁heart _ ▁failure HF ▁Nur sing _ out com es ▁Classifica tion ▁no c
D-1398	-0.77603679895401	admission_to_ discharge older_ adults heart_ failureHF Nursing_outcomes Classification noc
P-1398	-3.1351 -0.4116 -0.7700 -0.3586 -0.3024 -0.5824 -0.0852 -2.2564 -0.8734 -0.5747 -2.2847 -1.3595 -0.0927 -0.7429 -0.8877 -0.0091 -0.4650 -0.6395 -0.2902 -0.0136 -0.9073 -0.0280 -1.5165 -1.1248 -0.3133 -0.1523
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort_study saxagliptin sitagliptin antihyperglycemic_agents
H-1840	-0.5487054586410522	▁h HF ▁sax ag lip tin ▁si tag lip tin ▁anti hy per gly ce mic _ agent
D-1840	-0.5487054586410522	hHF saxagliptin sitagliptin antihyperglycemic_agent
P-1840	-0.0529 -1.1669 -0.2418 -0.0058 -0.1702 -2.9686 -0.5145 -0.2803 -0.0423 -2.3061 -0.0095 -0.5316 -0.1141 -0.1515 -0.2092 -0.3688 -1.0682 -0.1332 -0.5071 -0.1316
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate_analysis preoperative albumin mortality lvad implantation hazard_ratio confidence_interval
H-535	-0.6568037867546082	▁pre operativ e _ album in ▁mortal ity ▁l VAD
D-535	-0.6568037867546082	preoperative_albumin mortality lVAD
P-535	-1.2819 -0.1245 -0.0141 -0.3915 -0.0574 -0.3315 -0.8502 -1.4672 -0.2312 -0.0327 -2.9267 -0.1727
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients systolic_heart_failure qrs_duration crt death hospitalization heart_failure mortality
H-854	-0.8852443695068359	▁sy sto lic _ heart _ ▁failure ▁QR s ▁c RT ▁cardiac _ ▁failure ▁mortal ity
D-854	-0.8852443695068359	systolic_heart_ failure QRs cRT cardiac_ failure mortality
P-854	-0.1679 -0.0938 -0.1977 -0.0416 -1.7945 -1.3716 -0.0686 -0.1464 -0.6387 -1.0146 -3.0306 -3.9270 -0.9724 -0.4262 -0.4702 -1.2009 -0.2412 -0.1306
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially_expressed_genes degs ischemic_heart_failure healthy diagnosis heart_failure
H-1608	-1.020163893699646	▁de g s ▁non - ische mic ▁ ische mic _ heart ▁failure
D-1608	-1.020163893699646	degs non-ischemic ischemic_heart failure
P-1608	-2.4363 -2.1316 -0.4444 -0.8061 -0.0570 -0.0437 -0.2324 -2.3659 -0.0386 -0.2907 -0.4626 -2.3679 -0.7232 -2.7499 -0.1523
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse_events reoperation bleeding driveline infection gastrointestinal_bleeding stroke rankin_score
H-2003	-0.5240957140922546	▁re opera tion ▁ble ed ing ▁drive line _ ▁infection ▁gastro inte stin al _ ▁ble ed ing ▁de bilitat ing _ ▁stroke ▁Rank in _ ▁Score
D-2003	-0.5240957140922546	reoperation bleeding driveline_ infection gastrointestinal_ bleeding debilitating_ stroke Rankin_ Score
P-2003	-1.0732 -0.5413 -0.2455 -0.6359 -0.8234 -0.2755 -0.0876 -0.0840 -0.5846 -0.1398 -0.0253 -0.1636 -0.5333 -0.1565 -1.0397 -0.3542 -1.0438 -0.1869 -0.0139 -0.0163 -0.0847 -0.5285 -4.2939 -0.4446 -0.2312 -0.9619 -0.2023 -0.2789 -0.1485
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox_regression_models propensity_score oral glucocorticoid hf hospitalisations loop_diuretics
H-605	-0.45680204033851624	▁co x ▁re gression _ ▁models ▁pro pens ity _ ▁score ▁de cile ▁oral ▁gluco cor tico id ▁loop _ ▁di ure tics
D-605	-0.45680204033851624	cox regression_ models propensity_ score decile oral glucocorticoid loop_ diuretics
P-605	-0.0263 -0.0454 -0.8614 -0.0210 -0.9002 -0.5731 -0.0058 -0.0076 -0.6487 -1.1180 -0.1457 -0.1217 -0.0010 -0.0243 -0.3722 -0.2533 -0.2622 -0.3229 -2.1015 -0.1475 -2.0073 -0.6408 -0.2424 -0.4760 -0.0935
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin_resistance type_2_diabetes insulin_receptor_substrates_1 irs1 irs2 cellular_metabolism
H-653	-0.6827692985534668	▁in s ulin _ ▁resist ance ▁type _ ▁2 ▁diabetes ▁insulin ▁receptor _ ▁substrat es ▁i rs 2 ▁insulin - signal ing
D-653	-0.6827692985534668	insulin_ resistance type_ 2 diabetes insulin receptor_ substrates irs2 insulin-signaling
P-653	-0.4841 -0.7058 -0.0360 -0.4850 -1.0285 -0.0188 -0.0919 -1.3305 -1.1888 -0.3453 -0.0068 -0.7205 -0.7030 -0.0792 -0.0269 -1.2107 -1.9300 -1.6865 -0.1429 -0.0668 -0.0217 -0.0483 -3.8813 -0.1470
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous_hf electromechanical_delay emd myocyte_depolarization myofiber_shortening
H-1149	-0.32540610432624817	▁dys syn chron ous _ HF ▁electro me chan ical _ de lay ▁e em d ▁my o cy te ▁de po lar ization ▁my o fi ber
D-1149	-0.32540610432624817	dyssynchronous_HF electromechanical_delay eemd myocyte depolarization myofiber
P-1149	-0.0592 -0.0106 -0.0026 -0.6625 -0.3874 -1.0961 -0.0309 -0.1169 -0.0751 -0.3975 -0.1361 -0.5566 -0.2552 -1.0197 -1.7226 -0.0784 -0.5197 -0.0943 -0.2024 -0.0800 -0.2764 -0.1135 -0.0896 -0.3893 -0.4890 -0.0691 -0.0209 -0.0400 -0.6265 -0.1442
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta_blockers all-cause_mortality readmissions heart_failure_with_reduced_ejection_fraction hfref heart_rate
H-1936	-0.6512741446495056	▁Beta _ block ers ▁mortal ity ▁read missions ▁heart ▁failure ▁e je ction _ fraction HF r EF ▁heart _ ▁rate HR
D-1936	-0.6512741446495056	Beta_blockers mortality readmissions heart failure ejection_fractionHFrEF heart_ rateHR
P-1936	-0.6463 -1.4155 -1.4871 -0.0601 -2.3917 -1.1696 -0.0364 -0.0307 -0.5115 -0.4688 -0.7131 -0.0862 -0.0273 -0.2718 -0.0701 -1.5502 -0.1084 -0.6534 -1.2103 -1.1270 -0.3978 -0.6797 -0.4115 -0.1061
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional_electrical_stimulation fes exercise_capacity quality_of_life endothelial_function chronic_heart_failure systolic_function
H-1327	-0.5206239223480225	▁Fun ction al _ elektr al _ stimul ation ▁f es ▁exercise ▁capacity ▁emotional ▁en dot heli al _ ▁function ▁chronic _ heart ▁failure ▁sy sto lic _ function
D-1327	-0.5206239223480225	Functional_elektral_stimulation fes exercise capacity emotional endothelial_ function chronic_heart failure systolic_function
P-1327	-0.2718 -0.0052 -0.0427 -0.1554 -1.0145 -0.1829 -0.4198 -0.1284 -0.0777 -0.8387 -0.3887 -0.7906 -3.2143 -0.0596 -1.6768 -0.4282 -0.0641 -0.0049 -0.6371 -0.5803 -0.5453 -0.1294 -1.5167 -0.7242 -0.0876 -0.0560 -0.1468 -0.3931 -1.2370 -0.2135 -0.1080
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report patient right_atrial_myxoma massive_embolism pulmonary_arteries surgically right_atrial pulmonary_embolectomy
H-595	-0.4381583333015442	▁right _ at rial _ ▁my xo ma ▁massive _ e mbol ism ▁pulmonar y _ ▁arteri es ▁right _ at rial _ ▁mass _ ▁remo val ▁pulmonar y _ e mbol ecto my
D-595	-0.4381583333015442	right_atrial_ myxoma massive_embolism pulmonary_ arteries right_atrial_ mass_ removal pulmonary_embolectomy
P-595	-1.7025 -0.1499 -1.1472 -0.1583 -0.2611 -2.3883 -0.0245 -0.0823 -0.2854 -0.1782 -0.7886 -0.0177 -0.6834 -0.0372 -0.0614 -0.5502 -0.0148 -0.0344 -0.8142 -0.1706 -0.5938 -0.1255 -0.3905 -0.1584 -0.9240 -0.0341 -0.0492 -0.0037 -0.0552 -0.4582 -1.0627 -0.0748 -0.1176 -1.6952 -0.3830 -0.0978
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant patients pd hf clinical
H-896	-0.6644828915596008	▁transplant ▁in elig ible ▁patients ▁PD ▁ HF ▁volume ▁management PD
D-896	-0.6644828915596008	transplant ineligible patients PD HF volume managementPD
P-896	-0.3370 -0.6306 -0.0022 -0.1891 -1.1216 -1.5133 -0.6131 -0.1252 -0.4944 -1.0340 -1.6166 -0.8466 -0.1147
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker clinical therapeutic
H-1478	-0.5566904544830322	▁bio mark er _ studie s ▁bio mark er - guide d _ ▁clinic al _ ▁trial ▁ therapeut ic
D-1478	-0.5566904544830322	biomarker_studies biomarker-guided_ clinical_ trial therapeutic
P-1478	-0.3119 -0.1782 -0.0666 -2.0295 -1.1360 -0.0678 -0.0401 -0.0903 -0.0482 -0.1151 -0.0069 -0.0294 -0.7360 -0.4445 -0.0775 -0.2893 -0.4167 -2.8601 -0.0761 -0.0811 -2.9868 -0.1593
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf incidence liver nodularity
H-231	-0.7293104529380798	▁imagin g ▁ab normal _ liver _ ▁texture s ▁no du lar ity
D-231	-0.7293104529380798	imaging abnormal_liver_ textures nodularity
P-231	-1.5168 -0.1246 -1.0160 -0.0781 -0.1535 -1.4339 -0.5487 -0.2851 -2.7046 -0.0612 -0.0211 -0.3264 -2.2339 -0.3071 -0.1287
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty biological_phenotype physical activity
H-1004	-0.6768147945404053	▁fra il ty ▁bi ological _ ▁ph eno type ▁we ak _ grip _ ▁strength ▁physical _ ▁exhaust ion ▁slow ness ▁un inten tional _ gewicht _ ▁loss
D-1004	-0.6768147945404053	frailty biological_ phenotype weak_grip_ strength physical_ exhaustion slowness unintentional_gewicht_ loss
P-1004	-0.6058 -0.2923 -0.0680 -4.4489 -0.2655 -0.1680 -0.1813 -0.0526 -0.0010 -0.0030 -0.0278 -0.0778 -1.4645 -0.3707 -0.2918 -0.3755 -0.7939 -0.1514 -0.0310 -0.1763 -2.0263 -3.1103 -0.0553 -0.1181 -0.0817 -1.2050 -2.4410 -0.9409 -0.3459 -0.1329
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d patients ic crt-d ies
H-109	-1.0485835075378418	▁c RT - d ▁IE ▁IC ▁c RT - d ▁IE s
D-109	-1.0485835075378418	cRT-d IE IC cRT-d IEs
P-109	-1.4601 -1.4269 -0.0479 -1.0882 -2.8610 -0.3319 -0.8835 -1.7162 -0.0508 -1.0806 -2.8209 -0.5322 -0.2833 -0.0967
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds discharge patients heart_failure outcomes driven readmissions
H-467	-1.2476686239242554	▁ED s ▁dis charge ▁patients ▁heart _ ▁failure _ home ▁low - volu me _ ▁ED _ ▁cases ▁read missions ▁ED
D-467	-1.2476686239242554	EDs discharge patients heart_ failure_home low-volume_ ED_ cases readmissions ED
P-467	-7.1677 -0.5142 -2.5112 -0.0619 -0.9677 -1.5133 -2.0565 -0.0794 -0.4193 -0.7904 -2.1301 -0.0302 -0.3583 -0.1016 -0.2893 -1.7894 -2.7458 -1.1420 -0.5931 -0.0530 -2.4892 -0.7456 -0.1473
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs_morphology outcomes cardiac_resynchronization_therapy resynchronization-defibrillation_for_ambulatory_heart_failure_trial raft
H-879	-0.3756321966648102	▁QR s ▁ morph ology ▁cardiac ▁re syn chron ization _ therapy ▁re syn chron ization - Def i bril lation ▁amb ulator y _ ▁Heart _ ▁Fail ure _ tri al RAF t
D-879	-0.3756321966648102	QRs morphology cardiac resynchronization_therapy resynchronization-Defibrillation ambulatory_ Heart_ Failure_trialRAFt
P-879	-0.7358 -0.3161 -0.1562 -0.0133 -0.1505 -0.0946 -0.5350 -0.0227 -0.0074 -0.6340 -0.7076 -1.3872 -0.1576 -0.0185 -0.0162 -0.7729 -0.2923 -1.4000 -0.1775 -0.3109 -0.0641 -0.6731 -0.0869 -0.0659 -0.0237 -0.4419 -0.5721 -0.0791 -0.8701 -0.4202 -0.8414 -0.0625 -0.5659 -0.6160 -0.1233 -0.1104
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute_right_heart_failure therapy refractory_cardiogenic_shock heart extra_corporeal_membrane_oxygenation ecmo cpr icu
H-1295	-0.43345728516578674	▁a cute _ ▁right _ ▁heart _ ▁failure ▁ therapy ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁heart _ team ▁corpore al _ ▁membran e _ ▁oxygen ation ▁ec mo ▁c PR ICU
D-1295	-0.43345728516578674	acute_ right_ heart_ failure therapy refractory_ cardiogenic_ shock heart_team corporeal_ membrane_ oxygenation ecmo cPRICU
P-1295	-0.5943 -0.0038 -0.0375 -1.6693 -0.0666 -1.4260 -1.4195 -0.0283 -1.0981 -0.0091 -0.0883 -0.0221 -0.1825 -0.0251 -0.2637 -0.0639 -0.6980 -0.0257 -0.3725 -1.8606 -1.0194 -0.1636 -0.7682 -0.0293 -0.0884 -0.1549 -0.0211 -0.1240 -0.3566 -0.0486 -1.3761 -0.8686 -0.0844 -0.7386 -0.0539 -0.1178 -0.0695
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency_room undiagnosed heart_disease symptoms hf surgical_palliation
H-201	-0.689251184463501	▁guidelines ▁un diagnos ed _ heart _ ▁disease ▁ HF ▁sur g ical _ ▁palli ation
D-201	-0.689251184463501	guidelines undiagnosed_heart_ disease HF surgical_ palliation
P-201	-3.2091 -1.8418 -0.0197 -0.0294 -0.1388 -1.3860 -1.2745 -0.3386 -1.3123 -0.0843 -1.2703 -0.1152 -0.1717 -0.1299 -0.5582 -0.1135 -0.3049 -0.1085
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene_expression bax pacing bcl-2 mrna expression heart_failure bcl-2 bax
H-168	-0.6767327785491943	▁Gene _ expression _ of _ ▁Bax ▁b cl -2 ▁m RNA _ expression ▁moderat e _ ▁heart ▁failure ▁b cl - 2/ Ba x
D-168	-0.6767327785491943	Gene_expression_of_ Bax bcl-2 mRNA_expression moderate_ heart failure bcl-2/Bax
P-168	-1.8009 -0.4017 -0.4136 -1.1785 -1.4134 -0.6113 -0.0873 -0.3194 -0.0456 -0.0651 -0.1242 -0.0560 -1.6229 -0.5878 -1.7351 -0.0183 -0.0400 -1.6562 -0.6701 -1.4284 -0.1992 -0.0559 -0.0336 -3.2367 -0.0838 -0.2875 -0.0992
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart_magnetic_resonance_imaging chelation patient compliance heart_failure arrhythmias
H-745	-0.729232907295227	▁heart _ ▁magnetic _ re on ance _ ▁imagin g ▁che lation _ ▁choice s ▁patient _ ▁compliance ▁heart ▁failure ▁ar rhythm ias
D-745	-0.729232907295227	heart_ magnetic_reonance_ imaging chelation_ choices patient_ compliance heart failure arrhythmias
P-745	-1.3021 -1.3196 -0.1898 -0.1417 -1.7095 -0.7779 -0.4836 -0.0838 -0.6219 -0.1826 -0.0151 -0.0141 -2.6639 -0.2022 -0.0507 -3.1641 -2.4960 -0.5000 -0.7582 -0.5314 -0.0203 -0.0915 -0.4999 -0.3192 -0.0917
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl hno inotropic lusitropic vasodilator in_vivo camp
H-413	-0.399966299533844	▁ni tro x yl ▁h no ▁Angeli _ s _ ▁salt ▁in o tropi c ▁ lusi tropi c ▁vaso dila tor ▁effects ▁c AMP
D-413	-0.399966299533844	nitroxyl hno Angeli_s_ salt inotropic lusitropic vasodilator effects cAMP
P-413	-0.0119 -0.0218 -0.2599 -0.2002 -0.8759 -0.5175 -1.3363 -2.3964 -0.1897 -0.7461 -0.3040 -0.1149 -0.8107 -0.0131 -0.0669 -0.2199 -0.0052 -0.0168 -0.1250 -0.0084 -0.0043 -0.0278 -1.5922 -0.3815 -0.0513 -0.3910 -0.1104
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection_fraction ef patients nyha_class_iiib symptoms right_ventricular_dysfunction
H-897	-0.8235683441162109	▁e je ction _ fraction EF ▁pre - PD ▁NY HA _ ▁class _ ▁III b ▁right _ ▁vent ri cular _ ▁dys function
D-897	-0.8235683441162109	ejection_fractionEF pre-PD NYHA_ class_ IIIb right_ ventricular_ dysfunction
P-897	-0.1465 -0.0881 -0.0495 -0.5594 -0.0487 -1.5057 -4.4280 -0.0126 -0.0697 -1.1944 -0.6628 -2.3466 -1.1079 -0.8110 -0.5675 -0.4150 -1.4420 -0.2417 -2.5034 -1.1745 -0.7636 -0.5318 -0.2722 -0.1282 -0.2100 -0.1319
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs early-outgrowth_colony-forming_units eo-cfus cells
H-124	-0.6474092602729797	▁c PC s ▁early - out g row th ▁colon y - form ing _ ▁unit s ▁o - c FU s ▁circula ting ▁cd 34 ▁v EG FR 2 ▁cd 133
D-124	-0.6474092602729797	cPCs early-outgrowth colony-forming_ units o-cFUs circulating cd34 vEGFR2 cd133
P-124	-0.2141 -1.2725 -0.2071 -1.7081 -0.0535 -0.1220 -1.8493 -0.0674 -0.0519 -1.4983 -0.0414 -0.0218 -0.0120 -0.0176 -1.8890 -0.0280 -0.1285 -2.1827 -1.1708 -0.5578 -1.0495 -0.2184 -0.0010 -0.0310 -0.5344 -1.0778 -1.1181 -0.9441 -0.5107 -0.1967 -0.5991 -0.3791 -2.1268 -0.1315
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence clinical continuous-flow_lvads heartmate_ii hm_ii heartware btt dt patients
H-309	-0.7339181303977966	▁continuo us - flow _ ▁l VAD s ▁he art Mate _ ▁II HM _ ▁II ▁Heart War e ▁b t ▁ DT
D-309	-0.7339181303977966	continuous-flow_ lVADs heartMate_ IIHM_ II HeartWare bt DT
P-309	-1.0959 -0.0854 -0.2394 -0.2503 -0.4002 -5.3113 -0.1380 -0.1571 -0.0224 -0.8084 -0.1092 -0.5019 -0.4621 -0.6942 -0.7145 -1.7605 -0.9072 -0.2621 -0.0271 -0.7036 -0.9982 -1.9379 -0.2804 -0.3785 -0.1021
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy anticoagulation rate_control cardiovascular complications stroke cardiovascular_death acute_heart_failure patients atrial_fibrillation
H-1643	-0.5214952826499939	▁antico ag ulation ▁rate ▁control ▁cardiovascular ▁complica tions stro ke ▁cardiovascular _ ▁death ▁a cute _ heart _ ▁failure ▁at rial _ fi bril lation AF
D-1643	-0.5214952826499939	anticoagulation rate control cardiovascular complicationsstroke cardiovascular_ death acute_heart_ failure atrial_fibrillationAF
P-1643	-2.1873 -0.1764 -0.0719 -0.6638 -1.7385 -0.7550 -0.7938 -1.3905 -0.0519 -0.0230 -0.1114 -0.4828 -0.6920 -0.0283 -0.0351 -0.0260 -1.6538 -0.9298 -0.0797 -0.8909 -0.1335 -0.1848 -0.4464 -0.0657 -0.2521 -0.3167 -0.2928 -0.1282
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients baseline ef ef core
H-753	-0.668317973613739	▁EF ▁blind ed _ ▁core _ ▁laborator y
D-753	-0.668317973613739	EF blinded_ core_ laboratory
P-753	-3.1086 -1.2097 -0.2397 -0.0705 -0.5286 -0.2059 -0.7442 -0.0567 -0.3371 -0.1820
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef bnp bnp inhospital mortality
H-197	-1.037834644317627	▁b NP ▁in hospital _ ▁mortal ity
D-197	-1.037834644317627	bNP inhospital_ mortality
P-197	-3.9669 -1.7491 -1.6394 -0.2282 -0.5204 -0.1065 -0.7476 -0.2493 -0.1329
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash mortality hf nonsignificant
H-693	-0.7012849450111389	▁DAS h ▁die t ▁score s ▁mortal ity ▁ HF ▁Mediterrane an _ die t ▁score s
D-693	-0.7012849450111389	DASh diet scores mortality HF Mediterranean_diet scores
P-693	-0.1336 -0.1951 -2.3905 -0.1650 -0.3384 -0.0243 -1.4908 -1.1585 -1.2169 -0.1209 -0.4634 -1.3700 -0.2078 -1.3944 -1.6537 -0.5699 -0.0336 -0.2629 -0.1348
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal_muscle lean_mass z-score
H-1499	-0.7382343411445618	▁s kelet al _ ▁muscle _ ▁mass ▁appen di cular _ ▁lean _ ▁mass ▁index ▁z - s core
D-1499	-0.7382343411445618	skeletal_ muscle_ mass appendicular_ lean_ mass index z-score
P-1499	-3.8446 -0.0697 -0.1458 -0.2306 -1.7060 -1.1799 -1.4526 -1.4061 -0.1144 -0.3713 -0.2304 -1.3376 -0.1323 -1.4242 -0.5982 -0.6643 -0.1372 -0.0446 -0.1142 -0.1330 -0.1657
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 functional_capacity outcomes ambulatory patients hf
H-706	-0.7395324110984802	▁ST 2 ▁functional _ ▁capacity ▁well - tre ated ▁ambula tory _ ▁patients ▁ HF
D-706	-0.7395324110984802	ST2 functional_ capacity well-treated ambulatory_ patients HF
P-706	-1.5772 -0.1438 -0.1800 -1.1717 -1.0872 -2.3336 -0.0608 -0.0430 -0.7240 -1.0612 -0.2303 -0.8532 -0.8790 -1.2995 -0.1157 -0.6519 -0.1600
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality_of_life all-cause_mortality mortality
H-561	-1.017630934715271	▁Quality _ of _ ▁life ▁all - ca use _ ▁mortal ity
D-561	-1.017630934715271	Quality_of_ life all-cause_ mortality
P-561	-1.3633 -0.4028 -0.8410 -0.0814 -2.9207 -4.0732 -0.0421 -0.0557 -0.6548 -0.0891 -0.1713 -1.5379 -1.8678 -0.1456
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene_expression cardiomyocytes jq1 drug genes
H-1046	-0.5093897581100464	▁Gene _ expression _ ▁profil ing ▁culture d _ ▁cardio my o cy tes ▁j q 1 ▁drug ▁ phen yle ph rine - indu ced _ ▁gene s
D-1046	-0.5093897581100464	Gene_expression_ profiling cultured_ cardiomyocytes jq1 drug phenylephrine-induced_ genes
P-1046	-3.1102 -1.4584 -0.5509 -0.5099 -0.7117 -0.0151 -1.1841 -0.0957 -0.2131 -0.2207 -1.2232 -0.4415 -0.1672 -0.0508 -0.4318 -1.2270 -1.3746 -0.2653 -0.1712 -0.0675 -0.0407 -0.6143 -0.0140 -0.1308 -0.0007 -0.1261 -0.3633 -0.7208 -0.0284 -0.1854 -0.0768
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka polymorphism rs10927887 p.arg83gly heart_failure estimated_glomerular_filtration_rate renastur
H-1801	-0.4202531576156616	▁CL cn ka ▁poly morph ism ▁ar g 83 g ly ▁heart ▁failure ▁glo mer ular _ filter ation ▁rate ▁re NAS tur
D-1801	-0.4202531576156616	CLcnka polymorphism arg83gly heart failure glomerular_filteration rate reNAStur
P-1801	-0.4008 -1.1792 -0.3891 -0.1895 -0.0046 -0.3850 -0.4296 -0.0407 -0.3661 -1.0466 -0.0747 -0.2242 -0.7088 -0.0261 -0.1267 -0.0421 -0.2064 -0.7539 -0.2605 -1.3327 -0.7352 -0.0489 -0.3120 -1.1184 -0.1047
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular_diseases heart_failure hf incidence hf
H-285	-0.6404820680618286	▁cardiovascular _ ▁disease s ▁heart ▁failure HF ▁ HF
D-285	-0.6404820680618286	cardiovascular_ diseases heart failureHF HF
P-285	-0.4259 -0.6517 -2.0121 -0.0416 -0.3289 -0.9009 -0.6366 -1.2418 -0.1831 -0.4936 -0.1290
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac_vegf_expression endothelial_no_synthase_activation hearts
H-455	-0.5849520564079285	▁cardiac _ ve GF _ expression ▁Akt ▁en dot heli al _ no _ ▁synth ase _ activa tion ▁fail ing _ heart s
D-455	-0.5849520564079285	cardiac_veGF_expression Akt endothelial_no_ synthase_activation failing_hearts
P-455	-1.2813 -0.5919 -0.3208 -0.5274 -1.1516 -0.5947 -0.0470 -0.0834 -0.9652 -0.0631 -0.0121 -0.0853 -1.1620 -0.9871 -0.4667 -1.3297 -0.2377 -0.2545 -0.1330 -2.0825 -0.1218 -0.1373 -1.8134 -0.1110 -0.4924 -0.1559
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial exercise outcomes heart_failure patients heart_failure outcomes exercise training hf-action
H-1924	-0.5897358059883118	▁Psycho social _ factor s ▁Exerci se _ ad her ence ▁Heart ▁Fail ure ▁Patient s ▁Insight s ▁Heart _ ▁Fail ure ▁Exerci se _ training HF - ac tion
D-1924	-0.5897358059883118	Psychosocial_factors Exercise_adherence Heart Failure Patients Insights Heart_ Failure Exercise_trainingHF-action
P-1924	-0.9795 -0.0982 -0.6937 -1.0822 -0.0820 -0.3166 -0.0272 -0.9149 -0.3734 -0.2349 -0.2248 -1.1141 -0.9063 -0.8325 -1.5539 -0.0682 -0.4906 -0.0129 -0.8417 -0.9432 -0.0890 -0.6424 -1.7855 -0.0537 -0.2981 -0.6514 -1.0609 -0.0313 -0.5351 -1.6335 -0.1856 -0.1145
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart_failure left_ventricular_systolic_dysfunction post_hoc_analysis
H-402	-0.7923585176467896	▁heart ▁failure ▁left _ ▁vent ri cular _ sy sto lic _ ▁dys function ▁BB
D-402	-0.7923585176467896	heart failure left_ ventricular_systolic_ dysfunction BB
P-402	-1.8948 -1.2138 -0.4008 -0.5524 -2.0818 -1.4251 -0.4362 -0.3012 -1.0053 -0.1120 -0.3336 -0.2319 -0.1607 -0.0819 -2.7356 -0.3657 -0.1372
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients coronary_angiography diagnosis systolic_hf etiology ejection_fraction
H-1186	-0.4851406514644623	▁deriva tion _ co hor t ▁corona ry _ ang i ography ▁sy sto lic _ HF ▁un clear _ ▁et i ology ej ection _ fraction
D-1186	-0.4851406514644623	derivation_cohort coronary_angiography systolic_HF unclear_ etiologyejection_fraction
P-1186	-1.4023 -0.1170 -0.6760 -0.5565 -0.2808 -0.0448 -0.0893 -1.8189 -0.1307 -2.7820 -1.6017 -0.1942 -0.0183 -0.0136 -0.0423 -0.0782 -0.7375 -0.1225 -0.0476 -0.1368 -0.9779 -0.1367 -0.1002 -0.2301 -0.0314 -1.1342 -0.0106 -0.4328 -0.1243
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac insulin-resistance glycolysis glucose_oxidation plasma_membrane_translocation glucose
H-1784	-0.20891542732715607	▁cardiac _ ▁insulin - re si stance ▁a ac ▁insulin - stimul ated _ ▁rates ▁gly col ysis ▁gluco se _ ▁oxid ation ▁plasma ▁membran e ▁trans location ▁gluco se _ ▁transporter
D-1784	-0.20891542732715607	cardiac_ insulin-resistance aac insulin-stimulated_ rates glycolysis glucose_ oxidation plasma membrane translocation glucose_ transporter
P-1784	-0.1693 -0.2940 -0.1094 -0.0579 -0.0266 -0.3610 -0.0061 -0.5959 -0.3880 -0.2896 -0.0464 -0.0087 -0.1286 -1.2342 -0.0611 -0.0318 -0.0239 -0.1260 -0.0422 -0.3011 -0.2638 -0.2116 -0.0352 -0.0073 -0.3666 -0.0177 -0.1340 -0.3874 -0.2293 -0.0605 -0.0499 -0.5058 -0.3956 -0.1365
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells angiotensin_ii angii hypoxia scn5a mrna_splicing scn5a
H-1083	-0.4776923358440399	▁ang io ten sin _ ▁II Ang II ▁hypo xia ▁activa tors ▁s cn 5 a ▁m RNA ▁s plic ing ▁over express ▁s cn 5 a
D-1083	-0.4776923358440399	angiotensin_ IIAngII hypoxia activators scn5a mRNA splicing overexpress scn5a
P-1083	-1.6503 -0.5747 -0.0745 -0.8258 -0.9804 -1.0482 -0.9373 -0.6696 -0.0294 -0.0050 -0.3288 -0.0605 -0.8979 -0.2623 -0.5241 -0.1699 -0.4312 -0.1080 -0.3156 -0.2747 -0.0273 -0.5563 -0.0602 -0.5294 -0.3775 -0.8189 -0.2094 -0.9723 -0.1335
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced_pasp right_ventricular_contractile_reserve patients exercise-induced_pasp
H-824	-0.6638844609260559	▁exercise - indu ced _ pas p ▁vent ri cular _ contract ile ▁reserve ▁exercise - indu ced _ pas p
D-824	-0.6638844609260559	exercise-induced_pasp ventricular_contractile reserve exercise-induced_pasp
P-824	-2.8791 -0.0838 -0.0261 -0.0874 -1.0202 -0.4097 -0.8618 -1.9728 -1.0281 -0.5809 -0.2497 -0.5124 -0.2068 -0.4922 -2.1052 -0.0682 -0.0170 -0.1133 -1.1515 -0.3189 -0.6282 -0.3480 -0.1082
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial_elastance ea end-systolic_elastance ees ventricular-arterial_coupling ees ea
H-922	-0.4564724266529083	▁arterial _ ▁elastan ce ▁e a ▁end - sy sto lic _ ▁elastan ce ▁e es ▁vent ri cular - arte rial _ ▁coup ling ▁ratio ▁e es ▁e es
D-922	-0.4564724266529083	arterial_ elastance ea end-systolic_ elastance ees ventricular-arterial_ coupling ratio ees ees
P-922	-0.7610 -0.7607 -1.1552 -0.5894 -0.6253 -0.2042 -1.1619 -0.0683 -0.0374 -0.0196 -0.0404 -0.3860 -0.1301 -0.4887 -0.1690 -0.0163 -0.1152 -0.5918 -0.2059 -0.1129 -0.0702 -0.0462 -0.1506 -0.8413 -0.3947 -1.1466 -0.2325 -0.0320 -1.4486 -0.9461 -1.5226 -0.1366
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline central_blood_pressure radial_arterial_tonometry cardiovascular_function echocardiographic invasively
H-920	-0.6697041988372803	▁post - DAS h ▁s rd _ bra chi al _ central _ ▁blood _ ▁pressure ▁radi al _ ▁arterial _ ▁ton ometr y ▁cardiovascular _ ▁function ▁e cho car dio graphic
D-920	-0.6697041988372803	post-DASh srd_brachial_central_ blood_ pressure radial_ arterial_ tonometry cardiovascular_ function echocardiographic
P-920	-0.5383 -0.0486 -0.1102 -0.1329 -3.3726 -0.4678 -1.1132 -1.6851 -0.0754 -0.0182 -0.6827 -1.6355 -0.2540 -2.3152 -1.2971 -0.9283 -0.0528 -0.0309 -0.2170 -0.2613 -0.0698 -2.6086 -0.0575 -0.2235 -0.0401 -0.8174 -1.6218 -0.0520 -0.0211 -0.0052 -0.2646 -0.3974 -1.2308 -0.1231
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene_expression_profile gse9128 gene_expression_omnibus non-ischemic_heart_failure ischemic
H-1609	-0.41169971227645874	▁Gene _ expression _ ▁profile ▁g se 91 28 ▁Gene _ ▁Express ion _ ▁Omni bus ▁non - ische mic _ heart ▁failure ▁ ische mic
D-1609	-0.41169971227645874	Gene_expression_ profile gse9128 Gene_ Expression_ Omnibus non-ischemic_heart failure ischemic
P-1609	-0.9298 -0.7225 -0.2440 -0.2744 -0.3670 -0.4274 -0.4123 -0.1405 -0.0879 -0.5937 -1.0034 -0.4418 -0.0161 -0.1109 -0.2342 -0.3672 -0.1057 -0.0412 -0.0225 -0.2165 -0.1170 -1.1649 -0.6991 -1.1124 -0.0165 -0.3042 -1.2074 -0.1471
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm_control_therapy rhythm_control_therapy antiarrhythmic_drugs catheter_ablation electrocardiographic rhythm
H-1653	-0.373852401971817	▁ rhythm _ control _ therapy ▁anti ar rhythm ic ▁drugs ▁cat heter ▁ab lation ▁electro car dio graphic _ ▁device ▁ rhythm
D-1653	-0.373852401971817	rhythm_control_therapy antiarrhythmic drugs catheter ablation electrocardiographic_ device rhythm
P-1653	-0.2456 -0.6131 -0.7264 -0.0128 -2.0020 -0.0453 -0.9363 -0.2560 -0.0927 -0.0178 -0.8685 -0.0430 -0.0051 -0.2167 -0.0316 -0.0070 -0.0123 -0.3325 -0.2972 -0.3469 -0.5172 -0.9336 -0.4464 -0.2104 -0.1299
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures hospitalizations noncardiovascular diagnoses implantable_cardiac_arrhythmia_devices noncardiovascular drugs rate-control
H-1240	-0.4579765200614929	▁ex pendi tures ▁non car dio vas cular ▁diagnose s ▁implant able ▁cardiac _ ▁ar rhythm ia ▁devices ▁non car dio vas cular _ ▁drugs
D-1240	-0.4579765200614929	expenditures noncardiovascular diagnoses implantable cardiac_ arrhythmia devices noncardiovascular_ drugs
P-1240	-1.8177 -0.0766 -0.1218 -0.0755 -0.0510 -0.2394 -0.3721 -0.6679 -1.6775 -0.0306 -0.0493 -0.0342 -0.6613 -0.7961 -0.2491 -0.0295 -0.4674 -0.3663 -0.0189 -0.0332 -0.1613 -0.3123 -0.7117 -1.2655 -0.4690 -1.4729 -0.1373
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence hf_with_reduced_ejection_fraction hfref hf_with_preserved_ejection_fraction hfpef
H-1488	-0.7277264595031738	▁ HF _ met _ reducing d _ e je ction _ fraction HF r EF ▁treatment ▁ HF _ met _ ▁pres er ved _ e je ction _ fraction HF p EF
D-1488	-0.7277264595031738	HF_met_reducingd_ejection_fractionHFrEF treatment HF_met_ preserved_ejection_fractionHFpEF
P-1488	-1.2683 -0.1560 -3.8778 -1.8366 -0.2793 -1.4569 -0.5352 -0.0507 -0.3781 -0.2254 -0.1279 -0.1282 -0.2022 -2.1807 -0.1712 -0.3454 -1.6436 -1.2124 -0.1944 -1.2424 -1.8387 -0.0866 -2.2826 -0.0667 -0.3603 -0.0533 -0.3685 -0.2384 -0.1623 -0.1787 -0.1997 -1.6732 -0.2095 -0.5187 -0.3650 -0.0833
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal_life_support therapy patients acute_ischemic_right_heart_failure refractory_cardiogenic_shock reperfusion therapy
H-1298	-0.4090404808521271	▁extra corp o real _ ▁life _ support ▁ brid ging _ therapy ▁a cute _ ische mic _ ▁right _ ▁heart ▁failure ▁re frac tory _ ▁cardio ge nic _ ▁shock ▁reper fusion ▁ therapy
D-1298	-0.4090404808521271	extracorporeal_ life_support bridging_therapy acute_ischemic_ right_ heart failure refractory_ cardiogenic_ shock reperfusion therapy
P-1298	-0.1530 -0.0086 -0.2516 -0.0135 -0.0434 -0.8618 -0.6871 -0.5981 -0.3971 -0.2240 -0.0115 -0.7183 -0.0298 -2.1475 -0.0252 -0.0669 -0.2094 -0.1668 -0.0248 -2.1505 -0.1676 -2.1454 -0.2792 -0.0033 -0.0221 -0.1558 -0.1067 -0.0965 -0.1451 -1.3126 -0.0486 -0.4903 -0.0135 -0.0144 -1.3826 -0.0112 -0.2328 -0.1271
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart_failure reduced_left_ventricular_ejection_fraction fes exercise_capacity quality_of_life endothelial_function hfpef
H-1332	-0.5242892503738403	▁heart ▁failure ▁left _ ▁vent ri cular _ e je ction _ fraction ▁f es ▁exercise _ ▁capacity ▁en dot heli al _ function ▁ HF p EF
D-1332	-0.5242892503738403	heart failure left_ ventricular_ejection_fraction fes exercise_ capacity endothelial_function HFpEF
P-1332	-0.5017 -0.6543 -0.6419 -0.4109 -1.5228 -0.8264 -0.7136 -0.2008 -0.3632 -0.1523 -0.0634 -0.4504 -0.0173 -0.8306 -0.4013 -0.4877 -1.4538 -0.9834 -1.2755 -0.5818 -0.0617 -0.0095 -0.3360 -0.9650 -0.7065 -0.2655 -0.0675 -0.5035 -0.1569 -0.1232
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.7342881560325623	▁in tub ation _ ▁rates
D-220	-0.7342881560325623	intubation_ rates
P-220	-0.1149 -0.0483 -0.2425 -2.9090 -0.2854 -1.3716 -0.1684
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts heart_mass transgenic
H-1814	-0.5158208012580872	▁heart s ▁t g t et Men a _ mi ce ▁wild - type _ ▁litt er mates ▁heart ▁mass ▁trans ge nic _ mi ce
D-1814	-0.5158208012580872	hearts tgtetMena_mice wild-type_ littermates heart mass transgenic_mice
P-1814	-0.7094 -0.2494 -2.2533 -0.0856 -0.2211 -0.1194 -0.8241 -0.0301 -0.7270 -0.3001 -0.2621 -2.4119 -0.0709 -0.0057 -0.7731 -0.0128 -0.0268 -0.0681 -1.9121 -1.0069 -0.0167 -0.1367 -0.9146 -0.1226 -0.6505 -0.1858 -0.2703 -0.0760
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene heart_failure
H-1541	-0.6480511426925659	▁ra lo xi fen e ▁mechanism _ of _ action ▁heart ▁failure
D-1541	-0.6480511426925659	raloxifene mechanism_of_action heart failure
P-1541	-1.0352 -0.0097 -0.0268 -0.0451 -0.2448 -0.1938 -1.0874 -0.4635 -0.3949 -0.5604 -1.9162 -1.2808 -1.6699 -0.1441
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients hfref exercise respiratory_gas_analysis baseline
H-1938	-1.1376404762268066	▁h Fr ef ▁respirator y _ gas _ analyse
D-1938	-1.1376404762268066	hFref respiratory_gas_analyse
P-1938	-2.6303 -2.1260 -1.4619 -2.5673 -0.1181 -0.2430 -0.2455 -2.4009 -0.1404 -0.3981 -0.1826
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients drugs heart_failure biomedical nonprescribing patients
H-1126	-0.6049031615257263	▁guide line - re com mend ed _ ▁drugs _ voor _ heart ▁failure ▁chart _ review ▁bio medic al _ ▁reasons ▁non pre scribi ng
D-1126	-0.6049031615257263	guideline-recommended_ drugs_voor_heart failure chart_review biomedical_ reasons nonprescribing
P-1126	-4.0619 -0.0269 -0.3554 -0.0037 -0.0467 -0.0223 -0.1197 -1.0672 -0.3465 -1.2407 -1.6274 -0.1763 -0.8273 -0.8559 -0.1249 -0.5513 -0.6296 -0.0113 -0.0173 -0.0138 -2.2547 -0.0765 -1.1868 -0.0889 -0.0485 -0.0904 -0.8822 -0.1833
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients chronic_hf prevalence exercise hf hospitalization mortality exercise training
H-1641	-0.786273181438446	▁black _ race ▁chronic _ HF ▁modifi able _ risk _ ▁factors ▁exercise ▁performance ▁ HF ▁hospital ization ▁mortal ity ▁exercise ▁training
D-1641	-0.786273181438446	black_race chronic_HF modifiable_risk_ factors exercise performance HF hospitalization mortality exercise training
P-1641	-0.2448 -0.3902 -0.9731 -2.4092 -0.2860 -0.4215 -0.7312 -0.0762 -0.0786 -0.7878 -1.5410 -0.2403 -1.4114 -0.7196 -0.1148 -0.0900 -3.9850 -0.7385 -0.3694 -0.7588 -0.4003 -1.6443 -0.2769 -0.1817
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean_mass adverse_outcome adipose_tissue cardioprotective hf
H-1169	-0.5928863286972046	▁was ting _ of _ ▁fat ▁lean _ ▁mass ▁fat _ ▁loss ▁enhance d _ ▁cata bol ism ▁adi pose _ ▁tissu e ▁cardio protec tive ▁ HF
D-1169	-0.5928863286972046	wasting_of_ fat lean_ mass fat_ loss enhanced_ catabolism adipose_ tissue cardioprotective HF
P-1169	-2.3138 -0.0567 -1.1414 -2.6063 -0.1616 -1.7903 -0.5676 -0.0872 -0.5543 -1.9563 -1.3771 -0.7204 -0.4721 -0.0444 -0.0732 -0.2646 -0.1587 -0.1859 -0.0033 -0.0260 -0.0623 -0.1152 -0.0430 -0.0492 -0.2921 -0.6282 -1.6343 -0.1510 -0.1503 -0.0999
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads heartmate_ii thoratec_corp pleasanton calif hvad heartware framingham
H-546	-0.3990739583969116	▁l VAD s ▁CF _ ▁devices ▁Heart Mate _ ▁II _ ▁devices ▁tho a tec _ ▁Corp ▁Ple asan ton ▁cali f ▁h VAD _ ▁devices ▁heart War e _ in t l _ ▁Inc ▁Fram ing ham ▁Mass
D-546	-0.3990739583969116	lVADs CF_ devices HeartMate_ II_ devices thoatec_ Corp Pleasanton calif hVAD_ devices heartWare_intl_ Inc Framingham Mass
P-546	-0.2773 -0.0394 -0.1187 -0.5952 -0.9479 -0.4113 -2.0005 -0.0387 -0.0628 -0.4612 -0.9656 -0.1088 -0.1115 -0.3092 -0.0012 -0.0613 -0.0640 -0.5793 -0.0025 -0.0058 -0.5386 -0.0309 -0.2737 -0.2337 -1.3385 -0.2364 -1.0842 -0.1527 -0.0182 -0.0507 -0.1191 -0.2402 -0.0080 -2.0870 -1.6475 -0.4418 -0.0500 -0.0078 -0.3767 -0.1856 -0.0784
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts nucleolin chamber_patterning cardiac_looping myocyte_differentiation
H-97	-0.5288876891136169	▁heart s ▁nu cle olin ▁cha mber _ ▁pattern ing ▁cardiac ▁loop ing ▁my o cy te
D-97	-0.5288876891136169	hearts nucleolin chamber_ patterning cardiac looping myocyte
P-97	-0.6238 -0.1126 -1.8055 -0.0058 -0.0896 -0.6383 -0.0013 -1.3949 -0.0321 -0.0661 -2.5404 -0.2557 -0.0281 -0.7002 -0.1161 -0.0786 -0.0571 -1.4169 -0.0858
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma collected hf patients immunoreactive nt-probnp c-terminally nt-probnp
H-1520	-0.6284410953521729	▁plasma ▁collect ed ▁ HF ▁immun ore active ▁NT - pro b NP
D-1520	-0.6284410953521729	plasma collected HF immunoreactive NT-probNP
P-1520	-1.0353 -0.5286 -0.4789 -0.9809 -0.0887 -0.0383 -0.5414 -0.3954 -1.5935 -0.1290 -0.1134 -1.0133 -0.3132 -2.0863 -0.0905
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma_nps adiponectin baseline ffm correlate nps adiponectin follow_up
H-19	-0.7030922174453735	▁FM ▁plasma ▁ NP s ▁total _ ▁adi pon ect in ▁FM ▁f m ▁ NP s ▁adi pon ect in ▁follow _ up
D-19	-0.7030922174453735	FM plasma NPs total_ adiponectin FM fm NPs adiponectin follow_up
P-19	-1.9739 -0.7065 -0.7564 -0.0276 -0.0234 -1.1184 -0.2224 -0.6529 -0.0165 -0.2909 -1.1527 -1.7221 -0.6338 -1.7933 -2.1765 -0.3743 -0.0259 -0.5147 -0.0178 -0.4449 -0.4691 -0.4618 -2.2340 -0.0963 -0.2568 -0.1176
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages cardiomyocytes doxorubicin in_vitro resistin mrna protein_expression
H-935	-0.4649752676486969	▁Mac rop hage s ▁cardio my o cy tes ▁Hum - re t n _ mi ce ▁do xor ubi cin ▁h rem n human _ ▁resist in ▁m RNA ▁protein ▁expression
D-935	-0.4649752676486969	Macrophages cardiomyocytes Hum-retn_mice doxorubicin hremnhuman_ resistin mRNA protein expression
P-935	-1.6947 -0.0469 -0.0165 -0.0618 -0.0141 -0.3129 -0.1693 -0.0660 -0.0184 -0.9310 -0.0630 -0.9441 -1.1300 -0.0571 -1.3267 -0.6369 -0.2827 -0.7772 -0.0208 -0.0168 -0.1937 -0.0566 -2.4143 -0.0476 -1.9888 -0.2868 -0.9135 -0.0775 -0.0026 -0.0081 -0.1198 -0.8363 -0.1814 -0.0952
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt_interval ecgs baseline atrial_pacing esmolol isoprenaline atropine infusion
H-1438	-0.39756518602371216	▁beat - to - beat _ QT _ ▁interval ▁e CG s at rial ▁pa cing ▁es mol ol ▁iso pren a line ▁a tropi ne _ in fusion
D-1438	-0.39756518602371216	beat-to-beat_QT_ interval eCGsatrial pacing esmolol isoprenaline atropine_infusion
P-1438	-0.0090 -0.0353 -0.0245 -0.0356 -0.2004 -0.2251 -0.6948 -0.2362 -0.0362 -3.8497 -1.4587 -0.2951 -1.0137 -0.2175 -0.8548 -0.1156 -0.4347 -0.0027 -0.1190 -0.0016 -0.0449 -0.0565 -0.0266 -0.0202 -0.0351 -0.8769 -0.3486 -0.5087 -0.0146 -0.4089 -0.1231
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic_tone parasympathetic_tone heart_rate intravenous_bolus metoprolol atropine
H-1378	-0.5225023627281189	▁sympa the tic _ ▁tone ▁para sy mpa the tic _ ▁tone ▁heart ▁rate _ ▁response ▁met o pro lol ▁a tropi ne
D-1378	-0.5225023627281189	sympathetic_ tone parasympathetic_ tone heart rate_ response metoprolol atropine
P-1378	-0.1416 -0.6025 -0.7300 -0.2077 -0.4725 -0.1062 -0.0191 -0.1611 -0.9259 -1.0767 -0.0938 -0.3889 -0.7384 -0.9023 -4.0533 -0.2114 -0.5218 -0.3631 -0.0361 -0.1058 -0.0514 -0.0107 -0.8095 -0.2534 -0.0795
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef pathophysiologically hf_with_reduced_ef hfref hfref therapy
H-1533	-0.935662031173706	▁EH ▁ HF p EF ▁ HF _ met _ ▁reduce d _ ef ▁h bf r EF ▁h Fr EF ▁ therapy
D-1533	-0.935662031173706	EH HFpEF HF_met_ reduced_ef hbfrEF hFrEF therapy
P-1533	-0.3152 -0.6838 -0.5822 -0.2417 -0.6316 -0.6288 -0.7764 -4.2864 -1.5716 -0.6428 -1.1841 -0.0051 -0.0806 -0.7907 -2.4364 -1.9679 -0.6655 -0.5185 -0.5169 -1.4816 -1.0614 -1.9472 -0.0491 -0.2343 -0.0918
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse_event acute_myocardial_infarction congestive_heart_failure adverse_events
H-4	-0.6046901345252991	▁advers e _ ▁event _ ▁rates ▁a cute _ My o card ial _ in far ction ▁con ges tive _ heart ▁failure ▁in - hospital ▁advers e _ ▁events
D-4	-0.6046901345252991	adverse_ event_ rates acute_Myocardial_infarction congestive_heart failure in-hospital adverse_ events
P-4	-2.6608 -0.0246 -0.1186 -1.7204 -1.4409 -0.1334 -0.2759 -0.0451 -0.0691 -4.3424 -0.5569 -0.5594 -0.6405 -0.0932 -0.2470 -0.1754 -0.1251 -0.0756 -0.1466 -1.1073 -0.0243 -1.4432 -0.9663 -0.1635 -0.1330 -0.0392 -0.7525 -0.0335 -0.3003 -0.3430 -0.4525 -0.1407
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence_interval
H-803	-0.8882730007171631	
D-803	-0.8882730007171631	
P-803	-1.6377 -0.1388
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change follow-up readmissions hospital follow-up
H-721	-0.8692087531089783	▁follow - up _ ▁visit s
D-721	-0.8692087531089783	follow-up_ visits
P-721	-0.6065 -0.1053 -0.0324 -1.7488 -1.0507 -0.0792 -3.1954 -0.1354
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac jq1 bet pathological cardiac gene_expression
H-1049	-0.4071704149246216	▁tran scription al _ analyse ▁cardiac _ ▁tissu e ▁mi ce ▁ TAC - ▁sham - opera ted ▁j q 1 ▁vehicle ▁ BET _ ▁inhibi tion ▁path ological _ ▁cardiac _ ▁gene ▁expression _ programm e
D-1049	-0.4071704149246216	transcriptional_analyse cardiac_ tissue mice TAC- sham-operated jq1 vehicle BET_ inhibition pathological_ cardiac_ gene expression_programme
P-1049	-1.7537 -0.1238 -0.0587 -0.6356 -0.1785 -0.5534 -0.2950 -0.2335 -0.1633 -1.1983 -0.1977 -0.5198 -0.1181 -0.0075 -0.0917 -0.0582 -0.0037 -0.0243 -0.1862 -1.2791 -0.5120 -0.2891 -0.1581 -0.1795 -1.3113 -0.0467 -0.0835 -0.3500 -0.4259 -0.0787 -0.2332 -0.2939 -0.3596 -0.9467 -1.8968 -0.2910 -0.3543 -0.2450 -0.1442
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power_spectral_analysis hf dnx
H-1377	-0.6403437256813049	▁power _ ▁spec tral _ analyse ▁low - fre quen ncy ▁high - fre quen ncy LF HF ▁CHF - in v ▁sham - in v ▁sham ▁levels ▁DN x
D-1377	-0.6403437256813049	power_ spectral_analyse low-frequenncy high-frequenncyLFHF CHF-inv sham-inv sham levels DNx
P-1377	-0.0930 -0.8586 -1.7867 -0.0053 -1.0696 -0.1402 -0.2320 -0.0818 -0.1563 -1.9494 -0.3143 -1.7330 -0.0983 -0.1944 -1.5340 -0.1873 -0.2273 -2.1682 -2.1072 -0.0505 -0.1923 -0.4413 -0.0415 -0.2110 -0.2857 -0.3352 -0.0722 -3.2306 -0.2024 -0.0524 -0.3076 -0.1314
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal_pro-b-type_natriuretic_peptide nt-probnp misdiagnosis heart_failure hf
H-1511	-0.6239529848098755	▁na tri ure tic _ pe pti de nt - pro b NP ▁mis diagnos is ▁heart _ ▁failure HF
D-1511	-0.6239529848098755	natriuretic_peptident-probNP misdiagnosis heart_ failureHF
P-1511	-1.8103 -0.0955 -0.1549 -1.7231 -0.5128 -0.6231 -0.0555 -0.5802 -2.2529 -0.0196 -0.0145 -0.4027 -0.2718 -0.1855 -0.1067 -0.1330 -1.6069 -1.3726 -0.1185 -1.2061 -0.3345 -0.1465
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action randomized patients left_ventricular_ejection_fraction new_york_heart_association_class_ii hf exercise training
H-698	-0.9089581966400146	▁ HF - ac tion ▁left _ ▁vent ri cular _ e je ction _ fraction ▁New _ York _ ▁Heart _ association ▁ HF ▁exercise _ training
D-698	-0.9089581966400146	HF-action left_ ventricular_ejection_fraction New_York_ Heart_association HF exercise_training
P-698	-1.1856 -0.6871 -0.0816 -0.7439 -2.6275 -0.4054 -0.4224 -2.0636 -1.3307 -0.6656 -0.2837 -0.3949 -0.1846 -0.1439 -0.7987 -0.0346 -0.7327 -0.7416 -0.7867 -0.1788 -0.7708 -0.5538 -0.6529 -1.9410 -3.9038 -2.2215 -1.5396 -0.1579 -0.8413 -0.1927
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial_dd collagen_deposition titin obese diabetic zsf1 heart_failure_with_preserved_ejection_fraction
H-762	-0.34705525636672974	▁my o card ial _ DD ▁collage n ▁de position ▁titi n _ ▁modification ▁obes e ▁diabet ic ▁z SF 1 ▁rat s ▁heart ▁failure ▁pres er ved _ e je ction _ fraction
D-762	-0.34705525636672974	myocardial_DD collagen deposition titin_ modification obese diabetic zSF1 rats heart failure preserved_ejection_fraction
P-762	-1.0588 -0.1327 -0.1760 -0.2658 -1.5950 -0.0662 -0.0403 -0.1603 -0.1120 -0.2840 -0.0394 -0.0692 -2.1740 -0.1038 -0.5098 -0.0248 -0.0397 -0.0025 -0.2312 -0.1256 -1.2327 -0.6332 -0.0784 -0.2946 -0.4892 -0.1378 -0.1370 -0.5992 -0.3179 -0.4591 -0.0395 -0.0417 -0.1528 -0.0099 -0.5576 -0.1022
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac_magnetic_resonance_postcontrast_t1_time prognosis hfpef postcontrast_t1 biomarker hfpef
H-743	-0.5950133204460144	▁cardiac _ ▁magnetic _ ▁res on ance ▁post contra st _ t 1 ▁h FP EF ▁post contra st _ t 1 ▁bio mark er ▁h FP EF
D-743	-0.5950133204460144	cardiac_ magnetic_ resonance postcontrast_t1 hFPEF postcontrast_t1 biomarker hFPEF
P-743	-0.0626 -0.3488 -0.2641 -0.1424 -1.8280 -0.2266 -0.0973 -1.5168 -0.0629 -0.0294 -0.8687 -0.8406 -0.5155 -0.6551 -1.4770 -0.8724 -1.9797 -0.2013 -0.0331 -0.3634 -0.6077 -0.3762 -0.2208 -0.1068 -0.0664 -0.4276 -2.0576 -1.1410 -0.3096 -0.1509
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ventricular-arterial_coupling patients
H-524	-0.3904048204421997	▁contract ility ▁vent ri cular - arte rial _ ▁coup ling ▁SV ▁i va bra dine - tre ated
D-524	-0.3904048204421997	contractility ventricular-arterial_ coupling SV ivabradine-treated
P-524	-0.0399 -0.4076 -0.0209 -0.8813 -0.5211 -0.1670 -0.0621 -0.1219 -0.2755 -1.6174 -0.8307 -0.7318 -0.0529 -0.0291 -0.0558 -0.1533 -0.0839 -0.0116 -0.5814 -1.4013 -0.1516
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 hypertrophy fibrosis ventricular_dysfunction gene
H-642	-0.3553016781806946	▁condition al _ ge - tar get ed _ hand 2 _ mi ce ▁pressure - over load - indu ced ▁hyper trop hy ▁fibro sis ▁vent ri cular _ ▁dys function ▁fet al _ ▁gene _ programm
D-642	-0.3553016781806946	conditional_ge-targeted_hand2_mice pressure-overload-induced hypertrophy fibrosis ventricular_ dysfunction fetal_ gene_programm
P-642	-0.2423 -0.0381 -0.2672 -1.0830 -0.5721 -0.0270 -0.1209 -0.0586 -0.3894 -0.0154 -0.5988 -1.2381 -0.4026 -0.2682 -0.1496 -0.0502 -0.0062 -0.0948 -0.1783 -0.0023 -0.0773 -1.0396 -0.0044 -0.8193 -0.0016 -0.0959 -0.0055 -0.7941 -0.4133 -0.4220 -0.1372 -0.0216 -0.1204 -0.0403 -0.1743 -1.7012 -0.7351 -0.9291 -0.7151 -0.1615
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission nt-probnp patients acute_hf diagnosis
H-264	-0.6312858462333679	▁cut off _ waarde ▁ad mission ▁NT - pro b NP ▁ED ▁a cute _ HF ▁ diagnos is
D-264	-0.6312858462333679	cutoff_waarde admission NT-probNP ED acute_HF diagnosis
P-264	-0.6047 -0.0644 -0.8305 -0.9727 -0.3680 -0.3216 -0.1359 -0.0572 -0.0128 -0.5036 -0.1465 -3.7164 -0.8392 -0.0170 -0.0392 -1.3589 -2.5664 -0.2054 -0.0708 -0.2665 -0.1590
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical rule patients cad angiography patients systolic_hf cost
H-1193	-0.7252011895179749	▁clinic al _ ▁predict ion ▁rule ▁CAD ▁ang i ography ▁sy sto lic _ HF ▁kosten
D-1193	-0.7252011895179749	clinical_ prediction rule CAD angiography systolic_HF kosten
P-1193	-3.9068 -0.0264 -0.8594 -1.0871 -0.0326 -0.9251 -0.3267 -1.6651 -0.0798 -0.1428 -0.0383 -0.0250 -0.0684 -0.1036 -0.5399 -1.2139 -1.8753 -0.1374
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic cardiac cardiac gene signal_transduction pathological gene_expression hf
H-1053	-0.42138010263442993	▁epi gene tic _ ▁readers ▁cardiac _ ▁bi ology ▁cardiac _ ▁gene _ control ▁chr omat in - dependent _ signal ▁trans duction ▁path ological _ ▁gene _ expression ▁ HF ▁progression
D-1053	-0.42138010263442993	epigenetic_ readers cardiac_ biology cardiac_ gene_control chromatin-dependent_signal transduction pathological_ gene_expression HF progression
P-1053	-0.1649 -0.0377 -0.3699 -0.2161 -0.0618 -0.0957 -0.3024 -2.7122 -0.1750 -0.6519 -0.2137 -0.8042 -1.1160 -0.0348 -0.0337 -0.0314 -0.3610 -0.1153 -0.0271 -0.0336 -0.6333 -0.9511 -0.7036 -0.0552 -0.4186 -0.0975 -0.8476 -1.1581 -0.3222 -0.2684 -0.0976 -0.6560 -0.4333 -0.1262
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic_blood_pressure elevated left_ventricular hypertrophy
H-277	-0.6701168417930603	▁sy sto lic _ ▁blood _ ▁pressure ▁left _ ▁vent ri cular LV _ ▁hyper trop hy ▁AT ▁AN ▁AS ▁ ANS _ mi ce
D-277	-0.6701168417930603	systolic_ blood_ pressure left_ ventricularLV_ hypertrophy AT AN AS ANS_mice
P-277	-0.8387 -0.0495 -0.1194 -0.0711 -1.3245 -1.5383 -0.5752 -0.4003 -0.3693 -1.4875 -1.0217 -0.4227 -1.1938 -2.1220 -0.5489 -0.0209 -1.0847 -1.1908 -0.6110 -0.2352 -1.6106 -0.0852 -0.2118 -0.2375 -0.4340 -0.1705 -0.1181
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up patients combined_end_point death heart_failure death cardiac_transplant
H-1747	-0.6834641695022583	▁follow - up ▁heart ▁failure ▁sud den _ ▁death ▁non card iac ▁cardiac _ ▁transplant
D-1747	-0.6834641695022583	follow-up heart failure sudden_ death noncardiac cardiac_ transplant
P-1747	-2.9941 -0.1376 -0.0151 -4.2728 -1.0524 -0.1824 -0.0109 -0.1506 -0.5298 -0.0200 -0.0930 -0.0339 -0.0578 -0.8510 -0.6188 -0.4064 -0.1924
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous revascularization angioplasty stenting clinical patients randomized clinical
H-1601	-0.7083753943443298	▁per cuta ne ous _ re vas cular ization ▁ang io plast y ▁sten ting
D-1601	-0.7083753943443298	percutaneous_revascularization angioplasty stenting
P-1601	-2.7837 -0.0092 -0.2823 -2.8243 -0.1926 -0.1433 -0.1616 -0.4558 -0.8117 -1.5588 -0.9259 -0.0638 -0.3003 -0.1619 -0.2493 -1.0174 -0.1005
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic_response heart_rate exercise baseline follow-up tests heart_rate exercise
H-1176	-1.1118769645690918	▁load - corre cted _ ▁chr ono tropi c _ ▁response ▁heart _ ▁rate ▁exercise ▁follow - up _ ▁tests ▁heart ▁rate
D-1176	-1.1118769645690918	load-corrected_ chronotropic_ response heart_ rate exercise follow-up_ tests heart rate
P-1176	-2.6862 -0.1952 -0.0164 -0.3288 -0.8208 -1.1677 -0.0602 -0.2333 -0.0839 -0.9693 -1.2586 -3.9273 -1.5772 -1.2917 -2.7209 -1.1353 -0.0584 -0.0207 -0.7684 -0.5223 -2.5081 -2.8562 -1.3312 -0.1469
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak_oxygen_consumption vo2max resting_hr bpm p_value
H-1943	-0.7868139743804932	▁Peak _ ▁oxygen _ ▁consum p tion VO 2 max ▁rest ing _ HR ▁bp m ▁m L
D-1943	-0.7868139743804932	Peak_ oxygen_ consumptionVO2max resting_HR bpm mL
P-1943	-0.0789 -0.2240 -1.5858 -0.7412 -0.9600 -0.1556 -0.3711 -1.2631 -0.0789 -0.0508 -2.1844 -0.1390 -0.6742 -1.6518 -0.6525 -0.0606 -0.2710 -1.6802 -2.7743 -0.1387
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional_hazard_models negative_binomial_regression_models health
H-1624	-0.6452126502990723	▁co x - propor tional _ ▁hazard ▁models ▁negative _ bi nom ial _ re gression ▁models
D-1624	-0.6452126502990723	cox-proportional_ hazard models negative_binomial_regression models
P-1624	-0.2189 -0.0497 -0.0157 -0.0519 -0.0156 -0.0655 -1.2000 -1.8795 -0.0211 -0.1440 -3.6532 -1.3919 -0.0847 -0.0648 -0.3851 -0.0046 -0.6591 -2.2423 -0.1113
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients hf t2d erc vo2max maximum_oxygen_consumption skm biopsies
H-1251	-0.47298380732536316	▁ HF ▁t 2 d ▁consum ed ▁ ERC ▁tre ad m ill _ ▁testing VO 2 max ▁oxygen _ ▁consum p tion ▁Sk m ▁bio psi es
D-1251	-0.47298380732536316	HF t2d consumed ERC treadmill_ testingVO2max oxygen_ consumption Skm biopsies
P-1251	-1.1103 -0.1924 -1.0614 -0.0183 -0.3320 -1.5387 -0.3015 -0.1519 -0.0362 -0.0278 -0.0008 -0.2347 -0.1486 -2.2744 -0.3533 -1.1652 -0.0411 -0.0183 -2.3260 -1.1832 -0.2009 -0.1366 -0.2468 -0.2695 -0.1689 -0.0982 -0.1790 -0.0619 -0.2373 -0.0742
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient hospital gastrointestinal_bleeding patient ventricular_tachycardia terminal_heart_failure
H-1961	-0.476742684841156	▁gastro inte stin al _ ▁ble ed ing ▁ince ssant _ ▁vent ri cular _ ta chy car dia ▁storm ▁terminal _ heart _ ▁failure
D-1961	-0.476742684841156	gastrointestinal_ bleeding incessant_ ventricular_tachycardia storm terminal_heart_ failure
P-1961	-1.1882 -0.2350 -1.2173 -0.1093 -0.7075 -0.2517 -0.3146 -0.0719 -0.4294 -0.0085 -0.9481 -0.5967 -0.4701 -0.2158 -0.2470 -1.7337 -0.1081 -0.0168 -0.0234 -0.0806 -0.2512 -0.0615 -1.8396 -1.3789 -0.0680 -0.1755 -0.1235
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic β-ar catecholamine infusions pde2 expression camp activity correlated cardiac β-ar_responsiveness
H-1214	-0.5133742094039917	▁Chro nic _ ▁β - AR ▁cate chol amine ▁in fusion s ▁rat s ▁p de 2 ▁c AMP ▁hydro ly tic _ activ iteit ▁blu n ted _ ▁cardiac ▁β - AR _ ▁responsive ness
D-1214	-0.5133742094039917	Chronic_ β-AR catecholamine infusions rats pde2 cAMP hydrolytic_activiteit blunted_ cardiac β-AR_ responsiveness
P-1214	-3.5919 -0.2351 -0.4542 -0.2577 -0.0476 -0.8448 -0.4508 -0.0318 -0.0968 -0.3206 -0.0054 -0.2091 -0.7285 -0.1523 -0.2006 -1.9902 -0.0826 -0.4587 -0.0112 -0.2298 -0.7182 -1.3654 -0.6272 -0.4631 -0.6711 -0.0066 -0.2852 -0.3328 -0.1054 -0.0270 -0.4888 -0.0314 -0.4948 -1.3790 -0.4544 -1.0802 -0.3755 -0.2022
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild_hf qrs_prolongation lvef crt reverse_remodeling clinical systolic_dysfunction
H-758	-0.5017943978309631	▁ HF ▁QR s ▁prolong ation ▁LV EF ▁c RT ▁rever se _ ▁remodel ing ▁LV _ ▁sy sto lic _ ▁dys function
D-758	-0.5017943978309631	HF QRs prolongation LVEF cRT reverse_ remodeling LV_ systolic_ dysfunction
P-758	-0.4695 -0.2303 -0.2210 -0.6574 -0.3413 -0.0669 -0.3399 -0.2025 -1.3895 -2.7626 -0.3663 -0.0202 -0.0454 -0.1459 -0.0177 -1.7424 -2.3997 -0.3505 -0.0305 -0.0658 -0.1073 -0.1231 -0.0566 -0.2874 -0.1053
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic_pah clinical hospitalized patients acute rv_decompensation pharmacologic therapies rv_failure pah
H-1096	-0.6192925572395325	▁chronic _ p AH ▁ RV ▁de com pensa tion ▁ pharma c ologic _ therapie s ▁ RV ▁failure _ management ▁p AH
D-1096	-0.6192925572395325	chronic_pAH RV decompensation pharmacologic_therapies RV failure_management pAH
P-1096	-0.0273 -0.2079 -2.5240 -0.0443 -1.1184 -1.9058 -1.3420 -0.3707 -0.1951 -0.1590 -0.0900 -1.4445 -0.0215 -0.0782 -1.3462 -0.2750 -0.0260 -0.6168 -0.4283 -0.8298 -0.8170 -0.5404 -1.2000 -0.0313 -0.3151 -0.1471
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up patients
H-268	-1.364330768585205	
D-268	-1.364330768585205	
P-268	-2.5119 -0.2168
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians patients patient clinician medication patient
H-1129	-0.9098351001739502	▁co management ▁medication
D-1129	-0.9098351001739502	comanagement medication
P-1129	-0.5161 -0.0157 -3.2887 -0.5496 -0.1790
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty gill_index hf
H-628	-0.7964057922363281	▁non - fra il _ ▁participants ▁moderat e HR ▁severe _ fra il ty HR ▁Gill ▁index ▁ HF
D-628	-0.7964057922363281	non-frail_ participants moderateHR severe_frailtyHR Gill index HF
P-628	-1.2526 -0.0300 -0.0086 -0.0963 -3.1462 -0.4377 -2.8527 -0.0091 -2.6984 -0.5674 -0.2802 -0.5465 -0.0447 -0.2208 -1.8759 -0.6577 -0.3074 -1.1900 -0.1178 -0.2182 -0.1665
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty health_abc_short_physical_performance_battery habc_battery gill_index hf
H-625	-0.43985211849212646	▁fra il ty ▁health ▁ABC _ short _ ▁Physic al _ ▁Performance _ ▁Bat tery ▁h ABC _ bat tery ▁Gill ▁index ▁ HF
D-625	-0.43985211849212646	frailty health ABC_short_ Physical_ Performance_ Battery hABC_battery Gill index HF
P-625	-1.2220 -0.2288 -0.1607 -1.4170 -0.9346 -0.3816 -0.2296 -0.0069 -0.2941 -0.0650 -0.0706 -0.0494 -0.1848 -0.6822 -0.0054 -0.4615 -1.2103 -0.1328 -1.2452 -0.0130 -0.1191 -0.3181 -1.5975 -0.1490 -0.1608 -0.0958
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients rv_support lvad patients cardiogenic_shock myocardial_infarction chronic_decompensated_heart_failure
H-295	-0.6649873852729797	▁ RV _ support ▁l VAD _ insertion ▁cardio ge nic _ ▁shock ▁my o card ial _ in far ction ▁chronic _ de com pensa ted _ heart ▁failure
D-295	-0.6649873852729797	RV_support lVAD_insertion cardiogenic_ shock myocardial_infarction chronic_decompensated_heart failure
P-295	-1.4863 -0.7680 -2.8971 -1.1409 -1.4541 -0.0326 -1.6592 -0.0047 -0.1128 -0.0507 -1.8463 -0.1056 -0.4970 -1.0645 -0.3177 -0.6421 -1.0383 -0.1995 -0.2211 -0.1197 -0.0616 -0.5736 -0.7465 -0.6692 -0.2526 -0.1352 -0.3087 -0.0657 -1.0679 -1.1129 -0.4166 -0.2108
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic_heart_failure chf multisystem_disease comorbidities anemia insulin_resistance autonomic_dysbalance cardiac_cachexia
H-1357	-0.6764940619468689	▁Chro nic _ heart _ ▁failure CH f ▁multi system _ ▁disease ▁an emia ▁insulin ▁resist ance ▁autonomi c _ ▁dys balance ▁cardiac ▁cache xia
D-1357	-0.6764940619468689	Chronic_heart_ failureCHf multisystem_ disease anemia insulin resistance autonomic_ dysbalance cardiac cachexia
P-1357	-1.7147 -1.2358 -0.0346 -1.8898 -0.6726 -0.0712 -2.3719 -1.3557 -3.7778 -0.3517 -0.2895 -1.1797 -0.1316 -0.0111 -0.0060 -0.3946 -0.0133 -0.0016 -0.3983 -0.1782 -0.1267 -0.1008 -0.0034 -1.4868 -0.0423 -0.2896 -0.1359
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine_oxidase xo left_ventricular myocytes volume_overload vo mitral_regurgitation aortocaval_fistula acf
H-470	-0.3870930075645447	▁Xan thi ne _ ▁oxid ase XO ▁rat ▁left _ ▁vent ri cular LV ▁my o cy tes ▁volume ▁over load VO ▁mit ral ▁re gur gi tation ▁a orto ca val _ fi stu la ▁ac f
D-470	-0.3870930075645447	Xanthine_ oxidaseXO rat left_ ventricularLV myocytes volume overloadVO mitral regurgitation aortocaval_fistula acf
P-470	-0.0024 -0.0384 -0.3265 -0.2891 -0.5905 -0.5628 -0.6947 -1.5392 -0.1397 -0.1315 -1.2814 -0.5492 -0.2078 -1.3057 -0.6167 -0.0369 -0.0227 -0.0205 -0.1195 -0.3694 -0.0489 -1.8289 -0.2631 -0.0793 -1.0764 -0.0734 -0.0178 -0.0439 -0.0118 -0.0052 -0.0111 -0.0316 -0.1344 -0.4287 -0.0149 -0.2272 -1.1696 -0.9235 -0.1304 -0.1191
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese zsf1 heart_failure_with_preserved_ejection_fraction lung preserved_left_ventricular_ejection_fraction left_ventricular_dd
H-767	-0.6895695328712463	▁obes e ▁z SF 1 ▁groups ▁heart _ ▁failure ▁pres er ved _ e je ction _ fraction ▁lung _ ▁weight ▁pres er ved _ ▁left _ ▁vent ri cular _ e je ction _ fraction ▁left _ ▁vent ri cular ▁ DD
D-767	-0.6895695328712463	obese zSF1 groups heart_ failure preserved_ejection_fraction lung_ weight preserved_ left_ ventricular_ejection_fraction left_ ventricular DD
P-767	-1.1125 -0.0204 -0.5103 -0.2134 -1.6301 -4.0445 -2.1393 -1.3047 -0.0837 -1.8389 -0.0429 -0.2744 -0.1673 -0.4003 -0.1964 -0.1155 -0.1310 -0.0511 -0.5145 -0.6566 -0.7621 -0.6587 -0.0249 -0.2985 -1.0475 -0.6108 -0.1897 -1.4912 -1.2889 -0.4082 -0.3527 -0.4419 -0.2813 -0.2201 -0.2435 -0.0847 -0.1589 -0.1865 -1.6463 -1.3329 -0.3843 -2.7870 -0.2950 -0.2403 -0.1467
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients physicians mortality physicians hospitals
H-1727	-0.575716495513916	▁high - volu me _ ▁physician s ▁mortal ity ▁low - volu me _ ▁physician s ▁low - volu me _ hospital s
D-1727	-0.575716495513916	high-volume_ physicians mortality low-volume_ physicians low-volume_hospitals
P-1727	-3.3832 -0.0776 -0.5985 -0.1571 -0.2593 -0.5872 -0.0882 -1.2910 -1.6864 -0.3592 -0.0911 -0.5882 -0.0875 -0.1635 -1.3697 -0.0858 -0.9686 -0.1201 -1.2585 -0.1204 -0.2194 -0.3010 -0.2094 -0.1759 -0.1461
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western administrative health patients hf hospitalized ami
H-1307	-0.933641791343689	▁Western _ ▁Australian _ link ed _ administra tieve _ gesundheit ▁ HF ▁index ▁ AMI
D-1307	-0.933641791343689	Western_ Australian_linked_administratieve_gesundheit HF index AMI
P-1307	-0.2191 -0.2409 -1.9140 -1.1288 -0.2128 -0.1079 -0.0346 -0.2746 -2.8041 -0.1159 -3.4334 -1.5152 -2.0434 -0.0718 -1.9257 -0.2785 -0.3492 -0.1354
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report connection patients disease healthcare conditions turkey
H-1825	-2.4681270122528076	▁ europe se
D-1825	-2.4681270122528076	europese
P-1825	-5.4582 -3.1170 -0.0074 -3.6178 -0.1402
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome prospective hospitalized hf nursing outcomes
H-1403	-1.3231669664382935	▁nur sing - sensitiv e _ ▁outcome _ ▁measure s ▁science ▁ HF
D-1403	-1.3231669664382935	nursing-sensitive_ outcome_ measures science HF
P-1403	-4.6362 -0.0089 -0.0745 -0.0010 -0.0289 -0.9115 -2.2612 -2.0660 -1.3106 -0.0297 -0.9136 -3.9994 -1.6464 -1.8286 -0.1310
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence hf ami adjusted_odds_ratio
H-1310	-0.8784257769584656	▁ HF ▁ AMI ▁adjust ed _ ▁odds ▁ratio ▁ci
D-1310	-0.8784257769584656	HF AMI adjusted_ odds ratio ci
P-1310	-1.2905 -0.6347 -1.8363 -0.4898 -0.8026 -0.2057 -0.2524 -0.3021 -1.0885 -2.1288 -1.3761 -0.1337
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas rnas expression genes messenger_rna repression
H-1482	-0.3266020715236664	▁mi RNA s ▁non co ding _ RNA s ▁ binding ▁messenger _ RNA ▁degrada tion ▁translation al _ re pression
D-1482	-0.3266020715236664	miRNAs noncoding_RNAs binding messenger_RNA degradation translational_repression
P-1482	-0.7908 -0.0411 -0.1192 -0.2810 -0.0117 -0.1741 -0.1410 -0.0661 -0.0468 -1.8115 -0.8451 -0.3754 -0.5389 -0.6241 -0.5717 -0.1340 -0.2573 -0.1070 -0.1387 -0.1191 -0.0241 -0.2026 -0.0907
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse myocardial_t1 heart_failure
H-1055	-0.5378495454788208	▁free - bre a thing _ ▁puls e _ se quen nce ▁my o card ial _ t 1 ▁s win e _ model ▁ta chy car dia - indu ced _ heart _ ▁failure
D-1055	-0.5378495454788208	free-breathing_ pulse_sequennce myocardial_t1 swine_model tachycardia-induced_heart_ failure
P-1055	-0.6099 -0.1215 -0.0263 -0.0444 -1.0881 -0.0838 -1.3814 -0.0905 -1.1927 -0.7215 -0.6023 -3.3180 -0.5201 -0.1353 -0.2038 -0.1102 -0.1351 -1.3043 -0.3840 -1.2554 -0.0225 -0.0157 -1.5629 -0.6517 -1.1520 -0.0635 -0.0120 -0.0114 -0.0789 -0.0009 -0.3142 -0.0439 -1.0086 -1.2747 -0.0220 -0.1924 -0.1443
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients hfpef ivabradine placebo double-blind
H-1173	-0.4816308617591858	▁ HF p EF ▁i va bra dine
D-1173	-0.4816308617591858	HFpEF ivabradine
P-1173	-0.6522 -0.5666 -0.1438 -0.7247 -0.0164 -0.0406 -0.0637 -0.1627 -2.3430 -0.1025
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic new_york_heart_association_classes saf
H-229	-0.954831600189209	▁ PF _ co hor t New _ York _ ▁Heart _ association SAF ▁ PF
D-229	-0.954831600189209	PF_cohortNew_York_ Heart_associationSAF PF
P-229	-1.6961 -0.6979 -4.0137 -0.9724 -0.1844 -0.0546 -1.4227 -0.6840 -0.8356 -0.1077 -1.1156 -0.3928 -0.7960 -0.5777 -2.7555 -0.4655 -0.3234 -0.0913
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective_cohort eds diagnosis heart_failure
H-463	-1.7907978296279907	▁ diagnos is ▁heart _ ▁failure ▁ED
D-463	-1.7907978296279907	diagnosis heart_ failure ED
P-463	-4.3843 -3.8924 -0.3128 -3.0045 -1.1918 -0.2749 -1.6800 -1.1893 -0.1872
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac cells cardiac cells cardiac_functions myocardial_infarction
H-1335	-0.6554787755012512	▁Card iac ▁c - K it _ cell s ▁cardiac _ ex plant - der i ved _ ▁Cell s ▁cardiac _ ▁function s ▁my o card ial _ in far ction
D-1335	-0.6554787755012512	Cardiac c-Kit_cells cardiac_explant-derived_ Cells cardiac_ functions myocardial_infarction
P-1335	-1.9356 -0.0691 -0.1714 -0.0396 -1.4611 -0.0118 -0.7199 -4.2784 -0.1050 -0.7597 -0.7975 -1.1247 -0.0034 -0.0768 -0.2097 -0.2411 -0.1172 -0.5583 -2.0889 -0.0424 -0.3948 -0.5833 -1.3465 -0.2256 -1.9687 -0.2318 -0.4130 -1.2822 -0.1445 -0.2206 -0.1226 -0.1266 -0.2649 -0.1496
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses pathophysiology hf nursing medical symptoms pathophysiologic
H-2022	-1.0064375400543213	▁pat ho phy si ology ▁ HF ▁medical _ management ▁pat ho phy si ologic
D-2022	-1.0064375400543213	pathophysiology HF medical_management pathophysiologic
P-2022	-2.9963 -0.2620 -0.4881 -2.2192 -0.2620 -1.0008 -0.1691 -1.2062 -1.2174 -0.2454 -2.1305 -0.1620 -0.6167 -2.1240 -0.0905 -1.8048 -0.1144
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 bets chromatin downstream_signalling rna polymerase_ii pol_ii
H-1043	-0.5324232578277588	▁inhibi tor ▁j q 1 ▁ BET s ▁chr omat in ▁down stream _ signal ling ▁ RNA _ ▁poly mera se _ ▁II Pol _ ▁II
D-1043	-0.5324232578277588	inhibitor jq1 BETs chromatin downstream_signalling RNA_ polymerase_ IIPol_ II
P-1043	-0.6873 -0.0086 -0.4265 -1.0451 -0.5702 -0.7874 -0.6958 -0.8021 -0.0969 -0.0477 -0.4246 -1.3880 -0.0155 -1.6043 -0.4987 -0.3102 -0.3360 -0.0260 -0.8687 -0.9260 -0.0768 -0.0346 -0.4046 -0.3086 -1.1398 -0.8800 -0.7856 -0.1689 -0.0759
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps adverse_outcomes patients heart_failure pulmonary_embolism diabetes chemotherapy
H-1022	-0.6232762932777405	NP s ▁pulmonar y _ e mbol ism ▁diabetes ▁che mo therapy
D-1022	-0.6232762932777405	NPs pulmonary_embolism diabetes chemotherapy
P-1022	-0.9186 -0.1449 -4.7442 -0.0996 -0.6000 -0.8449 -0.0205 -0.6570 -0.0523 -0.0653 -0.1123 -0.0268 -0.3172 -0.1224
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome heart_failure hf acute_myocardial_infarction ami pneumonia pna
H-1691	-0.5766668319702148	▁em pir ically _ ▁deri ved _ com posit e _ quality _ ▁measure ▁heart ▁failure HF ▁a cute _ My o card ial _ in far ction AMI ▁pneu monia ▁p na
D-1691	-0.5766668319702148	empirically_ derived_composite_quality_ measure heart failureHF acute_Myocardial_infarctionAMI pneumonia pna
P-1691	-3.3262 -0.0197 -0.2564 -0.6749 -0.3594 -0.1763 -1.6301 -0.4423 -0.0112 -0.0083 -0.0469 -1.8563 -0.2012 -0.9072 -0.6942 -0.4159 -0.7461 -0.0566 -0.0106 -0.0204 -3.7110 -0.7708 -0.4213 -0.6875 -0.0470 -0.2715 -0.1007 -0.0815 -0.2638 -0.0213 -0.2381 -0.1918 -1.0135 -0.3292 -0.1742
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal_dysfunction intestinal lead chronic inflammatory catabolic anabolic cardiac_cachexia terminal chf prognosis
H-1360	-0.3275931179523468	▁intestinal _ ▁dys function ▁disturb ed _ ▁intestinal _ ▁barrier ▁chronic _ ▁infla mma tory _ ▁state ▁cata bo lic _ ana bo lic _ im balance ▁cardiac _ ▁cache xia ▁CHF
D-1360	-0.3275931179523468	intestinal_ dysfunction disturbed_ intestinal_ barrier chronic_ inflammatory_ state catabolic_anabolic_imbalance cardiac_ cachexia CHF
P-1360	-0.1761 -0.9072 -0.9830 -0.0330 -0.5286 -0.0515 -0.0896 -0.2916 -0.1408 -0.9792 -0.5237 -0.1696 -0.3925 -0.1663 -0.0884 -0.2397 -0.6117 -0.0453 -0.0075 -0.0604 -1.4372 -0.6156 -0.0165 -0.0451 -0.1800 -0.9269 -0.0092 -0.0023 -0.7189 -0.1130 -0.0087 -0.1753 -0.2773 -0.1265
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic heart_failure_with_preserved_ejection_fraction hfpef patients health symptoms quality_of_life
H-780	-0.6182871460914612	▁heart ▁failure ▁pres er ved _ e je ction _ fraction HF p EF
D-780	-0.6182871460914612	heart failure preserved_ejection_fractionHFpEF
P-780	-2.6484 -1.1037 -0.6880 -0.0811 -0.5897 -0.0589 -0.2946 -0.1297 -0.0743 -0.1029 -0.1311 -1.4795 -0.0426 -0.7022 -1.6545 -0.1114
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic_adenosine_monophosphate camp cyclic_guanosine_monophosphate cgmp hearts
H-1209	-0.5994288325309753	▁di minis hed _ cycli c _ ad enos ines _ ▁mono phos pha te ▁c AMP ▁aug mente d _ cycli c _ ▁gua no sine _ ▁mono phos pha te ▁c g m ▁fail ing _ heart s
D-1209	-0.5994288325309753	diminished_cyclic_adenosines_ monophosphate cAMP augmented_cyclic_ guanosine_ monophosphate cgm failing_hearts
P-1209	-2.7734 -0.2819 -0.3545 -0.2138 -0.3994 -0.1999 -1.0827 -0.4330 -0.4017 -3.4273 -0.7383 -0.1484 -0.0378 -0.0280 -0.2396 -0.2875 -0.0981 -0.3663 -0.0221 -0.0100 -0.2915 -0.5106 -0.2424 -0.7131 -0.7749 -0.0266 -1.3191 -0.4269 -0.0446 -0.0470 -0.0174 -0.1993 -0.1129 -1.9153 -0.7176 -2.6417 -0.1002 -0.1294 -2.5189 -0.2046 -0.4683 -0.2099
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality healthcare telehealth congestive_heart_failure chronic_obstructive_pulmonary_disease diabetes_mellitus
H-1618	-0.7252545952796936	▁mortal ity ▁health care ▁utiliza tion _ effect s ▁combinatie d _ care ▁management ▁tele health ▁con ges tive _ heart ▁failure ▁chronic _ ob struct ive _ ▁pulmonar y ▁disease ▁diabetes ▁mell itus
D-1618	-0.7252545952796936	mortality healthcare utilization_effects combinatied_care management telehealth congestive_heart failure chronic_obstructive_ pulmonary disease diabetes mellitus
P-1618	-0.7565 -1.2963 -0.5957 -0.0994 -1.5133 -0.1100 -4.3672 -0.1626 -1.8003 -4.2194 -0.5679 -0.6805 -0.9062 -0.5740 -0.7013 -0.2935 -0.0704 -0.0875 -1.4772 -0.0402 -1.9732 -0.4274 -0.0047 -0.3999 -0.4957 -0.1183 -0.0404 -0.0562 -0.2141 -0.1862 -1.4491 -0.0217 -0.0243 -0.0224 -0.2115 -0.1446
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter_ablation atrial_fibrillation patients heart_failure_with_preserved_ejection_fraction hfpef
H-942	-0.5072197318077087	▁cat heter ▁ab lation ▁at rial _ fi bril lation AF ▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁h bf ef
D-942	-0.5072197318077087	catheter ablation atrial_fibrillationAF heart failure preserved_ejection_fraction hbfef
P-942	-1.2190 -0.4424 -1.0958 -0.1725 -2.4433 -0.1820 -0.2210 -0.4674 -0.0601 -0.0330 -0.7655 -0.4752 -0.2565 -0.2047 -0.0963 -0.4344 -0.0644 -0.4293 -0.1548 -0.1133 -0.1149 -0.0475 -0.7158 -1.6652 -1.4827 -0.1955 -0.1425
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report patient diagnosis ischemic-hypertensive_cardiomyiopathy angina myocardial_ischemia coronary_arteries
H-998	-0.4864128530025482	▁ ische mic - hy per tensi ve _ ▁cardio my io pathy ▁ang ina ▁induc ible _ my o card ial _ ische mia ▁corona ry _ ▁arteri es
D-998	-0.4864128530025482	ischemic-hypertensive_ cardiomyiopathy angina inducible_myocardial_ischemia coronary_ arteries
P-998	-0.4689 -0.1603 -0.2027 -0.1352 -0.2210 -0.0317 -0.2877 -0.0522 -0.1109 -0.3199 -1.1492 -1.9700 -0.0490 -0.8150 -0.4013 -0.0217 -0.3845 -0.1200 -4.0689 -0.3166 -0.5273 -0.6439 -0.3050 -0.1285 -0.4851 -0.1811 -1.0265 -0.4176 -0.0156 -0.0793 -0.3707 -0.0978
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra methotrexate tnf_antagonist non-biological_disease_modifying_antirheumatic_drug nbdmard
H-604	-0.5850964188575745	▁RA ▁met ho tre xa te ▁t NF _ ▁anta gon ist ▁non - bi ological _ ▁disease ▁anti r heu matic _ drug ▁n b DM ARD
D-604	-0.5850964188575745	RA methotrexate tNF_ antagonist non-biological_ disease antirheumatic_drug nbDMARD
P-604	-0.5535 -0.3986 -0.0756 -0.0137 -0.7576 -0.0264 -1.3164 -0.3730 -3.4549 -0.0113 -0.0025 -0.1773 -0.1323 -0.0393 -2.2249 -0.1608 -0.3076 -0.1694 -0.0924 -1.8337 -0.5729 -0.3361 -0.7562 -0.5128 -1.1856 -0.0107 -0.2928 -1.3373 -0.2443 -0.1830
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate_cox_proportional_hazards_regression_modeling hospitalization acute_coronary_syndromes coronary_interventions patients
H-104	-0.4628852903842926	▁co x _ ▁proportion al _ ▁hazard s _ re gression _ model ing ▁i e ▁a cute _ ▁corona ry _ ▁syndrome s ▁corona ry _ intervention s
D-104	-0.4628852903842926	cox_ proportional_ hazards_regression_modeling ie acute_ coronary_ syndromes coronary_interventions
P-104	-0.0651 -0.0624 -0.9443 -0.4460 -0.0470 -0.0598 -0.7696 -0.2099 -0.5175 -0.4321 -0.0030 -1.3596 -1.0664 -0.0451 -1.2482 -1.3997 -0.4683 -0.0031 -0.0349 -0.4318 -1.5049 -0.3348 -0.0322 -0.0139 -0.0129 -1.5763 -0.4157 -0.2479 -0.0472 -0.3582 -0.1916
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate_receptor_1 s1pr1 β1-adrenergic_receptor β1ar g-protein-coupled_receptors heart
H-1405	-0.5043719410896301	▁sp hing os ines -1 - phos pha te _ ▁receptor ▁s 1 PR ▁β 1- ad r energi c _ ▁receptor β 1 AR ▁g - prote in - co up led _ ▁receptor s ▁heart
D-1405	-0.5043719410896301	sphingosines-1-phosphate_ receptor s1PR β1-adrenergic_ receptorβ1AR g-protein-coupled_ receptors heart
P-1405	-0.0103 -1.5020 -0.5853 -4.1163 -1.7173 -0.1790 -0.0184 -0.0208 -0.1825 -1.0175 -0.0286 -0.2167 -0.6607 -0.4362 -1.0579 -0.1837 -0.1738 -0.5083 -1.2746 -0.1211 -0.3192 -0.1601 -0.2847 -0.9890 -1.0914 -0.8556 -0.0804 -0.0197 -0.1191 -0.0893 -0.0108 -0.0242 -0.2822 -0.2119 -0.2849 -0.0772 -0.3391 -0.2856 -0.1353
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal correlated pcwp p_values
H-484	-1.148936152458191	▁e - sept al ▁pc WP ▁e / e _ lateral ▁e / e _ me an
D-484	-1.148936152458191	e-septal pcWP e/e_lateral e/e_mean
P-484	-0.2395 -6.0335 -0.0739 -0.0688 -0.2150 -1.6302 -0.2230 -1.7154 -0.0169 -4.3336 -0.0126 -0.1876 -2.0026 -0.0250 -3.7486 -0.0842 -0.1981 -0.8292 -0.1921
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy atrial_fibrillation patients carvedilol metoprolol
H-864	-0.5561798810958862	▁in appropria te _ therapy ▁at rial _ fi bril lation ▁car vedi lol ▁met o pro lol
D-864	-0.5561798810958862	inappropriate_therapy atrial_fibrillation carvedilol metoprolol
P-864	-3.9000 -0.0751 -0.0439 -0.5059 -0.0413 -1.7184 -0.1714 -0.2917 -0.5262 -0.1111 -0.2058 -0.0797 -0.0105 -0.0779 -0.3366 -0.9337 -0.0425 -0.2188 -1.7024 -0.1305
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls lvef prognostic clinical echocardiographic systolic
H-820	-0.68323814868927	▁g LS ▁LV EF ▁sa ▁CV _ ▁events ▁e cho car dio graphic _ sy sto lic ▁AF
D-820	-0.68323814868927	gLS LVEF sa CV_ events echocardiographic_systolic AF
P-820	-0.1960 -1.0103 -0.0944 -0.3951 -0.3035 -0.7356 -4.0081 -0.8984 -0.8860 -0.0364 -0.0254 -0.2896 -0.2687 -0.2552 -0.9027 -0.0648 -0.0954 -2.8826 -0.2032 -0.1133
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia intravenous metoprolol cardiac sympathetic_tone
H-1379	-0.3831903338432312	▁Brad y car dia ▁intra ven ous _ met o pro lol ▁cardiac _ ▁sympa the tic _ ▁tone ▁CHF - in v ▁rabbi ts ▁sham - in v ▁CHF - DN x
D-1379	-0.3831903338432312	Bradycardia intravenous_metoprolol cardiac_ sympathetic_ tone CHF-inv rabbits sham-inv CHF-DNx
P-1379	-0.0386 -0.0902 -0.0100 -0.0203 -1.1200 -0.0118 -3.6428 -0.5935 -0.0193 -0.3828 -0.0523 -0.2050 -0.0118 -0.4028 -0.8305 -0.1550 -0.6335 -0.1501 -0.2051 -0.4557 -0.0320 -0.2115 -0.3443 -0.0142 -0.0940 -0.0075 -0.0667 -0.4185 -0.2496 -0.4348 -0.0603 -1.8800 -0.1590 -0.2887 -0.1196
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes patients prescribed pharmacological discharge left_ventricular_function
H-1849	-0.824631929397583	▁c PG - re com mend ed _ pharma c ological _ ▁treatment ▁device _ ▁consideration ▁left _ ▁vent ri cular _ function _ ▁assessment
D-1849	-0.824631929397583	cPG-recommended_pharmacological_ treatment device_ consideration left_ ventricular_function_ assessment
P-1849	-5.1037 -0.3215 -0.3326 -0.0049 -0.0608 -0.0117 -0.0543 -0.4357 -0.5371 -0.0224 -0.5049 -1.0052 -1.5766 -0.8112 -3.0404 -0.2999 -0.7186 -0.3986 -1.2300 -1.0010 -0.6247 -0.1590 -1.0126 -2.0897 -0.3119 -0.3957 -0.2003
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized walking cardiac_rehabilitation functional_capacity outcomes patients severe_heart_failure
H-569	-1.1887593269348145	▁Nordic _ ▁walking ▁standard _ ▁cardiac ▁rehabilita tion _ care ▁functional _ capaci te it ▁severe _ heart _ ▁failure
D-569	-1.1887593269348145	Nordic_ walking standard_ cardiac rehabilitation_care functional_capaciteit severe_heart_ failure
P-569	-2.0489 -0.2723 -2.2041 -1.3157 -0.0841 -0.1732 -1.2347 -0.1696 -2.2172 -1.9403 -0.5048 -1.4137 -1.0012 -0.8094 -1.9613 -4.9071 -0.0949 -1.2271 -2.0288 -0.1044 -0.3054 -0.1346
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad q66p rad cav1.2 cav1.3 l-type_channel isoforms heart
H-1674	-0.4461853802204132	▁Rad ▁Q 66 p ▁inhibi tory _ ▁actions ▁Rad ▁ca v 1.2 ▁ca v 1.3 ▁l - type _ ▁channel ▁iso form s ▁heart
D-1674	-0.4461853802204132	Rad Q66p inhibitory_ actions Rad cav1.2 cav1.3 l-type_ channel isoforms heart
P-1674	-0.6831 -1.2707 -0.4397 -0.2390 -0.4201 -0.0461 -0.3708 -1.2363 -0.6622 -0.3014 -0.7708 -0.2686 -0.7999 -0.7284 -0.2426 -0.3817 -0.0294 -0.0016 -0.0397 -1.3867 -0.1593 -0.0957 -0.0945 -0.5512 -0.2357 -0.1459
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef lcx lad stenting infarcted left_ventricle lcx lad
H-512	-0.7885972261428833	▁EF ▁ LC x ▁ LAD ▁in far cted _ ▁left _ ▁vent ric le ▁ LC x ▁ LAD
D-512	-0.7885972261428833	EF LCx LAD infarcted_ left_ ventricle LCx LAD
P-512	-0.0998 -2.4999 -0.1401 -0.7871 -1.3466 -1.6362 -2.1529 -0.0358 -0.6611 -0.4698 -0.3089 -0.1181 -0.8420 -1.1717 -0.1253 -1.7914 -0.2499 -1.0523 -0.8676 -0.4337 -0.4426 -0.1162
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas expression bhlh transcription_factor hand2 myocardium gene heart_failure
H-644	-0.37979263067245483	▁signal ling ▁casca des ▁micro RNA s ▁b HL h ▁tran scription _ ▁factor ▁hand 2 ▁post na tal _ ▁mamma lian _ ▁my o car dium ▁em bry o nic _ ▁gene ▁programs ▁heart ▁failure
D-644	-0.37979263067245483	signalling cascades microRNAs bHLh transcription_ factor hand2 postnatal_ mammalian_ myocardium embryonic_ gene programs heart failure
P-644	-0.6265 -0.1976 -0.2817 -0.0105 -0.0153 -0.0249 -0.0665 -0.0343 -0.0871 -0.1231 -0.8511 -0.0537 -0.9934 -0.7447 -1.0903 -1.1110 -0.0071 -0.1681 -0.0169 -0.8662 -0.0136 -0.1992 -0.4339 -2.1641 -0.0850 -0.0244 -0.1171 -0.4711 -0.0133 -0.1849 -0.8451 -0.1487 -0.3741 -0.5841 -0.1538 -0.8920 -0.2439 -0.1141
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc dapc_protein sarcomeric_microstructure skm myofibre_regeneration
H-1254	-0.6107656955718994	▁ ERC ▁DAP c _ ▁protein ▁levels ▁sar come ric _ ▁micro structure ▁marker s ▁Sk m ▁growth ▁my o fi bre _ ▁regenera tion
D-1254	-0.6107656955718994	ERC DAPc_ protein levels sarcomeric_ microstructure markers Skm growth myofibre_ regeneration
P-1254	-1.1311 -0.0138 -1.1873 -0.4751 -1.5119 -0.6518 -2.6137 -0.0075 -0.1792 -0.2448 -0.1641 -0.9420 -0.0388 -0.5653 -0.0223 -0.4687 -0.2905 -2.1952 -2.1274 -0.0701 -0.0067 -0.0215 -0.9191 -0.1405 -0.2009 -0.2004 -0.1011
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva surgical implantation leaflet leaflet edge-to-edge_anastomosis
H-360	-0.5340060591697693	▁m va ▁sur g ical _ ▁ring _ ▁implant ation ▁le a flet _ ▁motion ▁le a flet _ ▁res ection ▁edge - to - ed ge _ an asto mos is
D-360	-0.5340060591697693	mva surgical_ ring_ implantation leaflet_ motion leaflet_ resection edge-to-edge_anastomosis
P-360	-0.1041 -2.2631 -3.5099 -0.1124 -0.3420 -0.2762 -1.0224 -2.4604 -0.1124 -0.0631 -0.0433 -0.0660 -0.0120 -0.8761 -0.2138 -0.0865 -0.0391 -0.0479 -0.3605 -3.4540 -0.0135 -0.0698 -0.0145 -0.0227 -0.0898 -0.0304 -0.0496 -0.2173 -1.4502 -0.0024 -0.3488 -0.0783 -0.1835 -0.1203
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart patients new_york_heart_association nyha hospitalized hf primary_outcome death hf hospitalization
H-239	-0.5927225351333618	▁h ART ▁New _ York _ heart _ association NY ha ▁ HF ▁self - management _ ▁counsel ing ▁death ▁ HF
D-239	-0.5927225351333618	hART New_York_heart_associationNYha HF self-management_ counseling death HF
P-239	-1.2370 -0.3064 -1.5402 -0.8338 -0.6786 -0.1079 -1.3129 -0.2038 -0.7337 -0.6258 -1.1322 -1.6034 -0.4789 -0.4805 -0.0441 -0.0044 -0.6389 -0.0535 -0.0180 -0.7294 -0.2057 -0.1923 -0.9323 -0.1317
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet bromodomain_proteins bets acetyl-lysine_reader_proteins hf pathogenesis hf
H-1038	-0.40356868505477905	▁ BET ▁bro modo main _ ▁protein s BET s ▁a ce tyl - ly sine _ ▁reader _ ▁protein s ▁ HF
D-1038	-0.40356868505477905	BET bromodomain_ proteinsBETs acetyl-lysine_ reader_ proteins HF
P-1038	-0.5548 -0.1594 -0.6112 -0.0175 -0.0749 -0.1520 -0.8682 -0.0886 -1.2244 -0.2800 -0.1509 -0.1330 -0.0439 -0.0305 -1.3244 -0.9011 -0.0400 -0.1350 -0.4135 -0.3602 -0.0281 -0.2022 -0.2063 -1.9642 -0.1248
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in_vivo cardiac_function echocardiography diastolic_dysfunction systolic_dysfunction ejection_fraction
H-1783	-0.4732694923877716	▁cardiac _ function ▁e cho card i ography ▁dia sto lic _ ▁dys function ▁e je ction _ fraction
D-1783	-0.4732694923877716	cardiac_function echocardiography diastolic_ dysfunction ejection_fraction
P-1783	-1.9431 -0.2667 -1.1899 -0.0313 -0.0646 -0.1265 -0.2403 -0.3255 -0.0135 -0.0167 -0.1558 -0.4900 -0.1516 -0.0217 -0.2981 -3.7490 -0.2211 -0.2556 -0.0125 -0.2558 -0.1095
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone_antagonism heart_failure aldosterone neurohormone electrolytes heart_failure patients systolic_dysfunction
H-1733	-0.4176081418991089	▁al do ster one _ ▁anta gon ism ▁heart ▁failure ▁al do ster one ▁neuro hormon e ▁electro ly tes ▁heart ▁failure ▁sy sto lic _ ▁dys function
D-1733	-0.4176081418991089	aldosterone_ antagonism heart failure aldosterone neurohormone electrolytes heart failure systolic_ dysfunction
P-1733	-0.6056 -0.1338 -0.0697 -0.1782 -2.3712 -0.1879 -0.0102 -0.5419 -2.4152 -0.9523 -1.0111 -0.0310 -0.0347 -0.1558 -0.0651 -0.0353 -0.0485 -0.0042 -0.2869 -0.0475 -1.9463 -0.4018 -0.0317 -0.0225 -0.0955 -0.3332 -0.0617 -0.0432 -0.2776 -0.1286
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv_compliance lv_end-diastolic_volume lv_end-diastolic_pressure β_coefficient
H-1531	-1.3292055130004883	▁EH ▁LV _ ▁compliance ▁CH LV ▁end - dia sto lic _ ▁volume ▁LV _ ▁end - dia sto lic _ ▁pressure ▁β _ co e ffi cient
D-1531	-1.3292055130004883	EH LV_ compliance CHLV end-diastolic_ volume LV_ end-diastolic_ pressure β_coefficient
P-1531	-0.4697 -3.4264 -2.9365 -0.9553 -5.5436 -2.1348 -5.0450 -0.0986 -0.0701 -0.0701 -0.1143 -0.2477 -0.1097 -3.9690 -1.1275 -3.8659 -0.1881 -0.0938 -0.0692 -0.1004 -0.1373 -1.9805 -3.4521 -0.4404 -1.0629 -0.1970 -0.0628 -0.0804 -1.6686 -0.1586
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade clinical
H-202	-0.4714518189430237	▁Grad ing _ of _ re com mend ations ▁evaluat ing GRAD e ▁practical _ re com mend ations ▁clinic al
D-202	-0.4714518189430237	Grading_of_recommendations evaluatingGRADe practical_recommendations clinical
P-202	-1.0483 -0.1093 -0.2062 -0.8229 -0.1233 -0.0684 -0.0469 -0.0593 -0.0056 -1.7306 -1.2075 -0.7966 -0.0652 -1.1048 -0.8648 -0.1514 -0.0331 -0.1423 -0.0058 -0.6135 -0.0392 -1.5094 -0.0889
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf hospitalization
H-563	-0.87890625	▁ HF
D-563	-0.87890625	HF
P-563	-1.1315 -0.7161 -1.4800 -0.1880
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right_heart_circulatory_failure disease right_heart
H-1460	-0.993575930595398	▁right _ heart ▁circula tory _ ▁failure ▁mechanism s _ of _ ▁disease ▁right _ heart
D-1460	-0.993575930595398	right_heart circulatory_ failure mechanisms_of_ disease right_heart
P-1460	-6.5808 -0.2692 -1.8803 -0.0786 -0.0702 -0.1955 -0.0590 -1.7134 -0.0900 -1.7880 -1.1877 -0.2216 -1.0862 -0.4641 -0.1482 -1.6789 -0.2192 -0.1535
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular_action_potentials excitation-contraction myocardium
H-1671	-0.5724127888679504	▁l - type ▁volta ge - ga ted _ ca (2 +) _ ▁channel s ▁vent ri cular _ action _ ▁potential s ▁excita tion - con traction ▁e c ▁coup ling ▁my o car dium
D-1671	-0.5724127888679504	l-type voltage-gated_ca(2+)_ channels ventricular_action_ potentials excitation-contraction ec coupling myocardium
P-1671	-2.1665 -0.0288 -0.0011 -0.2792 -0.1209 -0.0538 -0.0170 -0.0446 -2.2882 -0.2535 -1.8078 -0.0040 -0.7822 -1.4898 -0.0590 -0.0852 -1.3104 -0.8403 -0.3346 -0.5074 -2.2941 -0.7533 -0.1144 -0.0557 -0.1856 -0.0651 -0.0643 -0.1231 -1.0569 -1.3090 -1.2650 -0.2919 -0.9150 -0.0541 -0.0081 -0.2719 -0.2639 -0.1858
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1_receptors neprilysin renin-angiotensin-aldosteron ras vasodilatory diuretic natriuretic_peptides
H-1967	-0.4184725284576416	▁AT 1 ▁receptor s ▁nepri ly sin ▁block s ▁re nin - angi oten sin - al do ster on RAS ▁vaso dila tory ▁di ure tic _ effect ▁na tri ure tic _ pe pti des
D-1967	-0.4184725284576416	AT1 receptors neprilysin blocks renin-angiotensin-aldosteronRAS vasodilatory diuretic_effect natriuretic_peptides
P-1967	-1.9213 -0.4120 -0.6313 -0.1442 -0.0231 -0.1592 -1.3167 -0.8150 -0.0884 -0.0467 -0.1115 -0.0267 -0.0068 -0.0278 -1.7303 -0.1265 -0.0122 -0.5440 -0.0282 -0.2813 -0.6869 -0.8738 -0.0105 -0.0836 -0.2258 -0.1976 -1.1570 -1.5990 -0.0855 -0.0040 -0.0083 -0.1823 -1.1285 -0.3691 -0.4025 -0.1151 -0.3557 -0.2232 -0.1586
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine exercise_capacity left_ventricular_filling patients heart_failure_with_preserved_ejection_fraction hfpef
H-1171	-0.39236870408058167	▁i va bra dine ▁exercise ▁capacity ▁left _ ▁vent ri cular _ ▁fill ing ▁heart ▁failure ▁pres er ved _ e je ction _ fraction HF p EF
D-1171	-0.39236870408058167	ivabradine exercise capacity left_ ventricular_ filling heart failure preserved_ejection_fractionHFpEF
P-1171	-0.0170 -0.0267 -0.0307 -0.1446 -1.4036 -2.1641 -0.0141 -0.5667 -0.5795 -0.7929 -0.3917 -0.5301 -0.5546 -0.0183 -0.7853 -0.2552 -0.0466 -0.0539 -0.2582 -0.0884 -0.4042 -0.1179 -0.0721 -0.1067 -0.0282 -1.1286 -0.0763 -0.8092 -0.1762 -0.1295
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood_transfusions erythropoiesis-stimulating_agents anemia congestive_heart_failure coronary_heart_disease transfusion
H-42	-0.4633331298828125	▁blood ▁trans fusion s ▁ir on ▁er y thro po ies is - stimul ating _ agent ▁an emia ▁con ges tive _ ▁heart ▁failure ▁corona ry _ heart _ ▁disease ▁trans fusion
D-42	-0.4633331298828125	blood transfusions iron erythropoiesis-stimulating_agent anemia congestive_ heart failure coronary_heart_ disease transfusion
P-42	-3.4408 -0.1115 -0.0134 -0.1951 -0.0167 -0.0694 -0.0631 -0.2918 -0.4395 -0.2807 -0.7044 -0.1780 -0.1978 -0.0266 -0.1059 -0.8750 -0.2148 -0.8079 -0.0084 -0.0324 -0.1264 -1.5154 -0.0477 -1.7334 -0.3133 -0.0024 -1.1616 -0.0422 -1.6205 -0.8351 -0.3798 -0.0482 -0.0296 -0.1609 -0.1269
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate_analysis bnp estimated_glomerular_filtration_rate hypertension transmitral e-wave diastolic_mitral_annular_velocity
H-1570	-0.4788006842136383	▁b NP ▁glo mer ular _ filter ation _ ▁rate ▁hyper tension ▁transmit ral _ e - wa ve ear ly _ dia sto lic _ met ral _ ▁ann ular _ ▁veloci ty
D-1570	-0.4788006842136383	bNP glomerular_filteration_ rate hypertension transmitral_e-waveearly_diastolic_metral_ annular_ velocity
P-1570	-0.7783 -1.4846 -0.3004 -0.0986 -0.0255 -0.3829 -1.3218 -0.2367 -1.6983 -0.2146 -0.0415 -0.0039 -0.0183 -0.1144 -0.7461 -0.4446 -0.0757 -0.0380 -0.0266 -1.8576 -0.0245 -0.5292 -0.8543 -0.0292 -0.0295 -0.0460 -0.2721 -0.2373 -0.0486 -3.8305 -0.0033 -0.1171 -0.1681 -0.0312 -0.9437 -0.1637
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade halt disease protein_kinase pka β-adrenergic_receptor
H-1425	-0.3537124693393707	▁β - block ade ▁c AMP - dependent _ ▁protein ▁kina se ▁p ka ▁β - ad r energi c _ ▁receptor ▁activa tion
D-1425	-0.3537124693393707	β-blockade cAMP-dependent_ protein kinase pka β-adrenergic_ receptor activation
P-1425	-0.3679 -0.0753 -0.7924 -0.2184 -1.1254 -0.0850 -0.0561 -0.0188 -0.1033 -0.7511 -0.2146 -0.0919 -0.3038 -0.5564 -1.4279 -0.0268 -0.0358 -0.4909 -0.8504 -0.0590 -0.1294 -0.3564 -0.4556 -0.1423 -0.3261 -0.1357
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence erythropoiesis-stimulating_agent therapy venous_thromboembolism
H-47	-0.654129683971405	▁er y thro po ies is - stimul ating _ agent _ therapy
D-47	-0.654129683971405	erythropoiesis-stimulating_agent_therapy
P-47	-0.7875 -0.1955 -0.6642 -0.4311 -1.1545 -0.2159 -0.1147 -0.0386 -0.1690 -0.6185 -0.1938 -0.4515 -0.0584 -4.6328 -0.0860
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical genetic chf area_under_the_curve auc genetic auc clinical auc
H-1456	-0.807062029838562	▁ clin ical ▁genetic ▁CHF _ ▁predict ive _ model ▁cur ve AU c ▁genetic AU c ▁clinic al AU c
D-1456	-0.807062029838562	clinical genetic CHF_ predictive_model curveAUc geneticAUc clinicalAUc
P-1456	-4.0605 -0.0897 -0.3528 -1.8490 -0.7354 -1.4389 -0.9001 -0.0315 -0.4192 -0.8992 -1.6096 -0.0379 -0.6559 -1.5214 -0.0566 -0.2726 -1.3967 -0.0785 -0.0720 -0.2375 -1.5181 -0.2433 -0.0863
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable_adjustment mortality hospitalization hazard_ratio cardiovascular_mortality hf hospitalization
H-1638	-0.9181147217750549	▁black _ race ▁mortal ity ▁hospital ization haz ard _ ▁ratio ▁h ▁cardiovascular _ ▁mortal ity HF
D-1638	-0.9181147217750549	black_race mortality hospitalizationhazard_ ratio h cardiovascular_ mortalityHF
P-1638	-0.0119 -0.2633 -0.7390 -2.5522 -1.3155 -2.3229 -0.7575 -0.0088 -0.0188 -0.4086 -0.0522 -3.3023 -0.0982 -0.5269 -0.1806 -1.2007 -0.7166 -2.7285 -0.2396
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous chronic_myocardial_ischemia stent polytetrafluoroethylene
H-504	-0.5256790518760681	▁per cuta ne ous _ ▁one - ves sel _ model ▁chronic _ My o card ial _ ische mia ▁sten t ▁poly te tra flu oro e thy lene _ ▁tube ▁bottle ne ck
D-504	-0.5256790518760681	percutaneous_ one-vessel_model chronic_Myocardial_ischemia stent polytetrafluoroethylene_ tube bottleneck
P-504	-2.0939 -0.0039 -0.0910 -0.4649 -0.6410 -0.6271 -0.0225 -2.7117 -0.0061 -0.1963 -0.3668 -1.0708 -0.0773 -4.1916 -0.5161 -0.6646 -0.4473 -0.0794 -0.3559 -0.7943 -0.0348 -0.0305 -0.4706 -0.0161 -1.1655 -0.0068 -0.0222 -0.1189 -0.0487 -0.1521 -0.2414 -0.7023 -0.0843 -0.0356 -0.0180 -0.7792 -0.1008
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers_for_medicare_and_medicaid_services cms hospital outcomes reported mortality readmission penalties
H-1031	-0.6495259404182434	▁Center s _ for _ ▁Medica re _ en _ ▁Medica id _ ▁Services ▁c ms
D-1031	-0.6495259404182434	Centers_for_ Medicare_en_ Medicaid_ Services cms
P-1031	-0.2338 -0.0544 -0.0772 -1.3576 -0.2526 -0.0339 -0.0059 -0.6270 -2.2746 -0.6425 -0.0508 -0.0592 -0.5300 -0.2905 -0.2014 -0.5053 -4.3463 -0.1486
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart_failure hf tumor_necrosis_factor tnf tnf_antagonists disease severe_hf
H-601	-0.7176461815834045	▁heart ▁failure HF ▁tumor ▁nec rosi s _ ▁factor TN F ▁t NF _ ▁anta gon ists ▁ HF
D-601	-0.7176461815834045	heart failureHF tumor necrosis_ factorTNF tNF_ antagonists HF
P-601	-0.4879 -0.7964 -0.5416 -0.0643 -1.0422 -0.0060 -0.0835 -0.7571 -1.3522 -0.7510 -1.3349 -1.7917 -0.0718 -1.6417 -0.1237 -0.0119 -0.1956 -3.0047 -0.5482 -0.3582 -0.1058
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate signal_transduction transcription_factors pathological cardiomyocytes transcription_factors epigenetic chromatin_structure
H-1040	-0.4886888563632965	▁signal ▁trans duction _ ▁casca de ▁tran scription ▁factors ▁cardio my o cy tes ▁tran scription ▁factors ▁epi gene tic ▁chr omat in _ ▁structure
D-1040	-0.4886888563632965	signal transduction_ cascade transcription factors cardiomyocytes transcription factors epigenetic chromatin_ structure
P-1040	-0.4592 -0.4687 -1.5702 -1.1253 -0.1609 -0.0460 -0.9586 -0.0808 -1.1775 -0.1965 -0.7457 -0.4013 -0.0944 -0.0446 -0.5704 -0.0698 -0.5144 -0.0658 -0.1192 -0.7987 -1.1813 -0.0536 -0.3735 -0.6093 -0.7692 -0.3790 -0.1608
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox_proportional_hazard_models covariates follow-up physician discharge primary_outcome death all-cause_readmission
H-1416	-0.49701541662216187	▁co x ▁proportion al _ ▁hazard _ ▁models ▁follow - up ▁physician ▁dis charge ▁death
D-1416	-0.49701541662216187	cox proportional_ hazard_ models follow-up physician discharge death
P-1416	-0.0556 -0.0223 -0.2485 -0.0144 -0.0227 -0.3387 -1.0814 -0.9183 -0.0879 -0.0436 -0.0091 -0.8952 -0.4077 -0.0672 -0.8827 -3.2104 -0.1435
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable_logistic_analysis peak_oxygen_uptake metabolic_exercise cardiac kidney prognostic hf_index
H-1760	-0.8075992465019226	▁AT ▁pe ak _ ▁oxygen _ up take ▁metabol ic _ ▁exercise ▁cardiac ▁ki dne y ▁index _ ▁score ▁ HF ▁index
D-1760	-0.8075992465019226	AT peak_ oxygen_uptake metabolic_ exercise cardiac kidney index_ score HF index
P-1760	-3.7487 -6.7785 -0.0398 -0.0749 -0.6696 -0.7312 -0.5077 -0.0866 -0.1866 -0.0064 -0.2048 -0.1392 -0.0036 -0.4165 -0.1374 -0.0374 -0.6511 -1.5760 -0.1431 -1.1175 -0.2322 -1.5969 -0.1836 -0.1131
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular_dilatation
H-334	-0.49974361062049866	▁mechanism ▁ann ular _ ▁size ▁re duction ▁surgery ▁dia sto lic _ met ral _ ▁val ve ▁te ther ing ▁anterior _ le a flet ▁opening ▁papil lar y _ ▁muscle s ▁left _ ▁vent ri cular _ di la tation
D-334	-0.49974361062049866	mechanism annular_ size reduction surgery diastolic_metral_ valve tethering anterior_leaflet opening papillary_ muscles left_ ventricular_dilatation
P-334	-0.9036 -0.2075 -0.0015 -0.1535 -0.5539 -0.5281 -0.0172 -0.9318 -0.0016 -0.0193 -0.0777 -0.0547 -1.1021 -0.2936 -0.1103 -2.5653 -0.1732 -0.5633 -0.3800 -0.0437 -0.3470 -0.8195 -1.4255 -0.1645 -0.0062 -0.2047 -3.8294 -0.4906 -0.2696 -0.3997 -0.2156 -0.0375 -0.1958 -0.6852 -0.6238 -0.7879 -0.2168 -0.4728 -0.9870 -0.1506 -0.0317 -0.3013 -0.1445
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients hypertensive_hfpef dash ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling
H-926	-0.4307858347892761	▁hyper tensi ve _ h FP EF ▁so dium - re strict ed _ ▁DAS h ▁die t ▁vent ri cular _ ▁dia sto lic _ ▁function ▁arterial ▁elastan ce ▁vent ri cular - arte rial _ ▁coup ling
D-926	-0.4307858347892761	hypertensive_hFPEF sodium-restricted_ DASh diet ventricular_ diastolic_ function arterial elastance ventricular-arterial_ coupling
P-926	-0.8933 -0.1931 -0.0264 -1.2385 -0.2197 -1.5018 -0.8739 -0.0057 -0.0323 -0.0078 -0.0049 -0.0243 -0.0262 -1.2719 -0.3323 -0.2829 -2.8824 -0.0525 -0.0088 -0.8826 -0.1805 -0.3833 -0.6406 -0.0247 -0.0606 -0.6182 -0.5676 -0.0071 -0.8413 -0.0925 -0.0065 -0.9206 -0.3028 -0.1566 -0.1526 -0.0868 -0.2792 -0.5726 -0.5266 -0.3536 -0.1264
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf hct polymorphisms genes anthracycline metabolism iron_homeostasis anti-oxidant_defence myocardial_remodelling
H-1450	-0.3615777790546417	▁CHF ▁h CT ▁poly morph ism s ▁an thra cycli ne _ ▁metabolism ▁ir on _ ▁home osta sis ▁anti - oxid ant _ de fen ce ▁my o card ial _ ▁remodel ling
D-1450	-0.3615777790546417	CHF hCT polymorphisms anthracycline_ metabolism iron_ homeostasis anti-oxidant_defence myocardial_ remodelling
P-1450	-0.3074 -1.4845 -1.4781 -0.6948 -0.0045 -0.3261 -0.0604 -0.0698 -0.0111 -0.1128 -1.5321 -1.2886 -0.0343 -0.0141 -0.0333 -0.2021 -0.9891 -0.0445 -0.0850 -0.0005 -0.0119 -0.0040 -0.0462 -0.1797 -0.9330 -0.0484 -0.3080 -0.3417 -0.0968 -0.6878 -0.5081 -0.5253 -0.0142 -0.1310 -0.3136 -0.0939
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate_logistic_regression_analysis rule cad stenosis 3-vessel_cad 2-vessel_cad left_anterior_descending_artery
H-1187	-0.8242205381393433	▁significant _ re gression _ analyse ▁severe _ ▁CAD ▁diameter _ ▁sten osis ▁left _ main ▁3- ves sel _ ▁CAD ▁proxima l _ ▁left _ ▁anterior _ ▁descend ing _ ▁arter y
D-1187	-0.8242205381393433	significant_regression_analyse severe_ CAD diameter_ stenosis left_main 3-vessel_ CAD proximal_ left_ anterior_ descending_ artery
P-1187	-5.3547 -0.5955 -0.4123 -0.0078 -2.0044 -0.1281 -1.1717 -0.2064 -1.2851 -0.0601 -0.2668 -0.8224 -0.0145 -2.3453 -0.2982 -0.6389 -5.4854 -0.1139 -0.0035 -0.6133 -0.3522 -2.6493 -0.0184 -0.1215 -1.1523 -0.1665 -1.0398 -0.1511 -0.0724 -0.0651 -0.5150 -0.1145 -0.1736 -0.2923 -0.1357
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence mortality outcomes heart_failure acute_myocardial_infarction patients acute_myocardial_infarction western_australia
H-1305	-1.164483904838562	▁heart ▁failure ▁a cute _ My o card ial _ in far ction ▁a cute _ My o card ial _ in far ction ▁Western _ Australia
D-1305	-1.164483904838562	heart failure acute_Myocardial_infarction acute_Myocardial_infarction Western_Australia
P-1305	-3.0954 -0.8194 -1.6690 -0.0500 -0.0731 -5.0844 -0.9568 -1.1932 -1.4400 -0.1169 -0.3475 -0.2007 -0.1772 -4.0280 -0.1607 -0.0719 -4.4302 -1.2342 -1.8704 -1.9099 -0.1520 -0.2439 -0.2682 -0.2966 -1.6422 -0.4800 -0.9481 -0.5911 -0.2193
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized_aldactone_evaluation_study symptomatic_chronic_advanced_heart_failure patients aldosterone_antagonist spironolactone mortality placebo
H-1735	-0.584502100944519	▁Rand om ized _ al da cto ne _ evalua tion _ ▁Study ▁symptom a tic _ ▁chronic _ heart _ ▁failure ▁al do ster one ▁anta gon ist ▁spi rono lac tone ▁mortal ity
D-1735	-0.584502100944519	Randomized_aldactone_evaluation_ Study symptomatic_ chronic_heart_ failure aldosterone antagonist spironolactone mortality
P-1735	-2.1236 -0.3137 -0.0607 -0.2735 -0.4962 -0.0949 -0.1184 -0.6557 -0.2865 -0.1738 -0.1327 -0.7739 -0.0681 -2.2569 -0.0440 -0.3851 -0.6582 -2.0176 -0.0988 -3.1325 -1.3442 -0.0370 -1.2157 -0.1143 -0.0754 -0.2454 -1.3526 -0.0027 -0.4309 -0.0021 -0.0026 -0.0223 -0.0586 -0.5656 -1.3002 -0.5810 -0.1112
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-1.1897053718566895	▁medication ▁no nadh er ence ▁salt ▁in take
D-559	-1.1897053718566895	medication nonadherence salt intake
P-559	-1.1506 -1.1089 -3.5109 -0.0509 -2.0961 -0.6427 -0.5791 -0.4774 -2.1067 -0.1737
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological diagnostic prognostic
H-1278	-0.9439343214035034	▁pat ho phy si ological
D-1278	-0.9439343214035034	pathophysiological
P-1278	-1.0874 -0.3231 -0.3121 -1.8861 -0.5083 -2.3818 -0.1086
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad surgery patients albumin hypoalbuminemia surgery
H-534	-0.7278154492378235	▁l VAD ▁album in _ ▁levels ▁hypo album in emia ▁surgery
D-534	-0.7278154492378235	lVAD albumin_ levels hypoalbuminemia surgery
P-534	-0.5997 -0.0799 -2.5780 -0.3680 -3.5710 -0.6782 -0.0421 -0.1400 -0.1841 -0.0317 -0.8983 -0.1676 -0.1230
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical hm_ii heartware patients economic hm_ii
H-310	-1.053372859954834	▁scientific _ ▁literature ▁ HM _ ▁II ▁Heart War e _ ▁patients ▁economische ▁h m _ ▁II
D-310	-1.053372859954834	scientific_ literature HM_ II HeartWare_ patients economische hm_ II
P-310	-0.8731 -2.5627 -1.0176 -1.2602 -0.0601 -1.1050 -1.2759 -0.9272 -0.0372 -0.0297 -1.8831 -0.2262 -0.7595 -1.6520 -2.2657 -1.7440 -0.9163 -1.2522 -0.1664
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate_model creatinine hazard_ratio confidence_interval mortality
H-717	-0.48915499448776245	▁creati nine haz ard _ ▁ratio ▁post - trans plant ▁mortal ity
D-717	-0.48915499448776245	creatininehazard_ ratio post-transplant mortality
P-717	-0.0813 -0.4715 -0.0309 -0.0053 -0.6348 -0.0277 -1.4579 -0.0461 -0.0841 -0.0333 -2.1351 -1.3997 -0.2481 -0.1924
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications implantation lvad_therapy transplantation btt dt medical_therapy
H-313	-0.7750459909439087	▁complica tions ▁implant ation ▁l VAD _ therapy ▁transplant ation ▁e ligi bility _ status ▁device ▁b TT ▁ DT ▁medical _ therapy
D-313	-0.7750459909439087	complications implantation lVAD_therapy transplantation eligibility_status device bTT DT medical_therapy
P-313	-0.8469 -2.0469 -2.1236 -0.1073 -0.3909 -0.0146 -1.6616 -0.0213 -0.7884 -0.0766 -2.1101 -0.0123 -0.2377 -1.8928 -0.3639 -0.8060 -0.9398 -1.4154 -1.6044 -0.3845 -0.3841 -0.7845 -0.0331 -0.2253 -0.1040
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical artery_tonometry prospectively admission patients icu clinical
H-580	-0.687674343585968	▁radi al _ ▁arter y _ ▁ton ometr y ▁p ICU
D-580	-0.687674343585968	radial_ artery_ tonometry pICU
P-580	-1.2599 -0.0741 -0.2516 -0.3878 -0.3814 -0.1392 -1.3289 -0.0253 -0.2534 -2.8406 -1.2647 -0.6124 -0.1204
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized hr_variability hr_variability clinical risk_stratification cardiac patients
H-1591	-1.3041468858718872	▁HR ▁variabil ity _ tur bul ence ▁HR ▁variabil ity _ tur bul ence ▁cardiac _ ▁patients
D-1591	-1.3041468858718872	HR variability_turbulence HR variability_turbulence cardiac_ patients
P-1591	-2.6783 -0.4565 -1.8844 -0.8622 -0.1229 -0.5665 -2.5736 -0.9658 -0.3874 -2.3024 -1.1557 -0.9285 -0.4943 -2.9925 -3.5079 -1.5775 -0.8312 -0.2855 -0.2057
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine nesiritide renal_function patients acute_heart_failure renal_dysfunction
H-72	-0.5716392993927002	▁dop amine ▁nesi riti de ▁renal _ function ▁a cute _ heart ▁failure ▁renal _ ▁dys function
D-72	-0.5716392993927002	dopamine nesiritide renal_function acute_heart failure renal_ dysfunction
P-72	-2.3552 -0.0909 -1.0627 -0.0110 -0.2463 -0.2040 -0.8704 -0.9605 -0.2719 -0.0140 -0.0370 -1.6833 -0.9171 -0.0103 -0.7716 -0.6202 -0.0637 -0.5159 -0.1551
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death patients estimated_glomerular_filtration_rate odds_ratio confidence_interval
H-977	-0.8659507036209106	▁glo mer ular _ filter ation _ ▁rate odd s _ ▁ratio ▁confidence _ ▁interval
D-977	-0.8659507036209106	glomerular_filteration_ rateodds_ ratio confidence_ interval
P-977	-3.7515 -0.2660 -0.0824 -0.1707 -0.8670 -0.7932 -2.8000 -0.1844 -1.2408 -0.0041 -0.6416 -0.1037 -1.4463 -1.2682 -0.0760 -0.7978 -0.2273
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast_cancer patients medicare diagnosed breast_cancer chemotherapy seer-medicare texas medicare
H-672	-0.5651281476020813	▁breast _ cancer ▁patients ▁full _ ▁Medica re ▁coverage ▁stage _ ▁I - III _ ▁breast ▁cancer ▁che mo therapy ▁s EER - Medic are ▁Texas _ cancer ▁Registr y _ Medic are ▁database s
D-672	-0.5651281476020813	breast_cancer patients full_ Medicare coverage stage_ I-III_ breast cancer chemotherapy sEER-Medicare Texas_cancer Registry_Medicare databases
P-672	-1.1696 -1.5602 -0.8279 -1.0781 -0.1081 -0.9358 -0.0269 -0.0042 -1.1953 -1.4353 -0.1880 -1.4515 -0.0277 -0.0469 -0.4530 -0.2316 -1.6217 -0.0700 -0.1264 -0.0384 -0.5304 -0.0560 -0.0170 -0.2330 -0.3445 -0.1108 -0.5454 -0.5103 -1.4361 -0.0147 -0.7754 -1.5630 -0.4550 -1.2804 -0.0508 -0.2737 -0.1164
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome_complex scaffold_protein drives kinases phosphorylation effector_molecules
H-995	-0.4111517667770386	▁e RK 1/2 ▁signal ling ▁signal o some _ ▁complex ▁sc af fold _ ▁protein ▁kina ses ▁sequenti al _ phos phor y lation ▁effect or _ ▁mole cules
D-995	-0.4111517667770386	eRK1/2 signalling signalosome_ complex scaffold_ protein kinases sequential_phosphorylation effector_ molecules
P-995	-0.6431 -0.0644 -0.2427 -0.7871 -0.3298 -0.8914 -0.9576 -0.7532 -0.8745 -0.2015 -0.2875 -0.3624 -0.1387 -0.1002 -0.3460 -0.0147 -1.0445 -0.0840 -0.0886 -0.3391 -0.1853 -0.3346 -1.0464 -0.0369 -0.8329 -0.0964 -1.1287 -0.2117 -0.0289 -0.1875 -0.1055
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully_magnetically_levitated_centrifugal-flow_chronic_lvas adverse_event quality_of_life functional_status
H-2006	-0.5582702159881592	▁magnet ically _ le vita ted ▁centri fu gal - flow _ ▁chronic _ ▁l VAS
D-2006	-0.5582702159881592	magnetically_levitated centrifugal-flow_ chronic_ lVAS
P-2006	-1.4470 -0.3082 -0.4848 -0.4990 -0.0209 -0.0657 -1.2768 -0.2590 -0.1458 -0.1578 -0.0705 -0.4984 -0.9569 -0.2464 -2.7254 -0.1536 -0.6210 -0.1116
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased cardiomyocytes pde2 activity cgmp_synthesis nitric_oxide donors pde2_inhibition β-ar_responsiveness
H-1215	-0.5959104895591736	▁disease d _ ▁cardio my o cy tes ▁p de 2 ▁activity ▁c g MP ▁ni tric _ ▁oxid e ▁donor s ▁p de 2 ▁inhibi tion ▁β - AR _ ▁responsive ness
D-1215	-0.5959104895591736	diseased_ cardiomyocytes pde2 activity cgMP nitric_ oxide donors pde2 inhibition β-AR_ responsiveness
P-1215	-1.6140 -0.1797 -0.3576 -0.3499 -1.1264 -0.3850 -0.1269 -0.0475 -1.1499 -1.0808 -0.0952 -2.0908 -0.0195 -1.8244 -1.6967 -0.0580 -0.0553 -1.0442 -0.5519 -0.0455 -0.7884 -0.0574 -0.3757 -0.9150 -0.1717 -0.5565 -0.1042 -0.0426 -0.0145 -0.5277 -1.7166 -0.0941 -1.1214 -0.3304 -0.1415
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection_fraction b-type_natriuretic_peptide patients hospitalized heart_failure inhospital outcomes get_with_the_guideline-heart_failure_registry
H-186	-0.6395232081413269	▁e je ction _ fraction ▁na tri ure tic _ pe pti de ▁heart _ ▁failure ▁in hospital _ ▁outcome s ▁get _ met _ the _ guide line _ he art _ ▁Fail ure _ ▁Registr y
D-186	-0.6395232081413269	ejection_fraction natriuretic_peptide heart_ failure inhospital_ outcomes get_met_the_guideline_heart_ Failure_ Registry
P-186	-0.3188 -0.0445 -0.0122 -0.5317 -0.0356 -0.2752 -0.0532 -0.2677 -1.0759 -0.2597 -0.3297 -0.0137 -0.2697 -1.7912 -1.7060 -0.0546 -0.2485 -0.2945 -2.5189 -0.3272 -0.0262 -0.1832 -0.1186 -4.3257 -0.0418 -1.3872 -0.1652 -0.8264 -0.0512 -1.3756 -0.9254 -1.5332 -0.1330 -0.4252 -0.5124 -1.1646 -1.4773 -0.0910 -0.2081 -0.1810
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic_receptor sphingosine-1-phosphate_receptor_1 s1pr1 downregulation cardiac hypertrophic heart_failure s1pr1 cardiac gene therapy
H-1404	-0.5848313570022583	▁beta 1- ad r energi c _ ▁receptor ▁sp hing os ine -1 - phos pha te _ ▁receptor ▁s 1 PR ▁cardiac ▁hyper trop hic _ ▁response ▁heart ▁failure ▁s 1 PR 1 ▁cardiac _ ▁gene ▁ therapy
D-1404	-0.5848313570022583	beta1-adrenergic_ receptor sphingosine-1-phosphate_ receptor s1PR cardiac hypertrophic_ response heart failure s1PR1 cardiac_ gene therapy
P-1404	-0.4379 -0.6081 -0.1045 -0.2082 -0.3608 -0.0369 -0.8682 -0.0183 -0.0054 -0.6724 -0.1806 -3.7796 -1.1416 -0.1335 -0.0068 -0.0056 -0.1999 -0.8919 -0.0069 -0.2257 -0.8199 -1.4854 -2.2216 -1.2967 -0.0047 -0.4881 -0.6436 -0.0912 -0.7367 -0.5667 -0.3357 -0.4206 -0.6426 -2.2949 -0.0869 -0.3687 -0.5550 -0.8339 -0.0119 -0.0917 -0.0886
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs hdl phosphorylation
H-251	-0.5570741295814514	▁ec s ▁HD l ▁ phos phor y lation ▁e NOS - Ser ▁e NOS - Th r ▁PK c - β II - Ser ▁p 70 s 6 k - Ser
D-251	-0.5570741295814514	ecs HDl phosphorylation eNOS-Ser eNOS-Thr PKc-βII-Ser p70s6k-Ser
P-251	-1.7695 -1.5141 -0.7159 -1.4803 -0.0255 -0.0583 -0.0884 -0.9720 -0.1344 -0.0231 -0.0491 -0.0473 -0.6533 -0.0486 -0.0385 -0.0440 -2.3200 -0.0037 -0.3008 -0.7709 -0.0852 -0.1707 -1.9017 -0.0971 -0.1214 -0.0423 -1.0868 -0.2442 -0.8087 -2.6896 -0.0309 -0.2229 -0.2454 -0.1358
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts patients sts hh sts
H-155	-1.3159371614456177	▁r CT s ▁s ts ▁h ▁h ▁m ▁m ▁s s ▁s s ▁s ts ▁TM
D-155	-1.3159371614456177	rCTs sts h h m m ss ss sts TM
P-155	-2.6561 -0.5542 -0.3099 -0.8381 -1.3444 -0.6992 -1.7546 -2.1533 -2.7869 -0.4355 -1.8782 -0.6897 -1.7959 -1.3531 -1.7853 -2.1704 -0.3541 -0.1278
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular_myocytes sarcomere shortening
H-417	-0.6048902869224548	▁mouse ▁vent ri cular _ My o cy tes ▁sar com ere
D-417	-0.6048902869224548	mouse ventricular_Myocytes sarcomere
P-417	-0.2499 -0.1828 -0.5408 -0.2919 -0.1635 -3.1464 -0.1950 -0.0973 -0.0807 -0.5409 -0.0510 -0.0424 -2.7923 -0.0937
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative alberta discharged hospital diagnosis heart_failure
H-1415	-0.9391303658485413	▁administratie _ ▁database s ▁Albert a ▁dis charge d _ ▁ali ve _ van _ hospital ▁heart ▁failure
D-1415	-0.9391303658485413	administratie_ databases Alberta discharged_ alive_van_hospital heart failure
P-1415	-3.1671 -3.1934 -0.2568 -0.0418 -1.8121 -0.1589 -1.4898 -0.0674 -0.0364 -1.2344 -0.2141 -0.0401 -1.2420 -2.7210 -0.1688 -0.3171 -1.0876 -1.1264 -0.2851 -0.1222
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp 6-minute_walking_distance peak_o2
H-829	-1.1869605779647827	▁pas p
D-829	-1.1869605779647827	pasp
P-829	-2.2350 -0.4496 -1.9100 -0.1533
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates crt death hf hospitalization hazard_ratio lvef
H-757	-0.6191344261169434	▁c RT _ on _ ▁assign ment ▁time _ to _ ▁death ▁ HF _ hospital ization haz ard _ ▁ratio ▁LV EF
D-757	-0.6191344261169434	cRT_on_ assignment time_to_ death HF_hospitalizationhazard_ ratio LVEF
P-757	-0.2373 -2.6904 -1.6907 -0.1668 -0.1099 -0.0475 -0.0225 -1.0451 -1.7848 -0.8715 -0.5672 -0.2541 -0.2380 -0.3244 -2.6485 -0.3688 -0.6805 -0.0255 -0.0266 -0.5199 -0.0062 -0.1652 -0.6417 -0.2143 -0.1309
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart_failure histologically myocardial_collagen healthy heart_failure
H-1062	-1.0618444681167603	▁heart _ ▁failure ▁my o card ial _ ▁collage n ▁tissu e ▁control ▁heart ▁failure
D-1062	-1.0618444681167603	heart_ failure myocardial_ collagen tissue control heart failure
P-1062	-4.9574 -1.6107 -0.2362 -2.1240 -0.5638 -0.3346 -0.3256 -0.1584 -0.3355 -0.1721 -0.6542 -0.0398 -4.0773 -1.3205 -0.7987 -0.2337 -0.1090
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko cardiac irs1 irs2 proteins heart_failure cardiac_energy_metabolism_gene_expression p38α mitogen-activated_protein_kinase p38
H-656	-0.4733642339706421	▁l - d ko _ mi ce ▁cardiac _ ▁I RS 1 ▁i RS 2 _ ▁protein s ▁heart _ ▁failure ▁cardiac _ energie _ ▁metabolism ▁p 38 α ▁mit ogen - activa ted _ ▁protein ▁kina se
D-656	-0.4733642339706421	l-dko_mice cardiac_ IRS1 iRS2_ proteins heart_ failure cardiac_energie_ metabolism p38α mitogen-activated_ protein kinase
P-656	-1.0188 -0.1958 -0.7518 -0.2685 -1.1231 -0.2758 -0.1965 -0.1532 -0.9797 -1.5143 -0.0460 -1.8106 -0.7692 -0.1273 -0.1210 -2.3903 -0.3248 -0.0246 -0.2374 -1.4177 -0.0515 -0.4559 -0.2231 -0.8771 -1.4549 -0.0234 -0.0022 -0.1925 -0.1487 -0.3219 -0.0546 -0.1992 -0.0013 -0.1066 -0.0704 -0.4391 -0.1678 -0.0374 -0.2344 -0.1262
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil heart_failure hemodynamic mitochondrial_dysfunction antitumor activity
H-967	-0.31232863664627075	▁nic oran dil ▁do xor ubi cin - indu ced _ heart ▁failure ▁rat s ▁hem o dynamic _ ▁perturba tions ▁mito cho ndri al _ ▁dys function ▁ultra struct ural ▁anti tum or ▁activity
D-967	-0.31232863664627075	nicorandil doxorubicin-induced_heart failure rats hemodynamic_ perturbations mitochondrial_ dysfunction ultrastructural antitumor activity
P-967	-0.0232 -0.0180 -0.1159 -0.0426 -0.0035 -0.0061 -0.8996 -0.0736 -0.0053 -0.1918 -0.0733 -1.2804 -1.2902 -1.3503 -0.0326 -0.0502 -0.1017 -0.0012 -0.8269 -0.0176 -0.2577 -0.0076 -0.1642 -0.0640 -0.0503 -0.4583 -0.0593 -0.0106 -0.0210 -0.0156 -0.0155 -0.0330 -0.9331 -0.0661 -2.6387 -0.2508 -0.1064
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm_control_therapy diagnosis atrial sinus_rhythm rhythm_control symptoms rate_control
H-1646	-0.6241006255149841	▁ Rhythm _ control _ therapy ▁af ▁at rial _ ▁structure ▁sinus ▁ rhythm ▁de lay ed _ rhythm _ control
D-1646	-0.6241006255149841	Rhythm_control_therapy af atrial_ structure sinus rhythm delayed_rhythm_control
P-1646	-1.1028 -1.5079 -0.3416 -0.0175 -0.9422 -0.0183 -0.8604 -1.4928 -0.0462 -1.3089 -0.1408 -0.5899 -0.5282 -0.1703 -0.4082 -0.0133 -0.0159 -0.2503 -0.5425 -0.5525 -0.0385 -3.3817 -0.0838
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative_risk rr heart_failure bisphophonates rr confidence_interval hazard_ratio
H-1540	-1.0902999639511108	▁relative _ risk _ van _ heart _ ▁failure ▁bis pho phon ates ▁cru de _ RR ▁confidence _ ▁interval ▁CI ▁adjust ed _ ▁hazard _ ▁ratio HR
D-1540	-1.0902999639511108	relative_risk_van_heart_ failure bisphophonates crude_RR confidence_ interval CI adjusted_ hazard_ ratioHR
P-1540	-3.7122 -0.0962 -1.4717 -2.5701 -3.3506 -0.2245 -2.5498 -0.6412 -0.1326 -0.3306 -0.0235 -0.2426 -0.5690 -0.1598 -0.0402 -0.2398 -0.9633 -3.1575 -0.8309 -0.0435 -4.5414 -0.7465 -0.1219 -0.0978 -1.1513 -1.5558 -0.0609 -1.4635 -1.4206 -0.1999
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician heart_failure clinical_practice_guideline cpg outcomes heart_failure hf
H-1841	-0.8055025935173035	▁physician ▁ad her ence ▁guide line _ ▁recommendations ▁heart _ ▁failure ▁Clinic al _ ▁Practic e _ ▁Guide line ▁p g ▁heart ▁failure HF
D-1841	-0.8055025935173035	physician adherence guideline_ recommendations heart_ failure Clinical_ Practice_ Guideline pg heart failureHF
P-1841	-2.9016 -1.2221 -0.0710 -0.5281 -0.5107 -0.0411 -0.4411 -0.6737 -1.4152 -1.3847 -0.0507 -0.5542 -0.0439 -0.1414 -1.6439 -0.0434 -1.4054 -0.8627 -0.0475 -1.4431 -0.6538 -2.2923 -0.8981 -1.3222 -0.2442 -0.1069
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute_heart_failure renal_dysfunction dopamine nesiritide renal_function diuretic therapy
H-83	-0.4972098469734192	▁a cute _ heart ▁failure ▁renal _ ▁dys function ▁dop amine ▁nesi riti de ▁renal _ function ▁di ure tic _ therapy
D-83	-0.4972098469734192	acute_heart failure renal_ dysfunction dopamine nesiritide renal_function diuretic_therapy
P-83	-0.7724 -0.0318 -0.0340 -1.2488 -0.9038 -0.0508 -0.6309 -0.1952 -0.0315 -0.2453 -0.1020 -2.3494 -0.0283 -0.1616 -0.8080 -0.8685 -0.9138 -0.0720 -0.4184 -1.1595 -0.3954 -0.0635 -0.3261 -0.1221
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf prospective dual-energy_x-ray_absorptiometry echocardiography blood
H-1161	-0.6813972592353821	▁ HF ▁body _ ▁composition ▁s kin fold _ ▁thi ck ness ▁dual - ener gy _ x - ray _ ▁ab sor pti ometr y ▁e cho card i ography ▁blood
D-1161	-0.6813972592353821	HF body_ composition skinfold_ thickness dual-energy_x-ray_ absorptiometry echocardiography blood
P-1161	-1.4504 -0.8867 -4.5790 -2.1132 -0.2725 -1.4125 -3.0132 -0.0613 -0.2543 -1.3130 -0.0061 -0.3761 -0.0055 -0.0443 -0.0181 -0.0017 -0.0936 -2.2834 -0.2397 -0.1465 -0.0666 -0.5746 -0.5431 -0.2058 -0.1040 -0.1556 -0.0911 -0.0220 -0.1484 -0.2448 -0.2118 -0.0720 -2.0054 -0.1511
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare centers_for_medicare_and_medicaid_services clinics propensity-score
H-1621	-0.6044384837150574	▁hoog - co st _ ▁Medica re ▁fee - for - service ▁Center s _ voor _ ▁Medica re ▁Medica id _ ▁Services
D-1621	-0.6044384837150574	hoog-cost_ Medicare fee-for-service Centers_voor_ Medicare Medicaid_ Services
P-1621	-2.7623 -0.0390 -0.0464 -0.0527 -0.6820 -0.2419 -0.0168 -1.4403 -0.0215 -0.0276 -0.0796 -0.1099 -2.8021 -0.1386 -0.1147 -2.0070 -0.1094 -0.1534 -0.0080 -0.1864 -0.8766 -1.2243 -0.2622 -1.4991 -0.2093
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals patients hospitalized heart_failure hf conditions acute_myocardial_infarction pneumonia conditions
H-1032	-0.8838882446289062	▁hospital s ▁heart ▁failure HF ▁a cute _ My o card ial _ in far ction ▁pneu monia
D-1032	-0.8838882446289062	hospitals heart failureHF acute_Myocardial_infarction pneumonia
P-1032	-6.3399 -0.2446 -2.7149 -0.8575 -0.3996 -0.9979 -0.0063 -0.0624 -3.7923 -0.3308 -0.2622 -0.7471 -0.0657 -0.1758 -0.0407 -0.0708 -0.0100 -0.1009 -0.2883 -0.1702
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients heart_failure
H-1744	-1.5223820209503174	▁heart _ ▁failure
D-1744	-1.5223820209503174	heart_ failure
P-1744	-3.1493 -2.0639 -0.2907 -1.8570 -0.2510
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq new_york_heart_association_class patients hfpef hf_with_reduced_ef
H-788	-0.9217402935028076	▁k cc q ▁summary _ ▁score s ▁New _ York _ heart _ association ▁ HF p EF ▁ HF ▁EF
D-788	-0.9217402935028076	kccq summary_ scores New_York_heart_association HFpEF HF EF
P-788	-1.9583 -0.0919 -2.0868 -2.2407 -1.3759 -0.1491 -0.0190 -0.5185 -1.2164 -0.5479 -0.1646 -1.6181 -0.3478 -0.4982 -1.1371 -0.5455 -0.2948 -0.2687 -0.2130 -0.5582 -4.9255 -0.3259 -0.0980
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp red_blood_cell_transfusion hemoglobin hemoglobin hospitalized patients coronary_heart_disease
H-36	-0.9859535694122314	▁a CP ▁restrict ive _ ▁red _ ▁blood _ ▁cell _ ▁trans fusion _ strategi e tri gger _ ▁hem o glob in _ ▁thre s hold ▁hem o glob in _ ▁levels ▁corona ry _ ▁heart ▁disease
D-36	-0.9859535694122314	aCP restrictive_ red_ blood_ cell_ transfusion_strategietrigger_ hemoglobin_ threshold hemoglobin_ levels coronary_ heart disease
P-36	-1.5504 -1.5104 -0.2613 -0.0457 -0.1651 -2.2910 -0.3530 -1.8109 -0.8778 -2.3922 -0.2023 -0.8476 -0.0171 -2.8160 -0.4663 -0.4206 -1.0756 -0.0040 -0.1141 -2.6245 -1.1032 -0.9517 -1.3832 -2.2155 -0.0286 -0.0465 -0.1091 -1.7805 -0.9052 -0.7281 -0.7342 -2.3168 -0.6604 -0.2615 -1.6529 -0.0903 -2.5357 -1.5849 -0.3085 -0.1956
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted interatrial_shunt clinical haemodynamic outcomes patients heart_failure_with_reduced_ejection_fraction
H-1962	-0.6530053615570068	▁implant ed ▁left - to - right _ inter at rial _ ▁shu nt ▁ha emo dynamic ▁heart ▁failure ▁e je ction _ fraction
D-1962	-0.6530053615570068	implanted left-to-right_interatrial_ shunt haemodynamic heart failure ejection_fraction
P-1962	-5.7398 -0.0683 -1.5077 -0.0437 -0.0736 -0.1110 -0.2783 -0.2522 -0.2001 -0.4512 -0.3692 -0.2250 -2.3565 -0.2490 -0.0219 -0.0659 -0.0031 -1.1931 -0.3899 -2.0680 -0.0936 -0.1872 -0.3908 -0.0460 -0.3892 -0.2037
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise training peak_oxygen_consumption quality_of_life obese patients heart_failure_with_preserved_ejection_fraction randomized clinical
H-1973	-0.37146610021591187	▁Cal o ric _ re stri ction ▁aero bic _ ▁Exerci se ▁Training ▁Peak _ o xy gen _ ▁Consum p tion ▁Heart ▁Fail ure ▁Pres er ved _ e je ction _ fra ction
D-1973	-0.37146610021591187	Caloric_restriction aerobic_ Exercise Training Peak_oxygen_ Consumption Heart Failure Preserved_ejection_fraction
P-1973	-0.1996 -0.4229 -0.4078 -0.1314 -0.0292 -0.1246 -0.0282 -0.2550 -0.0866 -0.2083 -0.2157 -0.0686 -1.1503 -0.0276 -0.0956 -1.1710 -0.2602 -0.0433 -1.0820 -0.0214 -0.1284 -0.0508 -2.7510 -0.4158 -0.4589 -0.6854 -0.1136 -0.3675 -0.0340 -0.7116 -0.2657 -0.0255 -0.3046 -0.9645 -0.0103 -0.3155 -0.1117
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left_ventricular_assist_devices lvads chronic_end-stage_heart_failure bridge_to_transplantation btt patients destination_therapy dt
H-308	-0.5048500299453735	▁le ft _ ▁vent ri cular _ assist ▁devices ▁l VAD s ▁chronic _ ▁end - s tage _ heart _ ▁failure bridge _ ▁to _ ▁transplant ation ▁b t ▁transplant - ine ligi ble ▁patients ▁de stin ation _ therapy ▁d t
D-308	-0.5048500299453735	left_ ventricular_assist devices lVADs chronic_ end-stage_heart_ failurebridge_ to_ transplantation bt transplant-ineligible patients destination_therapy dt
P-308	-1.1950 -0.0113 -0.4368 -1.2909 -0.6210 -0.2491 -0.1052 -0.2057 -2.3356 -0.0468 -0.0360 -0.0601 -0.6082 -0.1148 -2.5244 -0.0756 -0.1448 -0.0219 -0.0327 -1.3118 -1.0266 -0.0935 -0.3420 -0.4797 -0.7828 -0.1486 -0.8647 -0.0598 -0.5719 -0.9981 -0.4460 -0.0859 -0.9271 -0.0216 -0.0646 -0.9112 -0.2753 -0.0857 -0.0312 -0.3115 -0.0499 -0.7279 -1.7432 -0.1211 -0.1206
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1_time correlated right_ventricular-pulmonary_arterial_coupling pulmonary_vascular_resistance right_ventricular_ejection_fraction
H-742	-0.6334990859031677	▁right _ ▁vent ri cular - pul mon ary _ ▁arterial _ ▁coup ling pul mon ary _ ▁vas cular _ ▁resist ance ▁right _ ▁vent ri cular _ e je ction _ fraction
D-742	-0.6334990859031677	right_ ventricular-pulmonary_ arterial_ couplingpulmonary_ vascular_ resistance right_ ventricular_ejection_fraction
P-742	-1.6168 -1.0717 -0.8342 -0.8928 -0.5858 -0.5205 -0.9740 -0.9064 -0.3917 -0.0915 -0.7794 -0.2045 -1.5096 -0.7027 -1.2537 -0.5225 -0.1413 -0.0989 -1.2834 -0.3037 -0.8802 -1.2338 -0.0220 -0.1279 -0.1982 -0.8738 -0.9399 -0.4862 -0.2871 -0.7878 -0.2965 -0.1830 -0.7867 -0.1128 -0.6787 -0.2263
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol metoprolol implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-855	-0.4108891189098358	▁car vedi lol ▁met o pro lol ▁implant able _ ▁cardio ver ter - de fi br illa tor ▁ therapy ▁MAD it - c RT ▁multi center _ automat ic _ de ib rilla tor ▁Implant ation ▁Card iac _ re syn chron ization ▁Therapy
D-855	-0.4108891189098358	carvedilol metoprolol implantable_ cardioverter-defibrillator therapy MADit-cRT multicenter_automatic_deibrillator Implantation Cardiac_resynchronization Therapy
P-855	-0.1549 -0.0053 -0.0312 -0.0754 -0.1089 -0.0099 -0.0682 -0.3303 -0.0211 -1.0353 -0.5647 -0.0493 -0.2473 -0.2847 -0.1572 -0.3952 -0.6771 -0.1518 -0.0922 -1.2843 -0.0089 -0.3931 -0.6420 -0.0157 -0.7832 -3.3062 -1.9406 -0.0156 -0.4182 -0.4683 -0.0177 -0.0792 -1.0905 -0.2514 -0.3810 -0.0504 -0.3530 -0.1187 -1.6926 -0.0991 -0.1923 -0.1768 -0.0319 -0.0009 -0.6939 -0.3207 -0.3036 -0.1326
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral glucocorticoids hf
H-610	-0.809637725353241	▁Oral _ ▁gluco cor tico ids ▁ HF
D-610	-0.809637725353241	Oral_ glucocorticoids HF
P-610	-0.9043 -1.0525 -0.2167 -0.3655 -0.8038 -0.3523 -0.5044 -0.2850 -3.4841 -0.1278
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ea tac placebo
H-523	-0.36173248291015625	▁HR ▁i va bra dine _ groep ▁Ea ▁ TAC
D-523	-0.36173248291015625	HR ivabradine_groep Ea TAC
P-523	-0.9578 -0.0187 -0.0184 -0.0272 -0.0273 -0.7816 -0.3119 -0.9345 -0.2867 -0.1900 -0.6727 -0.1139
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi death medical hospitalization hf clinic outpatients hf health
H-385	-0.8476648926734924	▁ HF PSI ▁risk _ of _ ▁death ▁medical _ hospital ization ▁ HF _ ▁clinic _ out patient s ▁ HF
D-385	-0.8476648926734924	HFPSI risk_of_ death medical_hospitalization HF_ clinic_outpatients HF
P-385	-0.4400 -0.5240 -0.3794 -5.6149 -1.7369 -0.8022 -0.2781 -0.8337 -0.8344 -0.6289 -0.2284 -0.1986 -0.2586 -0.1335 -1.4811 -0.4579 -0.1240 -0.2979 -0.0152 -0.0677 -0.4261 -0.6009 -3.8091 -0.1722
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up systemic adverse_events patients dcm heart_failure
H-1265	-0.7015051245689392	▁CH m ▁ad ju nc tive _ ▁treatment ▁d CM ▁heart ▁failure
D-1265	-0.7015051245689392	CHm adjunctive_ treatment dCM heart failure
P-1265	-3.9246 -0.2809 -1.0723 -0.0437 -0.0063 -0.3179 -1.3458 -1.2083 -0.1947 -0.1421 -0.3341 -0.5747 -0.2794 -0.0964
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol therapy metoprolol hazard_ratio confidence_interval
H-862	-0.6939437389373779	▁car vedi lol ▁in appropria te _ therapy ▁met o pro lol haz ard _ ▁ratio ▁cri
D-862	-0.6939437389373779	carvedilol inappropriate_therapy metoprololhazard_ ratio cri
P-862	-0.2165 -0.0134 -0.0720 -1.7141 -0.0918 -0.0373 -1.4088 -0.0676 -0.4480 -0.5501 -0.0600 -0.0774 -0.1044 -0.0086 -0.5331 -0.0151 -6.6173 -1.0046 -0.1447
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone_supplementation exercise_rehabilitation health outcomes patients chf testosterone
H-1325	-0.8785024285316467	▁testosteron e _ ▁supplement ation ▁exercise ▁rehabilita tion ▁CHF ▁low _ ▁testosteron e _ status
D-1325	-0.8785024285316467	testosterone_ supplementation exercise rehabilitation CHF low_ testosterone_status
P-1325	-0.7252 -0.0295 -2.1843 -0.6867 -0.1573 -2.2037 -1.4276 -0.2486 -2.0963 -1.6557 -0.4465 -0.1298 -0.0499 -1.6561 -0.7241 -0.3693 -0.1440
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change peak_vo2 correlated change lean_body_mass change thigh muscle
H-1987	-0.9431526064872742	▁VO 2 ▁lean _ ▁body _ ▁mass ▁th igh _ ▁muscle inter mus cular _ ▁fat _ ▁ratio
D-1987	-0.9431526064872742	VO2 lean_ body_ mass thigh_ muscleintermuscular_ fat_ ratio
P-1987	-2.8080 -0.0406 -0.8614 -0.1750 -2.2898 -0.9759 -0.9969 -1.8968 -1.0604 -2.1544 -0.3336 -0.4286 -0.4850 -0.2296 -0.1587 -1.3757 -1.8608 -0.0274 -0.5297 -0.1748
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals get_with_the_guidelines-heart_failure hf patients ef ef ef ef
H-189	-0.8766207695007324	▁get _ met _ the _ guide lines - he art _ ▁Fail ure ▁ HF EF ▁border line EF EF ▁pres er ved EF EF ▁EF
D-189	-0.8766207695007324	get_met_the_guidelines-heart_ Failure HFEF borderlineEFEF preservedEFEF EF
P-189	-1.4886 -0.2344 -4.1679 -0.3364 -2.0394 -0.3314 -0.5826 -0.1541 -0.1686 -1.3704 -0.6770 -0.2013 -0.6322 -0.4184 -0.4442 -0.3806 -3.9999 -1.0236 -0.0060 -0.9316 -0.8683 -1.3050 -0.0327 -0.3806 -0.5674 -0.6974 -1.6875 -0.1601 -0.1343
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate_cox_model pasp exercise peak_o2 prognostic hazard_ratio peak_o2 pasp
H-830	-1.4315061569213867	▁multi varia te _ co x _ model _ analyse ▁pas p ▁exercise ▁ha ard _ ▁ratio ▁pas p
D-830	-1.4315061569213867	multivariate_cox_model_analyse pasp exercise haard_ ratio pasp
P-830	-3.0603 -0.0192 -0.0593 -1.0430 -0.0669 -0.2288 -0.5355 -0.7167 -2.2006 -0.4313 -6.3855 -0.8639 -4.0853 -2.7842 -0.8941 -0.6342 -0.0207 -3.4182 -1.0784 -1.3728 -0.1628
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac insulin-resistance mitochondrial_oxidative_metabolism metabolic cardiac_hypertrophy hypertrophy heart_failure
H-1787	-0.4199935793876648	▁cardiac _ ▁insulin - re si stance ▁mito cho ndri al _ ▁oxid ative _ ▁metabolism ▁cardiac _ ▁hyper trop hy ▁energy ▁deficit ▁hyper trop hy ▁heart ▁failure
D-1787	-0.4199935793876648	cardiac_ insulin-resistance mitochondrial_ oxidative_ metabolism cardiac_ hypertrophy energy deficit hypertrophy heart failure
P-1787	-0.2349 -1.0145 -0.0686 -0.0455 -0.0130 -0.5445 -0.0028 -0.2100 -0.1848 -0.1190 -0.0372 -0.1693 -0.9818 -0.0537 -0.4948 -0.0663 -0.1225 -1.1096 -0.8151 -0.0200 -0.8531 -0.8386 -0.3417 -0.3509 -0.1451 -1.4004 -0.9974 -0.9869 -0.2428 -0.1351
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad rgk rem rem2 rad monomeric_g_proteins ventricular_action_potential gain cardiac l-type_channel activity
H-1672	-0.5598042011260986	▁r GK ▁re m ▁rem 2 ▁rad ▁gem _ Kir ▁mono me ric _ g _ ▁protein s ▁vent ri cular _ action ▁ec _ ▁coup ling ▁cardiac ▁l - type _ ▁channel ▁activity
D-1672	-0.5598042011260986	rGK rem rem2 rad gem_Kir monomeric_g_ proteins ventricular_action ec_ coupling cardiac l-type_ channel activity
P-1672	-1.0321 -0.8758 -1.1217 -0.0558 -0.1349 -0.0528 -0.8393 -0.5866 -2.0141 -0.2661 -0.0105 -0.0381 -0.1023 -0.0669 -0.6467 -0.3673 -0.1744 -0.0196 -0.0564 -0.9776 -0.4230 -0.7439 -0.7035 -1.9437 -1.0252 -0.4280 -0.1676 -0.8906 -1.8916 -0.0263 -0.0006 -0.0195 -1.2277 -0.8468 -0.2506 -0.1256
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination surgery diastolic_mitral_valve_tethering anterior_leaflet papillary_muscles left_ventricular dilatation
H-338	-0.5156092047691345	▁mechanism ▁ann ular _ ▁size ▁re duction ▁surgery ▁dia sto lic _ met ral _ ▁val ve ▁te ther ing ▁anterior _ le a flet ▁opening ▁papil lar y _ ▁muscle s ▁left _ ▁vent ri cular LV ▁di la tation
D-338	-0.5156092047691345	mechanism annular_ size reduction surgery diastolic_metral_ valve tethering anterior_leaflet opening papillary_ muscles left_ ventricularLV dilatation
P-338	-0.7475 -0.1801 -0.0013 -0.1584 -0.4857 -0.4415 -0.0146 -0.9416 -0.0018 -0.0166 -0.0806 -0.0514 -1.1002 -0.2998 -0.0927 -2.7347 -0.1513 -0.5808 -0.3614 -0.0439 -0.2766 -0.8566 -1.3882 -0.1388 -0.0058 -0.2635 -3.8286 -0.4020 -0.2170 -0.3288 -0.2527 -0.0376 -0.1182 -0.3225 -0.8759 -0.5955 -0.0909 -0.4977 -2.7000 -0.0982 -0.0516 -0.2057 -0.1328
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology heart_failure_with_preserved_ejection_fraction hfpef myocardial_extracellular_matrix
H-734	-0.5483648180961609	▁pat ho phy si ology ▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁h bf f ▁my o card ial _ extra cel lular _ ▁matri x ▁accumula tion
D-734	-0.5483648180961609	pathophysiology heart failure preserved_ejection_fraction hbff myocardial_extracellular_ matrix accumulation
P-734	-1.2762 -0.1974 -0.2609 -2.0949 -0.1777 -1.3968 -0.7858 -0.5001 -0.0744 -0.4858 -0.0765 -0.3841 -0.1083 -0.0456 -0.2190 -0.0771 -0.6478 -1.8636 -1.7332 -1.1396 -0.2910 -0.5144 -0.2962 -0.3148 -0.6181 -0.4769 -0.0988 -0.0937 -1.0286 -0.2291 -0.3067 -0.3104 -0.4016 -0.1194
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing cardiac_arrest advantage pulseless_ventricular_fibrillation pvf implanted cardioverter-defibrillator_device
H-1346	-0.37583544850349426	▁breath ing _ control ▁cardiac _ ▁arrest ▁puls e less _ ▁vent ri cular _ fi bril lation PV f ▁cardio ver ter - de fi br illa tor _ ▁device
D-1346	-0.37583544850349426	breathing_control cardiac_ arrest pulseless_ ventricular_fibrillationPVf cardioverter-defibrillator_ device
P-1346	-1.0038 -0.1015 -1.1927 -0.0043 -0.2890 -0.6764 -0.0804 -0.1111 -0.0351 -0.8107 -0.0843 -0.6881 -0.5530 -0.2430 -0.1300 -0.4517 -0.0831 -0.0777 -0.8733 -1.2368 -0.3097 -0.0151 -0.0567 -0.1805 -0.0311 -0.0577 -0.3522 -0.1264 -0.0365 -1.4390 -0.5415 -0.4173 -0.1127
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal_probnp nt-probnp midregional_proanp mr-proanp adiponectin elevated chf correlated bmi
H-14	-0.7715488076210022	▁n - termin al _ pro b NP ▁ nt - pro b NP ▁mid region al _ pro AN p ▁m - pro an p ▁total _ ▁adi pon ect in ▁CHF ▁b MI ▁FM
D-14	-0.7715488076210022	n-terminal_probNP nt-probNP midregional_proANp m-proanp total_ adiponectin CHF bMI FM
P-14	-3.1204 -0.0241 -0.0363 -0.0073 -0.7315 -0.3250 -1.3790 -0.3578 -4.3642 -0.8178 -0.0071 -0.0190 -1.0922 -0.4548 -0.3213 -0.1612 -0.0211 -0.3336 -0.3876 -2.3091 -0.4974 -0.9682 -0.2020 -0.0063 -2.5679 -0.4644 -0.8332 -0.1991 -0.4696 -0.0081 -0.0853 -0.4484 -0.1119 -1.4990 -2.0429 -2.3158 -0.2333 -0.0956
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase_inhibitor pyridostigmine sympathovagal_balance cardiac_remodeling cardiac_function hf myocardial_infarction
H-1136	-0.47413694858551025	▁a ce tyl cho line ster ase ▁inhibi tor ▁py rido stig mine ▁sympa t hova gal _ ▁balance ▁cardiac _ ▁remodel ing ▁cardiac _ ▁function ▁ HF ▁my o card ial _ in far ction
D-1136	-0.47413694858551025	acetylcholinesterase inhibitor pyridostigmine sympathovagal_ balance cardiac_ remodeling cardiac_ function HF myocardial_infarction
P-1136	-0.2208 -1.0151 -0.1379 -0.2079 -0.0824 -0.3182 -0.9690 -0.6914 -0.0098 -0.1022 -0.0075 -0.0014 -0.0918 -0.0292 -0.1302 -0.0479 -0.1463 -0.2588 -0.3595 -0.0019 -0.8037 -2.9125 -0.0102 -0.1792 -1.4345 -0.6287 -1.3392 -0.1204 -2.3270 -0.5286 -0.7048 -1.2296 -0.1369 -0.1826 -0.0726 -0.2399 -0.2353 -0.1025
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac_sympathetic_activity β-blocker
H-1112	-0.3995942771434784	▁cardiac _ ▁sympa the tic _ activ iteit ▁i - meta - i odob enz yl guan i dine ▁i - MI BG ▁β - block er
D-1112	-0.3995942771434784	cardiac_ sympathetic_activiteit i-meta-iodobenzylguanidine i-MIBG β-blocker
P-1112	-0.8890 -0.5873 -0.7430 -0.4709 -0.6894 -0.6750 -0.4773 -0.4208 -0.3018 -0.5650 -0.0253 -0.0427 -0.0725 -0.0507 -0.2587 -1.0213 -0.0078 -0.1592 -0.0680 -0.1604 -0.3248 -1.1924 -1.3918 -0.2002 -0.0240 -0.2218 -0.0665 -0.3163 -0.1643
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based heart_disease therapies patients cabg sweden
H-971	-0.5712715983390808	▁Swedish _ web - system _ voor _ en han ce ment _ ▁and _ ▁Development _ of _ e viden ce - based _ care ▁Heart _ ▁disease ▁Reco mmende d _ therapie s _ ▁registr y ▁ca BG ▁Sweden
D-971	-0.5712715983390808	Swedish_web-system_voor_enhancement_ and_ Development_of_evidence-based_care Heart_ disease Recommended_therapies_ registry caBG Sweden
P-971	-0.2143 -0.6448 -0.1702 -0.1128 -0.3950 -0.1902 -0.9481 -0.1661 -0.4173 -0.2611 -1.5889 -0.0157 -0.1264 -2.6075 -0.3413 -0.3554 -0.1183 -0.7434 -0.1539 -2.0396 -0.1024 -0.3639 -0.0250 -0.0125 -0.0315 -1.3068 -0.9757 -0.9662 -0.3857 -0.2771 -0.0026 -0.0171 -0.0968 -1.4213 -0.0188 -2.2094 -0.1738 -0.0155 -1.9468 -1.3145 -0.9997 -0.1783 -0.1128
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef clinical reverse_remodeling death hf hospitalization hazard_ratio
H-756	-0.577588677406311	▁LV EF ▁clinic al _ com posit e _ ▁response ▁rever se _ ▁remodel ing _ ▁parameter s ▁time _ to _ ▁death ▁ HF haz ard _ ▁ratio
D-756	-0.577588677406311	LVEF clinical_composite_ response reverse_ remodeling_ parameters time_to_ death HFhazard_ ratio
P-756	-0.1543 -0.3405 -3.0196 -0.0487 -0.6373 -0.3239 -0.0219 -0.0153 -0.2607 -1.8008 -0.0270 -0.0182 -0.0464 -0.1457 -0.0133 -2.2957 -0.1029 -0.0252 -1.1676 -1.3348 -0.9633 -0.5408 -0.2340 -0.6366 -0.1896 -2.7717 -0.0439 -0.2428 -0.0914 -0.2650 -0.1264
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients brain_natriuretic_peptide bnp bnp patients bnp bnp
H-1569	-0.7180812358856201	▁brain ▁na tri ure tic _ pe pti de ▁b NP ▁b NP
D-1569	-0.7180812358856201	brain natriuretic_peptide bNP bNP
P-1569	-0.2984 -0.2895 -0.0328 -0.1476 -2.2141 -0.1662 -0.5404 -0.1577 -0.8533 -0.6998 -0.4347 -1.5961 -0.5817 -2.6474 -0.1116
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde pde2 cgmp leading camp_hydrolysis cross_talk cgmp camp_signaling
H-1210	-0.554198145866394	▁p de _ super family ▁p de 2 ▁c g MP ▁c AMP ▁hydro lys is ▁negative _ cross _ talk ▁c g MP ▁c AMP _ signal ing
D-1210	-0.554198145866394	pde_superfamily pde2 cgMP cAMP hydrolysis negative_cross_talk cgMP cAMP_signaling
P-1210	-0.1714 -0.2893 -1.3130 -0.1397 -0.1163 -0.1411 -0.2319 -0.0199 -0.0206 -2.7987 -1.4705 -0.0285 -1.4022 -0.1420 -0.0298 -0.0255 -0.1655 -0.4714 -1.5785 -0.2526 -0.5871 -0.0081 -2.2617 -1.2696 -0.0125 -0.7730 -0.4865 -0.6108 -0.0404 -0.2095 -0.1124
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse longitudinal_rv_fiber_shortening pasp rv in_vivo rv prognosis
H-493	-0.785368800163269	▁t AP se long itud in al _ RV _ ▁fiber _ short en ing ▁pas p force ▁in ▁vivo _ RV ▁length - force _ ▁relationship
D-493	-0.785368800163269	tAPselongitudinal_RV_ fiber_shortening paspforce in vivo_RV length-force_ relationship
P-493	-2.9305 -1.1118 -0.6987 -0.8521 -0.1680 -0.5714 -0.0912 -0.1074 -2.3963 -0.5707 -0.2858 -0.3066 -0.7292 -0.0465 -0.0883 -0.8812 -0.2752 -2.4966 -1.4722 -0.8546 -0.4004 -1.1926 -1.3601 -0.0590 -0.0905 -1.3259 -0.5641 -0.7092 -0.1396
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides szeto-schiller ss ss20 cardiac_function proteomic_remodeling signaling_pathways
H-870	-0.3391032814979553	▁mito cho ndri al - tar get ed _ ▁antioxidant ▁Sze to - sch iller ▁s 20 ▁cardiac _ ▁function ▁prote om ic _ ▁remodel ing ▁signal ing ▁path ways
D-870	-0.3391032814979553	mitochondrial-targeted_ antioxidant Szeto-schiller s20 cardiac_ function proteomic_ remodeling signaling pathways
P-870	-0.7124 -0.2290 -0.4007 -0.0630 -0.0473 -0.0168 -0.1593 -0.0194 -0.2161 -0.2474 -0.3137 -0.0164 -0.0243 -1.0621 -0.3755 -1.7216 -0.7096 -0.0297 -0.6320 -0.8140 -0.0385 -0.1574 -0.1920 -0.2855 -0.0183 -0.0080 -0.6715 -0.1490 -1.0858 -0.0387 -0.2982 -0.0981
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model disease heart_failure
H-2017	-0.8083063960075378	▁Tools _ voor _ economic _ analys is _ of _ ▁Patient ▁Management _ ▁Interven tions _ in _ ▁Heart _ ▁Fail ure _ ▁Cost - effect ive ness _ model ▁disease ▁management ▁programs ▁heart ▁failure
D-2017	-0.8083063960075378	Tools_voor_economic_analysis_of_ Patient Management_ Interventions_in_ Heart_ Failure_ Cost-effectiveness_model disease management programs heart failure
P-2017	-1.0051 -0.6778 -1.6779 -0.1321 -1.9546 -0.2485 -0.4026 -0.0759 -1.3290 -1.1683 -0.5875 -0.3591 -1.3373 -1.0885 -0.1407 -0.4111 -1.2466 -0.4141 -0.1986 -0.6070 -0.6595 -0.1603 -0.8431 -2.5010 -1.1050 -0.0861 -2.0893 -0.1258 -1.6691 -1.0095 -0.5729 -1.3341 -0.2252 -1.4322 -0.9871 -0.4855 -0.1695 -0.1981
2021-01-18 20:27:31 | INFO | fairseq.logging.progress_bar | :    101 / 145 wps=213
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization admissions patient
H-900	-0.5054019689559937	▁re - hospital ization ▁ad missions
D-900	-0.5054019689559937	re-hospitalization admissions
P-900	-0.1556 -0.2031 -0.1710 -0.5918 -0.6723 -0.1281 -1.9892 -0.1321
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes coprimary_end_points end_point change serum_cystatin_c renal_function end_point
H-79	-0.5793346762657166	▁co prima ry ▁cum ul ative _ ▁urin e ▁volume ▁de con gestion _ ▁end ▁point ▁se rum ▁cyst atin _ c ▁en roll ment ren al _ function
D-79	-0.5793346762657166	coprimary cumulative_ urine volume decongestion_ end point serum cystatin_c enrollmentrenal_function
P-79	-0.7255 -0.0344 -0.4808 -3.1526 -0.0923 -0.0532 -0.0788 -1.3811 -0.0485 -0.3520 -0.0883 -0.0428 -0.0201 -0.8864 -1.6493 -1.0805 -0.0723 -0.1773 -0.5267 -0.1339 -0.9864 -0.6517 -1.3804 -0.1174 -0.0697 -0.3189 -0.0862 -0.1054 -1.1340 -1.8800 -0.1525
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical cardiac_arrest cardiopulmonary_resuscitation cpr diagnosis posterior_wall_infarction hospitalized cardiac
H-1291	-0.6730715036392212	▁cardiac _ ▁arrest ▁cardio pul mon ary _ re uscita tion ▁c PR ▁posterior _ ▁wall _ in far ction ▁cardiac _ centre
D-1291	-0.6730715036392212	cardiac_ arrest cardiopulmonary_reuscitation cPR posterior_ wall_infarction cardiac_centre
P-1291	-4.1058 -0.6517 -0.3146 -0.0644 -0.4573 -1.5206 -0.6352 -0.0911 -1.8440 -0.1467 -0.2864 -0.2425 -0.5135 -0.0205 -0.0615 -2.7314 -0.4469 -0.3025 -0.0590 -0.0638 -0.0380 -1.0044 -0.6418 -0.3904 -0.1929
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients patients type_2_diabetes therapy saxagliptin sitagliptin pioglitazone second-generation_sulfonylureas insulin
H-1831	-0.4177106022834778	▁diabetes ▁sax ag lip tin ▁si tag lip tin ▁pi og lita zone ▁sul fon yl ure as ▁long - ac ting _ ▁insulin ▁products
D-1831	-0.4177106022834778	diabetes saxagliptin sitagliptin pioglitazone sulfonylureas long-acting_ insulin products
P-1831	-2.5400 -0.2317 -0.0056 -0.1355 -1.8993 -0.2325 -0.0361 -0.0226 -2.0962 -0.0512 -0.0235 -0.0536 -0.0240 -0.6743 -0.0178 -0.2018 -0.1519 -0.0070 -0.0956 -0.0232 -0.0128 -0.0127 -0.3420 -0.0598 -1.5565 -0.6268 -0.1441
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence hyperkalemia mineralocorticoid_receptor_antagonists mineralocorticoid_receptor_antagonists heart_failure hf
H-1702	-0.6091707944869995	▁hyper kal emia ▁mineral o cor tico id _ ▁receptor _ ▁anta gon ists ▁race ▁mineral o cor tico id _ ▁receptor _ ▁anta gon ists ▁heart _ ▁failure HF
D-1702	-0.6091707944869995	hyperkalemia mineralocorticoid_ receptor_ antagonists race mineralocorticoid_ receptor_ antagonists heart_ failureHF
P-1702	-1.1346 -0.3873 -0.1617 -0.5984 -0.4723 -1.4472 -1.3332 -0.4712 -0.2772 -0.0699 -1.2596 -0.0874 -0.0210 -0.3567 -0.4700 -0.6592 -0.5186 -1.5842 -1.8199 -0.4537 -0.3013 -0.1497 -1.0861 -0.1163 -0.0586 -0.8177 -0.4850 -1.4565 -0.1516 -0.8890 -0.2514 -0.1472
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade evidence acp erythropoiesis-stimulating_agents patients anemia congestive_heart_failure coronary_heart_disease
H-37	-0.8209861516952515	▁a CP ▁er y thro po ies is - stimul ating _ agent ▁an emia ▁con ges tive _ heart ▁failure ▁corona ry _ heart _ ▁disease
D-37	-0.8209861516952515	aCP erythropoiesis-stimulating_agent anemia congestive_heart failure coronary_heart_ disease
P-37	-3.3802 -1.7453 -0.6479 -0.4171 -1.3013 -0.6397 -1.5213 -0.2208 -0.4467 -0.0903 -0.3868 -0.9430 -0.3038 -1.1320 -0.0130 -0.0454 -0.1781 -2.2695 -0.1043 -1.1805 -0.6673 -0.0068 -1.5829 -0.1095 -1.4417 -1.9039 -0.6460 -0.3243 -0.1589
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory patients heart_failure hf reduced_ejection_fraction renin-angiotensin_system ras β-blockers all-cause_mortality readmissions
H-175	-0.6491008400917053	▁heart ▁failure HF ▁e je ction _ fraction r EF ▁re nin - angi oten sin _ system RAS ▁β - block ers
D-175	-0.6491008400917053	heart failureHF ejection_fractionrEF renin-angiotensin_systemRAS β-blockers
P-175	-3.6418 -0.7661 -0.3922 -1.3580 -0.0590 -0.0374 -0.5095 -0.0250 -1.0834 -0.3437 -0.0114 -0.8882 -0.0503 -0.0331 -0.0476 -0.9884 -1.2600 -1.1794 -0.6960 -0.0735 -0.0138 -0.0832 -0.0308 -2.4995 -0.1561
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr scn5a ventricular_systolic_hf human_induced_pluripotent_stem_cell-derived_cardiomyocytes hipsc-cms
H-1082	-0.4815642833709717	▁u PR ▁s cn 5 a ▁vent ri cular _ ▁sy sto lic _ HF _ ▁tissu e ▁sample s ▁induc ed _ ▁pluri potent _ ▁stem ▁cell - der i ved _ ▁cardio my o cy tes hi PS c - CM s
D-1082	-0.4815642833709717	uPR scn5a ventricular_ systolic_HF_ tissue samples induced_ pluripotent_ stem cell-derived_ cardiomyocyteshiPSc-CMs
P-1082	-1.3080 -0.7778 -0.2751 -0.1460 -0.3562 -0.0784 -0.2315 -1.3115 -0.3894 -0.9453 -1.0401 -0.0114 -0.0412 -0.2136 -1.5986 -2.6922 -0.2032 -0.0632 -1.6444 -0.0599 -0.2551 -0.0702 -0.1890 -0.1741 -0.0015 -0.8757 -0.0361 -1.8754 -0.1162 -0.2252 -0.2167 -0.2456 -0.4210 -0.1313 -1.2195 -0.3047 -0.0638 -0.0326 -0.6544 -0.9152 -0.3118 -0.0229 -0.0712 -0.0106 -0.2128 -0.1121
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd chf crf icc kappa_coefficients
H-802	-0.611095130443573	▁co PD ▁CHF ▁c RF ▁ICC ▁ka ppa ▁co ef fici ents
D-802	-0.611095130443573	coPD CHF cRF ICC kappa coefficients
P-802	-1.3831 -1.3762 -0.0190 -0.6858 -1.2287 -1.2256 -0.0433 -0.0947 -0.7712 -0.0044 -0.0087 -1.3117 -0.2718 -0.1311
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient implantable_cardioverter-defibrillator implant change clinical
H-1865	-0.5583866238594055	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁implant
D-1865	-0.5583866238594055	implantable_ cardioverter-defibrillator deactivation implant
P-1865	-2.3160 -0.0512 -1.0885 -0.3639 -0.0465 -0.1641 -0.3206 -0.0519 -0.1716 -0.4662 -0.0848 -0.0655 -1.4924 -0.0052 -0.3537 -0.3574 -2.4863 -0.1653
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients stable_heart_failure left_ventricular_ejection_fraction training training
H-1913	-0.9284265637397766	▁heart ▁failure ▁left _ ▁vent ri cular _ e je ction _ fraction ▁aero bic _ training _ ▁period ▁integrat ed _ dynamic _ ▁resist ance _ training ▁lower _ ▁lim bs
D-1913	-0.9284265637397766	heart failure left_ ventricular_ejection_fraction aerobic_training_ period integrated_dynamic_ resistance_training lower_ limbs
P-1913	-5.3704 -1.1683 -0.2933 -0.6677 -1.0376 -1.2624 -0.7741 -0.3008 -0.4679 -0.1471 -0.0493 -2.2416 -0.0779 -0.3535 -0.2237 -1.2376 -0.0306 -3.4958 -2.0045 -1.9684 -0.0648 -0.6249 -0.1597 -0.2983 -2.0920 -0.0247 -1.0017 -0.0721 -0.4712 -0.5870 -0.2075 -2.2302 -0.3764 -0.1837
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients heart_failure myocardial_function dilated contracting ventricles aetiologies
H-987	-1.0905678272247314	▁heart ▁failure ▁my o card ial _ ▁function ▁dil ated _ ver ▁contract ing ▁vent ric les
D-987	-1.0905678272247314	heart failure myocardial_ function dilated_ver contracting ventricles
P-987	-2.9266 -0.8212 -2.5523 -0.4137 -0.6040 -1.3575 -0.4776 -1.2251 -0.9569 -0.1200 -1.3583 -4.2286 -0.7823 -0.0247 -0.6346 -0.8601 -0.9301 -0.3261 -0.1213
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial cochrane_effective_practice_and_organisation_of_care_taxonomy
H-1847	-0.5067731142044067	▁co ch rane _ ▁Effective _ ▁Practic e ▁organisation _ of _ care _ ▁Tax ono my
D-1847	-0.5067731142044067	cochrane_ Effective_ Practice organisation_of_care_ Taxonomy
P-1847	-0.6443 -0.1487 -0.0382 -1.1438 -0.9010 -0.0618 -0.7446 -0.0080 -1.4973 -0.2713 -0.5047 -0.1735 -0.4040 -0.0587 -1.8990 -0.0473 -0.5584 -0.4166 -0.1076
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad q65p murine rad q66p l-type_currents cav1.2 cav1.3 wild-type_rad
H-1675	-0.7500184774398804	▁mouse _ rad ▁Q 65 p ▁mur ine _ ▁equivalent _ of _ human _ rad ▁Q 66 p ▁l - type _ current s ▁ca v 1.2 ▁ca v 1.3 ▁wild - type _ Rad
D-1675	-0.7500184774398804	mouse_rad Q65p murine_ equivalent_of_human_rad Q66p l-type_currents cav1.2 cav1.3 wild-type_Rad
P-1675	-0.0262 -0.9856 -0.6966 -2.7465 -0.1813 -0.4277 -0.1517 -1.7642 -2.1325 -0.1044 -0.6589 -1.5679 -0.3279 -1.5902 -0.3178 -0.8203 -1.2012 -0.2372 -0.1548 -4.9104 -0.0455 -0.0022 -0.0704 -0.3276 -0.0724 -0.4980 -0.3679 -0.1492 -1.1816 -0.4061 -0.1511 -1.9870 -0.0213 -0.0037 -0.0371 -1.6735 -0.3657 -0.1371
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients implantable_cardioverter-defibrillator patients implantable_cardioverter-defibrillator
H-1866	-0.4904524087905884	▁implant able _ ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁di stress ing ▁implant able _ ▁cardio ver ter - de fi br illa tor _ ▁shock s
D-1866	-0.4904524087905884	implantable_ cardioverter-defibrillator deactivation distressing implantable_ cardioverter-defibrillator_ shocks
P-1866	-1.7599 -0.0689 -0.3362 -0.7110 -0.0688 -0.2370 -0.3496 -0.0880 -0.3641 -0.8444 -0.1540 -0.0973 -1.1162 -0.0095 -0.5542 -3.4967 -0.0152 -0.0940 -0.6019 -0.0736 -0.3449 -0.7810 -0.0661 -0.2472 -0.4415 -0.0439 -0.2545 -0.6647 -0.1924 -0.0618 -1.0951 -1.1001 -0.0942 -0.5347 -0.2033
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart_failure hf hypertensive_heart_disease hhd pathophysiology therapeutic hhd stable phenotypes
H-274	-0.7381397485733032	▁mouse _ ▁heart ▁failure HF ▁model ▁hyper tensi ve _ heart _ ▁disease ▁h HD ▁pat ho phy si ology ▁h HD
D-274	-0.7381397485733032	mouse_ heart failureHF model hypertensive_heart_ disease hHD pathophysiology hHD
P-274	-0.0089 -0.2967 -1.2834 -0.5358 -0.3449 -1.3102 -0.2447 -0.0730 -0.0580 -0.0265 -2.9257 -1.1584 -0.5841 -0.9255 -1.6877 -1.9040 -0.0389 -0.0885 -1.2990 -0.0829 -0.6004 -1.4368 -0.7262 -0.0753
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient mi hazard_ratios hf
H-1108	-1.072279691696167	▁MI _ karakter istic s ▁hazard ▁ratio s ▁ HF
D-1108	-1.072279691696167	MI_karakteristics hazard ratios HF
P-1108	-1.6910 -2.5096 -0.4731 -0.4639 -0.0839 -1.3557 -2.6379 -0.4685 -1.5985 -1.1751 -0.1688 -0.2414
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare patients acute hospital hf ami pna
H-1693	-1.0731351375579834	▁Medica re ▁patients ▁a cute _ care _ hospital ▁ HF ▁ AMI ▁p na
D-1693	-1.0731351375579834	Medicare patients acute_care_hospital HF AMI pna
P-1693	-3.7733 -0.0126 -3.6184 -0.6565 -0.1379 -0.0361 -2.0137 -0.2185 -0.3436 -2.1235 -0.9083 -1.9961 -0.3372 -0.3014 -1.3910 -0.2101 -0.1652
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt nt-probnp aric hf aucs nris
H-289	-0.43835577368736267	▁c t n t ▁NT - pro b NP ▁a RIC _ HF AU c s ▁continuo us _ ▁NR Is
D-289	-0.43835577368736267	ctnt NT-probNP aRIC_HFAUcs continuous_ NRIs
P-289	-0.0168 -0.2568 -0.0217 -0.2214 -0.1540 -0.0241 -0.0094 -0.4793 -0.2942 -0.1128 -1.0852 -0.1461 -1.4038 -2.0741 -0.5989 -0.5624 -0.3406 -0.0114 -0.1601 -0.4109 -0.4491 -1.1471 -0.1019
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular_events baseline sst2 metoprolol_succinate
H-404	-0.7856917977333069	▁cardio vas cular _ ▁events ▁s st 2 ▁BB _ ▁dose ▁met o pro lol _ ▁suc cina te
D-404	-0.7856917977333069	cardiovascular_ events sst2 BB_ dose metoprolol_ succinate
P-404	-2.6028 -0.5295 -0.6278 -1.4214 -1.0760 -0.0146 -1.3996 -0.2077 -2.6359 -3.0404 -0.2857 -0.3165 -0.4426 -0.0238 -0.1502 -1.0635 -0.1810 -0.0252 -0.0533 -0.3256 -0.0765
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl nyha-iiib phosphorylation phosphorylation hdl healthy
H-255	-0.5231969356536865	▁EC ▁HD l NY ha - III b ▁ phos phor y lation ▁e NOS - Ser ▁ phos phor y lation ▁e NOS - Th r ▁HD l
D-255	-0.5231969356536865	EC HDlNYha-IIIb phosphorylation eNOS-Ser phosphorylation eNOS-Thr HDl
P-255	-1.8039 -3.0355 -1.3883 -0.5863 -0.5982 -0.0394 -0.0872 -0.0182 -0.0498 -0.2474 -0.3958 -1.1430 -0.1163 -0.1196 -0.0185 -0.0645 -0.4517 -0.1912 -0.1925 -0.4495 -0.8509 -0.0846 -0.0607 -0.0176 -0.0468 -0.8921 -0.0036 -0.8033 -1.8494 -0.4799 -0.1333
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients hospitalized hf preserved_lvef mortality patients lvef lvef mortality
H-117	-0.9475604891777039	▁patients ▁hospital ized ▁ HF ▁LV EF ▁LV EF ▁LV EF
D-117	-0.9475604891777039	patients hospitalized HF LVEF LVEF LVEF
P-117	-2.3210 -0.8809 -0.1942 -1.2805 -0.1263 -1.4158 -0.2877 -1.6392 -0.1566 -1.3582 -0.1589 -2.3775 -0.1218
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic_reticular protein phospholamban infarcted hearts metoprolol
H-1551	-0.41517844796180725	▁sar co plas mic _ ▁reti cular SR ▁ca (2 +) - up take ▁protein _ ▁content ▁SR ▁ca (2 +) - pump ▁ phos pho lam ban ▁in far cted _ heart s ▁met o pro lol
D-1551	-0.41517844796180725	sarcoplasmic_ reticularSR ca(2+)-uptake protein_ content SR ca(2+)-pump phospholamban infarcted_hearts metoprolol
P-1551	-0.0339 -0.0342 -0.5585 -1.0563 -0.1813 -0.1872 -0.3111 -0.3151 -0.5505 -0.4522 -0.0023 -0.0169 -0.0757 -0.3040 -0.5948 -3.2567 -0.7931 -0.2614 -0.6802 -0.5308 -0.0044 -0.0136 -0.0426 -0.1297 -0.0203 -0.0310 -0.8136 -0.2331 -0.0120 -0.1283 -1.9068 -0.0859 -2.0318 -0.0494 -0.2616 -0.1610 -0.0480 -0.1714 -0.1694 -0.0969
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global_left_ventricular_longitudinal_systolic_strain gls left_ventricular cardiovascular atrial_fibrillation
H-809	-0.5336033701896667	▁global _ ▁left _ ▁vent ri cular _ ▁longitud in al _ sy sto lic _ ▁strain ▁g LS ▁left _ ▁vent ri cular _ ▁mechanic s ▁cardiovascular CV ▁at rial _ fi bril lation AF
D-809	-0.5336033701896667	global_ left_ ventricular_ longitudinal_systolic_ strain gLS left_ ventricular_ mechanics cardiovascularCV atrial_fibrillationAF
P-809	-0.1545 -0.8549 -0.8757 -0.3002 -1.5289 -0.9015 -0.5409 -0.3911 -0.0497 -0.1510 -0.0697 -0.1035 -1.2147 -0.1300 -0.0995 -0.2479 -0.2410 -0.0900 -0.9104 -1.1711 -0.4558 -0.7756 -1.1205 -0.3514 -0.2040 -0.9098 -0.0224 -0.3959 -0.2909 -3.6087 -0.0336 -0.2436 -0.7753 -0.0503 -0.0775 -0.6027 -0.1975 -0.1352
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf hf_with_reduced_ef hf_with_preserved_ef change hf mi
H-1109	-1.2236335277557373	▁early - ons et ▁late - ons et ▁ HF ▁ HF ▁ HF ▁ HF ▁EF ▁ HF ▁ HF ▁ HF _ met _ ▁pres er ved _ ▁EF ▁mix ▁ HF ▁ HF ▁MI
D-1109	-1.2236335277557373	early-onset late-onset HF HF HF HF EF HF HF HF_met_ preserved_ EF mix HF HF MI
P-1109	-4.9592 -0.0523 -0.0645 -0.0476 -4.0436 -0.0203 -0.1058 -0.0408 -1.7859 -0.4209 -1.0357 -0.2441 -2.2963 -0.1694 -3.5699 -0.2084 -3.2982 -0.5928 -0.2663 -2.1079 -0.2260 -3.0083 -0.2847 -3.8043 -1.6524 -0.2545 -3.1188 -0.0270 -0.2596 -0.1272 -1.1837 -2.2401 -0.6266 -0.6663 -2.5940 -0.8258 -0.9357 -0.4319 -0.1248
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol von_willebrand_factor metoprolol β2-adrenergic_receptor_haplotype
H-1118	-0.4566068947315216	▁car vedi lol ▁Will e brand _ ▁factor ▁met o pro lol ▁β 2- ad r energi c _ ▁receptor ▁ha plo type
D-1118	-0.4566068947315216	carvedilol Willebrand_ factor metoprolol β2-adrenergic_ receptor haplotype
P-1118	-0.8517 -0.0253 -0.1617 -4.0369 -0.0932 -0.0056 -2.0756 -0.8039 -0.1687 -0.4370 -0.0447 -0.1585 -0.1621 -0.0442 -0.0929 -0.3080 -0.8278 -0.0346 -0.1866 -0.1984 -0.2431 -0.0289 -0.0045 -0.3100 -0.1111
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise intramuscular_testosterone_supplementation patients chronic_heart_failure chf testosterone collected health outcomes
H-1317	-0.9571779370307922	▁exercise ▁intra mus cular _ ▁testosteron e _ ▁supplement ation ▁chronic _ ▁heart ▁failure CH f ▁low _ ▁testosteron e ▁status
D-1317	-0.9571779370307922	exercise intramuscular_ testosterone_ supplementation chronic_ heart failureCHf low_ testosterone status
P-1317	-5.3997 -1.4665 -0.1398 -0.3139 -0.2216 -0.1798 -0.0232 -2.3571 -0.2934 -0.0880 -1.4760 -0.0974 -2.3633 -0.6089 -3.0173 -0.7546 -0.1136 -0.1993 -0.1831 -0.0451 -2.0260 -0.5247 -0.1229
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart_failure hf plasma_b-type_natriuretic_peptide bnp preserved_ejection_fraction ef hf
H-187	-0.5981432199478149	▁heart ▁failure HF ▁plasma ▁na tri ure tic _ pe pti de ▁b NP ▁pres er ved _ e je ction _ fraction ▁e je ction _ fraction EF ▁ HF
D-187	-0.5981432199478149	heart failureHF plasma natriuretic_peptide bNP preserved_ejection_fraction ejection_fractionEF HF
P-187	-0.8352 -0.8006 -1.2480 -0.1903 -1.5039 -0.0355 -0.1668 -1.9441 -0.1101 -0.4538 -0.0455 -0.6344 -0.7178 -0.6204 -2.3307 -0.0586 -0.3794 -0.4432 -0.4024 -0.1319 -0.0494 -0.1829 -0.0357 -2.0323 -0.1419 -0.0600 -0.2640 -0.0238 -1.1112 -0.2464 -0.4659 -1.9527 -0.1196
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls left_ventricular_ejection_fraction lvef systolic_mitral_annulus_velocity multivariate_models
H-818	-0.5729975700378418	▁g LS ▁left _ ▁vent ri cular _ e je ction _ fraction LV EF ▁sy sto lic _ met ral _ ▁ann ulus _ ▁veloci ty ▁sa ▁CV
D-818	-0.5729975700378418	gLS left_ ventricular_ejection_fractionLVEF systolic_metral_ annulus_ velocity sa CV
P-818	-0.2441 -1.1311 -1.0050 -0.2850 -1.4588 -0.8390 -0.8514 -0.2071 -0.4252 -0.1816 -0.2730 -0.3445 -0.1461 -1.1551 -0.3957 -0.0179 -0.0353 -0.0715 -0.0455 -0.6845 -0.5034 -0.0429 -3.8961 -0.1561 -0.1216 -0.0977 -0.0197 -0.1479 -1.1486 -1.6834 -0.1485
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm telemonitoring implanted medical structured_telephone_support sts human-to-human_contact hh human-to-machine_interface
H-153	-0.6012095212936401	▁RM ▁home _ monitor ing TM ▁implant ed _ monitor ing ▁devices ▁medical _ support ▁structure d _ ▁telephone _ support ▁s s ▁human - to - human ▁contact HH ▁human - to - machine ▁interface ▁h m
D-153	-0.6012095212936401	RM home_monitoringTM implanted_monitoring devices medical_support structured_ telephone_support ss human-to-human contactHH human-to-machine interface hm
P-153	-1.8650 -3.8242 -0.3074 -0.1386 -0.0078 -1.8676 -0.1028 -0.1015 -0.1159 -0.1133 -0.0384 -1.2831 -1.7782 -2.2525 -0.4489 -0.7612 -0.0057 -0.1436 -0.3370 -0.3228 -0.5021 -1.6399 -0.3006 -1.0713 -0.0165 -0.0109 -0.0289 -0.0270 -0.5353 -1.3301 -0.3219 -0.0169 -0.0188 -0.0248 -0.0162 -0.1076 -0.6295 -1.3291 -0.2199 -0.0857
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug patients chronic_obstructive_pulmonary_disease copd chronic_heart_failure chf chronic_renal_failure crf
H-794	-0.8948823809623718	▁Time d _ up _ go ▁tu g ▁chronic _ ob struct ive _ ▁pulmonar y ▁disease co PD ▁chronic _ ▁heart ▁failure CH f ▁chronic _ ▁renal _ ▁failure cr f
D-794	-0.8948823809623718	Timed_up_go tug chronic_obstructive_ pulmonary diseasecoPD chronic_ heart failureCHf chronic_ renal_ failurecrf
P-794	-1.3987 -0.0493 -0.1118 -0.1635 -0.2590 -3.5882 -0.1063 -2.6689 -1.9829 -0.2207 -0.6882 -0.0692 -0.0672 -0.0714 -0.2682 -0.0562 -0.7189 -1.7736 -0.6560 -0.0280 -0.0519 -2.0853 -0.3144 -3.5256 -0.9151 -0.0656 -0.0649 -2.5343 -1.0283 -0.0917 -1.8823 -2.5687 -0.1757 -0.1760
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox_regression_analysis patients beta-blockers beta-blockers primary_endpoint therapy antitachycardia_pacing atp shock_therapy
H-859	-0.393202543258667	▁co x _ re gression _ analyse ▁beta - block ers ▁beta - block ers ▁in appropria te ▁anti ta chy car dia _ ▁pa cing ▁a TP ▁shock _ therapy
D-859	-0.393202543258667	cox_regression_analyse beta-blockers beta-blockers inappropriate antitachycardia_ pacing aTP shock_therapy
P-859	-0.2787 -0.0916 -0.9616 -0.3643 -0.0103 -2.0748 -0.2410 -0.9262 -0.0589 -0.2691 -0.0288 -0.1045 -0.0569 -0.2685 -0.0385 -1.4243 -0.0434 -0.0314 -0.7093 -0.5686 -0.0930 -0.0099 -0.0149 -0.8608 -0.9948 -0.1652 -0.4853 -0.5689 -0.0263 -0.8800 -0.0161 -0.1724 -0.1375
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically legal decisions
H-1680	-1.0560203790664673	▁et h ically _ ▁complex ▁pediatr ics ▁families ▁religious _ ▁belief s ▁life - s usta ining _ ▁treatment ▁legal _ ▁majority
D-1680	-1.0560203790664673	ethically_ complex pediatrics families religious_ beliefs life-sustaining_ treatment legal_ majority
P-1680	-0.3055 -0.1279 -0.8608 -1.7054 -2.0132 -1.1072 -0.5422 -2.4223 -0.4211 -0.4095 -1.3457 -0.0439 -3.5168 -0.0434 -0.4337 -0.5488 -0.7146 -0.7615 -1.4601 -2.3975 -0.9633 -1.1308 -1.9590 -0.1104
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient prescribing medications medical
H-1122	-1.114322304725647	▁ commissie ▁guide line - re com mend ed _ ▁medication s ▁medical ▁records ▁performance _ ▁measure ment
D-1122	-1.114322304725647	commissie guideline-recommended_ medications medical records performance_ measurement
P-1122	-4.5830 -4.9221 -2.8175 -0.0323 -0.1933 -0.0055 -0.1293 -0.0677 -0.1204 -1.1958 -0.2037 -0.0491 -1.1484 -1.1648 -0.0049 -1.1383 -1.6946 -0.0951 -2.5769 -0.1439
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost patient rhythm-control rate-control
H-1241	-1.1725592613220215	▁kosten ▁ rhythm - control ▁rate - control
D-1241	-1.1725592613220215	kosten rhythm-control rate-control
P-1241	-2.7996 -0.2347 -1.6550 -0.3879 -0.0075 -3.2762 -0.4071 -0.0091 -2.6470 -0.3014
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left_ventricular_ejection_fraction egfr
H-393	-1.0487793684005737	▁media n _ ▁age ▁women ▁media n _ ▁left _ ▁vent ri cular _ e je ction _ fraction ▁media n _ e g FR
D-393	-1.0487793684005737	median_ age women median_ left_ ventricular_ejection_fraction median_egFR
P-393	-3.4482 -0.0547 -0.6460 -1.4769 -2.0431 -2.5261 -0.1054 -0.5674 -1.2312 -0.2684 -1.3403 -0.9111 -0.6475 -0.2596 -0.4771 -0.2980 -0.3340 -0.6173 -0.1425 -1.9768 -0.0544 -0.8224 -0.7277 -3.0582 -1.0873 -2.9362 -0.2591
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells functional_capacity cells peak_vo2
H-127	-1.5246191024780273	▁cd 34 _ ve g FR 2 + ▁cell s ▁functional _ ▁capacity ▁10- cell ▁cd 34 _ ve g FR 2 + ▁cell s
D-127	-1.5246191024780273	cd34_vegFR2+ cells functional_ capacity 10-cell cd34_vegFR2+ cells
P-127	-0.9359 -0.3668 -5.0367 -0.1082 -1.8601 -1.2423 -0.4713 -3.9870 -1.0514 -0.0635 -0.3545 -1.9143 -1.4426 -2.8732 -0.2410 -2.4120 -0.3880 -4.1117 -0.2190 -2.1439 -1.7816 -0.2357 -2.7576 -1.2898 -0.0444 -3.7135 -0.1187
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf hazard_ratios body_mass_index obese
H-1773	-0.6307857632637024	▁fit ▁un fit ▁c RF ▁hazard ▁ratio s ▁fit ▁un fit ▁over weight _ ▁body _ ▁mass ▁index ▁obes e _ men
D-1773	-0.6307857632637024	fit unfit cRF hazard ratios fit unfit overweight_ body_ mass index obese_men
P-1773	-0.0934 -0.2217 -0.2288 -1.1015 -0.5624 -2.0351 -0.9511 -0.4773 -1.1035 -0.2082 -0.1055 -0.8282 -0.2286 -0.4412 -1.2471 -0.5475 -0.6957 -0.1746 -1.7889 -0.0974 -0.3899 -1.2053 -0.2643 -0.1417
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare_patient_safety_monitoring_system mpsms adverse_event patients hospitalized acute_myocardial_infarction congestive_heart_failure pneumonia conditions surgery
H-2	-0.5259711742401123	▁Medica re _ ▁Patient _ ▁Safety _ monitor ing _ system ▁m SMS ▁advers e _ event _ ▁rates ▁a cute _ My o card ial _ in far ction ▁con ges tive _ heart ▁failure ▁pneu monia ▁surgery
D-2	-0.5259711742401123	Medicare_ Patient_ Safety_monitoring_system mSMS adverse_event_ rates acute_Myocardial_infarction congestive_heart failure pneumonia surgery
P-2	-0.0588 -0.0018 -0.8777 -0.3087 -0.9500 -0.0759 -0.5952 -0.0047 -0.0091 -0.5512 -0.7554 -0.3654 -1.2592 -1.6012 -0.0158 -0.0483 -1.9147 -1.5019 -0.1146 -0.6463 -0.0076 -0.0256 -4.3393 -0.5039 -0.3987 -0.7745 -0.0441 -0.2669 -0.0839 -0.0627 -0.0166 -0.0978 -1.3385 -0.0249 -1.0932 -0.2653 -0.0049 -0.1070 -0.1301 -0.2089 -0.1146
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi blood_urea_nitrogen b-type_natriuretic_peptide new_york_heart_association_class diabetes atrial_fibrillation all-cause_hospitalization
H-382	-0.4506230056285858	▁ HF PSI ▁blood ▁u rea _ ▁nit rogen ▁na tri ure tic _ pe pti de ▁New _ York _ ▁Heart _ association ▁diabetes ▁at rial _ fi bril lation flu tter
D-382	-0.4506230056285858	HFPSI blood urea_ nitrogen natriuretic_peptide New_York_ Heart_association diabetes atrial_fibrillationflutter
P-382	-0.7061 -0.3452 -0.9617 -2.9120 -0.3862 -0.2058 -0.6149 -0.0894 -0.0473 -0.1626 -0.0284 -0.1177 -1.1591 -0.0808 -0.3753 -0.0337 -0.3748 -0.0769 -0.9405 -0.8212 -0.1014 -1.3540 -0.3064 -0.7359 -0.0881 -0.8565 -0.0479 -0.2261 -0.4339 -0.0318 -0.0438 -0.0671 -0.0230 -0.9162 -0.1000
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary_outcome patients crt hazard_ratio confidence_interval
H-852	-0.9092530608177185	▁c RT _ groep ▁hazard _ ▁ratio ▁95% _ ▁confidence _ ▁interval CI
D-852	-0.9092530608177185	cRT_groep hazard_ ratio 95%_ confidence_ intervalCI
P-852	-0.4919 -2.2580 -2.7240 -0.2410 -0.5043 -1.6075 -0.0289 -0.4869 -0.5906 -0.1920 -1.3365 -0.0536 -2.8359 -0.1482 -0.1395
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality_rate patients hf hf case-fatality_rate
H-1311	-1.0907478332519531	▁concurrent _ HF ▁concurrent _ HF ▁case - fat ality _ ▁rate
D-1311	-1.0907478332519531	concurrent_HF concurrent_HF case-fatality_ rate
P-1311	-4.3337 -0.2045 -0.9525 -0.9944 -0.2786 -1.5844 -2.2784 -0.2201 -0.1644 -0.0871 -2.2783 -0.3923 -1.3367 -0.1653
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients heart_failure_and_reduced_ejection_fraction patient
H-659	-0.9467036128044128	▁in patient s ▁heart ▁failure ▁reduce d _ e je ction _ fraction ▁treatment
D-659	-0.9467036128044128	inpatients heart failure reduced_ejection_fraction treatment
P-659	-7.5493 -0.0873 -0.0667 -3.0060 -0.7852 -0.4571 -0.0226 -0.1261 -0.5603 -0.0878 -0.0372 -0.1266 -0.0271 -1.2744 -0.7734 -0.1602
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame chf anthracycline stem_cell allogeneic autologous follow-up
H-1453	-0.6879879832267761	▁CHF ▁an thra cycli ne ▁stem ▁cell _ ▁source allo gene ic ▁auto logo us ▁follow - up
D-1453	-0.6879879832267761	CHF anthracycline stem cell_ sourceallogeneic autologous follow-up
P-1453	-3.5098 -4.0717 -0.1030 -0.1971 -0.8079 -0.5637 -1.1386 -2.6077 -0.1130 -0.0036 -0.1402 -0.0210 -0.0475 -0.0045 -0.0373 -0.0976 -0.0298 -0.0122 -0.1606 -0.0929
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting_tension fpassive muscle kcl-ki titin titin extracellular_matrix fpassive
H-765	-0.5393028855323792	▁rest ing _ ▁tension ▁f pass ive _ - sar com ere _ leng ▁relations ▁muscle ▁strip s ▁k c l - KI ▁treatment ▁titi n ▁extra cel lular _ ▁matri x ▁f pass ive
D-765	-0.5393028855323792	resting_ tension fpassive_-sarcomere_leng relations muscle strips kcl-KI treatment titin extracellular_ matrix fpassive
P-765	-2.7620 -0.0968 -0.4636 -1.2355 -3.9367 -0.1791 -0.0838 -1.1498 -0.4356 -0.0916 -0.0294 -0.0359 -0.4410 -0.6393 -1.6135 -1.9820 -0.5020 -0.0148 -0.8696 -0.4003 -0.0444 -0.0079 -0.0513 -1.6029 -0.0392 -0.0100 -0.0492 -0.0686 -0.0587 -0.1045 -0.0732 -0.0149 -0.5294 -0.0466 -0.0574 -0.1639 -0.0697
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training exercise_capacity muscle quality_of_life cardiac nt-probnp inflammatory il6 hscrp biomarkers
H-1922	-0.6549215912818909	▁aero bic _ en _ ▁resist ance _ training _ ▁intervention ▁aug mente d _ ▁feedback ▁exercise ▁capacity ▁muscle _ ▁strength ▁cardiac NT - pro b NP ▁infla mma tory IL 6 ▁h s cr p ▁bio mark ers
D-1922	-0.6549215912818909	aerobic_en_ resistance_training_ intervention augmented_ feedback exercise capacity muscle_ strength cardiacNT-probNP inflammatoryIL6 hscrp biomarkers
P-1922	-0.1063 -0.2273 -1.2039 -2.0804 -0.2277 -0.9828 -0.0382 -0.7660 -0.0607 -4.3738 -1.7779 -0.9829 -0.0167 -0.0041 -0.2443 -0.1945 -0.6605 -1.1291 -0.1208 -1.4238 -0.2528 -0.0422 -4.3848 -0.0168 -0.5024 -0.6589 -0.3305 -0.0951 -0.1809 -0.0768 -2.2696 -0.1572 -0.0252 -0.0061 -0.1008 -0.2111 -0.4159 -0.0967 -0.0763 -0.2362 -0.0938
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital readmission all-cause_readmission acr potential_preventable_readmission ppr medicare medicaid readmission cms
H-135	-0.8197134733200073	▁read mission ▁a cr ▁Potential _ preven en table _ ▁Read mission ▁p PR ▁Center s _ voor _ ▁Medica re ▁Medica id ▁30- day _ ▁read mission ▁c ms
D-135	-0.8197134733200073	readmission acr Potential_prevenentable_ Readmission pPR Centers_voor_ Medicare Medicaid 30-day_ readmission cms
P-135	-4.8061 -1.2665 -0.5836 -0.1992 -0.3561 -0.1532 -0.2643 -0.9006 -1.0991 -0.0971 -3.3183 -0.2766 -0.0465 -0.5373 -0.5206 -0.0279 -0.1580 -1.4933 -0.2454 -0.0400 -0.0115 -0.2041 -0.2778 -4.1617 -0.2113 -0.1386 -2.8725 -0.7246 -0.2079 -0.6849 -0.1890 -0.1569
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart_failure myocardial_infarction mi β-adrenoceptor_blockade infarcted metoprolol
H-1547	-0.4606034457683563	▁heart ▁failure ▁my o card ial _ in far ction ▁m ▁β - ad re no cept or _ block ade ▁in far cted _ ▁rat s ▁met o pro lol
D-1547	-0.4606034457683563	heart failure myocardial_infarction m β-adrenoceptor_blockade infarcted_ rats metoprolol
P-1547	-4.1543 -0.7512 -0.7972 -0.4574 -0.7296 -1.1874 -0.2329 -0.2457 -0.1548 -0.0747 -0.9161 -0.3908 -0.0073 -0.0146 -0.0629 -0.1160 -0.1193 -0.1351 -0.5451 -0.7223 -0.0570 -0.0620 -0.1055 -1.1562 -0.7142 -0.1789 -0.0167 -0.1535 -0.2011 -0.0388 -0.1718 -0.4483 -0.0812
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise rehabilitation walking minnesota_quality_of_life exercise
H-1882	-1.6113773584365845	▁Minnesota _ kwaliteit _ of _ ▁life ▁exercise _ groep
D-1882	-1.6113773584365845	Minnesota_kwaliteit_of_ life exercise_groep
P-1882	-6.9343 -2.1394 -1.5227 -0.6242 -0.4410 -0.1528 -2.7428 -2.5588 -1.0135 -0.6375 -0.4169 -0.1525
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive_heart_failure correlation_coefficient
H-218	-1.055369257926941	▁con ges tive _ heart _ ▁failure _ ▁visit s ▁ED
D-218	-1.055369257926941	congestive_heart_ failure_ visits ED
P-218	-1.2918 -0.0543 -1.0233 -0.0470 -2.1008 -1.1604 -0.1579 -3.0684 -1.0814 -0.0560 -1.4116 -2.1129 -0.1541
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine_vasopressin avp physiologic chf avp vasopressin_receptor_antagonist therapy therapeutic chf
H-637	-0.5265992879867554	▁argi nine _ ▁vaso press in ▁a VP ▁CHF ▁a VP ▁vaso press in _ ▁receptor _ ▁anta gon ist _ therapy ▁CHF
D-637	-0.5265992879867554	arginine_ vasopressin aVP CHF aVP vasopressin_ receptor_ antagonist_therapy CHF
P-637	-1.1946 -0.3342 -0.4445 -0.1364 -0.2295 -1.1086 -0.3670 -0.3666 -1.4750 -2.2097 -1.5538 -0.3434 -0.1045 -0.4200 -0.7820 -0.0378 -0.4444 -0.0717 -0.0030 -0.3473 -0.5185 -0.0181 -0.1736 -0.3202 -0.1606
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies medication physical_therapy implantable_defibrillators circulatory_support transplantation risk_stratification patient heart_failure therapies disease
H-1205	-0.419584184885025	▁medication ▁physical _ therapy ▁implant able _ de fi br illa tors ▁circula tory _ support ▁transplant ation ▁heart ▁failure ▁ therapie s ▁disease
D-1205	-0.419584184885025	medication physical_therapy implantable_defibrillators circulatory_support transplantation heart failure therapies disease
P-1205	-3.0251 -0.2488 -0.3947 -0.0022 -0.1057 -0.0266 -0.6882 -0.3382 -0.0205 -0.2931 -0.1081 -0.1543 -0.0008 -0.0237 -0.3373 -0.6936 -0.3211 -0.0488 -0.8019 -0.4597 -0.4841 -0.0887 -0.0394 -1.3271 -0.7403 -0.1370
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts caspase-3 activity phosphocreatine adenine_nucleotides cytochrome_c bcl2 bax caspase_3 expression
H-961	-0.27146029472351074	▁rat s ▁heart s ▁ex ci sed ▁cas pas e -3 ▁activity ▁ phos pho creati ne ▁a den ine _ ▁nucleo ti des ▁cy to ch rom e ▁b cl 2 ▁Bax ▁cas pas e
D-961	-0.27146029472351074	rats hearts excised caspase-3 activity phosphocreatine adenine_ nucleotides cytochrome bcl2 Bax caspase
P-961	-0.5714 -0.1486 -1.8152 -0.0268 -1.1608 -0.0206 -0.9264 -0.1634 -0.0212 -0.0733 -0.1204 -1.1376 -0.0385 -0.0085 -0.0553 -0.1045 -0.6487 -0.0158 -0.0071 -0.7164 -0.0942 -0.0287 -0.0547 -0.0523 -0.4336 -0.0291 -0.0509 -0.0014 -0.0250 -0.3948 -0.0185 -0.0271 -0.0079 -0.0362 -0.0327 -0.0765 -1.0864 -0.0851
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right_ventricular_pacing gene_expressions bax bcl-2 caspase-3 rtq-pcr interventricular_septum biopsies heart_failure
H-166	-0.358467161655426	▁rapid _ ▁right _ ▁vent ri cular _ pa cing ▁Bax ▁b cl -2 ▁Cas pas e -3 ▁RT q - PC r ▁interven tri cular _ ▁sept um ▁bio psi es ▁beag le _ ▁dog s ▁heart ▁failure
D-166	-0.358467161655426	rapid_ right_ ventricular_pacing Bax bcl-2 Caspase-3 RTq-PCr interventricular_ septum biopsies beagle_ dogs heart failure
P-166	-0.2719 -0.0794 -2.1981 -0.1245 -0.9052 -0.7132 -0.3612 -0.0746 -0.4272 -0.1904 -0.4931 -0.2637 -0.0693 -0.1052 -0.1300 -0.0115 -0.0118 -0.0859 -1.4799 -1.5748 -0.0389 -0.8764 -0.0845 -0.0056 -0.0542 -0.1890 -0.0914 -0.7703 -0.0219 -0.0949 -0.0350 -0.0216 -0.0122 -0.0379 -0.6384 -0.7415 -0.0135 -0.2151 -0.8924 -0.1895 -0.1023
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers β-blockers patients heart_failure_and_reduced_ejection_fraction
H-661	-0.6020265221595764	▁angin io ten sin - con ver ting _ ▁enzym e ▁inhibi tors angi oten sin _ ▁receptor _ block ers ▁β - block ers ▁heart ▁failure ▁e je ction _ fraction
D-661	-0.6020265221595764	anginiotensin-converting_ enzyme inhibitorsangiotensin_ receptor_blockers β-blockers heart failure ejection_fraction
P-661	-7.0922 -2.8014 -0.1384 -1.3530 -0.6058 -0.0170 -0.0312 -0.2357 -0.1693 -0.2384 -0.0242 -0.0733 -0.1332 -0.2632 -0.0303 -0.6623 -0.6051 -0.0123 -1.4405 -0.7187 -0.0110 -0.0184 -0.0243 -0.0748 -0.0334 -1.3227 -0.6396 -0.6735 -0.0397 -0.0821 -0.5330 -0.0551 -0.2027 -0.1129
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary_approaches_to_stop_hypertension dash left_ventricular_diastolic_function arterial_elastance ventricular-arterial_coupling hypertensive_hfpef
H-918	-0.5460041761398315	▁so dium - re strict ed _ ▁dieta ry _ ▁approach es ▁hyper tension ▁die t DAS h ▁s rd ▁left _ ▁vent ri cular _ ▁dia sto lic _ ▁function ▁arterial ▁elastan ce ▁vent ri cular - arte rial _ ▁coup ling ▁hyper tensi ve _ h FP EF
D-918	-0.5460041761398315	sodium-restricted_ dietary_ approaches hypertension dietDASh srd left_ ventricular_ diastolic_ function arterial elastance ventricular-arterial_ coupling hypertensive_hFPEF
P-918	-0.0115 -0.0254 -0.0055 -0.0038 -0.0249 -0.0154 -0.4741 -2.7186 -0.6616 -0.6839 -0.6995 -0.0301 -3.9653 -0.0446 -2.3042 -0.0433 -0.1637 -0.1375 -2.2273 -0.5300 -0.8320 -0.5126 -0.7949 -1.0220 -0.1498 -0.5180 -0.7749 -0.0109 -0.0378 -0.5911 -0.5136 -0.0088 -0.8784 -0.0647 -0.0041 -1.0205 -0.1787 -0.0768 -0.1048 -0.0349 -0.2073 -0.2918 -0.2046 -0.1871 -0.1075 -0.0314 -1.5392 -0.5549 -1.1884 -0.8950 -0.1861 -0.0996
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute_hf relax-ahf astronaut pronto patient patients end_points
H-1017	-0.5092761516571045	▁a cute _ HF ▁RELA x - a HF ▁ AST RON AUT ▁PR ONTO ▁patient ▁en roll ment ▁patients
D-1017	-0.5092761516571045	acute_HF RELAx-aHF ASTRONAUT PRONTO patient enrollment patients
P-1017	-0.4051 -0.0341 -0.0492 -0.7840 -1.7500 -1.1963 -0.0099 -0.0839 -1.6713 -0.6756 -0.3954 -0.2991 -0.0817 -0.0879 -0.0122 -0.7335 -0.2477 -0.0972 -0.0569 -2.0476 -0.3935 -0.0920
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol carvedilol sympathetic_activity von_willebrand_factor
H-1119	-0.47165346145629883	▁met o pro lol ▁car vedi lol ▁sympa the tic _ activ iteit ▁von _ Will e brand _ ▁factor ▁ar g 16 ▁g l n 27 ▁g ly 16 ▁g lu 27
D-1119	-0.47165346145629883	metoprolol carvedilol sympathetic_activiteit von_Willebrand_ factor arg16 gln27 gly16 glu27
P-1119	-0.1220 -0.1985 -0.0163 -0.0951 -0.0267 -0.0649 -0.1597 -0.4359 -0.3494 -0.7420 -0.6653 -0.2653 -0.1942 -1.7175 -0.3584 -2.1242 -0.0637 -0.0155 -0.4357 -0.9189 -0.8371 -0.0439 -0.9933 -0.2924 -0.2847 -0.0090 -0.4559 -0.0690 -0.5907 -0.4062 -1.9177 -0.9344 -0.3632 -0.2526 -0.0889
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized hf international_classification_of_diseases clinical principal discharge diagnosis
H-1832	-0.38745635747909546	▁ HF ▁international _ ▁Classifica tion _ of _ ▁Disease s ▁Nin th _ re vision ▁Clinic al _ ▁Modifica tion ▁code s ▁dis charge
D-1832	-0.38745635747909546	HF international_ Classification_of_ Diseases Ninth_revision Clinical_ Modification codes discharge
P-1832	-2.5335 -0.8903 -1.6290 -0.4384 -0.0147 -0.0170 -0.0634 -0.2660 -0.1712 -0.0514 -0.0121 -0.0112 -0.0138 -0.0310 -0.2129 -0.0960 -0.2449 -0.0125 -0.1088 -0.1503 -0.0793 -0.2485 -0.0527 -1.5062 -0.0686 -1.4049 -0.1328
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad q65p movement wild-type_rad q65p l-type_channel rgk_proteins
H-1676	-0.6911951899528503	▁Rad ▁Q 65 p ▁ga ting _ ▁movement ▁wild - type _ Rad ▁Q 65 p ▁l - type _ ▁channel ▁inhibi tion ▁r GK _ ▁protein s
D-1676	-0.6911951899528503	Rad Q65p gating_ movement wild-type_Rad Q65p l-type_ channel inhibition rGK_ proteins
P-1676	-0.5097 -1.4832 -0.4478 -0.5654 -2.9773 -0.0175 -0.3782 -0.4670 -1.2560 -0.0200 -0.0031 -0.1065 -1.4181 -1.5206 -0.2126 -0.4130 -3.8070 -0.0514 -0.0021 -0.0169 -2.4632 -0.1298 -0.2074 -0.6533 -0.2038 -0.8040 -0.1879 -0.0517 -0.2419 -0.1195
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 heart_failure proteomics actin_cytoskeleton ss20 mitochondrial metabolic_pathways
H-876	-0.6869294047355652	▁heart ▁failure ▁prote o mics ▁act in _ ▁cy tos kelet on _ ▁path ways ▁SS 20 ▁mito cho ndri al ▁metabol ic _ ▁path ways
D-876	-0.6869294047355652	heart failure proteomics actin_ cytoskeleton_ pathways SS20 mitochondrial metabolic_ pathways
P-876	-4.4087 -1.7383 -1.8274 -1.4827 -0.0097 -1.0015 -0.1466 -0.4943 -1.3408 -0.7754 -0.0860 -0.2413 -1.8965 -0.8495 -0.0270 -0.7022 -0.0694 -0.0629 -0.1183 -0.0724 -0.0326 -0.0707 -0.0125 -0.5380 -0.5588 -0.0273 -0.5215 -0.1217
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms left_ventricular_base midpapillary apex baseline ivc_occlusion bivp ste rs
H-324	-0.3903449773788452	▁e cho card i ogram s ▁left _ ▁vent ri cular _ ▁base ▁mid pap illa ry ▁ap ex ▁base line ▁IV c ▁oc clusi on ▁Bi VP ▁ STE ▁twist ▁ap ical ▁bas al ▁rota tions ▁CS ▁RS ▁synchron y
D-324	-0.3903449773788452	echocardiograms left_ ventricular_ base midpapillary apex baseline IVc occlusion BiVP STE twist apical basal rotations CS RS synchrony
P-324	-0.2930 -0.0182 -0.0768 -0.1137 -0.0096 -0.1087 -0.1763 -0.7109 -0.5178 -0.4908 -0.1468 -0.2909 -0.5379 -0.0452 -0.1809 -0.0556 -0.2621 -0.3455 -0.0248 -1.1906 -0.0141 -0.4828 -0.3569 -1.3409 -0.0010 -0.0570 -0.8214 -0.0937 -1.4899 -1.9001 -1.6708 -0.9556 -0.0228 -0.3581 -0.0057 -0.5218 -0.2259 -0.3443 -0.1220 -0.0290 -0.1208 -0.1696 -0.0846
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration pyridostigmine coronary_artery_ligation cardiac sympathetic_tone cardiac_remodeling left_ventricular_dysfunction hf
H-1145	-0.30814099311828613	▁py rido stig mine ▁corona ry _ ▁arter y _ ▁liga tion ▁cardiac ▁va gal ▁sympa the tic _ ▁tone ▁cardiac ▁remodel ing ▁left _ ▁vent ri cular _ ▁dys function ▁ HF
D-1145	-0.30814099311828613	pyridostigmine coronary_ artery_ ligation cardiac vagal sympathetic_ tone cardiac remodeling left_ ventricular_ dysfunction HF
P-1145	-0.2709 -0.0101 -0.0031 -0.0820 -0.0802 -0.4663 -0.3458 -0.1136 -0.2429 -1.1199 -0.0672 -0.2558 -0.4092 -0.5434 -0.0336 -0.1104 -0.2120 -0.4577 -0.1948 -0.2654 -0.0424 -0.4127 -0.0189 -0.0196 -0.3780 -0.9193 -0.9552 -0.4648 -0.6864 -0.1053 -0.0637 -0.5587 -0.2104 -0.5757 -0.0891
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes patients new_york_heart_association nyha heart_failure eplerenone placebo heart_failure medicines emphasis-hf
H-1229	-0.823910117149353	▁New _ York _ ▁Heart _ association NY ha ▁Class _ ▁II _ ▁Heart _ ▁Fail ure ▁e pler en one ▁Place bo ▁standard _ ▁Heart _ ▁Fail ure ▁Medicine s EMP ha SIS - HF
D-1229	-0.823910117149353	New_York_ Heart_associationNYha Class_ II_ Heart_ Failure eplerenone Placebo standard_ Heart_ Failure MedicinesEMPhaSIS-HF
P-1229	-3.9445 -0.7885 -2.9509 -0.1269 -1.4974 -0.2536 -1.0446 -0.9777 -0.9165 -1.1828 -0.2217 -0.5895 -0.0775 -0.5446 -1.3390 -0.0655 -0.7035 -0.2693 -0.0051 -0.0465 -0.1589 -4.1078 -0.0117 -2.2543 -0.0792 -0.5776 -1.4553 -0.0792 -0.8062 -0.3909 -0.0280 -0.1669 -0.9394 -1.4593 -0.1038 -0.1806 -0.7926 -0.1713
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge patients follow-up physician physician
H-1418	-1.18160080909729	▁dis charge ▁follow - up
D-1418	-1.18160080909729	discharge follow-up
P-1418	-4.4437 -0.4594 -0.1965 -0.1881 -0.0245 -2.7973 -0.1617
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life_expectancy heart_failure patients disease terminal_heart_failure
H-1665	-1.245924472808838	▁heart ▁failure ▁re frac tory ▁terminal _ heart ▁failure
D-1665	-1.245924472808838	heart failure refractory terminal_heart failure
P-1665	-5.1744 -1.0162 -1.2286 -0.0796 -0.1332 -2.6264 -0.1225 -1.7518 -1.2008 -0.2067 -0.1648
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart_failure discharges university_of_connecticut_health_center patients follow-up
H-723	-1.0513324737548828	▁heart _ ▁failure _ ▁dis charge s ▁University _ of _ ▁Connect i cut _ health ▁Center
D-723	-1.0513324737548828	heart_ failure_ discharges University_of_ Connecticut_health Center
P-723	-5.3285 -1.3530 -0.1879 -1.4800 -1.1856 -0.0366 -0.1106 -1.3592 -0.3617 -0.7266 -0.3186 -2.5838 -0.0259 -0.1273 -0.1318 -1.2288 -1.5852 -1.7285 -0.1156
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary_capillary_wedge_pressure baseline right_atrial_pressure pulmonary_arterial_pressure pulmonary_resistance
H-1959	-0.696735143661499	▁Pul mon ary _ cap illa ry _ ▁we dge _ ▁pressure ▁h g ▁s d ▁right _ at rial _ ▁pressure ▁pulmonar y _ ▁arterial _ ▁pressure ▁pulmonar y _ ▁resist ance
D-1959	-0.696735143661499	Pulmonary_capillary_ wedge_ pressure hg sd right_atrial_ pressure pulmonary_ arterial_ pressure pulmonary_ resistance
P-1959	-0.4101 -1.3340 -0.4914 -0.1015 -0.2790 -0.2263 -0.3506 -0.3362 -1.2131 -0.1486 -0.2954 -0.5308 -3.1795 -0.2779 -3.6759 -2.5841 -0.3677 -0.1034 -1.2835 -0.1245 -0.5517 -0.6113 -0.0031 -0.0381 -0.5935 -0.0365 -0.3301 -0.9749 -0.0008 -0.0913 -0.4039 -3.0263 -0.0278 -0.2832 -0.0998
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute_heart_failure hf pharmacologic therapeutics calcium-sensitizing_agents antagonists endothelin vasopressin adenosine
H-1015	-0.3858219087123871	▁a cute _ heart _ ▁failure HF ▁ pharma c ologic _ studie s ▁calci um - sensi t izing _ agent ▁en do the lin ▁vaso press in ▁ad enos ine
D-1015	-0.3858219087123871	acute_heart_ failureHF pharmacologic_studies calcium-sensitizing_agent endothelin vasopressin adenosine
P-1015	-0.2438 -0.0577 -0.0170 -1.2744 -0.6682 -0.0930 -0.7026 -0.5511 -0.9263 -0.0589 -0.1017 -1.5701 -0.5700 -0.1958 -0.1217 -0.0229 -0.0429 -0.0512 -1.2078 -0.0115 -0.6422 -0.2377 -0.4166 -0.0459 -0.1000 -1.8141 -0.0038 -0.0097 -0.1008 -0.0154 -0.0108 -0.8428 -0.2755 -0.1142
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic_insufficiency mechanical_circulatory_support continuous_flow left_ventricular_assist_devices lvads pulsatile_devices
H-542	-0.4276026487350464	▁a or tic _ insu ffi cie ncy AI ▁mechanic al _ ▁circula tory _ support ▁continuo us _ ▁flow CF ▁left _ ▁vent ri cular _ assist ▁devices ▁l VAD s ▁pulsa tile _ ▁devices
D-542	-0.4276026487350464	aortic_insufficiencyAI mechanical_ circulatory_support continuous_ flowCF left_ ventricular_assist devices lVADs pulsatile_ devices
P-542	-0.6304 -0.2508 -1.6681 -0.0916 -0.9276 -0.1730 -0.5562 -0.0721 -2.3414 -0.2795 -0.0189 -0.8715 -0.0290 -0.1000 -0.1979 -0.7880 -0.0172 -0.2047 -0.0662 -0.5791 -1.2694 -0.0869 -0.2085 -0.8470 -0.5066 -0.2377 -0.1332 -0.2681 -1.0463 -0.1144 -0.0207 -0.0465 -0.0541 -0.0404 -0.3283 -0.6681 -0.3536 -0.1560
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in_vivo hf phenylephrine haemodynamic surgical transverse_aortic_constriction tac jq1 pathological cardiac_hypertrophy
H-1047	-0.531205952167511	▁in ▁vivo _ experiment s ▁ HF ▁induc ed ▁mi ce ▁ phen yle ph rine ▁ha emo dynamic _ stress ▁trans verse _ a or tic _ con stri ction TAC ▁j q 1 ▁cardiac _ ▁hyper trop hy
D-1047	-0.531205952167511	in vivo_experiments HF induced mice phenylephrine haemodynamic_stress transverse_aortic_constrictionTAC jq1 cardiac_ hypertrophy
P-1047	-3.8519 -0.0143 -0.6319 -0.4800 -0.1244 -0.5579 -0.1043 -1.5285 -0.2414 -1.0977 -0.0779 -0.3133 -0.0074 -0.0081 -0.1070 -0.0280 -0.0031 -0.0131 -0.0014 -0.0668 -0.7022 -0.7502 -0.8921 -0.0408 -0.6870 -0.3843 -1.6055 -0.0310 -0.9624 -0.5820 -0.0347 -1.2938 -0.2854 -1.1295 -0.8896 -0.3973 -0.5808 -0.8575 -0.0093 -0.7538 -0.1166 -0.0662
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence drugs drugs raas renin_inhibitors endopeptidase_inhibitors vasopeptidase_inhibitors angiotensin_receptor_blockers
H-1490	-0.38223955035209656	▁drugs ▁RA as ▁direct _ re nin ▁inhibi tors ▁neutral _ en dop ep tida se _ ▁inhibi tors ▁vaso pe pti das e ▁inhibi tors ▁ang io ten sin _ ▁receptor _ block ers
D-1490	-0.38223955035209656	drugs RAas direct_renin inhibitors neutral_endopeptidase_ inhibitors vasopeptidase inhibitors angiotensin_ receptor_blockers
P-1490	-1.4982 -0.5790 -0.0679 -0.0016 -0.1947 -0.2185 -1.8645 -0.6719 -0.0264 -0.0321 -0.3412 -0.5792 -0.0857 -0.4043 -0.0091 -0.0474 -0.2916 -0.0149 -0.0297 -0.0036 -0.1270 -0.0653 -1.3218 -0.0165 -0.7815 -0.0457 -0.2549 -0.1484 -0.0691 -0.4599 -1.1079 -0.0019 -1.6067 -0.5857 -0.0158 -0.4246 -0.1486
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 healthy cardiomyocytes camp inotropic_effect acute β-ar contractility
H-1216	-0.35169702768325806	▁p de 2 ▁over expression ▁cardio my o cy tes ▁c AMP ▁ca 2 ▁in o tropi c ▁β - AR _ stimul ation ▁bas al _ contract ility
D-1216	-0.35169702768325806	pde2 overexpression cardiomyocytes cAMP ca2 inotropic β-AR_stimulation basal_contractility
P-1216	-0.3693 -0.1858 -0.0419 -0.6996 -0.0387 -1.1749 -0.7052 -0.3327 -0.1960 -0.0428 -0.0023 -0.0321 -1.6837 -0.0822 -0.1822 -0.8435 -0.0337 -0.0669 -0.4576 -0.0063 -0.5251 -1.0574 -0.1082 -0.0490 -0.0138 -0.0425 -0.1877 -0.6228 -0.6994 -0.2900 -0.1293
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck_stent implanted lad circumflex_artery lcx lcx lad
H-505	-0.6000237464904785	▁bottle ne ck _ ▁sten t ▁proxima l _ ▁left _ ▁anterior _ ▁descend ing LAD ▁proxima l _ ▁circum flex _ ▁arter y ▁l x ▁proxima l _ LC x ▁mid _ LAD
D-505	-0.6000237464904785	bottleneck_ stent proximal_ left_ anterior_ descendingLAD proximal_ circumflex_ artery lx proximal_LCx mid_LAD
P-505	-0.1427 -0.0590 -0.0194 -0.3919 -2.3055 -0.0398 -1.3951 -0.0137 -0.1731 -1.1621 -0.1296 -0.2323 -0.2776 -0.0253 -0.0235 -1.4869 -0.0373 -0.0304 -0.0985 -0.3586 -0.0097 -0.9676 -0.1348 -0.1400 -0.5361 -2.0742 -0.0465 -0.0093 -0.2481 -3.9022 -0.6936 -1.1596 -0.4750 -0.7992 -1.8547 -0.1480
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute_myocardial_infarction ami incidence deaths heart_failure hf ami
H-1306	-1.0150138139724731	▁a cute _ mi o card ial _ in far ction AMI ▁heart ▁failure HF ▁complicat ing AMI
D-1306	-1.0150138139724731	acute_miocardial_infarctionAMI heart failureHF complicatingAMI
P-1306	-3.4304 -0.2002 -0.0543 -4.4369 -0.6937 -0.6640 -1.2779 -0.1167 -0.3221 -0.1446 -0.1195 -1.4758 -2.6419 -0.2736 -0.4678 -1.9765 -0.1776 -1.3563 -0.3697 -0.1007
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac_washout carvedilol metoprolol β2-adrenergic_receptor_haplotype
H-1117	-0.7533049583435059	▁i - mi BG ▁cardiac _ was hout ▁car vedi lol ▁met o pro lol ▁β 2- ad r energi c _ ▁receptor ▁ha plo type
D-1117	-0.7533049583435059	i-miBG cardiac_washout carvedilol metoprolol β2-adrenergic_ receptor haplotype
P-1117	-0.0617 -0.7454 -0.8046 -4.6285 -1.4004 -0.9660 -5.1467 -0.2659 -0.1168 -0.0160 -0.0906 -0.2966 -0.7276 -0.0538 -0.1747 -3.0370 -0.0507 -0.0677 -0.2774 -0.7881 -0.0346 -0.2241 -0.3041 -0.3307 -0.0355 -0.0039 -0.2814 -0.1620
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle_aerobic_capacity postexercise_phosphocreatine_resynthesis fontan
H-1502	-0.38988518714904785	▁mus cle _ ▁aero bic _ ▁capacity ▁poste xer ci se _ phos pho creati ne _ re syn the sis ▁Font an ▁adults
D-1502	-0.38988518714904785	muscle_ aerobic_ capacity postexercise_phosphocreatine_resynthesis Fontan adults
P-1502	-0.2633 -0.1036 -0.9635 -0.2087 -0.1667 -0.3252 -1.1660 -0.1212 -0.0225 -0.0207 -0.4375 -0.2491 -0.0284 -0.1305 -0.4810 -2.2898 -0.2809 -0.3771 -0.0312 -0.3228 -0.6031 -0.1137 -0.0918 -0.8733 -0.3606 -0.1049
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac_resynchronization_therapy crt patients heart_failure hf outcomes crt dialysis reported
H-904	-0.7462219595909119	▁Card iac _ re syn chron ization _ therapy ▁c RT ▁di al ysis - dependent _ ▁patients ▁heart ▁failure HF ▁c RT ▁di al ysis
D-904	-0.7462219595909119	Cardiac_resynchronization_therapy cRT dialysis-dependent_ patients heart failureHF cRT dialysis
P-904	-1.1210 -0.0664 -0.3350 -0.1839 -0.0329 -0.0020 -1.0077 -0.8267 -0.1307 -0.6144 -2.1702 -1.3616 -0.1070 -0.0614 -0.1696 -0.0643 -1.5303 -1.0391 -2.0180 -0.7694 -0.5616 -1.2540 -2.4700 -2.3481 -0.1355 -0.2302 -0.1943 -0.0887
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone patients hyperkalemia renal_function emphasis-hf eplerenone patients hospitalization heart_failure
H-1221	-0.5462982654571533	▁e pler en one ▁hyper kal emia ▁renal _ ▁function ▁EM PHA SIS - HF ▁e pler en one _ in _ ▁Mil d ▁Patient s ▁Hospital ization ▁Sur v I val ▁Heart ▁Fail ure
D-1221	-0.5462982654571533	eplerenone hyperkalemia renal_ function EMPHASIS-HF eplerenone_in_ Mild Patients Hospitalization SurvIval Heart Failure
P-1221	-0.1054 -0.2769 -0.1768 -0.7401 -0.6991 -0.2609 -0.0282 -0.0281 -0.7081 -0.7038 -1.3835 -0.0729 -0.4017 -0.0392 -0.1060 -0.0905 -0.0928 -0.1706 -0.4722 -4.7383 -0.4462 -0.4991 -0.7210 -0.0185 -0.8643 -0.0657 -0.3753 -0.7554 -0.3247 -0.0549 -1.5959 -0.0188 -0.8297 -0.8973 -1.0872 -0.1720 -0.1921
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ventricular_mass cardiac_apoptosis fibrosis cardiac_metabolic_gene_expression atp
H-655	-0.6038017272949219	▁h - d ko ▁vent ri cular _ ▁mass ▁cardiac _ ▁apo pto sis ▁fibro sis ▁Akt _ for k head _ ▁box ▁o -1 ▁cardiac _ ▁metabol ic _ ▁gene ▁expression ▁ATP
D-655	-0.6038017272949219	h-dko ventricular_ mass cardiac_ apoptosis fibrosis Akt_forkhead_ box o-1 cardiac_ metabolic_ gene expression ATP
P-655	-1.1597 -0.3482 -0.5316 -0.3954 -0.9541 -0.9339 -0.4527 -0.5404 -0.9152 -0.0457 -0.7287 -0.5573 -0.0665 -0.2404 -0.0022 -0.0539 -0.8887 -3.3701 -0.1328 -0.1397 -0.7651 -0.1851 -0.2883 -1.7811 -0.6563 -0.6306 -1.3862 -0.0168 -0.0077 -0.4436 -0.3478 -0.5251 -0.7856 -0.7386 -0.1182
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp shock_therapy
H-863	-0.6922948360443115	▁in appropria te _ ▁ATP ▁in appropria te _ ▁shock _ therapy HR
D-863	-0.6922948360443115	inappropriate_ ATP inappropriate_ shock_therapyHR
P-863	-0.5436 -0.0486 -0.0604 -0.4875 -2.2039 -1.9225 -0.1207 -0.0662 -0.1546 -0.9433 -0.4534 -0.0228 -2.5967 -0.5889 -0.1715
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint cardiorespiratory_fitness crf body_mass_index heart_failure hf mortality cardiovascular hf mortality
H-1766	-0.6700880527496338	▁cardio re spira tory _ ▁fitness cr f ▁body ▁mass ▁index ▁heart ▁failure ▁ HF ▁cardiovascular _ risk ▁factors ▁ HF _ ▁mortal ity ▁fit ▁un fit _ ▁men
D-1766	-0.6700880527496338	cardiorespiratory_ fitnesscrf body mass index heart failure HF cardiovascular_risk factors HF_ mortality fit unfit_ men
P-1766	-2.2166 -0.0223 -0.2457 -0.1464 -0.2255 -0.8736 -0.9340 -2.2803 -0.0431 -0.4311 -0.0247 -0.2841 -0.5149 -1.7936 -0.0593 -0.7476 -0.8932 -0.6847 -1.2348 -0.4528 -0.2875 -1.9200 -0.2845 -0.8291 -0.3673 -0.7044 -0.0456 -0.2191 -1.3668 -0.4615 -0.1786
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized heart_failure dipeptidyl_peptidase-4 dpp-4 antihyperglycemic_agents
H-1827	-0.6361865401268005	▁post marketing _ ▁trial s ▁hospital ized _ heart _ ▁failure ▁h HF ▁di pe pti dy l _ ▁pep tida se -4 ▁d PP -4 ▁inhibi tors ▁anti hy per gly ce mic _ agent
D-1827	-0.6361865401268005	postmarketing_ trials hospitalized_heart_ failure hHF dipeptidyl_ peptidase-4 dPP-4 inhibitors antihyperglycemic_agent
P-1827	-0.7680 -0.0834 -3.3157 -0.6028 -0.0537 -3.1306 -0.1613 -0.2019 -1.5433 -1.0489 -0.0908 -0.5778 -0.4473 -0.0445 -0.0155 -0.0335 -4.7518 -1.4664 -0.2991 -0.0149 -0.0161 -0.2074 -0.0789 -0.0941 -0.5884 -0.0932 -1.1792 -0.1341 -0.0267 -0.6216 -0.0240 -0.1581 -0.1348 -0.4092 -1.0147 -0.2381 -0.3642 -0.1408
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox_modeling heart_failure_patient_severity_index hfpsi university_of_michigan hf clinic primary_outcome
H-380	-0.673100471496582	▁co x _ model ing ▁Heart _ ▁Fail ure _ ▁Patient _ ▁Sever ity _ index ▁h PSI ▁University _ of _ ▁Michigan ▁ HF _ ▁clinic um _ co hor t
D-380	-0.673100471496582	cox_modeling Heart_ Failure_ Patient_ Severity_index hPSI University_of_ Michigan HF_ clinicum_cohort
P-380	-0.7509 -0.0701 -1.8820 -0.9592 -0.0311 -1.1636 -1.5067 -0.1104 -0.2929 -0.2189 -0.1798 -0.7193 -0.0933 -0.7797 -0.3141 -0.4062 -2.3612 -1.7133 -0.9978 -0.2073 -0.6497 -0.1997 -0.1229 -1.1149 -0.9336 -1.1618 -0.3046 -0.4342 -1.3098 -0.7351 -0.5545 -0.0204 -0.4671 -0.1194
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart_rate cardiac patients patients acute_myocardial_infarction ami patients congestive_heart_failure chf left_ventricular dysfunction
H-1585	-0.8888137340545654	▁Heart ▁rate HR ▁cardiac _ ▁patients ▁a cute _ ▁my o card ial _ in far ction AMI ▁con ges tive _ ▁heart ▁failure CH f ▁left _ ▁vent ri cular LV
D-1585	-0.8888137340545654	Heart rateHR cardiac_ patients acute_ myocardial_infarctionAMI congestive_ heart failureCHf left_ ventricularLV
P-1585	-0.8481 -2.4501 -1.5643 -3.0573 -1.6187 -0.7487 -0.3447 -0.0274 -0.0914 -4.6951 -0.3970 -0.3088 -1.3281 -0.1639 -0.3554 -0.0855 -0.1375 -0.3337 -0.1327 -0.1235 -2.2310 -0.0822 -1.9750 -0.4101 -2.1063 -0.7977 -0.0176 -0.2394 -1.2351 -0.7123 -0.2175 -0.3351 -0.9044 -0.1442
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular_cardiomyocytes chronic insulin irs1 irs2 proteins insulin p38 cardiac_dysfunction insulin_resistance type_2_diabetes
H-657	-0.44700586795806885	▁ne ona tal _ ▁rat ▁vent ri cular _ ▁cardio my o cy tes ▁chronic _ ▁insulin ▁exposure ▁i RS 1 ▁i RS 2 _ ▁protein s ▁insulin ▁action ▁cardiac _ ▁dys function ▁insulin ▁resist ance ▁type _ ▁diabetes
D-657	-0.44700586795806885	neonatal_ rat ventricular_ cardiomyocytes chronic_ insulin exposure iRS1 iRS2_ proteins insulin action cardiac_ dysfunction insulin resistance type_ diabetes
P-657	-0.0350 -0.0096 -0.0230 -0.0913 -0.7438 -0.2626 -0.5368 -0.3502 -0.1167 -0.1262 -0.9785 -0.2039 -0.0882 -0.0579 -0.1668 -0.1170 -1.0844 -0.6996 -0.9701 -0.0172 -1.0328 -0.6398 -0.0807 -0.0614 -1.6948 -0.2101 -0.0196 -0.6416 -1.6748 -1.0264 -1.2078 -0.0553 -0.0109 -0.0140 -0.2142 -0.0089 -0.0497 -0.8721 -1.7518 -0.2587 -0.1232
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms left_ventricular midpapillary atrioventricular_delay avd interventricular_delay vvd ste circumferential_strain radial_strain rs
H-323	-0.41687455773353577	▁e cho card i ogram s ▁left _ ▁vent ri cular _ mid pap illa ry ▁level ▁at rio ven tri cular _ de lay ▁v d ▁interven tri cular _ de lay ▁v d ▁ste ▁circum fer ential _ ▁strain CS ▁radi al _ ▁strain RS
D-323	-0.41687455773353577	echocardiograms left_ ventricular_midpapillary level atrioventricular_delay vd interventricular_delay vd ste circumferential_ strainCS radial_ strainRS
P-323	-0.6370 -0.0241 -0.1126 -0.1257 -0.0142 -0.2634 -0.1600 -0.9230 -0.5777 -0.8784 -0.3811 -0.1027 -0.0223 -0.6069 -0.2517 -0.5599 -1.1247 -1.0004 -0.4854 -0.0399 -0.1503 -0.3002 -0.3852 -1.0074 -0.0325 -0.6739 -0.3117 -0.0026 -0.1422 -0.1382 -0.3847 -0.5723 -0.0706 -0.0779 -0.2017 -2.0424 -0.2335 -0.1498 -0.2748 -0.1547 -0.2555 -2.8570 -0.0426 -0.0709 -0.1153 -0.5199 -0.5638 -0.3173 -0.0867
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients new_york_heart_association nyha functional_class hf ejection_fractions chronic stable guideline-directed_medical_therapy gdmt united_states canada europe
H-1870	-0.5466567873954773	▁New ▁York _ ▁Heart _ association NY HA ▁functional _ class _ ▁III ▁ HF ▁e je ction _ fraction s ▁chronic _ ▁stable _ ▁guide line - direct ed _ ▁medical _ therapy GD MT
D-1870	-0.5466567873954773	New York_ Heart_associationNYHA functional_class_ III HF ejection_fractions chronic_ stable_ guideline-directed_ medical_therapyGDMT
P-1870	-1.1314 -1.5301 -0.0700 -1.4904 -0.2272 -1.0509 -0.4707 -1.1190 -0.0618 -0.2748 -0.7656 -0.6826 -0.3733 -1.1787 -0.1400 -0.0287 -0.0385 -0.0322 -0.4528 -0.0108 -0.0312 -0.1866 -0.2466 -1.1929 -0.7604 -1.9640 -0.0124 -0.2101 -0.0021 -0.0872 -0.0371 -1.2503 -0.5740 -0.0185 -1.1309 -1.0468 -0.8089 -0.0834
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients qrs hazard_ratio primary_outcome patients qrs hazard_ratio
H-889	-0.7010645866394043	▁non - LB bb ▁QR s
D-889	-0.7010645866394043	non-LBbb QRs
P-889	-0.3098 -0.0353 -0.5266 -0.8973 -0.3580 -0.7090 -2.6205 -0.1520
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka change riiα cα expression riiα ser96 cα thr197 phosphorylation hf
H-1428	-0.6835231184959412	▁p ka _ sub un its ▁type _ ▁II _ ▁regulator y RI i α ▁cata ly tic ▁c α ▁r II α ▁ser 96) ▁c α ▁ phos phor y lation ▁ HF
D-1428	-0.6835231184959412	pka_subunits type_ II_ regulatoryRIiα catalytic cα rIIα ser96) cα phosphorylation HF
P-1428	-0.4133 -0.3377 -2.6739 -1.0137 -0.3910 -0.0093 -0.1162 -0.3963 -0.7064 -0.2231 -1.5030 -0.1641 -1.5518 -0.2581 -0.2275 -0.1060 -0.1850 -0.3285 -1.2123 -1.2134 -1.2366 -1.4753 -0.3371 -0.5850 -0.2352 -0.5879 -0.3984 -3.0302 -0.3243 -0.2346 -0.4130 -0.0656 -2.0400 -0.3700 -0.1693 -0.0739
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous_hf myofiber_shortening septum myofiber_shortening stretch wall
H-1155	-0.764090895652771	▁ab normal _ ca (2 +) ▁handling ▁dys syn chron ous _ HF ▁my o fi ber ▁short en ing _ ▁veloci ty ▁sept um ▁de press es ▁my o fi ber ▁short en ing ▁stretch _ ▁rate ▁lateral _ wind
D-1155	-0.764090895652771	abnormal_ca(2+) handling dyssynchronous_HF myofiber shortening_ velocity septum depresses myofiber shortening stretch_ rate lateral_wind
P-1155	-3.4192 -0.0471 -1.2189 -0.0608 -0.1098 -0.0013 -2.0471 -0.1314 -0.0178 -0.0079 -1.1146 -0.0995 -1.7674 -3.1458 -0.1634 -0.0285 -0.0967 -3.5241 -0.0480 -0.2844 -1.2887 -0.2815 -0.0622 -0.4154 -0.0197 -1.8585 -0.0455 -0.1137 -1.6696 -0.1006 -0.0191 -0.0949 -1.6450 -0.0445 -0.1927 -0.6564 -1.4272 -0.6160 -1.0360 -0.2312 -3.2862 -0.2564 -0.1610
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells transforming_growth_factor-β tgf-β epithelial mesenchymal transition expression pluripotency_markers
H-1342	-0.4684309959411621	▁CHF - der i ved ▁c - K it _ + ▁cell s ▁transform ing _ ▁growth _ factor - β ▁t GF - β ▁epi the li al ▁mes en chy mal _ ▁transition _ ▁marker s ▁pluri pote ncy _ ▁marker s ▁sham s
D-1342	-0.4684309959411621	CHF-derived c-Kit_+ cells transforming_ growth_factor-β tGF-β epithelial mesenchymal_ transition_ markers pluripotency_ markers shams
P-1342	-3.2446 -0.1714 -1.2967 -0.1175 -0.2445 -0.0245 -0.1086 -1.5820 -0.0166 -0.5925 -2.0818 -0.7207 -0.0533 -1.9948 -0.0457 -0.5666 -1.2153 -0.5122 -0.7607 -0.2585 -0.0258 -0.5829 -0.3442 -0.0315 -0.0227 -0.3494 -0.0363 -0.0862 -0.0126 -0.0338 -0.1274 -0.2407 -1.3480 -0.0846 -1.2072 -0.9706 -0.1290 -0.0185 -0.1420 -0.0616 -0.0366 -0.4412 -0.1430 -0.0192 -0.0234 -0.0839 -0.1430 -0.1308
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics proteomics transverse_aortic_constriction tac heart_failure signaling_pathway ingenuity_pathway_analysis
H-871	-0.7309482097625732	▁label - free _ shot gun ▁prote o mics ▁trans verse _ a or tic _ con stri ction TAC - indu ced _ heart _ ▁failure
D-871	-0.7309482097625732	label-free_shotgun proteomics transverse_aortic_constrictionTAC-induced_heart_ failure
P-871	-0.7601 -0.0494 -0.0874 -0.3346 -0.8401 -0.0425 -1.7724 -1.1533 -0.0077 -2.2104 -0.5585 -0.0588 -0.6525 -0.3516 -1.8040 -0.0452 -0.9195 -1.5541 -0.0282 -1.6995 -1.9304 -0.0023 -0.1683 -0.0687 -0.8220 -1.3744 -0.0327 -1.7611 -0.1079
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients hfref left_ventricular_ejection_fraction hfpef left_ventricular_ejection_fraction β-blocker hf hospitalization
H-178	-0.6015927195549011	▁h Fr EF ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁ HF p EF ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁ RAS - ▁β - block er ▁index ▁ HF
D-178	-0.6015927195549011	hFrEF left_ ventricular_ejection fraction HFpEF left_ ventricular_ejection fraction RAS- β-blocker index HF
P-178	-0.3506 -1.3599 -1.1134 -0.4762 -0.3607 -2.0867 -1.3361 -2.0578 -0.2471 -0.4250 -0.2963 -0.4300 -1.0151 -0.0296 -0.2836 -0.4520 -0.3338 -0.2220 -0.2380 -0.2872 -2.1086 -1.9289 -1.6249 -0.3502 -0.4544 -0.4790 -0.5730 -0.8486 -0.0257 -0.3404 -0.0329 -0.0196 -0.0343 -0.0667 -0.0567 -0.0360 -0.0803 -1.3372 -0.1762 -0.5094 -0.1814
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated p70s6k pkc-βii hdl nyha-iiib malondialdehyde bound hdl nyha-iiib hdl healthy
H-257	-0.7987934350967407	▁activa tion ▁p 70 s 6 k ▁PK c - β II ▁malo ndi alde hy de ▁HD l ▁ny ha - III b
D-257	-0.7987934350967407	activation p70s6k PKc-βII malondialdehyde HDl nyha-IIIb
P-257	-1.8094 -0.1531 -0.1916 -0.4442 -0.4472 -0.1888 -1.8380 -0.0108 -0.4882 -0.0288 -0.0645 -1.0448 -1.7212 -0.0419 -0.0243 -1.2138 -0.1252 -4.1649 -1.2942 -1.3665 -0.3248 -0.1105 -1.0178 -0.0800 -2.4723 -0.1020
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross_talk g-protein-coupled_receptors physiological significance regulation hearts chronic β-adrenergic_receptor postischemic_heart_failure
H-1410	-0.4672720432281494	▁g - prote in - co up led _ ▁receptor s ▁reciproc al _ regula tion ▁mouse _ ▁heart s ▁chronic ▁β - ad r energi c _ ▁receptor _ stimul ation ▁post ische mic _ heart _ ▁failure
D-1410	-0.4672720432281494	g-protein-coupled_ receptors reciprocal_regulation mouse_ hearts chronic β-adrenergic_ receptor_stimulation postischemic_heart_ failure
P-1410	-0.5170 -0.1392 -0.0728 -0.2458 -0.0885 -0.0097 -0.0850 -0.6835 -0.1691 -0.4948 -0.1665 -2.2937 -0.0445 -0.2449 -1.5507 -0.1948 -0.0617 -0.8822 -0.8575 -0.0391 -1.1317 -0.7910 -0.0416 -0.0752 -0.4980 -0.7230 -0.0421 -0.1314 -0.1790 -2.6675 -0.3262 -0.0466 -0.2194 -0.0370 -0.4464 -0.0251 -0.9769 -1.5009 -0.0331 -0.3194 -0.1054
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise exercise
H-1989	-1.378552794456482	▁Body _ gewicht SD ▁die t _ groep SD ▁exercise _ groep SD ▁die t _ groep SD
D-1989	-1.378552794456482	Body_gewichtSD diet_groepSD exercise_groepSD diet_groepSD
P-1989	-2.5328 -2.5305 -1.2930 -1.2281 -1.4187 -0.1686 -1.0272 -0.9389 -2.3240 -1.0812 -2.0896 -0.7368 -1.4238 -3.2718 -0.2557 -0.7697 -0.8596 -1.7002 -1.8066 -0.1141
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp inflammatory biomarkers hscrp il6 patients hscrp
H-1920	-0.48148056864738464	▁NT - pro b NP ▁infla mma tory _ ▁bio mark ers ▁h s cr p ▁IL ▁6 ▁h s cr p
D-1920	-0.48148056864738464	NT-probNP inflammatory_ biomarkers hscrp IL 6 hscrp
P-1920	-0.1522 -0.1162 -0.4390 -0.5407 -0.1856 -0.1563 -0.1529 -0.3410 -0.2650 -0.3749 -0.0607 -0.0607 -0.0946 -0.0160 -0.1312 -0.5544 -1.8428 -3.3620 -1.0413 -0.0139 -0.1844 -0.3912 -0.9600 -0.1185
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection_fraction patients frail biological_phenotype death frailty deficit_index death
H-1010	-0.6134149432182312	▁e je ction _ fraction ▁fra il ▁bi ological _ ▁ph eno type ▁fra il ty ▁deficit ▁index
D-1010	-0.6134149432182312	ejection_fraction frail biological_ phenotype frailty deficit index
P-1010	-0.8027 -0.0425 -0.0156 -0.3649 -0.0162 -0.1856 -0.0766 -2.5764 -0.2033 -0.2311 -0.3578 -0.0164 -0.0013 -2.2843 -0.1628 -0.6209 -0.0192 -1.0526 -3.1176 -0.1204
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients resting_hr follow-up baseline vo2max patients resting_hr p_value
H-1945	-1.5813192129135132	▁rest ing _ HR
D-1945	-1.5813192129135132	resting_HR
P-1945	-2.6353 -0.1727 -0.4941 -0.9392 -5.0389 -0.2078
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β cell phenotype in_vitro cardiac_progenitor_function cell clinical
H-1344	-0.6272575855255127	▁t GF - β _ ▁inhibi tion ▁c - k it _ + _ ▁cell _ ▁ph eno type ▁cardiac _ ▁pro gen itor ▁function ▁cell _ exp an sion
D-1344	-0.6272575855255127	tGF-β_ inhibition c-kit_+_ cell_ phenotype cardiac_ progenitor function cell_expansion
P-1344	-1.7864 -0.6657 -0.0431 -0.0618 -0.9060 -0.4922 -0.1593 -0.0076 -0.0829 -2.0681 -0.0224 -0.1642 -1.2771 -0.6884 -1.3952 -0.5491 -0.3641 -0.0181 -0.0009 -1.6138 -0.3314 -1.2036 -0.0420 -0.1260 -1.0275 -0.2616 -0.7295 -0.4000 -0.6091 -1.7048 -1.1731 -0.0975
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets in_vitro neurohormonally heart_disease nanomolar jq1 phenylephrine-mediated_hypertrophy cardiomyocytes pathological gene_induction
H-1044	-0.3045411705970764	▁ BET s ▁neuro hormon ally _ ▁induc ed _ heart ▁disease ▁na nomo lar _ ▁dos es ▁j q 1 ▁ phen yle ph rine - media ted _ ▁hyper trop hy ▁cardio my o cy tes ▁path ological _ ▁gene ▁in duction
D-1044	-0.3045411705970764	BETs neurohormonally_ induced_heart disease nanomolar_ doses jq1 phenylephrine-mediated_ hypertrophy cardiomyocytes pathological_ gene induction
P-1044	-1.4103 -0.1923 -0.1420 -0.0731 -0.0209 -0.3678 -0.4075 -0.1755 -0.1018 -0.0703 -1.5841 -1.1250 -0.2952 -0.0080 -0.1524 -0.4647 -0.3470 -0.0013 -0.1768 -2.0549 -0.8275 -0.3265 -0.0127 -0.0057 -0.2751 -0.0133 -0.1194 -0.0598 -0.0201 -0.0457 -0.5034 -0.0021 -0.5669 -0.0554 -0.2387 -0.1399 -0.0354 -0.0149 -0.0064 -0.1795 -0.1588 -0.1613 -0.6467 -0.0208 -0.3074 -0.0944
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric_remodeling concentric_hypertrophy left_ventricular remodeling heart_failure_with_preserved_ejection_fraction hfpef eccentric_hypertrophy patients
H-1524	-0.6633937954902649	▁concentr ic _ ▁remodel ing cr ▁concentr ic _ ▁hyper trop hy CH ▁left _ ▁vent ri cular LV ▁heart ▁failure ▁pres er ved _ e je ction _ fraction HF p EF ▁ecce n tric _ ▁hyper trop hy EH
D-1524	-0.6633937954902649	concentric_ remodelingcr concentric_ hypertrophyCH left_ ventricularLV heart failure preserved_ejection_fractionHFpEF eccentric_ hypertrophyEH
P-1524	-0.0199 -0.0074 -0.1552 -1.2860 -0.0387 -0.7803 -2.3794 -0.0144 -0.0742 -1.2996 -0.0572 -0.9011 -2.1476 -0.3153 -0.3166 -1.5349 -0.7431 -0.2028 -0.2783 -5.7681 -0.2026 -0.8383 -0.0686 -0.2698 -0.0895 -0.3115 -0.1017 -0.0801 -0.1467 -0.0824 -2.4415 -0.0955 -0.7180 -0.0261 -0.0262 -0.2987 -0.0943 -1.0891 -0.0293 -0.8001 -1.9891 -0.2610 -0.1457
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat functional_status quality_of_life exercise_capacity n-terminal_pro-brain_natriuretic_peptide heart_failure hospitalizations patients nyha_functional_class_iii hf
H-1878	-0.7939485907554626	▁BAT ▁ nc - termin al _ pro - bra in _ ▁na tri ure tic _ pe pti de ▁burde n ▁heart ▁failure ▁hospital ization s ▁g m - tre ated _ ▁NY HA ▁functional _ class _ ▁III ▁ HF
D-1878	-0.7939485907554626	BAT nc-terminal_pro-brain_ natriuretic_peptide burden heart failure hospitalizations gm-treated_ NYHA functional_class_ III HF
P-1878	-0.0771 -4.5650 -2.6298 -0.0846 -0.0351 -0.0099 -0.4607 -1.0070 -0.0675 -0.0376 -0.0520 -1.7538 -0.5175 -0.0148 -0.1394 -1.2047 -0.4359 -0.3902 -0.0545 -0.2294 -1.8379 -0.0269 -1.0732 -0.3334 -4.7455 -0.9390 -0.1055 -2.5000 -0.8064 -0.1013 -0.0013 -0.4535 -1.5174 -0.8279 -0.7058 -0.7721 -0.2203 -0.8191 -0.8078 -0.6793 -1.4778 -0.1527 -0.1531 -0.1100
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change exercise exercise
H-1986	-1.3584280014038086	▁ ML HF _ Total _ ▁score ▁exercise ▁die t
D-1986	-1.3584280014038086	MLHF_Total_ score exercise diet
P-1986	-0.7283 -0.1136 -0.8219 -4.2891 -4.8693 -0.1802 -0.6068 -1.0552 -1.6399 -0.1500 -1.6761 -0.1706
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx dnx
H-1374	-0.9272661209106445	▁non pa ce ▁non - DN x ▁s ham - I nner vat ed ▁s ham - in v ▁non pa ce ▁DN x ▁s ham - DN x ▁pace ▁non - DN x ▁cm f - in v ▁pace ▁DN x ▁cm f - DN x
D-1374	-0.9272661209106445	nonpace non-DNx sham-Innervated sham-inv nonpace DNx sham-DNx pace non-DNx cmf-inv pace DNx cmf-DNx
P-1374	-0.1719 -0.2656 -0.1045 -0.1088 -0.1931 -2.9649 -0.6630 -1.5045 -0.6702 -0.0442 -2.8515 -0.0007 -0.1182 -0.0276 -1.5598 -0.4856 -0.0566 -0.1636 -0.2474 -0.2000 -0.0992 -0.0660 -1.8887 -0.1062 -1.6704 -0.1507 -0.0657 -5.4959 -0.1818 -0.2532 -0.4359 -0.0667 -3.8963 -0.3628 -2.5904 -2.2196 -0.0613 -0.0402 -0.1676 -1.5358 -2.1866 -0.1198 -3.1779 -1.7361 -0.0556 -3.5842 -0.2549 -0.4437 -0.1212
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise correlated psss btes exercise psss btes
H-1929	-1.3912469148635864	▁Exerci se _ ▁time ▁ps s ▁p s s ▁b tes
D-1929	-1.3912469148635864	Exercise_ time pss pss btes
P-1929	-3.2778 -0.0249 -1.1096 -1.3064 -2.4775 -0.6615 -3.2599 -1.7007 -0.4064 -1.5179 -0.2627 -1.9819 -0.0989
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin hgb hrqol hrqol patients heart_failure outcomes exercise training hf-action
H-836	-0.6301198601722717	▁hem o glob in ▁h gb ▁HR Qo l ▁HR Qo l ▁Heart ▁Fail ure ▁Exerci se _ training HF - ac TION
D-836	-0.6301198601722717	hemoglobin hgb HRQol HRQol Heart Failure Exercise_trainingHF-acTION
P-836	-0.3651 -0.1910 -0.0813 -0.5649 -0.6857 -0.0077 -0.4430 -0.0196 -1.6306 -0.9149 -0.0181 -1.4626 -1.6601 -0.4524 -0.3320 -2.3763 -0.0251 -0.2699 -0.9383 -1.1044 -0.0234 -0.7043 -1.2142 -0.1661 -0.1016
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv_dysfunction hazard_ratio confidence_interval cachexia hazard_ratio multivariate_analyses
H-1166	-0.7152513861656189	▁ RV _ ▁dys function haz ard _ ▁ratio ▁confidence _ ▁interval ▁ci ▁cache xia haz ard _ ▁ratio ▁ci
D-1166	-0.7152513861656189	RV_ dysfunctionhazard_ ratio confidence_ interval ci cachexiahazard_ ratio ci
P-1166	-1.3455 -0.9401 -1.8205 -0.2305 -0.0722 -1.0551 -0.0120 -0.8366 -0.2275 -1.2739 -0.7586 -0.0808 -1.7097 -0.4010 -0.3667 -0.2063 -0.0677 -0.4470 -0.0809 -2.4730 -1.0839 -0.2461
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial_fibrillation congestive_heart_failure health_care expenditures patients québec randomized rhythm rate-control
H-1234	-0.8422852754592896	▁At rial _ fi bril lation ▁con ges tive _ ▁Heart _ ▁Fail ure ▁Québec ▁ rhythm ▁rate - control _ ▁treatment
D-1234	-0.8422852754592896	Atrial_fibrillation congestive_ Heart_ Failure Québec rhythm rate-control_ treatment
P-1234	-1.7470 -0.0399 -0.4889 -0.1426 -0.0951 -0.0624 -0.5864 -0.2447 -1.8381 -0.0263 -0.9027 -0.7385 -0.1204 -0.9640 -4.5143 -0.5972 -0.6491 -0.3636 -0.0902 -0.0024 -2.1720 -0.8510 -2.8223 -0.1558
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report calcineurin nfat mir-25 expression basic_helix-loop-helix bhlh transcription_factor dhand hand2 diseased myocardium
H-640	-0.5138793587684631	▁calci ne uri n ▁n fat _ signal ling ▁mi r -25 _ expression ▁heli x - loop - heli x ▁b HL h ▁tran scription ▁factor ▁d hand ▁hand ▁disease d ▁human ▁mouse _ ▁my o car dium
D-640	-0.5138793587684631	calcineurin nfat_signalling mir-25_expression helix-loop-helix bHLh transcription factor dhand hand diseased human mouse_ myocardium
P-640	-0.0206 -0.3155 -0.0148 -0.0359 -2.0522 -0.2818 -1.9278 -0.3937 -0.1880 -0.3220 -1.5799 -0.0214 -1.6766 -0.1730 -0.1578 -0.1966 -0.0376 -0.0275 -0.0867 -0.0266 -0.1641 -0.6041 -0.4405 -0.2149 -0.2290 -0.0235 -0.2786 -0.6054 -0.2487 -0.8593 -3.0375 -0.0064 -1.1229 -0.0270 -0.9134 -2.2379 -0.0493 -0.0042 -0.0943 -0.2503 -0.1218
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart_failure patient compliance myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary_embolism infection renal_dysfunction
H-1668	-0.6172985434532166	▁heart ▁failure ▁my o card ial _ is cha emia ▁bra dy ar rhythm ias ▁val vu lar _ re gur gi tation ▁pulmonar y _ e mbol ism ▁infection ▁renal ▁dys function
D-1668	-0.6172985434532166	heart failure myocardial_ischaemia bradyarrhythmias valvular_regurgitation pulmonary_embolism infection renal dysfunction
P-1668	-5.3457 -0.7799 -0.9119 -0.1898 -0.6255 -0.4044 -0.3998 -2.2345 -0.0027 -0.0365 -3.8280 -1.1198 -0.0695 -0.1046 -0.1580 -0.0685 -0.0661 -0.1068 -0.9349 -0.3829 -0.1586 -0.0221 -0.0589 -0.0010 -0.0405 -0.4919 -0.8879 -0.0073 -0.3487 -0.0330 -0.0035 -1.2548 -0.0410 -0.3800 -0.1064
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc_battery hf health_abc_hf_model death
H-629	-1.177701711654663	▁h ABC _ ▁Bat tery _ ▁score ▁ HF _ risk ▁Health ▁ABC _ HF _ model ▁h ▁h b ▁ HF _ model ▁SD ▁control led _ for _ ▁death ▁competi ng _ risk ▁h
D-629	-1.177701711654663	hABC_ Battery_ score HF_risk Health ABC_HF_model h hb HF_model SD controlled_for_ death competing_risk h
P-629	-1.5968 -1.3888 -1.0704 -1.2889 -0.0068 -0.3423 -0.3306 -0.1861 -0.0743 -1.5540 -0.8742 -1.2111 -0.7135 -0.3589 -0.4205 -0.2201 -0.8938 -1.3110 -3.1979 -3.7198 -4.1521 -2.1112 -2.9753 -0.4369 -0.5023 -4.6640 -0.5870 -0.1272 -2.3115 -0.1311 -0.4114 -1.4959 -0.0633 -0.1122 -0.7749 -1.4528 -1.5554 -0.1280
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp admission sensitivity specificity confidence_interval area_under_the_curve
H-269	-0.5688843131065369	▁NT - pro b NP ▁cut off _ point ▁ sensitiv ity ▁confidence ▁interval ▁cur ve
D-269	-0.5688843131065369	NT-probNP cutoff_point sensitivity confidence interval curve
P-269	-0.5868 -0.0602 -0.0229 -0.4176 -0.4801 -0.4631 -0.0339 -0.8701 -0.4929 -1.7514 -0.0251 -0.6615 -0.4088 -1.6936 -1.7063 -0.1717 -0.2963 -0.0975
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic r-r_interval hr_variability short-term_fractal_scaling_exponent prognostic
H-1588	-0.3982137441635132	▁prognos tic _ power ▁r - r _ ▁interval _ os cilla tions ▁non - line ar _ HR _ ▁variabil ity _ ▁measure s ▁short - term _ fra c tal _ ▁scal ing _ ▁ex ponent
D-1588	-0.3982137441635132	prognostic_power r-r_ interval_oscillations non-linear_HR_ variability_ measures short-term_fractal_ scaling_ exponent
P-1588	-0.5224 -0.6041 -0.4269 -0.3513 -0.7490 -0.2266 -0.5916 -0.4895 -0.0262 -0.4786 -0.3510 -0.0322 -0.7763 -0.1530 -0.0377 -0.0158 -0.0280 -0.1472 -0.6566 -1.5406 -0.0051 -0.5989 -1.6672 -0.2673 -0.0454 -0.3474 -0.0869 -0.0918 -0.2612 -0.2570 -0.1652 -0.0712 -0.0896 -0.9781 -0.0478 -0.5012 -1.1386 -0.0399 -0.9179 -0.1460
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart_failure hf patients spontaneous_ventricular_tachycardia hf patients spontaneous_vt hearts
H-1437	-0.8725235462188721	▁heart ▁failure HF ▁vent ri cular _ ta chy car dia ▁ HF VT ▁ VT HF VT ▁structura lly _ normal _ ▁heart s ▁h Nor m
D-1437	-0.8725235462188721	heart failureHF ventricular_tachycardia HFVT VTHFVT structurally_normal_ hearts hNorm
P-1437	-0.8961 -0.6913 -1.4817 -0.9583 -1.0595 -0.4629 -0.2447 -1.2219 -0.0811 -0.0272 -0.0120 -1.6160 -0.2312 -2.3705 -2.5991 -1.9245 -2.9061 -1.3096 -0.6752 -0.0672 -0.1297 -0.5506 -0.2727 -1.0376 -0.0381 -1.5070 -1.3863 -0.0155 -0.3034 -0.0988
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls cox_model chronic_heart_failure hypertension diabetes stroke estimated_glomerular_filtration_rate lvef
H-819	-0.512264609336853	▁g LS ▁co x _ model ▁chronic _ heart _ ▁failure ▁hyper tension ▁diabetes ▁prior _ stro ▁score ▁glo mer ular _ filter ation ▁rate ▁LV EF ▁sa ▁CV
D-819	-0.512264609336853	gLS cox_model chronic_heart_ failure hypertension diabetes prior_stro score glomerular_filteration rate LVEF sa CV
P-819	-0.1319 -1.1613 -0.1113 -0.0285 -1.0015 -0.8636 -0.2704 -0.0517 -0.9830 -1.0131 -0.0376 -0.0349 -0.0056 -0.0446 -0.0147 -0.0371 -0.1042 -2.6651 -0.0987 -0.0612 -0.0317 -0.0891 -0.9733 -0.2068 -1.0489 -0.0547 -0.2886 -0.7684 -2.4667 -1.1639 -0.0680
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic_function diastolic_filling_formalism relaxation doppler_mitral_inflow_velocity e-wave
H-921	-0.3751734793186188	▁dia sto lic _ function ▁dia sto lic _ ▁fill ing _ ▁formal ism ▁relax ation vis co ela stic ▁passiv e _ sti ff ness ▁do pp ler _ met ral _ in flow _ ▁veloci ty ▁e - wa ve
D-921	-0.3751734793186188	diastolic_function diastolic_ filling_ formalism relaxationviscoelastic passive_stiffness doppler_metral_inflow_ velocity e-wave
P-921	-0.0479 -0.0189 -0.0257 -0.3148 -0.7740 -0.1737 -0.0343 -0.0819 -0.2195 -1.2115 -0.0323 -3.4594 -0.1523 -0.2937 -0.1037 -0.0240 -0.2453 -0.0079 -0.0017 -0.0190 -0.1636 -0.0091 -2.2391 -1.4135 -0.0852 -0.7398 -0.2575 -0.0259 -1.1978 -0.2372 -0.9269 -0.5631 -0.1024 -0.0944 -0.1118 -0.2648 -0.0680 -0.0674 -0.1696 -0.0357 -0.0426 -0.1396 -0.1675 -0.1436
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient vad patients ventricular_assist_device ecmo patients extracorporeal_membrane_oxygenation ecmo vad patients ecmo vad
H-1387	-0.94328373670578	▁ VAD ▁vent ri cular _ assist _ ▁device _ support ▁ec mo ▁extra corp o real _ ▁membran e _ ▁oxygen ation _ ▁membran e _ support ▁ec mo ▁ec mo ▁ VAD
D-1387	-0.94328373670578	VAD ventricular_assist_ device_support ecmo extracorporeal_ membrane_ oxygenation_ membrane_support ecmo ecmo VAD
P-1387	-1.6601 -0.2165 -0.0457 -1.2083 -0.2988 -0.1738 -0.2741 -0.8972 -0.6104 -1.8788 -0.9180 -1.0188 -1.6355 -0.5619 -0.1159 -0.9359 -0.3580 -0.0519 -0.9706 -0.0127 -0.1980 -0.6916 -0.1890 -0.1955 -0.1055 -0.0153 -1.7491 -1.1207 -1.4784 -1.8011 -3.7214 -1.6614 -3.4517 -2.6373 -0.8925 -0.2069
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional_status 6-mwt nyha_class patients hfpef hfref prescribed therapy patients hfpef death hf hospitalization
H-244	-0.7310890555381775	▁m t ▁NY ha ▁ HF p EF ▁h Fr EF ▁ HF p EF ▁ HF p EF ▁ HF _ hospital ization
D-244	-0.7310890555381775	mt NYha HFpEF hFrEF HFpEF HFpEF HF_hospitalization
P-244	-2.4011 -0.0259 -0.8788 -0.2940 -0.3793 -0.7267 -0.0656 -0.3805 -0.6529 -1.4597 -0.8568 -0.5402 -1.8771 -0.1227 -0.3341 -0.6305 -0.3432 -0.7297 -0.3148 -1.1098 -0.3372 -2.8752 -0.6801 -0.5833 -0.2830 -0.1261
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart_failure disease evidence-based health_care
H-2016	-1.5954489707946777	▁heart _ ▁failure _ ▁disease ▁management
D-2016	-1.5954489707946777	heart_ failure_ disease management
P-2016	-5.0056 -1.7778 -0.6029 -0.1781 -1.0253 -1.2114 -2.8147 -0.1479
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin heart_failure murine resistin transgenic retn gene resistin
H-930	-0.6207835078239441	▁resist in ▁heart ▁failure ▁human ized _ ▁mouse ▁mur ine _ ▁resist in ▁trans ge nic ▁Ret n _ ▁gene ▁h um - re t n _ mi ce ▁ inflammation - stimul ated _ ▁resist in ▁humans
D-930	-0.6207835078239441	resistin heart failure humanized_ mouse murine_ resistin transgenic Retn_ gene hum-retn_mice inflammation-stimulated_ resistin humans
P-930	-3.7397 -0.2698 -1.5854 -0.5498 -2.2607 -0.1766 -0.2007 -1.7793 -1.7192 -1.0263 -0.1234 -1.3447 -0.2569 -0.5100 -0.0432 -0.1037 -1.1342 -0.0124 -0.0925 -0.4185 -0.3517 -0.0457 -0.0134 -0.5067 -0.2876 -0.0065 -0.1160 -0.4104 -0.1825 -0.9785 -0.0089 -0.0199 -0.0114 -0.2426 -0.3536 -2.1466 -0.0672 -1.4490 -0.1714 -0.1150
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients angiotensin-converting_enzyme_inhibitors angiotensin_receptors_blockers β-blockers
H-1745	-0.5395748615264893	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors angi oten sin _ ▁receptor s ▁block ers ▁β - block ers ▁devices
D-1745	-0.5395748615264893	angiotensin-converting_ enzyme inhibitorsangiotensin_ receptors blockers β-blockers devices
P-1745	-3.7989 -1.3241 -0.2372 -1.7502 -0.8263 -0.0183 -0.0388 -0.3393 -0.2168 -0.3100 -0.0333 -0.2538 -0.1485 -0.1587 -0.0320 -0.8528 -0.6000 -0.0213 -0.0855 -1.9540 -0.0456 -0.0219 -0.0248 -0.0991 -0.0559 -0.8854 -0.7674 -0.2082
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac_injury ejection_fraction fractional_shortening heart_dilatation hypertrophy transverse_aortic_constriction tac
H-1815	-0.3426378071308136	TTA ▁t g t et Men a _ mi ce ▁cardiac _ ▁injury ▁e je ction _ fraction ▁ fraction al _ short en ing ▁heart ▁di la tation ▁hyper trop hy ▁trans verse _ a or tic _ con stri ction TAC
D-1815	-0.3426378071308136	TTA tgtetMena_mice cardiac_ injury ejection_fraction fractional_shortening heart dilatation hypertrophy transverse_aortic_constrictionTAC
P-1815	-1.3032 -1.2508 -0.1339 -0.1968 -0.0597 -0.9748 -0.0351 -1.0274 -0.2239 -0.3102 -0.1098 -0.7200 -0.0627 -0.0635 -0.0170 -0.0516 -0.8280 -0.0152 -0.4831 -0.0007 -0.1456 -0.3904 -0.5967 -0.0289 -0.0924 -0.2949 -1.0679 -0.1099 -0.0171 -0.0478 -0.0086 -0.3387 -0.0004 -0.2604 -0.0561 -0.6467 -0.5193 -0.9657 -0.0288 -0.7085 -0.4483 -0.0644 -0.4413 -0.1608 -0.1119
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart_failure patients italy confirmatory_factor_analysis cfa schfi_v.6.2 self-care_maintenance self-care_management self-care_confidence
H-1505	-0.5407421588897705	▁heart ▁failure _ ▁patients ▁Italy ▁confirma tory _ factor _ analyse ▁c fa ▁ SCH fi ▁Self - Car e _ ▁Main ten ance ▁Self - Car e _ management ▁Self - Car e _ ▁Confi den ce
D-1505	-0.5407421588897705	heart failure_ patients Italy confirmatory_factor_analyse cfa SCHfi Self-Care_ Maintenance Self-Care_management Self-Care_ Confidence
P-1505	-1.7132 -0.5092 -2.3727 -0.6389 -0.7711 -0.0328 -0.0161 -0.0433 -0.7970 -0.9082 -0.2979 -0.4602 -0.7803 -0.5165 -0.7252 -1.1521 -1.2112 -0.0985 -1.5197 -0.0765 -0.1809 -0.3176 -0.0866 -0.0165 -0.1792 -0.0741 -0.9701 -0.0604 -1.3853 -0.7178 -0.1301 -0.0596 -0.8097 -0.1016 -0.1333 -1.2785 -0.0880 -0.1121 -0.1698 -0.1180
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation_for_ambulatory_heart_failure_trial implantable primary_end_point all-cause_mortality heart_failure hospitalization
H-882	-0.4977196455001831	▁re syn chron ization - Def i bril lation ▁amb ulator y _ ▁Heart _ ▁Fail ure ▁tri al ▁implant able _ ▁cardio ver ter _ de fi br illa tor - c RT ▁mortal ity ▁heart ▁failure
D-882	-0.4977196455001831	resynchronization-Defibrillation ambulatory_ Heart_ Failure trial implantable_ cardioverter_defibrillator-cRT mortality heart failure
P-882	-0.1625 -0.0261 -0.0132 -0.8912 -0.1682 -1.1917 -0.1998 -0.3789 -0.0645 -0.5797 -0.1385 -0.1052 -0.0349 -0.9258 -0.8587 -0.1030 -0.9465 -0.8989 -0.1115 -0.0552 -0.0314 -0.3131 -0.2074 -0.0452 -0.0941 -0.7980 -0.7317 -0.0335 -0.1247 -0.0469 -0.0254 -0.1448 -0.6642 -2.1693 -2.8276 -1.2532 -0.3270 -0.8724 -1.2314 -0.1136
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic_events ies patients ischemic_cardiomyopathy ic cardiac_resynchronization_therapy defibrillator crt-d
H-102	-0.5555302500724792	▁ ische mic _ ▁events IE s ▁ ische mic _ ▁cardio my o pathy ▁i ic ▁cardiac ▁re syn chron ization ▁ therapy ▁de fi br illa tor ▁c RT - d
D-102	-0.5555302500724792	ischemic_ eventsIEs ischemic_ cardiomyopathy iic cardiac resynchronization therapy defibrillator cRT-d
P-102	-1.0995 -0.0571 -0.4135 -0.2282 -3.4371 -1.4865 -0.0835 -0.4806 -0.0481 -0.1459 -0.1276 -0.3837 -1.6617 -0.4306 -0.0174 -0.7638 -0.9716 -0.0175 -1.2046 -0.0112 -0.0047 -0.9719 -0.9088 -0.0093 -0.0648 -0.0154 -0.1233 -0.1054 -0.0385 -0.2884 -1.6789 -0.0167 -0.9993 -1.0278 -0.1210
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal_dysfunction chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks follow-up mortality ischemic_cardiomyopathy
H-69	-0.35531407594680786	▁renal ▁dys function ▁chronic _ ob struct ive _ ▁pulmonar y ▁disease ▁diabetes ▁per i pher al _ vas cular _ ▁disease ▁left _ ▁vent ri cular _ e je ction _ fraction ▁i CD ▁shock s ▁ ische mic _ ▁cardio my o pathy ▁male _ sex
D-69	-0.35531407594680786	renal dysfunction chronic_obstructive_ pulmonary disease diabetes peripheral_vascular_ disease left_ ventricular_ejection_fraction iCD shocks ischemic_ cardiomyopathy male_sex
P-69	-0.0206 -0.5385 -0.0294 -0.0093 -0.2262 -0.4178 -0.0428 -0.1055 -0.0891 -0.1531 -0.0512 -0.8137 -0.0250 -0.0080 -0.0387 -0.0363 -0.1476 -0.0471 -1.7894 -0.1738 -1.2165 -0.2762 -0.3181 -0.2467 -1.4714 -0.7252 -0.2860 -0.2328 -0.4733 -0.1241 -0.0844 -0.4287 -0.1189 -0.2158 -0.1998 -0.5203 -0.0176 -2.2244 -0.0185 -0.1648 -0.0496 -0.1671 -0.7099 -0.2058 -0.0135 -0.1216 -0.4458 -1.6260 -0.1695 -0.1303
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients chf testosterone exercise testosterone placebo
H-1318	-0.5952262282371521	▁CHF ▁SD _ ▁testosteron e
D-1318	-0.5952262282371521	CHF SD_ testosterone
P-1318	-0.2439 -0.5383 -0.7442 -0.1779 -0.0272 -2.3334 -0.1016
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold_proteins cardiac_remodelling field therapeutic
H-996	-0.5777953863143921	▁Raf - MEK 1/2 - er k 1/2 _ sc af fold _ ▁protein s ▁cardiac _ ▁remodel ling ▁ therapeut ic
D-996	-0.5777953863143921	Raf-MEK1/2-erk1/2_scaffold_ proteins cardiac_ remodelling therapeutic
P-996	-0.0738 -0.1208 -0.0170 -0.4296 -0.0481 -0.5882 -0.2780 -1.4721 -0.5072 -2.5339 -1.3044 -0.1146 -0.2874 -0.7491 -0.0372 -1.7888 -0.8513 -0.0314 -0.0896 -0.4824 -0.0774 -0.0741 -1.8310 -0.0795
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional_ms lv_dilatation heart_failure hf functional_ms hf prolapse degenerative_mitral_valve
H-341	-0.782640814781189	▁functional _ ▁MS ▁LV ▁di la tation ▁treatment _ for _ ▁heart ▁failure ▁ HF ▁LV ▁functional _ ▁MS ▁ HF ▁ HF ▁MR ▁de genera tive _ met ral _ ▁val ve
D-341	-0.782640814781189	functional_ MS LV dilatation treatment_for_ heart failure HF LV functional_ MS HF HF MR degenerative_metral_ valve
P-341	-0.0341 -0.9922 -1.8701 -1.1229 -0.2640 -0.0481 -0.0075 -2.8214 -0.9951 -1.5984 -0.2960 -1.5020 -0.5313 -1.4516 -0.0702 -2.7381 -0.1081 -0.3553 -2.5423 -0.5826 -0.1145 -2.0707 -0.1112 -0.5184 -0.0116 -0.0012 -0.2503 -0.0692 -2.0352 -0.1769 -0.3261 -1.2037 -0.0543 -0.4378 -0.0803
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blockers β-blockers patients heart_failure medications medical
H-1130	-0.7730532288551331	▁ang io ten sin ▁convert ing _ ▁enzym e ▁inhibi tor ▁ang io ten sin - recept or ▁block ers ▁β - block ers ▁heart ▁failure ▁medication s
D-1130	-0.7730532288551331	angiotensin converting_ enzyme inhibitor angiotensin-receptor blockers β-blockers heart failure medications
P-1130	-5.8526 -2.2108 -0.2167 -0.9980 -0.3109 -0.1145 -0.1306 -0.1752 -0.0260 -0.6655 -0.0454 -1.2960 -1.3375 -0.4887 -1.2373 -0.5817 -0.3659 -0.1864 -2.3045 -0.0825 -0.1374 -0.0357 -0.1178 -0.0767 -0.8666 -0.6755 -1.8528 -0.0907 -0.5189 -0.1931
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new_york_heart_association_class kccq symptom spearman_correlations 2-way_anova patients hf_with_reduced_ef hfpef
H-783	-0.7274535894393921	▁New _ York _ ▁Heart _ association ▁k cc q ▁over all _ ▁Summa ry ▁symptom _ ▁domain s ▁Spe ar man _ ▁corre lation s ▁2- way _ a NOVA ▁patients ▁ HF ▁EF ▁ HF p EF
D-783	-0.7274535894393921	New_York_ Heart_association kccq overall_ Summary symptom_ domains Spearman_ correlations 2-way_aNOVA patients HF EF HFpEF
P-783	-1.7114 -0.9258 -1.1742 -0.1207 -1.2605 -0.2642 -0.4183 -1.3837 -0.0620 -1.1199 -2.4377 -0.2192 -0.0655 -0.6275 -0.1386 -2.2593 -2.4790 -0.0232 -0.0210 -0.0885 -0.0127 -0.0328 -2.4644 -0.0876 -0.0043 -0.0177 -2.9865 -0.1066 -0.0997 -0.1852 -0.0097 -3.0307 -0.6264 -0.4524 -1.4572 -0.5108 -0.2082 -0.0702 -0.3233 -0.2549 -0.0840
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic lv_ejection_fraction lv_strain strain systole diastolic lv_strain_rate diastole transmitral_flow patients sinus_rhythm follow-up
H-951	-0.4719485640525818	▁LV ▁sy sto lic _ ▁indice s LV ▁e je ction _ fraction ▁LV ▁strain _ ▁rate ▁sy stol e ▁dia sto lic _ ▁indice s ▁LV ▁strain _ ▁rate ▁dia stol e ▁early _ ▁transmit ral _ ▁flow ▁sinus ▁ rhythm ▁follow - up
D-951	-0.4719485640525818	LV systolic_ indicesLV ejection_fraction LV strain_ rate systole diastolic_ indices LV strain_ rate diastole early_ transmitral_ flow sinus rhythm follow-up
P-951	-0.4165 -2.4736 -0.0476 -0.0288 -0.1105 -1.5487 -0.0056 -0.1981 -0.2616 -0.0785 -0.0418 -0.1776 -0.0896 -0.3531 -0.3942 -0.4835 -1.6879 -0.7201 -0.2913 -0.1036 -0.1358 -0.2071 -0.0307 -0.1856 -0.7633 -0.0056 -2.3559 -0.4867 -0.1392 -0.1660 -0.3756 -0.0728 -0.0853 -2.3244 -0.0402 -1.5571 -0.3499 -0.1518 -0.7525 -0.1165 -0.7086 -0.1820 -1.0819 -0.0499 -0.0081 -0.1984 -0.1384
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang_ii_infusion ang_ii_infusion uninephrectomy ang_ii_infusion salt_loading ang_ii_infusion uninephrectomy salt_loading
H-276	-0.8250215649604797	▁c 57 BL ▁ANG _ ▁II _ in fusion AT ▁ANG _ ▁II _ in fusion ▁un ine ph r ecto my ▁ANG _ ▁II _ in fusion ▁salt _ ▁load ing ▁as ▁ANG _ ▁II _ in fusion ▁un ine ph r ecto my ▁salt _ ▁load ing ANS
D-276	-0.8250215649604797	c57BL ANG_ II_infusionAT ANG_ II_infusion uninephrectomy ANG_ II_infusion salt_ loading as ANG_ II_infusion uninephrectomy salt_ loadingANS
P-276	-0.6822 -0.9623 -1.3340 -4.7752 -0.6889 -1.4947 -0.6573 -0.7252 -0.0072 -3.5577 -1.2767 -0.5193 -0.7179 -0.5267 -0.6232 -0.0073 -0.0145 -1.8283 -1.6263 -0.1304 -0.0642 -0.6793 -2.3951 -0.5786 -1.6645 -0.4343 -0.4103 -0.0119 -0.1536 -0.6387 -0.2193 -0.0168 -1.0399 -1.0903 -0.7071 -1.6852 -0.5201 -0.4610 -0.0099 -0.0270 -1.3462 -1.4884 -0.1117 -0.1828 -0.6504 -0.0193 -0.8506 -0.3016 -0.0201 -2.5803 -0.2750 -0.1119
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral_blood_flow_velocity tissue_doppler diastolic_mitral_annulus_velocity pulmonary_capillary_wedge_pressure pcwp patients decompensated_systolic_heart_failure hf
H-480	-0.5091953277587891	▁early _ ▁transmit ral _ ▁blood _ ▁flow _ ▁veloci ty ▁do pp ler ▁early _ dia sto lic _ met ral _ ▁ann ulus _ ▁veloci ty ▁pulmonar y _ cap illa ry _ ▁we dge _ ▁pressure ▁pc p ▁de com pensa ted _ ▁sy sto lic _ ▁heart ▁failure HF
D-480	-0.5091953277587891	early_ transmitral_ blood_ flow_ velocity doppler early_diastolic_metral_ annulus_ velocity pulmonary_capillary_ wedge_ pressure pcp decompensated_ systolic_ heart failureHF
P-480	-2.4063 -0.2119 -3.3245 -0.7306 -0.1012 -1.2795 -1.0037 -0.1241 -0.3523 -0.4900 -0.0152 -1.4004 -0.0128 -0.3322 -1.6113 -0.0936 -0.9773 -0.0888 -0.0760 -0.0252 -0.9320 -0.3758 -0.0380 -2.0187 -0.0774 -0.6000 -0.0326 -0.0078 -0.0017 -0.0116 -0.3192 -0.1568 -0.0383 -0.3894 -0.1338 -0.7291 -0.1297 -0.4113 -0.2397 -0.1686 -1.3168 -0.3124 -0.0258 -0.0473 -0.0680 -0.2005 -1.1426 -0.0573 -0.1284 -0.0195 -1.7079 -0.3938 -0.7482 -0.2724 -0.0966
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak_vo2 exercise
H-1984	-1.9560117721557617	▁VO 2 ▁exercise ▁m L / kg _ ▁body _ ▁mass
D-1984	-1.9560117721557617	VO2 exercise mL/kg_ body_ mass
P-1984	-6.0375 -0.0898 -2.5065 -2.3711 -2.2323 -3.1863 -0.2577 -0.3008 -2.3971 -0.7444 -0.8381 -4.2185 -0.2482
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami patient hospital hospital_compare p-value
H-1698	-0.8604224920272827	▁ AMI ▁hospital ▁best _ ▁quin tile _ of _ ▁performance ▁Hospital _ ▁Compar e
D-1698	-0.8604224920272827	AMI hospital best_ quintile_of_ performance Hospital_ Compare
P-1698	-0.7126 -0.0527 -2.1344 -3.7767 -0.2086 -0.3015 -0.0080 -0.5999 -1.1117 -0.2666 -0.0390 -1.0907 -0.5970 -0.2655 -0.0400 -3.2264 -0.1958
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq patients hfpef log_rank ef
H-789	-0.9951242804527283	▁k cc q ▁ HF p EF log _ ▁rank ▁EF
D-789	-0.9951242804527283	kccq HFpEFlog_ rank EF
P-789	-2.5987 -0.0635 -1.7493 -0.8335 -0.5048 -0.0562 -0.7000 -1.1115 -2.1242 -0.9822 -1.7480 -0.3107 -0.1540
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt nt-probnp report ctnt nt-probnp clinical hf
H-292	-0.3773064613342285	▁c t n t ▁NT - pro b NP ▁c t n t ▁NT - pro b NP ▁ HF
D-292	-0.3773064613342285	ctnt NT-probNP ctnt NT-probNP HF
P-292	-0.1031 -0.3044 -0.0404 -0.4541 -0.5122 -0.0491 -0.0235 -0.5648 -0.2151 -0.3210 -0.4160 -0.0321 -0.5001 -0.6268 -0.0724 -0.0618 -0.6849 -0.3511 -0.2809 -0.8183 -1.7524 -0.1161
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass_spectrometry c-terminally nt-probnp physiological proteolysis
H-1517	-0.605741024017334	▁Mass _ spec tro met ry ▁circula ting ▁NT - pro b NP ▁physio logic al _ prote ol ysis ▁le u 3- g ly
D-1517	-0.605741024017334	Mass_spectrometry circulating NT-probNP physiological_proteolysis leu3-gly
P-1517	-0.1249 -1.1996 -1.5151 -0.1013 -0.0496 -2.1862 -0.0425 -0.0201 -0.8753 -0.0494 -0.1171 -1.3307 -0.2388 -0.0453 -0.3695 -0.0525 -0.5358 -1.0798 -0.4754 -0.3427 -0.3335 -0.0031 -0.0923 -1.6450 -0.0852 -3.3784 -0.0658
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef patients new_york_heart_association_class_ii ejection_fraction fes placebo
H-1329	-0.8792275786399841	▁ HF p EF ▁New _ York _ ▁Heart _ association ▁mean _ e je ction _ fraction
D-1329	-0.8792275786399841	HFpEF New_York_ Heart_association mean_ejection_fraction
P-1329	-0.5058 -2.8247 -0.1772 -0.5247 -3.7059 -1.1707 -1.6065 -0.1531 -1.1675 -0.4367 -0.8532 -0.2751 -0.1576 -0.4570 -0.1367 -0.0337 -0.3302 -0.0381 -2.9191 -0.1109
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left_ventricular systolic_pressure ejection_fraction fractional_shortening cardiac_output lv_end-diastolic_pressure mi metoprolol
H-1548	-0.4722107946872711	▁de press ed _ ▁left _ ▁vent ri cular LV ▁sy sto lic _ ▁pressure ▁pressure ▁e je ction _ fraction ▁ fraction al _ short en ing ▁cardiac _ ▁output ▁LV _ ▁end - dia sto lic _ ▁pressure ▁MI ▁animals ▁met o pro lol
D-1548	-0.4722107946872711	depressed_ left_ ventricularLV systolic_ pressure pressure ejection_fraction fractional_shortening cardiac_ output LV_ end-diastolic_ pressure MI animals metoprolol
P-1548	-0.0794 -0.0217 -0.0875 -0.7797 -0.5470 -0.1079 -1.4342 -0.7110 -0.1934 -0.5490 -0.9381 -0.1330 -0.1911 -0.1364 -1.4627 -0.4931 -0.5091 -0.0305 -0.0197 -0.4741 -0.0154 -0.4376 -0.0010 -0.0849 -0.1593 -0.8039 -0.0317 -0.0845 -0.7171 -0.8013 -0.0149 -0.2834 -1.5031 -1.6787 -0.0509 -0.0321 -0.0660 -0.0732 -0.0782 -0.6027 -3.7190 -1.7735 -0.1647 -0.1429 -0.0196 -0.1491 -0.1674 -0.1114
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex_activation_therapy_for_the_treatment_of_heart_failure_with_a_reduced_ejection_fraction clinical carotid baroreflex_activation_therapy bat heart_failure hf
H-1867	-0.5483482480049133	▁bar ore flex _ activ ation ▁Therapy ▁Heart _ ▁Fail ure ▁Red u ced _ e je ction _ fra ction ▁caro tid _ ▁baro re flex _ activa tion _ therapy BAT ▁advanced _ heart _ ▁failure HF
D-1867	-0.5483482480049133	baroreflex_activation Therapy Heart_ Failure Reduced_ejection_fraction carotid_ baroreflex_activation_therapyBAT advanced_heart_ failureHF
P-1867	-2.6117 -0.5813 -0.4876 -0.0846 -0.7502 -0.1746 -0.3154 -1.0875 -1.1728 -0.1385 -0.4531 -3.2070 -0.0350 -0.6649 -0.0323 -0.4787 -0.0893 -0.0322 -0.0686 -0.6885 -0.0062 -1.6022 -0.1301 -0.3749 -0.6913 -0.6818 -0.0947 -0.1890 -0.1847 -0.2564 -0.4940 -0.0376 -0.3107 -0.5664 -0.0293 -1.1694 -1.4367 -0.0397 -0.7011 -0.2242 -0.1080
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome hazard_ratio
H-1748	-1.26863694190979	▁en roll ment _ ▁period haz ard _ ▁ratio HR HR
D-1748	-1.26863694190979	enrollment_ periodhazard_ ratioHRHR
P-1748	-2.4347 -0.0869 -0.2679 -4.0424 -2.1101 -2.5897 -0.0555 -0.4269 -0.0718 -0.3163 -1.5329 -2.3400 -0.2171
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf blood_glucose obesity systemic_hypertension rheumatic_fever disease
H-1793	-0.4718070924282074	▁ HF ▁raised _ ▁blood ▁gluco se _ ▁levels ▁obes ity ▁to ba cco ▁system ic _ ▁hyper tension SH ▁rhe u matic _ fe ver ▁Cha gas _ ▁disease ▁c ' d
D-1793	-0.4718070924282074	HF raised_ blood glucose_ levels obesity tobacco systemic_ hypertensionSH rheumatic_fever Chagas_ disease c'd
P-1793	-0.9402 -0.1094 -1.3784 -0.1183 -1.3039 -0.3001 -0.0576 -0.8167 -0.2344 -0.0853 -1.0465 -0.0035 -0.0626 -0.0450 -0.0815 -0.0313 -0.0816 -0.7229 -0.0163 -1.1950 -0.0213 -0.0163 -0.0657 -0.0611 -0.1298 -0.0774 -0.9795 -0.0101 -0.9794 -0.2796 -1.6573 -1.3008 -0.2308 -1.9581 -0.1155
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard_ratios confidence_interval hf hf
H-1107	-1.0181571245193481	▁age - ▁sex - ad just ed _ risk ▁hazard _ ▁ratio s ▁ci ▁early - ons et _ HF ▁ci ▁late - ons et _ HF
D-1107	-1.0181571245193481	age- sex-adjusted_risk hazard_ ratios ci early-onset_HF ci late-onset_HF
P-1107	-2.8423 -0.0776 -5.5563 -0.0923 -0.0161 -0.0119 -0.0796 -0.5382 -0.7748 -0.8840 -1.9620 -0.5586 -0.2002 -3.4360 -2.5941 -0.1124 -0.3960 -0.0517 -0.9624 -0.6732 -4.0012 -0.4345 -0.0862 -0.8462 -0.0616 -0.7274 -1.2229 -0.1724 -0.1543
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard_ratios crf obese body_mass_index
H-1772	-0.9029356241226196	▁c RF ▁over weight ▁obes e _ ▁body _ ▁mass ▁index
D-1772	-0.9029356241226196	cRF overweight obese_ body_ mass index
P-1772	-2.6121 -2.2114 -0.9628 -0.2900 -0.1149 -0.0553 -0.1473 -1.7413 -0.6539 -1.7269 -0.2592 -0.8055 -0.1575
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline egfr egfr egfr hypertension diuretics esrd
H-395	-0.9552736878395081	▁e g FR ▁e g FR ▁groep _ ▁III ▁e g FR ▁un control led _ ▁hyper tension ▁di ure tics ▁age ▁ES RD
D-395	-0.9552736878395081	egFR egFR groep_ III egFR uncontrolled_ hypertension diuretics age ESRD
P-395	-0.4394 -1.7942 -0.6380 -1.8182 -1.4975 -0.8212 -3.4839 -1.9403 -1.6843 -0.1290 -1.7937 -0.7323 -0.2083 -0.0029 -1.2322 -0.1470 -0.9066 -0.0315 -0.2484 -0.7105 -0.1857 -0.9392 -2.5677 -0.6092 -0.1396 -0.1361
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial phosphodiesterase-2 pde2 heart_failure hf beta-adrenergic_receptor β-ar healthy diseased cardiomyocytes
H-1208	-0.5580477118492126	▁my o card ial _ phos pho dies tera se -2 ▁p de 2 ▁heart ▁failure HF ▁beta - ad r energi c _ ▁receptor β - AR ▁cardio my o cy tes
D-1208	-0.5580477118492126	myocardial_phosphodiesterase-2 pde2 heart failureHF beta-adrenergic_ receptorβ-AR cardiomyocytes
P-1208	-1.0777 -0.2266 -0.4588 -1.0778 -0.5009 -0.0246 -0.1573 -2.9801 -0.0993 -0.7894 -0.3540 -0.2279 -1.1809 -1.2754 -0.8394 -0.1518 -0.6655 -2.1047 -0.0226 -0.0284 -0.4199 -1.2538 -0.0980 -0.3416 -0.0691 -0.1424 -0.0177 -0.4543 -0.6931 -1.0398 -0.2248 -0.1417 -0.0689 -0.2084 -0.1153
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart_failure patients cardiac_resynchronization_therapy defibrillator implantable_cardioverter-defibrillator carvedilol atp shock_therapy metoprolol
H-866	-0.332669734954834	▁heart ▁failure ▁cardiac _ re syn chron ization _ therapy ▁de fi br illa tor ▁implant able _ ▁cardio ver ter - de fi br illa tor _ ▁device ▁car vedi lol ▁ATP ▁shock _ therapy ▁met o pro lol
D-866	-0.332669734954834	heart failure cardiac_resynchronization_therapy defibrillator implantable_ cardioverter-defibrillator_ device carvedilol ATP shock_therapy metoprolol
P-866	-0.9864 -0.4608 -0.2588 -0.6408 -0.4237 -0.0549 -0.0066 -1.0535 -1.7895 -0.0987 -0.0114 -0.0600 -0.3792 -0.1854 -0.0790 -0.2247 -0.0194 -0.3988 -0.5936 -0.0280 -0.0915 -0.3509 -0.0399 -0.0856 -0.4514 -0.2316 -0.0826 -0.8467 -0.4368 -0.0115 -0.0046 -0.0426 -1.2755 -0.0968 -1.3266 -0.0102 -0.0854 -0.1749 -0.0205 -0.0828 -0.3512 -0.1191
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich_cocoa skm mitochondrial_structure taub ramirez-sanchez ciaraldi perkins murphy naviaux hogan ceballos maisel henry
H-1245	-0.32684624195098877	▁e pica tech in - rich _ ▁coco a ▁Sk m ▁mito cho ndri al _ ▁structure ▁ta ub ▁ram i rez - s anche z ▁ci ar aldi ▁per kin s ▁ci ar aldi ▁per kin s ▁Murphy ▁na vi aux ▁Hoga n ▁ce ball os ▁mais el ▁Henry
D-1245	-0.32684624195098877	epicatechin-rich_ cocoa Skm mitochondrial_ structure taub ramirez-sanchez ciaraldi perkins ciaraldi perkins Murphy naviaux Hogan ceballos maisel Henry
P-1245	-0.6242 -0.0576 -0.1642 -0.1702 -0.0422 -0.0106 -0.1051 -0.1981 -0.0182 -1.9304 -0.3539 -0.1599 -0.2992 -0.4436 -0.0206 -0.6436 -1.1866 -2.0357 -0.0521 -0.2165 -0.0697 -0.0152 -0.0398 -1.2902 -0.0179 -0.0088 -0.0062 -0.0145 -0.0010 -0.4246 -0.3600 -0.0086 -1.6758 -0.0181 -0.0044 -0.3151 -0.2263 -0.0054 -0.8004 -0.0154 -0.0026 -0.0064 -0.4323 -0.0107 -0.5668 -0.1902 -0.0223 -1.0160 -0.0024 -0.2542 -0.3654 -0.0766
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up death readmission patients physician physicians
H-1420	-1.3392831087112427	▁follow - up _ ▁visit s ▁death ▁urgent _ ▁read mission ▁physician s
D-1420	-1.3392831087112427	follow-up_ visits death urgent_ readmission physicians
P-1420	-0.3002 -0.0856 -0.0217 -1.7693 -2.1223 -0.0445 -5.1587 -0.3086 -0.1183 -4.1694 -0.6968 -2.2154 -0.8541 -2.0807 -0.1436
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena_overexpression tac surgery mena cardiac_hypertrophy cardiac
H-1816	-0.6004053950309753	▁men a ▁over expression ▁ TTA ▁t g t et Men a _ mi ce ▁ TAC _ ▁surgery ▁cardiac _ ▁hyper trop hy ▁ TTA ▁t g t et Men a
D-1816	-0.6004053950309753	mena overexpression TTA tgtetMena_mice TAC_ surgery cardiac_ hypertrophy TTA tgtetMena
P-1816	-0.5491 -0.1358 -0.2163 -0.0223 -1.0690 -0.0302 -1.9524 -0.0825 -0.2470 -0.0985 -0.5135 -0.0395 -2.4624 -0.2183 -0.1749 -0.3788 -0.0856 -1.8522 -0.2517 -0.1862 -1.3534 -0.6606 -0.0095 -0.6043 -0.7118 -0.0332 -1.5337 -0.0777 -0.1876 -0.0326 -0.8621 -0.0141 -3.6625 -0.1045
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd diuretic hf outcomes clinical hospitalizations pdrelated complications
H-901	-0.8047414422035217	▁PD ▁di ure tic _ re frac tory ▁severe - end - s tage _ HF
D-901	-0.8047414422035217	PD diuretic_refractory severe-end-stage_HF
P-901	-4.0459 -0.2152 -0.1674 -1.1345 -0.0662 -0.1370 -0.0721 -0.1561 -2.3378 -0.3636 -1.3441 -0.0919 -0.1046 -0.0129 -0.7172 -0.7714 -2.6740 -0.0733
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp mitochondrial_oxidation glucose lactate fatty_acids myocardial glycolysis
H-1785	-0.3172440826892853	▁ATP ▁mito cho ndri al _ ▁oxid ation ▁gluco se ▁lac tate ▁fa tty _ ▁acid s ▁my o card ial _ ▁gly col ysis
D-1785	-0.3172440826892853	ATP mitochondrial_ oxidation glucose lactate fatty_ acids myocardial_ glycolysis
P-1785	-0.4128 -1.8814 -0.2536 -0.1910 -0.0183 -0.5949 -0.5001 -0.0609 -0.0590 -0.0709 -0.0020 -0.0407 -0.0129 -0.1139 -0.3013 -0.1242 -0.0313 -0.8824 -0.1507 -0.4447 -0.9301 -0.1291 -0.1107 -0.0569 -0.1882 -0.8929 -0.1108
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic vegf_pathway intravenously injected adenoviral vegf_receptor adenovirus
H-456	-0.5618353486061096	▁pro angi ogen ic _ effect ▁b ▁activa tion _ van _ ve GF _ ▁path way ▁a den ovi ral _ ve ctor ▁de co y _ ve GF _ ▁receptor ▁ad - f lk ▁ade no virus ▁ad - c ▁treatment
D-456	-0.5618353486061096	proangiogenic_effect b activation_van_veGF_ pathway adenoviral_vector decoy_veGF_ receptor ad-flk adenovirus ad-c treatment
P-456	-0.1648 -0.0491 -0.1227 -0.0507 -1.2301 -0.7894 -2.8660 -2.6821 -0.0974 -1.3608 -1.7105 -0.4637 -0.9352 -0.7231 -0.2711 -0.4974 -0.0838 -0.5302 -0.0347 -0.0353 -0.2775 -0.1422 -0.7289 -0.0131 -0.0227 -0.0008 -0.0404 -0.3853 -0.3221 -1.4002 -0.5842 -0.0499 -0.2680 -0.0319 -0.5140 -0.0639 -0.4741 -0.0108 -0.0044 -0.2639 -0.0498 -0.2081 -1.7010 -2.9216 -0.1058
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients eplerenone potassium potassium hospitalization hyperkalemia medication adverse_events
H-1226	-0.5418949723243713	▁e pler en one ▁po tas s ium ▁po tas s ium ▁hyper kal emia ▁medication
D-1226	-0.5418949723243713	eplerenone potassium potassium hyperkalemia medication
P-1226	-0.0819 -0.0353 -0.0638 -0.4590 -1.6904 -0.5258 -0.1862 -0.4165 -1.2511 -0.6854 -0.1449 -0.5128 -1.0852 -0.2138 -0.0300 -1.5468 -0.7169 -0.1083
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation bottleneck_stent lad lcx myocardial_ischemia stent ischemic_heart_failure stent therapeutic
H-514	-0.5545106530189514	▁bottle ne ck _ ▁sten t ▁proxima l _ LAD ▁l lc x ▁rever sible _ my o card ial _ ische mia open _ ▁sten t ▁ ische mic _ heart _ ▁failure ▁o clu ded _ ▁sten t
D-514	-0.5545106530189514	bottleneck_ stent proximal_LAD llcx reversible_myocardial_ischemiaopen_ stent ischemic_heart_ failure ocluded_ stent
P-514	-0.8115 -0.0981 -0.0208 -0.3056 -2.4477 -0.0348 -0.0498 -0.0063 -0.8333 -0.3997 -0.9938 -1.0647 -0.3580 -2.0825 -0.0050 -0.1784 -3.4380 -0.2264 -0.2244 -0.2513 -0.1703 -0.1551 -0.4113 -0.0716 -0.2180 -1.3796 -0.0283 -0.5528 -0.0105 -0.1077 -0.0431 -1.1309 -1.2572 -0.0128 -2.0874 -0.0102 -0.1727 -0.1126 -1.1053 -0.0182 -0.3230 -0.0813
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient new_york_heart_association_class_iii heart_failure hf left_ventricular_ejection_fraction periodic_breathing pb report
H-1347	-0.6605538129806519	▁New ▁York _ heart _ association _ ▁class _ ▁III _ heart _ ▁failure HF ▁le ft _ ▁vent ri cular _ e je ction ▁p b ▁permanent _ ▁periodic _ ▁breath ing ▁p b
D-1347	-0.6605538129806519	New York_heart_association_ class_ III_heart_ failureHF left_ ventricular_ejection pb permanent_ periodic_ breathing pb
P-1347	-2.5355 -2.2699 -0.0697 -1.4655 -0.2489 -0.5064 -1.4881 -0.6236 -0.8767 -0.3359 -0.0619 -1.0731 -1.3723 -0.0731 -1.3524 -0.6467 -0.0852 -0.1008 -1.8092 -0.7372 -0.2597 -0.0924 -0.2195 -0.0889 -0.0210 -1.9512 -0.2048 -0.3209 -0.0642 -1.1448 -0.2035 -1.5019 -0.0448 -0.0436 -0.2639 -0.1634 -0.1198
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium spironolactone aas
H-1705	-0.6187611222267151	▁po tas s ium ▁spi rono lac tone ▁non - AA s ▁AA s ▁race
D-1705	-0.6187611222267151	potassium spironolactone non-AAs AAs race
P-1705	-2.8673 -0.1701 -0.1517 -0.1042 -0.0215 -0.0147 -0.0543 -0.0795 -2.4220 -0.0207 -0.2147 -0.1097 -0.2935 -0.2143 -0.6805 -2.9816 -0.1184
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom cpet patients chf patients exercise exercise patients exercise rehabilitation
H-1880	-0.9061412215232849	▁symptom _ ▁limited _ c PET ▁CHF ▁exercise ▁exercise
D-1880	-0.9061412215232849	symptom_ limited_cPET CHF exercise exercise
P-1880	-0.8127 -1.1512 -0.8662 -0.1129 -0.9843 -0.4067 -0.1169 -0.7970 -2.1427 -2.4643 -0.1127
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography lv_end-diastolic_volume mitral_valve_opening mva
H-357	-0.5770781636238098	▁e cho card i ography ▁LV ▁end - dia sto lic _ ▁volume ▁MR ▁mit ral _ ▁val ve ▁m VA ▁pressure ▁gradi ent
D-357	-0.5770781636238098	echocardiography LV end-diastolic_ volume MR mitral_ valve mVA pressure gradient
P-357	-0.0815 -0.0610 -0.1587 -0.2523 -0.2676 -1.7701 -3.0979 -0.0447 -0.0139 -0.0174 -0.0240 -1.5090 -0.0705 -2.4631 -0.0425 -0.0343 -0.1806 -0.9711 -0.0426 -0.3232 -0.7879 -0.8079 -0.6216 -0.0328 -1.2379 -0.0900
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical post-lvad_ai aortic_valve leaflet bioprosthetic_aortic_valve_replacement functional_capacity lvad patients symptomatic
H-552	-0.9245041012763977	▁post - L VAD _ AI ▁a or tic _ val ve ▁over se wing ▁le a flet ▁repair ▁bio pro sthetic _ a or tic _ val ve _ ▁replace ment ▁CF ▁l VAD ▁AI
D-552	-0.9245041012763977	post-LVAD_AI aortic_valve oversewing leaflet repair bioprosthetic_aortic_valve_ replacement CF lVAD AI
P-552	-2.7976 -0.0194 -4.1084 -0.1036 -1.5895 -2.1222 -0.7216 -0.1614 -1.2160 -0.0472 -1.7858 -0.3365 -0.6672 -0.3181 -0.3570 -0.0036 -0.0080 -0.0046 -1.4556 -0.0010 -0.0117 -0.0046 -1.5091 -0.4214 -0.1156 -1.1280 -0.0471 -2.2687 -0.3685 -1.4284 -0.2317 -0.0552 -1.1882 -2.5016 -0.1168 -3.7319 -2.0598 -0.1185
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods_study health_care systolic_heart_failure prescribed β-blocker angiotensin_converting_enzyme_inhibitor angiotensin-receptor_blocker
H-1123	-0.612378716468811	▁sy sto lic _ heart ▁failure ▁β - block er ▁ang io ten sin _ ▁convert ing _ ▁enzym e ▁inhibi tor ▁ang io ten sin - recept or _ block er
D-1123	-0.612378716468811	systolic_heart failure β-blocker angiotensin_ converting_ enzyme inhibitor angiotensin-receptor_blocker
P-1123	-5.6775 -0.0927 -0.1556 -0.0285 -1.3342 -1.4890 -0.2912 -0.0243 -0.1516 -0.0814 -2.0120 -0.6495 -0.2750 -0.6537 -1.0518 -0.0478 -0.0474 -0.3018 -0.0495 -0.0317 -0.1490 -0.0120 -0.7665 -0.9257 -0.4150 -0.9239 -0.3572 -0.5184 -0.0905 -1.0353 -0.6009 -0.0871 -0.3728 -0.1205
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced_pulmonary_artery_systolic_pressure pasp stress_doppler_echocardiography right_ventricular_contractile_reserve patients pulmonary_hypertension right_heart_failure
H-822	-0.46841034293174744	▁exercise - indu ced _ ▁pulmonar y _ ▁arter y ▁sy sto lic _ ▁pressure PAS p ▁stress ▁do pp ler _ e cho card i ography ▁right _ ▁vent ri cular _ contract ile ▁reserve ▁pulmonar y _ ▁hyper tension ▁right _ ▁heart ▁failure
D-822	-0.46841034293174744	exercise-induced_ pulmonary_ artery systolic_ pressurePASp stress doppler_echocardiography right_ ventricular_contractile reserve pulmonary_ hypertension right_ heart failure
P-822	-3.7997 -0.0883 -0.0086 -0.2459 -0.7397 -0.2747 -0.0746 -0.4643 -0.1453 -0.1412 -1.5877 -0.0462 -0.1269 -0.0901 -0.9133 -1.4663 -0.3686 -0.2589 -0.4884 -0.0132 -0.6042 -0.5469 -0.3239 -0.3811 -0.3302 -0.1318 -0.2003 -0.1585 -0.3568 -0.7507 -0.9219 -0.2597 -0.1147 -0.6902 -0.0879 -0.0446 -0.1276 -0.0592 -0.8903 -0.6080 -0.0113 -0.1585 -0.0889 -1.4111 -0.9613 -0.3205 -0.1332
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline embase healthstar cinahl cochrane_library campbell_collaboration joanna_briggs_institute_evidence_based_practice centre_for_reviews_and_dissemination evidence_based_practice_centres
H-1844	-0.4181584417819977	▁MED line EMBA se ▁he al th star ▁c INA HL ▁co ch rane _ ▁Library ▁Campbell _ ▁Col labora tion ▁Joan na _ ▁Brig gs ▁Institute _ voor _ review s _ ▁and ▁Disse mination ▁e viden ce _ based _ prac tice ▁Centre s
D-1844	-0.4181584417819977	MEDlineEMBAse healthstar cINAHL cochrane_ Library Campbell_ Collaboration Joanna_ Briggs Institute_voor_reviews_ and Dissemination evidence_based_practice Centres
P-1844	-1.5335 -0.4615 -1.0930 -0.4168 -0.9099 -0.2281 -0.5842 -0.5627 -0.7562 -1.0840 -0.3891 -0.0292 -0.0269 -0.0074 -0.3053 -0.0387 -0.0026 -0.7684 -0.5370 -0.0111 -0.0017 -0.0249 -0.0462 -0.3886 -0.1013 -0.1253 -1.5482 -0.1173 -0.5206 -0.1004 -0.3521 -0.0151 -0.7013 -1.1267 -0.4606 -0.0174 -0.9692 -0.0120 -0.0481 -0.4521 -0.9986 -0.0398 -0.4480 -0.3460 -0.9195 -0.2023 -0.1211 -0.1218
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart_failure neuro-hormonal_system angiotensin_converting_enzyme_inhibitors angiotensin_receptor_blockers angiotensin_converting_enzyme_inhibitors beta_receptor_blockers mineralocorticoid_receptor_antagonists
H-647	-0.4711855947971344	▁heart ▁failure ▁neuro - hormon al _ systeem ▁ang io ten sin _ ▁convert ing _ ▁enzym e ▁inhibi tors angi oten sin _ ▁receptor ▁block ers ▁ang io ten sin _ ▁convert ing _ ▁enzym e ▁inhibi tors ▁in tolerance ▁beta _ ▁receptor ▁block ers ▁mineral o cor tico id _ ▁receptor ▁anta gon ists
D-647	-0.4711855947971344	heart failure neuro-hormonal_systeem angiotensin_ converting_ enzyme inhibitorsangiotensin_ receptor blockers angiotensin_ converting_ enzyme inhibitors intolerance beta_ receptor blockers mineralocorticoid_ receptor antagonists
P-647	-3.4308 -1.0711 -0.0637 -0.0398 -0.0111 -0.0255 -0.6179 -1.0885 -0.9014 -0.4480 -0.2268 -1.3513 -1.2975 -0.1229 -0.1144 -0.1475 -0.2204 -0.0394 -0.2766 -0.0849 -0.1302 -0.0934 -0.9478 -0.2738 -0.2024 -1.5648 -0.0199 -0.5797 -0.3148 -0.1827 -0.8368 -0.7377 -0.1905 -0.1147 -0.1273 -0.1976 -0.0525 -0.2545 -0.1480 -1.3306 -0.0027 -0.0129 -0.8646 -0.0526 -1.6047 -0.0161 -0.0074 -0.1368 -0.9783 -0.6876 -0.1134 -0.8796 -0.0038 -0.6080 -0.0027 -0.9654 -0.3835 -0.1295
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest rs rs_synchrony ste noninvasive rvpo rs_synchrony strain bivp
H-330	-0.8217208981513977	▁open _ ▁che st _ model ▁twist ▁RS ▁RS ▁synchron y ▁CS ▁ STE ▁ rv po ▁RS ▁synchron y ▁CS ▁Bi VP
D-330	-0.8217208981513977	open_ chest_model twist RS RS synchrony CS STE rvpo RS synchrony CS BiVP
P-330	-0.0294 -0.0845 -2.9702 -0.0302 -1.2646 -0.7147 -0.0015 -0.2446 -0.2123 -0.0983 -0.2115 -0.8689 -0.7245 -1.4393 -1.8949 -0.8347 -1.1601 -1.9723 -0.1052 -0.2905 -0.4354 -3.4167 -0.2408 -1.1876 -0.1104
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse pasp tapse pasp cox_regression kaplan-meier_analyses tapse pasp
H-498	-0.8345093131065369	▁t AP se ▁pas p ▁t AP se - to - pas p _ ▁ratio TA PS e _ pas p ▁co x _ ▁re gression ▁ka plan - me ier _ analyse s ▁t AP se ▁pas p
D-498	-0.8345093131065369	tAPse pasp tAPse-to-pasp_ ratioTAPSe_pasp cox_ regression kaplan-meier_analyses tAPse pasp
P-498	-2.6265 -0.7685 -0.4873 -1.1157 -0.5739 -2.4697 -0.5156 -0.4344 -0.0374 -0.0328 -0.0430 -0.6218 -0.6426 -1.4480 -0.0266 -2.4911 -1.1144 -0.1448 -1.9852 -3.2071 -0.4056 -0.3822 -0.0886 -0.6240 -0.9515 -0.0052 -0.1694 -0.0636 -0.0256 -0.1973 -0.0796 -3.8027 -0.0438 -0.0638 -2.3626 -0.4682 -0.4022 -1.9639 -0.5727 -0.6373 -0.1188
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese body_mass_index chronic stable hfpef
H-1978	-0.8961586952209473	▁obes e SD ▁body ▁mass ▁index ▁chronic _ ▁stable _ h FP EF
D-1978	-0.8961586952209473	obeseSD body mass index chronic_ stable_hFPEF
P-1978	-2.4341 -0.0708 -1.8276 -0.7514 -0.5947 -0.2226 -0.9985 -1.2902 -0.9540 -0.7963 -0.5855 -1.1415 -1.0507 -0.5922 -0.1322
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart_failure hf mrna_splicing cardiac scn5a endoplasmic_reticulum
H-1080	-0.40911605954170227	▁human _ heart _ ▁failure HF ▁m RNA ▁s plic ing ▁volta ge - ga ted _ ▁cardiac _ na + _ ▁channel ▁α - sub un it ▁s cn 5 a ▁en co ding ▁tru nca ted ▁non function al _ ▁channel s ▁en do plas mic _ ▁reti culum
D-1080	-0.40911605954170227	human_heart_ failureHF mRNA splicing voltage-gated_ cardiac_na+_ channel α-subunit scn5a encoding truncated nonfunctional_ channels endoplasmic_ reticulum
P-1080	-3.1338 -0.1227 -1.5200 -1.0691 -0.0559 -0.8656 -0.0121 -0.0461 -1.7104 -0.0300 -0.0309 -0.0068 -0.0443 -0.1238 -0.0311 -0.0805 -0.0610 -0.1157 -0.4170 -0.5979 -1.2778 -0.1063 -1.3921 -1.4170 -0.0135 -0.0043 -0.0203 -0.0116 -0.1106 -0.3592 -0.8958 -0.0869 -0.7235 -0.1407 -0.0450 -0.0674 -0.0079 -0.0042 -1.6630 -0.0132 -0.0125 -0.5819 -0.6024 -0.0081 -0.2321 -0.3755 -0.0700 -0.8118 -0.1126 -0.1254 -0.0014 -0.1868 -0.1275
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart_failure diagnosis myocarditis dilated_cardiomyopathy heart_failure heart_failure anthracycline disease
H-988	-0.569141685962677	▁pa e dia tric _ heart _ ▁failure ▁my o card itis ▁dil ated _ ▁cardio my o pathy ▁heart ▁failure ▁an thra cycli ne ▁child hood ▁malign ant _ ▁disease
D-988	-0.569141685962677	paediatric_heart_ failure myocarditis dilated_ cardiomyopathy heart failure anthracycline childhood malignant_ disease
P-988	-0.4891 -0.0829 -0.1304 -1.0592 -0.0823 -2.1849 -1.4485 -0.0899 -1.1247 -0.2106 -0.4573 -0.1504 -0.0888 -0.1054 -0.0912 -0.0949 -0.7454 -0.2363 -0.0151 -0.9237 -0.4758 -1.4925 -0.0727 -0.1683 -0.5849 -2.4595 -0.7578 -0.5552 -0.3544 -0.3200 -0.7331 -0.8355 -0.1608
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools_for_economic_analysis_of_patient_management_interventions_in_heart_failure_cost-effectiveness_model clinical evidence-based medications costs outcomes
H-2010	-0.7724553346633911	▁Tools _ voor _ economic _ analys is _ of _ ▁Patient ▁Management ▁Interven tions _ in _ ▁Heart _ ▁Fail ure _ ▁Cost - E ff ective ness _ model
D-2010	-0.7724553346633911	Tools_voor_economic_analysis_of_ Patient Management Interventions_in_ Heart_ Failure_ Cost-Effectiveness_model
P-2010	-0.7942 -0.5121 -1.7541 -0.1045 -1.8944 -0.2805 -0.3017 -0.0870 -1.2826 -0.9544 -0.6694 -0.4405 -1.1145 -0.7978 -0.3225 -1.4558 -0.3009 -0.1718 -0.8369 -0.7489 -0.1413 -0.5947 -1.1261 -1.6007 -0.0770 -2.1904 -0.8709 -0.0069 -0.9042 -0.3985 -0.3843 -2.2846 -0.0869
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic_peptides nps b-type_np n-terminal_pro-b-type_np diagnosis acute_heart_failure patients emergency_department acute_dyspnea
H-1020	-0.4682706296443939	▁na tri ure tic _ pe pti des NP s ▁b - type _ NP ▁n - termin al _ ▁pro - b - type _ NP ▁a cute _ heart _ ▁failure ▁Emer gen cy _ ▁Department ED ▁a cute _ ▁dys pne a
D-1020	-0.4682706296443939	natriuretic_peptidesNPs b-type_NP n-terminal_ pro-b-type_NP acute_heart_ failure Emergency_ DepartmentED acute_ dyspnea
P-1020	-0.0040 -0.0199 -0.2186 -1.9616 -0.1872 -0.5778 -0.0740 -0.5561 -0.4474 -0.3019 -2.0754 -0.0256 -0.0062 -0.5294 -0.2286 -0.8394 -0.0208 -0.0071 -0.0058 -1.1996 -0.9695 -0.0092 -0.8776 -0.0100 -0.0018 -0.1088 -0.7212 -0.2294 -0.0295 -0.0164 -1.7812 -1.1665 -0.0265 -0.4649 -0.0778 -0.2177 -0.1940 -0.2044 -2.4956 -1.0726 -0.0280 -0.0309 -0.9717 -0.0019 -0.1114 -0.7429 -0.1609
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak_oxygen_consumption peak_vo2 exercise exercise_oscillatory_ventilation eov partial_pressure_of_end-tidal_co2 petco2 gain cardiopulmonary_exercise_testing
H-1275	-0.5545355081558228	▁pe ak _ ▁oxygen _ ▁consum p tion ▁VO 2 ven ▁v co 2 ▁s lope ▁exercise ▁os cilla tory _ ▁ventilation ▁e OV ▁parti al _ ▁pressure ▁end - ti dal _ co 2 PET co 2 ▁cardio pul mon ary _ ▁exercise ▁testing
D-1275	-0.5545355081558228	peak_ oxygen_ consumption VO2ven vco2 slope exercise oscillatory_ ventilation eOV partial_ pressure end-tidal_co2PETco2 cardiopulmonary_ exercise testing
P-1275	-0.6170 -0.0323 -0.0961 -1.9779 -0.7699 -0.4794 -0.1827 -0.2958 -3.0315 -0.6864 -0.9955 -0.4402 -0.5497 -0.0519 -2.3253 -0.2446 -0.1418 -0.4786 -0.0232 -0.1849 -0.0577 -0.0754 -0.1372 -0.1160 -1.5176 -0.0099 -0.0509 -0.6512 -2.4670 -0.0339 -0.0231 -0.0743 -0.1488 -0.2027 -0.1625 -0.2498 -0.2644 -0.9262 -0.0944 -0.2381 -0.6425 -0.5425 -0.2596 -0.9730 -2.0982 -0.2995 -0.1422
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective_cohort_study denmark bisphosphonates raloxifene
H-1536	-0.799639880657196	▁danes ▁bis phos phon ates ▁ra lo xi fen e
D-1536	-0.799639880657196	danes bisphosphonates raloxifene
P-1536	-4.3917 -0.7452 -0.0171 -0.1282 -0.2884 -1.4603 -0.0290 -0.0436 -0.0619 -0.2022 -2.1256 -0.1025
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal strain left_ventricle echocardiographic patients baseline echocardiography crt follow-up echocardiograms
H-429	-0.5655466914176941	▁longitud in al _ ▁strain ▁left _ ▁vent ric le ▁e cho car dio graphic _ ▁measure ments ▁base line _ e cho card i ography ▁c RT ▁follow - up _ e cho card i ogram s
D-429	-0.5655466914176941	longitudinal_ strain left_ ventricle echocardiographic_ measurements baseline_echocardiography cRT follow-up_echocardiograms
P-429	-1.7331 -0.3534 -0.0702 -0.1037 -2.3784 -0.8069 -0.1596 -1.9496 -1.8054 -0.6565 -0.1683 -0.0504 -0.0372 -0.5510 -0.3501 -1.5534 -1.0022 -0.2483 -1.2046 -0.0209 -0.4527 -0.4972 -0.0470 -0.4289 -0.6489 -0.2628 -0.3935 -1.4877 -0.0069 -0.0438 -0.0233 -0.4680 -0.8498 -0.1270 -0.2932 -0.7908 -0.0296 -0.1605 -0.3154 -0.0915
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension lv_dilatation lv_dysfunction mitral_valve organic lesion systolic diastolic_tethering etiology
H-365	-0.47513073682785034	▁hyper tension ▁LV ▁di la tation ▁LV ▁dys function ▁m ▁m ▁mit ral _ ▁val ve ▁organic _ ▁les ion ▁sy sto lic ▁dia sto lic _ te ther ing ▁functional _ ▁et i ology ▁MR ▁MS
D-365	-0.47513073682785034	hypertension LV dilatation LV dysfunction m m mitral_ valve organic_ lesion systolic diastolic_tethering functional_ etiology MR MS
P-365	-0.5845 -0.0188 -0.0750 -0.2118 -0.0391 -0.0102 -0.0085 -0.1013 -0.0120 -1.7442 -0.8968 -0.4218 -0.0127 -0.3880 -1.5763 -0.0289 -4.7660 -0.7976 -0.8114 -0.0241 -0.0262 -0.0066 -0.0067 -0.0091 -0.0111 -0.0182 -0.2537 -0.9966 -0.3370 -0.0217 -1.5780 -0.6989 -0.8720 -0.0323 -0.0823 -0.5460 -0.2528 -0.1904 -0.0615
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl healthy hdl healthy patients chf-nyha-iii hdl nyha-iiib patients chf-nyha-ii hdl nyha-ii
H-250	-1.2172346115112305	▁HD l ▁healthy _ control s HD l ▁CHF - NY ha - III HD l ▁ny ha - III b ▁ET ▁CHF - NY ha - II HD l ▁ny ha - II
D-250	-1.2172346115112305	HDl healthy_controlsHDl CHF-NYha-IIIHDl nyha-IIIb ET CHF-NYha-IIHDl nyha-II
P-250	-2.2281 -2.2128 -3.2608 -3.2022 -0.0028 -0.6324 -1.7502 -2.0378 -0.9658 -0.0622 -0.0682 -1.1159 -0.0622 -0.1606 -2.9374 -1.1647 -4.2875 -0.2702 -0.0456 -0.3352 -2.0249 -2.1600 -0.4761 -0.0901 -0.1760 -0.6684 -0.0475 -0.7314 -3.4479 -1.1506 -3.9541 -0.2607 -0.0581 -1.0508 -0.6221 -0.0990
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating_factor paf metabolic enzymes follow-up patients diagnosed heart_failure hf healthy
H-1267	-0.6123097538948059	▁plate let - activa ting _ factor ▁p bf ▁metabol ic _ ▁enzym es ▁heart ▁failure HF
D-1267	-0.6123097538948059	platelet-activating_factor pbf metabolic_ enzymes heart failureHF
P-1267	-0.7920 -0.9523 -0.1667 -0.0047 -0.2631 -0.2959 -1.0202 -1.8281 -1.5370 -0.0377 -0.0046 -0.1139 -0.0794 -0.0154 -1.6867 -0.9182 -1.1622 -0.6695 -0.0865
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute_care_surgery acs consultations oht transplantation medical_therapy intravenous inotropes ventricular_assist_devices vads
H-1281	-0.43051233887672424	▁a cute _ care _ ▁surgery ac s ▁o HT ▁transplant ation ▁medical _ therapy ▁m ▁intra ven ous _ in o trop es ▁vent ri cular _ assist ▁devices VAD s
D-1281	-0.43051233887672424	acute_care_ surgeryacs oHT transplantation medical_therapy m intravenous_inotropes ventricular_assist devicesVADs
P-1281	-0.0241 -0.0182 -0.0738 -1.8918 -0.5443 -0.6368 -1.8775 -0.2085 -0.2890 -1.6494 -0.8819 -0.0671 -0.3646 -1.0800 -0.0047 -0.2163 -0.0364 -0.0053 -1.6234 -0.1223 -0.0970 -0.4296 -0.0220 -0.0517 -0.0020 -0.4922 -0.1208 -0.1272 -0.2603 -0.7246 -0.2121 -0.0888 -0.2967 -0.0972
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone_system raas hfref angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers aldosterone_blockade evidence hfpef
H-1489	-0.3999108672142029	▁re nin - angi oten sin - al do ster one ▁system RA as ▁h Fr EF ▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors ▁ang io ten sin _ ▁receptor ▁block ers ▁al do ster one _ ▁block ade ▁ HF p EF
D-1489	-0.3999108672142029	renin-angiotensin-aldosterone systemRAas hFrEF angiotensin-converting_ enzyme inhibitors angiotensin_ receptor blockers aldosterone_ blockade HFpEF
P-1489	-0.0096 -0.4782 -0.0669 -0.0350 -0.0218 -1.2776 -0.1182 -0.0151 -0.4445 -0.0626 -0.4560 -1.4482 -1.1907 -0.0618 -1.9544 -1.7608 -0.7601 -0.3537 -0.4587 -0.1502 -0.8924 -0.2846 -0.0101 -0.0251 -0.0591 -0.1932 -0.0675 -0.0195 -0.0226 -0.0547 -0.1373 -0.4300 -0.0896 -0.4525 -0.5956 -0.0154 -1.3734 -0.0170 -0.0137 -0.1007 -0.0475 -0.1138 -1.1663 -0.9796 -0.0647 -0.3308 -0.4564 -0.0720 -0.9179 -0.1839 -0.0845
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients hfpef ivabradine exercise_capacity left_ventricular_filling_pressure exercise peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1178	-0.6628626585006714	▁ HF p EF ▁i va bra dine ▁left _ ▁vent ri cular _ ▁fill ing _ ▁pressure ▁exercise ▁dia sto lic _ met ral _ ▁flow _ ▁veloci ty ▁dia sto lic _ met ral _ ▁ann ular _ ▁veloci ty
D-1178	-0.6628626585006714	HFpEF ivabradine left_ ventricular_ filling_ pressure exercise diastolic_metral_ flow_ velocity diastolic_metral_ annular_ velocity
P-1178	-1.2754 -0.2756 -0.1596 -0.7710 -0.0759 -0.0440 -0.0523 -0.1381 -3.8648 -0.9291 -1.1095 -1.1828 -0.3198 -1.4439 -0.8588 -0.0456 -0.1976 -0.8443 -2.4708 -0.8383 -0.0401 -0.0322 -0.0564 -0.9435 -0.2298 -0.1019 -1.7362 -0.6384 -0.2217 -0.0479 -1.2944 -0.0635 -0.1240 -0.0743 -1.2035 -0.5335 -0.0851 -4.0438 -0.0037 -0.3247 -0.0761 -0.0690 -0.1867 -0.1382
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission lvet patients outcome tonometric
H-583	-0.5548161268234253	▁l VET ▁un favor able _ ▁outcome ▁milli second s ▁to no metric _ ▁indice s
D-583	-0.5548161268234253	lVET unfavorable_ outcome milliseconds tonometric_ indices
P-583	-0.4489 -1.2099 -1.6498 -0.1549 -0.2422 -0.6668 -2.0322 -0.0666 -0.3007 -0.1488 -0.4980 -0.2033 -0.1806 -0.6191 -1.0383 -0.0326 -0.3287 -0.1653
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart_rate blood_pressure renal_function spironolactone ras_blockers β-blockers
H-182	-0.6645600199699402	▁heart ▁rate ▁blood ▁pressure ▁renal _ ▁function ▁spi rono lac tone ▁ RAS _ block ers ▁β - block ers
D-182	-0.6645600199699402	heart rate blood pressure renal_ function spironolactone RAS_blockers β-blockers
P-182	-2.8064 -0.9609 -1.0488 -0.9436 -0.0472 -1.1938 -0.6460 -0.0011 -0.0031 -0.0152 -0.0292 -0.4841 -0.1190 -1.5026 -0.8293 -0.0405 -1.6547 -0.0391 -0.1497 -0.0938 -1.8822 -0.1302
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac β-adrenoceptor_blockade heart_failure reverse cardiac_remodeling elevated plasma_catecholamines
H-1553	-0.43389132618904114	▁cardiac ▁performance ▁β - ad re no cept or _ block ade ▁heart _ ▁failure ▁SR _ ca (2 +) - pump _ ▁function ▁rever se _ ▁cardiac _ ▁remodel ing ▁plasma _ ▁cate chol amine s
D-1553	-0.43389132618904114	cardiac performance β-adrenoceptor_blockade heart_ failure SR_ca(2+)-pump_ function reverse_ cardiac_ remodeling plasma_ catecholamines
P-1553	-2.3393 -1.1047 -0.0216 -0.0274 -0.0872 -0.1021 -0.2043 -0.1308 -0.1745 -0.8180 -0.7247 -0.1512 -0.9621 -1.2865 -0.0934 -0.2176 -1.5965 -0.1091 -1.4904 -0.0062 -0.0272 -0.0442 -0.7479 -0.7176 -0.7116 -0.0045 -0.0457 -0.1375 -0.4868 -0.0186 -0.0223 -0.0255 -1.1125 -0.5972 -0.0243 -0.0800 -0.0578 -0.2897 -0.1234
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 congestive_heart_failure phenotypes mitochondrial tac mitochondrial_proteome mitochondrial nonmitochondrial_protein
H-874	-0.6425115466117859	▁SS 31 ▁con ges tive _ heart _ ▁failure ▁mito cho ndri al _ ▁damage ▁ TAC ▁mito cho ndri al _ prote ome _ ▁changes ▁mito cho ndri al ▁non mi to cho ndri al _ ▁protein
D-874	-0.6425115466117859	SS31 congestive_heart_ failure mitochondrial_ damage TAC mitochondrial_proteome_ changes mitochondrial nonmitochondrial_ protein
P-874	-0.3788 -0.8425 -0.2911 -0.2254 -1.8861 -0.0376 -2.8502 -0.6716 -0.0704 -0.8692 -0.4491 -0.8258 -0.0599 -0.7829 -1.3249 -1.2608 -0.0097 -0.1033 -0.2584 -0.8439 -0.0732 -0.4211 -0.9364 -0.0619 -4.0110 -0.3090 -0.3139 -0.2641 -0.5130 -0.0356 -0.3255 -0.5911 -0.1281 -0.5327 -0.2289 -0.0450 -0.1380 -0.7696 -1.8906 -0.0703
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action randomized exercise training patients hf left_ventricular_ejection_fractions hrqol kansas_city_cardiomyopathy_questionnaire kccq baseline
H-837	-0.5669383406639099	▁ HF - ac tion ▁exercise _ training ▁ HF ▁low _ ▁left _ ▁vent ri cular _ e je ction _ fraction s ▁HR Qo l ▁Kansas ▁City _ ▁Card i om yo pathy ▁Question naire ▁k cc q
D-837	-0.5669383406639099	HF-action exercise_training HF low_ left_ ventricular_ejection_fractions HRQol Kansas City_ Cardiomyopathy Questionnaire kccq
P-837	-0.9660 -0.1477 -0.0217 -0.3062 -1.0832 -1.0439 -1.7890 -0.2419 -0.8904 -0.0701 -0.6951 -0.0517 -2.2123 -0.1986 -2.6209 -0.9030 -0.5855 -0.1366 -0.2944 -0.1547 -0.0763 -0.7761 -0.0112 -0.0164 -0.3497 -0.0057 -1.2245 -0.0087 -0.6723 -0.1761 -2.1549 -0.0209 -0.0248 -0.9299 -0.0445 -1.0028 -0.0069 -0.5229 -0.0734 -1.1143 -0.0874 -0.0988
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan hyponatremia united_states japan congestive_heart_failure patients diuretic therapy serum_sodium systolic_function
H-1196	-0.548893928527832	▁to lv ap tan ▁hypo na trem ia ▁Japan ▁con ges tive _ heart ▁failure ▁di ure tic _ therapy ▁se rum ▁so dium ▁levels ▁sy sto lic _ ▁function
D-1196	-0.548893928527832	tolvaptan hyponatremia Japan congestive_heart failure diuretic_therapy serum sodium levels systolic_ function
P-1196	-0.0237 -0.5021 -0.1559 -0.0350 -1.4212 -0.0441 -0.0217 -0.2358 -2.3590 -0.3301 -0.1206 -1.3284 -0.0613 -1.6906 -0.4494 -2.6186 -0.8874 -0.5704 -0.5415 -0.0334 -0.7683 -0.0922 -0.0308 -0.0038 -1.2480 -0.0037 -0.0235 -0.0612 -0.4199 -1.0009 -0.4039 -0.0782
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar atpase activity mrna phospholamban α-myosin_heavy_chain mrna β-myosin_heavy_chain metoprolol
H-1552	-0.485444575548172	▁mijn o fi bril lar ▁ca (2 +) - stimul ated _ ▁ATP ase ▁m RNA ▁levels ▁SR ▁ca (2 +) - pump ▁ phos pho lam ban ▁α - my os in _ ▁heavy _ ▁chain ▁m RNA ▁m RNA ▁β - my os in _ ▁heavy _ ▁chain ▁met o pro lol
D-1552	-0.485444575548172	mijnofibrillar ca(2+)-stimulated_ ATPase mRNA levels SR ca(2+)-pump phospholamban α-myosin_ heavy_ chain mRNA mRNA β-myosin_ heavy_ chain metoprolol
P-1552	-3.0956 -0.2505 -0.0319 -0.1289 -0.2675 -1.0272 -0.9437 -0.0028 -0.0082 -0.0540 -0.3234 -0.3666 -2.8917 -0.9635 -0.1055 -0.0719 -3.0673 -0.9219 -1.4962 -0.6755 -0.0033 -0.0143 -0.0934 -0.1277 -0.0167 -0.0409 -0.5730 -0.2129 -0.0301 -0.0190 -0.5861 -0.0756 -0.8566 -0.1270 -0.3878 -0.1302 -0.1174 -0.0038 -0.1417 -1.7144 -0.6714 -1.2947 -0.0208 -0.6614 -0.0919 -0.4471 -0.1043 -0.4600 -0.0899 -0.1163 -0.2092 -0.3182 -0.1140 -0.2402 -0.2600 -0.1199
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized coronary_microembolization-induced_hf cxl-1020 left_ventricular_end-diastolic_pressure myocardial_oxygen_consumption ejection_fraction maximal_ventricular_power_index
H-420	-0.44737812876701355	▁an est het ized _ dog s ▁corona ry _ ▁micro e mbol ization - indu ced ▁ HF ▁c XL -10 20 ▁left _ ▁vent ri cular _ ▁end - dia sto lic _ ▁pressure ▁my o card ial _ ▁oxygen ▁consum p tion ▁e je ction ▁ fraction ▁maximal _ ▁vent ri cular _ power ▁index
D-420	-0.44737812876701355	anesthetized_dogs coronary_ microembolization-induced HF cXL-1020 left_ ventricular_ end-diastolic_ pressure myocardial_ oxygen consumption ejection fraction maximal_ ventricular_power index
P-420	-1.3495 -0.1580 -0.7595 -0.1287 -0.6887 -0.4451 -0.0240 -0.3360 -0.6034 -0.1423 -0.9271 -0.1933 -0.0106 -0.6492 -0.0686 -0.0007 -0.0312 -0.9779 -0.0695 -1.6912 -0.1657 -0.6250 -0.0496 -0.4146 -0.4533 -1.4668 -0.9214 -0.2648 -0.8436 -2.5250 -0.0509 -0.0335 -0.0177 -0.0418 -0.1305 -0.4602 -0.3122 -0.1618 -0.5284 -0.6945 -0.0630 -0.9736 -0.4569 -0.0923 -0.2265 -0.0209 -0.0362 -0.0263 -1.6121 -0.0018 -0.5249 -0.2132 -0.7126 -0.9778 -0.5547 -0.0726 -0.2516 -0.2429 -0.2382 -0.1290
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline heart_failure t1-mapping administration administration
H-1061	-1.350020408630371	▁heart _ ▁failure ▁contrast _ agent
D-1061	-1.350020408630371	heart_ failure contrast_agent
P-1061	-3.3419 -1.3639 -0.3783 -2.5319 -0.7735 -0.3464 -1.9170 -0.1473
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard_error_of_measurement mdc mdc
H-805	-0.7207562923431396	▁m DC ▁95% _ ▁confidence ▁level ▁m DC ▁m DC ▁95% _ ▁confidence ▁level ▁m DC
D-805	-0.7207562923431396	mDC 95%_ confidence level mDC mDC 95%_ confidence level mDC
P-805	-0.3447 -0.2754 -3.1359 -0.8771 -0.2972 -0.3736 -0.0446 -0.1878 -1.5030 -0.2839 -1.4072 -0.6441 -0.3311 -0.3903 -0.0419 -0.2481 -2.4624 -0.1254
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies hf idiopathic_dilated_cardiomyopathy ischemic valvular
H-1794	-0.47451722621917725	▁et i ologie s ▁ HF ▁la ▁ idio pathi c ▁dil ated _ ▁cardio my o pathy ▁c ' d ▁ ische mic ▁SH ▁val vu lar ▁alcohol
D-1794	-0.47451722621917725	etiologies HF la idiopathic dilated_ cardiomyopathy c'd ischemic SH valvular alcohol
P-1794	-2.9289 -0.1079 -0.0127 -0.2994 -0.6783 -0.2458 -1.3583 -1.3348 -0.0190 -0.0179 -0.0983 -1.2446 -0.1270 -0.0882 -0.2290 -0.9482 -0.4023 -0.0047 -0.1166 -2.1389 -0.1387 -0.0533 -0.0200 -0.1013 -0.1687 -0.0638 -0.0027 -0.0502 -0.1249 -1.4852 -0.1004
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 functional_capacity clinical outcomes ambulatory patients hf heart_failure outcomes exercise training hf-action randomized exercise training hf
H-697	-0.5051833987236023	▁ST 2 ▁functional _ ▁capacity ▁ambula tory ▁patients ▁ HF ▁Heart _ ▁Fail ure ▁tri al _ ▁Investiga ting _ out com es ▁Exerci se _ ▁Training ▁ HF - ac TION ▁exercise _ training ▁ HF
D-697	-0.5051833987236023	ST2 functional_ capacity ambulatory patients HF Heart_ Failure trial_ Investigating_outcomes Exercise_ Training HF-acTION exercise_training HF
P-697	-0.2233 -0.1157 -0.1976 -0.8694 -1.8742 -0.2713 -0.1441 -0.8537 -0.3505 -0.1054 -1.0442 -1.5192 -0.0849 -0.2157 -2.5118 -0.0903 -0.1501 -0.0210 -0.0431 -0.1460 -0.8847 -0.1503 -0.0225 -0.4602 -0.0319 -0.2923 -0.7395 -1.7849 -0.0812 -0.0829 -0.2769 -1.1733 -0.2750 -0.9816 -0.3075 -0.7220 -0.1977 -0.2916 -0.1150
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol metoprolol endpoint implantable_cardioverter-defibrillator therapy madit-crt multicenter_automatic_defibrillator_implantation_with_cardiac_resynchronization_therapy
H-856	-0.4438311457633972	▁car vedi lol ▁met o pro lol ▁in appropria te _ ▁implant able _ ▁cardio ver ter - de fi br illa tor _ therapy ▁MAD it - c r ▁multi center _ automat ic _ de ib rilla tor ▁Implant ation _ ▁With _ ▁Card iac _ re syn chron ization ▁Therapy
D-856	-0.4438311457633972	carvedilol metoprolol inappropriate_ implantable_ cardioverter-defibrillator_therapy MADit-cr multicenter_automatic_deibrillator Implantation_ With_ Cardiac_resynchronization Therapy
P-856	-0.4254 -0.0216 -0.0552 -0.0832 -0.1223 -0.0138 -0.0876 -1.7998 -0.0292 -0.0502 -1.9079 -0.2441 -0.0136 -0.4077 -0.3105 -0.0515 -0.2229 -0.4444 -0.1055 -0.1837 -0.6130 -0.1685 -0.0771 -1.2382 -0.0143 -0.2930 -1.1094 -0.0105 -0.7246 -3.0421 -1.0253 -0.0337 -0.2379 -0.4091 -0.0156 -0.0466 -1.5536 -0.8443 -0.3958 -0.0533 -0.5507 -0.1167 -0.6270 -0.8495 -0.1031 -0.8607 -0.0864 -0.1790 -0.4013 -0.0488 -0.0027 -1.0021 -0.7169 -0.2674 -0.1124
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate_ratio confidence_interval angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers therapy confidence_interval β-blockers therapy
H-666	-0.646126389503479	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors angi oten sin _ ▁receptor _ block ers ▁ therapy ▁β - block ers ▁ therapy
D-666	-0.646126389503479	angiotensin-converting_ enzyme inhibitorsangiotensin_ receptor_blockers therapy β-blockers therapy
P-666	-7.1191 -1.5797 -0.1137 -0.8155 -0.4513 -0.0068 -0.0282 -0.0589 -0.2222 -0.0841 -0.0252 -0.1763 -0.0808 -0.1415 -0.0270 -0.3292 -0.4969 -0.0505 -0.7486 -1.0355 -0.0351 -2.5756 -0.0153 -0.9425 -0.0278 -0.1132 -0.0416 -1.8443 -0.0404 -0.5568 -0.2463
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ischemic_hf pathogenesis nyha_functional_class_iv estimated_glomerular_filtration_rate heart_rate hypertension diabetes_mellitus myocardial_infarction
H-1704	-0.572648823261261	▁ ische mic _ HF ▁NY HA ▁glo mer ular _ filter ation _ ▁rate ▁heart ▁rate ▁hyper tension ▁diabetes ▁mell itus ▁my o card ial _ in far ction
D-1704	-0.572648823261261	ischemic_HF NYHA glomerular_filteration_ rate heart rate hypertension diabetes mellitus myocardial_infarction
P-1704	-1.4901 -0.0359 -0.1290 -0.1478 -0.5692 -1.8822 -0.5138 -1.6692 -0.1086 -0.0289 -0.1197 -1.2486 -0.2663 -1.6036 -0.1912 -1.0870 -1.0086 -0.0607 -0.0049 -0.0114 -0.0033 -0.0043 -1.5544 -0.3799 -0.3944 -0.9888 -0.1120 -0.2879 -0.1042 -0.1489 -2.0403 -0.1295
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt systolic_dysfunction outcomes resynchronization_reverses_remodeling_in_systolic_left_ventricular_dysfunction reverse patients left_ventricular ejection_fraction lvef
H-752	-0.4886725842952728	▁c RT ▁sy sto lic _ ▁dys function ▁re syn chron ization ▁re ve rse s _ re model ing ▁sy sto lic _ ▁left _ en tri cular _ ▁dys function ▁re vers e ▁left _ ▁vent ri cular LV ▁e je ction _ fraction LV EF
D-752	-0.4886725842952728	cRT systolic_ dysfunction resynchronization reverses_remodeling systolic_ left_entricular_ dysfunction reverse left_ ventricularLV ejection_fractionLVEF
P-752	-0.3255 -2.6168 -0.2462 -0.0242 -0.1794 -0.1158 -0.6991 -0.0622 -0.4301 -0.0371 -0.0038 -0.9739 -0.2734 -0.9109 -0.1188 -0.0223 -1.2385 -0.0805 -0.2785 -0.0174 -1.4010 -0.0041 -0.0350 -0.1264 -0.4192 -0.2077 -4.3209 -0.4956 -0.2862 -0.2468 -0.1312 -0.0813 -0.8862 -1.7957 -0.1450 -0.2626 -0.2809 -0.8201 -0.2759 -0.1105 -0.9572 -0.6320 -0.0551 -0.0650 -0.4421 -0.0381 -0.3861 -0.5555 -0.1904 -0.1257
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars s1pr1s myocyte camp report receptors g-protein-coupled_receptor kinase-2
H-1408	-0.5363922715187073	▁signal ing ▁paradigm s ▁β 1 AR s ▁s 1 PR 1 s ▁my o cy te ▁c AMP _ ▁production ▁receptor s ▁g - prote in - co up led _ ▁receptor ▁kina se -2
D-1408	-0.5363922715187073	signaling paradigms β1ARs s1PR1s myocyte cAMP_ production receptors g-protein-coupled_ receptor kinase-2
P-1408	-4.2176 -0.0469 -0.3148 -0.0980 -0.8436 -0.5630 -0.6002 -0.2938 -0.7658 -0.7546 -0.1474 -2.7321 -0.2578 -1.1099 -0.0960 -0.0798 -0.0409 -0.1658 -0.0645 -3.1665 -0.3586 -0.3639 -0.3407 -1.1406 -0.1106 -0.0452 -0.0772 -0.0535 -0.0079 -0.0538 -0.4226 -0.0685 -0.0802 -0.4109 -0.0221 -0.0700 -0.2975 -0.0999
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up paf-cpt paf lyso-paf-at downregulated paf-ah lp-pla2 elevated
H-1270	-0.90037602186203	▁follow - up ▁PA f - c pt ▁PA f - at ▁lys o - pa f - at ▁pa f - AH ▁l p - PLA 2
D-1270	-0.90037602186203	follow-up PAf-cpt PAf-at lyso-paf-at paf-AH lp-PLA2
P-1270	-4.9300 -0.0666 -0.0097 -0.8297 -1.1417 -0.1097 -0.3647 -1.1837 -1.3241 -1.8031 -3.7605 -1.9361 -1.3656 -0.0907 -0.0370 -0.4042 -1.0797 -0.1562 -0.9018 -2.4329 -1.3465 -0.1049 -0.7014 -0.1617 -0.0093 -0.0411 -0.0205 -0.0655 -0.5011 -0.1313
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic patients auc auc
H-488	-1.5777761936187744	▁diagnosti ▁performance ▁s ' lateral ▁a UC ▁s ' lateral ▁a UC
D-488	-1.5777761936187744	diagnosti performance s'lateral aUC s'lateral aUC
P-488	-4.7748 -1.8719 -0.0991 -3.2249 -0.3348 -1.2518 -1.4401 -0.2501 -4.4309 -0.5304 -1.5003 -1.7535 -0.4184 -0.2079
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control patients cardiac driven cardioversions costs antiarrhythmic_drugs cad patient confidence_interval patient
H-1239	-0.8108839988708496	▁Rate - control ▁patients ▁cardiac _ procedure s ▁cardio version s ▁kosten ▁anti ar rhythm ic _ ▁drugs CAD ▁confidence _ ▁interval ▁CI
D-1239	-0.8108839988708496	Rate-control patients cardiac_procedures cardioversions kosten antiarrhythmic_ drugsCAD confidence_ interval CI
P-1239	-3.9515 -0.2189 -0.0023 -2.1746 -0.8574 -0.7619 -0.7274 -0.0372 -0.4545 -0.0923 -0.0717 -1.2228 -0.0781 -0.3108 -0.1277 -0.0337 -0.6905 -0.5661 -1.5718 -1.8388 -1.0348 -0.0327 -2.0682 -1.1961 -0.1505
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients follow-up patients spironolactone hospitalization hazard_ratio confidence_interval death hazard_ratio confidence_interval
H-443	-0.7370558977127075	▁spi rono lac tone
D-443	-0.7370558977127075	spironolactone
P-443	-0.2561 -0.0075 -0.0255 -0.0431 -3.8957 -0.1945
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients bundle_branch_morphology diabetes_mellitus cardiomyopathy β-blocker angiotensin-converting_enzyme_inhibitor angiotensin_ii_receptor_blocker
H-906	-0.32154208421707153	▁diabetes ▁mell itus ▁cardio my o pathy ▁β - block er ▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tor ▁ang io ten sin _ ▁II _ ▁receptor _ block er
D-906	-0.32154208421707153	diabetes mellitus cardiomyopathy β-blocker angiotensin-converting_ enzyme inhibitor angiotensin_ II_ receptor_blocker
P-906	-2.0777 -0.0144 -0.0204 -0.0077 -0.5026 -0.4296 -0.0118 -0.2842 -0.0158 -0.1009 -0.0350 -0.7441 -0.3501 -0.2642 -0.6253 -0.2873 -0.0110 -0.0304 -0.0452 -0.1072 -0.1604 -0.0264 -0.1075 -0.0188 -0.6502 -0.4039 -0.2520 -0.5262 -0.3650 -0.6193 -0.1708 -0.1174 -0.7262 -0.9415 -0.0804 -0.6246 -0.1412
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone_post_myocardial_infarction_heart_failure_efficacy_and_survival_study ephesus post-myocardial_infarction patients heart_failure mortality hospitalizations patients randomized aldosterone_antagonist eplerenone
H-1737	-0.6222525835037231	▁e pler en one ▁post _ my o card ial _ in far ction _ ▁Heart _ ▁failure ▁SU rvi val ▁e ▁eura s ▁post - my o card ial _ in far ction ▁heart ▁failure ▁mortal ity ▁al do ster one ▁anta gon ist ▁e pler en one
D-1737	-0.6222525835037231	eplerenone post_myocardial_infarction_ Heart_ failure SUrvival e euras post-myocardial_infarction heart failure mortality aldosterone antagonist eplerenone
P-1737	-0.1221 -0.0085 -0.0730 -0.2298 -0.2558 -0.3835 -3.1799 -0.6772 -1.2488 -1.5586 -0.0911 -0.2565 -0.1669 -0.1148 -0.3894 -0.5787 -1.7946 -0.0426 -1.1505 -0.0115 -0.0121 -0.6657 -5.2845 -0.9227 -0.0211 -0.0311 -1.4178 -0.6192 -1.9718 -1.0504 -0.1808 -0.2020 -0.2235 -0.1103 -1.3232 -0.2613 -0.8211 -1.1506 -0.2649 -0.0445 -0.0255 -0.1422 -1.2637 -0.0015 -0.4054 -0.1361 -0.0099 -0.0331 -0.5063 -0.1478 -0.1510
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report cardiopulmonary_exercise_testing exercise_rehabilitation patients chronic_heart_failure exercise_rehabilitation patient chronic_heart_failure chf clinical cardiopulmonary_exercise_testing cpet exercise_rehabilitation china
H-1879	-0.9554930329322815	▁cardio pul mon ary _ ▁exercise _ ▁testing _ ▁guide ▁exercise ▁rehabilita tion ▁chronic _ heart _ ▁failure ▁chronic _ heart _ ▁failure CH f ▁Card io P ul mon ary _ ▁Exerci se _ ▁Test ing ▁c PET ▁exercise ▁rehabilita tion
D-1879	-0.9554930329322815	cardiopulmonary_ exercise_ testing_ guide exercise rehabilitation chronic_heart_ failure chronic_heart_ failureCHf CardioPulmonary_ Exercise_ Testing cPET exercise rehabilitation
P-1879	-0.2956 -0.7402 -1.5687 -0.5969 -0.2638 -0.9874 -0.9863 -1.2830 -2.5600 -0.8035 -0.7532 -1.1253 -0.1768 -2.3226 -0.0516 -1.7926 -1.0197 -0.0806 -3.2637 -0.0726 -2.6253 -1.4630 -0.0458 -3.1832 -1.2454 -0.8978 -0.3869 -2.5819 -0.2404 -1.0145 -0.1372 -0.0587 -0.2014 -0.1093 -0.3698 -1.3882 -0.0205 -0.3441 -0.6642 -0.2282 -0.9710 -0.1166 -2.8556 -0.1485
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence_interval heart mortality death
H-1749	-0.9098799824714661	▁risk ▁re duction HR ▁heart ▁failure - related _ ▁mortal ity ▁sud den _ ▁death ▁HR
D-1749	-0.9098799824714661	risk reductionHR heart failure-related_ mortality sudden_ death HR
P-1749	-3.5827 -0.7573 -0.0772 -0.8306 -3.3735 -1.0234 -0.3783 -0.1754 -0.2068 -0.2811 -1.1356 -1.5881 -0.0186 -0.1214 -0.6649 -1.3653 -0.6730 -0.1248
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash clinic brachial_systolic_pressure central_end-systolic_pressure
H-924	-0.798637866973877	▁DAS h ▁s rd ▁bra chi al _ sy sto lic _ ▁pressure ▁central _ en - sy sto lic _ ▁pressure
D-924	-0.798637866973877	DASh srd brachial_systolic_ pressure central_en-systolic_ pressure
P-924	-0.0198 -0.0803 -3.5588 -0.9932 -1.2188 -0.1139 -0.2981 -0.1964 -1.3121 -0.1346 -0.2096 -0.4562 -0.8494 -1.6671 -0.2107 -3.6141 -1.2988 -0.1221 -0.0516 -0.1177 -0.1629 -0.8611 -1.5026 -0.1173
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause_mortality hospitalization hf lvef patients heart_failure_survey israel
H-113	-1.0401266813278198	▁ HF ▁LV EF ▁Heart ▁Fail ure _ ▁Survey ▁is ra el
D-113	-1.0401266813278198	HF LVEF Heart Failure_ Survey israel
P-113	-2.9526 -1.0502 -0.3915 -0.3100 -3.0961 -0.8265 -1.0450 -0.4755 -0.0546 -3.6838 -0.2738 -0.0210 -0.2181 -0.1630
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients hf obese body_mass_index idiopathic-dilated_cardiomyopathy
H-558	-0.38191986083984375	▁ HF ▁obes e ▁body ▁mass ▁index ▁black _ ▁et hni city ▁ idio pathi c - dila ted _ ▁cardio my o pathy
D-558	-0.38191986083984375	HF obese body mass index black_ ethnicity idiopathic-dilated_ cardiomyopathy
P-558	-1.3509 -0.2500 -1.9050 -0.0535 -0.8698 -0.9787 -0.1140 -0.1469 -0.3969 -0.5709 -0.0882 -0.4516 -0.0459 -0.0187 -0.0256 -0.1547 -0.1595 -0.0058 -0.0457 -0.0815 -0.1168 -1.2614 -0.4028 -0.0111 -0.2837 -0.1401
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients left_ventricular_ejection_fraction world_health_organization idiopathic_dilated_cardiomyopathy coronary_angiography followed_up
H-1743	-0.7402933835983276	▁left _ ▁vent ri cular _ e je ction _ fraction ▁world _ health _ ▁Organization ▁ idio pathi c _ ▁dil ated _ ▁cardio my o pathy ▁negative _ ▁corona ry _ ▁ang i ography
D-1743	-0.7402933835983276	left_ ventricular_ejection_fraction world_health_ Organization idiopathic_ dilated_ cardiomyopathy negative_ coronary_ angiography
P-1743	-3.6345 -0.5201 -1.4049 -1.1479 -0.6850 -0.2114 -0.3153 -0.1252 -0.0820 -0.5888 -0.0068 -0.6328 -0.7221 -2.5885 -0.7352 -1.9127 -0.8229 -0.0123 -0.0222 -0.1787 -0.1724 -1.4715 -0.2044 -0.0596 -0.2849 -1.9479 -0.3643 -0.0124 -0.0216 -0.1042 -0.6350 -1.3692 -0.1307 -3.6603 -0.4421 -0.2141 -0.5321 -0.1551
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european_society_of_cardiology hfpef symptoms heart_failure preserved_lv_ejection_fraction non-dilated_left_ventricle evidence diastolic_dysfunction lv_relaxation lv_diastolic_stiffness elevated lv_filling_pressures
H-27	-0.45315876603126526	▁ europe se _ soci e _ of _ card i ology ▁h FP EF ▁heart ▁failure ▁LV ▁e je ction _ fraction ▁non - dila ted _ ▁left _ ▁vent ric le ▁dia sto lic _ ▁dys function impa i red _ ▁LV _ ▁relax ation ▁LV ▁dia sto lic _ ▁sti ff ness ▁LV ▁fill ing _ ▁pressure s
D-27	-0.45315876603126526	europese_socie_of_cardiology hFPEF heart failure LV ejection_fraction non-dilated_ left_ ventricle diastolic_ dysfunctionimpaired_ LV_ relaxation LV diastolic_ stiffness LV filling_ pressures
P-27	-0.8778 -0.0126 -0.0216 -0.0452 -0.7243 -1.1962 -0.1521 -1.3473 -0.0740 -1.2560 -0.3771 -0.1501 -1.1382 -2.2776 -0.9010 -0.7759 -0.6226 -2.3894 -0.7461 -0.0279 -0.0167 -1.3174 -0.0096 -1.2685 -0.0082 -0.0008 -0.0043 -0.2328 -0.2040 -0.0688 -0.9676 -1.1042 -0.1553 -0.0809 -0.0207 -0.0347 -0.1981 -0.3638 -0.0072 -0.7200 -0.0121 -0.0121 -0.9480 -0.1725 -1.3189 -0.0695 -0.0156 -0.3885 -0.0454 -0.0212 -0.0492 -0.2231 -0.1788 -0.1249 -0.4627 -1.0276 -0.2702 -0.0251 -0.4949 -0.4412 -0.0255 -0.2351 -0.0902
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated_glomerular_filtration_rate egfr type_2_diabetes cholesterol ldl-cholesterol clcnka genotype
H-1803	-0.6039672493934631	▁glo mer ular _ filter ation ▁e g FR ▁diabetes ▁total _ ▁cholesterol ▁l DL - ch olesterol ▁CL cn ka _ gg ▁geno type
D-1803	-0.6039672493934631	glomerular_filteration egFR diabetes total_ cholesterol lDL-cholesterol CLcnka_gg genotype
P-1803	-0.3257 -0.3367 -0.0892 -0.1868 -1.2328 -0.5525 -1.3893 -2.2767 -0.5255 -0.5390 -0.1341 -0.3316 -0.9591 -0.4994 -0.5878 -0.2897 -0.3687 -0.0009 -0.1242 -1.7062 -0.4805 -0.9098 -1.1725 -1.0110 -0.0023 -0.1551 -0.1199
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography lv_end-diastolic_dimension lv_end-diastolic_pressure wall_stress lung acf
H-474	-0.705825686454773	▁e cho card i ography ▁LV ▁end - dia sto lic _ dimension ▁LV ▁end - dia sto lic _ ▁pressure wall _ ▁stress ▁lung _ ▁weight ▁un tre ated _ a CF ▁sham _ groep
D-474	-0.705825686454773	echocardiography LV end-diastolic_dimension LV end-diastolic_ pressurewall_ stress lung_ weight untreated_aCF sham_groep
P-474	-0.1340 -0.0425 -0.2544 -0.2242 -0.2268 -2.6456 -1.5378 -0.0820 -0.0531 -0.0610 -0.1143 -0.4665 -0.0666 -2.8377 -2.1676 -0.0804 -0.0708 -0.0644 -0.1116 -0.2799 -2.0835 -1.4398 -0.6972 -1.1752 -0.0861 -0.7631 -1.0551 -2.0240 -0.0067 -0.4862 -0.9715 -1.0264 -0.9150 -0.2661 -1.1462 -0.6952 -0.3189 -0.1439
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients heart_failure ejection_fraction cardiac_rehabilitation walking exercise
H-570	-0.7340453267097473	▁heart ▁failure ▁e je ction _ fraction ▁standard _ ▁cardiac _ ▁rehabilita tion _ care ▁Nordic _ ▁walking
D-570	-0.7340453267097473	heart failure ejection_fraction standard_ cardiac_ rehabilitation_care Nordic_ walking
P-570	-3.0908 -1.0485 -0.6765 -0.0749 -0.0282 -0.4672 -0.0065 -1.4109 -0.2411 -0.0624 -1.1227 -0.3844 -0.1690 -0.9620 -0.8942 -1.4782 -0.1098 -1.4872 -0.8187 -0.1477
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard_ratios sitagliptin pioglitazone sitagliptin sulfonylureas sitagliptin insulin
H-1836	-0.9511528015136719	▁d RS - stra t ified _ ▁hazard _ ▁ratio s ▁ci ▁si tag lip tin ▁pi og lita zone ▁si tag lip tin ▁sul fon yl ure as ▁ci ▁si tag lip tin ▁insulin
D-1836	-0.9511528015136719	dRS-stratified_ hazard_ ratios ci sitagliptin pioglitazone sitagliptin sulfonylureas ci sitagliptin insulin
P-1836	-0.5308 -0.6695 -0.0253 -0.0465 -0.0875 -0.1039 -0.3640 -0.5982 -1.9723 -0.1049 -0.0941 -1.3655 -4.6446 -0.2501 -0.2663 -3.5014 -1.4199 -0.2183 -0.1369 -0.0551 -2.9776 -0.8250 -0.1665 -3.1911 -0.5262 -0.0253 -0.1560 -0.3250 -0.0266 -1.6133 -2.8659 -0.5581 -0.3157 -4.3124 -0.4116 -0.2994 -0.1420
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal_muscle t-score fontan sarcopenic_range_muscle_wasting t-score clinically t-score
H-1501	-0.9060566425323486	▁skelet al _ ▁muscle _ massa ▁t - s core ▁figuur ▁sar co pen ic _ ▁range _ ▁muscle _ was ting ▁t - s core
D-1501	-0.9060566425323486	skeletal_ muscle_massa t-score figuur sarcopenic_ range_ muscle_wasting t-score
P-1501	-0.2008 -0.0322 -0.1194 -1.1777 -0.8324 -1.4891 -0.8982 -0.0845 -0.0941 -0.2598 -4.2518 -3.7908 -0.0227 -0.1418 -0.1270 -0.1504 -0.0791 -0.2570 -2.4849 -1.6069 -3.0548 -0.0460 -1.2299 -0.0596 -0.0644 -0.4577 -2.2665 -0.0901
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker uptitrations composite_end-point all-cause_mortality hf readmissions hfref hazard_ratio confidence_interval
H-181	-0.9426103830337524	▁ RAS - ▁β - block er _ up ti tra tions ▁all - ca use _ ▁mortal ity ▁ HF _ ▁read missions ▁h Fr ef haz ard _ ▁ratio HR ▁confidence _ ▁interval ▁ci
D-181	-0.9426103830337524	RAS- β-blocker_uptitrations all-cause_ mortality HF_ readmissions hFrefhazard_ ratioHR confidence_ interval ci
P-181	-1.2833 -0.0342 -0.0319 -0.0839 -0.0184 -0.0912 -0.0269 -0.8035 -0.3212 -0.3565 -1.3128 -1.0742 -6.1259 -0.0209 -0.0268 -0.4040 -0.0669 -0.1096 -1.2736 -0.4783 -0.1550 -2.1597 -2.0496 -0.2064 -0.3073 -1.1367 -1.0149 -0.3271 -0.0379 -0.1604 -0.0774 -3.1077 -3.1471 -0.8666 -0.0412 -2.4342 -4.5323 -0.1135
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise testosterone baseline peak_oxygen_uptake beck_depression_inventory leg medical_outcomes_study_short-form quality_of_life exercise placebo
H-1323	-0.4801296889781952	▁testosteron e _ groep ▁pe ak _ ▁oxygen _ up take ▁Beck _ de pression _ in ven tory ▁leg _ ▁strength ▁Medical _ out com es ▁Short - Form _ ▁quality _ of _ ▁life
D-1323	-0.4801296889781952	testosterone_groep peak_ oxygen_uptake Beck_depression_inventory leg_ strength Medical_outcomes Short-Form_ quality_of_ life
P-1323	-2.5674 -0.0115 -0.7694 -0.5577 -1.4891 -0.0254 -0.0644 -0.1802 -0.5700 -0.3722 -0.0664 -0.0822 -0.7582 -0.5728 -0.0328 -0.1710 -0.2834 -0.1512 -0.0162 -0.0909 -1.0857 -0.2438 -0.4661 -1.5761 -0.9798 -0.0857 -0.0091 -0.1280 -0.0224 -0.3060 -0.0799 -0.6016 -0.0738 -0.4820 -0.0669 -0.6344 -2.3667 -0.2045
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients heart_failure outcomes exercise training hf-action exercise perceived_social_support_score psss barriers_to_exercise_score btes
H-1927	-0.722794771194458	▁Heart _ ▁Fail ure ▁control led _ tri al _ ▁Investiga ting _ out com es _ of _ ▁Exerci se _ training HF - ac tion ▁social _ ▁support _ ▁score ▁p s s ▁barrier s _ ▁to _ ▁exercise _ ▁score ▁b tes
D-1927	-0.722794771194458	Heart_ Failure controlled_trial_ Investigating_outcomes_of_ Exercise_trainingHF-action social_ support_ score pss barriers_ to_ exercise_ score btes
P-1927	-2.7427 -1.7246 -0.1663 -0.3032 -2.9434 -1.0984 -0.0349 -0.2706 -0.0783 -0.1142 -0.0188 -0.0307 -0.1366 -0.6866 -0.2010 -0.0227 -0.5236 -0.6672 -0.1417 -0.2571 -0.0392 -0.1919 -0.7251 -2.3510 -0.0290 -0.3279 -1.5328 -0.8237 -0.3337 -2.1354 -1.9209 -2.0021 -0.8711 -0.8575 -0.0815 -2.3532 -0.0160 -0.6430 -0.6564 -0.1759 -0.4667 -1.5351 -0.1234 -1.1077 -0.2268 -0.1487 -0.1329
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable_analysis st2 death hospitalization hazard_ratio cardiovascular_death hf hospitalization hazard_ratio all-cause_mortality hazard_ratio hazard_ratios
H-703	-0.6922695636749268	▁ST 2 ▁cardiovascular _ ▁death ▁ HF _ hospital ization haz ard _ ▁ratio ▁all - ca use _ ▁mortal ity haz ard _ ▁ratio ▁hazard _ ▁ratio s ▁log 2
D-703	-0.6922695636749268	ST2 cardiovascular_ death HF_hospitalizationhazard_ ratio all-cause_ mortalityhazard_ ratio hazard_ ratios log2
P-703	-1.0741 -0.2745 -3.1103 -0.6450 -0.6467 -0.3380 -0.0649 -2.7589 -0.6464 -1.2613 -0.3121 -0.0810 -0.5125 -0.0700 -2.7144 -0.0433 -0.0159 -0.4183 -0.0855 -0.0795 -1.6418 -0.5461 -0.1100 -0.4310 -0.0560 -1.8574 -0.7362 -0.1117 -0.2652 -0.4091 -0.2122 -1.0892 -0.2267
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients new_york_heart_association_class_i fontan cardiopulmonary_exercise_testing lean_mass_quantification dual_x-ray_absorptiometry dxa calf muscle magnetic_resonance_spectroscopy healthy
H-1495	-0.5614933371543884	▁New _ York _ heart _ association _ class _ ▁I _ font an _ ▁adults ▁cardio pul mon ary _ ▁exercise ▁lean _ ▁mass _ ▁quant ification ▁dual _ ▁x - ray _ ▁ab sor pti ometr y ▁d XA ▁cal f _ ▁muscle ▁magnetic _ re on ance _ spec tros copy
D-1495	-0.5614933371543884	New_York_heart_association_class_ I_fontan_ adults cardiopulmonary_ exercise lean_ mass_ quantification dual_ x-ray_ absorptiometry dXA calf_ muscle magnetic_reonance_spectroscopy
P-1495	-1.7307 -0.5060 -1.6110 -0.0973 -1.6050 -0.2533 -0.3999 -1.2434 -0.9320 -0.4773 -1.7345 -0.9145 -2.2490 -0.3372 -1.8532 -0.0658 -0.0086 -0.2619 -0.7489 -0.3388 -0.3501 -0.1993 -0.2281 -0.0548 -1.4764 -1.3180 -0.0395 -0.0527 -0.0841 -0.0628 -1.2764 -0.1823 -0.0944 -0.0380 -0.9617 -0.6602 -0.3551 -0.1393 -0.1446 -0.2096 -0.2723 -0.0221 -0.0124 -0.6336 -0.0543 -0.2241 -0.0855 -1.6180 -0.5644 -0.1683 -0.1767 -0.6044 -0.3946 -0.9482 -0.2336 -0.1357
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo dopamine nesiritide bolus diuretic therapy renal_function patients acute_heart_failure renal_dysfunction
H-73	-0.5441285967826843	▁dop amine ▁nesi riti de ▁di ure tic _ therapy ▁renal _ function ▁a cute _ heart _ ▁failure ▁renal _ ▁dys function
D-73	-0.5441285967826843	dopamine nesiritide diuretic_therapy renal_function acute_heart_ failure renal_ dysfunction
P-73	-3.2075 -0.0632 -0.2896 -0.0058 -0.1059 -1.4430 -0.5477 -0.7277 -0.4553 -0.0260 -0.0912 -0.4663 -0.9201 -0.2918 -0.0174 -0.0242 -1.3922 -1.1712 -0.0310 -0.0099 -0.7105 -0.9814 -0.1185 -0.3906 -0.1151
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized crt patients new_york_heart_association_class_iii heart_failure left_ventricular_ejection_fraction qrs_duration echocardiographic evidence left_ventricular_dyssynchrony
H-847	-0.7149518728256226	▁ nc ord _ heart _ association ▁heart ▁failure ▁left _ ▁vent ri cular _ e je ction ▁ fraction ▁QR s ▁e cho car dio graphic ▁left _ ▁vent ri cular _ ▁dys syn chron y
D-847	-0.7149518728256226	ncord_heart_association heart failure left_ ventricular_ejection fraction QRs echocardiographic left_ ventricular_ dyssynchrony
P-847	-2.2028 -3.0967 -1.8081 -0.1903 -0.8126 -0.3056 -0.3253 -3.5987 -1.1913 -0.0773 -0.3894 -1.5449 -1.0397 -0.3937 -0.5010 -0.2971 -0.1136 -0.0583 -2.2743 -0.0298 -0.0832 -0.3142 -0.1081 -0.0150 -0.0127 -0.1325 -0.1481 -0.6204 -0.3830 -1.2776 -1.8165 -0.9442 -0.3248 -0.5750 -0.0381 -0.0021 -0.4184 -0.2857 -0.1327
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients left_ventricular ejection_fraction stable_hf right-sided_cardiac_catheterization transthoracic_echocardiography transmitral_flow mitral_annulus_velocities systole diastole
H-482	-0.3213789761066437	▁left _ ▁vent ri cular LV ▁e je ction ▁ fraction ▁ HF ▁right - side d _ ▁cardiac _ ▁cat heter ization ▁trans t hora cic _ e cho card i ography ▁transmit ral _ ▁flow _ ▁veloci ties ▁mit ral _ ▁ann ulus ▁veloci ties ▁sy stol e ▁dia stol e
D-482	-0.3213789761066437	left_ ventricularLV ejection fraction HF right-sided_ cardiac_ catheterization transthoracic_echocardiography transmitral_ flow_ velocities mitral_ annulus velocities systole diastole
P-482	-0.1026 -0.4349 -1.3304 -0.7829 -0.2421 -0.6254 -1.5147 -0.0342 -0.0273 -0.1234 -0.0187 -0.4692 -0.5077 -1.0034 -0.0593 -0.4437 -0.1742 -0.0961 -0.0675 -0.4471 -0.3189 -0.0191 -0.4825 -0.0015 -0.2930 -0.0182 -0.0648 -0.1129 -0.3615 -0.1891 -0.2668 -0.1454 -0.1646 -0.0938 -0.2779 -0.0942 -0.3040 -1.1712 -0.0967 -0.0028 -0.0493 -0.0581 -0.0478 -2.7382 -0.0476 -0.6472 -0.0033 -0.0921 -0.0115 -0.0801 -0.0281 -0.0065 -0.0772 -0.7043 -0.1011
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients acute_coronary_syndromes patients stable cad bnp nt-probnp cad prognostic clinical outcome
H-1367	-0.489828884601593	▁a cute _ ▁corona ry _ ▁syndrome s ▁CAD ▁b NP ▁NT - pro b NP ▁CAD
D-1367	-0.489828884601593	acute_ coronary_ syndromes CAD bNP NT-probNP CAD
P-1367	-0.2258 -0.0126 -0.0348 -0.6100 -1.4340 -0.3235 -0.1570 -0.0186 -1.2492 -1.4635 -0.1454 -0.3355 -0.0548 -0.0067 -0.5028 -0.1964 -1.9385 -0.4652 -0.1323
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline patients hf lyso-paf-at paf-cpt paf paf-ah lp-pla2
H-1269	-0.7529044151306152	▁ HF ▁lys o - pa f - AT ▁PA f - c pt ▁PA f - AH ▁l p - PLA 2
D-1269	-0.7529044151306152	HF lyso-paf-AT PAf-cpt PAf-AH lp-PLA2
P-1269	-1.3074 -0.1847 -0.7228 -0.0493 -0.0388 -0.4575 -1.1778 -0.1058 -0.7656 -0.9129 -1.4630 -0.0745 -0.7437 -0.7548 -0.8176 -1.3482 -1.3967 -4.1924 -1.5777 -0.0136 -0.0746 -0.0112 -0.0641 -0.4383 -0.1296
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical_therapy patients redo_sternotomy aortic_valve bioprosthetic_valve_replacement dacron_patch_closure aortic_valve patients transcatheter_aortic_valve_procedure surgery aortic_valve
H-549	-0.5903244018554688	▁redo _ ster no to my ▁a or tic _ val ve ▁bio pro sthetic _ val ve _ ▁replace ment ▁da cro n _ ▁patch _ closure ▁a or tic _ ▁val ve ▁trans cat heter ▁a or tic _ ▁val ve ▁procedure ▁open _ ▁surgery ▁a or tic _ ▁val ve _ ▁replace ment
D-549	-0.5903244018554688	redo_sternotomy aortic_valve bioprosthetic_valve_ replacement dacron_ patch_closure aortic_ valve transcatheter aortic_ valve procedure open_ surgery aortic_ valve_ replacement
P-549	-1.1691 -1.1568 -0.4508 -0.0757 -0.2032 -1.1648 -0.2539 -0.1252 -1.7743 -0.0985 -2.5021 -0.2574 -0.1065 -0.0514 -0.0215 -0.2647 -1.3730 -0.1364 -1.8299 -0.9969 -0.0832 -0.0857 -0.0042 -0.0219 -0.3176 -0.1428 -0.5068 -0.0246 -0.0345 -0.1349 -0.9899 -0.0795 -2.1465 -0.1282 -0.9123 -0.1684 -0.0193 -0.6537 -0.1357 -1.2437 -0.0566 -2.8759 -0.0696 -1.8766 -0.0666 -0.1250 -0.3410 -0.5292 -0.1001 -1.3142 -0.0502 -2.5546 -0.1400 -1.3445 -0.3175 -0.1410 -0.3544 -0.1362
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma_n-terminal_pro-b-type_natriuretic_peptide nt-probnp patients acute_heart_failure hf admission emergency_department
H-263	-0.6202341318130493	▁cut off _ waarde ▁plasma _ n - termin al _ pro - b - type _ ▁na tri ure tic _ pe pti de NT - pro b NP ▁a cute _ heart _ ▁failure HF ▁emergency _ ▁department ED
D-263	-0.6202341318130493	cutoff_waarde plasma_n-terminal_pro-b-type_ natriuretic_peptideNT-probNP acute_heart_ failureHF emergency_ departmentED
P-263	-1.3917 -0.0875 -0.9939 -1.3573 -0.4139 -3.1537 -1.4350 -0.0480 -0.0598 -0.0173 -0.6273 -0.7235 -0.0283 -0.9913 -0.0239 -0.0019 -0.6529 -0.8509 -0.0358 -0.2208 -1.7809 -0.2194 -0.6410 -0.0503 -0.3268 -1.5614 -0.0141 -0.0147 -0.3744 -0.1992 -0.4735 -0.0843 -0.0155 -1.9445 -1.1179 -0.0433 -0.7652 -0.1355 -0.3213 -0.1651 -3.0115 -0.1673 -0.1281
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac_troponin_t ctnt n-terminal_pro-b-type_natriuretic_peptide nt-probnp biomarkers hf hf atherosclerosis_risk_in_communities aric
H-286	-0.5042217969894409	▁cardiac _ ▁trop onin _ t ▁c t n t ▁high - sensitiv ity ▁as say ▁n - termin al _ pro - b - type ▁na tri ure tic _ pe pti de nt - pro b NP ▁incident _ HF ▁ HF ▁ HF ▁Ath eros cle rosi s _ ▁Risk _ in _ ▁Communi ties ARI c
D-286	-0.5042217969894409	cardiac_ troponin_t ctnt high-sensitivity assay n-terminal_pro-b-type natriuretic_peptident-probNP incident_HF HF HF Atherosclerosis_ Risk_in_ CommunitiesARIc
P-286	-0.0108 -1.2131 -0.1584 -0.0393 -0.3883 -0.7907 -0.2281 -0.1010 -0.0035 -0.4251 -2.0340 -0.0065 -0.0007 -0.3217 -0.4911 -0.0235 -1.3998 -0.0149 -0.1093 -0.0052 -0.8994 -1.1012 -0.0180 -1.2643 -0.0177 -0.0010 -0.8765 -0.0221 -0.1305 -1.2854 -0.1899 -0.4523 -0.0788 -0.6299 -1.8611 -0.0059 -0.0074 -0.3257 -0.2585 -0.6356 -0.8149 -0.7220 -0.4943 -0.2612 -2.0012 -0.4973 -3.4999 -0.0397 -0.2726 -0.0802 -0.0194 -1.0348 -0.1585 -0.3021 -0.2806 -0.0875 -0.4664 -0.0081 -1.6397 -0.4799 -0.1397 -0.1358
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body_mass_index fat_mass fat-free_mass
H-1167	-1.7836105823516846	▁body _ ▁mass ▁index HR _ per _ ▁kg / m _ index ▁fat - free _ ▁mass _ ▁index
D-1167	-1.7836105823516846	body_ mass indexHR_per_ kg/m_index fat-free_ mass_ index
P-1167	-4.8550 -0.5160 -3.5227 -0.4401 -2.5715 -2.4460 -1.2979 -1.2600 -1.4161 -1.5657 -0.0535 -4.5268 -5.6649 -2.9303 -0.9290 -0.4716 -0.1324 -1.4912 -1.1015 -0.9596 -0.9261 -0.1615
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile_range body_mass_index interquartile_range copd chf crf
H-797	-1.1484004259109497	▁figuur inter quart ile _ ▁range ▁media n _ ▁body _ ▁mass ▁index inter quart ile _ ▁range ▁advanced _ ▁COP d ▁CHF ▁c RF
D-797	-1.1484004259109497	figuurinterquartile_ range median_ body_ mass indexinterquartile_ range advanced_ COPd CHF cRF
P-797	-4.3548 -3.8468 -0.1946 -0.0413 -0.5200 -0.0693 -2.4049 -0.0629 -0.2811 -1.9971 -0.6249 -1.4183 -0.2817 -0.6447 -0.1782 -0.0348 -0.5698 -0.0594 -3.8204 -0.9285 -2.0734 -1.5774 -0.0757 -1.0993 -3.1143 -0.4741 -0.2591
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse_remodeling ejection_fraction mortality all-cause_hospitalizations hf hospitalizations dialysis patients
H-911	-0.5874298810958862	▁rever se _ ▁remodel ing ▁e je ction _ fraction ▁mortal ity ▁ HF ▁di al ysis _ ▁patients
D-911	-0.5874298810958862	reverse_ remodeling ejection_fraction mortality HF dialysis_ patients
P-911	-0.5527 -0.0883 -0.0701 -0.9196 -0.0484 -0.0165 -0.0686 -0.0425 -0.3133 -0.0197 -0.9246 -2.0334 -2.0423 -0.6308 -2.2723 -0.0512 -0.0938 -1.1949 -0.5423 -0.3013 -0.1094
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates lv_contractility lvef β_coefficient confidence_interval systolic_blood_pressure end-systolic_volume β_coefficient
H-1530	-1.2417750358581543	▁EH ▁LV _ ▁contract ility ▁CH ▁LV EF ▁sy sto lic _ ▁blood _ ▁pressure ▁end - sy sto lic _ ▁volume β ▁co e ffi cient
D-1530	-1.2417750358581543	EH LV_ contractility CH LVEF systolic_ blood_ pressure end-systolic_ volumeβ coefficient
P-1530	-0.9637 -3.3659 -3.0350 -0.2299 -0.0497 -4.6583 -1.6887 -0.8596 -7.7749 -0.0745 -0.1035 -0.0886 -1.2346 -0.9394 -0.6192 -2.0554 -0.0724 -0.0903 -0.1711 -0.1159 -0.1057 -0.1701 -1.6449 -2.5086 -0.2335 -0.1193 -0.1227 -2.7859 -0.1298
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography dilated_lv end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mva
H-348	-0.5293832421302795	▁e cho card i ography ▁dil ated ▁LV ▁end - dia sto lic _ ▁volume ▁index ▁m L / m 2 ▁LV ▁e je ction ▁ fraction ▁mild _ ▁MR ▁mit ral _ ▁val ve ▁opening ▁MS ▁m VA ▁pressure ▁gradi ent
D-348	-0.5293832421302795	echocardiography dilated LV end-diastolic_ volume index mL/m2 LV ejection fraction mild_ MR mitral_ valve opening MS mVA pressure gradient
P-348	-0.3464 -0.0265 -0.2676 -0.2108 -0.1717 -5.1035 -0.0904 -0.3948 -1.1699 -0.0320 -0.0209 -0.0186 -0.0210 -0.3216 -0.0418 -0.4407 -0.6206 -1.1126 -2.9408 -0.0585 -0.0147 -1.3334 -0.4228 -0.0263 -0.0276 -0.7162 -0.0012 -0.1731 -0.7961 -0.5328 -0.1023 -0.0193 -0.1005 -1.2034 -0.0512 -0.7278 -0.3866 -0.1067 -0.7109 -0.3841 -0.3013 -0.0202 -1.6226 -0.1010
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind clinical renal_optimization_strategies_evaluation rose hospitalized patients acute_heart_failure renal_dysfunction estimated_glomerular_filtration_rate randomized admission
H-74	-0.5609959363937378	▁re nal _ optim ization _ strategi es _ evalua tion ROS e ▁a cute _ heart _ ▁failure ▁renal _ ▁dys function ▁glo mer ular _ filter ation _ ▁rate
D-74	-0.5609959363937378	renal_optimization_strategies_evaluationROSe acute_heart_ failure renal_ dysfunction glomerular_filteration_ rate
P-74	-2.1616 -0.9747 -0.2569 -0.1349 -0.5895 -0.8275 -0.2182 -0.4257 -0.6222 -0.0823 -0.1630 -1.4162 -0.0489 -0.8464 -0.0048 -0.0368 -1.3939 -1.3196 -0.0216 -0.0076 -0.9029 -0.0796 -0.0371 -0.0515 -0.1077 -0.0256 -0.0977 -1.1747 -0.3499 -2.1948 -0.1950 -1.5938 -0.1502
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets signal_transduction pol_ii transcription_factor hf pathogenesis nuclear_factor_of_activated_t_cells nfat nuclear_factor-κb nf-κb transcription_factor gata4
H-1051	-0.5502819418907166	▁ BET s ▁chr omat in - media ted _ signal ▁trans duction ▁Pol _ ▁II ▁co - activa ting _ ▁tran scription _ ▁factor _ ▁network s ▁ HF ▁nuclear _ factor ▁activa ted _ t _ ▁cell s ▁n FAT ▁nuclear _ factor - κ b NF - κ b ▁tran scription _ ▁factor ▁g ATA 4
D-1051	-0.5502819418907166	BETs chromatin-mediated_signal transduction Pol_ II co-activating_ transcription_ factor_ networks HF nuclear_factor activated_t_ cells nFAT nuclear_factor-κbNF-κb transcription_ factor gATA4
P-1051	-2.0951 -0.4386 -0.1628 -0.2303 -0.0274 -0.3726 -0.0421 -0.0578 -0.0646 -0.0614 -0.2382 -0.0707 -0.2109 -1.3171 -1.3393 -0.4446 -0.3916 -0.0126 -0.0008 -0.0668 -0.3121 -1.9747 -0.0768 -1.1629 -0.5553 -1.0807 -1.5523 -0.0232 -0.3055 -0.5751 -0.5037 -0.1178 -0.5930 -1.1645 -0.0412 -0.0313 -1.5840 -0.5970 -0.6382 -0.0282 -1.5244 -0.2406 -0.1166 -0.1338 -0.4351 -0.9858 -0.7505 -0.1767 -2.0036 -0.0716 -0.6483 -0.1486 -0.5951 -0.2072 -1.0144 -0.4839 -2.5794 -0.2761 -0.2839 -0.2184 -0.1105
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes mortality hospitalization exercise_tolerance quality_of_life cardiovascular_events myocardial_infarction congestive_heart_failure arrhythmia cardiac_death hypertension venous_thromboembolic_events ischemic_cerebrovascular_events
H-33	-0.5608405470848083	▁guide line ▁cardiovascular _ ▁events ▁my o card ial _ in far ction ▁con ges tive _ heart ▁failure ▁ar rhythm ia ▁cardiac _ ▁death ▁hyper tension ▁ve nous _ thro mbo e mbol ic _ ▁events ▁ ische mic _ ▁cerebro vas cular _ ▁events
D-33	-0.5608405470848083	guideline cardiovascular_ events myocardial_infarction congestive_heart failure arrhythmia cardiac_ death hypertension venous_thromboembolic_ events ischemic_ cerebrovascular_ events
P-33	-3.5602 -0.0952 -3.8639 -1.0342 -0.8123 -0.7115 -0.2761 -0.3648 -0.5612 -0.1631 -0.3479 -0.1186 -0.0760 -0.0191 -0.1732 -1.3371 -0.0610 -2.1571 -0.4497 -0.2473 -0.1174 -0.6603 -0.0144 -0.5459 -0.3313 -0.2284 -0.0404 -0.0906 -0.0659 -0.1487 -0.2599 -0.9685 -0.2165 -0.0096 -0.0795 -1.2130 -0.3420 -0.9645 -0.0165 -0.2280 -0.0531 -0.5108 -0.0749 -0.4371 -1.3994 -0.8876 -0.4490 -0.1376
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus diabetes patients diabetes peak_vo2 patients diabetes eo-cfus peak_vo2
H-128	-1.296507716178894	▁ EO - c FU s ▁diabetes ▁10- EO - c FU ▁ EO - c FU ▁VO 2 ▁diabetes ▁diabetes ▁ EO - c FU s
D-128	-1.296507716178894	EO-cFUs diabetes 10-EO-cFU EO-cFU VO2 diabetes diabetes EO-cFUs
P-128	-1.7085 -0.2109 -0.0499 -0.7405 -1.9541 -0.9117 -0.0981 -4.2155 -0.1342 -0.0950 -1.1716 -0.8158 -4.3061 -0.3010 -0.1317 -1.5669 -1.3217 -4.5499 -0.1165 -1.1970 -0.8501 -3.0577 -0.1854 -0.1273 -1.3287 -1.6298 -2.0860 -2.5747 -0.1623
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular_mortality multivariable_adjustment hazard_ratio confidence_interval hazard_ratio confidence_interval
H-562	-0.9636355638504028	▁cardiovascular _ ▁mortal ity ▁hazard _ ▁ratio
D-562	-0.9636355638504028	cardiovascular_ mortality hazard_ ratio
P-562	-1.7148 -0.6070 -0.1708 -1.7047 -0.9562 -1.2616 -0.2409 -1.8517 -0.1651
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting video_edge_detection epifluorescence_microscopy myocardial_tissues cardiomyocytes hf
H-1212	-0.41209253668785095	▁immun o blo tting ▁radio en zy matic - ▁fluor esc ence _ ▁res on ance _ ener gy _ transfer - based _ as say s ▁video ▁edge _ ▁det ection ▁epi flu o resc ence _ ▁micro s copy ▁l - type _ ca 2 ▁ca 2 ▁my o card ial _ ▁tissu es ▁cardio my o cy tes ▁ HF
D-1212	-0.41209253668785095	immunoblotting radioenzymatic- fluorescence_ resonance_energy_transfer-based_assays video edge_ detection epifluorescence_ microscopy l-type_ca2 ca2 myocardial_ tissues cardiomyocytes HF
P-1212	-0.0905 -0.1266 -0.0199 -0.3059 -0.0839 -0.1416 -0.1438 -0.2016 -0.2384 -1.2894 -1.3515 -0.7722 -0.1354 -2.3533 -0.1324 -0.1382 -0.3276 -1.2604 -0.1045 -0.9043 -0.5407 -0.1210 -0.0049 -0.2714 -0.0489 -0.0245 -0.0310 -0.3432 -0.9648 -0.2755 -0.0792 -0.0183 -0.0371 -0.0042 -0.5496 -0.1469 -0.6899 -0.1546 -0.6272 -0.0545 -0.1797 -0.4712 -0.0135 -0.0013 -1.3556 -0.0968 -0.0366 -1.8032 -0.1062 -2.1922 -0.1083 -0.3455 -0.3786 -0.3609 -0.0409 -0.0115 -0.5872 -0.6033 -0.2366 -0.1531 -0.0206 -1.6394 -0.7450 -0.1093 -0.0806
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes exercise_capacity peak_oxygen_consumption vo2 co-primary_outcome qol minnesota heart_failure heart qol co-primary_outcome
H-1980	-0.9560771584510803	▁Exerci se _ ▁capacity ▁pe ak _ ▁oxygen _ ▁consum p tion VO 2 ▁m l / kg / min ▁Q OL ▁Minnesota ▁Living _ ▁with _ ▁Heart _ ▁Fail ure ▁m HF ▁heart _ ▁failure - related _ ▁Q OL
D-1980	-0.9560771584510803	Exercise_ capacity peak_ oxygen_ consumptionVO2 ml/kg/min QOL Minnesota Living_ with_ Heart_ Failure mHF heart_ failure-related_ QOL
P-1980	-1.6617 -0.0419 -0.1803 -1.4153 -3.5499 -0.0297 -0.0431 -1.5527 -0.7107 -0.3101 -0.0845 -0.2311 -1.2084 -0.0417 -3.7991 -1.7819 -2.0651 -0.2712 -1.1740 -0.1027 -1.9555 -0.3799 -0.0515 -0.3964 -0.0246 -1.7019 -0.0261 -1.1048 -0.4059 -0.1622 -1.4553 -0.4485 -2.7595 -3.1571 -1.3782 -0.5687 -0.2503 -0.0775 -1.4518 -2.1970 -0.5794 -0.1887 -0.1352
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east early_treatment_of_atrial_fibrillation_for_stroke_prevention_trial randomize patients stroke rhythm_control_therapy prospective randomized outcome
H-1649	-0.921150267124176	▁e ast ▁At rial _ fi bril lation _ for _ stro ke _ ▁pre vention _ tri al ▁AF _ at _ risk _ for _ stro ke CHA 2 ds 2 VAS c
D-1649	-0.921150267124176	east Atrial_fibrillation_for_stroke_ prevention_trial AF_at_risk_for_strokeCHA2ds2VASc
P-1649	-0.6038 -0.7177 -4.2918 -0.0528 -0.2118 -0.4154 -0.0515 -0.0543 -1.1587 -0.8727 -0.2099 -0.2121 -0.3576 -0.2381 -1.3803 -0.0060 -0.8134 -0.8932 -0.0211 -0.4413 -3.2403 -1.3892 -0.3522 -1.2965 -0.3852 -0.9173 -0.2923 -0.5953 -2.3091 -1.9866 -0.2204 -2.5073 -0.6003 -0.8567 -0.0834 -3.9482 -0.0988
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients left_ventricular_ejection_fraction patients hf preserved_left_ventricular_ejection_fraction hospital physicians acute outpatient epidemic medical financial_costs
H-55	-0.9213550686836243	▁low _ ▁left _ ▁vent ri cular _ e je ction _ fraction ▁ HF ▁pres er ved _ ▁left _ ▁vent ri cular _ e je ction _ fraction ▁hospital ▁physician s
D-55	-0.9213550686836243	low_ left_ ventricular_ejection_fraction HF preserved_ left_ ventricular_ejection_fraction hospital physicians
P-55	-2.4666 -0.1099 -2.7813 -0.1928 -2.8197 -1.3276 -1.4247 -0.0952 -0.4257 -0.2896 -0.1560 -0.2907 -0.0782 -1.4171 -0.1918 -3.4945 -0.0401 -0.5386 -0.1536 -0.7282 -0.1500 -2.3714 -1.6755 -0.9247 -0.1585 -0.3393 -0.4078 -0.1857 -0.4694 -0.0391 -1.3591 -0.8764 -0.0401 -4.0791 -0.1492
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic mitochondrial-targeted_peptide ss31 mitochondrial_function tac clinical mitochondrial-targeted_peptide drugs heart_failure
H-878	-0.4804941415786743	▁ TAC - indu ced _ prote om ic _ ▁altera tions ▁mito cho ndri al - tar get ed _ pe pti de ▁SS 31 ▁per tur bed _ ▁mito cho ndri al _ ▁function ▁ TAC ▁mito cho ndri al - tar get ed _ pe pti de ▁drugs ▁heart ▁failure
D-878	-0.4804941415786743	TAC-induced_proteomic_ alterations mitochondrial-targeted_peptide SS31 perturbed_ mitochondrial_ function TAC mitochondrial-targeted_peptide drugs heart failure
P-878	-0.6222 -0.0845 -0.1604 -0.0098 -0.5128 -0.1460 -1.1413 -0.2230 -0.1078 -1.8607 -0.2919 -0.4145 -0.5564 -0.5536 -1.3292 -0.1480 -0.2059 -0.1037 -0.3602 -0.0473 -0.1206 -1.0380 -0.0898 -0.4065 -0.5883 -0.5354 -0.2031 -0.0190 -1.7658 -0.1226 -1.6518 -0.5817 -0.6002 -0.0374 -0.1571 -0.9184 -0.5910 -0.1697 -0.2861 -0.3117 -1.6060 -0.1346 -0.1367 -0.0994 -0.4172 -0.0223 -0.0974 -1.1218 -0.2182 -0.7270 -0.7087 -0.8595 -0.9810 -0.1430 -0.0812
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf patients hfref left_ventricular ejection_fraction hfpef echo-doppler n-terminal_pro-brain-type_natriuretic_peptide adverse_events
H-494	-0.6680483818054199	▁ HF ▁tho r EF ▁pres er ved ▁left _ ▁vent ri cular LV ▁e je ction _ fraction HF p EF ▁e cho - D opp ler ▁studies ▁na tri ure tic _ pe pti de
D-494	-0.6680483818054199	HF thorEF preserved left_ ventricularLV ejection_fractionHFpEF echo-Doppler studies natriuretic_peptide
P-494	-1.0838 -0.3854 -5.0515 -0.0320 -0.7267 -1.3333 -0.0272 -0.4366 -0.7319 -0.2528 -1.5549 -0.6652 -0.1913 -0.4053 -0.3500 -0.0768 -0.0521 -0.7288 -0.0538 -1.9795 -0.9758 -0.6519 -0.1080 -0.0132 -0.0127 -0.5415 -0.0258 -0.3951 -1.7918 -0.8624 -0.0542 -0.3662 -1.7328 -0.3099 -0.3930 -0.0844 -0.7971 -0.7023 -0.1170
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds comorbidities hospitalized adjusted_odds_ratio aor confidence_interval eds aor
H-464	-1.0950343608856201	▁low - volu me _ ED s ▁como rbi di ties ▁hospital ized ▁medium ▁a OR ▁confidence _ ▁interval ▁high - volu me _ ▁ED s ▁a OR
D-464	-1.0950343608856201	low-volume_EDs comorbidities hospitalized medium aOR confidence_ interval high-volume_ EDs aOR
P-464	-0.7711 -0.0958 -0.4487 -0.1409 -0.2783 -3.8960 -0.1139 -3.8294 -0.0008 -0.1441 -0.0195 -1.4910 -0.3604 -1.3728 -3.3542 -0.6195 -5.3106 -0.9271 -0.1107 -2.3168 -0.1564 -1.1334 -0.0864 -0.2252 -4.0677 -0.0422 -0.3933 -0.4144 -0.5694 -0.1611
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc_battery health_abc_hf_risk_model change c-index net-reclassification-improvement hf
H-631	-0.644829511642456	▁h ABC _ bat tery _ ▁score s ▁health ▁ABC _ HF _ risk _ model ▁discrimina tion ▁c - index ▁re class ification - improv ement ▁ HF
D-631	-0.644829511642456	hABC_battery_ scores health ABC_HF_risk_model discrimination c-index reclassification-improvement HF
P-631	-1.2579 -1.6524 -1.5498 -1.1248 -0.0065 -0.4560 -0.2166 -0.0064 -1.1111 -0.6663 -0.6871 -0.3419 -0.1156 -0.8918 -0.1441 -0.2330 -0.3997 -0.2960 -0.4185 -0.1449 -0.0044 -2.4285 -0.0316 -2.0296 -0.2354 -0.1026 -0.7328 -0.6618 -1.7119 -0.2214 -0.1093
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients cardiac_transplant ecct patients diabetes_mellitus chronic_kidney_disease estimated_glomerular_filtration_rate
H-715	-0.5459020137786865	▁cardiac _ ▁transplant ▁ec CT ▁diabetes ▁mell itus ▁chronic _ ▁ki dne y ▁disease ▁glo mer ular _ filter ation
D-715	-0.5459020137786865	cardiac_ transplant ecCT diabetes mellitus chronic_ kidney disease glomerular_filteration
P-715	-0.1933 -1.6127 -0.5130 -0.5389 -0.6966 -0.1882 -0.0044 -0.0136 -0.0349 -0.3713 -1.0117 -0.2595 -0.1406 -0.8504 -0.0574 -0.1261 -0.0301 -0.1618 -1.5642 -0.7558 -2.6739 -0.2114
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi rmsea self-care_maintenance cfi rmsea self-care_management cfi rmsea self-care_confidence
H-1507	-0.7592926621437073	▁c fi ▁RM se a ▁Self - Car e _ ▁Main ten ance _ ▁Scal e ▁c fi ▁RM se a ▁Self - Car e _ management _ ▁Scal e ▁c fi ▁RM se a ▁Self - Car e _ ▁Confi den ce _ ▁scale
D-1507	-0.7592926621437073	cfi RMsea Self-Care_ Maintenance_ Scale cfi RMsea Self-Care_management_ Scale cfi RMsea Self-Care_ Confidence_ scale
P-1507	-3.1469 -1.3314 -2.6495 -0.4766 -0.3296 -0.6851 -0.0839 -1.6051 -0.2026 -0.1980 -1.0846 -0.4572 -0.1157 -0.9490 -0.2175 -0.0303 -0.7391 -1.2436 -2.0117 -0.5029 -0.2945 -0.4046 -0.1270 -1.6554 -0.1669 -0.4967 -0.6752 -0.7422 -0.1946 -0.0208 -0.8340 -1.4160 -3.0886 -0.4305 -0.4225 -0.4902 -0.0944 -1.6028 -0.1939 -0.1677 -1.9365 -0.1958 -0.1940 -1.0959 -0.2482 -0.2504 -0.1871
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients bat patients quality-of-life nyha_functional_class change
H-1876	-0.8267397880554199	▁BAT ▁quality - of - life ▁score ▁NY HA ▁functional _ class _ ▁ranking
D-1876	-0.8267397880554199	BAT quality-of-life score NYHA functional_class_ ranking
P-1876	-0.2552 -4.4819 -0.1237 -0.0284 -0.2947 -0.3132 -1.9724 -1.5644 -0.8474 -0.6172 -0.2600 -0.9603 -0.4980 -0.3413 -0.4851 -0.1846
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients preoperative hypoalbuminemia postoperative albumin hypoalbuminemia albumin lvad
H-537	-0.6018663644790649	▁hypo album in emia ▁post operativ e _ normal ization ▁album in ▁levels ▁hypo album in emia ▁de cre as ing _ album in _ ▁levels ▁l VAD
D-537	-0.6018663644790649	hypoalbuminemia postoperative_normalization albumin levels hypoalbuminemia decreasing_albumin_ levels lVAD
P-537	-1.9779 -0.3874 -0.4086 -0.0403 -0.2014 -0.5112 -0.0644 -1.1757 -0.8726 -1.2314 -1.5821 -0.4503 -1.6546 -0.3027 -0.3088 -0.5070 -0.0343 -1.6502 -0.0688 -0.0876 -0.1156 -0.6662 -0.1593 -0.3174 -1.9780 -0.3185 -0.3514 -0.0382 -0.4856 -0.1087
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization confidence_interval acute_myocardial_infarction ami complications kidney_infection urinary_tract_infection uti complications
H-1717	-0.8052170872688293	▁re hospital ization ▁a cute _ mi o card ial _ in far ction AMI ▁ki dne y ▁infection ▁urin ary _ ▁tract ▁infection UTI
D-1717	-0.8052170872688293	rehospitalization acute_miocardial_infarctionAMI kidney infection urinary_ tract infectionUTI
P-1717	-4.3630 -0.0609 -0.7031 -1.4103 -0.1786 -0.0605 -4.2286 -0.5343 -0.4292 -0.6647 -0.1503 -0.3073 -0.0674 -0.1839 -0.1088 -2.6999 -0.4771 -0.0566 -0.2617 -0.0028 -0.1337 -0.1048 -2.9590 -0.7967 -0.2439 -0.3964 -0.1573
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients heart_failure hf ischemic nonischemic_cardiomyopathies pharmacological implantable_cardioverter_defibrillators cardiac_resynchronization_therapy cardiac_transplantation right_ventricular_assist_devices
H-54	-0.4590032398700714	▁heart ▁failure HF ▁ ische mic ▁non ische mic _ ▁cardio my o pathi es ▁ pharma c ological _ arma ment arium ▁implant able _ ▁cardio ver ter _ de fi br illa tors ▁cardiac ▁re syn chron ization ▁ therapy ▁cardiac ▁transplant ation ▁left ▁vent ri cular _ assist ▁devices
D-54	-0.4590032398700714	heart failureHF ischemic nonischemic_ cardiomyopathies pharmacological_armamentarium implantable_ cardioverter_defibrillators cardiac resynchronization therapy cardiac transplantation left ventricular_assist devices
P-54	-5.3649 -0.4617 -0.8520 -0.9672 -0.0403 -0.1706 -1.0481 -0.0459 -0.3859 -0.0854 -0.6768 -1.4579 -0.3857 -0.0392 -0.1285 -0.9104 -0.2178 -0.0412 -0.2730 -1.5113 -0.2469 -0.0081 -0.0005 -0.0380 -0.0170 -0.3315 -0.3285 -0.0233 -0.0986 -0.0932 -0.3530 -0.0353 -0.2331 -0.0511 -0.1502 -0.0136 -0.8256 -0.0087 -0.0015 -0.7474 -1.2628 -0.0100 -0.0172 -0.8822 -0.0418 -0.0194 -1.1800 -0.4560 -0.1091 -0.1132 -0.1952 -1.4205 -0.3145 -0.0955
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf catheterization central_venous_pressure svr cardiac_index
H-230	-1.5026192665100098	▁ SAF ▁ PF _ ▁mean _ ▁cat heter ization ▁central _ ve nous _ ▁pressure ▁h g ▁s VR _ ▁index ▁dyn _ ▁s / cm (5) / m (2) ▁cardiac _ ▁index
D-230	-1.5026192665100098	SAF PF_ mean_ catheterization central_venous_ pressure hg sVR_ index dyn_ s/cm(5)/m(2) cardiac_ index
P-230	-2.3670 -0.4479 -3.2444 -0.1054 -3.8265 -2.2602 -0.2571 -3.6221 -0.2275 -1.1292 -3.2220 -0.2091 -2.3531 -0.4741 -0.1335 -1.5787 -2.9794 -0.6129 -0.4235 -0.9106 -1.7425 -0.9394 -2.9982 -2.0600 -1.6408 -4.4175 -0.8133 -0.8600 -3.7182 -0.8172 -0.5836 -0.3475 -0.7814 -0.9103 -0.9114 -0.1686
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission bnp reduced_ef preserved_ef bnp ef
H-193	-1.7923117876052856	▁women ▁ad mission ▁media n _ b NP _ ▁levels ▁reduc d _ ef ▁pres er ved _ ▁EF ▁media n _ b NP _ in _ ▁women _ ▁vs _ ▁men ▁EF
D-193	-1.7923117876052856	women admission median_bNP_ levels reducd_ef preserved_ EF median_bNP_in_ women_ vs_ men EF
P-193	-3.0874 -2.3489 -1.1183 -0.1476 -0.0252 -0.1877 -0.5144 -0.5629 -5.4766 -1.0594 -2.9988 -1.2450 -0.8470 -1.4676 -5.7377 -0.1547 -0.2935 -1.2013 -1.7984 -2.9029 -0.0267 -0.1035 -0.5882 -1.4923 -5.5578 -2.0119 -1.3098 -1.1363 -3.0702 -4.9258 -0.3730 -0.8406 -4.3291 -3.5976 -0.1927
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart_failure admission heart_transplantation lv_assist_device death hazard_ratio confidence_interval death hazard_ratio confidence_interval ischemic functional_class
H-435	-0.8370091915130615	▁heart ▁failure _ ad mission ▁heart ▁transplant ation LV _ assist _ ▁device ▁death haz ard _ ▁ratio
D-435	-0.8370091915130615	heart failure_admission heart transplantationLV_assist_ device deathhazard_ ratio
P-435	-1.6177 -0.8657 -2.5673 -0.5252 -0.2445 -0.5431 -1.4112 -0.0980 -0.4751 -0.4627 -0.3144 -0.9594 -0.8922 -0.2731 -0.2492 -0.0214 -0.8990 -0.1244 -4.0463 -0.1504
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv_ejection_fraction shortening systolic_elastance contractile_efficiency acf acf allopurinol cardiomyocytes extracellular_flux_analyzer
H-475	-0.29712581634521484	▁e je ction _ fraction ▁veloci ty ▁circum fer ential _ short en ing ▁sy sto lic _ ▁elastan ce ▁contract ile _ ▁efficiency ▁a cf ▁allo puri nol ▁rat s ▁maximum _ o 2 ▁consum p tion _ ▁rate ▁isola ted _ ▁cardio my o cy tes ▁extra cel lular _ ▁flux _ ▁anal y zer
D-475	-0.29712581634521484	ejection_fraction velocity circumferential_shortening systolic_ elastance contractile_ efficiency acf allopurinol rats maximum_o2 consumption_ rate isolated_ cardiomyocytes extracellular_ flux_ analyzer
P-475	-0.8411 -0.0336 -0.0257 -0.3868 -0.0385 -1.1775 -0.0376 -0.1645 -0.6929 -0.4702 -0.0985 -0.4512 -0.0374 -0.0624 -0.4048 -0.0262 -0.0187 -0.2243 -0.0270 -0.3070 -0.0013 -0.0816 -0.4932 -0.5003 -0.1978 -0.6696 -0.7124 -0.0050 -0.2577 -0.4431 -0.0143 -0.3355 -0.5494 -0.7906 -0.0877 -0.3755 -0.2015 -0.1935 -1.3461 -0.0503 -0.8683 -0.0055 -0.0945 -0.0395 -0.6588 -0.1196 -0.0506 -0.0240 -0.0108 -0.1562 -0.0307 -0.0670 -0.1794 -0.6371 -1.1584 -0.0785 -0.0907 -0.3232 -0.1053
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively patients hfpef lv_hypertrophy lvh relative_wall_thickness rwt lvh rwt lvh rwt lvh rwt
H-1526	-0.9038512706756592	▁ HF p EF ▁LV _ ge ometr y ▁LV ▁hyper trop hy ▁v h ▁relative _ wind _ ▁thi ck ness ▁r w t ▁CR ▁v h ▁r w t ▁eh ▁v h ▁v h ▁r w t
D-1526	-0.9038512706756592	HFpEF LV_geometry LV hypertrophy vh relative_wind_ thickness rwt CR vh rwt eh vh vh rwt
P-1526	-1.3230 -0.2334 -0.0432 -0.3610 -2.1797 -2.7504 -0.8573 -0.1156 -0.1439 -1.3728 -1.1054 -0.0270 -0.6505 -1.9306 -1.2829 -0.1930 -0.0240 -2.9042 -0.5161 -1.4452 -0.0145 -0.7595 -1.3358 -0.1585 -0.0040 -0.2509 -1.8387 -0.9570 -0.9413 -0.0821 -0.1601 -2.6868 -0.5277 -1.2424 -1.3031 -1.3764 -1.4992 -0.1138 -0.8915 -1.3530 -0.1025
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 angiotensin_receptor_neprilysin_inhibitor neprilysin_inhibitor prodrug angiotensin_receptor_antagonist valsartan hypertension heart_failure_with_preserved_ejection_fraction outcomes heart_failure_with_reduced_ejection_fraction
H-1463	-0.5684699416160583	▁l CZ 696 ▁ang io ten sin _ ▁receptor ▁nepri ly sin _ ▁inhibi tor ▁nepri ly sin _ ▁inhibi tor ▁nepri ly sin _ ▁inhibi tor ▁pro drug ▁ang io ten sin _ ▁receptor ▁anta gon ist ▁val sar tan ▁hyper tension ▁heart ▁failure ▁pres er ved _ e je ction _ fraction ▁heart ▁failure _ met _ ▁reduce d _ e je ction _ fraction
D-1463	-0.5684699416160583	lCZ696 angiotensin_ receptor neprilysin_ inhibitor neprilysin_ inhibitor neprilysin_ inhibitor prodrug angiotensin_ receptor antagonist valsartan hypertension heart failure preserved_ejection_fraction heart failure_met_ reduced_ejection_fraction
P-1463	-2.4967 -0.6714 -0.0788 -0.9268 -0.9678 -0.3436 -1.7176 -1.2877 -0.0234 -0.0605 -0.2340 -1.3504 -1.1252 -0.0184 -0.0094 -0.0382 -0.1705 -1.8914 -0.7304 -0.0233 -0.0210 -0.8452 -0.1739 -2.0004 -0.5665 -0.0348 -0.0218 -0.7593 -0.0034 -0.3430 -0.6031 -0.3279 -1.2855 -0.6116 -0.0198 -0.9483 -0.0019 -0.3022 -0.6288 -0.0461 -0.0151 -0.0434 -0.0098 -0.8620 -0.2385 -1.5160 -0.0488 -0.4868 -0.1091 -0.3270 -0.1491 -0.0998 -0.2424 -0.0125 -1.0258 -0.7885 -1.8696 -3.0993 -0.1588 -3.1060 -0.0425 -0.0498 -0.4402 -0.1195 -0.1208 -0.1098 -0.0152 -0.2605 -0.1477
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood_pressure mitral_valve_plasty degenerative_mr p3_prolapse chordal_ruptures triangular_resection edge-to-edge_anastomosis ring_annuloplasty physio_ring_30 edwards_lifesciences irvine
H-343	-0.39126795530319214	▁blood ▁pressure ▁mit ral _ val ve _ plast y ▁de genera tive _ ▁MR ▁chor dal _ ▁rup tures ▁tri ang ular _ re ection ▁edge - to - ed ge _ an asto mos is ▁ring _ ▁ann ulo plast y ▁Ph y sio _ ▁Ring Ed ward s _ ▁Life science s ▁ir vine
D-343	-0.39126795530319214	blood pressure mitral_valve_plasty degenerative_ MR chordal_ ruptures triangular_reection edge-to-edge_anastomosis ring_ annuloplasty Physio_ RingEdwards_ Lifesciences irvine
P-343	-0.2728 -0.5023 -0.0390 -0.0294 -0.1904 -1.5136 -0.0689 -1.1542 -0.9979 -0.2415 -0.0150 -0.0030 -0.2901 -0.2293 -0.3502 -1.3487 -0.0731 -0.2326 -0.0949 -0.1005 -0.0047 -0.0257 -0.0027 -0.1810 -1.2464 -0.0479 -0.0074 -0.0065 -0.0086 -0.0450 -0.0222 -0.0244 -0.2313 -0.9158 -0.0011 -0.2494 -0.0166 -0.0022 -0.2014 -2.3062 -0.0560 -0.0280 -0.0484 -0.7313 -0.0063 -0.0061 -0.3994 -1.3930 -3.6188 -0.0133 -0.0064 -0.0291 -1.0605 -0.0418 -0.0026 -0.4427 -0.0088 -1.8148 -0.0838
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes incremental_shuttle_walk_test peak_oxygen_uptake muscular echocardiographic n-terminal_pro-brain_natriuretic_peptide inflammatory beck_depression_inventory health-related_quality_of_life minnesota_living_with_heart_failure_questionnaire medical_outcomes_study_short-form
H-1320	-0.4369645416736603	▁shu ttle _ walk _ ▁test ▁pe ak _ ▁oxygen _ up take ▁muscular _ ▁strength ▁e cho car dio graphic ▁na tri ure tic _ pe pti de ▁infla mma tory _ ▁marker s ▁depression ▁be ck _ de pression _ in ven tory ▁min nes ota _ ▁Living _ ▁with _ heart _ ▁Fail ure _ ▁Question naire ▁Medical
D-1320	-0.4369645416736603	shuttle_walk_ test peak_ oxygen_uptake muscular_ strength echocardiographic natriuretic_peptide inflammatory_ markers depression beck_depression_inventory minnesota_ Living_ with_heart_ Failure_ Questionnaire Medical
P-1320	-0.2309 -0.0012 -0.0542 -1.1933 -1.0604 -0.8423 -2.0629 -0.0128 -0.0806 -0.3010 -0.1947 -0.3960 -0.0477 -0.0062 -0.6419 -1.1165 -0.0090 -0.0093 -0.0064 -0.0892 -0.2279 -2.1085 -0.0251 -0.1537 -1.4492 -0.4343 -0.3282 -0.0959 -0.4422 -0.0058 -0.2332 -0.0451 -0.7851 -0.1125 -0.0088 -0.0236 -0.1252 -0.0107 -0.9716 -0.3824 -0.2426 -0.2492 -0.1670 -0.1344 -0.0182 -2.4567 -0.9752 -0.0814 -1.3211 -0.3102 -0.0802 -0.8133 -0.0335 -0.8756 -0.2213 -0.1732 -0.4356 -1.2025 -0.0487 -0.0079 -0.5755 -0.6133 -0.1669
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction_term_analysis lvef patients patients mortality lvef p_value
H-116	-1.3558104038238525	▁evaluat e _ term _ analyse ▁LV EF ▁significant e _ reducing d _ ▁LV EF ▁long - term _ ▁mortal ity ▁pres er ved ▁severe ly _ reducing d _ ▁LV EF
D-116	-1.3558104038238525	evaluate_term_analyse LVEF significante_reducingd_ LVEF long-term_ mortality preserved severely_reducingd_ LVEF
P-116	-6.0903 -1.4180 -0.3849 -0.7033 -0.5227 -0.1576 -4.3019 -0.2570 -5.5717 -3.6877 -0.5200 -3.2469 -0.3842 -0.6141 -1.6011 -0.3548 -1.6842 -0.1886 -0.1651 -0.2320 -0.2167 -1.2455 -0.5033 -0.2391 -0.2071 -3.4706 -0.6122 -0.8807 -2.3837 -0.4146 -0.7533 -1.7493 -0.2435 -2.3091 -0.1384
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto zsf1 obese zsf1 obese zsf1 followed_up metabolic renal echocardiographic hemodynamically euthanization
H-763	-0.7045103907585144	▁we star - k yo to ▁lean _ z SF ▁obes e _ z SF ▁obes e _ z SF ▁z SF ▁high - fat _ die t ▁metabol ic ▁renal ▁e cho car dio graphic ▁hem o dynamic ally ▁eu than ization
D-763	-0.7045103907585144	westar-kyoto lean_zSF obese_zSF obese_zSF zSF high-fat_diet metabolic renal echocardiographic hemodynamically euthanization
P-763	-1.3304 -0.0996 -0.0362 -3.9328 -0.3045 -0.0231 -0.0322 -0.5776 -1.4324 -0.7766 -0.3096 -0.0247 -1.3885 -0.7523 -1.1825 -0.5956 -0.0284 -1.2252 -0.7866 -1.0670 -3.4589 -1.0703 -4.1987 -0.0320 -0.3788 -0.2525 -1.4930 -0.3476 -0.1592 -0.0029 -0.1246 -0.0116 -0.0046 -0.0047 -0.0928 -0.2392 -2.2242 -0.0731 -0.0037 -0.5507 -0.0058 -0.0962 -0.7012 -0.1591 -0.1118
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier_curves log-rank_testing risk_stratification patients patients
H-384	-0.8441024422645569	▁ka plan - me ier _ ▁cur ves ▁log - rank _ ▁testing
D-384	-0.8441024422645569	kaplan-meier_ curves log-rank_ testing
P-384	-0.3188 -0.0114 -0.0465 -0.2488 -0.1818 -0.7143 -2.8078 -1.0062 -0.5208 -0.0798 -0.1041 -1.2774 -0.9475 -4.2263 -0.1700
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate_cox_regression_analyses hypertension sinus_rhythm hazard_ratio confidence_interval
H-950	-0.957511842250824	▁multi varia te _ co x _ re gression _ analyse s ▁AF _ type ▁hyper tension ▁sinus ▁ rhythm haz ard _ ▁ratio HR ▁confidence _ ▁interval ▁ci
D-950	-0.957511842250824	multivariate_cox_regression_analyses AF_type hypertension sinus rhythmhazard_ ratioHR confidence_ interval ci
P-950	-1.2733 -0.0200 -0.0465 -0.1625 -0.1554 -0.1002 -0.8758 -0.6073 -0.0042 -3.4889 -0.0325 -0.0807 -0.7642 -3.0466 -0.8480 -2.8061 -0.0247 -1.1264 -1.1534 -0.2901 -0.3486 -0.0067 -0.5496 -0.0075 -2.8804 -1.4145 -0.6732 -0.0352 -1.7589 -4.9625 -0.1385
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients chronic hf-ref nyha_functional_class_ii egfr potassium eplerenone hyperkalemia
H-1228	-0.5910524725914001	▁chronic _ HF - re f ▁NY HA ▁functional _ class _ ▁II ▁e g FR ▁po tas s ium ▁e pler en one ▁hyper kal emia ▁w RF
D-1228	-0.5910524725914001	chronic_HF-ref NYHA functional_class_ II egFR potassium eplerenone hyperkalemia wRF
P-1228	-0.4444 -0.5978 -1.0207 -0.0428 -0.2217 -1.4970 -0.5064 -0.7057 -1.1686 -0.5008 -1.0818 -0.8881 -0.6392 -0.0715 -3.2557 -0.8296 -0.7169 -0.6384 -0.0968 -0.0727 -0.0398 -0.0396 -0.0218 -0.1466 -0.9195 -0.1575 -0.0351 -0.1206 -1.5213 -0.1830 -0.1412
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm dual_energy_x-ray_absorptiometry dxa patients chronic_heart_failure chf non-cachectic_chf myocardial
H-12	-0.5193350315093994	▁f FM ▁f m ▁body _ ▁fat ▁distribution ▁dual _ energie _ ▁X - ray _ ▁ab sor pti ometr y ▁d XA ▁non - dia be tic _ ▁patients ▁chronic _ ▁heart ▁failure cc cc ▁non - ca che ctic _ ▁CHF ▁my o card ial _ in far ction - bo th
D-12	-0.5193350315093994	fFM fm body_ fat distribution dual_energie_ X-ray_ absorptiometry dXA non-diabetic_ patients chronic_ heart failurecccc non-cachectic_ CHF myocardial_infarction-both
P-12	-0.5053 -0.7768 -2.4485 -1.0577 -0.8310 -0.7856 -1.1237 -0.7985 -0.0174 -0.1705 -0.8773 -0.4701 -2.3136 -0.1107 -0.0962 -0.0591 -0.6926 -0.6295 -0.1933 -0.2253 -0.2280 -0.2365 -0.0999 -0.2552 -0.0360 -0.0136 -0.1032 -0.2341 -1.9238 -0.4430 -0.8297 -0.0544 -2.6125 -0.8048 -2.1475 -0.7339 -0.3886 -0.0339 -0.0019 -0.0422 -0.0871 -0.4686 -0.1318 -0.7942 -0.2122 -0.2274 -0.4559 -0.0703 -0.1083 -0.0426 -0.1425 -0.2483 -0.0252 -0.0929 -0.4792 -0.0909
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline drug spironolactone combined_end_point death hospitalization hf hazard_ratio confidence_interval aas hazard_ratio confidence_interval p_value
H-1707	-0.5639835596084595	▁spi rono lac tone ▁ HF haz ard _ ▁ratio ▁AA s haz ard _ ▁ratio
D-1707	-0.5639835596084595	spironolactone HFhazard_ ratio AAshazard_ ratio
P-1707	-0.2890 -0.0047 -0.0214 -0.0568 -3.7108 -0.3156 -1.6756 -0.0328 -0.6097 -0.0985 -0.8179 -0.1819 -0.4360 -0.0746 -0.1984 -0.3412 -1.1619 -0.1247
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective_study patients invasively diagnosed pulmonary_arterial_hypertension inoperable chronic_thromboembolic_pulmonary_hypertension right_ventricular pump stable pulmonary_arterial_hypertension medication noninvasive stress_echocardiography cardiopulmonary_exercise_testing
H-823	-0.46087080240249634	▁invasi ve ly ▁pulmonar y _ ▁arterial _ ▁hyper tension ▁in opera ble ▁chronic _ thro mbo e mbol ic _ ▁pulmonar y _ ▁hyper tension ▁right _ ▁vent ri cular _ pump ▁pulmonar y ▁arterial _ ▁hyper tension ▁medication ▁stress ▁e cho card i ography ▁cardio pul mon ary _ ▁exercise
D-823	-0.46087080240249634	invasively pulmonary_ arterial_ hypertension inoperable chronic_thromboembolic_ pulmonary_ hypertension right_ ventricular_pump pulmonary arterial_ hypertension medication stress echocardiography cardiopulmonary_ exercise
P-823	-1.1315 -0.0324 -1.3771 -0.8531 -0.0553 -1.5280 -0.0657 -0.2649 -1.4789 -0.0144 -0.0808 -0.0340 -0.1583 -0.6733 -0.1959 -0.2216 -0.3226 -0.0508 -0.0182 -0.0562 -0.1886 -0.1103 -0.0754 -0.2416 -1.6104 -0.0304 -2.3762 -0.1604 -2.3245 -0.8722 -0.1403 -0.1125 -0.5770 -1.8031 -0.0251 -0.3928 -0.2022 -1.0188 -0.0242 -0.1963 -0.0324 -0.1731 -0.0161 -0.1335 -0.1340 -0.3108 -0.0538 -0.3376 -0.4676 -0.4414 -0.2030 -0.3757 -1.0078 -0.1045
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular_death hf hospitalization randomization btes btes cardiovascular_death hf hospitalization exercise hazard_ratio confidence_interval hazard_ratio confidence_interval
H-1930	-0.7632824778556824	▁cardiovascular _ ▁death ▁ HF _ hospital ization ▁b tes ▁cardiovascular _ ▁death ▁ HF _ hospital ization ▁exercise _ groep haz ard _ ▁ratio
D-1930	-0.7632824778556824	cardiovascular_ death HF_hospitalization btes cardiovascular_ death HF_hospitalization exercise_groephazard_ ratio
P-1930	-0.4115 -0.4962 -1.2921 -0.2338 -0.1444 -3.3250 -0.2816 -0.5243 -1.4075 -0.4297 -0.3433 -0.6559 -0.9092 -0.1172 -0.1030 -3.5231 -0.3832 -0.5699 -0.2742 -0.7150 -0.8994 -0.1353 -0.0238 -0.3904 -0.0322 -2.8709 -0.1163
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients hospitalized death all-cause_readmission aor eds aor
H-466	-1.0122390985488892	▁index _ ed _ ▁visit ▁low - volu me _ ed _ ▁cases ▁death _ all - ca use _ ▁read mission ▁medium ▁a OR ▁high - volu me _ ▁ED s ▁a OR
D-466	-1.0122390985488892	index_ed_ visit low-volume_ed_ cases death_all-cause_ readmission medium aOR high-volume_ EDs aOR
P-466	-0.0743 -0.2356 -4.6108 -0.5116 -2.6239 -0.6588 -0.0857 -0.5864 -0.0834 -0.1558 -4.8427 -0.8297 -0.8940 -4.7066 -1.9672 -0.8234 -0.2730 -0.0206 -0.2124 -0.0566 -0.8220 -0.5819 -0.7291 -0.2526 -0.6390 -1.9701 -0.1082 -0.9676 -0.0606 -0.1749 -4.4344 -0.1185 -0.3483 -0.5741 -0.2569 -0.1499
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients implantable_cardioverter-defibrillator implantation engage patients decisions implantable_cardioverter-defibrillator
H-1863	-0.6008782386779785	▁implant able _ ▁cardio ver ter - de fi br illa tor _ de activa tion ▁implant able _ ▁cardio ver ter - de fi br illa tor _ de activa tion
D-1863	-0.6008782386779785	implantable_ cardioverter-defibrillator_deactivation implantable_ cardioverter-defibrillator_deactivation
P-1863	-0.8084 -0.0568 -0.2694 -0.8478 -0.0744 -0.3269 -0.4885 -0.1090 -0.4284 -0.8101 -0.1998 -0.0769 -0.7706 -0.8496 -0.0439 -0.5411 -4.3550 -2.4565 -0.3502 -0.8900 -0.0873 -0.3116 -0.5260 -0.1048 -0.3886 -0.6687 -0.2055 -0.0661 -0.6408 -0.5071 -0.1039 -0.4636 -1.4791 -0.1232
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac_magnetic_resonance t1_time hazard_ratio confidence_interval left_atrial_area hazard_ratio confidence_interval pulmonary_vascular_resistance hazard_ratio confidence_interval cardiac_events
H-739	-0.8459900617599487	▁Card iac _ ▁magnetic _ ▁res on ance ▁left _ at rial _ ▁area haz ard _ ▁ratio ▁95% _ ▁confidence _ ▁interval ▁pulmonar y _ ▁vas cular _ ▁resist ance haz ard _ ▁ratio ▁95% _ ▁confidence _ ▁interval ▁cardiac
D-739	-0.8459900617599487	Cardiac_ magnetic_ resonance left_atrial_ areahazard_ ratio 95%_ confidence_ interval pulmonary_ vascular_ resistancehazard_ ratio 95%_ confidence_ interval cardiac
P-739	-0.8954 -0.0287 -0.2720 -0.4967 -0.2018 -2.8918 -0.8342 -0.4587 -3.5224 -0.2484 -1.1419 -0.1463 -2.3620 -0.5738 -0.7662 -0.0275 -0.7241 -0.3441 -2.8252 -0.6958 -0.1520 -1.1572 -0.0479 -0.0116 -0.0630 -0.2100 -1.2157 -0.4117 -0.8684 -2.8641 -0.0111 -0.2615 -0.0809 -0.5889 -0.4589 -1.7634 -0.6429 -0.6623 -0.9799 -0.1012 -0.0729 -4.0840 -0.2112
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively followed_up hf patients systolic left_ventricular_ejection_fraction hf stable clinical conditions new_york_heart_association_class_i clinical echocardiographic cardiopulmonary_exercise_test
H-1755	-0.532369077205658	▁ HF ▁sy sto lic ▁le ft _ ▁vent ri cular _ e je ction _ fraction ▁ HF ▁New _ York _ ▁Heart _ association ▁e cho car dio graphic ▁cardio pul mon ary _ ▁exercise
D-1755	-0.532369077205658	HF systolic left_ ventricular_ejection_fraction HF New_York_ Heart_association echocardiographic cardiopulmonary_ exercise
P-1755	-0.7737 -1.8678 -0.9395 -0.0325 -0.0248 -2.0856 -0.1747 -0.1536 -2.5737 -0.7469 -0.7142 -0.1344 -0.1943 -0.1670 -0.1238 -1.0079 -0.0161 -0.1614 -1.0387 -0.4870 -0.8196 -0.8764 -0.1292 -1.0126 -0.3342 -0.6263 -0.1075 -0.0126 -0.0030 -0.1185 -0.1099 -0.0452 -0.4007 -0.6488 -0.2749 -0.1748 -0.2478 -1.2959 -0.1071
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients end_stage_heart_failure abcd_classification american_college_of_cardiology acc american_heart_association aha new_york_heart_association nyha heart_disease symptoms heart_failure physical medical_treatment
H-1666	-0.9433243274688721	▁end _ ▁stage _ heart _ ▁failure ▁ABC d _ ▁classifica tion ▁American _ ▁College _ of _ ▁Card i ology ▁a cc American _ ▁Heart _ association ▁ AHA ▁New _ York _ heart _ association ▁ny ha ▁structura l _ ▁heart _ ▁disease ▁heart ▁failure
D-1666	-0.9433243274688721	end_ stage_heart_ failure ABCd_ classification American_ College_of_ Cardiology accAmerican_ Heart_association AHA New_York_heart_association nyha structural_ heart_ disease heart failure
P-1666	-7.2102 -0.2826 -1.3527 -0.0419 -2.7804 -0.4691 -0.2933 -0.3753 -0.1785 -2.2908 -0.0238 -0.0155 -1.4047 -0.2145 -1.1818 -0.0503 -0.7909 -0.1573 -1.1025 -0.1782 -0.0553 -0.2053 -0.0827 -3.4373 -0.0636 -1.3212 -0.2873 -0.9556 -2.7776 -0.0776 -1.9868 -0.3480 -0.8640 -0.1331 -1.7629 -0.3277 -0.5982 -1.0815 -0.6666 -2.5793 -0.0309 -0.0506 -1.4457 -1.1365 -0.7983 -0.8736 -0.7771 -0.9819 -0.1227
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva continuity_equation lv_end-diastolic_volume lv_end-systolic_volume mitral_filling_flow mva mitral_filling_flow continuous_wave_doppler_echocardiography mitral_valve_plasty
H-345	-0.48775869607925415	▁m va ▁continu ity _ e qu ation LV ▁end - dia sto lic _ ▁volume ▁LV _ ▁end - sy sto lic _ ▁volume ▁mit ral _ ▁fill ing _ ▁flow ▁m VA ▁veloci ty _ ▁time ▁integral ▁mit ral _ ▁fill ing _ ▁flow ▁continuo us _ ▁wa ve ▁do pp ler _ e cho card i ography ▁MR ▁mit ral _ ▁val ve _ plast y
D-345	-0.48775869607925415	mva continuity_equationLV end-diastolic_ volume LV_ end-systolic_ volume mitral_ filling_ flow mVA velocity_ time integral mitral_ filling_ flow continuous_ wave doppler_echocardiography MR mitral_ valve_plasty
P-345	-0.6512 -2.5568 -1.3014 -0.2225 -0.7385 -0.6264 -0.2744 -0.0463 -2.4902 -2.1742 -0.0336 -0.1506 -0.0315 -0.0398 -0.3034 -0.0520 -0.9588 -1.9468 -0.5398 -0.0508 -0.0652 -0.0394 -0.0412 -0.3261 -0.0800 -0.1610 -0.0931 -0.4339 -1.1437 -0.0478 -0.3373 -0.5018 -1.3319 -1.6405 -0.3764 -0.0077 -0.1307 -0.9038 -1.6654 -0.2280 -0.0390 -0.5692 -0.5245 -0.0291 -0.6172 -0.2017 -0.8938 -0.0525 -0.1087 -0.2097 -0.0147 -1.0685 -0.0455 -0.4855 -0.3797 -0.4151 -0.0357 -0.1486 -0.1368 -0.1151 -0.0469 -0.2088 -0.0237 -0.1310 -1.4141 -0.0500 -0.3988 -0.9295 -0.3172 -0.1395 -0.1366
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance rm all-cause_mortality sts hh cri cri cri
H-157	-1.5335876941680908	▁stati tis tical _ ▁significa nce ▁RM ▁mortal ity ▁s ts ▁ HH ▁c r i ▁TM
D-157	-1.5335876941680908	statitistical_ significance RM mortality sts HH cri TM
P-157	-1.7427 -0.5223 -0.3854 -2.4633 -1.1339 -1.4324 -2.1134 -3.0021 -1.1259 -0.2483 -1.3337 -1.7519 -0.2035 -2.1374 -0.1146 -3.2516 -1.3826 -4.7169 -0.0763
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi hf clinic outcomes hfpsi outcomes tracking patients hfpsi
H-381	-0.7677547931671143	▁ HF PSI ▁Ann ▁ar bor ▁Veteran s _ ▁Affairs ▁ HF _ ▁clinic ▁va - rt _ co hor t ▁ HF PSI ▁va - RT _ co hor t ▁ HF PSI ▁ HF PSI
D-381	-0.7677547931671143	HFPSI Ann arbor Veterans_ Affairs HF_ clinic va-rt_cohort HFPSI va-RT_cohort HFPSI HFPSI
P-381	-0.6902 -1.1881 -0.6712 -0.1278 -0.3166 -0.0408 -0.8994 -0.0294 -0.3195 -0.3796 -1.5226 -0.4322 -0.6089 -0.7707 -0.8618 -0.9006 -1.8844 -0.2893 -0.2713 -0.3315 -0.0216 -0.3411 -1.2382 -0.9742 -0.8760 -0.8327 -2.1964 -0.8421 -0.2449 -0.6499 -0.0245 -1.0793 -1.5433 -1.2250 -2.1363 -0.8880 -0.8916 -1.2949 -0.1064
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas spironolactone hyperkalemia potassium hypokalemia potassium
H-1706	-0.7376777529716492	▁AA s ▁spi rono lac tone ▁dose ▁hyper kal emia po tas s ium po tas s ium ▁hypo kal emia po tas s ium
D-1706	-0.7376777529716492	AAs spironolactone dose hyperkalemiapotassiumpotassium hypokalemiapotassium
P-1706	-0.8437 -0.9055 -0.4963 -0.0147 -0.0685 -0.0852 -4.4377 -0.4941 -0.3343 -0.0321 -0.6521 -0.9184 -0.1313 -0.5212 -2.9145 -1.0164 -0.0855 -0.6420 -1.5911 -0.6853 -0.0284 -0.5033 -0.6455 -0.1219 -0.6676 -0.9556 -0.1253
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate_analysis patients preserved_lvef mortality patients lvef hazard_ratio lvef preserved_lvef
H-115	-1.0322833061218262	▁pres er ved _ ▁LV EF ▁long - term _ ▁mortal ity ▁LV EF haz ard _ ▁ratio HR ▁pres er ved _ ▁LV EF
D-115	-1.0322833061218262	preserved_ LVEF long-term_ mortality LVEFhazard_ ratioHR preserved_ LVEF
P-115	-4.9837 -0.2032 -0.3722 -0.8614 -1.9303 -0.3550 -4.6178 -0.1441 -0.1189 -0.2759 -0.2818 -1.4963 -1.6585 -0.3784 -0.3098 -0.0233 -0.2471 -0.0064 -1.3514 -2.6866 -0.2386 -0.5991 -0.4857 -1.6374 -0.6346 -1.8046 -0.1697
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients hfpef primary_outcome odds_ratio nyha_class_iii 6-minute_walk_test 6-mwt feet prescribed medications
H-242	-1.1617472171783447	▁ HF p EF ▁male _ ▁gender odd s _ ▁ratio ▁ny ha _ ▁class _ ▁III ▁walk _ ▁test ▁m t
D-242	-1.1617472171783447	HFpEF male_ genderodds_ ratio nyha_ class_ III walk_ test mt
P-242	-0.9784 -0.1052 -0.0385 -0.4709 -6.0033 -0.4079 -0.8081 -0.0167 -0.0034 -1.9726 -0.0017 -1.5187 -0.1738 -2.3200 -0.5807 -0.9000 -0.5623 -3.6937 -0.5048 -1.0237 -2.8668 -0.2095 -2.5539 -0.1676
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived_pulmonary_arterial_systolic_pressure pasp right_ventricular rv tricuspid_annular_plane_systolic_excursion tapse diastole end-systole clinical follow-up heart_failure hf patients cardiac
H-492	-0.4205635190010071	▁e cho - der i ved ▁pulmonar y _ ▁arterial _ sy sto lic _ ▁pressure PAS p ▁right _ ▁vent ri cular ▁v ▁tri cus pid _ ▁ann ular _ ▁plane _ ▁sy sto lic _ excursion TA PS e ▁dia stol e ▁end - sy stol e ▁heart ▁failure HF ▁cardiac _ risk
D-492	-0.4205635190010071	echo-derived pulmonary_ arterial_systolic_ pressurePASp right_ ventricular v tricuspid_ annular_ plane_ systolic_excursionTAPSe diastole end-systole heart failureHF cardiac_risk
P-492	-1.4883 -0.0046 -0.0211 -0.1676 -0.0915 -0.2101 -0.1939 -0.0658 -0.5580 -0.1560 -0.1523 -0.9853 -0.0580 -0.1472 -0.0919 -0.7246 -0.7348 -0.7147 -0.3010 -0.1240 -1.0104 -0.5408 -0.1187 -1.3892 -0.0414 -0.0510 -0.0656 -0.0689 -1.5410 -0.0014 -0.0179 -0.6131 -0.2850 -0.4186 -0.0777 -0.1393 -0.3180 -0.0074 -3.3189 -1.6529 -0.1461 -0.0234 -0.0112 -0.0420 -0.2192 -0.0372 -0.0752 -0.0491 -0.0265 -0.7091 -0.2841 -0.6921 -0.4759 -1.0509 -1.1917 -0.1534 -0.1172
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad diabetes odds_ratio electrocardiographic_q_waves left_bundle_branch_block odds_ratio nondiabetes dyslipidemia hypertension odds_ratio
H-1190	-0.4796577990055084	▁severe _ ▁CAD ▁diabetes ▁electro car dio graphic _ q _ ▁wa ves ▁left _ ▁bund le _ ▁bran ch _ ▁block ▁non dia bete s ▁dys li pide mia ▁hyper tension ▁to ba cco _ ▁use odd s _ ▁ratio
D-1190	-0.4796577990055084	severe_ CAD diabetes electrocardiographic_q_ waves left_ bundle_ branch_ block nondiabetes dyslipidemia hypertension tobacco_ useodds_ ratio
P-1190	-1.7427 -0.7719 -1.2135 -0.2850 -0.0972 -0.0061 -0.0948 -0.1291 -0.4784 -1.3470 -0.8560 -0.1004 -0.2036 -0.0200 -0.3491 -0.1863 -0.4898 -0.1119 -0.4090 -0.0639 -0.9705 -0.4492 -0.9423 -0.2490 -0.0483 -0.0077 -2.5794 -0.0113 -0.0094 -0.2710 -0.0326 -0.0062 -0.0083 -0.2271 -0.9369 -0.6449 -2.1825 -0.1813 -0.0103 -1.1552 -0.1609 -0.4348 -0.1506
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area_under_the_receiver_operating_characteristic_curve auc pcwp confidence_interval septal p_values
H-485	-1.027468204498291	▁receive r _ ▁operating _ ▁character istic _ cur ve ▁e / e _ ▁ratio s ▁pc w p ▁confidence _ ▁interval ▁eg e _ sept al ▁e / e lateral
D-485	-1.027468204498291	receiver_ operating_ characteristic_curve e/e_ ratios pcwp confidence_ interval ege_septal e/elateral
P-485	-2.1978 -0.0313 -1.1034 -0.2213 -0.3323 -0.5227 -0.0386 -0.4778 -0.4618 -0.1189 -3.5062 -1.8005 -0.0188 -1.2917 -0.0658 -0.0248 -0.0997 -2.5036 -0.6048 -0.8368 -1.6980 -0.0618 -2.0470 -1.4823 -2.5915 -0.0174 -0.0063 -1.1332 -3.5908 -0.0159 -1.0926 -3.7424 -0.1687
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients coronary_artery_disease hypertension trastuzumab administration chf
H-680	-1.177750825881958	▁tras tuz um ab - tre ated ▁patients ▁corona ry _ ▁arter y ▁disease HR ▁hyper tension HR ▁week ly _ ▁tras tuz um ab _ administration ▁h ▁CHF
D-680	-1.177750825881958	trastuzumab-treated patients coronary_ artery diseaseHR hypertensionHR weekly_ trastuzumab_administration h CHF
P-680	-1.4686 -0.0693 -0.0422 -2.0639 -0.3745 -0.0336 -1.1518 -2.9184 -2.7057 -0.8188 -0.4423 -0.0535 -0.2159 -0.7195 -2.8613 -1.5328 -0.0249 -3.7200 -2.8209 -0.5824 -1.6588 -2.0810 -0.0215 -0.0461 -1.0834 -1.6692 -0.7027 -3.5505 -0.7239 -0.2075 -0.1453
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef clinical crt crt systolic_volume_index lv_mass
H-754	-0.963714599609375	▁LV EF ▁clinic al _ com posit e _ ▁response ▁c RT _ on ▁c RT _ ▁OFF ▁LV _ ▁end _ ▁sy sto lic _ ▁volume ▁index ▁LV _ ▁mass
D-754	-0.963714599609375	LVEF clinical_composite_ response cRT_on cRT_ OFF LV_ end_ systolic_ volume index LV_ mass
P-754	-1.5582 -0.3967 -2.2213 -0.0443 -0.4027 -0.2160 -0.0085 -0.0184 -0.9278 -1.3801 -0.2641 -0.7972 -1.5475 -0.5192 -1.7951 -1.9571 -0.6004 -1.6541 -1.4492 -0.6682 -3.9890 -0.2239 -0.5892 -0.0181 -0.0641 -0.0851 -0.1038 -0.3378 -3.1954 -0.5761 -3.7327 -0.3448 -0.1164
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β_signaling tgf-β_receptor_type_i cell yield epithelial mesenchymal transition pluripotency_marker nanog cell cells in_vitro
H-1343	-0.4057302474975586	▁t GF - β _ signal ing ▁t GF - β _ ▁receptor _ type _ ▁I ▁s mad ▁small - mo le cule _ ▁inhibi tors ▁c - K it _ + _ ▁cell ▁yi eld ▁epi the li al ▁mes en chy mal _ ▁transition ▁marker s ▁pluri pote ncy _ ▁marker ▁na nog ▁c - K it _ + _ ▁cell ▁differenti ation ▁cardio my o cy te - like _ ▁cell s
D-1343	-0.4057302474975586	tGF-β_signaling tGF-β_ receptor_type_ I smad small-molecule_ inhibitors c-Kit_+_ cell yield epithelial mesenchymal_ transition markers pluripotency_ marker nanog c-Kit_+_ cell differentiation cardiomyocyte-like_ cells
P-1343	-1.2943 -0.1923 -0.0595 -0.0798 -1.0280 -0.9855 -0.0502 -2.1446 -0.1298 -0.1357 -0.2010 -0.5751 -0.7792 -1.6789 -0.5245 -1.1415 -0.6174 -0.0675 -0.0218 -0.1128 -0.0340 -0.2141 -0.3247 -0.0546 -0.2003 -0.0215 -0.0634 -0.0159 -0.1579 -2.3750 -0.0141 -0.4838 -2.0658 -1.0661 -0.7792 -0.0418 -0.0001 -0.0059 -0.0126 -0.0539 -0.0065 -0.0159 -0.0561 -0.0980 -0.6008 -0.2071 -0.2464 -0.9283 -0.0466 -0.0920 -0.0308 -0.0133 -0.3054 -0.2549 -0.0448 -0.0034 -0.0126 -0.0399 -1.7387 -0.0126 -0.5747 -1.0724 -0.5807 -1.2842 -0.1704 -0.0379 -0.0156 -0.4578 -0.2294 -0.0655 -0.0299 -0.3641 -0.2086 -0.1860 -1.1819 -0.0146 -0.5456 -0.0690
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients hfref diuretics co-morbidities 6-mwt feet nyha_class_iii
H-243	-1.0244231224060059	▁h Fr ef ▁di ure tics ▁co - mor bid ities ▁w ha _ class _ ▁III
D-243	-1.0244231224060059	hFref diuretics co-morbidities wha_class_ III
P-243	-1.3245 -1.6191 -1.7071 -0.4947 -1.2616 -0.4805 -1.3602 -0.0443 -0.0697 -0.0671 -0.9219 -2.5538 -1.7232 -1.6275 -1.0301 -0.6766 -0.5928 -1.7573 -0.1521
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery hf postoperative echocardiography end-diastolic_volume_index lv_ejection_fraction mitral_valve_opening mitral_valve_area mva
H-344	-0.5073890089988708	▁ HF ▁post operativ e _ e cho card i ography ▁LV ▁end - dia sto lic _ ▁volume ▁index ▁LV ▁e je ction ▁ fraction ▁MR ▁pres er ved ▁mit ral _ ▁val ve ▁opening ▁mit ral _ ▁val ve ▁m VA ▁pressure ▁gradi ent
D-344	-0.5073890089988708	HF postoperative_echocardiography LV end-diastolic_ volume index LV ejection fraction MR preserved mitral_ valve opening mitral_ valve mVA pressure gradient
P-344	-1.9944 -0.1765 -1.1169 -0.6056 -0.0090 -0.6901 -0.3135 -0.2372 -0.4841 -0.2926 -0.1896 -1.6000 -0.7261 -0.0445 -0.0276 -0.0103 -0.0209 -0.1986 -0.0366 -0.3797 -1.7264 -1.0458 -0.0479 -0.0221 -0.6471 -0.0007 -0.0868 -2.6041 -0.0597 -0.2682 -0.1848 -0.0559 -0.0983 -1.2260 -0.0493 -0.6173 -0.0424 -0.0510 -0.1653 -0.9005 -0.0411 -1.1618 -1.5810 -1.1972 -0.4861 -0.0135 -0.7481 -0.0723
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients systolic_heart_failure ejection_fraction randomized placebo ivabradine shift systolic_heart_failure_treatment_with_the_if_inhibitor_ivabradine_trial patients placebo ivabradine echocardiographic
H-519	-0.5561350584030151	▁sy sto lic _ heart _ ▁failure ▁i va bra dine ▁SHI ft ▁sy sto lic _ ▁Heart _ ▁Fail ure ▁If _ in hib itor _ ▁i va bra dine _ tri al ▁i va bra dine
D-519	-0.5561350584030151	systolic_heart_ failure ivabradine SHIft systolic_ Heart_ Failure If_inhibitor_ ivabradine_trial ivabradine
P-519	-0.7478 -0.0749 -0.1668 -0.0572 -1.5912 -1.6015 -0.0948 -2.0587 -0.3049 -0.0947 -0.3726 -0.0834 -1.1358 -0.5264 -0.0143 -0.0745 -0.0457 -0.5873 -1.5508 -0.1160 -0.2709 -2.1218 -0.4221 -0.2071 -0.0067 -0.0263 -0.7426 -1.4859 -0.0746 -0.0485 -0.2251 -1.2090 -0.2787 -0.0446 -1.0606 -0.0793 -0.1064 -0.2707 -2.1643 -0.1008
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard_ratios multivariate_regression tapse pasp hazard_ratio tapse new_york_heart_association_functional_class
H-499	-1.4796937704086304	▁Hazard _ ▁ratio s ▁t AP se ▁pas p haz ard _ ▁ratio ▁t AP se ▁ nc w _ heart _ association ▁functional _ ▁class
D-499	-1.4796937704086304	Hazard_ ratios tAPse pasphazard_ ratio tAPse ncw_heart_association functional_ class
P-499	-1.5530 -1.2355 -0.1863 -0.1395 -2.9927 -0.9731 -1.7849 -1.9879 -0.2781 -1.7916 -0.0947 -0.4971 -0.0396 -4.3966 -1.2472 -1.2388 -3.0965 -4.5189 -2.8315 -1.0625 -1.4987 -0.7185 -0.2984 -0.9590 -0.5130 -1.1432 -4.1954 -0.1591
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal_function the_chronic_kidney_disease_epidemiology_collaboration patients estimated_glomerular_filtration_rate egfr
H-390	-0.8917155861854553	▁Ren al _ function ▁Chro nic _ ▁Kid ney ▁Disease ▁Epidemi ology _ col labora tion ▁e qu ation ▁glo mer ular _ filter ation _ ▁rate ▁e g FR ▁m L / min
D-390	-0.8917155861854553	Renal_function Chronic_ Kidney Disease Epidemiology_collaboration equation glomerular_filteration_ rate egFR mL/min
P-390	-3.4914 -0.1473 -0.5226 -1.0831 -0.0683 -0.9867 -0.0776 -0.2714 -0.4322 -0.2545 -0.4064 -0.1295 -1.3312 -1.1150 -0.0416 -0.0346 -2.4744 -0.1166 -0.0929 -0.5549 -0.4466 -0.0994 -0.1824 -1.1219 -0.6049 -1.7725 -0.3723 -0.2020 -2.2144 -2.2039 -0.4893 -2.7082 -2.5233 -0.3607 -2.9815 -0.1863
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective randomized paradigm-hf chronic_heart_failure systolic_dysfunction lv_ef functional_class nyha elevated bnp nt-pro_bnp primary_endpoint cardiovascular_death hospitalization heart_failure arni lcz696 sacubiltril valsartan
H-1968	-0.5596209764480591	▁para dig m - HF ▁chronic _ heart ▁failure ▁sy sto lic _ ▁dys function LV _ ef ▁functional _ ▁class ▁NY HA _ ▁II - III ▁b NP ▁b NP car dio vas cular _ ▁death ▁hospital ization ▁heart ▁failure ▁ar ni ▁l z 696 ▁sa cubi lt ril ▁val sar tan
D-1968	-0.5596209764480591	paradigm-HF chronic_heart failure systolic_ dysfunctionLV_ef functional_ class NYHA_ II-III bNP bNPcardiovascular_ death hospitalization heart failure arni lz696 sacubiltril valsartan
P-1968	-0.8874 -0.9267 -0.2264 -0.0237 -0.3115 -1.5132 -0.2042 -1.2157 -1.0501 -0.2243 -0.0209 -0.1431 -0.1647 -0.0914 -0.0095 -1.3657 -1.3249 -2.1871 -0.1682 -1.4545 -0.3629 -0.1133 -0.5235 -1.4428 -0.5492 -0.0214 -0.0107 -0.2424 -0.3322 -1.1535 -1.1310 -0.9207 -0.0178 -0.2574 -0.3294 -0.9422 -0.5015 -0.3054 -0.6098 -2.4161 -0.9001 -0.2684 -1.1419 -0.6936 -1.4703 -0.0429 -0.0133 -0.0031 -0.0100 -0.0288 -0.0801 -0.0375 -0.0422 -0.2560 -0.0946
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia outcomes african_americans aas new_york_heart_association nyha hf left_ventricular_dysfunction randomized spironolactone titrated placebo randomized_aldactone_evaluation_study rales
H-1703	-0.5844306349754333	▁hyper kal emia ▁African _ American s ▁non - AA s ▁white ▁New ▁York _ ▁Heart _ association NY ha ▁class ▁III ▁ HF ▁left _ ▁vent ri cular _ ▁dys function ▁spi rono lac tone ▁al da cto ne _ evalua tion _ ▁Study RAL es
D-1703	-0.5844306349754333	hyperkalemia African_Americans non-AAs white New York_ Heart_associationNYha class III HF left_ ventricular_ dysfunction spironolactone aldactone_evaluation_ StudyRALes
P-1703	-1.2809 -0.2766 -0.0554 -0.5678 -1.0605 -0.9977 -0.2019 -1.2880 -0.0329 -0.2871 -0.0214 -1.0053 -2.3644 -1.0514 -0.1185 -1.0549 -0.6237 -0.8044 -0.9908 -1.2132 -0.6288 -0.9119 -1.5254 -0.2296 -0.0194 -0.1546 -1.2979 -0.9632 -0.1891 -0.4423 -0.0672 -0.0344 -0.0027 -0.0015 -0.0060 -0.0222 -2.7551 -0.0554 -0.0427 -0.5905 -0.5938 -0.0686 -0.1188 -1.5604 -0.6139 -0.0569 -0.1514 -0.1360 -0.1007
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv_reverse_remodeling lv_end-diastolic_dimension longitudinal strain left_ventricle left_atrial_area right_ventricular_end-diastolic_area_index right_atrial right_ventricular_fractional_area change
H-432	-1.1482986211776733	▁LV _ ▁rever se _ ▁remodel ing ▁left _ ▁vent ric le ▁left _ at rial _ ▁area ▁right _ ▁vent ri cular _ en - dia sto lic _ index ▁right _ at rial _ ▁area ▁right _ ▁vent ri cular _ fraction al _ ▁area
D-432	-1.1482986211776733	LV_ reverse_ remodeling left_ ventricle left_atrial_ area right_ ventricular_en-diastolic_index right_atrial_ area right_ ventricular_fractional_ area
P-432	-0.9908 -2.3143 -1.5574 -0.0294 -0.0710 -0.3316 -0.0413 -4.7176 -0.3221 -4.0175 -1.3914 -0.4839 -0.6082 -0.3379 -2.6640 -0.2282 -1.7887 -0.8406 -1.4438 -0.2003 -2.4173 -0.7762 -0.4915 -0.8291 -5.6755 -0.6634 -0.0263 -0.1047 -0.2868 -0.5487 -3.3536 -0.4509 -0.0901 -3.9559 -0.2866 -0.7755 -0.9295 -1.8992 -0.1835 -2.4430 -1.3102 -0.8357 -0.9019 -0.2243 -0.0138 -0.1554 -1.0047 -1.0848 -0.1684
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type_natriuretic_peptide n-terminal_pro-b-type_natriuretic_peptide diagnostic stable coronary_artery_disease b-type_natriuretic_peptide bnp nt-probnp ventricular_cardiomyocytes ventricular wall_stress myocardial_ischemia
H-1364	-0.6574686765670776	▁b - type _ na tri ure tic _ pe pti de ▁n - termin al _ pro - b - type _ na tri ure tic _ pe pti de ▁corona ry _ ▁arter y ▁disease ▁na tri ure tic _ pe pti de ▁b NP ▁n - termin al _ ▁fragment ▁ nt - pro b NP ▁vent ri cular _ ▁cardio my o cy tes ▁vent ri cular _ wind ▁stress ▁my o card ial _ ische mia
D-1364	-0.6574686765670776	b-type_natriuretic_peptide n-terminal_pro-b-type_natriuretic_peptide coronary_ artery disease natriuretic_peptide bNP n-terminal_ fragment nt-probNP ventricular_ cardiomyocytes ventricular_wind stress myocardial_ischemia
P-1364	-2.0063 -0.2329 -0.0601 -0.6059 -1.3678 -0.0947 -0.3022 -1.9403 -0.2017 -0.9401 -0.1952 -0.4232 -2.2026 -0.0137 -0.0259 -0.0078 -1.9098 -0.9260 -0.0426 -1.2905 -0.0551 -0.0116 -0.2156 -1.0925 -0.0680 -0.3642 -2.3132 -0.1661 -1.2489 -0.2396 -0.2510 -1.6720 -1.1410 -0.1975 -0.2202 -0.4012 -0.4133 -1.6271 -0.1884 -0.3059 -2.1567 -0.3671 -1.3692 -0.2545 -0.4532 -0.2555 -0.7253 -2.1489 -0.0117 -0.0456 -0.0022 -0.4288 -0.2912 -4.4706 -0.4112 -0.0110 -0.0109 -0.5882 -1.1969 -0.0207 -0.6066 -0.5571 -0.1505 -1.4429 -0.5567 -0.2435 -0.0517 -0.0295 -0.0146 -0.8428 -0.8076 -0.1232 -2.5408 -0.5976 -0.3552 -0.2399 -0.7085 -0.6076 -0.2970 -0.4761 -0.7104 -0.2512 -0.1579
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 irs2 heart hyperinsulinemia myocardial_insulin_resistance cellular_dysfunction irs1 irs2 heart-specific_irs1_and_irs2_gene_double-knockout h-dko liver-specific_irs1_and_irs2_double-knockout l-dko
H-654	-0.6737122535705566	▁i RS 1 ▁i RS 2 ▁heart ▁hyper insu line mia ▁my o card ial _ ▁insulin ▁resist ance ▁cel lular _ ▁dys function ▁i RS 2 ▁heart - specific ▁i RS 1 ▁i RS 2 ▁i RS 2 ▁double - k no ckou t ▁h - d ko ▁ liver - specific ▁i RS 1 ▁i RS 2 ▁i RS 2 ▁double - k no ckou t ▁l - d ko
D-654	-0.6737122535705566	iRS1 iRS2 heart hyperinsulinemia myocardial_ insulin resistance cellular_ dysfunction iRS2 heart-specific iRS1 iRS2 iRS2 double-knockout h-dko liver-specific iRS1 iRS2 iRS2 double-knockout l-dko
P-654	-0.3592 -0.2124 -2.3955 -0.5666 -0.3565 -0.2127 -4.2478 -0.5640 -0.0153 -0.0517 -1.2097 -0.4759 -0.1630 -0.3194 -0.3350 -0.1507 -0.0745 -1.1150 -0.0089 -2.5029 -0.0320 -0.4282 -0.0831 -0.0181 -0.2980 -0.0451 -1.0054 -3.7421 -0.0491 -0.0862 -1.0263 -0.0539 -2.5505 -0.6893 -0.1603 -0.2852 -3.0551 -0.2179 -0.2660 -1.2611 -0.0407 -1.2733 -0.1084 -0.0468 -0.0036 -1.8338 -0.1340 -0.4775 -0.2230 -0.3559 -0.6305 -0.0453 -0.1549 -0.8723 -0.1414 -2.4371 -0.8815 -0.2084 -0.9549 -3.3609 -0.3521 -0.6130 -1.3000 -0.0644 -1.1382 -0.0954 -0.0834 -0.0057 -0.1478 -0.0691 -0.5948 -0.1774 -0.2207 -0.1191
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription angiotensin-converting_enzyme_inhibitors angiotensin_receptor_blockers interquartile_range β-blockers interquartile_range interquartile_range
H-665	-0.44667792320251465	▁ang io ten sin - con ver ting _ ▁enzym e ▁inhibi tors angi oten sin _ ▁receptor _ block ers ▁inter quart ile _ ▁range ▁β - block ers ▁inter quart ile _ ▁range
D-665	-0.44667792320251465	angiotensin-converting_ enzyme inhibitorsangiotensin_ receptor_blockers interquartile_ range β-blockers interquartile_ range
P-665	-5.5528 -1.6210 -0.1034 -0.9639 -0.2758 -0.0105 -0.0322 -0.0493 -0.2291 -0.1025 -0.0229 -0.1931 -0.0593 -0.2777 -0.0168 -0.3631 -0.6471 -0.0367 -1.0819 -0.7833 -0.0209 -0.0611 -0.0391 -0.0258 -0.8803 -0.1396 -0.4829 -0.0154 -0.0914 -0.0380 -0.2375 -0.0889 -0.0536 -0.9150 -0.2868 -0.5316 -0.1969
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ivabradine change peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity correlates exercise_capacity therapy ivabradine correlated peak_oxygen_uptake
H-1177	-0.6672281622886658	▁i va bra dine ▁dia sto lic _ met ral _ ▁flow _ ▁veloci ty ▁early _ ▁dia sto lic _ met ral _ ▁ann ular _ ▁veloci ty ▁exercise _ ▁capacity ▁i va bra dine
D-1177	-0.6672281622886658	ivabradine diastolic_metral_ flow_ velocity early_ diastolic_metral_ annular_ velocity exercise_ capacity ivabradine
P-1177	-0.6781 -0.0825 -0.0719 -0.3782 -2.8102 -0.0704 -0.0512 -0.1274 -0.7070 -0.4767 -0.2430 -2.9604 -1.2434 -0.3318 -0.0387 -0.8271 -0.6780 -0.9984 -0.0981 -0.0805 -0.0818 -0.7158 -0.6107 -0.0836 -3.2925 -0.0061 -0.2553 -0.0316 -0.0309 -0.6026 -1.1292 -0.8133 -0.3065 -0.0996 -0.0817 -0.6079 -3.4538 -0.1987
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence transfusion mortality relative_risk mortality patients acute_coronary_syndrome
H-45	-1.165054440498352	▁Low - streng th ▁liberal _ trans fusion _ ▁protocol s ▁aggressiv e _ ▁protocol s ▁significant _ risk ▁ commissie ▁a cute _ ▁corona ry _ ▁syndrome
D-45	-1.165054440498352	Low-strength liberal_transfusion_ protocols aggressive_ protocols significant_risk commissie acute_ coronary_ syndrome
P-45	-6.9597 -0.0484 -0.0048 -0.1335 -1.4177 -0.1140 -0.7503 -0.2096 -1.3740 -0.5084 -0.0332 -3.9735 -0.0267 -0.1807 -2.8281 -0.0204 -2.7194 -0.1698 -0.8157 -4.0264 -4.7881 -0.7763 -0.0459 -0.0127 -0.8730 -1.1313 -0.2174 -0.0534 -0.5141 -0.2252
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death readmission patients physician hazard_ratio confidence_interval physician follow-up patients follow-up
H-1419	-1.1631219387054443	▁un plan ned _ ▁read mission ▁familiar _ ▁physician ▁adjust ed _ ▁hazard _ ▁ratio HR ▁confidence _ ▁interval ▁CI ▁un fa milia r _ ▁physician ▁adjust ed _ HR ▁ci ▁ci
D-1419	-1.1631219387054443	unplanned_ readmission familiar_ physician adjusted_ hazard_ ratioHR confidence_ interval CI unfamiliar_ physician adjusted_HR ci ci
P-1419	-3.3028 -0.0562 -0.2006 -0.0367 -3.9916 -0.5831 -2.9181 -0.4478 -0.5028 -1.5241 -0.0359 -0.0878 -0.9221 -1.5131 -0.0835 -2.8071 -0.8636 -0.6421 -0.1015 -3.1427 -0.5296 -0.2158 -0.0134 -0.0163 -0.1120 -0.2353 -2.1406 -0.0452 -0.1362 -3.0553 -2.6552 -3.4382 -3.0239 -0.1660
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek human_embryonic_kidney cells β1ar s1pr1 β1ar downregulation sphingosine-1-phosphate s1pr1_agonist s1pr1 downregulation isoproterenol β-adrenergic_receptor_agonist
H-1409	-0.9449300169944763	▁h ek ▁human _ em bry o nic _ ▁ki dne y ▁cell s ▁over express ing ▁β 1 AR ▁s 1 PR 1 ▁β 1 AR _ ▁down regul ation ▁sp hing os ine -1 - phos pha te ▁s 1 PR 1 _ ▁ago nist ▁iso prot eren ol ▁β - ad r energi c _ ▁receptor _ ▁ago nist
D-1409	-0.9449300169944763	hek human_embryonic_ kidney cells overexpressing β1AR s1PR1 β1AR_ downregulation sphingosine-1-phosphate s1PR1_ agonist isoproterenol β-adrenergic_ receptor_ agonist
P-1409	-1.0320 -1.2662 -5.2041 -0.2492 -0.1106 -0.0126 -0.2279 -0.5705 -0.0559 -0.7142 -0.4655 -0.1121 -4.0820 -0.1019 -0.7008 -0.2436 -0.0348 -1.0652 -1.5241 -1.2969 -2.9435 -1.3930 -1.5605 -3.0537 -2.0727 -1.2968 -1.9273 -2.7044 -3.5878 -0.5968 -0.0481 -0.0553 -1.0670 -0.0784 -2.6594 -0.6256 -0.0554 -0.0076 -0.0045 -0.0621 -0.4962 -0.5829 -1.0295 -1.6953 -2.5118 -2.4811 -0.1077 -1.7533 -0.0159 -0.0469 -0.2392 -0.1188 -0.0343 -0.0403 -0.3991 -1.5425 -0.0777 -0.0903 -0.2611 -0.5463 -0.8671 -0.0971 -0.4547 -0.1161
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline training 6-minute_walked_distance quality_of_life kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire symptoms beck_depression_inventory zung_self-rated_depression_scores b-type_natriuretic_peptide endothelial_function flow-mediated_dilatation left_ventricular_diastolic_function
H-1330	-0.3904017210006714	▁kan sas _ city _ card i om yo pathy _ ▁Question naire ▁Minnesota ▁Living _ ▁with _ heart _ ▁Fail ure _ ▁Question naire ▁ depressiv e ▁symptoms ▁be ck _ de pression _ in ven tory ▁z ung ▁na tri ure tic _ pe pti de ▁en dot heli al _ ▁function flow - media ted _ di la tation ▁left _ ▁vent ri cular _ dia sto lic _ function
D-1330	-0.3904017210006714	kansas_city_cardiomyopathy_ Questionnaire Minnesota Living_ with_heart_ Failure_ Questionnaire depressive symptoms beck_depression_inventory zung natriuretic_peptide endothelial_ functionflow-mediated_dilatation left_ ventricular_diastolic_function
P-1330	-0.8871 -0.0004 -0.9425 -0.4831 -0.3743 -0.6490 -0.0376 -0.0295 -0.8436 -0.0903 -2.8594 -0.0727 -0.0059 -0.0053 -0.7831 -0.0681 -1.6400 -0.0394 -0.8907 -0.3018 -0.2080 -0.3627 -0.4539 -0.0926 -0.0118 -0.2199 -0.0038 -0.0107 -1.6324 -0.0813 -0.0046 -0.9428 -0.4300 -0.0822 -0.5161 -0.3116 -0.1229 -0.0051 -0.6453 -0.2529 -0.3128 -0.0093 -0.1185 -0.5800 -0.1162 -0.4445 -0.0261 -0.1674 -0.2124 -1.1333 -0.1158 -0.0051 -0.6470 -0.6960 -0.2693 -0.0231 -0.0660 -0.0445 -0.0622 -0.6238 -0.0314 -0.0147 -0.0256 -0.4192 -0.9511 -0.5464 -0.5150 -0.1396 -0.6368 -0.0089 -0.1665 -0.9162 -1.3690 -0.3503 -0.1215
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds_ratios confidence_intervals cardiovascular_events atrial_fibrillation left_ventricular_ejection_fraction diabetes_mellitus peripheral_vascular_disease myocardial_infarction heart_failure stroke patients estimated_glomerular_filtration_rate nonsignificant acute_kidney_injury
H-976	-0.5128861665725708	▁odds _ ▁ratio s ▁cardiovascular _ ▁events ▁at rial _ fi bril lation ▁left _ ▁vent ri cular _ e je ction _ fraction ▁diabetes ▁mell itus ▁per i pher al _ vas cular _ ▁disease ▁my o card ial _ in far ction ▁heart ▁failure ▁stroke ▁glo mer ular _ ▁filtr ation _ ▁rate ▁a cute _ ▁ki dne y ▁injury
D-976	-0.5128861665725708	odds_ ratios cardiovascular_ events atrial_fibrillation left_ ventricular_ejection_fraction diabetes mellitus peripheral_vascular_ disease myocardial_infarction heart failure stroke glomerular_ filtration_ rate acute_ kidney injury
P-976	-4.5033 -0.6074 -1.8897 -0.0191 -1.9104 -0.3776 -0.7523 -1.5276 -0.0477 -0.3097 -0.5733 -0.0164 -0.0777 -0.0379 -0.2585 -1.7298 -0.6457 -0.4655 -0.2215 -0.3467 -0.0651 -0.0651 -0.4023 -0.0294 -0.0173 -0.0043 -0.0115 -0.0144 -0.0368 -0.1553 -0.1219 -0.0292 -2.2561 -0.1712 -1.3938 -0.6702 -0.3407 -0.1716 -0.3126 -0.4531 -0.1247 -0.2393 -0.0616 -0.0864 -0.1173 -0.0520 -0.1644 -0.0269 -0.1425 -0.0201 -0.0858 -1.6474 -0.0906 -2.5627 -0.1542 -0.7797 -0.1337 -0.0361 -1.4503 -0.6340 -0.0958 -0.6386 -0.3411 -0.0997
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic_function ea ventricular-arterial_coupling ees ea
H-925	-0.8671109676361084	▁dia sto lic _ function ▁Ea ▁vent ri cular - arte rial _ ▁coup ling ▁e es ▁e a
D-925	-0.8671109676361084	diastolic_function Ea ventricular-arterial_ coupling ees ea
P-925	-0.3791 -0.1467 -0.1785 -0.5689 -0.6561 -4.9866 -1.6426 -1.2288 -0.3387 -0.3195 -0.1336 -0.1004 -0.2675 -1.5198 -0.7618 -0.6889 -0.6155 -2.5728 -0.2723 -0.6061 -0.2253
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard_ratios disease_risk_score drs saxagliptin sitagliptin saxagliptin pioglitazone saxagliptin sulfonylureas saxagliptin insulin
H-1835	-1.1431725025177002	▁hazard _ ▁ratio s ▁disease _ risk _ ▁score ▁d RS _ - stra t ified _ analyse s ▁sax ag lip tin ▁si tag lip tin ▁ci ▁sax ag lip tin ▁pi og lita zone ▁sax ag lip tin ▁sul fon yl ure as ▁ci ▁sax ag lip tin ▁insulin
D-1835	-1.1431725025177002	hazard_ ratios disease_risk_ score dRS_-stratified_analyses saxagliptin sitagliptin ci saxagliptin pioglitazone saxagliptin sulfonylureas ci saxagliptin insulin
P-1835	-2.8738 -2.6619 -0.6530 -0.0419 -0.5059 -1.1871 -0.5008 -1.6996 -0.0440 -0.2386 -0.4742 -5.7858 -0.6852 -0.0081 -0.0355 -0.0334 -1.0826 -0.0292 -0.0215 -2.3644 -0.0419 -0.5212 -3.1371 -2.7088 -0.6733 -0.3059 -3.2247 -1.1939 -5.4273 -0.0208 -0.5419 -2.8424 -1.7969 -0.1086 -0.0891 -0.0366 -2.7270 -0.0512 -0.5914 -3.2069 -0.9061 -0.0228 -0.1428 -0.4177 -0.0237 -1.6635 -1.3459 -0.0397 -0.7135 -3.5440 -1.1990 -0.2693 -0.1270
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients revascularization coronary_artery_bypass_surgery hazard_ratio percutaneous_coronary_intervention systolic_blood_pressure left_bundle_branch_block_pattern baseline electrocardiogram
H-106	-0.5438739061355591	▁i ▁re vas cular ization ▁co ron ary _ ▁arter y _ ▁by pass ▁surgery ▁hazard ▁ratio ▁per cuta ne ous _ ▁corona ry _ intervention ▁HR ▁sy sto lic _ ▁blood ▁pressure ▁left ▁bund le _ ▁bran ch _ ▁block _ ▁pattern ▁base line _ ▁electro card i ogram ▁IE
D-106	-0.5438739061355591	i revascularization coronary_ artery_ bypass surgery hazard ratio percutaneous_ coronary_intervention HR systolic_ blood pressure left bundle_ branch_ block_ pattern baseline_ electrocardiogram IE
P-106	-1.9557 -1.1492 -0.0470 -0.1587 -0.6708 -0.8854 -0.4297 -0.6058 -0.2884 -0.1027 -0.2013 -0.2398 -1.7007 -0.0398 -0.3386 -0.6742 -0.4167 -1.0325 -0.0015 -0.2027 -0.6716 -0.0786 -0.3992 -1.2725 -0.9435 -0.3835 -0.9898 -0.4568 -0.0142 -0.0945 -0.0699 -0.4629 -1.4649 -1.6841 -0.3607 -0.1216 -0.1790 -0.1918 -0.0650 -1.2137 -0.5468 -1.5575 -0.0104 -0.1351 -0.0134 -0.3925 -0.1006 -0.0750 -0.2421 -0.0311 -2.5481 -0.7742 -0.1398
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical biomedical relative_risk confidence_interval left_ventricular_ejection_fraction left_ventricular_diastolic_end_diameter outcome
H-1262	-0.8257408738136292	▁bio medic al _ ▁treatment ▁bio medic al _ ▁treatment ▁CH m ▁left _ ▁vent ri cular _ e je ction _ fraction ▁left _ ▁vent ri cular _ dia sto lic _ ▁end _ ▁diameter
D-1262	-0.8257408738136292	biomedical_ treatment biomedical_ treatment CHm left_ ventricular_ejection_fraction left_ ventricular_diastolic_ end_ diameter
P-1262	-0.0054 -0.0773 -0.0190 -2.1343 -1.2993 -2.1713 -0.0697 -0.0176 -1.6165 -1.2492 -2.4526 -0.2402 -2.7031 -0.4782 -1.5497 -0.7845 -0.5128 -0.3359 -0.5324 -0.2324 -0.1257 -0.8088 -0.0318 -0.5821 -0.6223 -0.9926 -1.1262 -0.4531 -0.5104 -1.0587 -0.0180 -0.1528 -0.1187 -2.2980 -1.5161 -0.2425 -2.0446 -0.1943
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective randomized crossover_study outcome stable_heart_failure patients left_ventricular_ejection_fraction homozygous haplotype β2-receptor randomized carvedilol metoprolol
H-1114	-0.5096616148948669	▁open - label _ ▁cross over _ studie s ▁cardiovascular _ ▁failure ▁vent ri cular _ e je ction ▁ fraction ▁ar g 16 ▁g l n 27 ▁g ly 16 ▁g lu 27 ▁ha plo type ▁β 2- recept or ▁car vedi lol ▁met o pro lol
D-1114	-0.5096616148948669	open-label_ crossover_studies cardiovascular_ failure ventricular_ejection fraction arg16 gln27 gly16 glu27 haplotype β2-receptor carvedilol metoprolol
P-1114	-2.0216 -0.0961 -0.0843 -0.5188 -1.0748 -0.0045 -0.9078 -0.6080 -0.3009 -4.7056 -0.2212 -0.1276 -2.4275 -0.7549 -0.3203 -0.2871 -0.2743 -0.1203 -0.0515 -1.2277 -0.0057 -0.1647 -0.0992 -0.8731 -0.2943 -0.2596 -0.0099 -0.2390 -0.1081 -0.9499 -0.1933 -1.4126 -2.3218 -0.7537 -0.1063 -0.0128 -0.0094 -0.0413 -0.0090 -0.0615 -0.0365 -0.1300 -0.0082 -0.1719 -0.1281 -0.2449 -0.0538 -0.3944 -0.1596 -0.0955
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients death hospitalization aor aor aor aor
H-465	-1.5746710300445557	▁low - volu me _ ed _ ▁cases ▁a OR ▁high - volu me _ ed _ com ité ▁a OR
D-465	-1.5746710300445557	low-volume_ed_ cases aOR high-volume_ed_comité aOR
P-465	-1.4278 -0.1019 -0.4710 -0.1075 -0.3407 -4.5563 -1.4037 -3.0789 -4.7089 -0.4901 -3.6621 -0.1127 -1.2739 -0.1173 -0.2834 -4.2340 -0.8549 -5.1040 -1.0212 -1.1104 -0.5580 -1.0321 -0.1666
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health_buddy_program all-cause_mortality hazard_ratio confidence_interval inpatient admissions baseline
H-1625	-1.120373249053955	▁health _ ▁Budd y _ program haz ard _ ▁ratio HR ▁confidence _ ▁interval CI ▁quarter ly ▁in patient _ ad missions
D-1625	-1.120373249053955	health_ Buddy_programhazard_ ratioHR confidence_ intervalCI quarterly inpatient_admissions
P-1625	-2.9939 -1.2380 -2.4524 -0.0784 -0.3567 -1.8582 -3.5243 -0.0340 -0.1837 -0.0123 -1.4760 -0.1912 -0.7968 -0.0703 -2.3223 -3.1462 -0.0996 -1.3920 -0.1219 -0.8085 -0.2786 -0.1062 -3.2054 -0.1421
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted_hazard_ratios dash
H-691	-0.8899601697921753	▁multi vari able - ad just ed _ ▁hazard _ ▁ratio s ▁
D-691	-0.8899601697921753	multivariable-adjusted_ hazard_ ratios
P-691	-0.3850 -0.0657 -0.1194 -0.4016 -0.0189 -0.0184 -0.1167 -0.2052 -1.2862 -1.4928 -0.1431 -0.0720 -3.1638 -4.9706
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt nt-probnp report aric hf systolic_blood_pressure antihypertensive_medication diabetes body_mass_index coronary_heart_disease heart_rate hf area_under_the_receiver_operating_characteristic_curve auc integrated_discrimination_improvement net_reclassification_improvement nri
H-287	-0.5153251886367798	▁c t n t ▁NT - pro b NP labora tory _ report ▁a RIC _ HF ▁sy sto lic _ ▁blood ▁pressure ▁anti hy per tensi ve ▁medication ▁smoking ▁diabetes ▁body ▁mass ▁index ▁corona ry _ heart ▁disease ▁heart ▁rate ▁ HF ▁receive r _ ▁operating _ ▁character istic _ cur ve ▁eg ▁discrimina tion ▁net _ ▁re class ification _ ▁improvement ▁n RI
D-287	-0.5153251886367798	ctnt NT-probNPlaboratory_report aRIC_HF systolic_ blood pressure antihypertensive medication smoking diabetes body mass index coronary_heart disease heart rate HF receiver_ operating_ characteristic_curve eg discrimination net_ reclassification_ improvement nRI
P-287	-0.0140 -0.1020 -0.1154 -0.2183 -0.1311 -0.0101 -0.0079 -0.2516 -0.2781 -2.4608 -0.0107 -0.0509 -0.1441 -0.2095 -0.5739 -0.1561 -1.8944 -0.5885 -0.0269 -0.0708 -0.0287 -0.2594 -0.9706 -0.0036 -0.5806 -0.0109 -0.0119 -0.0050 -1.4602 -0.4049 -0.1119 -0.0686 -0.2162 -0.0615 -0.0067 -0.3278 -0.0211 -1.4564 -1.1469 -0.0677 -0.7958 -0.7806 -1.1036 -0.4495 -0.0090 -1.1421 -0.0830 -1.1456 -0.0947 -0.0027 -0.1375 -0.5036 -0.0276 -3.8693 -1.4214 -0.0601 -1.2287 -0.4846 -1.0695 -0.0249 -0.0847 -3.4170 -0.2326 -0.6505 -0.0833 -1.0103 -0.0788
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone patients hyperkalemia renal_function emphasis-hf patients heart_failure_and_reduced_ejection_fraction hf-ref new_york_heart_association nyha functional_class estimated_glomerular_filtration_rate egfr serum_potassium
H-1222	-0.49068546295166016	▁e pler en one ▁hyper kal emia ▁renal _ function ▁w RF ▁EM PHA SIS - HF ▁heart ▁failure ▁reduce d _ e je ction _ fraction ▁h - re f ▁New ▁York _ ▁Heart _ association ▁ny ha ▁glo mer ular _ ▁filtr ation ▁rate ▁e ▁g FR ▁se rum _ po tas s ium
D-1222	-0.49068546295166016	eplerenone hyperkalemia renal_function wRF EMPHASIS-HF heart failure reduced_ejection_fraction h-ref New York_ Heart_association nyha glomerular_ filtration rate e gFR serum_potassium
P-1222	-0.1201 -0.0534 -0.0665 -0.2441 -0.1189 -0.1161 -0.0043 -0.7238 -0.7640 -1.5008 -0.6706 -0.4395 -1.2394 -0.0840 -0.8445 -0.0143 -0.1218 -0.5081 -0.2476 -0.6341 -0.0114 -0.3039 -0.3311 -0.1111 -0.0303 -0.2767 -0.0229 -2.8879 -0.6516 -0.1825 -1.6204 -0.4068 -0.9513 -0.1374 -0.5849 -0.4232 -1.0384 -0.5261 -0.4073 -0.0224 -0.1484 -0.0315 -0.0816 -1.5602 -0.0567 -1.1235 -0.0548 -2.2174 -1.2458 -0.1159 -0.2241 -0.3287 -0.8367 -0.4714 -0.1339 -0.0586 -0.2178 -0.1090
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide nesiritide placebo change cystatin_c nesiritide placebo
H-81	-1.4321497678756714	▁low - dos e _ ▁nesi riti de ▁cum ul ative _ ▁urin e ▁volume nesi riti de ▁place bo ▁cyst atin _ c _ ▁level nesi riti de
D-81	-1.4321497678756714	low-dose_ nesiritide cumulative_ urine volumenesiritide placebo cystatin_c_ levelnesiritide
P-81	-4.2692 -0.1017 -2.7253 -0.1530 -2.4945 -1.7827 -0.0405 -0.2435 -2.1302 -0.0704 -0.0468 -0.2717 -2.2745 -0.2414 -0.6712 -3.0197 -0.1299 -0.3900 -8.0715 -0.0343 -3.1797 -0.1283 -0.7645 -0.3274 -1.9670 -0.3432 -3.2237 -0.1184 -0.2228 -4.7829 -0.1765
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking functional_capacity 6mwt physical activity symptoms hospital_anxiety_and_depression_scale
H-572	-1.64359712600708	▁Nordic _ ▁walking ▁functional _ ▁capacity ▁m MW t ▁physical _ activ iteit ▁right _ ▁grip _ ▁strength ▁kw h
D-572	-1.64359712600708	Nordic_ walking functional_ capacity mMWt physical_activiteit right_ grip_ strength kwh
P-572	-3.7847 -0.3364 -1.6377 -0.2268 -1.4723 -0.9686 -1.6550 -3.8755 -0.0467 -2.8659 -0.7968 -0.6081 -0.4769 -5.5701 -0.1865 -0.8252 -1.4025 -0.2833 -3.4872 -1.3350 -4.1452 -0.1725
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients hyperkalemia patients diabetes egfr systolic_blood_pressure potassium hyperkalemia leading hospitalization hospitalization primary_outcome hospitalization hf cardiovascular_mortality
H-1225	-0.8317244052886963	▁hyper kal emia ▁w r ▁diabetes ▁e g FR ▁sy sto lic _ ▁blood _ ▁pressure ▁p tas s ium ▁hyper kal emia ▁study - drug _ ▁dis continu ation ▁w r ▁cardiovascular _ ▁mortal ity
D-1225	-0.8317244052886963	hyperkalemia wr diabetes egFR systolic_ blood_ pressure ptassium hyperkalemia study-drug_ discontinuation wr cardiovascular_ mortality
P-1225	-1.6216 -0.4478 -0.0953 -0.1679 -2.5117 -0.1002 -0.0639 -1.9735 -0.8022 -0.6410 -0.0467 -0.1708 -0.0970 -0.9539 -0.9228 -0.5982 -3.6281 -4.1171 -0.0291 -0.2720 -0.9783 -0.5296 -0.0377 -2.8045 -0.0149 -0.0032 -1.2866 -0.2296 -0.0021 -0.1435 -0.5531 -2.6133 -1.1048 -1.0272 -0.0606 -0.6667 -0.2011 -0.0880
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf biosynthetic_enzymes lyso-paf_acetyltransferase lyso-paf-at 1-alkyl-2-acetyl-sn-glycerol_cholinephosphotransferase paf-cpt catabolic_isoenzymes paf-acetylhydrolase paf-ah lipoprotein-associated_phospholipase_a2 lp-pla2 leukocytes
H-1268	-0.4570278227329254	▁PA f ▁bio syn the tic _ ▁enzym es lys o - pa f _ a ce tyl transfer ase lys o - pa f - at ▁di thi oth rei tol ▁cd p ▁cho line ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁cho line phos pho transfer ase ▁p bf - c pt ▁cata bo lic _ ▁iso en zy mes ▁p bf - ace tyl hydro lase ▁p bf - AH ▁lipo prote in - as soci ated _ phos pho lipa se ▁l p - PLA 2]
D-1268	-0.4570278227329254	PAf biosynthetic_ enzymeslyso-paf_acetyltransferaselyso-paf-at dithiothreitol cdp choline 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase pbf-cpt catabolic_ isoenzymes pbf-acetylhydrolase pbf-AH lipoprotein-associated_phospholipase lp-PLA2]
P-1268	-0.9832 -1.4851 -0.0167 -0.0107 -0.4024 -1.1416 -0.3089 -0.0897 -0.0246 -0.3544 -0.0765 -0.0465 -0.3935 -2.3260 -1.0018 -0.5927 -0.9379 -0.5509 -0.1106 -1.2934 -0.6035 -0.0363 -0.0338 -0.2050 -2.1311 -0.1955 -0.9095 -0.0457 -0.0723 -0.2262 -0.0521 -0.4319 -0.6542 -0.3020 -1.9039 -0.0399 -2.2228 -0.0234 -0.0353 -0.0919 -0.0770 -0.4590 -0.0422 -0.0325 -0.0435 -0.0085 -0.0244 -0.0279 -0.0422 -0.1421 -1.5706 -0.0803 -1.4387 -0.3735 -0.4910 -0.8065 -1.1253 -0.9480 -0.0742 -0.7523 -0.7493 -0.0376 -0.0173 -0.0057 -0.6961 -0.0545 -0.0628 -0.0223 -0.0888 -2.5853 -1.3592 -0.0330 -0.2130 -0.0758 -0.0308 -0.0339 -1.3344 -1.5139 -0.0341 -0.3716 -0.0093 -0.0819 -0.0630 -0.0742 -0.0083 -0.0002 -0.3045 -0.2445 -0.1025 -0.0856 -0.0611 -0.5639 -1.7660 -0.0109 -0.0841 -0.0600 -0.6757 -0.6635 -0.1442
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine baseline follow-up exercise_capacity mets mets peak_oxygen_uptake peak_early_diastolic_mitral_flow_velocity peak_early_diastolic_mitral_annular_velocity
H-1175	-0.7658311724662781	▁i va bra dine _ groep ▁follow - up _ ▁exercise _ ▁capacity ▁pe ak _ ▁oxygen _ up take
D-1175	-0.7658311724662781	ivabradine_groep follow-up_ exercise_ capacity peak_ oxygen_uptake
P-1175	-0.0138 -0.0365 -0.0523 -0.1042 -0.6853 -0.6115 -0.2353 -0.0462 -0.0086 -0.1939 -1.2541 -1.0725 -1.7853 -2.4024 -0.0495 -0.0560 -2.2930 -0.3745 -0.4300 -0.3306 -4.6720 -0.1410
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate_analysis chf odds_ratio chest hypertension genes rac2 doxorubicin_efflux_transporter abcc2
H-1455	-0.9289533495903015	▁CHF ▁o ds _ ra tio ▁h ct ▁che st _ ▁radi ation ▁hyper tension ▁ NAD ( p h - oxid ase _ ▁sub un it ▁ RAC 2 ▁h fe ▁do xor ubi cin _ eff lux _ ▁transporter ▁ABC c 2
D-1455	-0.9289533495903015	CHF ods_ratio hct chest_ radiation hypertension NAD(ph-oxidase_ subunit RAC2 hfe doxorubicin_efflux_ transporter ABCc2
P-1455	-3.4685 -2.5358 -0.0890 -0.5108 -0.2553 -0.3779 -0.5544 -2.1602 -1.1081 -0.0338 -1.7682 -0.1412 -0.0849 -0.0722 -0.0198 -1.0384 -1.2180 -3.8105 -0.9907 -2.1735 -0.1547 -0.0421 -1.9880 -1.7998 -0.2486 -0.4243 -0.0438 -1.1209 -0.2101 -0.0599 -4.4650 -2.2194 -0.7255 -0.0433 -0.0107 -0.1744 -0.6278 -0.0893 -0.1511 -0.2084 -0.4473 -1.7855 -1.2227 -0.8175 -1.0885 -0.1520
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline follow-up nyha_classification patients patient change patient quality_of_life duke_activity_status_index kansas_city_cardiomyopathy_questionnaire 6_min_walk_test
H-1958	-0.9586523771286011	▁NY ha ▁classifica tion ▁class _ ▁II ▁class _ ▁III ▁class _ ▁I ▁patient ▁Duke _ activ ity _ status _ index ▁Duke _ activ ity _ status _ index ▁Kansas ▁City _ car i om yo pathy _ ▁Question naire
D-1958	-0.9586523771286011	NYha classification class_ II class_ III class_ I patient Duke_activity_status_index Duke_activity_status_index Kansas City_cariomyopathy_ Questionnaire
P-1958	-1.5141 -0.7289 -1.6644 -0.0679 -1.3996 -2.4485 -1.6828 -0.8362 -1.8310 -0.8608 -3.9368 -0.7651 -0.6976 -2.4839 -0.3614 -0.8804 -0.2243 -0.3473 -0.0867 -0.8457 -0.9874 -0.4254 -1.1624 -0.2496 -0.0808 -1.0552 -0.0541 -1.2743 -0.2696 -0.3707 -1.6148 -1.9213 -0.1977 -1.5562 -0.3748 -0.0343 -0.8644 -0.0687 -1.8395 -0.1019 -0.0101 -2.8241 -0.2214
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo dopamine dopamine placebo change cystatin_c dopamine placebo
H-80	-1.1764466762542725	▁low - dos e _ ▁dop amine ▁cum ul ative _ ▁urin e ▁volume dop amine
D-80	-1.1764466762542725	low-dose_ dopamine cumulative_ urine volumedopamine
P-80	-2.6069 -0.0953 -2.5186 -0.1960 -2.0450 -0.3816 -0.1375 -0.6104 -0.0788 -0.0368 -0.2161 -2.0251 -0.2184 -0.4565 -1.9309 -0.1102 -7.3184 -0.1935
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard_ratio confidence_interval baseline glomerular_filtration_rate chronic_obstructive_pulmonary_disease diabetes peripheral_vascular_disease left_ventricular_ejection_fraction icd_shocks new_york_heart_association_class atrial_fibrillation congestive_hf mortality
H-66	-1.1523141860961914	▁ha ard _ ▁ratio ▁ cc ▁base line _ ▁glo mer ular _ filter ation _ ▁rate ▁h ▁m l / min _ ▁decrease ▁chronic _ ob struct ive _ ▁pulmonar y ▁disease ▁diabetes ▁( HR ▁per i pher al _ vas cular _ ▁disease HR ▁left _ ▁vent ri cular _ e je ction _ fraction ▁ fraction ▁i CD _ ▁shock s ▁New _ York _ heart _ association _ ▁class ▁at rial _ fi bril lation ▁con ges tive _ HF
D-66	-1.1523141860961914	haard_ ratio cc baseline_ glomerular_filteration_ rate h ml/min_ decrease chronic_obstructive_ pulmonary disease diabetes (HR peripheral_vascular_ diseaseHR left_ ventricular_ejection_fraction fraction iCD_ shocks New_York_heart_association_ class atrial_fibrillation congestive_HF
P-66	-2.8799 -0.3544 -0.3927 -0.1950 -5.0965 -4.3976 -1.3453 -0.0849 -0.2600 -1.3870 -0.1732 -0.0251 -0.1025 -0.9779 -0.2331 -2.9440 -0.1263 -2.6205 -6.6272 -1.4273 -2.7370 -0.2879 -4.7699 -0.5431 -0.1258 -0.4324 -0.3873 -0.0487 -0.0549 -0.1137 -0.1056 -0.1343 -0.9634 -0.5903 -4.4835 -1.9875 -3.6590 -0.0632 -0.4435 -0.0959 -0.0497 -1.5836 -0.2720 -1.5423 -0.7127 -4.8582 -3.6078 -0.3250 -1.6367 -1.1757 -0.2167 -0.3197 -0.3256 -0.1399 -0.0479 -0.5950 -0.0515 -4.2490 -0.1045 -2.6247 -1.0274 -1.2143 -0.0811 -0.0225 -4.4099 -0.6621 -2.1017 -0.2133 -1.2648 -0.5169 -0.2543 -2.1402 -0.4277 -0.0761 -0.0975 -0.3834 -0.8378 -0.0294 -0.0738 -0.0657 -0.1094 -1.3937 -0.0571 -0.4142 -2.9347 -0.1746
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable_analysis end_point peak_oxygen_uptake hazard_ratio confidence_interval ventilatory_efficiency_slope hemoglobin left_ventricular_ejection_fraction renal_function renal_disease sodium
H-1761	-1.1595052480697632	▁pe ak _ ▁oxygen _ up take ▁hazard _ ▁ratio ▁confidence _ ▁interval ▁ci s ▁ventilator y _ ▁efficiency _ ▁s lope ▁hem o glob in ▁left _ ▁vent ri cular _ e je ction _ fraction ▁HR =0 0.9 48 ▁renal _ function ▁renal _ ▁disease ▁so dium
D-1761	-1.1595052480697632	peak_ oxygen_uptake hazard_ ratio confidence_ interval cis ventilatory_ efficiency_ slope hemoglobin left_ ventricular_ejection_fraction HR=00.948 renal_function renal_ disease sodium
P-1761	-3.3994 -0.0656 -0.0859 -1.2921 -0.4890 -0.3315 -0.2579 -0.1099 -1.8361 -0.3462 -3.7274 -0.8676 -0.1660 -1.8991 -4.9946 -2.7706 -0.1397 -0.3897 -0.7082 -2.6548 -0.7190 -0.0338 -2.9197 -0.2897 -0.1024 -0.7392 -2.3371 -0.3501 -1.0831 -0.8937 -0.4361 -0.3384 -0.4094 -0.1456 -0.0700 -1.1368 -0.0113 -2.1161 -5.0828 -0.4842 -0.6461 -0.1704 -0.3308 -3.4947 -1.2619 -0.8376 -2.6075 -0.0414 -0.1678 -3.1695 -0.1774
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute_walked_distance kansas_city_cardiomyopathy_questionnaire minnesota_living_with_heart_failure_questionnaire beck_depression_inventory flow-mediated_dilatation fes placebo b-type_natriuretic_peptide mitral
H-1331	-0.5004521012306213	▁Kansas ▁City _ card i om yo pathy _ ▁Question naire ▁Minnesota ▁Living _ ▁with _ ▁Heart _ ▁Fail ure _ ▁Question naire ▁Beck _ de pression _ in ven tory ▁z ung ▁flow - media ted _ di la tation ▁diameter ▁f es _ groep ▁na tri ure tic _ pe pti de ▁mit ral _ e / e _ wa ve _ ▁ratio
D-1331	-0.5004521012306213	Kansas City_cardiomyopathy_ Questionnaire Minnesota Living_ with_ Heart_ Failure_ Questionnaire Beck_depression_inventory zung flow-mediated_dilatation diameter fes_groep natriuretic_peptide mitral_e/e_wave_ ratio
P-1331	-0.8601 -1.4289 -0.8658 -1.5115 -0.0357 -0.0396 -0.5319 -0.0930 -2.5423 -0.2299 -0.0040 -0.6425 -0.5263 -0.1239 -1.0209 -0.0407 -0.5928 -0.7778 -0.0714 -0.4920 -0.8943 -0.0655 -0.0054 -0.3947 -1.0549 -0.4350 -0.0977 -0.1891 -0.3373 -0.2159 -0.0240 -0.4933 -0.5827 -0.0663 -0.0229 -0.2164 -0.0697 -0.0279 -0.3808 -0.0772 -0.0153 -0.4511 -1.1682 -1.6470 -1.6959 -0.3222 -0.5209 -0.0220 -0.2831 -0.9395 -0.3158 -0.3374 -0.0425 -0.2620 -1.4881 -0.0359 -0.3151 -0.1731 -1.8042 -0.0066 -0.4348 -1.5061 -0.0296 -0.8567 -0.0598 -0.5135 -0.2022
2021-01-18 20:28:53 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-18 20:28:53 | INFO | fairseq_cli.generate | Translated 2,024 sentences (37,032 tokens) in 189.4s (10.68 sentences/s, 195.48 tokens/s)
2021-01-18 20:28:53 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 28.93, 55.0/35.1/25.0/17.8 (BP=0.950, ratio=0.951, syslen=37032, reflen=38932)
